PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ARAGAY, AM; KATZ, A; SIMON, MI				ARAGAY, AM; KATZ, A; SIMON, MI			THE G-ALPHA-Q AND G-ALPHA-11 PROTEINS COUPLE THE THYROTROPIN-RELEASING-HORMONE RECEPTOR TO PHOSPHOLIPASE-C IN GH3 RAT PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; INOSITOL TRISPHOSPHATE FORMATION; REGULATORY PROTEINS; PERTUSSIS-TOXIN; SUBUNITS; HYDROLYSIS; MEMBRANES; PURIFICATION; DISTINCT; ACTIVATION	Thyrotropin-releasing hormone stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in GH3 cell membranes. The stimulation of the phosphoinositide phospholipase C (PI/PLC) activity can be blocked by incubation of GH3 membranes with polyclonal antibodies directed against a peptide derived from the C-terminal region of Galphaq and Galpha11. Antibodies directed against the C-terminal region of other Galpha-subunits had no detectable effect. The inhibition was specific since addition of the peptide that was used to prepare the antibody completely reversed the inhibition. Further evidence for the coupling of the TRH receptor to Galpha(q) or Galpha11 comes from a reconstitution experiment in which human embryonic kidney cells were transiently transfected with cDNAs corresponding to the TRH receptor, Galpha(q) or Galpha11. The PIP2 hydrolysis detected with membranes from cells that over-expressed the TRH receptor alone was low, however, co-expression with the Galpha(q) or Galpha11 subunits produced a synergistic stimulation of PI-PLC activity. In contrast, co-expression of these alpha-subunits with the M2 muscarinic acetylcholine receptor induced a weak stimulation of PIP2 hydrolysis. The results presented here suggest that the TRH-dependent stimulation of PI-PLC in GH3 cells is mediated through the G-protein alpha-subunits, Galpha(q) and/or Galpha11.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012; Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NIGMS NIH HHS [GM 34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; AUB DL, 1987, J BIOL CHEM, V262, P9521; AUB DL, 1986, J BIOL CHEM, V261, P9333; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HINKLE PM, 1984, J BIOL CHEM, V259, P3445; HINKLE PM, 1984, P NATL ACAD SCI-BIOL, V81, P6183, DOI 10.1073/pnas.81.19.6183; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IMAI A, 1985, J BIOL CHEM, V260, P536; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS DO, 1985, BIOCHEM BIOPH RES CO, V132, P721, DOI 10.1016/0006-291X(85)91192-1; MARTIN MW, 1985, BIOCHEM J, V229, P539, DOI 10.1042/bj2290539; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARK D, 1992, J BIOL CHEM, V267, P16048; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRAUB RE, 1986, J BIOL CHEM, V261, P2712; STRAUB RE, 1991, P NATL ACAD SCI USA, V87, P9414; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; UI M, 1990, ADP RIBOSYLATING TOX, P45; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811	40	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24983	24988						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334076				2022-12-27	WOS:A1992KB60300014
J	BOOTMAN, MD; TAYLOR, CW; BERRIDGE, MJ				BOOTMAN, MD; TAYLOR, CW; BERRIDGE, MJ			THE THIOL REAGENT, THIMEROSAL, EVOKES CA2+ SPIKES IN HELA-CELLS BY SENSITIZING THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; CELLULAR GLUTATHIONE; CA-2+ SEQUESTRATION; CHROMAFFIN CELLS; TUMOR PROMOTER; OSCILLATIONS; HEPATOCYTES; RELEASE; INHIBITION; STORES	The thiol reagent, thimerosal, has been shown to cause an increase in intracellular Ca2+ concentration ([Ca2+]i) in several cell types, and to cause Ca2+ spikes in unfertilized hamster eggs. Using single cell video-imaging we have shown that thimerosal evokes repetitive Ca2+ spikes in intact Fura-2-loaded HeLa cells that were similar in shape to those stimulated by histamine. Both thimerosal- and histamine-stimulated Ca2+ spikes occurred in the absence of extracellular (Ca2+o), suggesting that they result from mobilization of Ca2+ from intracellular stores. Whereas histamine stimulated formation of inositol phosphates, thimerosal, at concentrations that caused sustained Ca2+ spiking, inhibited basal and histamine-stimulated formation of inositol phosphates. Thimerosal-evoked Ca2+ spikes are therefore not due to the stimulated production of inositol 1,4,5-trisphosphate (InsP3). The effects of thimerosal on Ca2+ spiking were probably due to alkylation of thiol groups on intracellular proteins because the spiking was reversed by the thiol-reducing compound dithiothreitol, and the latency between addition of thimerosal and a rise in [Ca2+]i was greatly shortened in cells where the intracellular reduced glutathione concentration had been decreased by preincubation with DL-buthionine (S,R)-sulfoximine. In permeabilized cells, thimerosal caused a concentration-dependent inhibition of Ca2+ accumulation, which was entirely due to inhibition of Ca2+ uptake into stores because thimerosal did not affect unidirectional Ca-45(2+) efflux from stores preloaded with Ca-45(2+). Thimerosal also caused a concentration-dependent sensitization of InSP3-induced Ca2+ mobilization: half-maximal mobilization of Ca2+ stores occurred with 161 +/- 20 nM InsP3 in control cells and with 62 +/- 5 nM InsP3 after treatment with 10 muM thimerosal. We conclude that thimerosal can mimic the effects of histamine on intracellular Ca2+ spiking without stimulating the formation of InsP3 and, in light of our results with permeabilized cells, suggest that thimerosal stimulates spiking by sensitizing cells to basal InsP3 levels.	DEPT ZOOL,AFRC,MOLEC SIGNALLING LAB,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND; DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019; Taylor, Colin/G-2447-2010	Bootman, Martin/0000-0002-6447-3451; Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLOMO G, 1983, FEBS LETT, V163, P136, DOI 10.1016/0014-5793(83)81180-6; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; CARROLL J, 1992, J BIOL CHEM, V267, P11196; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GUILLEMETTE G, 1988, MOL ENDOCRINOL, V2, P1249, DOI 10.1210/mend-2-12-1249; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JONES DP, 1983, J BIOL CHEM, V258, P6390; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PRUIJN FB, 1990, BIOCHEM PHARMACOL, V40, P1947, DOI 10.1016/0006-2952(90)90223-8; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RICE GC, 1986, CANCER RES, V46, P6105; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; STRAUSS WL, 1984, MEMBRANES DETERGENTS, P85; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	42	261	264	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25113	25119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334081				2022-12-27	WOS:A1992KB60300033
J	WESTON, BW; SMITH, PL; KELLY, RJ; LOWE, JB				WESTON, BW; SMITH, PL; KELLY, RJ; LOWE, JB			MOLECULAR-CLONING OF A 4TH MEMBER OF A HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE FAMILY - MULTIPLE HOMOLOGOUS SEQUENCES THAT DETERMINE EXPRESSION OF THE LEWIS-X, SIALYL LEWIS-X, AND DIFUCOSYL SIALYL LEWIS-X EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; D-GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; LEUKOCYTE ADHESION MOLECULE-1; BLOOD-GROUP ANTIGENS; GDP-L-FUCOSE; EMBRYONIC ANTIGEN; HUMAN ALPHA-3-FUCOSYLTRANSFERASES; CARBOHYDRATE LIGANDS; LEX DETERMINANT	We and others have previously described the isolation of three human alpha(1,3)fucosyltransferase genes which form the basis of a nascent glycosyltransferase gene family. We now report the molecular cloning and expression of a fourth homologous human alpha(1,3)fucosyltransferase gene. When transfected into mammalian cells, this fucosyltransferase gene is capable of directing expression of the Lewis x (Galbeta1-->4[Fucalpha1-->3] GlcNAc), sialyl Lewis x (NeuNAcalpha2-->3Galbeta1-->4 [Fucalpha1-->3]GlcNAc),and difucosyl sialyl Lewis x (NeuNAcalpha2-->3Galbeta1-->4[Fucalpha1-->3]GlcNAcbeta1-->3Galbeta1-->4[Fucalpha1-->3]GlcNAc) epitopes. The enzyme shares 85% amino acid sequence identity with Fuc-TIII and 89% identity with Fuc-TV but differs substantially in its acceptor substrate requirements. Polymerase chain reaction analyses demonstrate that the gene is syntenic to Fuc-TIII and Fuc-TV on chromosome 19. Southern blot analyses of human genomic DNA demonstrate that these four alpha(1,3)fucosyltransferase genes account for all DNA sequences that cross-hybridize at low stringency with the Fuc-TIII catalytic domain. Using similar methods, a catalytic domain probe from Fuc-TIV identifies a new class of DNA fragments which do not cross-hybridize with the chromosome 19 fucosyltransferase probes. These results extend the molecular definition of a family of human alpha(1,3)fucosyltransferase genes and provide tools for examining fucosyltransferase gene expression.	HOWARD HUGHES MED INST, DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL, MED SCI RES BLDG I,RM 3510, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan			/L-2667-2019		NIGMS NIH HHS [GM47455, GM14279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014279, R01GM047455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; COLLINS FS, 1987, SCIENCE, V235, P1046, DOI 10.1126/science.2950591; COUILLIN P, 1991, CYTOGENET CELL GENET, V56, P108, DOI 10.1159/000133061; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOX N, 1983, CANCER RES, V43, P669; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HOFF SD, 1990, ARCH SURG-CHICAGO, V125, P206; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KIM YS, 1988, CANCER RES, V48, P475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1993, IN PRESS HDB IMMUNOP; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maniatis T, 1989, MOL CLONING; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MOLLICONE R, 1988, BLOOD, V71, P1113; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; MUROI K, 1992, BLOOD, V79, P713; ORNTOFT TF, 1991, BLOOD, V77, P1389; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	74	313	339	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24575	24584						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1339443				2022-12-27	WOS:A1992KA26300065
J	GRINSTEIN, S; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; ROTIN, D				GRINSTEIN, S; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; ROTIN, D			ACTIVATION OF THE NA+/H+ ANTIPORTER DURING CELL-VOLUME REGULATION - EVIDENCE FOR A PHOSPHORYLATION-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; GROWTH-FACTORS; PH REGULATION; OKADAIC ACID; EXCHANGE; FIBROBLASTS	A variety of cell types regulate their volume in anisotonic media by stimulating Na+/H+ exchange. Like growth factors, osmotic challenge activates the Na+/H+ antiport by increasing its sensitivity to intracellular [H+]. To investigate the molecular mechanism underlying this shift in pH sensitivity, the antiporter of P-32-labeled human bladder carcinoma cells and of Chinese hamster ovary cells was immunoprecipitated using antibodies raised against the cytosolic domain of the NHE-1 isoform of the Na+/H+ exchanger. Unlike the effects of growth promoters, activation of the antiport during volume regulation was not associated with increased phosphorylation. The possible coexistence of multiple antiporter isoforms was considered. The cytosolic alkalosis normally elicited by hypertonic media was found to be absent in Na+/H+ exchange-deficient fibroblasts. Responsiveness to osmotic challenge was restored by stable transfection of these cells with the cDNA encoding NHE-1. In these transfectants, phosphorylation of the antiporter was also unaffected during osmotic activation. The unchanged phosphate content of the antiporter might be explained by dephosphorylation of one site with concomitant phosphorylation at a different site. However, this possibility appears unlikely since phosphoamino acid analysis revealed that serine was the only residue phosphorylated in immunoprecipitated antiports of both control and osmotically stimulated cells. Moreover, phosphopeptide maps of control and hypertonically activated antiports were identical. These findings reveal a novel mode of activation of Na+/H+ exchange not requiring direct phosphorylation of the antiporter. We propose the existence of dual control of Na+/H+ exchange by phosphorylation-dependent and -independent mechanisms.	UNIV NICE PARC VALROSE,CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CALA PM, 1980, J GEN PHYSIOL, V76, P683, DOI 10.1085/jgp.76.6.683; CASSEL D, 1986, J BIOL CHEM, V261, P5460; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; Hille B., 1992, IONIC CHANNELS EXCIT; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROTIN D, 1989, CANCER RES, V49, P205; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424	24	224	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23823	23828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331102				2022-12-27	WOS:A1992JZ23900060
J	BLANK, JL; BRATTAIN, KA; EXTON, JH				BLANK, JL; BRATTAIN, KA; EXTON, JH			ACTIVATION OF CYTOSOLIC PHOSPHOINOSITIDE PHOSPHOLIPASE-C BY G-PROTEIN BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; MUSCARINIC K+-CHANNEL; ALPHA-SUBUNITS; ADENYLYL CYCLASE; BOVINE BRAIN; IMMUNOLOGICAL IDENTIFICATION; AFFINITY-CHROMATOGRAPHY; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; PERTUSSIS TOXIN	Bovine liver cytosol contains a phosphoinositide phospholipase C (PLC(cyt)) that is activated by guanosine 5'-O-(3-thio)triphosphate (GTPgammaS)-activated G-proteins from liver plasma membranes. Heparin-Sepharose chromatography indicated that PLC(cyt) was immunologically distinct from PLC-beta1, PLC-gamma1, or PLC-delta1 from brain. Initial purification of the GTPgammaS-activated G-proteins that stimulated PLC(cyt) indicated that the betagamma complex was responsible. G-proteins were subsequently extracted from liver membranes as heterotrimers and purified in the presence of AlCl3, MgCl2, and NaF to allow reversible activation. Immunoblot analysis with an antiserum selective for the beta subunit showed that the stimulatory activity corresponded with the presence of this protein at every chromatographic step. When liver betagamma complex was purified and separated from all detectable alpha subunits, as shown by immunoblotting and silver staining, it strongly stimulated PLC(cyt) after removal of the activating ligand [AlF4]- by gel filtration. Betagamma prepared from brain was approximately equipotent with that from liver. Betagamma was half-maximally effective at 33 nM and produced a maximal 50-fold activation of the PLC. Under identical conditions, betagamma had no effect on brain PLC-gamma1 or PLC-delta1 and produced a 2-fold stimulation of PLC-beta1 activity. Addition of purified GDP-bound alpha(o) which had no effect by itself, completely reversed the betagamma activation of PLC(cyt), confirming that betagamma was the active species. These data provide evidence for a novel mechanism by which betagamma subunits of pertussis toxin-sensitive or -insensitive G-proteins activate phospholipase C.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURNE HR, 1987, NATURE, V325, P296, DOI 10.1038/325296a0; BOURNE HR, 1989, NATURE, V337, P504, DOI 10.1038/337504a0; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARDEN TK, 1990, AM REV RESPIR DIS, V141, pS119, DOI 10.1164/ajrccm/141.3_Pt_2.S119; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRIZ R, 1990, CIBA F SYMP, V150, P112; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PRICE SR, 1989, BIOCHEMISTRY-US, V28, P3803, DOI 10.1021/bi00435a027; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAW K, 1992, BIOCHEMISTRY-US, V31, P6347, DOI 10.1021/bi00142a026; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	65	171	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23069	23075						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331076				2022-12-27	WOS:A1992JY16300057
J	CLONEY, LP; BEKKAOUI, DR; WOOD, MG; HEMMINGSEN, SM				CLONEY, LP; BEKKAOUI, DR; WOOD, MG; HEMMINGSEN, SM			ASSESSMENT OF PLANT CHAPERONIN-60 GENE-FUNCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-BINDING-PROTEIN; GROEL PROTEIN; CYANOBACTERIAL	Brassica napus chaperonin-60alpha and chaperonin-60beta genes expressed separately and in combination produce three novel Escherichia coli strains: alpha, beta, and alphabeta. In beta and alphabeta cells, the plant gene products assemble efficiently into tetradecameric cpn60(14) species, including novel hybrids containing both bacterial and plant gene products. The levels of authentic groEL(14) are reduced in these cells (Cloney, L. P., Wu, H. B., and Hemmingsen, S. M. (1992) J. Biol. Chem. 267,23327-23332). The assembly of cyanobacterial ribulose-P2 carboxylase (rubisco) in E. coli requires the activities of the endogenous chaperonin proteins. Furthermore, the extent to which assembly occurs is limited by the normal levels of expression of the groE operon (Goloubinoff, P., Gatenby, A. A., and Lorimer, G. H. (1989) Nature 337, 44-47). We have now monitored the accumulation of cyanobacterial rubisco in E. coli alpha, beta, and alphabeta cells to assess the activity of the plant cpn60 gene products and effects on endogenous chaperonin functions. Expression of cpn-60alpha alone did not enhance rubisco assembly, which is consistent with our previous observation that p60cpn-60alpha required the presence of p60cpn-60beta for assembly into cpn60(14) species. In contrast, expression of cpn-60beta alone resulted in markedly enhanced rubisco assembly in cells that accumulated normal levels of both endogenous chaperonin polypeptides (groEL and groES). This demonstrates that assembled p60cpn-60beta is functional as a chaperonin in E. coli. Co-expression of cpn-60alpha and cpn-60beta in cells with normal levels of expression of groES and groEL suppressed rubisco assembly. Increased expression of groES in cells in which cpn-60alpha and cpn-60beta were co-expressed relieved this suppression and resulted in enhanced rubisco assembly. Implications with respect to dependence of chloroplast cpn60 function on cpn10 are discussed.	NATL RES COUNCIL CANADA,INST PLANT BIOTECHNOL,110 GYMNASIUM PL,SASKATOON S7N 0W9,SASKATCHEWAN,CANADA	National Research Council Canada								BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BRADLEY D, 1986, PHILOS T ROY SOC B, V313, P447, DOI 10.1098/rstb.1986.0051; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLONEY LP, 1992, J BIOL CHEM, V267, P23327; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; TSUPRUN VL, 1991, FEBS LETT, V289, P205, DOI 10.1016/0014-5793(91)81070-O; VANDERVIES SM, 1986, EMBO J, V5, P2439, DOI 10.1002/j.1460-2075.1986.tb04519.x; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	26	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23333	23336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358883				2022-12-27	WOS:A1992JY16300095
J	MIRAYLOPEZ, R; JARAMILLO, S; WAXMAN, S				MIRAYLOPEZ, R; JARAMILLO, S; WAXMAN, S			REDUNDANT REGULATION OF UROKINASE PLASMINOGEN-ACTIVATOR TRANSCRIPTION BY THE 2 MAJOR ISOZYMES OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; AMP RECEPTOR PROTEINS; CYCLIC-AMP; CATALYTIC SUBUNIT; RETINOIC ACID; ADENOSINE-MONOPHOSPHATE; SELECTIVE ACTIVATION; GENE-TRANSCRIPTION; MOLECULAR-CLONING; CARCINOMA-CELLS	The regulation of urokinase plasminogen activator (uPA) gene expression by the two major cAMP-dependent protein kinase isozymes was studied in SC115 mouse mammary carcinoma cells using the site-selective cAMP analog approach. SC115 cells expressed both type I and type II cAMP-dependent protein kinase holoenzyme (at a ratio of 2:3), and selective, partial activation of each holoenzyme could be demonstrated in vitro using appropriate combinations of cAMP analogs. When cells were exposed to the same analog combinations, uPA expression was upregulated 2- to 4-fold when either holoenzyme I or holoenzyme II was targeted. For comparison, a high concentration (1 mM) of 8-bromo-cAMP, an analog that does not discriminate between kinase isoforms, up-regulated uPA 10-fold. These findings suggest that there are two pathways of cAMP-dependent regulation of uPA, one mediated by holoenzyme I, the other by holoenzyme II, and that the end result of activation of each pathway is the same. Differences in the mechanism whereby each pathway regulates uPA were searched for but not found. Both pathways were shown to be dependent on catalytically active enzyme, to be potentiated by retinoic acid treatment, and to regulate uPA transcriptionally. The most likely interpretation of these findings is that uPA transcription is mediated solely by the action of the common catalytic subunit, regardless of whether it originated from holoenzyme I or holoenzyme II.			MIRAYLOPEZ, R (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,DIV MED ONCOL,BOX 1178,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R29CA054273, R01CA054273] Funding Source: NIH RePORTER; NCI NIH HHS [CA54273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BEEBE SJ, 1987, MOL ENDOCRINOL, V1, P639, DOI 10.1210/mend-1-9-639; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1989, JNCI-J NATL CANCER I, V81, P982, DOI 10.1093/jnci/81.13.982; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLLART MA, 1987, J IMMUNOL, V139, P949; CORBIN JD, 1982, EUR J BIOCHEM, V125, P259, DOI 10.1111/j.1432-1033.1982.tb06677.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; LIVESEY SA, 1985, CANCER RES, V45, P5734; LIVESEY SA, 1988, METHOD ENZYMOL, V159, P105; LU X, 1990, GENE, V86, P185, DOI 10.1016/0378-1119(90)90278-Y; Maniatis T, 1989, DECONTAMINATION DILU; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MIRAYLOPEZ R, 1991, J CELL PHYSIOL, V147, P46, DOI 10.1002/jcp.1041470107; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NG KW, 1983, CANCER RES, V43, P794; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; PLET A, 1982, J BIOL CHEM, V257, P889; ROGELJ S, 1984, EUR J BIOCHEM, V139, P351, DOI 10.1111/j.1432-1033.1984.tb08013.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TOURNIER S, 1991, J BIOL CHEM, V266, P19018; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WALTER U, 1977, J BIOL CHEM, V252, P6494; WU JC, 1989, J BIOL CHEM, V264, P9989; ZAJAC JD, 1986, ENDOCRINOLOGY, V118, P2059, DOI 10.1210/endo-118-5-2059	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23063	23068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331075				2022-12-27	WOS:A1992JY16300056
J	MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R				MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R			LUMINAL CA2+ CONTROLS THE ACTIVATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR BY CYTOSOLIC CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; ACINAR-CELLS; CA-2+ STORES; RAT; TRISPHOSPHATE; ENTRY; OSCILLATIONS; HEPATOCYTES; PHOSPHATES	Luminal Ca2+-controls the sensitivity of the intracellular Ca2+ stores to inositol 1,4,5-trisphosphate (Ins(1,4,5)P3). Ins(1,4 5)P3-induced Ca2+ release is also controlled by cytosolic Ca2+; low concentrations of Ca2+ stimulate the release. The aim of this work was to investigate whether luminal Ca2+ would affect the stimulation of the Ins(1,4,5)P3 receptor by cytosolic Ca2+ in permeabilized A7r5 smooth muscle cells. We also report that the Ins(1,4,5)P3, receptor in A7r5 cells is activated by low concentrations of cytosolic Ca2+. Cytoplasmic Ca2+ increases the Ins(1,4,5)P3 sensitivity without affecting the cooperativity. The increase in Ins(1,4,5)P3 sensitivity becomes relatively more pronounced when the Ca2+ content of the stores decreases. This modulatory effect of luminal Ca2+ on the responsiveness to cytosolic Ca2+ is an intrinsic property of the Ins(1,4 5)P3 receptor.			MISSIAEN, L (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CASTEELS R, 1981, PFLUG ARCH EUR J PHY, V392, P139, DOI 10.1007/BF00581262; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189	34	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22961	22966						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331072				2022-12-27	WOS:A1992JY16300041
J	KOCHHAR, S; CHUARD, N; HOTTINGER, H				KOCHHAR, S; CHUARD, N; HOTTINGER, H			GLUTAMATE 264 MODULATES THE PH-DEPENDENCE OF THE NAD+-DEPENDENT D-LACTATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; ESCHERICHIA-COLI; ACTIVE-SITE; CATALYSIS; FRAMEWORK; CLONING; GENE	Recently, we amplified the Lactobacillus bulgaricus NAD+-dependent D-lactate dehydrogenase gene by the polymerase chain reaction, cloned and overexpressed it in Escherichia coli (Kochhar, S., Chuard, N., and Hottinger, H. (1992) Biochem. Biophys. Res. Commun. 185, 705-712). Polymerase chain reaction-amplified DNA fragments may contain base changes resulting in mutant gene products. A comparison of specific activities of D-lactate dehydrogenase in the crude extracts of 50 recombinant clones indicated that one of the clones had drastically reduced enzyme activity. Nucleotide sequence analysis of the insert DNA showed an exchange of A to G at position 795 resulting in substitution of Glu264 to Gly in the D-lactate dehydrogenase. The purified mutant D-lactate dehydrogenase showed a shift of 2 units in its optimum pH toward the acidic range. The dependence of k(cat)/K(m) on the pH of the mutant enzyme showed that the pK(a) of the free enzyme was around 4, at least 2 pH units lower than that of the wild-type enzyme. Both the wild-type and the mutant enzyme at their respective optimum pH values showed similar k(cat) and K(m) values. The data suggest that the highly conserved Glu264 is not critical for enzyme catalysis, but it must be situated within hydrogen bonding distance to amino acid residue(s) involved in substrate binding as well as in catalysis.			KOCHHAR, S (corresponding author), NESTLE RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							BEAUMONT A, 1992, J BIOL CHEM, V267, P2138; BERNARD N, 1991, FEBS LETT, V290, P61, DOI 10.1016/0014-5793(91)81226-X; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P145, DOI 10.1016/0968-0004(89)90147-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CLARKE AR, 1988, BIOCHEMISTRY-US, V27, P1617, DOI 10.1021/bi00405a034; Fersht A., 1985, ENZYME STRUCTURE MEC; KOCHHAR S, 1992, BIOCHEM BIOPH RES CO, V185, P705, DOI 10.1016/0006-291X(92)91683-H; KOCHHAR S, 1992, J BIOL CHEM, V267, P8499; KOCHHAR S, 1992, BIOCHEM BIOPH RES CO, V184, P60, DOI 10.1016/0006-291X(92)91157-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	15	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20298	20301						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356978				2022-12-27	WOS:A1992JR85800087
J	MATTS, RL; XU, ZY; PAL, JK; CHEN, JJ				MATTS, RL; XU, ZY; PAL, JK; CHEN, JJ			INTERACTIONS OF THE HEME-REGULATED EIF-2-ALPHA KINASE WITH HEAT-SHOCK PROTEINS IN RABBIT RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; STEROID-RECEPTOR COMPLEXES; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; 59-KILODALTON PROTEIN; TISSUE DISTRIBUTION; HORMONE RECEPTORS; HELA-CELLS	Inhibition of protein synthesis in rabbit reticulocyte lysates occurs in response to a variety of conditions including heme deficiency, addition of oxidants, and heat stress. The inhibition of translation is due to the activation of a heme-regulated protein kinase (HRI) which specifically phosphorylates the alpha-subunit of the eukaryotic initiation factor eIF-2. In this report, immunoadsorption with monoclonal antibodies (mAbs) and Western blot analysis were used to investigate the interaction of HRI, the 90-kDa heat shock protein (hsp 90), hsp 70, and the EC1 antigen in rabbit reticulocyte lysates under protein synthesizing conditions. The data indicate that hsp 90, hsp 70, and the EC 1 antigen interact with HRI in rabbit reticulocyte lysate. The EC1 antigen is a protein that has been demonstrated to be associated with several steroid hormone receptor-hsp 90 complexes and reacts with the KN 382/EC1 mAb (EC1). The association of HRI with hsp 90 and the EC1 antigen in the reticulocyte lysate was found to be dependent on the presence of hemin at a concentration of 5-mu-M or higher; little HRI was coadsorbed by the 8D3 anti-hsp 90 mAb or the EC1 mAb in the absence of hemin. Hsp 70 remains associated with HRI in the absence of hemin, suggesting that hsp 90 and 70 may bind to HRI at different sites. The immunological properties of the hsp 70 associated with HRI indicate that it may be the constitutively express heat shock cognate protein (hsc 73). The results suggest that the association of HRI with hsp 90 and the EC1 antigen may be in a dynamic equilibrium, in which complex formation is either facilitated or stabilized by the presence of hemin, and supports the notion that these proteins in conjunction with hsp 70 may play a role in regulating HRI activity or activation in situ.	OKLAHOMA STATE UNIV,OKLAHOMA AGR EXPT STN,STILLWATER,OK 74078; MIT,HARVARD MIT DIV HLTH SCI,CAMBRIDGE,MA 02139	Oklahoma State University System; Oklahoma State University - Stillwater; Harvard University; Massachusetts Institute of Technology (MIT)	MATTS, RL (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM,454 PS 2,STILLWATER,OK 74078, USA.			Pal, Jayanta/0000-0003-1840-6458	NIDDK NIH HHS [R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES-04299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOND U, 1988, ADV GENET, V24, P1; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DENIS M, 1989, J BIOL CHEM, V264, P6005; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ERHART JC, 1988, ONCOGENE, V3, P595; ERNST V, 1978, J BIOL CHEM, V253, P7163; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; LANKS KW, 1986, EXP CELL RES, V165, P1, DOI 10.1016/0014-4827(86)90528-8; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Livingston D M, 1974, Methods Enzymol, V34, P723; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PAIN VM, 1983, BIOCHEMISTRY-US, V22, P726, DOI 10.1021/bi00273a003; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROSE DW, 1989, J BIOL CHEM, V264, P6239; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	65	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18160	18167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355482				2022-12-27	WOS:A1992JM22300104
J	AESCHLIMANN, D; PAULSSON, M; MANN, K				AESCHLIMANN, D; PAULSSON, M; MANN, K			IDENTIFICATION OF GLN(726) IN NIDOGEN AS THE AMINE ACCEPTOR IN TRANSGLUTAMINASE-CATALYZED CROSS-LINKING OF LAMININ-NIDOGEN COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FACTOR-XIIIA; YEAST PHOSPHOGLYCERATE KINASE; PIG LIVER TRANSGLUTAMINASE; BASEMENT-MEMBRANE PROTEIN; COAGULATION FACTOR-XIII; ACID-SEQUENCE; STRUCTURAL FEATURES; PROTEOLYTIC FRAGMENTS; GLUTAMINE RESIDUES; BINDING	The laminin-nidogen complex, the most abundant noncollagenous component of basement membranes, was recently shown to be a specific substrate for tissue transglutaminase (Aeschlimann, D., and Paulsson, M. (1991) J. Biol. Chem. 266, 15308-15317). Saturation experiments to determine the number of amine acceptor site(s) indicated a single reactive Gln residue in nidogen and none in laminin. Murine nidogen was labeled with [H-3]putrescine in the tissue transglutaminase-catalyzed reaction, and two major radioactively labeled fragments, T70 and T40, were isolated after limited trypsin digestion. NH2-terminal sequencing showed that T40 is contained in T70 and corresponds to the rodlike structure of nidogen, made up of epidermal growth factor-like repeats. Three radioactively labeled peptides, obtained by extensive trypsin digestion of reduced and alkylated T40, were sequenced. In all a single residue, Gln726, was found to contain label. Sequencing of additional peptides, obtained after further treatment of the largest radioactively labeled peptide with endoproteinase Asp-N, gave the same result. Gln726 is located in an exposed loop between the second and the third EGF-like repeat in nidogen. This site is also conserved in the human sequence.	MAX PLANCK INST BIOCHEM,DEPT CONNECT TISSUE RES,W-8033 MARTINSRIED,GERMANY	Max Planck Society	AESCHLIMANN, D (corresponding author), UNIV BERN,ME MULLER INST BIOMECH,POB 30,CH-3010 BERN,SWITZERLAND.		Mann, Karlheinz/C-4254-2008	Aeschlimann, Daniel/0000-0003-0930-7706				ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BIRCKBICHLER PJ, 1977, CANCER RES, V37, P1340; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CONNELLAN JM, 1971, J BIOL CHEM, V246, P1093; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; COUSSONS PJ, 1991, BIOCHEM J, V273, P73, DOI 10.1042/bj2730073; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FESUS L, 1986, EUR J BIOCHEM, V154, P371, DOI 10.1111/j.1432-1033.1986.tb09407.x; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1965, J BIOL CHEM, V240, P2951; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HOHL D, 1991, J BIOL CHEM, V266, P6626; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; NAGAYOSHI T, 1989, DNA-J MOLEC CELL BIO, V8, P581, DOI 10.1089/dna.1989.8.581; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1986, EUR J BIOCHEM, V156, P467, DOI 10.1111/j.1432-1033.1986.tb09605.x; PEREZPAYA E, 1991, FEBS LETT, V278, P51, DOI 10.1016/0014-5793(91)80081-D; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SIMON M, 1988, J BIOL CHEM, V263, P18093; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1983, EUR J BIOCHEM, V137, P455, DOI 10.1111/j.1432-1033.1983.tb07849.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; WILSON CAB, 1987, BIOCHEM J, V241, P609, DOI 10.1042/bj2410609; WU CY, 1991, J BIOL CHEM, V266, P18802	57	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11316	11321						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350783				2022-12-27	WOS:A1992HX16900060
J	REHABER, V; JAENICKE, R				REHABER, V; JAENICKE, R			STABILITY AND RECONSTITUTION OF D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM THE HYPERTHERMOPHILIC EUBACTERIUM THERMOTOGA-MARITIMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; AMINO-ACID-SEQUENCE; LACTIC-DEHYDROGENASE; PHYSICAL CONDITIONS; THERMAL-STABILITY; REACTIVATION; PROTEINS; DENATURATION; MECHANISM; DISSOCIATION	The molecular basis of thermal stability of globular proteins is a highly significant yet unsolved problem. The most promising approach to its solution is the investigation of the structure-function relationship of homologous enzymes from mesophilic and thermophilic sources. In this context, D-glyceraldehyde-3-phosphate dehydrogenase has been the most extensively studied model system. In the present study, the most thermostable homolog isolated so far is described with special emphasis on the stability of the enzyme under varying solvent conditions. D-Glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic eubacterium Thermotoga maritima is an intrinsically thermostable enzyme with a thermal transition temperature around 110-degrees-C. The amino acid sequence, electrophoresis, and sedimentation analysis prove the enzyme to be a homotetramer with a gross structure similar to its mesophilic counterparts. The enzyme in the absence and in the presence of its coenzyme, NAD+, exhibits no drastic structural differences except for a 3% change in sedimentation velocity reflecting slight alterations in the quaternary structure of the enzyme. At low temperature, in the absence of denaturants, neither "cold denaturation" nor subunit dissociation are detectable. Guanidinium chloride and pH-dependent deactivation precede the decrease in fluorescence emission and ellipticity, suggesting a complex denaturation mechanism. An up to 3-fold activation of the enzyme at low guanidinium concentration may be interpreted in terms of a compensation of the tight packing of the thermophilic enzyme at low temperature. Under destabilizing conditions, e.g. moderate concentrations of chaotropic agents, low temperature favors denaturation. The effect becomes important in reconstitution experiments after preceding guanidinium denaturation; the reactivation yield at low temperature drops to zero, whereas between 35 and 80-degrees-C reactivation exceeds 80%. Shifting the temperature from almost-equal-to 0-degrees-C to greater-than-or-equal-to 30-degrees-C releases a trapped tetrameric intermediate in a fast reaction. Concentration-dependent reactivation experiments prove renaturation of the enzyme to involve consecutive folding and association steps. Reconstitution at room temperature yields the native protein, in spite of the fact that the temperature of the processes in vitro and in vivo differ by more than 60-degrees-C.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,DEPT BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY	University of Regensburg								ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; BARTHOLMES P, 1978, EUR J BIOCHEM, V87, P563, DOI 10.1111/j.1432-1033.1978.tb12407.x; BARTHOLMES P, 1975, BIOCHEM BIOPH RES CO, V64, P485, DOI 10.1016/0006-291X(75)90347-2; CHAN WWC, 1973, J BIOL CHEM, V248, P2778; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; CONSTANTINIDES SM, 1970, J BIOL CHEM, V245, P246; DURCHSCHSLAG H, 1971, EUR J BIOCHEM, V19, P9, DOI 10.1111/j.1432-1033.1971.tb01282.x; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; HARRIS JI, 1976, ENZYMES, V13, P1; HARRIS JI, 1977, FEBS S, V49, P43; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HENSEL R, 1987, EUR J BIOCHEM, V170, P325, DOI 10.1111/j.1432-1033.1987.tb13703.x; HOCKING JD, 1980, EUR J BIOCHEM, V108, P567, DOI 10.1111/j.1432-1033.1980.tb04752.x; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JAENICKE R, 1969, EUR J BIOCHEM, V10, P158; JAENICKE R, 1981, ANNU REV BIOPHYS BIO, V10, P1, DOI 10.1146/annurev.bb.10.060181.000245; JAENICKE R, 1990, FEBS LETT, V268, P344, DOI 10.1016/0014-5793(90)81283-T; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1990, PHILOS T R SOC B, V326, P535, DOI 10.1098/rstb.1990.0030; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JAENICKE R, 1991, CIBA F SYMP, V161, P206; Jaenicke R, 1986, Methods Enzymol, V131, P218; JAENICKE R, 1980, P NATL ACAD SCI-BIOL, V77, P1966, DOI 10.1073/pnas.77.4.1966; JAENICKE R, 1990, PHIL T R SOC, V13, P326; JAENICKE R, 1992, IN PRESS ACS BIOCH; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KREBS H, 1979, EUR J BIOCHEM, V100, P359, DOI 10.1111/j.1432-1033.1979.tb04178.x; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; NOJIMA H, 1978, J MOL BIOL, V122, P33, DOI 10.1016/0022-2836(78)90106-7; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P193; RUDOLPH R, 1977, EUR J BIOCHEM, V81, P563, DOI 10.1111/j.1432-1033.1977.tb11983.x; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHULTES V, 1990, EUR J BIOCHEM, V192, P25, DOI 10.1111/j.1432-1033.1990.tb19190.x; STANCEL GM, 1969, BIOCHEMISTRY-US, V8, P4005, DOI 10.1021/bi00838a017; STANCEL GM, 1968, BIOCHEM BIOPH RES CO, V31, P398, DOI 10.1016/0006-291X(68)90489-0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; Von Hippel P. H., 1969, STRUCTURE STABILITY, P417; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; WRBA A, 1990, EUR J BIOCHEM, V188, P195, DOI 10.1111/j.1432-1033.1990.tb15388.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZAVODSZKY P, 1991, 15TH INT C BIOCH JER; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; ZETTLMEISSL G, 1982, EUR J BIOCHEM, V125, P605, DOI 10.1111/j.1432-1033.1982.tb06725.x	47	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10999	11006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1366231				2022-12-27	WOS:A1992HX16900014
J	DEGUCHI, Y; THEVENIN, C; KEHRL, JH				DEGUCHI, Y; THEVENIN, C; KEHRL, JH			STABLE EXPRESSION OF HB24, A DIVERGED HUMAN HOMEOBOX GENE, IN LYMPHOCYTES-T INDUCES GENES INVOLVED IN T-CELL ACTIVATION AND GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN GENE; LEUKEMIA-VIRUS; TRANSCRIPTION FACTOR; HOMEOTIC GENES; PROTO-ONCOGENE; BETA-ACTIN; B-CELLS; PROTEINS; DROSOPHILA; SEQUENCE	A diverged homeobox gene, HB24, which is known to be induced following lymphocyte activation, was introduced into Jurkat T cells under the control of a constitutive promoter. Stable transfectants of HB24 were established that expressed high levels of HB24 mRNA and possessed an altered phenotype suggestive of activated T cells. A number of genes known to be induced following T cell activation and associated with cell growth were increased in the transfectants, including c-fos, c-myc, c-myb, HLA-DR, lck, NF-kappa-B, interleukin-2 and interleukin-2 receptor-alpha (IL-2R-alpha). Analysis of IL-2R-alpha-expression by transient transfection of IL-2R-alpha-promoter constructs into the HB24 transfectants revealed constitutive expression (about 60% of phytohemagglutinin- and phorbol ester-activated Jurkat cells) that was dependent on the kappa-B site in the IL-2R-alpha-promoter. Furthermore, as a consequence of the increased HB24 mRNA levels, the Jurkat HB24 transfectants proliferated more rapidly than control cell lines. Thus, stable expression of HB24 confers an activation phenotype on a human T cell line, implicating this gene as an important transcriptional factor during T cell activation and growth.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURILLA AM, 1989, J EXP MED, V170, P105, DOI 10.1084/jem.170.1.105; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEGUCHI Y, 1991, NEW BIOL, V3, P353; DEGUCHI Y, 1991, BLOOD, V78, P323; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DORSETT DL, 1983, J VIROL, V48, P218, DOI 10.1128/JVI.48.1.218-228.1983; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; Favaloro J, 1980, Methods Enzymol, V65, P718; FREEDMAN AS, 1987, LEUKEMIA, V1, P9; FU SM, 1978, J EXP MED, V148, P1423, DOI 10.1084/jem.148.5.1423; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PASCO DS, 1988, J BIOL CHEM, V263, P8671; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	53	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8222	8229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349016				2022-12-27	WOS:A1992HQ18500041
J	WOLOSKER, H; PACHECO, AGF; DEMEIS, L				WOLOSKER, H; PACHECO, AGF; DEMEIS, L			LOCAL-ANESTHETICS INDUCE FAST CA2+ EFFLUX THROUGH A NONENERGIZED STATE OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED CA-2+ RELEASE; INDUCED CALCIUM RELEASE; SYNAPTOSOMAL PLASMA-MEMBRANE; RABBIT SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SOLVENT ACCESSIBILITY; INORGANIC-PHOSPHATE; CATALYTIC SITE; ATP SYNTHESIS; VESICLES	The effect of the local anesthetics SKF 525-A, dibucaine, tetracaine, procaine, and benzocaine on sarcoplasmic reticulum vesicles was studied. All the anesthetics tested inhibited the phosphorylation of the Ca2+-ATPase by P(i) in a competitive manner. Tertiary amine and positively charged anesthetics, in addition to competing with P(i), also decreased the apparent affinity of the ATPase for Mg2+. There was a good correlation between the octanol/water partition coefficients and the inhibitory activity of the different anesthetics. All the anesthetics tested induced a 5- to 10-fold increase in the rate of Ca2+ efflux. This was promoted by the same drug concentration that inhibited the phosphorylation of the ATPase by P(i). The effect on Ca2+ efflux was antagonized by the ligands of the ATPase (Mg2+, K+, Ca2+, MgATP, and ADP) and by the organic polyamines ruthenium red, spermine, spermidine, and putrescine. The natural anion heparin was found to potentiate the effect of the positively charged anesthetics on the rate of Ca2+ efflux. It is concluded that the local anesthetics increase the Ca2+ efflux through a nonenergized state of the Ca2+-ATPase, rather than promoting a nonspecific Ca2+ leakage through the membrane.			WOLOSKER, H (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, BR-21910 RIO DE JANEIRO, BRAZIL.		Pacheco, Antonio Guilherme/E-6378-2013	Pacheco, Antonio Guilherme/0000-0003-3095-1774; Wolosker, Herman/0000-0001-5508-9194				ALVES EW, 1986, J BIOL CHEM, V261, P6854; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; COURTNEY KR, 1980, J PHARMACOL EXP THER, V213, P114; DEBOLAND AR, 1975, J BIOL CHEM, V250, P7501; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1984, J BIOL CHEM, V259, P6090; DEMEIS L, 1982, J BIOL CHEM, V257, P4993; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1988, EUR J BIOCHEM, V171, P343; DEMEIS L, 1991, EUR J BIOCHEM, V200, P209; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P334; FROUD RJ, 1986, BIOCHEM J, V237, P207, DOI 10.1042/bj2370207; GARCIAMARTIN E, 1990, J NEUROCHEM, V55, P370, DOI 10.1111/j.1471-4159.1990.tb04147.x; GARCIAMARTIN E, 1990, J NEUROCHEM, V54, P1238, DOI 10.1111/j.1471-4159.1990.tb01954.x; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P180, DOI 10.1016/0005-2736(83)90116-5; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUTIERREZMERINO C, 1989, BIOCHEMISTRY-US, V28, P3398, DOI 10.1021/bi00434a039; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KAMINSKA AM, 1982, EXP NEUROL, V78, P331, DOI 10.1016/0014-4886(82)90051-6; KIRINO Y, 1982, J BIOCHEM-TOKYO, V92, P1287, DOI 10.1093/oxfordjournals.jbchem.a134047; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KUREBAYASHI N, 1982, J BIOCHEM-TOKYO, V92, P915, DOI 10.1093/oxfordjournals.jbchem.a134006; KURTENBACH E, 1985, J BIOL CHEM, V260, P9636; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACWHIRTER JM, 1987, BIOCHEM J, V245, P731; MARTIN DW, 1981, BIOCHEMISTRY-US, V20, P4597, DOI 10.1021/bi00519a013; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MELTZER S, 1984, J BIOL CHEM, V259, P4244; MORII H, 1983, J BIOCHEM-TOKYO, V93, P1271, DOI 10.1093/oxfordjournals.jbchem.a134261; NAGASAKI K, 1981, J BIOCHEM-TOKYO, V90, P749, DOI 10.1093/oxfordjournals.jbchem.a133529; NASHADLER P, 1980, MOL PHARMACOL, V17, P61; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; ORENTLICHER M, 1974, J GEN PHYSIOL, V63, P168, DOI 10.1085/jgp.63.2.168; PALADE P, 1987, J BIOL CHEM, V262, P6142; PALADE P, 1987, J BIOL CHEM, V262, P6149; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; PICK U, 1983, EUR J BIOCHEM, V131, P393, DOI 10.1111/j.1432-1033.1983.tb07276.x; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SUKO J, 1976, BIOCHIM BIOPHYS ACTA, V443, P571, DOI 10.1016/0005-2736(76)90474-0; VOLPE P, 1983, J BIOL CHEM, V258, P2434; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762	61	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5785	5789						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372893				2022-12-27	WOS:A1992HK31800013
J	MAUVIEL, A; KAHARI, VM; EVANS, CH; UITTO, J				MAUVIEL, A; KAHARI, VM; EVANS, CH; UITTO, J			TRANSCRIPTIONAL ACTIVATION OF FIBROBLAST COLLAGENASE GENE-EXPRESSION BY A NOVEL LYMPHOKINE, LEUKOREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; C-JUN; GLUCOCORTICOID RECEPTOR; SYNOVIAL FIBROBLASTS; TISSUE INHIBITOR; PROTEIN; DNA; PROCOLLAGENASE; INTERLEUKIN-1	Leukoregulin (LR) is a novel T-cell derived cytokine with unique anti-tumor properties. We have recently demonstrated that LR is also able to modulate the biosynthetic repertoire of normal human skin fibroblasts in culture (Mauviel, A., Redini, F., Hartmann, D. J., Pujol, J.-P., and Evans, C. H. (1991) J. Cell Biol. 113, 1455-1462). In this study, we have examined in detail the effects of LR on collagenase gene expression in human skin fibroblast cultures. The results indicated time- and dose-dependent induction of collagenase mRNA steady-state levels, the maximum elevation being approximately 35-fold. In contrast, the mRNA levels for tissue inhibitor of metalloproteases remained unchanged in the same RNA preparations. The enhancement of collagenase mRNA levels was shown to be dependent on protein synthesis, and it could be counteracted by dexamethasone or all-trans-retinoic acid. Transient transfections of cultured fibroblasts with a human collagenase promoter/reporter gene construct indicated up-regulation of the promoter activity, which could be blocked by dexamethasone and all-trans-retinoic acid. The observation suggested regulation at the transcriptional level of collagenase gene expression. LR was also shown to induce the mRNA levels for junB, suggesting possible involvement of the AP-1 complex in the regulation. The ability of LR to selectively induce collagenase gene expression in skin fibroblasts suggests that this cytokine may significantly contribute to the degradation of the extracellular matrix in physiological situations, such as tissue development and repair, and in diseases characterized by excessive degradation and turnover of collagen.	NCI,DIV CANC ETIOL,BIOL LAB,TUMOR BIOL SECT,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University			MAUVIEL, Alain/F-6251-2013; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368; Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R01-AR35297, T32-AR-0751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035297] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNETT SC, 1986, CANCER RES, V46, P2686; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHUA CC, 1990, CONNECT TISSUE RES, V25, P161, DOI 10.3109/03008209009006990; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; EVANS CH, 1987, LYMPHOKINE RES, V6, P277; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; EVANS CH, 1987, LEUKOLYSINS CANCER, P3; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRIS ED, 1989, COLLAGEN REL RES, V6, P493; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURPHY G, 1985, J BIOL CHEM, V260, P3079; NAGASE H, 1983, BIOCHEM J, V214, P281, DOI 10.1042/bj2140281; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; RANSOM JH, 1985, CANCER RES, V45, P851; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5644	5648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372007				2022-12-27	WOS:A1992HH74700096
J	BEAVIS, AD; VERCESI, AE				BEAVIS, AD; VERCESI, AE			ANION UNIPORT IN PLANT-MITOCHONDRIA IS MEDIATED BY A MG2+-INSENSITIVE INNER MEMBRANE ANION CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORN MITOCHONDRIA; LIGHT-SCATTERING; TRANSPORT; INHIBITION; PROTONS; MATRIX; OXALOACETATE; CONTRACTION; CATIONS	It has long been established that the inner membrane of plant mitochondria is permeable to Cl-. Evidence has also accumulated which suggests that a number of other anions such as P(i) and dicarboxylates can also be transported electrophoretically. In this paper, we present evidence that anion uniport in plant mitochondria is mediated via a pH-regulated channel related to the so-called inner membrane anion channel (IMAC) of animal mitochondria. Like IMAC, the channel in potato mitochondria transports a wide variety of anions including NO3-, Cl-, ferrocyanide, 1,2,3-benzene-tricarboxylate, malonate, P(i), alpha-ketoglutarate, malate, adipate, and glucuronate. In the presence of nigericin, anion uniport is sensitive to the medium pH (pIC50 = 7.60, Hill coefficient = 2). In the absence of nigericin, transport rates are much lower and much less sensitive to pH, suggesting that matrix H+ inhibit anion uniport. This conclusion is supported by measurements of H+ flux which reveal that ''activation'' of anion transport at high pH by nigericin and at low pH by respiration is associated with an efflux of matrix H+. Other inhibitors of IMAC which are found to block anion uniport in potato mitochondria include propranolol (IC50 = 14-mu-M, Hill coefficient = 1.28), tributyltin (IC50 = 4 nmol/mg, Hill coefficient = 2.0), and the nucleotide analogs Erythrosin B and Cibacron Blue 3GA. The channel in plant mitochondria differs from IMAC in that it is not inhibited by matrix Mg2+, mercurials, or N,N'-dicyclohexylcarbodiimide. The lack of inhibition by Mg2+ suggests that the physiological regulation of the plant channel may differ from IMAC and that the plant IMAC may have functions such as a role in the malate/oxaloacetate shuttle in addition to its proposed role in volume homeostasis.	MED COLL OHIO,DEPT PHARMACOL,POB 10008,TOLEDO,OH 43699; UNIV ESTADUAL CAMPINAS,DEPT BIOCHEM,BR-13100 CAMPINAS,SP,BRAZIL	Universidade Estadual de Campinas			Vercesi, Aníbal E/C-8767-2012	Vercesi, Anibal Eugenio/0000-0001-6671-7125	NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V135, P444, DOI 10.1016/0005-2736(67)90033-8; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1990, J BIOL CHEM, V265, P2538; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V4003, P111; BONNER WD, 1967, METHOD ENZYMOL, V10, P126; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P697, DOI 10.1021/bi00806a001; DAY DA, 1984, PHYSIOL VEG, V22, P241; Day DA, 1977, PLANT SCI LETT, V11, P399; DIOLEZ P, 1983, PHYSIOL PLANTARUM, V59, P177, DOI 10.1111/j.1399-3054.1983.tb00754.x; DOUCE R, 1972, BIOCHEM BIOPH RES CO, V47, P619, DOI 10.1016/0006-291X(72)90923-0; DOUCE R, 1972, BIOCHIM BIOPHYS ACTA, V275, P148, DOI 10.1016/0005-2728(72)90035-7; EBBIGHAUSEN H, 1985, BIOCHIM BIOPHYS ACTA, V810, P184, DOI 10.1016/0005-2728(85)90134-3; GARLID KD, 1985, J BIOL CHEM, V260, P3434; HANSON JB, 1975, ION TRANSPORT PLANT, P79; HANSON JB, 1985, ENCY PLANT PHYSL, V18, P248; HENSLEY JR, 1975, PLANT PHYSIOL, V56, P13, DOI 10.1104/pp.56.1.13; HUER SC, 1979, PLANT PHYSIOL, V64, P115; JUNG DW, 1973, ARCH BIOCHEM BIOPHYS, V158, P139, DOI 10.1016/0003-9861(73)90606-1; KIRK BI, 1973, PLANT PHYSIOL, V51, P357, DOI 10.1104/pp.51.2.357; KROMER S, 1991, BIOCHIM BIOPHYS ACTA, V1057, P42, DOI 10.1016/S0005-2728(05)80082-9; LATIES GG, 1973, BIOCHEMISTRY-US, V12, P3350, DOI 10.1021/bi00741a032; LORIMER GH, 1969, PLANT PHYSIOL, V44, P839, DOI 10.1104/pp.44.6.839; MOORE AL, 1977, J EXP BOT, V28, P607, DOI 10.1093/jxb/28.3.607; MOORE AL, 1978, J EXP BOT, V29, P1, DOI 10.1093/jxb/29.1.1-a; MULLER RJ, 1970, PLANT PHYSIOL, V46, P471; MURRAY AG, 1988, EBEC REP, V5, P206; NELSON RH, 1972, PLANT CELL PHYSL, V13, P1103; NEUBURGER M, 1985, ENCY PLANT PHYSL, V18, P7; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; POWERS M F, 1991, Biophysical Journal, V59, p596A; POWERS MF, 1990, BIOPHYS J, V57, pA179; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RAISON JK, 1973, BIOENERGETICS, V4, P409; SELWYN MJ, 1976, ORGANOTIN COMPOUNDS, P204; STONER CD, 1966, PLANT PHYSIOL, V41, P255, DOI 10.1104/pp.41.2.255; STONER CD, 1964, NATURE, V203, P258, DOI 10.1038/203258a0; TEDESCHI H, 1959, J BIOPHYS BIOCHEM CY, V6, P241, DOI 10.1083/jcb.6.2.241; WARHURST IW, 1982, FEBS LETT, V149, P249, DOI 10.1016/0014-5793(82)81110-1; WISKICH JT, 1977, ANNU REV PLANT PHYS, V28, P45, DOI 10.1146/annurev.pp.28.060177.000401; YOSHIDA K, 1968, Journal of the Faculty of Science University of Tokyo Section III Botany, V10, P49; YOSHIDA K, 1968, Journal of the Faculty of Science University of Tokyo Section III Botany, V10, P63; ZOGLOWEK C, 1988, PLANT PHYSIOL, V87, P109, DOI 10.1104/pp.87.1.109	50	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3079	3087						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371111				2022-12-27	WOS:A1992HD15400042
J	PARK, ST; ALDAPE, RA; FUTER, O; DECENZO, MT; LIVINGSTON, DJ				PARK, ST; ALDAPE, RA; FUTER, O; DECENZO, MT; LIVINGSTON, DJ			PPIASE CATALYSIS BY HUMAN FK506-BINDING PROTEIN PROCEEDS THROUGH A CONFORMATIONAL TWIST MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; CYTOSOLIC-BINDING-PROTEIN; OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; PEPTIDYL-PROLYL ISOMERASE; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; IMMUNOSUPPRESSANT FK506; PHENOTYPIC SELECTION; CYCLOSPORIN-A; CYCLOPHILIN	FK506-binding protein (FKBP) catalyzes the cis-trans isomerization of the peptidyl-prolyl amide bond (the PPIase reaction) and is the major intracellular receptor for the immunosuppressive drugs FK506 and rapamycin. One mechanism proposed for catalysis of the PPIase reaction requires attack of an enzyme nucleophile on the carbonyl carbon of the isomerized peptide bond. An alternative mechanism requires conformational distortion of the peptide bond with or without assistance by an enzyme hydrogen bond donor. We have determined the kinetic parameters of the human FKBP-catalyzed PPIase reaction. At 5-degrees-C, the isomerization of Suc-Ala-Leu-Pro-Phe-pNA proceeds in 2.5% trifluorethanol with k(cat) = 600 s-1, K(m) = 0.5 mM and k(cat)/K(m) = 1.2 x 10(6) m-1 s-1. The k(cat)/K(m) shows little pH dependence between 5 and 10. A normal secondary deuterium isotope effect is observed on both k(cat) and k(cat)/K(m). To investigate dependence on enzyme nucleophiles and proton donors, we have replaced eight potential catalytic residues with alanine by site-directed mutagenesis. Each FKBP variant efficiently catalyzes the PPIase reaction. Taken together, these data support an unassisted conformational twist mechanism with rate enhancement due in part to desolvation of the peptide bond at the active site. Fluorescence quenching of the buried tryptophan 59 residue by peptide substrate suggests that isomerization occurs in a hydrophobic environment.	VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BUELL G, 1985, NUCLEIC ACIDS RES, V13, P1923, DOI 10.1093/nar/13.6.1923; DRAKENBERG T, 1972, J PHYS CHEM-US, V76, P2178, DOI 10.1021/j100659a020; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GALARDY RE, 1982, INT J PEPT PROT RES, V19, P123; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1988, TRANSPLANTATION, V46, pS29; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, J AM CHEM SOC, V112, P7063, DOI 10.1021/ja00175a052; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; ISERENTANT D, 1980, GENE, V9, P1, DOI 10.1016/0378-1119(80)90163-8; KAY JE, 1989, IMMUNOLOGY, V67, P473; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MATSUKI S, 1990, BIOTECHNOL APPL BIOC, V12, P284; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; REITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52; YOSHIMURA N, 1989, TRANSPLANTATION, V47, P356, DOI 10.1097/00007890-198902000-00035; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	52	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3316	3324						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371117				2022-12-27	WOS:A1992HD15400079
J	WIELAND, HA; LUDDENS, H; SEEBURG, PH				WIELAND, HA; LUDDENS, H; SEEBURG, PH			A SINGLE HISTIDINE IN GABA-A RECEPTORS IS ESSENTIAL FOR BENZODIAZEPINE AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINOBUTYRIC ACIDA RECEPTOR; INVERSE AGONIST; SITE; SUBUNIT; PHARMACOLOGY; ANTAGONIST; CELLS; RAT; DNA	Benzodiazepines (BZ) modulate neurotransmitter-evoked chloride currents at the gamma-aminobutyric acid type A (GABA(A)) receptor, the major inhibitory ion channel in the mammalian brain. This receptor is composed of structurally distinct subunits whose numerous molecular variants underlie the observed diversity in the properties of the BZ site. Pharmacologically distinct BZ sites can be recreated by the recombinant coexpression of any one of six a subunits, a beta-subunit variant, and the gamma-2 subunit. In these receptors the a variant determines the affinity for ligand binding of the BZ site. Notably, the alpha-1 and alpha-6-variants impart on alpha(x)beta-2-gamma-2 receptors high and negligible affinity, respectively, to BZ ligands with sedative as well as anxiolytic activities. By exchanging domains between the alpha-1 and alpha-6 variants, we show that a portion of the large extracellular domain determines sensitivity toward these ligands. Furthermore, we identify a single histidine residue in the alpha-1 variant, replaced by an arginine in alpha-6, as a major determinant for high affinity binding of BZ agonists. This residue also plays a role in determining high affinity binding for BZ antagonists. Hence, this histidine present in the alpha-1, alpha-2, alpha-3, and alpha-5-subunits appears to be a key residue for the action of clinically used BZ ligands.	UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,INF 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ALLEN MS, 1990, J MED CHEM, V33, P2343, DOI 10.1021/jm00171a007; ARBILLA S, 1985, N-S ARCH PHARMACOL, V330, P248, DOI 10.1007/BF00572441; BENKE D, 1991, J BIOL CHEM, V266, P4478; BURCH TP, 1981, P NATL ACAD SCI-BIOL, V78, P3945, DOI 10.1073/pnas.78.6.3945; CHANGEUX JP, 1987, TRENDS NEUROSCI, V10, P245, DOI 10.1016/0166-2236(87)90167-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; Costa E, 1988, Adv Biochem Psychopharmacol, V45, P367; DIAZARAUZO H, 1991, LIFE SCI, V49, P207, DOI 10.1016/0024-3205(91)90005-V; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAEFELY W, 1990, TRENDS PHARMACOL SCI, V11, P452, DOI 10.1016/0165-6147(90)90126-S; HAEFELY W, 1981, HDB EXPT PHARMACOLOG, V55, P13; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; IZQUIERDO I, 1989, TRENDS PHARMACOL SCI, V10, P473, DOI 10.1016/0165-6147(89)90040-0; KAO PN, 1986, J BIOL CHEM, V261, P8085; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; LAMBOLEZ B, 1989, NEUROCHEM INT, V15, P145, DOI 10.1016/0197-0186(89)90093-4; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MAKSAY G, 1991, MOL PHARMACOL, V39, P725; MATSUMOTO RR, 1989, BRAIN RES REV, V14, P203, DOI 10.1016/0165-0173(89)90001-5; MOHLER H, 1984, EUR J PHARMACOL, V102, P191, DOI 10.1016/0014-2999(84)90358-3; NIELSEN M, 1980, NATURE, V286, P606, DOI 10.1038/286606a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1986, RECEPTOR BIOCH METHO, V5, P1; PAUL SM, 1982, PHARMACOL BIOCHEM BE, V17, P37, DOI 10.1016/0091-3057(82)90508-1; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1990, COLD SPRING HARB SYM, V55, P651; SNODGRASS S R, 1990, FASEB Journal, V4, P2775; SQUIRES RF, 1979, PHARMACOL BIOCHEM BE, V10, P825, DOI 10.1016/0091-3057(79)90341-1; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1990, BIOCHEM J, V264, P199; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; VILLAR HO, 1991, LIFE SCI, V48, P593, DOI 10.1016/0024-3205(91)90533-H	40	383	388	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1426	1429						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346133				2022-12-27	WOS:A1992HA48500007
J	XU, RX; ANTHOLINE, WE; PETERING, DH				XU, RX; ANTHOLINE, WE; PETERING, DH			REACTION OF DNA-BOUND CO(II)BLEOMYCIN WITH DIOXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND SCISSION; BLEOMYCIN; OXYGEN; ORIENTATION; SYSTEM; IRON; INTERMEDIATE; RESONANCE; COMPLEX; BINDING	The aerobic oxidation of Co(II)bleomycin bound to calf thymus DNA has been investigated in relation to the mechanism of reaction in solution in the absence of DNA. Kinetics of dioxygenation of the Co(II) complex were followed by spectrophotometric and electron spin resonance spectroscopy as well as dioxygen analysis. The reaction is slower than when carried out in solution; its rate is inversely related to the ratio of DNA base pairs to Co(II)bleomycin. The subsequent oxidation reaction, observed spectrophotometrically and by dioxygen analysis, is second order in cobalt complex. The calculated second order rate constant is also inversely related to the base pair to metal complex ratio. Once this ratio exceeds three, the reaction rate slows significantly with each additional increment of DNA added to the starting reaction mixture. Taking advantage of the high stability of O2-Co(II)bleomycin bound to greater than a 3-fold excess of DNA base pairs, it could be demonstrated that the rate constant for oxidation Of two O2-Co(II)bleomycin molecules is much slower than that for O2-Co(II)bleomycin plus Co(II)bleomycin. With the same technique it was observed that the metal centers of O2-Co(II)bleomycin and Fe(II)bleomycin also undergo oxidation. The binding to DNA of both solution products of the oxidation of Co(II)bleomycin by O2 was examined by H-1 NMR spectroscopy. Peroxy-Co(III)bleomycin, Form I, binds with higher affinity than Co(III)bleomycin, Form II. At lower ionic strength, the size of the DNA binding site for each form is about 2 base pairs/molecule of drug.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201; MED COLL WISCONSIN,NATL BIOMED ESR CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT RADIOL,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Milwaukee; Medical College of Wisconsin; Medical College of Wisconsin					NCI NIH HHS [CA-22184] Funding Source: Medline; NCRR NIH HHS [RR-01008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTINI JP, 1982, BIOCHEMISTRY-US, V21, P6777, DOI 10.1021/bi00269a025; ALBERTINI JP, 1982, BIOCHEM BIOPH RES CO, V104, P557, DOI 10.1016/0006-291X(82)90673-8; ANTHOLINE WE, 1981, P NATL ACAD SCI-BIOL, V78, P7517, DOI 10.1073/pnas.78.12.7517; ANTHOLINE WE, 1979, BIOCHEM BIOPH RES CO, V91, P528, DOI 10.1016/0006-291X(79)91554-7; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1979, J BIOL CHEM, V254, P906; BURGER RM, 1982, J BIOL CHEM, V257, P8612; BYRNES RW, 1990, CANCER RES, V50, P5275; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; CHIKIRA M, 1989, J BIOL CHEM, V264, P21478; CHIKIRA M, 1991, J BIOL CHEM, V266, P2859; CIROLO MR, 1987, J BIOL CHEM, V262, P6290; GARNIERSUILLEROT A, 1981, BIOCHEM BIOPH RES CO, V102, P499, DOI 10.1016/0006-291X(81)91547-3; KAKINUMA J, 1982, NUKLEARMED, V21, P232, DOI 10.1055/s-0037-1620585; KURAMOCHI H, 1981, J ANTIBIOT, V34, P576, DOI 10.7164/antibiotics.34.576; LEVY MJ, 1988, BIOCHEMISTRY-US, V27, P2647, DOI 10.1021/bi00408a002; NATRAJAN A, 1990, J AM CHEM SOC, V112, P3997, DOI 10.1021/ja00166a042; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; ROY SN, 1984, CANCER RES, V44, P1541; SHIELDS H, 1982, BIOCHIM BIOPHYS ACTA, V697, P113, DOI 10.1016/0167-4781(82)90051-3; SHIELDS H, 1984, BIOCHIM BIOPHYS ACTA, V800, P277, DOI 10.1016/0304-4165(84)90406-9; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIURA Y, 1980, J AM CHEM SOC, V102, P5216, DOI 10.1021/ja00536a016; SUGIURA Y, 1978, J ANTIBIOT, V31, P1310, DOI 10.7164/antibiotics.31.1310; XU RX, 1992, J BIOL CHEM, V267, P944	26	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					950	955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370471				2022-12-27	WOS:A1992GY96000044
J	WU, J; FILER, D; FRIEDHOFF, AJ; GOLDSTEIN, M				WU, J; FILER, D; FRIEDHOFF, AJ; GOLDSTEIN, M			SITE-DIRECTED MUTAGENESIS OF TYROSINE-HYDROXYLASE - ROLE OF SERINE-40 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; N-TERMINAL REGION; CELL-LINE; PHOSPHORYLATION; PURIFICATION	We have investigated the role of serine 40 (Ser-40) in tyrosine hydroxylase (TH) catalysis of basal and activated enzymes by protein kinase A (PKA)-mediated phosphorylation. Wild type and mutant TH were transiently and stably expressed in AtT-20 cells, and the enzymatic activities of the recombinant enzymes were analyzed. The specific enzymatic activity of transiently expressed TH mutants Ser-40-->leucine or --> tyrosine (Leu-40m or Tyr-40m) was higher than that of the wild type enzyme or of other mutants in which Ser-8, -19, and -31 were replaced by leucine. The kinetic studies carried out with the stably expressed TH show that the K(m) for the cofactor 6-methyltetrahydropterine is lower and the K(i) for dopamine is higher when the enzymatic hydroxylation is catalyzed by the Leu-40m or Tyr-40m than by the wild type enzyme. The kinetic parameters and the pH profile of the enzymatic hydroxylation catalyzed by the Leu-40m or Tyr-40m are similar to the enzyme activated by PKA-mediated phosphorylation. We suggest that Ser-40 in TH exerts an inhibitory influence on the enzymatic activity, and its replacement with another amino acid by site-directed mutagenesis or its modification by phosphorylation leads to a change in conformation with an increased enzymatic activity. The importance of Ser-40 in the activation of TH by PKA-mediated phosphorylation was investigated by comparing the activation of the wild type enzyme with that of Leu-40m or Tyr-40m. The findings that the enzymatic activity is increased by PKA-mediated phosphorylation of the wild type enzyme, but not of the Leu-40m or Tyr-40m, demonstrate that phosphorylation at Ser40 is essential for activation of TH by PKA. The findings that addition of ATP plus cAMP to homogenates from transfected AtT-20 cells stimulates the recombinant wild type TH activity indicate that these cells contain endogenous cAMP-dependent protein kinase.	NYU MED CTR,DEPT PSYCHIAT,MILLHAUSER LABS,NEW YORK,NY 10016; NYU MED CTR,NEUROCHEM RES LABS,NEW YORK,NY 10016	New York University; New York University	GOLDSTEIN, M (corresponding author), NYU MED CTR,DEPT PSYCHIAT,MILLHAUSER LABS,NEW YORK,NY 10016, USA.				NIMH NIH HHS [MH-43230, MH 35976] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH035976, P01MH043230] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABATE C, 1991, J MOL NEUROSCI, V2, P203; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; ANAGNOSTE B, 1974, J PHARMACOL EXP THER, V101, P370; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; DIXON M, 1964, ENZYMES, P65; GOLDSTEIN M, 1977, PSYCHOPHARMACOLOGY 3, P75; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUIDOTTI A, 1977, BIOCHEM PHARMACOL, V26, P817, DOI 10.1016/0006-2952(77)90393-8; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IWAKI M, 1986, J BIOL CHEM, V261, P2051; LEE KY, 1989, J NEUROCHEM, V53, P1238, DOI 10.1111/j.1471-4159.1989.tb07420.x; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; MITCHELL JP, 1990, J BIOL CHEM, V265, P22358; NAGATSU T, 1964, ANAL BIOCHEM, V9, P122, DOI 10.1016/0003-2697(64)90092-2; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; THOENEN H, 1974, HDB PSYCHOPHARMACOLO, V5, P443; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	23	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25754	25758						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361189				2022-12-27	WOS:A1992KD07300028
J	COHEN, D; HIGMAN, SM; HSU, SIH; HORWITZ, SB				COHEN, D; HIGMAN, SM; HSU, SIH; HORWITZ, SB			THE INVOLVEMENT OF A LINE-1 ELEMENT IN A DNA REARRANGEMENT UPSTREAM OF THE MDR1A GENE IN A TAXOL MULTIDRUG-RESISTANT MURINE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSPOSABLE ELEMENT; P-GLYCOPROTEIN PRECURSORS; J774.2 CELLS; MOUSE CELLS; AMPLIFICATION; SEQUENCES; FAMILY; LOCALIZATION; MEMBERS; OVEREXPRESSION	Two closely related but functionally distinct P-glycoprotein isoforms are encoded by the murine multidrug-resistance genes mdr1a and mdr1b. In a series of independently selected multidrug-resistant (MDR) J774.2 cell lines, mdr gene amplification and/or overexpression and overproduction of either the mdr1a or mdr1b products, or both gene products, correlates with the MDR phenotype. To investigate the possibility that mutations in the promoter regions of the mdr1a or mdr1b genes could influence their differential expression, mdr promoter-specific probes were used to detect and map potential structural alterations. An unusual structural rearrangement was found in the 5'-region of the amplified mdr1a allele in J7.T1, a cell line selected with taxol. To characterize this rearrangement, the regulatory regions of the mdr1a and mdr1b genes were analyzed. Whereas no gross structural alterations were detected by Southern blot hybridization using the mdr1b promoter probe, a novel amplified EcoRI fragment was detected by the mdr1a promoter probe. To determine the precise nature of this mutation, an mdr1a 5'-genomic clone was isolated from J7.T1 cells. Sequence analysis revealed an unusual DNA rearrangement consisting of the mdr1b gene, from its fourth intron toward its 3'-end, upstream of an intact mdr1a promoter on the amplified allele. We propose that this event occurred by an unequal sister chromatid exchange that was mediated by LINE-1 repetitive elements.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [CA 39821, P30 CA13330] Funding Source: Medline; NIGMS NIH HHS [2T32GM 7288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039821, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COHEN D, 1991, J BIOL CHEM, V266, P2239; DANIELS GR, 1985, NUCLEIC ACIDS RES, V13, P8939, DOI 10.1093/nar/13.24.8939; DEBATISSE M, 1988, MOL CELL BIOL, V8, P17, DOI 10.1128/MCB.8.1.17; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FURANO AV, 1986, NUCLEIC ACIDS RES, V14, P3717, DOI 10.1093/nar/14.9.3717; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HSU SIH, 1989, J BIOL CHEM, V264, P12053; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; MARTINSSON T, 1987, CYTOGENET CELL GENET, V45, P99, DOI 10.1159/000132437; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RONINSON IB, 1991, MOL CELLULAR BIOL MU, P189; ROY SN, 1985, CANCER RES, V45, P3856; SEHEE WR, 1989, J MOL BIOL, V205, P41; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; USDIN K, 1989, J BIOL CHEM, V264, P15681; USDIN K, 1989, J BIOL CHEM, V264, P20736; YANG CPH, 1990, J BIOL CHEM, V265, P10282; ZACK DJ, 1984, TOPICS CHEM MUTAGENE, P233; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20248	20254						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356977				2022-12-27	WOS:A1992JR85800079
J	CHAU, CMA; EVANS, MJ; SCARPULLA, RC				CHAU, CMA; EVANS, MJ; SCARPULLA, RC			NUCLEAR RESPIRATORY FACTOR-I ACTIVATION SITES IN GENES ENCODING THE GAMMA-SUBUNIT OF ATP SYNTHASE, EUKARYOTIC INITIATION FACTOR-2-ALPHA, AND TYROSINE AMINOTRANSFERASE - SPECIFIC INTERACTION OF PURIFIED NRF-1 WITH MULTIPLE TARGET GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CYTOCHROME-C; TRANSCRIPTION FACTOR; DNA-BINDING; PROCESSED PSEUDOGENES; SEQUENCE; EXPRESSION; RNA; UPSTREAM; PROMOTER; PROTEIN	Transcription factor nuclear respiratory factor 1 (NRF-1) was originally identified as an activator of the cytochrome c gene and subsequently found to stimulate transcription through specific sites in other nuclear genes whose products function in the mitochondria. These include subunits of the cytochrome oxidase and reductase complexes and a component of the mitochondrial DNA replication machinery. Here we establish that a functional recognition site for NRF-1 is present in the ATP synthase gamma-subunit gene extending the proposed respiratory role of NRF-1 to complex V. In addition, biologically active NRF-1 sites are found in genes encoding the eukaryotic translation initiation factor 2-alpha-subunit and tyrosine aminotransferase, both of which participate in the rate-limiting step of their respective pathways of protein biosynthesis and tyrosine catabolism. The recognition sites from each of these genes form identical complexes with NRF-1 as established by competition binding assays, methylation interference footprinting, and UV-induced DNA cross-linking. Cloned oligomers of each NRF-1 binding site also stimulate the activity of a truncated cytochrome c promoter in transfected cells. The NRF-1 binding activities for the various target sites copurified approximately 33,000-fold and resided in a single protein of 68 kDa. These observations further support a role for NRF-1 in the expression of nuclear respiratory genes and suggest it may help coordinate respiratory metabolism with other biosynthetic and degradative pathways.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM032525, R01GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BASU A, 1991, J BIOL CHEM, V266, P15450; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Maxam A M, 1980, Methods Enzymol, V65, P499; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; OHTA S, 1988, J BIOL CHEM, V263, P11257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPULLA RC, 1984, MOL CELL BIOL, V4, P2279, DOI 10.1128/MCB.4.11.2279; STRYER L, 1988, BIOCHEMISTRY-US, P479; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1989, BIOCHEM BIOPH RES CO, V161, P371, DOI 10.1016/0006-291X(89)91607-0; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791	33	112	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6999	7006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348057				2022-12-27	WOS:A1992HM05300083
J	TANG, BL; WONG, SH; LOW, SH; HONG, WJ				TANG, BL; WONG, SH; LOW, SH; HONG, WJ			RETENTION OF A TYPE-II SURFACE-MEMBRANE PROTEIN IN THE ENDOPLASMIC-RETICULUM BY THE LYS-ASP-GLU-LEU SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; IDENTIFICATION; SIGNAL; ER	Soluble luminal proteins of the endoplasmic reticulum (ER) are known to be retained by a tetrapeptide retention signal KDEL. We report in this communication that the KDEL sequence when appended to the carboxy terminus of a cell surface membrane protein, dipeptidyl peptidase IV (DPPIV), resulted in its retention in the endoplasmic reticulum of transfected Madin-Darby canine kidney cells as assessed by indirect immunofluorescence. Selective surface biotinylation revealed that about 90-95% of the expressed DPPIV was retained in the ER. Appendance of the sequence KDEV did not, however, result in ER retention, illustrating the functional specificity of the retention signal. The ER retention was not due to misfolding of the mutant protein, as the mutant proteins remained enzymatically active. Our data suggest that the KDEL receptor is able to recognize and recycle type II membrane proteins containing a carboxyl-terminal KDEL sequence and postulates the existence of such yet to be identified endogenous proteins.			TANG, BL (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X				ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; DAHLLOF B, 1991, J BIOL CHEM, V26, P1804; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HONG WJ, 1989, BIOCHEMISTRY-US, V28, P8474, DOI 10.1021/bi00447a030; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LOW SH, 1991, J BIOL CHEM, V266, P13391; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; OGATA S, 1989, J BIOL CHEM, V264, P3596; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	20	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7072	7076						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348058				2022-12-27	WOS:A1992HM05300094
J	DUDLER, R; HERTIG, C				DUDLER, R; HERTIG, C			STRUCTURE OF AN MDR-LIKE GENE FROM ARABIDOPSIS-THALIANA - EVOLUTIONARY IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; CLASS-II REGION; BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN GENE; CYSTIC-FIBROSIS; MESSENGER-RNAS; FAMILY; IDENTIFICATION; ORGANIZATION; DUPLICATION	Multidrug resistance of mammalian tumor cells is caused by the enhanced expression of P-glycoproteins. These proteins are encoded by mdr genes and mediate the energy-dependent efflux of a variety of lipophilic drugs from cells. To test whether in plants mdr-like genes might be involved in certain cases of cross-resistance to different herbicides, we have cloned and characterized a gene from Arabidopsis thaliana, atpgp1, encoding a putative P-glycoprotein homologue. Like the mammalian P-glycoproteins, with which it shares extensive sequence homology and a similar organization in structural domains, this protein is internally duplicated. Seven of the nine introns in the atpgp1 gene match introns in the mammalian mdr genes to within a few nucleotides, and the positions of these suggest that P-glycoprotein genes evolved by duplication and subsequent fusion of an intron-containing primordial gene prior to the evolutionary separation of plants and mammals. The atpgp1 gene gives rise to transcripts present in all plant parts but particularly abundant in inflorescence axes.			DUDLER, R (corresponding author), UNIV ZURICH, INST PLANT BIOL, ZOLLIKERSTR 107, CH-8008 ZURICH, SWITZERLAND.							AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CANGELOSI GA, 1989, J BACTERIOL, V171, P1609, DOI 10.1128/jb.171.3.1609-1615.1989; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HEAP J, 1982, AUST J AGR RES, V37, P149; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; LINCKE CR, 1991, J BIOL CHEM, V266, P5303; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MOSS SR, 1987, BIOL CHEM APPROACHES, P200; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PUTWAIN PD, 1989, SOC EXP BIOL SEM SER, V38, P211; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAMUELSON J, 1990, MOL BIOCHEM PARASIT, V38, P281, DOI 10.1016/0166-6851(90)90031-G; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STANFIELD SW, 1988, J BACTERIOL, V170, P3523, DOI 10.1128/jb.170.8.3523-3530.1988; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	40	120	143	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5882	5888						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372894				2022-12-27	WOS:A1992HK31800028
J	PITTLER, SJ; LEE, AK; ALTHERR, MR; HOWARD, TA; SELDIN, MF; HURWITZ, RL; WASMUTH, JJ; BAEHR, W				PITTLER, SJ; LEE, AK; ALTHERR, MR; HOWARD, TA; SELDIN, MF; HURWITZ, RL; WASMUTH, JJ; BAEHR, W			PRIMARY STRUCTURE AND CHROMOSOMAL LOCALIZATION OF HUMAN AND MOUSE ROD PHOTORECEPTOR CGMP-GATED CATION CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; FUNCTIONAL RECONSTITUTION; MOLECULAR-BASIS; EXPRESSION; GENE; CONDUCTANCE; MEMBRANE; CELLS; DNA	We have determined the primary structures of the human and mouse retinal rod cGMP-gated cation channel by analysis of cDNA clones and amplified DNA. The open reading frames predicted polypeptides of 690 and 683 residues exhibiting 88% sequence similarity. Sequence comparison indicated that the rod channels consist of a variable 90-residue N-terminal region, a short highly charged segment rich in lysine and glutamate, and a 540-residue C-terminal portion that is well conserved in three mammalian species. Significant sequence similarity (59%) of the visual cGMP-gated channel to the olfactory cAMP-gated channel established the existence of a family of cyclic nucleotide-gated ion channel genes. RNA blot analysis revealed transcripts of 3.2 kilobases (kb) in human, mouse, and dog, 3.2, 4.6, and 5.2 kb in bovine, and 3.6 kb in fish. The human channel gene was mapped by polymerase chain reaction of somatic cell hybrid DNAs to chromosome 4 (p14-q13) near the centromere. The mouse channel gene locus (Cncg) was mapped by interspecific backcross haplotype analysis 0.9 centimorgan proximal of the Kit locus on chromosome 5.	BAYLOR COLL MED,CULLEN EYE INST,DEPT OPHTHALMOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV CALIF IRVINE,CALIF COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; DUKE UNIV,MED CTR,DEPT MED & MICROBIOL,DURHAM,NC 27710	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California Irvine; Duke University			Pittler, Steven/J-7091-2013	Pittler, Steven/0000-0002-8464-9303	NEI NIH HHS [F32 EY06172, EY06656] Funding Source: Medline; NHGRI NIH HHS [HG 00101] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006172] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGUIRRE G, 1978, SCIENCE, V201, P1133, DOI 10.1126/science.210508; AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; COOK NJ, 1986, J BIOL CHEM, V261, P7033; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODEL V, 1979, CLIN GENET, V16, P277; Green EL, 1981, GENETICS PROBABILITY, P77; HEJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HIGGINS CF, 1991, NATURE, V352, P194, DOI 10.1038/352194a0; HOGEWIND BL, 1977, ACTA MED SCAND, V202, P323; HURWITZ R, 1991, J BIOL CHEM, V266, P7975; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SELDIN MF, 1990, CYTOGENET CELL GENET, V54, P68, DOI 10.1159/000132959; SELDIN MF, 1989, GENOMICS, V5, P24, DOI 10.1016/0888-7543(89)90082-7; SENIOR B, 1961, AM J OPHTHALMOL, V52, P625, DOI 10.1016/0002-9394(61)90147-7; SMITH B, 1988, AM J HUM GENET, V42, P335; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; TABAS JA, 1991, GENOMICS, V9, P283, DOI 10.1016/0888-7543(91)90254-C; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	37	67	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6257	6262						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372902				2022-12-27	WOS:A1992HK31800081
J	WEISSENBORN, DL; WITTEKINDT, N; LARSON, TJ				WEISSENBORN, DL; WITTEKINDT, N; LARSON, TJ			STRUCTURE AND REGULATION OF THE GLPFK OPERON ENCODING GLYCEROL DIFFUSION FACILITATOR AND GLYCEROL KINASE OF ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; LAC CARRIER PROTEIN; NUCLEOTIDE-SEQUENCE; SN-GLYCEROL-3-PHOSPHATE PERMEASE; CLONING VEHICLES; DNA-SEQUENCE; TRANSCRIPTION; GENE; EXPRESSION; TRANSPORT	The glpFK operon maps near minute 88 on the linkage map of Escherichia coli K-12 with glpF promoter proximal. The glpF gene encodes a cytoplasmic membrane protein which facilitates the diffusion of glycerol into the cell. The glpK gene encodes glycerol kinase. In the present work, the nucleotide sequence of the 5'-end of the operon, including the control region, the glpF gene, and part of the glpK gene, was determined. The facilitator was predicted to contain 281 amino acids with a calculated molecular weight of 29,780. It is a highly hydrophobic protein with a minimum of six potential transmembrane a helices. The transcription start site for the glpFK operon was located 71 base pairs upstream from the proposed translation start codon for glpF. Preceding the transcription start site were sequences similar to the -10 and -35 consensus sequences for bacterial promoters. Binding sites for the cAMP-cAMP receptor protein (CRP) complex and the glp repressor were identified by DNase I footprinting. The region protected by the cAMP . CRP complex contained tandem sequences resembling the consensus sequence for CRP binding. The CRP sites were centered at 37.5 and 60.5 base pairs upstream of the start of transcription. The glp repressor protected an extensive area (-89 to -7 relative to the start point of transcription), sufficient for the binding of four repressor tetramers. Two additional binding sites for the repressor were identified within the glpK coding region. The DNA containing these two operators synergistically increased the apparent affinity of glp repressor for DNA fragments containing the four operators in the promoter region of the glpFK operon. With this study, a total of 13 operators for the glp regulon have been characterized. Comparison of these operators revealed the consensus 5'-WATGTTCGWT-3' for the operator half-site (W = A or T). The relative affinity of the glp repressor for the various glp operators was assessed in vivo using a promoter-probe vector. The relative apparent affinity of the control regions for glp repressor was glpFK > glpD > glpACB > glpTQ. The degree of catabolite repression for each of the operons was assessed using a similar system. In this case, the relative sensitivity of the glp operons to catabolite repression was glpTQ > glpFK > glpACB > glpD.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24061; UNIV CONSTANCE,DEPT BIOL,W-7750 CONSTANCE,GERMANY	Virginia Polytechnic Institute & State University; University of Konstanz			Wittekindt, Nicola/G-3469-2013	Wittekindt, Nicola/0000-0002-3310-0919				ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AUSTIN D, 1991, J BACTERIOL, V173, P101, DOI 10.1128/jb.173.1.101-107.1991; BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COZZARELLI NR, 1968, J MOL BIOL, V31, P371, DOI 10.1016/0022-2836(68)90415-4; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EHRMANN M, 1987, J BACTERIOL, V169, P526, DOI 10.1128/jb.169.2.526-532.1987; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FREEDBERG WB, 1973, J BACTERIOL, V115, P816, DOI 10.1128/JB.115.3.816-823.1973; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HACKETT P, 1988, INTRO RECOMBINANT DN, P43; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HASPEL HC, 1988, J BIOL CHEM, V263, P398; IRANI M, 1983, P NATL ACAD SCI-BIOL, V80, P4775, DOI 10.1073/pnas.80.15.4775; IUCHI S, 1990, J BACTERIOL, V172, P179, DOI 10.1128/JB.172.1.179-184.1990; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; KOCH JP, 1964, J BIOL CHEM, V239, P3106; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LARSON TJ, 1992, J BIOL CHEM, V267, P6114; LARSON TJ, 1987, J BIOL CHEM, V262, P15869; LARSON TJ, 1982, J BACTERIOL, V152, P1008; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P244; Liss L, 1987, FOCUS, V9, P13; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; LUPSKI JR, 1990, J BACTERIOL, V172, P6129, DOI 10.1128/jb.172.10.6129-6134.1990; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; Miller J. H, 1972, EXPT MOL GENETICS; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PETTIGREW DW, 1988, J BIOL CHEM, V263, P135; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RODRIGUEZ RL, 1983, RECOMBINANT DNA TECH, P164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER K, 1987, METHOD ENZYMOL, V153, P452; SCHWEIZER H, 1987, J BACTERIOL, V169, P507, DOI 10.1128/jb.169.2.507-513.1987; SCHWEIZER H, 1986, MOL GEN GENET, V202, P488, DOI 10.1007/BF00333282; SHANBLATT SH, 1986, BIOCHEMISTRY-US, V25, P5539, DOI 10.1021/bi00367a029; SHANBLATT SH, 1987, J BIOL CHEM, V262, P11422; SILHAVY TJ, 1976, J BACTERIOL, V126, P951, DOI 10.1128/JB.126.2.951-958.1976; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YE SZ, 1988, J BACTERIOL, V170, P4209, DOI 10.1128/jb.170.9.4209-4215.1988	63	85	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6122	6131						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372899				2022-12-27	WOS:A1992HK31800062
J	AUGER, KR; CARPENTER, CL; SHOELSON, SE; PIWNICAWORMS, H; CANTLEY, LC				AUGER, KR; CARPENTER, CL; SHOELSON, SE; PIWNICAWORMS, H; CANTLEY, LC			POLYOMA-VIRUS MIDDLE-T ANTIGEN-PP60C-SRC COMPLEX ASSOCIATES WITH PURIFIED PHOSPHATIDYLINOSITOL 3-KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; TYROSINE PHOSPHORYLATION; TRANSFORMING PROTEIN; PDGF RECEPTOR; ANTIGEN; PP60C-SRC; PRODUCT; BINDING; CELLS; GENE	Reconstitution of the polyoma virus middle T antigen (mT)-pp60-src complex and phosphatidylinositol 3-kinase (PtdIns 3-kinase) has been accomplished in vitro with immunopurified baculovirus-expressed mT-pp60c-src and PtdIns 3-kinase purified from rat liver. Both the 110- and 85-kDa subunits of the PtdIns 3-kinase associated with the mT-pp60c-src complex. The association of PtdIns 3-kinase with the mT-pp60c-src complex was dependent on the protein-tyrosine kinase activity of pp60c-src as a kinase-inactive mutant (pp60(295c-src)) still complexed with mT, but the mT-pp60(295c-src) complex was unable to bind PtdIns 3-kinase. The mT-pp60c-src complex phosphorylated both subunits of PtdIns 3-kinase on tyrosine residues. The immunopurified mT-pp60c-src complex also associated with PtdIns 3-kinase activity from whole cell lysates, and this association was dependent upon the protein-tyrosine kinase activity of pp60c-src. Comparison of S-35-labeled proteins from whole cell lysates which associated with immunopurified mT-pp60c-src and mT-pp60(295c-src) revealed proteins of 110 and 85 kDa as the major peptides dependent on protein-tyrosine kinase activity for association with the complex. In addition, a synthetic phosphopeptide (13-mer) containing sequences conserved between the major tyrosine phosphorylation site of murine polyoma virus mT, hamster polyoma virus mT, and the insulin receptor substrate (IRS-1) specifically blocked the association of the 85- and 110-kDa polypeptides with the mT-pp60c-src complex. The ability to block the association was dependent on the tyrosine phosphorylation of the peptide. Association of PtdIns 3-kinase activity was blocked concurrently. This is the first demonstration that the 110-kDa subunit of PtdIns 3-kinase can associate with mT-pp60c-src. This association in vitro is a step toward understanding protein-protein interactions important in the signal transduction pathway of oncogenic proteins.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Massachusetts General Hospital	AUGER, KR (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.		Cantley, Lewis C/D-1800-2014; Piwnica-Worms, Helen/C-5214-2012	Cantley, Lewis C/0000-0002-1298-7653; 	NCI NIH HHS [CA 50767] Funding Source: Medline; NIGMS NIH HHS [GM 41890, GM 36624, R01 GM041890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624, R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHATTERJEE S, 1992, IN PRESS PEPTIDES CH; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, ONCOGENE RES, V4, P283; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Stewart JM, 1984, SOLID PHASE PEPTIDE; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	44	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5408	5415						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372000				2022-12-27	WOS:A1992HH74700063
J	GAVINI, N; PULAKAT, L				GAVINI, N; PULAKAT, L			THE TRANSFER-RNA SPECIES FOR REDUNDANT GENETIC CODONS NNU AND NNC - A THOUGHT ON THE ABSENCE OF PHENYLALANINE TRANSFER-RNA WITH AAA ANTICODON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; IDENTITY; USAGE; PHER	The redundant genetic codons NNU and NNC (where N is A, T, G, or C) specify the same amino acid and are decoded by their cognate tRNAs, which contain either a guanosine or a modified base in the wobble position of the anticodons. Since tRNAs with an adenosine in the wobble position of the anticodon, which are complementary to the NNU codons, are not found naturally, we have generated a tRNA(Phe), with AAA anticodon and examined how an adenosine in the wobble position would affect its biological function in Escherichia coli. We found that the tRNA(Phe) with GAA anticodon (wild-type) repressed the expression of the pheA gene via tRNA(Phe)-mediated attenuation of transcription, whereas the tRNA(Phe) with AAA anticodon did not influence the expression of the pheA gene. Furthermore, elevated levels of tRNA(Phe) (AAA) did not support the growth of an E. coli strain carrying a temperature-sensitive mutation in the pheS gene at 42-degrees-C. Since the presence of a multicopy plasmid carrying the gene that encodes tRNA(Phe)(GAA), a substrate for phenylalanyl tRNA synthetase, enables the E. coli strain carrying the pheS(Ts) mutation to grow at 42-degrees-C, the above observation suggests that unlike tRNA(Phe)(GAA), tRNA(Phe)(AAA) is not a good substrate for phenylalanyl-tRNA synthetase. Therefore, we postulate that the presence of adenosine at the wobble position of anticodons was specifically eliminated and the tRNAs with guanosine or a modified base in the wobble position were selected to decode both NNU and NNC codons in E. coli.			GAVINI, N (corresponding author), UNIV CALIF IRVINE,SCH BIOL SCI,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.							BARE L, 1985, BIOCHEMISTRY-US, V24, P2354, DOI 10.1021/bi00330a034; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAILLET J, 1985, NUCLEIC ACIDS RES, V13, P3699, DOI 10.1093/nar/13.10.3699; FITCH WM, 1976, SCIENCE, V194, P1173, DOI 10.1126/science.996548; GAVINI N, 1990, J BIOL CHEM, V265, P21527; GAVINI N, 1991, J GEN MICROBIOL, V137, P679, DOI 10.1099/00221287-137-3-679; GAVINI N, 1990, J BIOL CHEM, V265, P21532; GAVINI N, 1991, J BIOL CHEM, V266, P7750; GAVINI N, 1991, J BACTERIOL, V173, P4904, DOI 10.1128/jb.173.15.4904-4907.1991; GAVINI N, 1988, THESIS U MELBOURNE A; GOWRISHANKAR J, 1982, J BACTERIOL, V152, P1; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GRUMBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, V2, P1386; HOU YM, 1989, TRENDS BIOCHEM SCI, V14, P233, DOI 10.1016/0968-0004(89)90033-9; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; KNOWLTON RG, 1980, J MOL BIOL, V139, P705, DOI 10.1016/0022-2836(80)90056-X; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LANDICK R, 1987, ESCHERICHIA COLI SAL, V2, P1453; Maniatis T., 1982, MOL CLONING; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miller J.H., 1972, EXPT MOL GENETICS; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; PITTARD J, 1990, J BACTERIOL, V172, P6077, DOI 10.1128/jb.172.10.6077-6083.1990; RUSSELL RRB, 1971, J BACTERIOL, V107, P736, DOI 10.1128/JB.107.3.736-740.1971; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHWARTZ I, 1983, NUCLEIC ACIDS RES, V11, P4379, DOI 10.1093/nar/11.13.4379; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WILSON RK, 1986, NUCLEIC ACIDS RES, V14, P5937, DOI 10.1093/nar/14.14.5937; YARUS M, 1977, NUCLEIC ACID PROTEIN, pPP391; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P4271, DOI 10.1073/pnas.75.9.4271	34	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2240	2243						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370814				2022-12-27	WOS:A1992HB53200021
J	JOHNSON, AC; KAGEYAMA, R; POPESCU, NC; PASTAN, I				JOHNSON, AC; KAGEYAMA, R; POPESCU, NC; PASTAN, I			EXPRESSION AND CHROMOSOMAL LOCALIZATION OF THE GENE FOR THE HUMAN TRANSCRIPTIONAL REPRESSOR GCF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR GENE; REGION GENES; CHAIN LOCUS; TRANSLOCATION; PROMOTER; RNA; LYMPHOMA; INVITRO; ANTIGEN; CELLS	GCF is a human transcriptional regulator that represses transcription of certain genes and is encoded by a 3-kilobase (kb) mRNA (Kageyama, R., and Pastan, I. (1989) Cell 59, 815-825). The expression of GCF was examined in a variety of clonal cell lines. The 3.0-kb GCF mRNA was found to be expressed at the highest level in HUT 102 cells (derived from a T-cell lymphoma). Elevated levels of the GCF mRNA were also noted in KATO III and AGS (gastric carcinomas), FEM-X (melanoma), and U266B1 (myeloma) cell lines. A human fibroblast cell line (WI38) did not express GCF mRNA, and no cross-hybridization to a mouse cell line (NIH 3T3) or monkey cell line (CV-1) could be detected. The GCF cDNA also hybridizes to RNA species of 4.5 and 1.2 kb. The 4.5-kb RNA has the same general expression pattern as the GCF mRNA. Hybridization of cellular RNA with various probes derived from the 3-kb cDNA revealed that the 4.5-kb RNA species only hybridizes to GCF cDNA probes from the extreme 5' end. By using single-stranded RNA probes, hybridization to the three RNA species was detected with the antisense probe for the 5' end (nucleotides 1-561). The single-stranded antisense probe for the region encompassing nucleotides 561-1692 hybridized to the 3.0- and 1.2-kb RNA species. The sense probes for these regions did not hybridize to these RNAs. The GCF gene was localized to a single locus, the chromosome 2 p11.1-11.2 region, by in situ hybridization. Treatment of human KB epidermoid carcinoma cells with phorbol 12-myristate 13-acetate (PMA) lead to a rapid induction of GCF RNA after 1 h and a decline to lower than control levels after 6 h. Epidermal growth factor receptor mRNAs were not increased by PMA until 2 h after treatment and were at their highest level only after GCF mRNAs were decreased. The 4.5- and 1.2-kb RNAs were also induced by PMA with the same kinetics as the GCF mRNA. These results show that the GCF gene is widely expressed in human tissues and cell lines and that the 4.5- and 1.2-kb RNAs have similar expression patterns.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRISSENDEN JE, 1985, CANCER RES, V45, P5593; BROWNELL E, 1988, ONCOGENE, V2, P527; BRUNS G, 1985, HUM GENET, V70, P311, DOI 10.1007/BF00295366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; DYAN WS, 1985, NATURE, V316, P774; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GARDNER DP, 1990, FEBS LETT, V269, P288, DOI 10.1016/0014-5793(90)81178-Q; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; JOHNSON AC, 1988, BIOCHEM BIOPH RES CO, V150, P412, DOI 10.1016/0006-291X(88)90536-0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON PF, 1989, ANN REV BIOCH, V58, P779; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LORENZ W, 1987, NUCLEIC ACIDS RES, V15, P9667, DOI 10.1093/nar/15.23.9667; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; MANIATIS T, 1976, CELL, V8, P163, DOI 10.1016/0092-8674(76)90001-5; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; POPESCU NC, 1990, ONCOGENE RES, V5, P295; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOMERVILLE MJ, 1988, GENOME, V30, P499, DOI 10.1139/g88-083; STRUM R, 1987, GENE DEV, V1, P1147; SUKHATME VP, 1985, J EXP MED, V161, P429, DOI 10.1084/jem.161.2.429; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THOMAS PS, 1980, P NATL ACAD SCI USA, V77, P501; VANDENBERGHE H, 1979, HUM GENET, V46, P173, DOI 10.1007/BF00291919; [No title captured]	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1689	1694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370479				2022-12-27	WOS:A1992HA48500046
J	MCGEOCH, JEM; GUIDOTTI, G				MCGEOCH, JEM; GUIDOTTI, G			AN INSULIN-STIMULATED CATION CHANNEL IN SKELETAL-MUSCLE - INHIBITION BY CALCIUM CAUSES OSCILLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SOLEUS MUSCLE; NA-K TRANSPORT; GLUCOSE-TRANSPORT; CAMP PHOSPHODIESTERASE; KINASE-ACTIVITY; (NA+,K+)-ADENOSINE TRIPHOSPHATASE; FUNCTIONAL EXPRESSION; IONIC SELECTIVITY; ACTIVATED CHANNEL; SODIUM-CHANNELS	A cation channel has been identified in the plasma membrane of skeletal muscle that oscillates open and closed in a regular manner. In an experimental system of patch-clamped reconstituted plasma membrane in phospholipid bilayers, the oscillations are calcium-dependent and constitute regular closing events due to inhibition of the channel by calcium with a K(i) of 2.2 +/-1 x 10(-6) M, followed by reopening. There are 3.7 +/- 1 calcium binding sites/channel. With sodium as the current vehicle, conductance is increased by voltage, insulin (K(m) = 5 +/- 0.6 x 10(-9) M), and hydrolyzable guanine nucleotides. Cyclic GMP alone will increase the conductance with a K(m) of 3.7 +/- 0.6 x 10(-7) M. In the absence of calcium, the unitary conductance with insulin + GTP or cGMP at 150 mm NaCl is 153 picosiemens. Sodium current is insensitive to 10(-5) M tetrodotoxin but inhibited by mu-conotoxin (K(i) = 5 x 10(-8) M). These findings in the reconstituted system were verified in patch-clamped whole muscle cells where an insulin and cGMP-dependent sodium current inhibited by mu-conotoxin could be demonstrated. In the whole cell experiments, slow calcium-dependent oscillations of the sodium current were also detected.			MCGEOCH, JEM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; BAKER PF, 1983, J PHYSIOL-LONDON, V336, P397, DOI 10.1113/jphysiol.1983.sp014588; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Briggs AP, 1924, J BIOL CHEM, V58, P721; BRODSKY JL, 1990, J BIOL CHEM, V265, P10458; CERVETTO L, 1988, J PHYSIOL-LONDON, V406, P181, DOI 10.1113/jphysiol.1988.sp017375; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CIARALDI TP, 1989, BIOCHEM J, V264, P389, DOI 10.1042/bj2640389; CLAUSEN T, 1987, AM J PHYSIOL, V252, pE492, DOI 10.1152/ajpendo.1987.252.4.E492; CLAUSEN T, 1977, J PHYSIOL-LONDON, V265, P19, DOI 10.1113/jphysiol.1977.sp011703; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P415, DOI 10.1113/jphysiol.1977.sp011959; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMANI S, 1984, BIOCHIM BIOPHYS ACTA, V804, P77; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; FLATMAN JA, 1979, NATURE, V281, P580, DOI 10.1038/281580a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUIDOTTI G, 1990, CHEMTRACTS BIOCH MOL, V1, P447; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HOUSLAY MD, 1986, BIOCHEM SOC T, V14, P183, DOI 10.1042/bst0140183; HSU YM, 1991, J BIOL CHEM, V266, P427; ILLIANO G, 1973, P NATL ACAD SCI USA, V70, P2443, DOI 10.1073/pnas.70.8.2443; KAO I, 1975, SCIENCE, V188, P740, DOI 10.1126/science.1124397; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KONO T, 1983, RECENT PROG HORM RES, V39, P519; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEVITAN IB, 1986, ION CHANNEL RECONSTI, P528; LYTTON J, 1985, J BIOL CHEM, V260, P1177; LYTTON J, 1985, J BIOL CHEM, V260, P75; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MONTROLL EW, 1982, P NATL ACAD SCI USA, V79, P3380, DOI 10.1073/pnas.79.10.3380; MOORE RD, 1981, BIOPHYS J, V33, P203, DOI 10.1016/S0006-3495(81)84881-3; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NORGAARD A, 1981, NATURE, V293, P739, DOI 10.1038/293739a0; OFFERIJNS FGJ, 1958, J PHYSIOL-LONDON, V141, P377, DOI 10.1113/jphysiol.1958.sp005981; OTSUKA M, 1970, AM J PHYSIOL, V219, P1178, DOI 10.1152/ajplegacy.1970.219.5.1178; PATTON C, 1990, MAX CHELATOR SOFTWAR; RAFAELOFF R, 1990, DIABETES, V39, pA11; RESH MD, 1980, J BIOL CHEM, V255, P938; RESH MD, 1982, J BIOL CHEM, V257, P1946; ROBINSON FW, 1989, J BIOL CHEM, V264, P16458; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSIC NK, 1985, J BIOL CHEM, V260, P6206; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHANAHAN MF, 1989, ENDOCRINOLOGY, V125, P1074, DOI 10.1210/endo-125-2-1074; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TSIEN RY, 1989, METHOD ENZYMOL, V172, P256; UEDA M, 1984, J BIOL CHEM, V259, P9520; VYDELINGUM N, 1978, HORM METAB RES, V10, P38, DOI 10.1055/s-0028-1093478; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	65	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					832	841						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370468				2022-12-27	WOS:A1992GY96000026
J	KOLLMAR, R; LINDSTROM, MJ; FARNHAM, PJ				KOLLMAR, R; LINDSTROM, MJ; FARNHAM, PJ			HEAT SENSITIVITY AND SP1 ACTIVATION OF COMPLEX-FORMATION AT THE SYRIAN-HAMSTER CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING) ASPARTATE CARBAMOYLTRANSFERASE DIHYDROOROTASE PROMOTER INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SV40 EARLY PROMOTER; WHOLE-CELL EXTRACT; ACCURATE TRANSCRIPTION; CAD GENE; DNA-BINDING; INITIATION; UPSTREAM; TATA; SEQUENCES	To study the regulation of transcription of the carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase (CAD) gene from the Syrian hamster, Mesocricetus auratus, we developed a homologous in vitro transcription system on the basis of nuclear extract from Syrian hamster kidney cells. We optimized the reaction temperature and the concentrations of DNA template, KCl, and MgCl2 simultaneously with the response surface method and found an unusually low temperature optimum of 20-degrees-C. We therefore investigated whether CAD transcription in vitro depended on a heat-labile component of nuclear extract. Preincubating extract alone at 30-degrees-C reduced transcription from the CAD promoter but not from the major late promoter of adenovirus 2. The formation of stable initiation complexes at the CAD promoter was diminished in heat-treated extract; run-off transcripts, however, accumulated at the same rate as in untreated extract. The heat sensitivity of complex formation correlated with the heat sensitivity of DNA binding by transcription factor Sp1, which binds to two sites in the CAD promoter; moreover, both preformed initiation complexes and DNA-bound Sp1 were heat-resistant. Adding purified Spl to heat-treated extract restored complex formation. We propose that Sp1 activates CAD transcription by stabilizing initiation complexes at the CAD promoter.	UNIV WISCONSIN, MCARDLE LAB CANC RES, 1400 UNIV AVE, MADISON, WI 53706 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, CTR BIOSTAT, MADISON, WI 53706 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, PROGRAM CELL & MOLEC BIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, P01CA023076, P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA14520, CA23076, CA07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1982, J BIOL CHEM, V257, P432; BEIN K, 1991, J BIOL CHEM, V266, P3791; BORRELLI MJ, 1987, EXP CELL RES, V170, P363, DOI 10.1016/0014-4827(87)90313-2; BOX GEP, 1954, BIOMETRICS, V10, P16, DOI 10.2307/3001663; BOX GEP, 1987, EMPIRICAL MODEL BUIL, P375; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; FIRE A, 1984, J BIOL CHEM, V259, P2509; GISSINGER F, 1974, BIOCHIMIE, V56, P319, DOI 10.1016/S0300-9084(74)80139-2; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES ME, 1972, CURR TOP CELL REGUL, V6, P227; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO GN, 1987, MOL CELL BIOL, V7, P1961, DOI 10.1128/MCB.7.5.1961; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RAO GN, 1988, DNA-J MOLEC CELL BIO, V7, P423, DOI 10.1089/dna.1.1988.7.423; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TYLER BM, 1985, P NATL ACAD SCI USA, V82, P5450, DOI 10.1073/pnas.82.16.5450; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEIL PA, 1979, CELL, V18, P469; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					385	391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346130				2022-12-27	WOS:A1992GY43900063
J	WOHLFART, P; HAASE, W; MOLDAY, RS; COOK, NJ				WOHLFART, P; HAASE, W; MOLDAY, RS; COOK, NJ			ANTIBODIES AGAINST SYNTHETIC PEPTIDES USED TO DETERMINE THE TOPOLOGY AND SITE OF GLYCOSYLATION OF THE CGMP-GATED CHANNEL FROM BOVINE ROD PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; PLASMA-MEMBRANE; OUTER SEGMENT; FUNCTIONAL RECONSTITUTION; CATION CHANNEL; SODIUM-CHANNEL; CONDUCTANCE; PROTEIN; LOCALIZATION; BINDING	Peptides corresponding to amino acids 321-339 (peptide GS21) and 416-431 (peptide GS31) of the cGMP-gated channel from bovine rod photoreceptors were synthesized and used as antigens for the preparation of polyclonal antibodies. After affinity purification, both antipeptide antibodies were found to bind specifically to the channel protein after Western blotting, but only the antibody against GS21 gave satisfactory results on enzyme-linked immunosorbent assay and electron microscopy. Using immunocytochemistry, we were able to localize amino acids 321-339 to the extracellular side of the rod photoreceptor plasma membrane. By synthesizing heptapeptides corresponding to amino acids 324-330 (peptide GS2s) and 420-426 (peptide GS3s), we were able to affinity purify antibodies specific for two N-glycosylation consensus sites in the channel protein. As assessed by Western blotting, antibodies against GS3s were found to bind to both the glycosylated and deglycosylated channel proteins, whereas antibodies against GS2s only bound to the channel protein after enzymatic deglycosylation. Together, these results allow the refinement of folding models for the cGMP-gated channel and implicate Asn-327 as being the sole site of N-glycosylation.	MAX PLANCK INST BIOPHYS,MOLEK MEMBRANBIOL ABT,HEINRICH HOFFMANN STR 7,W-6000 FRANKFURT 71,GERMANY; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	Max Planck Society; University of British Columbia					NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COOK NJ, 1986, J BIOL CHEM, V261, P7033; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAASE W, 1990, J NEUROSCI, V10, P1486; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					644	648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370452				2022-12-27	WOS:A1992GY43900099
J	TAO, JG; HAYNES, DH				TAO, JG; HAYNES, DH			ACTIONS OF THAPSIGARGIN ON THE CA2+-HANDLING SYSTEMS OF THE HUMAN PLATELET - INCOMPLETE INHIBITION OF THE DENSE TUBULAR CA2+ UPTAKE, PARTIAL INHIBITION OF THE CA2+ EXTRUSION PUMP, INCREASE IN PLASMA-MEMBRANE CA2+ PERMEABILITY, AND CONSEQUENT ELEVATION OF RESTING CYTOPLASMIC CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM CA-2+-ATPASE; FURA-2-LOADED HUMAN-PLATELETS; INTRACELLULAR CA-2+ STORES; PAROTID ACINAR-CELLS; TUMOR PROMOTER; SARCOPLASMIC-RETICULUM; INOSITOL PHOSPHATE; CALCIUM PUMPS; ENTRY; TRANSPORT	Thapsigargin (Tg) effects on Ca2+ handling in the intact human platelet were studied using Quin2 and chlorotetracycline to measure free cytoplasmic and dense tubular (DT) Ca2+ concentrations ([Ca2+]cyt and [Ca2+]dt, respectively). Tg inhibits Ca2+ uptake by the DT Ca2+-ATPase pumps, but incompletely, lowering the V(m) to 32% of control (IC50,Tg = 0.18 +/- 0.10 muM). The kinetics of loss of DT Ca2+, transient increases in [Ca2+]cyt, and lowered steady-state [Ca2+]dt after Tg addition are all explained by pump inhibition, with no effect on the rate constant of Ca2+ leakage across the DT membrane (k(leak,DT) = 1.14 min-1). Tg lowers by 30% the V(m) of the Ca2+ extrusion pump located in the plasma membrane (PM), as shown by a Quin2-based method measuring active Ca2+ extrusion (Johansson, J. S., and Haynes, D. H. (1988) J. Membr. Biol. 104, 147-163). This effect (IC50,Tg = 0.45 +/- 0.06 muM), together with a 24 +/- 16% increase in k(leak,PM,Ca) (to 3 x 10(-4) min-1), accounts for a Tg-dependent sustained elevation [Ca2+]cyt (to 708 +/- 78 nM) which is independent of DT Ca2+ status or history. Thrombin and Tg release 30 and 70% (respectively) of the DT Ca2+ available at any instant, independent of order of challenge, consistent with a single class of DT with respect to these agents.			TAO, JG (corresponding author), UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038228, T32HL007188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38228, HL 07188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADUNYAH SE, 1985, BIOCHEM BIOPH RES CO, V128, P1274, DOI 10.1016/0006-291X(85)91078-2; ADUNYAH SE, 1987, BIOCHIM BIOPHYS ACTA, V930, P401, DOI 10.1016/0167-4889(87)90013-9; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BURK SE, 1989, J BIOL CHEM, V264, P18561; DEAN WL, 1989, CELL CALCIUM, V10, P289, DOI 10.1016/0143-4160(89)90055-9; DIXON D, 1984, J BIOL CHEM, V259, P3737; DIXON DA, 1989, J BIOL CHEM, V264, P13612; ELY JA, 1991, J BIOL CHEM, V266, P18635; ENOUF J, 1989, BIOCHEM J, V263, P547, DOI 10.1042/bj2630547; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HAYNES DH, 1991, ANN NY ACAD SCI, V639, P592, DOI 10.1111/j.1749-6632.1991.tb17357.x; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; JOHANSSON JS, 1988, J MEMBRANE BIOL, V104, P147, DOI 10.1007/BF01870927; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19, DOI 10.1016/0005-2736(92)90158-I; JY W, 1984, CIRC RES, V55, P595, DOI 10.1161/01.RES.55.5.595; JY W, 1987, BIOCHIM BIOPHYS ACTA, V929, P88, DOI 10.1016/0167-4889(87)90244-8; JY WC, 1987, CIRC RES, V60, P346, DOI 10.1161/01.RES.60.3.346; JY WC, 1988, BIOCHIM BIOPHYS ACTA, V944, P374, DOI 10.1016/0005-2736(88)90508-1; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MILLMAN MS, 1980, MEMBRANE BIOCHEM, V3, P291, DOI 10.3109/09687688009063890; OZAKI Y, 1992, CELL CALCIUM, V13, P19, DOI 10.1016/0143-4160(92)90026-O; PAPP B, 1991, J BIOL CHEM, V266, P14593; QUINTON T, 1992, FASEB J, V6, pA391; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAXENA S P, 1991, FASEB Journal, V5, pA902; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAO JG, 1992, BIOCHIM BIOPHYS ACTA, V1107, P213, DOI 10.1016/0005-2736(92)90407-D; TAO JG, 1992, BIOCHIM BIOPHYS ACTA, V1105, P29, DOI 10.1016/0005-2736(92)90159-J; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; VALANT PA, 1992, IN PRESS J MEMBR BIO; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; WRZOSEK A, 1992, CELL CALCIUM, V13, P281, DOI 10.1016/0143-4160(92)90063-X	44	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24972	24982						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334075				2022-12-27	WOS:A1992KB60300013
J	GEORGE, DJ; BLACKSHEAR, PJ				GEORGE, DJ; BLACKSHEAR, PJ			MEMBRANE ASSOCIATION OF THE MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) PROTEIN APPEARS TO INVOLVE MYRISTATE-DEPENDENT BINDING IN THE ABSENCE OF A MYRISTOYL PROTEIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PHORBOL ESTERS; CELLULAR SUBSTRATE; PLASMA-MEMBRANE; GENE-PRODUCT; PHOSPHORYLATION; FIBROBLASTS; ACTIVATION; EXPRESSION; PP60V-SRC	The myristoylated alanine-rich C kinase substrate, or MARCKS protein, has been implicated in several cellular processes, yet its physiological function remains unknown. We have studied the molecular basis of its membrane association in a cell-free system in order to help elucidate its regulation and function. First, we showed that the MARCKS protein incorporated [H-3]myristate when its mRNA was translated in vitro in reticulocyte lysates. The myristoylated protein bound rapidly to freshly fractionated cell membranes, while a nonmyristoylated mutant associated to a much lesser extent (<15% of wild type). To determine whether this binding was due to a specific cytoplasmic-face protein "receptor," as is seen with pp60v-src, we pretreated the membranes in several ways. Prior treatment of membranes with heat (100-degrees-C for 3 min) or trypsin did not affect subsequent MARCKS binding. Binding was markedly decreased in 50 mM EDTA, 0.5 M NaCl, or 1.0% Triton X-100; it was restored to normal after removal of the NaCl and EDTA but was still decreased after removal of the Triton X-100. These findings argued against the existence of a protein receptor for the MARCKS protein on cellular membranes. Finally, MARCKS protein phosphorylated in vitro with protein kinase C bound to the cell membranes to the same extent as the nonphosphorylated protein; this binding was also unaffected by an excess of a synthetic peptide corresponding to the phosphorylation site domain of the protein. We conclude that, at least in this in vitro system, the membrane association of the MARCKS protein is primarily dependent on the amino-terminal myristate moiety and does not appear to involve a specific cytoplasmic-face protein receptor.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,POB 3897,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRAFF JM, 1989, J BIOL CHEM, V264, P2181; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; NIEDEL J E, 1986, P47; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	33	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24879	24885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332970				2022-12-27	WOS:A1992KA26300107
J	FLANAGAN, CA; THORNER, J				FLANAGAN, CA; THORNER, J			PURIFICATION AND CHARACTERIZATION OF A SOLUBLE PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; BOVINE BRAIN; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; 2ND MESSENGERS; RAT-LIVER; GENE; RECEPTOR	A phosphatidylinositol (PI) 4-kinase was purified 25,000-fold from the cytosolic fraction of extracts from the yeast Saccharomyces cerevisiae. The purification consisted of an ammonium sulfate fractionation followed by chromatography on sulfonated-agarose (S-Sepharose), phosphocellulose, threonine-agarose, and quaternary amino (Mono Q), and sulfonated (Mono S) beads. Major contaminants in the purification, Hsc82 and Hsp82 (yeast homologs of the mammalian heat shock protein Hsp90), were eliminated by using a combination of molecular genetics (to construct a null mutation in HSC82), altered growth conditions (to minimize expression from the inducible HSP82 gene), and high ionic strength fractionation conditions (to remove the residual Hsp82). The purified enzyme had an apparent subunit molecular weight of 125,000, much larger than any other well characterized PI-4-kinase reported previously. Like mammalian PI-4-kinases, the yeast enzyme specifically phosphorylated PI on position 4 of the inositol ring and was stimulated by Triton X-100. However, activity was not inhibited by adenosine, a potent inhibitor of certain (type II) mammalian PI-4-kinases. The enzyme displayed typical Michaelis-Menten kinetics with apparent K(m) values of 100 muM for ATP and 50 muM for PI. To date, this yeast enzyme is the first soluble PI-4-kinase purified from any source.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,RM 401,BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P87; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CULBERTSON MR, 1975, GENETICS, V80, P23; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FIELDS FO, 1992, THESIS U CALIFORNIA; FLANAGAN CA, 1991, THESIS U CALIFORNIA; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MICHELL RH, 1967, BIOCHIM BIOPHYS ACTA, V144, P649, DOI 10.1016/0005-2760(67)90053-7; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SKOLNIK EY, 1991, CELL, V65, P75; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TUAZON PT, 1987, METHOD ENZYMOL, V141, P210; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WHEELER GE, 1972, BIOCHEM J, V127, pP64; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	60	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24117	24125						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331109				2022-12-27	WOS:A1992JZ23900103
J	LEMOSY, EK; ERICKSON, HP; BEYER, WF; RADEK, JT; JEONG, JM; MURTHY, SNP; LORAND, L				LEMOSY, EK; ERICKSON, HP; BEYER, WF; RADEK, JT; JEONG, JM; MURTHY, SNP; LORAND, L			VISUALIZATION OF PURIFIED FIBRONECTIN-TRANSGLUTAMINASE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; FACTOR-XIII; TISSUE TRANSGLUTAMINASE; PURIFICATION; FIBRINOGEN; TENASCIN; PROTEINS; PLASMA	It has been reported previously (Turner, P. M., and Lorand, L. (1989) Biochemistry 28, 628-635) that human erythrocyte transglutaminase forms a noncovalent complex with human plasma fibronectin near its collagen-binding domain. In the present study, we show by nondenaturing electrophoresis that guinea pig liver transglutaminase, similarly to the erythrocyte enzyme, forms a complex with human fibronectin. Studies of anisotropic shifts of fluorescein-labeled liver and erythrocyte transglutaminases, upon addition of fibronectin, indicated that both transglutaminases bind to fibronectin with a stoichiometry of about 2:1. Polymerization of fibrinogen by human erythryocyte transglutaminase was inhibited after complex formation with fibronectin. Complexes of fibronectin with either erythrocyte or liver transglutaminase were isolated by glycerol gradient zone sedimentation and examined by rotary shadowing electron microscopy. The globular transglutaminase could be readily identified binding to the thin fibronectin strand. The binding site for transglutaminase was within 5-10 nm of the N terminus of fibronectin, consistent with its proximity to the collagen-binding domain. Under some experimental conditions, the complex of fibronectin with erythrocyte transglutaminase appeared as a ring-shaped structure in which two transglutaminase molecules had probably dimerized. The molecular weight of the erythrocyte transglutaminase was determined by sedimentation equilibrium to be 71,440 +/- 830.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Duke University; Northwestern University	LEMOSY, EK (corresponding author), DUKE UNIV, MED CTR, DEPT CELL BIOL, BOX 3011, DURHAM, NC 27710 USA.			LeMosy, Ellen/0000-0001-5192-2804	NCI NIH HHS [CA 47056] Funding Source: Medline; NHLBI NIH HHS [HL 03512, HL 02212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL002212, K06HL003512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CHURCHICH JE, 1967, BIOCHIM BIOPHYS ACTA, V147, P511, DOI 10.1016/0005-2795(67)90010-4; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; ERICKSON HP, 1981, J CELL BIOL, V91, P673, DOI 10.1083/jcb.91.3.673; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FREYSSINET JM, 1978, BIOCHEM J, V169, P403, DOI 10.1042/bj1690403; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LORAND L, 1988, P NATL ACAD SCI USA, V85, P1057, DOI 10.1073/pnas.85.4.1057; LORAND L, 1979, ANAL BIOCHEM, V93, P453, DOI 10.1016/S0003-2697(79)80178-5; LORAND L, 1981, METHOD ENZYMOL, V80, P333; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; MORROW JS, 1981, J SUPRAMOL STR CELL, V17, P275, DOI 10.1002/jsscb.380170308; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; RADEK J T, 1991, Biophysical Journal, V59, p478A; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SVEDBERG T, 1940, ULTRACENTRIFUGE, P48; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; TURNER PM, 1989, BIOCHEMISTRY-US, V28, P628, DOI 10.1021/bi00428a032; WEBER K, 1969, J BIOL CHEM, V244, P4406	30	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7880	7885						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348509				2022-12-27	WOS:A1992HN48500095
J	RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS				RUF, W; MILES, DJ; REHEMTULLA, A; EDGINGTON, TS			COFACTOR RESIDUES LYSINE-165 AND LYSINE-166 ARE CRITICAL FOR PROTEIN SUBSTRATE RECOGNITION BY THE TISSUE FACTOR-FACTOR-VIIA PROTEASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THROMBOMODULIN; HOMOLOGY DOMAIN; FACTOR PATHWAY; COAGULATION; ACTIVATION; BINDING; THROMBIN; SITE	High affinity binding of factor VIIa (VIIa) to its cellular receptor tissue factor (TF), as well as association of factor X with phospholipid are required for optimal assembly of the extrinsic activation complex. In addition to the interactions of substrate with phospholipid and enzyme, we here provide evidence that cofactor residues Lys-165 and Lys-166 specifically contribute to the recognition of macromolecular substrate. Ala for Lys replacement in TF(A165A166) Was compatible with high affinity binding of VIIa when analyzed on cell surfaces as well as in the absence of phospholipid. Dissociation of TF(A165A166). VIIa did not occur with a faster rate compared to TF . VIIa, further supporting unaltered VIIa binding function of TF(A165A166). Cleavage of chromogenic peptidyl substrate by TF(A165A166)-VIIa complexes was not diminished, demonstrating that TF(A165A166) supported enhancement of catalytic function of the VIIa protease domain. In contrast, factor X activation was reduced in the presence and absence of phospholipid. Further, TF(A165A166) effectively competed with wild-type TF in the cleavage of factor X at limited VIIa concentrations. Selective reduction in macromolecular substrate hydrolysis combined with normal VIIa binding by TF(A165A166) indicates that the cofactor TF does contribute, either directly or indirectly via specific interactions with VIIa, to factor X recognition.			RUF, W (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; FAIR DS, 1987, J BIOL CHEM, V262, P11692; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; KUMAR A, 1991, J BIOL CHEM, V266, P915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MANN KG, 1990, BLOOD, V76, P1; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1989, OXFORD SURVEYS EUKAR, P67; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROY S, 1991, J BIOL CHEM, V266, P4665; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, BIOCHEM J, V278, P729, DOI 10.1042/bj2780729; SAKAI T, 1990, J BIOL CHEM, V265, P1890; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	32	105	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6375	6381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372908				2022-12-27	WOS:A1992HK31800097
J	HIROSE, S; MOHNEY, RP; MUTKA, SC; RAVI, L; SINGLETON, DR; PERRY, G; TARTAKOFF, AM; MEDOF, ME				HIROSE, S; MOHNEY, RP; MUTKA, SC; RAVI, L; SINGLETON, DR; PERRY, G; TARTAKOFF, AM; MEDOF, ME			DERIVATION AND CHARACTERIZATION OF GLYCOINOSITOL-PHOSPHOLIPID ANCHOR-DEFECTIVE HUMAN K562 CELL CLONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; HUMAN-ERYTHROCYTES; MEMBRANE-PROTEIN; REACTIVE LYSIS; COMPLEMENT; BIOSYNTHESIS; DEFICIENT; MOLECULES	To aid in studies of human glycoinositol-phospholipid (GPI) anchor pathway biochemistry in normal and affected paroxysmal nocturnal hemoglobinuria cells, GPI anchor-defective human K562 cell lines were derived by negative fluorescent sorting of anti-decay-accelerating factor (DAF) monoclonal antibody-stained cells either following or in the absence of ethylmethylsulfonate pretreatment. The resulting cloned cells showed deficiencies of both DAF and GPI-anchored CD59, some (designated group A) exhibiting total absence and some (designated group B) exhibiting approximately 10% levels of surface expression of the two proteins. In heterologous cell fusions, group A clones complemented defective Thy-1 expression by class A, B, C, E, and I Thy-1-negative lymphoma lines, but not H or D lines, the latter of which is defective in the Thy-1 structural gene. In contrast, group B clones complemented all previously described GPI anchor pathway-defective lymphoma classes. Immunoradiomatic assays of cells and supernatants and S-35 biosynthetic labeling showed that group A cells degraded DAF protein while group B cells secreted it but failed to attach a GPI anchor structure. [H-3]Man labeling of intact cells and UDP-[H-3]GlcNAc and GDP-[H-3]Man labeling of broken cell preparations demonstrated that group A cells failed to synthesize GlcNAc- and GlcN-PI (GPI-A and -B) as well as more polar mannolipids, whereas group B cells showed accumulation of GlcNAc-PI with approximately 10-fold diminished levels of GlcN-PI and more polar mannolipids. The failed assembly of GlcNAc-PI in group A cells and the reduced conversion of this intermediate to GlcN-PI in group B cells indicates that the former harbors a defect in UDP-GIcNAc transferase or in assembly of its PI acceptor, while the latter harbors a defect in GlcN-PI deacetylase activity.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University			Perry, George/A-8611-2009	Perry, George/0000-0002-6547-0172; Mutka, Sarah/0000-0002-9744-8439; Singleton, David/0000-0002-6154-6774	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAROTHERS DJ, 1990, J CLIN INVEST, V85, P47, DOI 10.1172/JCI114432; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GROUX H, 1989, J IMMUNOL, V142, P3013; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1991, FASEB J, V5, P2459; HIROSE S, 1990, J CELL BIOL, V3, P1094; HOLGUIN MH, 1989, J CLIN INVEST, V84, P1387, DOI 10.1172/JCI114311; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; MEDOF ME, 1987, J CLIN INVEST, V80, P165, DOI 10.1172/JCI113043; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1989, BIOCHEM SOC T, V16, P996; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; OKADA N, 1989, J IMMUNOL, V143, P2262; ROSSE WF, 1990, ANNU REV MED, V41, P431; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TARTAKOFF A, 1990, MOL CELL BIOL MEMBRA, P111	35	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5272	5278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371997				2022-12-27	WOS:A1992HH74700044
J	HARADA, N; OGAWA, H; SHOZU, M; YAMADA, K; SUHARA, K; NISHIDA, E; TAKAGI, Y				HARADA, N; OGAWA, H; SHOZU, M; YAMADA, K; SUHARA, K; NISHIDA, E; TAKAGI, Y			BIOCHEMICAL AND MOLECULAR GENETIC ANALYSES ON PLACENTAL AROMATASE (P-450AROM) DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING HUMAN AROMATASE; CYTOCHROME-P-450; ANDROSTENEDIONE; AROMATIZATION; PURIFICATION; MICROSOMES; EXPRESSION; PROTEINS; TISSUE; MOUSE	Biochemical and molecular genetic studies were made on a case of placental aromatase (P-450AROM) deficiency. Of the enzymes participating in the electron transport system of placental microsomes, only aromatase activity was decreased specifically in the patient, being less than 0.3% of the normal activity. Northern and Western blotting analyses showed that the transcription of the aromatase gene and the translation of its mRNA proceeded normally in the placenta of this patient. However, aromatase cDNA isolated from a placental cDNA library of the patient was found to have an insert of 87 base pairs, encoding 29 amino acids in frame with no termination codon. The insert was located at the splicing point between exon 6 and intron 6 of the normal aromatase gene, and the extra DNA fragment was the first part of intron 6, except that its initial GT was altered to GC. These findings indicated that in this patient with aromatase deficiency, splicing between exon 6 and intron 6 did not occur at the normal position because of a point mutation in its consensus sequence and was forwarded to GT in the next cryptic consensus sequence 87 base pairs downstream according to the canonical GT/AG rule, resulting in translation of an abnormal protein molecule with 29 extra amino acids. During the transient expression in COS-7 cells, the aromatase cDNA of the patient was found to produce a protein with a trace of activity. This is the first report of a genetic defect for aromatase deficiency.	KANAZAWA UNIV,SCH MED,DEPT OBSTET & GYNECOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,FAC SCI,DEPT CHEM,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University	HARADA, N (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,DIV MOLEC GENET,TOYOAKE,AICHI 47011,JAPAN.							CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; COVEY DF, 1988, BIOCHEM BIOPH RES CO, V157, P81, DOI 10.1016/S0006-291X(88)80014-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HARADA N, 1988, J BIOCHEM-TOKYO, V103, P106, DOI 10.1093/oxfordjournals.jbchem.a122213; HARADA N, 1984, J BIOL CHEM, V259, P1265; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; KEENAN BS, 1974, J CLIN ENDOCR METAB, V38, P1143, DOI 10.1210/jcem-38-6-1143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGCOPE C, 1978, J CLIN ENDOCR METAB, V46, P146, DOI 10.1210/jcem-46-1-146; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MANGO D, 1978, EUR J OBSTET GYN R B, V8, P65, DOI 10.1016/0028-2243(78)90129-6; Maniatis T., 1982, MOL CLONING; MEANS GD, 1989, J BIOL CHEM, V264, P19385; Miller J. H, 1972, EXPT MOL GENETICS; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; RYAN KJ, 1972, AM J OBSTET GYNECOL, V114, P454, DOI 10.1016/0002-9378(72)90204-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER AE, 1972, J CLIN ENDOCR METAB, V35, P627, DOI 10.1210/jcem-35-4-627; SCHWEIKERT HU, 1975, J CLIN ENDOCR METAB, V40, P413, DOI 10.1210/jcem-40-3-413; SETHUMADHAVAN K, 1991, MOL CELL ENDOCRINOL, V78, P25, DOI 10.1016/0303-7207(91)90182-R; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; [No title captured]	31	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4781	4785						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371509				2022-12-27	WOS:A1992HF64200075
J	BURNS, DL; KESSEL, M; ARCINIEGA, JL; KARPAS, A; GOULDKOSTKA, J				BURNS, DL; KESSEL, M; ARCINIEGA, JL; KARPAS, A; GOULDKOSTKA, J			IMMUNOCHEMICAL LOCALIZATION OF A REGION OF CHAPERONIN-60 IMPORTANT FOR PRODUCTIVE INTERACTION WITH CHAPERONIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; PROTEIN; GROE; PURIFICATION; ATP	An IgG, monoclonal antibody (mAb 54G8) which binds to both Bordetella pertussis chaperonin-60 (cpn60) and Escherichia coli cpn60 (GroEL) was produced. mAb 54G8 as well as Fab fragments prepared from this antibody were found to abolish the ability of chaperonin-10 (cpn10, GroES) to inhibit the ATPase activity of both B. pertussis cpn60 and E. coli cpn60. Electron microscopy was used to localize the binding site of the monoclonal antibody on the B. pertussis cpn60 molecule. In the absence of the antibody, the B. pertussis molecule exhibited the tetradecameric structure typical of cpn60. Both end views (showing 7-fold symmetry of the face of the molecule) and side views were evident. When mAb 54G8 was bound, B. pertussis cpn60 molecules appeared to be cross-linked so that they formed long chains. Only side views of the molecules were seen in these long chains. When B. pertussis cpn60 complexed with Fab fragments of mAb 54G8 was examined, chains were no longer observed. Instead, side views of B. pertussis cpn60 were often seen with Fab fragments extending from the ends of the molecule. These data indicate that mAb 54G8 appears to bind at or near the end of the B. pertussis cpn60 molecule and that binding of mAb 54G8 at this location affects the ability of cpn10 to productively interact with cpn60, most likely either by sterically blocking the binding of cpn10, by affecting the conformation of cpn60 in such a way that it no longer binds cpn10, or by inhibiting proper transduction of the effects of cpn10 binding.	UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park	BURNS, DL (corresponding author), US FDA,DIV BACTERIAL PROD,CBER,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURNS DL, 1991, INFECT IMMUN, V59, P1417, DOI 10.1128/IAI.59.4.1417-1422.1991; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; ROUSE DA, 1990, INFECT IMMUN, V58, P1445, DOI 10.1128/IAI.58.5.1445-1449.1990; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	21	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25632	25635						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361184				2022-12-27	WOS:A1992KD07300004
J	BEEBE, SJ; SALOMONSKY, P; JAHNSEN, T; LI, YX				BEEBE, SJ; SALOMONSKY, P; JAHNSEN, T; LI, YX			THE C-GAMMA SUBUNIT IS A UNIQUE ISOZYME OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; INHIBITOR PROTEIN; MOLECULAR-CLONING; RAT TESTIS; CELLS; FORM; IDENTIFICATION; PURIFICATION; MECHANISM; ISOFORMS	There are at least three isozymes (Calpha, Cbeta, and Cgamma) of the mammalian catalytic (C) subunit of cAMP-dependent protein kinase (PKA) (Beebe, S., Oyen, O., Sandberg, M., Froysa, A., Hansson, V., and Jahnsen, T. (1990) Mol. Endocrinol. 4, 465-475). To compare the Cgamma and Calpha isozymes, the respective cDNAs were expressed in permanently transformed Kin-8 PKA-deficient Y1 adrenal cells using the mouse metallothionein promoter. The recombinant C subunits were characterized as immunoreactive, zinc-inducible, cAMP-dependent kinase activities. In contrast to Calpha, histone was a better substrate than Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) for Cgamma. Furthermore, Cgamma histone kinase activity was not inhibited by the protein kinase inhibitor peptide (5-24 amide), which has been widely used as a PKA-specific inhibitor. The major Cgamma peak (type I) eluted from DEAE-Sepharose at a higher NaCl concentration (120 mM) than the Calpha type I eluted (70 mM). Cgamma and Calpha type II eluted between 220 and 240 mM NaCl. Cgamma required higher concentrations of cAMP than Calpha did for dissociation from the mutant type I holoenzyme. These differences provided a basis for the separation of the mutant RI-associated isozymes on DEAE-Sepharose. Both Calpha (41-42 kDa) and Cgamma (39-40 kDa) were identified by a C subunit antibody after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis. Zinc induced the PKA-mediated rounding phenotype in Cgamma and Calpha clones, thereby restoring the cells to the parent Y1 adrenal cell phenotype. Collectively, these data indicate that Cgamma is an active PKA C subunit but suggest that Cgamma and Calpha have different protein and peptide recognition determinants.	EASTERN VIRGINIA MED SCH, PEDIAT RES CTR, DEPT PEDIAT, NORFOLK, VA 23501 USA; UNIV OSLO, DEPT MED BIOCHEM, N-0317 OSLO, NORWAY; UNIV OSLO, RIKSHOSP, N-0317 OSLO, NORWAY; EASTERN VIRGINIA MED SCH, PEDIAT RES CTR, DEPT PHYSIOL, NORFOLK, VA 23501 USA	Eastern Virginia Medical School; University of Oslo; University of Oslo; National Hospital Norway; Eastern Virginia Medical School				Oyen, Ole/0000-0001-6615-3542	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY CD, 1973, J BIOL CHEM, V248, P1255; BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEEBE SJ, 1984, MOL CELL ENDOCRINOL, V36, P67, DOI 10.1016/0303-7207(84)90086-8; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1992, DEV BIOL, V151, P48, DOI 10.1016/0012-1606(92)90212-Y; BEEBE SJ, 1986, ENZYMES, V17, P43; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; FOSS KB, 1992, CYTOGENET CELL GENET, V60, P22, DOI 10.1159/000133286; GLASS DB, 1986, J BIOL CHEM, V261, P2166; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; OLSON M, 1991, END SOC ABSTR, V622, P186; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; REED J, 1983, ARCH BIOCHEM BIOPHYS, V222, P276, DOI 10.1016/0003-9861(83)90525-8; ROBINSONSTEINER A, 1984, J BIOL CHEM, V250, P10596; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	36	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25505	25512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334096				2022-12-27	WOS:A1992KB60300089
J	WU, Y; RICH, CB; LINCECUM, J; TRACKMAN, PC; KAGAN, HM; FOSTER, JA				WU, Y; RICH, CB; LINCECUM, J; TRACKMAN, PC; KAGAN, HM; FOSTER, JA			CHARACTERIZATION AND DEVELOPMENTAL EXPRESSION OF CHICK AORTIC LYSYL OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; ELASTIN SYNTHESIS; SMOOTH-MUSCLE; TROPOELASTIN; RAT; CLONING; GENE; CARTILAGE; CULTURES; SEQUENCE	The complete primary structure of chick lysyl oxidase was determined by recombinant DNA techniques. The nucleotide sequence of contiguous chick lysyl oxidase cDNA clones contained an open reading frame of 1260 bases which encodes a predicted protein of 420 amino acid residues (48,150 Da). In comparison to the deduced primary structure of rat lysyl oxidase, the chick enzyme is larger in size and exhibits a strong conservation of sequence within the latter two thirds of the molecule (92% identity) and a high degree of divergence in the first 150 amino acid residues (60% identity allowing for several insertions in both sequences). The developmental steady-state levels of lysyl oxidase mRNA together with the mRNAs encoding two of the enzyme's substrates (tropoelastin and type I collagen) increased between 8 and 16 days of embryonic development. Although levels of lysyl oxidase mRNA increased during aortic embryogenesis, the specific activity of the enzyme remained fairly constant suggesting that lysyl oxidase activity increases in direct proportion to total protein synthesis and cell number. In situ hybridization showed that the spatial expressions of lysyl oxidase and tropoelastin transcripts differ suggesting that the enzyme and substrate genes are differentially regulated within the cells of the arterial wall.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University			Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL030061] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42414, HL30061, HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARONE LM, 1988, BIOCHEMISTRY-US, V27, P3175, DOI 10.1021/bi00409a008; BARRINEAU LL, 1981, DEV BIOL, V87, P46, DOI 10.1016/0012-1606(81)90059-2; BAULE VJ, 1988, BIOCHEM BIOPH RES CO, V154, P1054, DOI 10.1016/0006-291X(88)90247-1; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P1894; DADD C, 1990, THESIS SYRACUSE U; DUBICK MA, 1985, EXP LUNG RES, V8, P227, DOI 10.3109/01902148509087806; EICHNER R, 1979, ARCH BIOCHEM BIOPHYS, V198, P414, DOI 10.1016/0003-9861(79)90515-0; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FRANZBLAU C, 1981, CELL BIOL EXTRACELLU, P65; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GALLOP PM, 1975, PHYSIOL REV, V55, P418, DOI 10.1152/physrev.1975.55.3.418; GLUKHOVA MA, 1990, J BIOL CHEM, V265, P13042; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARRIS ED, 1986, J NUTR, V116, P252, DOI 10.1093/jn/116.2.252; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KADAR A, 1979, EXP PATHOL S, V5, P9; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; Maniatis T., 1982, MOL CLONING; MARIANI TJ, 1992, IN PRESS MATRIX; OLLIVER L, 1987, COLLAGEN REL RES, V7, P77; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; POLLOCK J, 1990, J BIOL CHEM, V265, P3697; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; STASSEN FLH, 1976, BIOCHIM BIOPHYS ACTA, V438, P49, DOI 10.1016/0005-2744(76)90222-9; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V276, P8666; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	40	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24199	24206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360009				2022-12-27	WOS:A1992KA26300012
J	ANDERSON, GL; WILLIAMS, J; HILLE, R				ANDERSON, GL; WILLIAMS, J; HILLE, R			THE PURIFICATION AND CHARACTERIZATION OF ARSENITE OXIDASE FROM ALCALIGENES-FAECALIS, A MOLYBDENUM-CONTAINING HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-SPIN-RESONANCE; ESCHERICHIA-COLI; XANTHINE-OXIDASE; PSEUDOMONAS-PUTIDA; ADP-ARSENATE; RESISTANCE; CENTERS; SYSTEMS; CLUSTER	The purification and initial characterization of arsenite oxidase from Alcaligenes faecalis are described. The enzyme consists of a monomer of 85 kDa containing one molybdenum, five or six irons, and inorganic sulfide. In the presence of denaturants arsenite oxidase releases a fluorescent material with specral properties identical to the pterin cofactor released by the hydroxylase class of molybdenum-containing enzymes. Azurin and a c-type cytochrome, both isolated from A. faecalis, each serves as an electron acceptor to arsenite oxidase and may form a periplasmic electron transfer pathway for arsenite detoxification. Full reduction of arsenite oxidase requires 3-4 reducing equivalents, using either arsenite or dithionite as the electron source. Below 20 K, oxidized arsenite oxidase exhibits an EPR signal with g values of 2.03, 2.01, and 2.00, which integrates to approximately 0.4 spins/protein. Since enrichment in Fe-57 results in broadening of this EPR signal, the center giving rise to this signal must contain iron. The most plausible candidates are a [4Fe-4S] high potential iron protein center or a [3Fe-4S] center. The EPR signal observed in oxidized arsenite oxidase disappears upon reduction of the protein with either arsenite or dithionite. Concomitantly, a rhombic EPR signal (g = 2.03, 1.89, 1.76) appears which is similar to that of Rieske-type [2Fe-2S] clusters and spin quantifies to one spin/protein.	OHIO STATE UNIV,DEPT MED BIOCHEM,1645 NEIL AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL PHARM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIEHS NIH HHS [ES 04882] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004882] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; Bard A. J., 1985, STANDARD POTENTIALS; BENKO V, 1977, ENVIRON RES, V13, P386; CHANDRASEKAR R, 1986, J BIOL CHEM, V261, P3616; CODDINGTON K, 1986, TOXICOL ENVIRON CHEM, V11, P281, DOI 10.1080/02772248609357139; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRANE RK, 1953, J BIOL CHEM, V201, P235; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; FEE JA, 1984, J BIOL CHEM, V259, P124; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOX BG, 1988, J BIOL CHEM, V263, P10553; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; Goyer R.A., 1986, CASARETT DOULLS TOXI, P582; Green H. H., 1918, REP DIR VET RES S AF, V5, P593; GRESSER MJ, 1981, J BIOL CHEM, V256, P5981; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; HEMMERICH P, 1964, HELV CHIM ACTA, V47, P464, DOI 10.1002/hlca.19640470214; Hille R., 1985, Metal Ions in Biology, V7, P443; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; ISHINISHI N, 1986, HDB TOXICOLOGY METAL, P43; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KNOWLES FC, 1983, TRENDS BIOCHEM SCI, V8, P178, DOI 10.1016/0968-0004(83)90168-8; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN AG, 1979, J AM CHEM SOC, V101, P2302, DOI 10.1021/ja00503a009; LEGGE JW, 1954, AUST J BIOL SCI, V7, P504, DOI 10.1071/BI9540504; LEGGE JW, 1954, AUST J BIOL SCI, V7, P496, DOI 10.1071/BI9540496; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKIN R, 1978, BIOCHIM BIOPHYS ACTA, V505, P147, DOI 10.1016/0304-4173(78)90011-3; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; MITRA S, 1982, P NATL ACAD SCI USA, V79, P6907; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; MOORE SA, 1983, J BIOL CHEM, V258, P6266; OEHME FW, 1972, TOXICOLOGY, V5, P215; OSBORNE FH, 1976, J APPL BACTERIOL, V41, P295, DOI 10.1111/j.1365-2672.1976.tb00633.x; PALMER G, 1975, ENZYMES, V12, P1; PHILLIPS SE, 1976, APPL ENVIRON MICROB, V32, P392, DOI 10.1128/AEM.32.3.392-399.1976; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; RINDERLE SJ, 1984, FED PROC, V43, P2060; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; SAUBER K, 1977, EUR J BIOCHEM, V74, P89, DOI 10.1111/j.1432-1033.1977.tb11370.x; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; TURNER AW, 1954, AUST J BIOL SCI, V7, P479, DOI 10.1071/BI9540479; TURNER AW, 1954, AUST J BIOL SCI, V7, P452, DOI 10.1071/BI9540452; TURNER AW, 1949, NATURE, V164, P76, DOI 10.1038/164076a0; TWILFER H, 1981, EUR J BIOCHEM, V119, P595, DOI 10.1111/j.1432-1033.1981.tb05649.x; VAHTER M, 1983, ENVIRON RES, V32, P13; WILLIAMS JW, 1986, FASEB J, V45, P1660; WILLSKY GR, 1980, J BACTERIOL, V144, P366, DOI 10.1128/JB.144.1.366-374.1980; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; [No title captured]	61	225	247	3	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23674	23682						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331097				2022-12-27	WOS:A1992JZ23900040
J	ARMENDARIZBORUNDA, J; KATAYAMA, K; SEYER, JM				ARMENDARIZBORUNDA, J; KATAYAMA, K; SEYER, JM			TRANSCRIPTIONAL MECHANISMS OF TYPE-I COLLAGEN GENE-EXPRESSION ARE DIFFERENTIALLY REGULATED BY INTERLEUKIN-1-BETA, TUMOR-NECROSIS-FACTOR-ALPHA, AND TRANSFORMING GROWTH-FACTOR-BETA IN ITO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; EXPERIMENTAL HEPATIC-FIBROSIS; ALCOHOLIC LIVER-DISEASE; VITAMIN-A; DISSE SPACE; FIBROBLASTS; MATRIX; RAT; RESPONSIVENESS; FACTOR-BETA-1	Regulation of the procollagen type I (Pro-alpha-1) gene in cultured Ito cells by diverse cytokines was studied. Specifically, we have examined the effect of interleukin-1-beta (IL-1-beta), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta) on collagen biosynthesis, levels of Pro-alpha-1(I) mRNA, and rate of transcription of Pro-alpha-1(I) gene. TGF-beta stimulated procollagen synthesis at least 2-fold at every concentration tested (5-20 ng/ml), whereas TNF-alpha inhibited it at the same concentrations. In contrast to what occurs in dermal fibroblasts, IL-1-beta (5-20 units/ml) preferentially inhibited procollagen production as measured by [H-3]proline incorporation. A similar pattern was obtained when total protein synthesis was analyzed by [25S]methionine radiolabeling. Interestingly, while TGF-beta-treated cells exhibited greater than 3-fold increase in steady-state levels of Pro-alpha-1(I) mRNA, the treatment with IL-1 had no effect on procollagen mRNA levels. TNF-alpha treatment resulted in a 2-fold decrease in the amount of collagen mRNA. The treatment with combinations of cytokines indicated that collagen gene expression in Ito cells is differentially regulated by these cytokines. Furthermore, nuclear run-off transcription experiments were performed. The results obtained suggest that TGF-beta regulates increasing collagen type I gene expression at transcriptional levels, and TNF-alpha inhibits the transcriptional rate of Pro-alpha-1 (I) gene. It is noteworthy that IL-1-beta acts on collagen type I gene regulation by a separate mechanism at a posttranscriptional level.	ASAHIKAWA RED CROSS HOSP,DEPT ORTHOPED,HOKKAIDO 070,JAPAN; VET AFFAIRS MED CTR,RES SERV,MEMPHIS,TN 38014; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center	ARMENDARIZBORUNDA, J (corresponding author), UNIV TENNESSEE,DEPT MED,MEMPHIS,TN 38103, USA.		Armendáriz-Borunda, Juan/AAU-1471-2021		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM016505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039166, R01AR026034] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM16505] Funding Source: Medline; NIAMS NIH HHS [AR39166, AR26034] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; ARMENDARIZBORUNDA J, 1989, MATRIX, V9, P150, DOI 10.1016/S0934-8832(89)80034-4; Ausubel FM, 1988, MOL REPROD DEV; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1990, SEMIN LIVER DIS, V10, P1; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P1233; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENWEL P, 1991, LAB INVEST, V65, P644; KENT G, 1976, P NATL ACAD SCI USA, V73, P3719, DOI 10.1073/pnas.73.10.3719; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZHERNANDEZ A, 1991, HEPATOLOGY, V14, P864, DOI 10.1002/hep.1840140519; MATSUOKA M, 1989, LIVER, V9, P71; MINATO Y, 1983, HEPATOLOGY, V3, P559; NAKAGAWA S, 1989, EXP CELL RES, V182, P572, DOI 10.1016/0014-4827(89)90260-7; OHYAMA K, 1990, J LAB CLIN MED, V116, P219; ORREGO H, 1979, GUT, V20, P673, DOI 10.1136/gut.20.8.673; PIQUET PF, 1989, 2ND P INT C TUM NECR, P63; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; RAGHOW R, 1987, J BIOL CHEM, V262, P8409; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; SCHAFFNER F, 1963, GASTROENTEROLOGY, V44, P239; SENOO H, 1985, LAB INVEST, V52, P182; SHIRATORI Y, 1987, DIGEST DIS SCI, V32, P1281, DOI 10.1007/BF01296379; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAKASE S, 1988, J HEPATOL, V6, P267, DOI 10.1016/S0168-8278(88)80042-4; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; YOKOI Y, 1988, LIVER, V8, P48; [No title captured]	36	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14316	14321						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352775				2022-12-27	WOS:A1992JD32500081
J	WERTHEIMER, SJ; MYERS, CL; WALLACE, RW; PARKS, TP				WERTHEIMER, SJ; MYERS, CL; WALLACE, RW; PARKS, TP			INTERCELLULAR-ADHESION MOLECULE-1 GENE-EXPRESSION IN HUMAN ENDOTHELIAL-CELLS - DIFFERENTIAL REGULATION BY TUMOR-NECROSIS-FACTOR-ALPHA AND PHORBOL-MYRISTATE ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MESSENGER-RNA; TRANSENDOTHELIAL MIGRATION; INTERFERON-GAMMA; ICAM-1; LFA-1; ACTIVATION; IDENTIFICATION; ADHERENCE; SEQUENCE	Intercellular adhesion molecule-1 (ICAM-1) is an inducible glycoprotein expressed on the surface of inflamed endothelium which mediates in part the extravasation of granulocytes into sites of infection or injury. ICAM-1 mRNA is not detected in unstimulated human umbilical vein endothelial cells (HUVECs), but accumulates transiently following tumor necrosis factor-alpha (TNF-alpha) or phorbol myristate acetate (PMA) treatment with maximal steady state levels occurring at 2 or 4 h, respectively. Pretreating HUVECs with PMA for 72 h down-regulates protein kinase C and inhibits the subsequent induction of ICAM-1 mRNA by PMA, but does not affect TNF-alpha-induced message accumulation. Nuclear run-on assays showed that the ICAM-1 gene is transcribed under basal conditions in HUVECs, and that TNF-alpha stimulates transcriptional activity 3- to 4-fold within 30 min of treatment. In contrast, PMA has little effect on ICAM-1 gene transcription up to 4 h following stimulation. Message stability studies established that ICAM-1 mRNA induced by PMA has a longer half-life than the TNF-alpha-induced message. These results suggest that PMA acts through protein kinase C to up-regulate ICAM-1 expression primarily at a post-transcriptional level by stabilizing ICAM-1 mRNA, whereas TNF-alpha transcriptionally regulates ICAM-1 gene expression through an undefined, protein kinase C-independent pathway.			WERTHEIMER, SJ (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT BIOCHEM,RIDGEFIELD,CT 06877, USA.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTON RW, 1989, J IMMUNOL, V143, P1278; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; COSIMI AB, 1990, J IMMUNOL, V144, P4604; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9722; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLAVIN T, 1991, TRANSPLANT P, V23, P533; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARLAN JM, 1985, BLOOD, V65, P513; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNRO JM, 1989, AM J PATHOL, V135, P121; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; POBER JS, 1987, J IMMUNOL, V138, P3319; POBER JS, 1986, J IMMUNOL, V137, P1893; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4282; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YAMOTO K, 1989, J CELL PHYSL, V139, P610	54	257	258	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12030	12035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351055				2022-12-27	WOS:A1992HY94700059
J	LOHSE, MJ; ANDEXINGER, S; PITCHER, J; TRUKAWINSKI, S; CODINA, J; FAURE, JP; CARON, MG; LEFKOWITZ, RJ				LOHSE, MJ; ANDEXINGER, S; PITCHER, J; TRUKAWINSKI, S; CODINA, J; FAURE, JP; CARON, MG; LEFKOWITZ, RJ			RECEPTOR-SPECIFIC DESENSITIZATION WITH PURIFIED PROTEINS - KINASE DEPENDENCE AND RECEPTOR SPECIFICITY OF BETA-ARRESTIN AND ARRESTIN IN THE BETA-2-ADRENERGIC RECEPTOR AND RHODOPSIN SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; NUCLEOTIDE-BINDING-PROTEIN; ROD OUTER SEGMENTS; ADRENERGIC-RECEPTOR; HETEROLOGOUS DESENSITIZATION; PHOSPHORYLATION SITES; DISTINCT PATHWAYS; LIGHT-SCATTERING; 48-KDA PROTEIN; ACTIVATION	Homologous desensitization of beta-adrenergic receptors, as well as adaptation of rhodopsin, are thought to be triggered by specific phosphorylation of the receptor proteins. However, phosphorylation alone seems insufficient to inhibit receptor function, and it has been proposed that the inhibition is mediated, following receptor phosphorylation, by the additional proteins beta-arrestin in the case of beta-adrenergic receptors and arrestin in the case of rhodopsin. In order to test this hypothesis with isolated proteins, beta-arrestin and arrestin were produced by transient overexpression of their cDNAs in COS7 cells and purified to apparent homogeneity. Their functional effects were assessed in reconstituted receptor/G protein systems using either beta-2-adrenergic receptors with G(s) or rhodopsin with G(t). Prior to the assays, beta-2-receptors and rhodopsin were phosphorylated by their specific kinases beta-adrenergic receptor kinase (beta-ARK) and rhodopsin kinase, respectively. Beta-arrestin was a potent inhibitor of the function of beta-ARK-phosphorylated beta-2-receptors. Half-maximal inhibition occurred at a beta-arrestin:beta-2-receptor stoichiometry of about 1:1. More than 100-fold higher concentrations of arrestin were required to inhibit beta-2-receptor function. Conversely, arrestin caused half-maximal inhibition of the function of rhodopsin kinase-phosphorylated rhodopsin when present in concentrations about equal to those of rhodopsin, whereas beta-arrestin at 100-fold higher concentrations had little inhibitory effect. The potency of beta-arrestin in inhibiting beta-2-receptor function was increased over 10-fold following phosphorylation of the receptors by beta-ARK, but was not affected by receptor phosphorylation using protein kinase A. This suggests that beta-arrestin plays a role in beta-ARK-mediated homologous, but not in protein kinase A-mediated heterologous desensitization of beta-adrenergic receptors. It is concluded that even though arrestin and beta-arrestin are similar proteins, they display marked specificity for their respective receptors and that phosphorylation of the receptors by the receptor-specific kinases serves to permit the inhibitory effects of the "arresting" proteins by allowing them to bind to the receptors and thereby inhibit their signaling properties. Furthermore, it is shown that this mechanism of receptor inhibition can be reproduced with isolated purified proteins.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV PARIS 06,INSERM,F-75270 PARIS 06,FRANCE	Duke University; Howard Hughes Medical Institute; Baylor College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	LOHSE, MJ (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Pitcher, Julie/ABH-2078-2020; Lohse, Martin J/A-7160-2012; Lefkowitz, Robert/AAW-2649-2021	Lohse, Martin J/0000-0002-0599-3510; 	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NIDDK NIH HHS [DK 19318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CODINA J, 1984, J BIOL CHEM, V259, P5871; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; DOREY C, 1982, OPHTHALMIC RES, V14, P249, DOI 10.1159/000265199; FAURE JP, 1984, CURR EYE RES, V3, P867, DOI 10.3109/02713688409000800; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIGGETT SB, 1989, MOL PHARMACOL, V36, P343; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SHICHI H, 1984, VISION RES, V24, P1523, DOI 10.1016/S0042-6989(84)80001-2; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6875; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STIEMER RH, 1992, IN PRESS J AUTOIMMUN; WAGNER R, 1988, FEBS LETT, V235, P103, DOI 10.1016/0014-5793(88)81242-0; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZIGLER JS, 1984, INVEST OPHTH VIS SCI, V25, P977	43	284	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8558	8564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349018				2022-12-27	WOS:A1992HQ18500090
J	IMAMURA, T; TOKITA, Y; MITSUI, Y				IMAMURA, T; TOKITA, Y; MITSUI, Y			IDENTIFICATION OF A HEPARIN-BINDING GROWTH FACTOR-I NUCLEAR TRANSLOCATION SEQUENCE BY DELETION MUTATION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; FIBROBLAST; RECEPTOR; LOCALIZATION; PURIFICATION; ONCOPROTEIN; 3T3-CELLS; PROTEINS	We have shown previously that a deletion mutant of human heparin-binding growth factor (HBGF)-1, HBGF-1U, lacking the sequence Asn-Tyr-Lys-Lys-Pro-Lys-Leu is capable of initiating c-fos mRNA expression and polypeptide phosphorylation on tyrosine residues at concentrations that do not induce either DNA synthesis or cell proliferation (1). The fact that addition of the nuclear translocation signal from the yeast histone 2B protein to the HBGF-1U mutant caused reconstitution of the biological activity of HBGF-1 indicated that nuclear translocation may be an important component of the mitogenic signal induced by HBGF-1. In order to examine the nuclear translocation potential of HBGF-1-alpha, the deletion mutant HBGF-1U, and the yeast histone 2B-HBGF-1 chimera, HBGF-1U2, we expressed these forms of HBGF1 in murine endothelial cells. Western blot and two-dimensional Western blot analysis of cytosol and nuclei demonstrate that although the three forms of HBGF-1 are readily detectable in the cytosol of the individual transfectants, HBGF-1-alpha and HBGF-1U2 but not HBGF-1U was detected in the nucleus. Furthermore, murine endothelial cells expressing HBGF-1-alpha and HBGF-1U2 exhibited an atypical cellular phenotype in vitro that was absent in the HBGF-1U transfectants. These data suggest that HBGF-1 contains a functional nuclear translocation sequence that may be responsible for the initiation of DNA synthesis, and these data further correlate the presence of the nuclear translocation sequence with an abnormal endothelial cell phenotype in vitro.			IMAMURA, T (corresponding author), FERMENTAT RES INST, DIV CELL SCI & TECHNOL, HIGASHI 1-1-3, TSUKUBA, IBARAKI 305, JAPAN.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARCIS I, 1989, ONCOGENE, V4, P335; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	30	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5676	5679						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372009				2022-12-27	WOS:A1992HH74700101
J	SCHNABEL, D; SCHRODER, M; FURST, W; KLEIN, A; HURWITZ, R; ZENK, T; WEBER, J; HARZER, K; PATON, BC; POULOS, A; SUZUKI, K; SANDHOFF, K				SCHNABEL, D; SCHRODER, M; FURST, W; KLEIN, A; HURWITZ, R; ZENK, T; WEBER, J; HARZER, K; PATON, BC; POULOS, A; SUZUKI, K; SANDHOFF, K			SIMULTANEOUS DEFICIENCY OF SPHINGOLIPID ACTIVATOR PROTEINS-1 AND PROTEINS-2 IS CAUSED BY A MUTATION IN THE INITIATION CODON OF THEIR COMMON GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO-BETA-GLUCOSIDASE; METACHROMATIC LEUKODYSTROPHY; CEREBROSIDE-SULFATASE; ENZYMATIC-HYDROLYSIS; HUMAN-FIBROBLASTS; GAUCHERS-DISEASE; MESSENGER-RNA; ACID; PURIFICATION; DEGRADATION	Sphingolipid activator proteins (SAPs) are small, nonenzymic glycoproteins that stimulate lysosomal degradation of various sphingolipids. SAP-1, SAP-2, and two additional potential activator proteins are derived from a common precursor by proteolytic processing. A severe case of sphingolipid storage disease that led to death within 16 weeks was attributed to a possible total deficiency of the SAPs generated by this gene (Harzer, K., Paton, B. C., Poulos, A., Kustermann-Kuhn, B., Roggendorf, W., Grisar, T., and Popp, M. (1989) Eur. J. Pediatr. 149, 31-39). Analysis of the SAP precursor cDNA from the patient and his fetal sibling showed an A to T transversion in the initiation codon. Allele-specific oligonucleotide hybridization revealed that both parents are heterozygous carriers for this mutation. In pulse-chase experiments using antisera raised against SAP-1 or SAP-2, no cross-reacting material could be detected in the patients' fibroblasts.	UNIV BONN, INST ORGAN CHEM & BIOCHEM, GERHARD DOMAGK STR 1, W-5300 BONN 1, GERMANY; UNIV BONN, INST CLIN BIOCHEM, W-5300 BONN, GERMANY; UNIV TUBINGEN, INST BRAIN RES, W-7400 TUBINGEN 1, GERMANY; ADELAIDE MED CTR WOMEN & CHILDREN, DEPT CHEM PATHOL, ADELAIDE, SA 5006, AUSTRALIA; UNIV N CAROLINA, SCH MED, BRAIN & DEV RES CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT NEUROL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PSYCHIAT, CHAPEL HILL, NC 27599 USA	University of Bonn; University of Bonn; Eberhard Karls University of Tubingen; Womens & Childrens Hospital Australia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Schnabel, Dirk/0000-0002-7944-7790	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289, R01NS028997] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [R01-NS28997, R01-NS24289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P491; BANKS MN, 1987, GLYCOCONJUGATE J, V4, P157, DOI 10.1007/BF01049453; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG J, 1985, BIOL CHEM H-S, V366, P887, DOI 10.1515/bchm3.1985.366.2.887; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; CHRISTOMANOU H, 1980, H-S Z PHYSIOL CHEM, V361, P1489, DOI 10.1515/bchm2.1980.361.2.1489; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; CONZELMANN E, 1987, METHOD ENZYMOL, V138, P792; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; CONZELMANN E, 1989, MOL BASIS MEMBRANE A, P379; FISCHER G, 1978, BIOCHIM BIOPHYS ACTA, V528, P69, DOI 10.1016/0005-2760(78)90053-X; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1991, BIOCHEM BIOPH RES CO, V177, P1211, DOI 10.1016/0006-291X(91)90670-3; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1988, J BIOL CHEM, V263, P6588; MEIER EM, 1991, J BIOL CHEM, V266, P1879; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PETERS SP, 1977, J BIOL CHEM, V252, P563; POTIER M, 1990, BIOCHEM BIOPH RES CO, V173, P449, DOI 10.1016/S0006-291X(05)81079-4; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; STEVENS RL, 1981, AM J HUM GENET, V33, P900; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	45	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3312	3315						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371116				2022-12-27	WOS:A1992HD15400078
J	ERBAN, JK; WAGNER, DD				ERBAN, JK; WAGNER, DD			A 130-KDA PROTEIN ON ENDOTHELIAL-CELLS BINDS TO AMINO-ACIDS 15-42 OF THE B-BETA CHAIN OF FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; VONWILLEBRAND-FACTOR; ADHESION MOLECULE-1; ACTIVATED PLATELETS; GLYCOPROTEIN-IIB; HUMAN-BLOOD; FRAGMENT-D; RECEPTOR; RELEASE	Factors which stimulate the release of von Willebrand factor (vWf) from endothelial cell Weibel-Palade bodies and which induce the expression of the leukocyte-binding adhesion molecule P-selectin (PADGEM, GMP-140, CD62) on the endothelial cell surface remain incompletely characterized. Fibrin but not fibrinogen is a potent stimulus for the release of stored von Willebrand factor from endothelial cells. Removal of fibrinopeptides A and B from fibrinogen occurs during the formation of fibrin, and the removal of fibrinopeptide B is a requirement for fibrin to induce vWf secretion. The cleavage of fibrinopeptide A by reptilase enzyme forms a fibrin gel yet it is incapable of stimulating Weibel-Palade body degranulation. As a consequence of removing fibrinopeptide B, B-beta-15-42 becomes the new NH2 terminus of the beta-chain of fibrin. We have shown that the peptide B-beta-15-42 in solution inhibits the release of vWf stimulated by fibrin. In addition, B-beta-15-42 coupled to ovalbumin supports the binding and spreading of endothelial cells, while a scrambled form of this peptide coupled to the same carrier does not. We investigated whether these determinants near the amino terminus of the beta-chain of fibrin bind to a specific protein on the surface of endothelial cells. A 130-kDa protein was isolated from surface-labeled human umbilical vein endothelial cells by specific binding to B-beta-15-42 immobilized on Sepharose. This glycoprotein was eluted with the B-beta-15-42 peptide in solution but not with the scrambled form of this peptide. The fibrin-derived peptides B-beta-19-26 and B-beta-37-56-cysteine were also incapable of eluting the 130-kDa protein bound to immobilized B-beta-15-42 as were the arginine-glycine-aspartic acid-serine RGDS tetrapeptide and EDTA. The 130-kDa protein is recognized neither by antibodies to the known integrins found on endothelial cells nor by antibodies to CD31(endoCAM, PECAM-1), a member of the immunoglobulin family of receptors found on endothelial cells. The beta-chain of fibrin thus contains a sequence near its amino terminus which specifically binds to what is likely a novel endothelial cell surface protein. This glycoprotein may promote endothelial cell adhesion to fibrin during the wound healing process and is a candidate for a receptor involved in fibrin-mediated release of Weibel-Palade bodies from endothelial cells.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University	ERBAN, JK (corresponding author), NEW ENGLAND MED CTR HOSP,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.				NHLBI NIH HHS [HL08188, P01 HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443, F32HL008188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA S, 1990, J CELL BIOL, V220, P1227; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLOMBACK B, 1958, ARK KEMI, V12, P321; BONFANTI R, 1989, BLOOD, V73, P1109; BUNCE LA, 1991, THROMB HAEMOSTASIS, V65, P1225; CHEN CS, 1988, BIOCHEMISTRY-US, V27, P6121, DOI 10.1021/bi00416a044; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CONFORTI G, 1989, BLOOD, V73, P1576; DANG CV, 1985, SCIENCE, V227, P1487, DOI 10.1126/science.4038818; DAYHOFF M, 1973, ATLAS PROTEIN SEQUEN, V5, pS29; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DELVOS U, 1988, HAEMOSTASIS, V18, P99; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GIMBRONE M, 1984, J CELL BIOL, V60, P673; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KADISH JL, 1979, TISSUE CELL, V11, P99, DOI 10.1016/0040-8166(79)90010-7; KAPLAN K, 1987, THROMB HAEMOSTASIS, V58, P939; KAPLAN KL, 1989, ARTERIOSCLEROSIS, V9, P43, DOI 10.1161/01.ATV.9.1.43; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KOPEC M, 1978, HDB EXP PHARMACOL, V46, P81; KUDRYK B, 1982, THROMB RES, V25, P277, DOI 10.1016/0049-3848(82)90247-X; KWANN H, 1971, THROMB DIATH HAEMO, V47, P361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVINE JD, 1982, BLOOD, V60, P531; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MURANO G, 1971, FEBS LETT, V14, P37, DOI 10.1016/0014-5793(71)80269-7; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NUEWUARIWSJU S, 1970, BIOCHIM BIOPHYS ACTA, V221, P326; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PLOW EF, 1984, J BIOL CHEM, V259, P5388; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; REINDERS JH, 1987, J CELL PHYSIOL, V133, P79, DOI 10.1002/jcp.1041330110; RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROWLAND FN, 1984, AM J PATHOL, V117, P418; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SHAINOFF JR, 1990, THROMB HAEMOSTASIS, V63, P193; SHEN LL, 1977, AM J PHYSIOL, V232, P629; SKOGEN WF, 1988, BLOOD, V71, P1475; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; WAGNER D, 1982, J CELL BIOL, V99, P2123; WEIMAR B, 1985, ARTERIOSCLEROSIS, V6, P139; WRIGHT S, 1988, P NATL ACAD SCI USA, V80, P5699	65	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2451	2458						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370821				2022-12-27	WOS:A1992HB53200053
J	VOGEL, LK; SPIESS, M; SJOSTROM, H; NOREN, O				VOGEL, LK; SPIESS, M; SJOSTROM, H; NOREN, O			EVIDENCE FOR AN APICAL SORTING SIGNAL ON THE ECTODOMAIN OF HUMAN AMINOPEPTIDASE-N	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELL; MICROVILLUS AMINOPEPTIDASE; ENDOPLASMIC-RETICULUM; MEMBRANE; PROTEINS; INSERTION; SURFACE; BIOSYNTHESIS	In polarized epithelial cells aminopeptidase N is targeted to the apical membrane. The aim of this study was to determine whether a sorting signal is necessary for its correct transport to the apical membrane and, if so, to localize this sorting signal to one of the domains of the transmembrane protein. Anchor-minus aminopeptidase N, consisting of the hemagglutinin signal peptide including its cleavage site, and the ectoplasmic domain of human aminopeptidase N were stably expressed in Madin-Darby canine kidney cells cultured on polycarbonate filters. By measurement of the enzymatic activity it was found that the anchor-minus aminopeptidase N was secreted in a polarized manner to the apical side. As a reference the secretion of the secretory granule protein, cystatin C, was likewise studied. Cystatin C was found to be secreted in a nonpolarized manner to both domains. Our data thus show that human aminopeptidase N carries an apical sorting signal and that it is localized on the ectodomain of the enzyme.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND	University of Basel	VOGEL, LK (corresponding author), UNIV COPENHAGEN, PANUM INST, DEPT BIOCHEM C, BLEGDAMSVEJ 3, DK-2200 COPENHAGEN, DENMARK.			Vogel, Lotte K./0000-0001-9920-0982; Spiess, Martin/0000-0001-7139-0550				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; DANIELSEN EM, 1985, EUR J BIOCHEM, V152, P493, DOI 10.1111/j.1432-1033.1985.tb09223.x; FINIDORI J, 1987, J CELL BIOL, V104, P1705, DOI 10.1083/jcb.104.6.1705; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GRUBB A, 1985, SCAND J CLIN LAB INV, V45, P7; HANSEN GH, 1988, MAMMALIAN BRUSH BORD, P29; HUSSAIN MM, 1981, BIOCHEM J, V199, P179, DOI 10.1042/bj1990179; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH MG, 1989, ANNU REV PHYSIOL, V51, P797; Sambrook J, 1989, MOL CLONING LABORATO; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WANDINGERNESS A, 1991, INTRACELLULAR TRAFFI, P575; WESSELS HP, 1989, J BIOL CHEM, V264, P17; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	30	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2794	2797						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346396				2022-12-27	WOS:A1992HB53200101
J	YASUHIRA, S; YASUI, A				YASUHIRA, S; YASUI, A			VISIBLE LIGHT-INDUCIBLE PHOTOLYASE GENE FROM THE GOLDFISH CARASSIUS-AURATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI PHOTOLYASE; DNA PHOTOLYASE; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; ACTIVE-SITE; PHR1 GENE; EXPRESSION; CLONING; REPAIR; PROTEINS	By introducing and expressing a cDNA library constructed from mRNA of the cultured goldfish Carassius auratus cells in Escherichia coli, a gene encoding photolyase of the vertebrate was isolated, the first example from metazoa. The amino acid sequence deduced from the nucleotide sequence differs significantly from those of microorganisms. Five out of 6 tryptophan residues strictly conserved in photolyases from microorganisms and thought to play important roles in DNA and chromophore binding of the enzyme are substituted by other residues of different characteristics. By Northern analysis the expression of the photolyase gene was found to be induced more than 10 times by exposure of the cells to visible light. These results indicate a unique evolution of the photolyase gene and a novel mechanism of gene regulation, in which visible light triggers the production of the light-dependent enzyme for repair of DNA damages induced by harmful ultraviolet part of sunlight.	TOHOKU UNIV,TB & CANC RES INST,SEIRYOMACHI 4-1,ADBA KU,SENDAI,MIYAGI 980,JAPAN; UNIV TOKYO,FAC SCI,INST ZOOL,BUNKYO KU,TOKYO 113,JAPAN	Tohoku University; University of Tokyo	YASUI, A (corresponding author), TOHOKU UNIV,TB & CANC RES INST,SEIRYOMACHI 4-1,ADBA KU,SENDAI,MIYAGI 980,JAPAN.							[Anonymous], 1985, DNA REPAIR; DULBECCO R, 1949, NATURE, V163, P949, DOI 10.1038/163949b0; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; HART RW, 1977, P NATL ACAD SCI USA, V74, P5574, DOI 10.1073/pnas.74.12.5574; INA Y, 1991, ODEN MOL EVOLUTIONAR; KELNER A, 1949, P NATL ACAD SCI USA, V35, P73, DOI 10.1073/pnas.35.2.73; KOBAYASHI T, 1989, NUCLEIC ACIDS RES, V17, P4731, DOI 10.1093/nar/17.12.4731; KOBAYASHI T, 1990, MUTAT RES, V236, P27, DOI 10.1016/0921-8777(90)90029-5; LI YF, 1991, BIOCHEMISTRY-US, V30, P6322, DOI 10.1021/bi00239a034; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LI YF, 1991, NUCLEIC ACIDS RES, V19, P4885, DOI 10.1093/nar/19.18.4885; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MITANI H, 1989, J CELL SCI, V93, P731; SANCAR GB, 1989, MOL CELL BIOL, V9, P4767, DOI 10.1128/MCB.9.11.4767; SANCAR GB, 1984, J BIOL CHEM, V259, P6033; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SEBASTIAN J, 1990, MOL CELL BIOL, V10, P4630, DOI 10.1128/MCB.10.9.4630; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YASUHIRA S, 1992, PHOTOCHEM PHOTOBIOL, V55, P97, DOI 10.1111/j.1751-1097.1992.tb04214.x; YASUHIRA S, 1990, PHOTOCHEM PHOTOBIOL, V53, P211; YASUI A, 1985, GENE, V36, P349, DOI 10.1016/0378-1119(85)90190-8; YASUI A, 1988, NUCLEIC ACIDS RES, V16, P4447, DOI 10.1093/nar/16.10.4447	27	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25644	25647						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1339447				2022-12-27	WOS:A1992KD07300007
J	VANIWAARDEN, JF; VANSTRIJP, JAG; VISSER, H; HAAGSMAN, HP; VERHOEF, J; VANGOLDE, LMG				VANIWAARDEN, JF; VANSTRIJP, JAG; VISSER, H; HAAGSMAN, HP; VERHOEF, J; VANGOLDE, LMG			BINDING OF SURFACTANT PROTEIN-A (SP-A) TO HERPES-SIMPLEX VIRUS TYPE 1-INFECTED CELLS IS MEDIATED BY THE CARBOHYDRATE MOIETY OF SP-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG SURFACTANT; PULMONARY SURFACTANT; ALVEOLAR PROTEINOSIS; II CELLS; GLYCOPROTEINS; PHAGOCYTOSIS; COMPLEMENT; PNEUMONIA; MACROPHAGES; EXPRESSION	Pulmonary surfactant protein A (SP-A) has been shown to act as an opsonin in the phagocytosis of viruses by alveolar macrophages. To determine whether SP-A binds to viral proteins and which part of the SP-A molecule is involved in this interaction, binding studies were undertaken. SP-A was labeled with fluorescein isothiocyanate, and its binding to herpes simplex virus type 1-infected HEp-2 cells, as a model for virus-infected cells in general, was studied using flow cytometry. The binding of SP-A to virus-infected cells was saturable, reversible, and both time- and concentration-dependent, reaching a maximal level after 30 min at an SP-A concentration of 10 mug/ml. An approximately 4-fold increase in binding of SP-A to infected cells over control cells was observed. Yeast mannan, a mannose homopolysaccharide, did not influence the binding. However, heparin inhibited binding of SP-A in a concentration-dependent manner. In addition, heparin could also dissociate cell-bound SP-A, indicating that polyanionic oligosaccharides are involved in the binding of SP-A to virus-infected cells. Deglycosylated SP-A, obtained by digestion with N-glycosidase F, did not bind to infected cells. Heparin or deglycosylation of SP-A had no effect on the stimulation of alveolar macrophages by SP-A. It is concluded that the carbohydrate moiety of SP-A is involved in the recognition of viruses by SP-A and may play a role in the antiviral defenses of the lung.	UNIV UTRECHT, EIJKMAN WINKLER LAB MED MICROBIOL, 3508 TD UTRECHT, NETHERLANDS	Utrecht University	VANIWAARDEN, JF (corresponding author), UNIV UTRECHT, VET BIOCHEM LAB, 3508 TD UTRECHT, NETHERLANDS.		Haagsman, Henk P/F-8919-2010; van Strijp, Jos A.G./J-9549-2014	van Strijp, Jos A.G./0000-0001-6253-0830				BHATTACHARYYA SN, 1984, ARCH BIOCHEM BIOPHYS, V231, P72, DOI 10.1016/0003-9861(84)90364-3; BOBAK DA, 1987, J IMMUNOL, V138, P1150; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FRIEDMAN HM, 1984, NATURE, V309, P633, DOI 10.1038/309633a0; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.physiol.53.1.441; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; JENNINGS SR, 1987, J VIROL, V61, P104, DOI 10.1128/JVI.61.1.104-112.1987; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LJUNGMAN P, 1990, J INFECT DIS, V162, P244, DOI 10.1093/infdis/162.1.244; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MUNAKATA H, 1982, BIOCHEM BIOPH RES CO, V108, P1401, DOI 10.1016/S0006-291X(82)80062-4; OLOFSSON S, 1981, ARCH VIROL, V70, P321, DOI 10.1007/BF01320247; PHELPS DS, 1991, AM REV RESPIR DIS, V143, P1072, DOI 10.1164/ajrccm/143.5_Pt_1.1072; PIZER LI, 1980, J VIROL, V34, P142, DOI 10.1128/JVI.34.1.142-153.1980; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SAWITZKY D, 1990, J GEN VIROL, V71, P1221, DOI 10.1099/0022-1317-71-5-1221; SPEAR PG, 1985, HERPESVIRUSES, V3, P315; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; VAHERI A, 1964, ACTA PATHOL MIC SC, P7; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1987, AM REV RESPIR DIS, V136, P426, DOI 10.1164/ajrccm/136.2.426; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	37	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25039	25043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334078				2022-12-27	WOS:A1992KB60300022
J	PRASAD, PD; LEIBACH, FH; MAHESH, VB; GANAPATHY, V				PRASAD, PD; LEIBACH, FH; MAHESH, VB; GANAPATHY, V			SPECIFIC INTERACTION OF 5-(N-METHYL-N-ISOBUTYL)AMILORIDE WITH THE ORGANIC CATION-PROTON ANTIPORTER IN HUMAN PLACENTAL BRUSH-BORDER MEMBRANE-VESICLES - TRANSPORT AND BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; CIMETIDINE TRANSPORT; TURNOVER RATE; AMILORIDE; SYSTEM; RABBIT; KIDNEY; SITE; PH; RESIDUES	The interaction of 5-(N-methyl-N-isobutyl)amiloride (MIBA) with brush-border membrane vesicles isolated from normal human term placentas was investigated using two parameters: binding and transport. The binding of MIBA to placental membranes was specific and temperature- and pH-dependent, and the apparent dissociation constant (K(d)) for the process was 58 +/- 2 muM. The binding was inhibited by other amiloride analogs and also by clonidine and cimetidine with a rank order potency: MIBA > benzamil > dimethylamiloride > amiloride > clonidine > cimetidine. These compounds also inhibited Na+-H+ exchanger activity in these membrane vesicles, but with a different order of potency: dimethylamiloride > MIBA > amiloride > benzamil > cimetidine > clonidine. The membrane vesicles were also able to transport MIBA into the intra-vesicular space, and the transport was stimulated many-fold by the presence of an outwardly directed H+ gradient across the membrane. The H+ gradient was the driving force for uphill accumulation of MIBA inside the vesicles. The transport process was electrically silent. The transport of MIBA was inhibited by other amiloride analogs and by clonidine and cimetidine, and the order of potency was the same as the order with which these compounds inhibited the binding of MIBA. The Michaelis-Menten constant (K(t)) for the transport process was 46 +/- 2 muM. The binding as well as the transport were also inhibited by Na+ and Li+. Interestingly, tetraethylammonium and N1-methylnicotinamide, two of the commonly used substrates in organic cation transport studies, failed to inhibit the binding and transport of MIBA. Furthermore, although the outwardly directed H+ gradient-dependent uphill transport of tetraethylammonium could be demonstrated in renal brush-border membrane vesicles, there was no evidence for the presence of a transport system for this prototypical organic cation in placental brush-border membrane vesicles. It is concluded that the human placental brush-border membranes possess an organic cation-proton antiporter which accepts MIBA as a substrate, the low affinity binding site for MIBA observed in these membranes represents this antiporter, and that the placental organic cation-proton antiporter is distinct from the widely studied renal organic cation-proton antiporter.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					NICHD NIH HHS [HD 22103] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022103] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BALKOVETZ DF, 1986, AM J PHYSIOL, V251, pC852, DOI 10.1152/ajpcell.1986.251.6.C852; DESIR GV, 1991, J BIOL CHEM, V266, P2267; DIXON SJ, 1987, J BIOL CHEM, V262, P3626; FRELIN C, 1988, BIOCHIMIE, V70, P1285, DOI 10.1016/0300-9084(88)90196-4; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GANAPATHY ME, 1986, BIOCHEM PHARMACOL, V35, P3989, DOI 10.1016/0006-2952(86)90016-X; GANAPATHY V, 1987, BIOCHEM J, V245, P473, DOI 10.1042/bj2450473; GANAPATHY V, 1986, J PHARMACOL EXP THER, V239, P192; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GISCLON L, 1987, AM J PHYSIOL, V253, pF141, DOI 10.1152/ajprenal.1987.253.1.F141; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; JEAN T, 1985, J BIOL CHEM, V260, P9678; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KULANTHAIVEL P, 1992, BIOCHEM J, V284, P33, DOI 10.1042/bj2840033; KULANTHAIVEL P, 1990, BIOCHEMISTRY-US, V29, P10807, DOI 10.1021/bi00500a013; KULANTHAIVEL P, 1990, BIOCHIM BIOPHYS ACTA, V1024, P385, DOI 10.1016/0005-2736(90)90369-Y; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; KULANTHAIVEL P, 1989, BIOCHIM BIOPHYS ACTA, V985, P139, DOI 10.1016/0005-2736(89)90358-1; MIYAMOTO Y, 1988, FEBS LETT, V231, P263, DOI 10.1016/0014-5793(88)80744-0; MIYAMOTO Y, 1988, AM J PHYSIOL, V255, pG85, DOI 10.1152/ajpgi.1988.255.1.G85; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; ROSS CR, 1983, ANNU REV PHARMACOL, V23, P65, DOI 10.1146/annurev.pa.23.040183.000433; ROSS W, 1990, J BIOL CHEM, V265, P5341; ROSSKOPF D, 1991, BIOCHEM BIOPH RES CO, V176, P639, DOI 10.1016/S0006-291X(05)80232-3; SAITO H, 1992, AM J PHYSIOL, V262, pC59, DOI 10.1152/ajpcell.1992.262.1.C59; SIMON BJ, 1992, BIOCHEM J, V287, P423, DOI 10.1042/bj2870423; TAKANO M, 1985, LIFE SCI, V37, P1579, DOI 10.1016/0024-3205(85)90476-X; TALOR Z, 1989, LIFE SCI, V45, P517, DOI 10.1016/0024-3205(89)90102-1; VIGNE P, 1984, EMBO J, V3, P2647, DOI 10.1002/j.1460-2075.1984.tb02188.x; VIGNE P, 1985, J BIOL CHEM, V260, P4120; WRIGHT SH, 1988, J BIOL CHEM, V263, P19494; WRIGHT SH, 1989, AM J PHYSIOL, V256, pF462, DOI 10.1152/ajprenal.1989.256.3.F462	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23632	23639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331095				2022-12-27	WOS:A1992JZ23900034
J	VONAKIS, BM; VANDERHOEK, JY				VONAKIS, BM; VANDERHOEK, JY			15-HYDROXYEICOSATETRAENOIC ACID (15-HETE) RECEPTORS - INVOLVEMENT IN THE 15-HETE-INDUCED STIMULATION OF THE CRYPTIC 5-LIPOXYGENASE IN PT-18 MAST/BASOPHIL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTE RECEPTORS; MAST BASOPHIL CELLS; ARACHIDONIC-ACID; ENDOTHELIAL-CELLS; 15-LIPOXYGENASE PRODUCTS; LIPOXYGENASE PATHWAY; HUMAN-NEUTROPHILS; BINDING; LEUKOTRIENE-B4; METABOLISM	The mechanism of stimulation of the inactive 5-lipoxygenase in mast/basophil PT-18 cells by muM 15-hydroxyeicosatetraenoic acid (15-HETE) was investigated. Treatment of PT-18 cells with pM 15-[H-3]HETE at 4-degrees for 3 h resulted in the cell association of 10% of the ligand: two-thirds was incorporated into cellular lipids and a third was bound to specific 15-HETE cellular binding sites. Binding data analysis indicated a single class of 15-HETE binding sites with a K(d) of 162 nm and a B(max) of 7.1 x 10(5) sites/cell. Unlabeled 15-HETE, 12-HETE, and 5,15-diHETE inhibited the binding of 15-[H-3]HETE to cells, whereas LTB, and PGF2alpha were relatively ineffective. 2.4 muM 15-HETE (unlabeled) prevented 50% 15-[H-3]HETE incorporation. Examination of the effects of 15-HETE methyl ester, 12-HETE, 5,15-diHETE, and pertussis toxin on both the 15-HETE-induced 5-lipoxygenase activation and 15-HETE cell association processes indicated a preponderant correlation of this activation process with specific 15-HETE binding rather than 15-HETE incorporation into phospholipids. In addition, 5,15-diHETE itself stimulated the inactive 5-lipoxygenase and eight times more [H-3]diHETE was bound to cells than became incorporated into cellular lipids. The results support the involvement of low affinity 15-HETE receptors, rather than 15-HETE incorporation into cellular lipids, in the 15-HETE-induced stimulation of the 5-lipoxygenase in PT-18 cells.			VONAKIS, BM (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20037, USA.			Vanderhoek, Jack/0000-0002-2051-2236; Vonakis, Becky/0000-0003-4174-6514				BORNESTEIN DG, 1987, ARTHRITIS RHEUM, V30, pS65; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; DAHLEN SE, 1991, LIPOXYGENASES THEIR, P235; DUELL EA, 1988, J INVEST DERMATOL, V91, P446, DOI 10.1111/1523-1747.ep12476562; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; GOLDMAN DW, 1987, FASEB J, V46, P200; GROSS E, 1990, J INVEST DERMATOL, V94, P446, DOI 10.1111/1523-1747.ep12874543; HAAS TA, 1988, BIOCHIM BIOPHYS ACTA, V961, P153, DOI 10.1016/0005-2760(88)90108-7; HALUSHKA PV, 1987, FASEB J, V46, P149; HAMBERG M, 1980, ACTA PHYSIOL SCAND, V110, P219, DOI 10.1111/j.1748-1716.1980.tb06656.x; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; KUHN H, 1985, PROSTA LEUKOTR MED, V17, P291, DOI 10.1016/0262-1746(85)90118-0; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LIN AH, 1984, PROSTAGLANDINS, V28, P837, DOI 10.1016/0090-6980(84)90038-8; MAGHNI K, 1991, J PHARMACOL EXP THER, V258, P784; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MEXMAIN S, 1985, J IMMUNOL, V135, P1361; MEXMAIN S, 1984, PROSTA LEUKOTR MED, V13, P93, DOI 10.1016/0262-1746(84)90108-2; NICHOLS RC, 1991, BIOCHIM BIOPHYS ACTA, V1085, P77, DOI 10.1016/0005-2760(91)90234-9; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; RABIER M, 1988, BIOCHEM BIOPH RES CO, V152, P1179, DOI 10.1016/S0006-291X(88)80409-1; ROSSI GL, 1990, AGENTS ACTIONS, V31, P257, DOI 10.1007/BF01997617; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1985, BIOCHIM BIOPHYS ACTA, V837, P119, DOI 10.1016/0005-2760(85)90234-6; VANDERHOEK JY, 1982, J BIOL CHEM, V257, P2191	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23625	23631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331094				2022-12-27	WOS:A1992JZ23900033
J	YEN, PM; SUGAWARA, A; CHIN, WW				YEN, PM; SUGAWARA, A; CHIN, WW			TRIIODOTHYRONINE (T3) DIFFERENTIALLY AFFECTS T3-RECEPTOR RETINOIC ACID RECEPTOR AND T3-RECEPTOR RETINOID-X RECEPTOR HETERODIMER BINDING TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RESPONSE ELEMENT; LIGAND-BINDING; NEGATIVE REGULATION; NUCLEAR RECEPTORS; PROTEIN; DOMAIN; PROMOTER; 3,5,3'-TRIIODOTHYRONINE	Thyroid hormone receptor (TR) heterodimerizes with retinoic acid receptor (RAR), retinoid X receptor (RXR), and triiodothyronine receptor auxiliary protein (TRAP) on natural and synthetic hormone response elements. Recently we showed that triiodothyronine (T3) decreased TR homodimer, but not TR/TRAP heterodimer, binding to several thyroid hormone response elements (TREs). The effect of ligand on TR/RAR and TR/RXR heterodimer binding to DNA is not known. In this study, we showed that TR formed heterodimers with RAR and RXR on a retinoic acid (RA) response element and two TREs. Surprisingly, T3, but not RA, decreased TR/RAR heterodimer binding to DNA. In contrast, T3, all-trans-RA, or 9-cis-RA did not affect TR/RXR binding to DNA. This finding suggests that TR/RXR heterodimer is a stable receptor complex that remains bound to response elements in the presence of ligand and therefore may be a receptor complex involved in T3-regulated transcription.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	YEN, PM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,HOWARD HUGHES MED INST,GW THORN RES BLDG,RM 905,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CASANOVA J, 1992, CLIN RES, V40, pA252; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FORMAN BM, 1989, MOL ENDOCRINOL, V6, P248; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HALLENBECK P, 1991, THYROID, V1, pS60; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PARILLA R, 1991, J CLIN INVEST, V88, P2123; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, IN PRESS J CLIN INVE; YEN PM, ENDOCRINOLOGY, V130, P1539; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23248	23252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331079				2022-12-27	WOS:A1992JY16300083
J	LOWE, DG; FENDLY, BM				LOWE, DG; FENDLY, BM			HUMAN NATRIURETIC PEPTIDE RECEPTOR-A GUANYLYL CYCLASE - HORMONE CROSS-LINKING AND ANTIBODY REACTIVITY DISTINGUISH RECEPTOR GLYCOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL ZONA GLOMERULOSA; HEAT-STABLE ENTEROTOXIN; SIGNAL TRANSDUCTION; PORCINE BRAIN; GENE-PRODUCT; ATRIAL; EXPRESSION; ACTIVATION; PROTEIN; DOMAIN	Most of the physiological actions of atrial natriuretic peptide (ANP) may be attributed to activation of the natriuretic peptide receptor-A (NPR-A) guanylyl cyclase. We report here that truncation of the NPR-A cytoplasmic domain results in increased expression of cell surface ANP binding sites. The truncated receptor exhibited a hyperbolic time course for ANP binding and had a high affinity for [I-125]hANP, K(d) = 8 pM. Cells expressing truncated NPR-A were used as an immunogen to obtain monoclonal antibodies against the native conformation of the extracellular domain. These antibodies were used to select for high levels of stable NPR-A expression in 293 cells, by fluorescence-activated cell sorting. Disuccinimidyl suberate cross-linked [I-125]ANP to 135-kDa NPR-A on intact cells. Monoclonal antibody immunoprecipitation of S-35-labeled proteins revealed NPR-A size heterogeneity, with 135- and 125-kDa species. A synthetic peptide antibody directed against the extracellular domain immunoprecipitated 125-kDa NPR-A, but recognized both sizes of receptor by Western blotting. The 125-kDa NPR-A did not bind to or cross-link ANP. NPR-A size variants were expressed on the cell surface, and heterogeneity was removed by deglycosylation with protein:N-glycosidase F. Our results suggest that the degree of N-linked glycosylation of the NPR-A extracellular domain influences the ability to bind ANP.	GENENTECH INC,DEPT MEDICINAL & ANALYT CHEM,SAN FRANCISCO,CA 94080	Roche Holding; Genentech	LOWE, DG (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,SAN FRANCISCO,CA 94080, USA.							ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DAYANITHI G, 1990, J ENDOCRINOL, V125, P39, DOI 10.1677/joe.0.1250039; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; FENDLY BM, 1990, CANCER RES, V50, P1550; FULLER F, 1988, J BIOL CHEM, V263, P9395; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KAMBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P599, DOI 10.1016/S0006-291X(05)80077-4; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LARAGH JH, 1985, NEW ENGL J MED, V313, P1330; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MELOCHE S, 1987, J BIOL CHEM, V262, P10252; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; Oi V.T., 1980, SELECTED METHODS CEL, P351; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TAWARAGI Y, 1991, BIOCHEM BIOPH RES CO, V175, P645, DOI 10.1016/0006-291X(91)91614-I; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	39	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21691	21697						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356991				2022-12-27	WOS:A1992JV01100068
J	OKUMA, Y; REISINE, T				OKUMA, Y; REISINE, T			IMMUNOPRECIPITATION OF ALPHA-2A-ADRENERGIC RECEPTOR-GTP-BINDING PROTEIN COMPLEXES USING GTP-BINDING PROTEIN SELECTIVE ANTISERA - CHANGES IN RECEPTOR/GTP-BINDING PROTEIN-INTERACTION FOLLOWING AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ADENYLYL CYCLASE; IDENTIFICATION; SUBTYPES; EXPRESSION; ANTIBODIES; INHIBITION; PLATELETS; CELLS	The nature of the interaction of cloned alpha-2a-adrenergic receptors from LLC-PK1-O clone cells with G proteins was investigated using an immunoprecipitation approach. Following solubilization of the alpha-2a receptors, antiserum 8730, which is directed against the C-terminal region of G(i-alpha), immunoprecipitated alpha-2a receptor-G(i)alpha complexes. The immunoprecipitation was specific since it could be blocked by the peptide to which antiserum 8730 was generated. Antisera 3646 (anti-G(i-alpha-1), 1521 (anti-G(i-alpha-2) and 1518 (anti-G(i-alpha-3) immunoprecipitated solubilized alpha-2a receptor-G(i-alpha) complexes, indicating that all three G(i-alpha) subtypes couple with the alpha-2a receptor. Antiserum 9072, which is directed against the C-terminal region of G(o-alpha), immunoprecipitated solubilized alpha-2a receptor-G(alpha) complexes indicating that these receptors are also coupled to G(o-alpha). Antiserum 8132, which is directed against G(beta-36), immunoprecipitated solubilized alpha-2a receptors while the G(beta-35) antiserum 8129, did not, indicating that alpha-2a receptors selectively associate with G(beta-36). The binding of the partial agonist p-aminoclonidine to the solubilized alpha-2a receptor alters the association of the receptor with G proteins. Following p-aminoclonidine binding to the solubilized alpha-2a receptor, the ability of the C-terminal directed G(alpha) antisera 8730 and 9072 to coimmunoprecipitate the alpha-2a receptor-G(alpha) complex was greatly reduced. The effect of p-aminoclonidine was concentration dependent, mimicked by the full agonist UK 14304 and blocked by the alpha-2 receptor antagonist yohimbine. In contrast, antisera directed against internal regions of G(i-alpha) and G(o-alpha), immunoprecipitated the agonist-bound and agonist-free alpha-2a receptor equally well. These findings indicate that following the binding of agonists to the alpha-2a receptor, G(i-alpha) and G(o-alpha), remain physically associated with the receptor but either the conformation of G(alpha) linked to the receptor or the conformation of the receptor itself is modified such that the epitope for the C-terminal directed anti-G(i-alpha) and anti-G(o-alpha) antisera are not accessible. These agonist-induced conformational changes in the alpha-2a receptor-G(alpha) complex may be important for the activation of the G protein and the stimulation of the alpha-2a receptor signal transduction pathway.	UNIV PENN,SCH MED,DEPT PHARMACOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104	University of Pennsylvania					PHS HHS [48158, 34781, 45533] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; HSU WH, 1990, J BIOL CHEM, V265, P11220; JONES DT, 1987, J BIOL CHEM, V262, P14241; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIMBIRD LE, 1988, ALPHA2 ADRENERGIC RE; LIMBIRD LL, 1980, P NATL ACAD SCI USA, V77, P7754; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; NORTH RA, 1985, J PHYSIOL-LONDON, V358, P17, DOI 10.1113/jphysiol.1985.sp015537; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLIAMS AG, 1990, BLOOD, V76, P721; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	22	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14826	14831						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353077				2022-12-27	WOS:A1992JF08800050
J	LOHSE, P; RADER, DJ; BREWER, HB				LOHSE, P; RADER, DJ; BREWER, HB			HETEROZYGOSITY FOR APOLIPOPROTEIN-E-4(PHILADELPHIA)(GLU(13)-]LYS, ARG(145)-]CYS) IS ASSOCIATED WITH INCOMPLETE DOMINANCE OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; RECEPTOR-BINDING ACTIVITY; AMINO-ACID-SEQUENCE; HUMAN-E APOPROTEIN; FAMILIAL DYSBETALIPOPROTEINEMIA; VARIANT; HETEROGENEITY; PATIENT; GENE; E2(LYS146->GLN)	Apolipoprotein (apo) E-4Philadelphia is a double mutant of apoE in which residue 13 of the mature protein, glutamic acid (GAG), is replaced by lysine (AAG) and amino acid 145, arginine (CGT), is converted to cysteine (TGT). These mutations result in two restriction fragment length polymorphisms for the enzymes AvaI and BbvI, a smaller apparent molecular weight of apoE-4Philadelphia on sodium dodecyl polyacrylamide gels, and severe type III hyperlipoproteinemia (HLP) in a 24-year-old homozygous female (Lohse, P., Mann, W. A., Stein, E. A., and Brewer, H. B., Jr. (1991) J. Biol. Chem. 266, 10479-10484). In the current study, we have extended our analysis to include nine additional family members of the Philadelphia kindred spanning four generations. DNA and protein analysis demonstrated that the originally described propositus is a true homozygote for the epsilon-4Philadelphia allele and that six of the nine family members are heterozygous for the mutated allele and the normal-epsilon-3 allele or, in one case, the epsilon-4 allele. Heterozygosity for apoE-4Philadelphia leads to the expression of a moderate form of type III HLP without clinical manifestations. These results are consistent with a dominant mode of inheritance of this dyslipoproteinemia. The simultaneous presence of unaffected individuals, heterozygotes, and a homozygote in the Philadelphia kindred makes it possible for the first time to demonstrate that the mutant apoE exhibits an incomplete or partial dominance of type III HLP. Heterozygosity for the normal epsilon-3 allele appears to have an influence on the expression of type III HLP, resulting in a phenotype intermediate between that of the two homozygous states.			LOHSE, P (corresponding author), NHLBI, MOLEC DIS BRANCH, 9000 ROCKVILLE PIKE, BLDG 10, RM 7N117, BETHESDA, MD 20892 USA.							BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; GHISELLI G, 1982, J CLIN INVEST, V70, P474, DOI 10.1172/JCI110638; GREGG RE, 1988, CLIN CHEM, V34, pB28; GREGG RE, 1983, NIH831266 PUBL, P383; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1982, MED CLIN N AM, V66, P441, DOI 10.1016/S0025-7125(16)31429-8; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; LEWIN B, 1987, GENES, V3, P20; LOHSE P, 1991, J BIOL CHEM, V266, P10479; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MAILLY F, 1991, J LIPID RES, V32, P613; MANN AW, 1989, CLIN RES, V37, pA520; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; RALL SC, 1983, J CLIN INVEST, V72, P1288, DOI 10.1172/JCI111085; RALL SC, 1982, J BIOL CHEM, V257, P4171; SMIT M, 1990, J LIPID RES, V31, P45; TAJIMA S, 1989, J BIOCHEM-TOKYO, V105, P249, DOI 10.1093/oxfordjournals.jbchem.a122648; TAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P48, DOI 10.1093/oxfordjournals.jbchem.a122420; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P1; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1990, J LIPID RES, V31, P535; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEISGRABER KH, 1984, J CLIN INVEST, V73, P1024, DOI 10.1172/JCI111287; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; ZANNIS VI, 1989, ADV LIPID RES, V23, P1; 1974, DHEW75628 NAT HEART	39	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13642	13646						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352296				2022-12-27	WOS:A1992JB74600086
J	MURAKAMI, T; NISHIYAMA, T; SHIROTANI, T; SHINOHARA, Y; KAN, M; ISHII, K; KANAI, F; NAKAZURU, S; EBINA, Y				MURAKAMI, T; NISHIYAMA, T; SHIROTANI, T; SHINOHARA, Y; KAN, M; ISHII, K; KANAI, F; NAKAZURU, S; EBINA, Y			IDENTIFICATION OF 2 ENHANCER ELEMENTS IN THE GENE ENCODING THE TYPE-1 GLUCOSE TRANSPORTER FROM THE MOUSE WHICH ARE RESPONSIVE TO SERUM, GROWTH-FACTOR, AND ONCOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; INDUCE EXPRESSION; MESSENGER-RNA; SARCOMA-VIRUS; FOS GENE; DNA; TRANSFORMATION; ACTIVATION	The type 1 glucose transporter (GLUT1) gene encodes an integral membrane glycoprotein responsible for facilitating transfer of glucose across plasma membrane and is rapidly activated by serum, growth factors, and by oncogenic transformation. To elucidate the molecular mechanisms of regulation of GLUT1 gene expression, we isolated and characterized the mouse GLUT1 gene. DNA elements regulating transcription of the gene were analyzed in transient expression assays after transfection of NIH/3T3 cells with a low background chloramphenicol acetyltransferase (CAT) vector system pSVOOCAT. We identified two enhancer elements; the first one is located 2.7 kilobases upstream of the cap site of the gene which contains the homologous sequences with two 12-O-tetradecanoylphorbol-13-acetate-responsive elements (TREs), a serum response element, a cyclic AMP-responsive element (CRE) and three GC boxes, and the second one is located in the second intron of the gene which contains the homologous sequences with two TREs and one CRE. With the promoter alone the transcription of the gene is activated by src, only slightly activated by ras and is not activated by serum and platelet-derived growth factor. When the gene is accompanied by one of these enhancers, the transcription is activated by all these stimuli.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,KURAMOTO CHO,TOKUSHIMA 770,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT METAB MED,KUMAMOTO 860,JAPAN; UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,DEPT UROL,TOKUSHIMA 770,JAPAN	Tokushima University; Kumamoto University; Tokushima University; Tokushima University			Ishii, Kazuo/N-9946-2019; Ishii, Kazuo/M-3099-2016; ishii, kazuo/K-7428-2014	Ishii, Kazuo/0000-0002-8363-8266; ishii, kazuo/0000-0001-7801-1891				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BIRNBAUM MJ, 1987, SCIENCE, V235, P1492; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304-419X(74)90008-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HIRAKI Y, 1989, MOL ENDOCRINOL, V3, P1470, DOI 10.1210/mend-3-9-1470; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIYAZAKI J, 1989, GENE, V79, P269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	47	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9300	9306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1339457				2022-12-27	WOS:A1992HR85400091
J	LEGOUX, R; DELPECH, B; DUMONT, X; GUILLEMOT, JC; RAMOND, P; SHIRE, D; CAPUT, D; FERRARA, P; LOISON, G				LEGOUX, R; DELPECH, B; DUMONT, X; GUILLEMOT, JC; RAMOND, P; SHIRE, D; CAPUT, D; FERRARA, P; LOISON, G			CLONING AND EXPRESSION IN ESCHERICHIA-COLI OF THE GENE ENCODING ASPERGILLUS-FLAVUS URATE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ALPHA-ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PROTEINS; YEAST; NIDULANS; SPECIFICITY; PEROXISOMES	Amino acid sequencing of peptides obtained after proteolytic hydrolysis of Aspergillus flavus urate oxidase (uricase) permitted the design of oligodeoxynucleotide probes that were used to obtain 1.2- and 5-kilobase pair DNA fragments from A. flavus cDNA and genomic libraries, respectively. The cDNA fragment contained the entire coding region for uricase, and comparison with the genomic fragment revealed the presence of two short introns in the coding region of the gene. A. flavus uricase has around 40% overall identity with uricases from higher organisms but with many conserved amino acids. Hitherto highly conserved consensus patterns found in other uricases were found to be modified in the A. flavus enzyme, notably the sequence Val-Leu-Lys-Thr-Thr-Gln-Ser near position 150, which in the filamentous fungus is uniquely modified to Val-Leu-Lys-Ser-Thr-Asn-Ser. Silent mutations were introduced by cassette mutagenesis near the 5'-extremity of the coding sequence in order to conform with Escherichia coli codon usage, and the uricase was expressed in the E. coli cytoplasm in a completely soluble, biologically active form.	SANOFI ELF BIORECH,VOIE 1 INNOPOLE,BP 137,F-31676 LABEGE,FRANCE	Sanofi-Aventis								ALVARES K, 1989, BIOCHEM BIOPH RES CO, V158, P991, DOI 10.1016/0006-291X(89)92820-9; Arst HN, 1985, GENE MANIPULATIONS F, P309; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunaud M, 1969, Therapie, V24, P785; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CONLEY TG, 1980, BIOCHEM J, V187, P727, DOI 10.1042/bj1870727; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOY CH, 1985, DNA-J MOLEC CELL BIO, V4, P105, DOI 10.1089/dna.1985.4.105; ELION GB, 1968, AM J MED, V45, P69, DOI 10.1016/0002-9343(68)90008-9; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRIEDMAN TB, 1985, COMP BIOCHEM PHYS B, V81, P653, DOI 10.1016/0305-0491(85)90381-5; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; LABOUREUR P, 1968, B SOC CHIM BIOL, V50, P811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEE FJS, 1989, J BIOL CHEM, V264, P12339; MELLOR J, 1989, MOL CELL BIOL YEASTS, P1; MOTOJIMA K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P116, DOI 10.1016/0167-4781(89)90178-4; NGUYEN T, 1985, P NATL ACAD SCI USA, V82, P5040, DOI 10.1073/pnas.82.15.5040; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PESTANA A, 1975, BIOCHEMISTRY-US, V14, P1404, DOI 10.1021/bi00678a010; RAMBOSEK J, 1987, CRIT REV BIOTECHNOL, V6, P357, DOI 10.3109/07388558709089387; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHIRE D, 1990, GENE, V93, P183, DOI 10.1016/0378-1119(90)90223-E; SUZUKI H, 1991, PLANT PHYSIOL, V95, P384, DOI 10.1104/pp.95.2.384; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153; ZOLLER M, 1985, DNA NY, V3, P479	38	70	85	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8565	8570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1339455				2022-12-27	WOS:A1992HQ18500091
J	ROSS, L; HASSMAN, F; MOLONY, L				ROSS, L; HASSMAN, F; MOLONY, L			INHIBITION OF MOLT-4-ENDOTHELIAL ADHERENCE BY SYNTHETIC PEPTIDES FROM THE SEQUENCE OF ICAM-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; HUMAN ENDOTHELIAL-CELLS; LEUKOCYTE ADHESION; SURFACE RECEPTORS; LFA-1; INTEGRIN; LYMPHOCYTES; MECHANISMS; EXPRESSION	Previous studies have shown that inflammatory pathologies are mediated by lymphocyte adhesion to endothelium and subsequent transmigration through the endothelial monolayer. Lymphocyte-endothelial adherence is, in part, caused by the leukocyte integrin LFA-1 binding to ICAM-1, its ligand on endothelial cells. Synthetic peptides based on specific amino acid sequences of human ICAM-1 inhibit the adherence of a lymphocytic cell line, Molt-4, to cytokine-stimulated endothelial cells. A total of 26 peptides spanning the extracellular domains of ICAM-1 were evaluated for their inhibitory activity in two cell adhesion assays. Binding of fluorescently labeled Molt-4 cells to TNF-stimulated human umbilical vein endothelial cells was inhibited reproducibly by peptides ICAM1-20, ICAM26-50 ICAM40-64, ICAM132-146, and ICAM345-375. Three overlapping sequences of the peptide ICAM40-64, KELLLPGNNRKVYELSNVQEDSQPM, were synthesized and tested as well, and the sequence KELLLPGNNRKV showed the greatest inhibition. The inhibitory activity of these peptides was confirmed using a second assay, inhibition of aggregation of the Epstein-Barr virus-transformed B-lymphoblast line JY. Polyclonal antibodies were developed in rabbits by immunization with two of the peptides and characterized for their ability to inhibit lymphocyte-endothelial adherence. These studies predict potential sites for interaction of the integrin receptor, LFA-1, with its ligand, ICAM-1. Thus lymphocyte-endothelial interaction, and resulting inflammation, may be partially mediated by the association of ICAM-1 with LFA-1 at the specific molecular locations identified in this study.	GLAXO RES INST, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA; GLAXO RES INST, DEPT STRUCT CHEM, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline								ADAMS DH, 1989, LANCET, V2, P1122; ALTIERI DC, 1990, J IMMUNOL, V145, P662; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARLOS TM, 1990, BLOOD, V76, P965; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GRIFFITHS CEM, 1989, AM J PATHOL, V135, P1045; HALE LP, 1989, ARTHRITIS RHEUM, V32, P22, DOI 10.1002/anr.1780320105; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEEUWENBERG JFM, 1990, CLIN EXP IMMUNOL, V81, P496; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MILESKI WJ, 1990, SURGERY, V108, P206; NICKOLOFF BJ, 1990, J INVEST DERMATOL, V94, pS151, DOI 10.1111/1523-1747.ep12876134; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PLUMB JA, 1989, CANCER RES, V49, P4435; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0	38	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8537	8543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349017				2022-12-27	WOS:A1992HQ18500088
J	RAY, K; GANGULY, R				RAY, K; GANGULY, R			THE DROSOPHILA G-PROTEIN GAMMA-SUBUNIT GENE (D-G-GAMMA-1) PRODUCES 3 DEVELOPMENTALLY REGULATED TRANSCRIPTS AND IS PREDOMINANTLY EXPRESSED IN THE CENTRAL-NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC K+-CHANNEL; STIMULATORY G-PROTEIN; GTP-BINDING PROTEINS; HEAD-SPECIFIC GENES; ALPHA-SUBUNIT; MOLECULAR CHARACTERIZATION; PHOTORECEPTOR CELL; MESSENGER-RNA; RAS PROTEINS; BETA-SUBUNIT	A genomic clone, 536, located at the 44CD region of polytene chromosomes of Drosophila melanogaster, has been characterized for its neurobiological importance. We found that this clone contains a gene which produces 2.6-, 1.3- and 1.1-kilobase (kb) RNAs. While the 2.6-kb RNA is expressed only in the head, the 1.3-kb RNA is present exclusively in the body. The 1.1-kb RNA, however, is found in both the head and body, but in much higher concentration in the head. DNA sequence analysis of a 2.6-kb RNA-specific cDNA showed that this gene encodes a 70-amino acid polypeptide which is the putative Drosophila homologue to the gamma-subunit of the bovine G-protein. The Drosophila protein, named D-G-gamma-1, shares 46, 43, and 28% identity, and 59, 52, and 60% similarity, with the gamma-2, gamma-3, and gamma-t proteins of bovine G proteins, respectively. Sequencing of the 1.1-kb RNA-specific cDNA clone revealed that the 1.1-kb RNA is produced from the 2.6-kb transcription unit by usage of an alternative polyadenylation site, and has a coding region identical to that of the 2.6-kb RNA. Genomic Southern blot hybridization indicated that the Drosophila genome has only one D-G-gamma-1 gene. Throughout development the 1.1-kb RNA is found to be the most prevalent species; its level peaks between 9 and 12 h of embryogenesis. As is the case for the other G protein genes of Drosophila, the D-G-gamma-1 gene is predominantly expressed in the central nervous system of the fly.	UNIV TENNESSEE,DEPT ZOOL,KNOXVILLE,TN 37996; UNIV TENNESSEE,CELL MOLEC & DEV BIOL PROGRAM,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville								ASHBURNMER M, 1989, DROSOPHILA LABORATOR, P173; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BRAKE AJ, 1985, CURRENT COMMUNICATIO, P103; Campos-Ortega J A, 1990, Adv Genet, V27, P403; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DESOUSA SM, 1989, J BIOL CHEM, V264, P18544; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FRYXELL KJ, 1987, EMBO J, V6, P443, DOI 10.1002/j.1460-2075.1987.tb04774.x; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Inoue Y., 1980, DROSOPHILA INFORMATI, V5, P206; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRISHNAN R, 1990, NUCLEIC ACIDS RES, V18, P5894, DOI 10.1093/nar/18.19.5894; KRISHNAN R, 1991, CHROMOSOMA, V100, P125, DOI 10.1007/BF00418246; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEVY LS, 1982, DEV BIOL, V94, P465, DOI 10.1016/0012-1606(82)90363-3; LEVY LS, 1982, DEV BIOL, V94, P451, DOI 10.1016/0012-1606(82)90362-1; LINDSLEY DL, 1985, DROSOPHILA INFORMATI, V62, P113; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Maniatis T., 1982, MOL CLONING; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; PALAZZOLO MJ, 1987, GENE, V52, P197, DOI 10.1016/0378-1119(87)90046-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; PROVOST NM, 1988, J BIOL CHEM, V263, P12070; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1989, GENETICS, V121, P101; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH RC, 1988, GENE DEV, V2, P1296, DOI 10.1101/gad.2.10.1296; THAMBI NC, 1989, J BIOL CHEM, V264, P18552; WALKER G, 1990, FASEB J, V4, P2924, DOI 10.1096/fasebj.4.11.2116341; WANG N, 1990, J BIOL CHEM, V265, P1239; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697; YOON JS, 1989, J BIOL CHEM, V264, P18536; ZIPURSKY SL, 1985, P NATL ACAD SCI USA, V82, P1855, DOI 10.1073/pnas.82.6.1855	55	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6086	6092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372898				2022-12-27	WOS:A1992HK31800057
J	SZABO, I; BERNARDI, P; ZORATTI, M				SZABO, I; BERNARDI, P; ZORATTI, M			MODULATION OF THE MITOCHONDRIAL MEGACHANNEL BY DIVALENT-CATIONS AND PROTONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; INNER MEMBRANE; PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; SULFHYDRYL-GROUPS; CYCLOSPORINE-A; CHANNEL; INHIBITION; CONDUCTANCE	In patch-clamp experiments on rat liver mitoplasts, the 1.3 nanosiemens (in 150 mM KCl) mitochondrial mega-channel was activated by Ca'' and competitively inhibited by Mg2+, Mn2+, Ba2+, and Sr2+. Cyclosporin A, which inhibits the mega-channel, also showed a competitive behavior versus Ca2+. The pore is regulated by pH in the physiological range; lower pH values cause its closure in a Ca2+-reversible manner. The modulating sites involved in these effects are located on the matrix side of the membrane. As illustrated in the companion paper (Bernardi, P., Vassanelli, S., Veronese, P., Colonna, R., Szabo, I., and Zoratti, M. (1992) J. Biol. Chem. 267, 2934-2939), the calcium-induced permeability transition of mitochondria is affected by these various agents in a similar manner. The results support the identification of the mega-channel with the pore believed to be involved in the permeabilization process. The kinetic characteristics of the single channel events support the idea that the mega-channel is composed of cooperating subunits.	CNR, CTR STUDI FISIOL MITOCONDRI, IST PATOL GEN, VIA TRIESTE 75, I-35121 PADUA, ITALY	Consiglio Nazionale delle Ricerche (CNR)			Padova, Ildiko/K-5344-2016; Szabo, Ildiko/AAW-5972-2021; Bernardi, Paolo/C-3656-2008	Szabo, Ildiko/0000-0002-3637-3947; Bernardi, Paolo/0000-0001-9187-3736				ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V113, P438, DOI 10.1016/S0926-6593(66)80002-4; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, MECHANICS SWELLING C; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; HILLERED L, 1983, FEBS LETT, V154, P247, DOI 10.1016/0014-5793(83)80158-6; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IGBAVBOA U, 1989, BIOCHEM BIOPH RES CO, V161, P619, DOI 10.1016/0006-291X(89)92644-2; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LEQUOC K, 1982, ARCH BIOCHEM BIOPHYS, V216, P639, DOI 10.1016/0003-9861(82)90254-5; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; OSHEA PS, 1984, BIOCHEM J, V219, P719, DOI 10.1042/bj2190719; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1990, J BIOENERG BIOMEMBR, V22, P663, DOI 10.1007/BF00809070; SARIS NEL, 1988, J BIOENERG BIOMEMBR, V20, P749, DOI 10.1007/BF00762551; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; TONINELLO A, 1982, FEBS LETT, V142, P63, DOI 10.1016/0014-5793(82)80220-2; ZOCCARATO F, 1981, EUR J BIOCHEM, V114, P195, DOI 10.1111/j.1432-1033.1981.tb05136.x; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1991, TRENDS BIOMEMBRANES, P263	40	205	210	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2940	2946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371109				2022-12-27	WOS:A1992HD15400022
J	GEISER, AG; BURMESTER, JK; WEBBINK, R; ROBERTS, AB; SPORN, MB				GEISER, AG; BURMESTER, JK; WEBBINK, R; ROBERTS, AB; SPORN, MB			INHIBITION OF GROWTH BY TRANSFORMING GROWTH-FACTOR-BETA FOLLOWING FUSION OF 2 NONRESPONSIVE HUMAN CARCINOMA CELL-LINES - IMPLICATION OF THE TYPE-II RECEPTOR IN GROWTH INHIBITORY RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; HUMAN-LUNG FIBROBLASTS; PLASMINOGEN-ACTIVATOR INHIBITOR; MESSENGER-RNA EXPRESSION; TGF-BETA; REVERSIBLE INHIBITION; IV COLLAGENASE; PROLIFERATION; FACTOR-BETA-1; BINDING	Loss of growth regulation by transforming growth factor-beta (TGF-beta) may be an important step in carcinogenesis. We have used a cell fusion system to show that inhibition of growth by TGF-beta can be restored to carcinoma cell lines that are unresponsive to the inhibitory effects of TGF-beta. In a previous study, the EJ bladder carcinoma line was fused to the SW480 colon adenocarcinoma line and found to produce nontumorigenic hybrid cells along with one hybrid cell clone of low tumorigenicity. Here we show that the capacity of the nontumorigenic hybrid cells to respond to either TGF-beta-1 or TGF-beta-2 has been restored, while the parental or tumorigenic hybrid cells show little or no inhibition of growth following TGF-beta treatment. Crosslinking analyses with labeled TGF-beta-1 demonstrated much higher levels of the type II (85 kDa) receptor in the hybrid cells compared with the parental tumor lines. Both the parental and tumorigenic hybrid cell lines were capable of responding to TGF-beta as evidenced by increased levels of mRNA for fibronectin, type IV collagenase, and plasminogen activator inhibitor after treatment with TGF-beta-1. These results suggest that the type II receptor is necessary for mediating the effects of TGF-beta on inhibition of growth but not on gene activation of the hybrid cells.			GEISER, AG (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.							ARTEAGA CL, 1988, CANCER RES, V48, P3898; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BROWN PD, 1990, CANCER RES, V50, P6184; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; FAFEUR V, 1991, J CELL BIOCH B, V15, P172; Fafeur V, 1990, GROWTH FACTORS, V3, P237, DOI 10.3109/08977199009043908; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GEISER AG, 1989, CANCER RES, V49, P1572; GEISER A G, 1989, Critical Reviews in Oncogenesis, V1, P261; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUGGETT AC, 1990, CANCER RES, V50, P7468; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINASK KK, 1991, EXP CELL RES, V192, P1, DOI 10.1016/0014-4827(91)90149-O; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1977, J NATL CANCER I, V58, P1743, DOI 10.1093/jnci/58.6.1743; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCMAHON JB, 1986, CANCER RES, V46, P4665; MULDER KM, 1990, CANCER RES, V50, P7581; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAHL SM, 1988, J IMMUNOL, V140, P3026; Wakefield L. M., 1990, TUMOR SUPPRESSOR GEN, P217; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOLLENBERG GK, 1987, CANCER RES, V47, P6595	48	177	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2588	2593						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370826				2022-12-27	WOS:A1992HB53200074
J	ROYCHOUDHURY, S; CHAKRABARTY, K; HO, YK; CHAKRABARTY, AM				ROYCHOUDHURY, S; CHAKRABARTY, K; HO, YK; CHAKRABARTY, AM			CHARACTERIZATION OF GUANOSINE DIPHOSPHO-D-MANNOSE DEHYDROGENASE FROM PSEUDOMONAS-AERUGINOSA - STRUCTURAL-ANALYSIS BY LIMITED PROTEOLYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; ALGINATE SYNTHESIS; RAS ONCOGENE; BINDING; GENE; PROTEIN; INFECTION; SEQUENCE; DOMAIN; TU	Alginate is believed to be a major virulence factor in the pathogenicity of Pseudomonas aeruginosa in the lungs of patients suffering from cystic fibrosis. Guanosine diphospho-D-mannose dehydrogenase (GDPmannose dehydrogenase, EC 1.1.1.132) is a key enzyme in the alginate biosynthetic pathway which catalyzes the oxidation of guanosine diphospho-D-mannose (GDP-D-mannose) to GDP-D-mannuronic acid. In this paper, we report the structural analysis of GMD by limited proteolyses using three different proteases, trypsin, submaxillary Arg-C protease, and chymotrypsin. Treatment of GMD with these proteases indicated that the amino-terminal part of this enzyme may fold into a structural domain with an apparent molecular mass of 25-26 kDa. Multiple proteolytic cleavage sites existed at the carboxyl-terminal end of this domain, indicating that this segment may represent an exposed region of the protein. Initial proteolysis also generated a carboxyl-terminal fragment with an apparent molecular mass of 16-17 kDa which was further digested into smaller fragments by trypsin and chymotrypsin. The proteolytic cleavage sites were localized by partial amino-terminal sequencing of the peptide fragments. Arg-295 was identified as the initial cleavage site for trypsin and Tyr-278 for chymotrypsin. Catalytic activity of GMD was totally abolished by the initial cleavage. However, binding of the substrate, GDP-D-mannose, increased stability toward proteolysis and inhibited the loss of enzyme activity. GMP and GDP (guanosine 5'-mono- and diphosphates) also blocked the initial cleavage, but NAD and mannose showed no effect. These results suggest that binding of the guanosine moiety at the catalytic site of GMD may induce a conformational change that reduces the accessibility of the cleavage sites to proteases. Binding of [C-14]GDP-D-mannose to the amino-terminal domain was not affected by the removal of the carboxyl-terminal 16-kDa fragment. Furthermore, photoaffinity labeling of GMD with [P-32]arylazido-beta-alanine-NAD followed by proteolysis demonstrated that the radioactive NAD was covalently linked to the amino-terminal domain. These observations imply that the amino-terminal domain (25-26 kDa) contains both the substrate and cofactor binding sites. However, the carboxyl-terminal fragment (16-17 kDa) may possess amino acid residues essential for catalysis. Thus, proteolysis had little effect on substrate binding, but totally eliminated catalysis. These biochemical data are in complete agreement with amino acid sequence analysis for the existence of substrate and cofactor sites of GMD. A linear peptide map of GMD was constructed for future structure/functional studies.	UNIV ILLINOIS,COLL MED,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NEI NIH HHS [EY-05788] Funding Source: Medline; NIAID NIH HHS [AI-16790] Funding Source: Medline; NATIONAL EYE INSTITUTE [R23EY005788, R01EY005788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI016790, R01AI016790] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRY A, 1989, J BACTERIOL, V171, P2313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN S, 1977, J BIOL CHEM, V252, P8990; DERETIC V, 1987, J BACTERIOL, V169, P351, DOI 10.1128/jb.169.1.351-358.1987; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DEVAULT JD, 1990, MOL MICROBIOL, V4, P737, DOI 10.1111/j.1365-2958.1990.tb00644.x; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; EVANS LR, 1973, J BACTERIOL, V116, P9115; HOIBY N, 1974, ACTA PATH MICRO IM B, VB 82, P551; JENG SJ, 1975, J SUPRAMOL STR CELL, V3, P448, DOI 10.1002/jss.400030506; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; KIMBARA K, 1989, BIOCHEM BIOPH RES CO, V164, P601, DOI 10.1016/0006-291X(89)91502-7; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; REYNOLDS HY, 1975, ANN INTERN MED, V82, P819, DOI 10.7326/0003-4819-82-6-819; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUSSELL NJ, 1988, MOL ASPECTS MED, V10, P1, DOI 10.1016/0098-2997(88)90002-7; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZIELINSKI NA, 1991, J BIOL CHEM, V266, P9754	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					990	996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370473				2022-12-27	WOS:A1992GY96000051
J	WALAJTYSRHODE, E; ZAPATERO, J; MOEHREN, G; HOEK, JB				WALAJTYSRHODE, E; ZAPATERO, J; MOEHREN, G; HOEK, JB			THE ROLE OF THE MATRIX CALCIUM LEVEL IN THE ENHANCEMENT OF MITOCHONDRIAL PYRUVATE CARBOXYLATION BY GLUCAGON PRETREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; DEHYDROGENASE PHOSPHATE PHOSPHATASE; FREE CA-2+ CONCENTRATION; ISOLATED HEPATOCYTES; PHOSPHORYLATION-DEPHOSPHORYLATION; 2-OXOGLUTARATE DEHYDROGENASE; OXOGLUTARATE DEHYDROGENASE; INORGANIC PYROPHOSPHATE; HORMONAL-STIMULATION; ADENINE-NUCLEOTIDES	The effect of Ca2+ on the rate of pyruvate carboxylation was studied in liver mitochondria from control and glucagon-treated rats, prepared under conditions that maintain low Ca2+ levels (1-3 nmol/mg of protein). When the matrix-free [Ca2+] was low (< 100 nM), the rate of pyruvate carboxylation was not significantly different in mitochondria from control and glucagon-treated rats. Accumulation of 5-8 nmol of Ca2+/mg, which increased the matrix [Ca2+] to 2-5-mu-M in both preparations, significantly enhanced pyruvate carboxylase flux by 20-30% in the mitochondria from glucagon-treated rats, but had little effect in control preparations. Higher levels of Ca2+ (up to 75 nmol/mg) inhibited pyruvate carboxylation in both preparations, but the difference between the mitochondria from control and glucagon-treated animals was maintained. The enhancement of pyruvate dehydrogenase flux by mitochondrial Ca2+ uptake was also significantly greater in mitochondria from glucagon-treated rats. These differential effects of Ca2+ uptake on enzyme fluxes did not correlate with changes in the mitochondrial ATP/ADP ratio, the pyrophosphate level, or the matrix volume. Arsenite completely prevented (CO2)-C-14 incorporation when pyruvate was the only substrate, but caused only partial inhibition when succinate and acetyl carnitine were present as alternative sources of energy and acetyl-CoA. Under these conditions, mitochondria from glucagon-treated rats were less sensitive to arsenite than the control preparations, even at low Ca2+ levels. We conclude that the Ca2+-dependent enhancement of pyruvate carboxylation in mitochondria from glucagon-treated rats is a secondary consequence of pyruvate dehydrogenase activation; glucagon treatment is suggested to affect the conditions in the mitochondria that change the sensitivity of the pyruvate dehydrogenase complex to dephosphorylation by the Ca2+-sensitive pyruvate dehydrogenase phosphatase.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38461] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM PAJ, 1969, J BIOL CHEM, V244, P6444; AGIUS L, 1985, EUR J BIOCHEM, V152, P699, DOI 10.1111/j.1432-1033.1985.tb09250.x; ALLAN EH, 1983, BIOCHEM J, V212, P417, DOI 10.1042/bj2120417; ALTIN JG, 1986, BIOCHEM J, V238, P653, DOI 10.1042/bj2380653; ASSIMACOPOULOSJEANNET F, 1986, J BIOL CHEM, V261, P8799; ASSIMACOPOULOSJEANNET F, 1983, FEBS LETT, V159, P83, DOI 10.1016/0014-5793(83)80421-9; BABCOCK DF, 1979, J BIOL CHEM, V254, P8117; BADDAMS HM, 1983, BIOCHEM J, V210, P73, DOI 10.1042/bj2100073; BLACKMORE PF, 1979, J BIOL CHEM, V254, P6945; BOND M, 1987, J BIOL CHEM, V262, P15630; BRYTE J, 1977, FEBS LETT, V80, P443; CHAN TM, 1979, J BIOL CHEM, V254, P8730; COOK GA, 1978, ANAL BIOCHEM, V91, P557, DOI 10.1016/0003-2697(78)90543-2; DAVIDSON AM, 1988, BIOCHEM J, V254, P379, DOI 10.1042/bj2540379; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; FOLDES M, 1977, J BIOL CHEM, V252, P5372; GARRISON JC, 1975, J BIOL CHEM, V250, P2769; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1984, BIOCHEM J, V223, P677, DOI 10.1042/bj2230677; HANSON RL, 1969, J BIOL CHEM, V244, P4351; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; HAYNES RC, 1986, HORMONAL CONTROL GLU, P19; HOEK JB, 1983, J BIOL CHEM, V258, P54; KIMMICH GA, 1969, J BIOL CHEM, V244, P190; KRAUSFRIEDMANN N, 1986, TRENDS BIOCHEM SCI, V11, P276, DOI 10.1016/0968-0004(86)90023-X; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; LUKACS GL, 1988, FEBS LETT, V229, P219, DOI 10.1016/0014-5793(88)80831-7; MCCLURE WR, 1971, J BIOL CHEM, V246, P3591; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1985, BIOCHEM J, V231, P597, DOI 10.1042/bj2310597; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; MCCORMACK JG, 1985, AM J PHYSIOL, V249, pE543; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; MORGAN NG, 1983, J BIOL CHEM, V258, P5110; MORIKOFE.S, 1973, J BIOL CHEM, V248, P7588; MURPHY E, 1980, J BIOL CHEM, V255, P6600; Perrin D. D., 2012, BUFFERS PH METAL ION; RASHED HM, 1988, J BIOL CHEM, V263, P5700; Reed L J, 1981, Curr Top Cell Regul, V18, P95; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; SAAVEDRAMOLINA A, 1990, BIOCHEM BIOPH RES CO, V167, P148, DOI 10.1016/0006-291X(90)91743-C; SCRUTTON MC, 1976, FEBS LETT, V62, P220, DOI 10.1016/0014-5793(76)80057-9; SCRUTTON MC, 1981, SHORT TERM REGULATIO, P175; SIESS EA, 1988, EUR J BIOCHEM, V173, P369, DOI 10.1111/j.1432-1033.1988.tb14007.x; SIESS EA, 1977, BIOCHEM J, V166, P225, DOI 10.1042/bj1660225; SIESS EA, 1985, EUR J BIOCHEM, V52, P131; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; STADDON JM, 1985, BIOCHEM J, V225, P327, DOI 10.1042/bj2250327; STADDON JM, 1986, BIOCHEM J, V238, P737, DOI 10.1042/bj2380737; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; TAYLOR WM, 1980, BIOCHEM J, V188, P443, DOI 10.1042/bj1880443; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2376; VANTHIENEN WD, 1981, J BIOL CHEM, V256, P8371; VONGLUTZ G, 1976, FEBS LETT, V72, P299, DOI 10.1016/0014-5793(76)80991-X; WALAJTYS EI, 1974, J BIOL CHEM, V249, P1857; WAN B, 1989, J BIOL CHEM, V264, P13430; WEBB JL, 1966, ENZYMES METABOL INH, V111, P121; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; YAMAZAKI RK, 1975, ARCH BIOCHEM BIOPHYS, V166, P575, DOI 10.1016/0003-9861(75)90422-1	67	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					370	379						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370447				2022-12-27	WOS:A1992GY43900061
J	CHAN, SDH; KARPF, DB; FOWLKES, ME; HOOKS, M; BRADLEY, MS; VUONG, V; BAMBINO, T; LIU, MYC; ARNAUD, CD; STREWLER, GJ; NISSENSON, RA				CHAN, SDH; KARPF, DB; FOWLKES, ME; HOOKS, M; BRADLEY, MS; VUONG, V; BAMBINO, T; LIU, MYC; ARNAUD, CD; STREWLER, GJ; NISSENSON, RA			2 HOMOLOGS OF THE DROSOPHILA POLARITY GENE FRIZZLED (FZ) ARE WIDELY EXPRESSED IN MAMMALIAN-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; RECEPTOR; LOCUS; ACID	The frizzled (fz) locus of Drosophila encodes a protein (Fz) with a seven-transmembrane-domain profile characteristic of G-protein-coupled receptors. In Drosophila, genetic evidence suggests that Fz functions to transmit and transduce polarity signals in epidermal cells during hair and bristle development. We have isolated from a UMR 106 rat osteosarcoma cell library a cDNA (fz-1) encoding a predicted 641-residue protein (Fz-1) with 46% homology with Drosophila Fz. We also identified a second cDNA (fz-2) encoding a protein (Fz-2) of 570 amino acids that is 80% homologous with Fz-1, with divergence most evident in the extracellular domains. Southern blots of rat genomic DNA indicated that fz-1 and fz-2 represent distinct genes. Northern analysis revealed the presence of a single fz-1 mRNA (4.7 kilobases) and two fz-2 mRNAs (2.5 and 4.5 kilobases) in rat tissues. The fz-1 and fz-2 genes are widely expressed in rat tissues with the highest steady-state levels of mRNA in kidney, liver, heart, uterus, and ovary. fz-1 and -2 mRNA levels were greater in neonatal than in corresponding adult tissues. Treatment of UMR 106 cells with bone resorbing agents including parathyroid hormone, epidermal growth factor, and 1,25-dihydroxyvitamin D3 produced increases in fz-1 and -2 mRNA levels. We suggest that hormonal induction of Fz proteins in osteoblasts serves to promote intercellular signaling required for functional responses such as increased bone resorption. Fz-1 and Fz-2 may represent products of a gene family whose members serve as transducers or intercellular transmitters of signals required for normal morphogenesis and/or differentiated function in diverse tissues.	VET AFFAIRS MED CTR,ENDOCRINE RES UNIT,111N,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK21614, DK35323, DK42146] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042146, R01DK035323, R01DK021614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Libert F, 1991, CURR OPIN CELL BIOL, V3, P218, DOI 10.1016/0955-0674(91)90142-L; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0	20	100	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25202	25207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334084				2022-12-27	WOS:A1992KB60300045
J	ELMOATASSIM, C; DUBYAK, GR				ELMOATASSIM, C; DUBYAK, GR			A NOVEL PATHWAY FOR THE ACTIVATION OF PHOSPHOLIPASE-D BY P(2Z) PURINERGIC RECEPTORS IN BAC1.2F5 MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHORBOL-MYRISTATE ACETATE; EXTRACELLULAR ATP; PHOSPHATIDYLCHOLINE HYDROLYSIS; ADENOSINE 5'-TRIPHOSPHATE; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; GROWTH-FACTOR; CELL-LINE; GUANINE-NUCLEOTIDES	Macrophages express two distinct types of nucleotide (P2 purinergic) receptors for extracellular ATP: one type induces a Ca2+-mobilizing response via the activation of phosphatidylinositol-phospholipase C (PI-PLC) while the second type induces the rapid formation of nonselective pores which are permeated by ions and small (<1 kDa) organic molecules. We have confirmed the presence of these two ATP receptor types in the BAC1.2F5 murine macrophage cell line and have identified 3'-O-(4-benzoyl)benzoyl-ATP (BzATP) as a selective and potent agonist for the so-called P2z or pore-forming ATP receptor type. Several lines of evidence indicated that occupation of these P2z receptors is also accompanied by a rapid and large increase in the activity of a phosphatidylcholine-selective phospholipase D (PLD) effector enzyme. In cells metabolically labeled with [H-3]oleic acid or [H-3]glycerol and stimulated in the presence of ethanol, ATP and BzATP induced a severalfold increase in the rate and extent of [H-3]phosphatidylethanol (PEt) accumulation. These responses were stimulated only by ATP, BzATP, and ATPgammaS (adenosine 5'-O-(3-thiotriphosphate) with the rank order of potency: BzATP >> ATP > ATPgammaS; there was no response to other adenine nucleotides or to non-adenine nucleotides. Significantly, the ability Of P2z receptor agonists to stimulate this PLD activity was not dependent on the presence of extracellular [Ca2+] or elevation of cytosolic [Ca2+]. The inability of ionomycin, gramicidin, digitonin, UTP, platelet-activating factor, or phorbol ester to quantitatively mimic these nucleotide effects suggested that activation of this PLD by P2z receptor agonists was not a secondary response due to: 1) enhanced Ca2+ influx; 2) membrane depolarization; 3) nonselective permeabilization of the plasma membrane; 4) stimulation of Ca2+-mobilizing ATP receptors; 5) stimulation of a primary PI-PLC pathway; or 6) activation of protein kinase C. These findings suggest that activation of a novel PLD-based signaling pathway may play an important role in the modulation of macrophage function by pore-forming P2z receptors for extracellular ATP.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University				Dubyak, George/0000-0001-9720-4226	NIGMS NIH HHS [GM-36387] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOYER JL, 1990, J BIOL CHEM, V265, P13515; BOYER JL, 1989, MOL PHARMACOL, V36, P831; BOYER JL, 1989, J BIOL CHEM, V264, P884; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P23147; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; ELMOATASSIM C, 1987, BIOCHIM BIOPHYS ACTA, V927, P437, DOI 10.1016/0167-4889(87)90110-8; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; GONZALEZ FA, 1990, P NATL ACAD SCI USA, V87, P9717, DOI 10.1073/pnas.87.24.9717; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HUANG R, 1991, J BIOL CHEM, V266, P1652; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KINSKY SC, 1989, BIOCHEM BIOPH RES CO, V162, P788, DOI 10.1016/0006-291X(89)92379-6; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; MARTIN TW, 1990, BIOCHIM BIOPHYS ACTA, V1053, P162, DOI 10.1016/0167-4889(90)90009-3; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; PAI JK, 1988, J BIOL CHEM, V263, P12472; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROZENGURT E, 1979, J BIOL CHEM, V254, P708; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WEISMAN GA, 1989, METHOD ENZYMOL, V171, P857; WILLIAMS N, 1986, METHOD ENZYMOL, V126, P667; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; XING MZ, 1992, J BIOL CHEM, V267, P6602; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545	62	141	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23664	23673						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331096				2022-12-27	WOS:A1992JZ23900039
J	BULLESBACH, EE; YANG, S; SCHWABE, C				BULLESBACH, EE; YANG, S; SCHWABE, C			THE RECEPTOR-BINDING SITE OF HUMAN RELAXIN-II - A DUAL PRONG-BINDING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE RELAXIN; INSULIN; SEQUENCE; CHAIN; BRAIN; GENE	Recent structure/function studies on human relaxin II have led to the conclusion that the arginines B13 and/or B17 are important for biological activity. These studies have been confirmed and extended with the help of chemically synthesized derivatives, i.e. dicitrulline (B13, B17), two monocitrulline (B13 and B17), a dilysine (B13,17), and alanine (B17) relaxins. The CD spectra of synthetic human relaxin and of the derivatives are indistinguishable. Yet, only the native human relaxin II is biologically active and binds strongly to relaxin receptor preparations in vitro. The inactivation is strictly due to side chain functions, in particular the replacement of either or both arginines in the positions B13 or B17. Binding is mediated by a two-prong electrostatic and hydrogen-binding interaction via arginines B13 and B17. Neither B13 nor B17 alone are sufficient and a positive charge equidistant from the B chain helix is equally insufficient. This binding mechanism appears to be unique, as concerns hormone receptor interaction.			BULLESBACH, EE (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038348] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 23877] Funding Source: Medline; NIDDK NIH HHS [DK 38348] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler A J, 1973, Methods Enzymol, V27, P675; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BERNATOWICZ MS, 1986, INT J PEPT PROT RES, V28, P107; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; DODSON GG, 1982, INT J BIOL MACROMOL, V4, P399, DOI 10.1016/0141-8130(82)90083-6; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; LEE YA, 1992, ENDOCRINOLOGY, V130, P1165, DOI 10.1210/en.130.3.1165; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SHIRE SJ, 1991, BIOCHEMISTRY-US, V30, P7703, DOI 10.1021/bi00245a006; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1991, ENDOCRINOLOGY, V129, P375, DOI 10.1210/endo-129-1-375; STULTS JT, 1990, BIOMED ENVIRON MASS, V19, P655, DOI 10.1002/bms.1200191105; WOODS AS, 1991, INT J MASS SPECTROM, V111, P77, DOI 10.1016/0168-1176(91)85049-R; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	24	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22957	22960						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331071				2022-12-27	WOS:A1992JY16300040
J	YANG, JM; LONDON, IM; CHEN, JJ				YANG, JM; LONDON, IM; CHEN, JJ			EFFECTS OF HEMIN AND PORPHYRIN COMPOUNDS ON INTERSUBUNIT DISULFIDE FORMATION OF HEME-REGULATED EIF-2-ALPHA KINASE AND THE REGULATION OF PROTEIN-SYNTHESIS IN RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 2-ALPHA; DOUBLE-STRANDED-RNA; HEAT-SHOCK PROTEIN; CONTROLLED TRANSLATIONAL REPRESSOR; RABBIT RETICULOCYTE; ALPHA-SUBUNIT; GLOBIN SYNTHESIS; BINDING FACTOR; FACTOR EIF-2; FACTOR-II	To study the mechanism by which heme regulates the heme-regulated eIF-2alpha kinase (HRI), the effects of various protoporphyrin IX (PP) compounds on the kinase activities and intersubunit disulfide formation of HRI and on protein synthesis in reticulocyte lysates were examined. Hemin and cobalt protoporphyrin (CoPP) are more effective than ZnPP, NiPP, SnPP, and metal-free PP in promoting intersubunit disulfide bond formation in HRI, in inhibiting the autokinase and eIF-2alpha kinase activities of HRI, in inhibiting phosphorylation of eIF-2alpha in rabbit reticulocytes, in maintaining protein synthesis, and in reversing the inhibition of protein synthesis in heme deficiency. There is an apparent correlation of in vitro intersubunit disulfide formation of HRI and the regulation of HRI kinase activities and protein synthesis by these porphyrin compounds. HRI in the reticulocyte lysate can be cross-linked by 1,6-bismaleimidohexane (bis-NEM). The formation of bis-NEM cross-linked dimers in lysates is prevented completely by N-ethylmaleimide (NEM) which alkylates free sulfhydryl groups and is diminished by hemin and CoPP. These results support the view that HRI in hemin-supplemented lysates is in equilibrium between the noncovalently linked dimer and the disulfide-linked dimer. The molecular size of HRI in control, hemin-supplemented, or NEM-treated hemin-supplemented lysates is identical to that of purified HRI; activation of HRI and changes in its thiol status do not significantly affect its molecular size.	HARVARD MASSACHUSETTS INST TECHNOL,DIV HLTH SCI & TECHNOL,E25-537,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)					NIDDK NIH HHS [DK-16272, R01 DK016272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016272, R01DK016272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON SD, 1969, J MOL BIOL, V42, P247, DOI 10.1016/0022-2836(69)90041-2; BONANOUTZEDAKI SA, 1978, EUR J BIOCHEM, V84, P601, DOI 10.1111/j.1432-1033.1978.tb12203.x; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; ERNST V, 1980, P NATL ACAD SCI-BIOL, V77, P1286, DOI 10.1073/pnas.77.3.1286; ERNST V, 1979, P NATL ACAD SCI USA, V76, P2118, DOI 10.1073/pnas.76.5.2118; ERNST V, 1982, HEAT SHOCK BACTERIA, P215; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; FARRELL PJ, 1978, EUR J BIOCHEM, V89, P517, DOI 10.1111/j.1432-1033.1978.tb12556.x; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1987, BIOCHIM BIOPHYS ACTA, V908, P123, DOI 10.1016/0167-4781(87)90051-0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HRONIS TS, 1981, J BIOL CHEM, V256, P1409; HRONIS TS, 1986, J BIOL CHEM, V2611, P6234; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; HURST R, 1987, J BIOL CHEM, V262, P15939; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX A, 1982, P NATL ACAD SCI-BIOL, V79, P2147, DOI 10.1073/pnas.79.7.2147; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MAXWELL CR, 1969, BIOCHEM BIOPH RES CO, V35, P79, DOI 10.1016/0006-291X(69)90485-9; MAXWELL CR, 1971, J MOL BIOL, V58, P317, DOI 10.1016/0022-2836(71)90249-X; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; RANU RS, 1976, P NATL ACAD SCI USA, V73, P4349, DOI 10.1073/pnas.73.12.4349; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	38	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20519	20524						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356981				2022-12-27	WOS:A1992JR85800119
J	WYNN, RM; DAVIE, JR; COX, RP; CHUANG, DT				WYNN, RM; DAVIE, JR; COX, RP; CHUANG, DT			CHAPERONINS GROEL AND GROES PROMOTE ASSEMBLY OF HETEROTETRAMERS (ALPHA-2-BETA-2) OF MAMMALIAN MITOCHONDRIAL BRANCHED-CHAIN ALPHA-KETO ACID DECARBOXYLASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEHYDROGENASE COMPLEX; PROTEIN; IDENTIFICATION; EXPRESSION	We have investigated the possible role of chaperonins groEL and groES in the folding and assembly of heterotetramers (alpha-2-beta-2) of Mammalian mitochondrial branched-chain alpha-keto acid decarboxylase (E1) in Escherichia coli. The mature E1-alpha subunit fused to maltose-binding protein (MBP) was coexpressed with mature E1-beta on the same vector in ES- and EL- mutant strains. Only small or trace amounts of active E1 component were obtained. Cotransformation of the ES- mutant host with a second vector overexpressing groEL and groES resulted in a greater than 500-fold increase in E1-specific activity. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the content of both MBP-E1-alpha and E1-beta polypeptides was markedly increased in the presence of overexpressed chaperonin proteins. The time course studies showed that the increase in E1-specific activity and subunit levels correlated with the increase in groEL and groES until the concentration of the chaperonins reached a saturating level in the cell. The functional MBP-E1 fusion protein from ES- double transformants were purified by amylose resin affinity chromatography. The MBP moiety was removed by subsequent digestion with Factor Xa endoprotease, followed by Sephacryl S-300HR chromatography. It was found that E1-alpha and E1-beta assembled into an active 160-kDa species, which was consistent with the alpha-2-beta-2 structure of E1. The present results demonstrate that chaperonins groEL and groES promote folding and assembly of heterotetrameric proteins of mammalian mitochondrial origin.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wynn, Richard/0000-0002-1879-2136; Davie, James/0000-0002-0420-6888	NIDDK NIH HHS [DK-37373, DK-26758] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; Ellis R J, 1990, Semin Cell Biol, V1, P1; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HU CWC, 1988, J BIOL CHEM, V263, P9007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Sambrook J, 1989, MOL CLONING LABORATO; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; WYNN RM, 1992, J BIOL CHEM, V267, P1881; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHI W, 1992, IN PRESS PROTEIN SCI	18	77	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12400	12403						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352285				2022-12-27	WOS:A1992HZ48300003
J	FAHIEN, LA; TELLER, JK				FAHIEN, LA; TELLER, JK			GLUTAMATE-MALATE METABOLISM IN LIVER-MITOCHONDRIA - A MODEL CONSTRUCTED ON THE BASIS OF MITOCHONDRIAL LEVELS OF ENZYMES, SPECIFICITY, DISSOCIATION-CONSTANTS, AND STOICHIOMETRY OF HETERO-ENZYME COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; KETOGLUTARATE DEHYDROGENASE COMPLEX; CARBAMOYL-PHOSPHATE SYNTHETASE; HEART CITRATE SYNTHASE; RAT-LIVER; ORNITHINE TRANSCARBAMYLASE; ISOCITRATE DEHYDROGENASE; ALPHA-KETOGLUTARATE; SUBUNIT STRUCTURE; ASPARTATE-AMINOTRANSFERASE	The level of aspartate aminotransferase in liver mitochondria was found to be approximately 140-mu-M, or 2-3 orders of magnitude higher than its dissociation constant in complexes with the inner mitochondrial membrane and the high molecular weight enzymes (M(r) = 1.6 x 10(5) to 2.7 x 10(6)) carbamyl-phosphate synthase I, glutamate dehydrogenase, and the alpha-ketoglutarate dehydrogenase complex. The total concentration of aminotransferase-binding sites on these structures in liver mitochondria was more than sufficient to accommodate all of the aminotransferase. Therefore, in liver mitochondria, the aminotransferase could be associated with the inner mitochondrial membrane and/or these high molecular weight enzymes. The aminotransferase in these hetero-enzyme complexes could be supplied with oxalacetate because binding of aminotransferase to the high molecular weight enzymes can enhance binding of malate dehydrogenase, and binding of both malate dehydrogenase and the aminotransferase facilitated binding of fumarase. The level of malate dehydrogenase was found to be so high (140-mu-M) in liver mitochondria, compared with that of citrate synthase (25-mu-M) and the pyruvate dehydrogenase complex (0.3-mu-M), that there would also be a sufficient supply of oxalacetate to citrate synthase-pyruvate dehydrogenase.			FAHIEN, LA (corresponding author), UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, 1300 UNIV AVE, MADISON, WI 53706 USA.				NATIONAL CANCER INSTITUTE [R01CA040445] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD F, 1986, BIOCHEM J, V236, P527, DOI 10.1042/bj2360527; BALL DJ, 1980, J BIOL CHEM, V255, P805; BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; BLOXHAM DP, 1981, P NATL ACAD SCI-BIOL, V78, P5381, DOI 10.1073/pnas.78.9.5381; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; BUSTAMANTE E, 1977, ANAL BIOCHEM, V80, P401, DOI 10.1016/0003-2697(77)90661-3; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CASSMAN M, 1971, BIOCHEMISTRY-US, V10, P1015; CHARLES R, 1980, BIOCHIM BIOPHYS ACTA, V629, P36, DOI 10.1016/0304-4165(80)90262-7; CHAZOTTE B, 1991, J BIOL CHEM, V266, P5973; CHURCHICH JE, 1978, BIOCHEM BIOPH RES CO, V83, P1105, DOI 10.1016/0006-291X(78)91509-7; CHURCHICH JE, 1976, BIOCHEM BIOPH RES CO, V68, P409, DOI 10.1016/0006-291X(76)91160-8; DATTA A, 1985, J BIOL CHEM, V260, P5008; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; DEROSA G, 1979, BIOCHIM BIOPHYS ACTA, V567, P116, DOI 10.1016/0005-2744(79)90178-5; DSOUZA SF, 1983, J BIOL CHEM, V258, P4706; DUSZYNSKI J, 1978, J BIOL CHEM, V253, P6149; EGAN RR, 1971, BIOCHIM BIOPHYS ACTA, V250, P47, DOI 10.1016/0005-2744(71)90118-5; EHRLICH RS, 1987, BIOCHEM J, V248, P269, DOI 10.1042/bj2480269; EHRLICH RS, 1976, BIOCHEMISTRY-US, V15, P4034, DOI 10.1021/bi00663a018; FAHIEN LA, 1978, J BIOL CHEM, V253, P5745; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P478, DOI 10.1016/0003-9861(69)90060-5; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P449, DOI 10.1016/0003-9861(69)90057-5; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FAHIEN LA, 1985, J BIOL CHEM, V260, P6069; FAHIEN LA, 1983, ARCH BIOCHEM BIOPHYS, V220, P386, DOI 10.1016/0003-9861(83)90428-9; FAHIEN LA, 1979, ARCH BIOCHEM BIOPHYS, V192, P33, DOI 10.1016/0003-9861(79)90069-9; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FAHIEN LA, 1979, J BIOL CHEM, V254, P5983; FAHIEN LA, 1984, ARCH BIOCHEM BIOPHYS, V230, P213, DOI 10.1016/0003-9861(84)90102-4; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P468, DOI 10.1016/0003-9861(69)90059-9; FAHIEN LA, 1977, J BIOL CHEM, V252, P1250; FAHIEN LA, 1988, J BIOL CHEM, V263, P10687; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P456, DOI 10.1016/0003-9861(69)90058-7; FAHIEN LA, 1976, ARCH BIOCHEM BIOPHYS, V176, P298, DOI 10.1016/0003-9861(76)90168-5; FELISS N, 1970, BIOCHEM BIOPH RES CO, V40, P932, DOI 10.1016/0006-291X(70)90993-9; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; GITOMER WL, 1987, BIOCHEM J, V248, P997, DOI 10.1042/bj2480997; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; HAYAKAWA T, 1969, J BIOL CHEM, V244, P3660; HIRASHIMA M, 1967, J BIOL CHEM, V242, P902; KANAREK L, 1964, J BIOL CHEM, V239, P4202; KANAREK L, 1964, J BIOL CHEM, V239, P4207; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KISPAL G, 1986, J BIOL CHEM, V261, P14209; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEE YH, 1975, J BIOL CHEM, V250, P5604; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LOPES C, 1970, EUR J BIOCHEM, V83, P635; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1981, BIOCHEMISTRY-US, V20, P3665, DOI 10.1021/bi00516a001; LUSTY CJ, 1979, J BIOL CHEM, V254, P30; MARSHALL M, 1980, J BIOL CHEM, V255, P7301; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MARTINEZCARRION M, 1967, BIOCHEMISTRY-US, V6, P1715, DOI 10.1021/bi00858a021; MERZ JM, 1987, ARCH BIOCHEM BIOPHYS, V258, P132, DOI 10.1016/0003-9861(87)90330-4; MORIYAMA T, 1971, J BIOL CHEM, V246, P3217; MULLINAX TR, 1982, J BIOL CHEM, V257, P13233; NOYES B E, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1334, DOI 10.1073/pnas.71.4.1334; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; RUOHO A, 1975, BIOCHEM BIOPH RES CO, V63, P417, DOI 10.1016/0006-291X(75)90704-4; RUTTER GA, 1989, BIOCHEM J, V263, P445, DOI 10.1042/bj2630445; SIEBERT G, 1957, J BIOL CHEM, V226, P965; SINGH M, 1970, J BIOL CHEM, V245, P4636; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; SMITH EL, 1970, P NATL ACAD SCI USA, V67, P724, DOI 10.1073/pnas.67.2.724; Sols A., 1970, CURRENT TOPICS CELLU, V2, P227; SPIVEY HO, 1989, BIOESSAYS, V10, P127, DOI 10.1002/bies.950100409; Srere P. A., 1972, ENERGY METABOLISM RE, P79; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; SUMEGI B, 1983, BIOCHIM BIOPHYS ACTA, V749, P163, DOI 10.1016/0167-4838(83)90248-0; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; SWICK RW, 1965, J BIOL CHEM, V240, P3334; TELLER JK, 1990, J BIOL CHEM, V265, P19486; VIRDEN R, 1972, BIOCHEM J, V127, P503, DOI 10.1042/bj1270503; WANDERS RJA, 1983, EUR J BIOCHEM, V133, P245, DOI 10.1111/j.1432-1033.1983.tb07455.x; WILLSON VJC, 1981, EUR J BIOCHEM, V113, P477, DOI 10.1111/j.1432-1033.1981.tb05088.x; WIMMER MJ, 1975, J BIOL CHEM, V250, P710	92	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10411	10422						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350279				2022-12-27	WOS:A1992HV09000035
J	NTAMBI, JM				NTAMBI, JM			DIETARY-REGULATION OF STEAROYL-COA DESATURASE-1 GENE-EXPRESSION IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; MESSENGER-RNA; RAT-LIVER; THYROID-HORMONE; S14 GENE; TRANSCRIPTIONAL ACTIVATION; 3T3-L1 PREADIPOCYTES; CHROMATIN STRUCTURE; TERMINAL ENZYME	Expression of the murine liver stearoyl-CoA desaturase gene (SCD1) is induced upon feeding fasted mice a fat-free, high carbohydrate diet (Ntambi, J. M., Buhrow, S. A., Kaestner, K. H., Christy, R. J., Sibley, E., Kelly, T. J., and Lane, M. D. (1988) J. Biol. Chem. 263, 17291-17300). In the present study, SCD1-specific RNA riboprobes and cDNA probes were used to study the mechanism for the induction of SCD1 mRNA. Based on the time course of induction, the SCD1 mRNA increased from 2-fold within 6 h to 45-fold within 36 h. Nuclear run-on transcription studies showed that the accumulation of SCD1 mRNA after refeeding starved mice a fat-free, high carbohydrate diet was a consequence of the transcriptional activation of the SCD1 gene. The SCD1 mRNA level decreased rapidly (t1/2 = approximately 4 h) within 24 h when mice fed the fat-free, high carbohydrate diet were switched to a regular chow diet. Furthermore, when the fat-free diet was supplemented with triacylglycerides containing polyunsaturated fatty acids, the transcription of the SCD1 gene and the induction of the SCD1 mRNA were significantly blunted. Triacylglycerides containing saturated and monounsaturated fatty acids were without dramatic effects. In contrast, synthesis of liver albumin mRNA was little affected by any of these dietary variations, indicating that the observed changes in the transcription of the SCD1 gene and mRNA levels were specific. These data demonstrate that both dietary carbohydrates and polyunsaturated fatty acids or their metabolites directly or indirectly regulate the expression of the SCD1 gene in mouse liver.			NTAMBI, JM (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,3900 RESERVOIR RD,WASHINGTON,DC 20007, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; ESNER M, 1982, BIOCHEM J, V206, P561; GOODRIDGE AG, 1983, ARCH BIOPHYS, V227, P54; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JEFFCOAT R, 1979, EUR J BIOCHEM, V101, P439, DOI 10.1111/j.1432-1033.1979.tb19737.x; JOSHI VC, 1979, J BIOL CHEM, V254, P1779; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1987, J BIOL CHEM, V262, P778; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KASTURI R, 1984, ARCH BIOCHEM BIOPHYS, V233, P530, DOI 10.1016/0003-9861(84)90476-4; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PRASAD MR, 1979, J BIOL CHEM, V254, P6362; SONG MKH, 1988, J BIOL CHEM, V263, P17970; THIEDE MA, 1985, J BIOL CHEM, V260, P4459; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; TOMLINSON JE, 1988, J NUTR, V118, P408, DOI 10.1093/jn/118.3.408; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	31	240	252	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10925	10930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350282				2022-12-27	WOS:A1992HV09000107
J	COUPRY, I; DUZIC, E; LANIER, SM				COUPRY, I; DUZIC, E; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .2. PREFERENTIAL COUPLING OF THE ALPHA-2C-ADRENERGIC RECEPTOR TO THE GUANINE NUCLEOTIDE-BINDING PROTEIN, GO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED MUSCARINIC RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; HIGH-AFFINITY; REGULATORY PROTEINS; FUNCTIONAL RECONSTITUTION; PHOSPHOLIPID-VESICLES; MOLECULAR-CLONING; CALCIUM CHANNELS; ALPHA-SUBUNIT; HYBRID-CELLS	Cell to cell communication by many hormones and neurotransmitters involves three major entities: receptor (R), G-protein (G), and effector molecule (E). Plasticity in this system is conferred by the existence of each entity as isoforms or closely related subtypes that are expressed in a tissue-specific and developmentally regulated manner. Factors that determine signal specificity in this system are poorly understood. Such factors include the relative affinity and stoichiometry of R-G or G-E and the possible colocalization of R-G-E in cellular microdomains. Utilizing the alpha-2-adrenergic receptor (alpha-2-AR) system as a representative subfamily of this class of signal transducers, we determined the relative importance of these factors. By analysis of R-G coupling in mammalian cells cotransfected With alpha-2-AR genes and G(alpha) cDNA, we demonstrate preferential coupling between an alpha-2-AR subtype and G(o). Our data implicate R-G affinity as an important determinant of signal transduction specificity and indicate that a critical level of G(o-alpha) is required for coupling. This report indicates the utility of R-G cotransfection in mammalian cells as a "natural environment model" to characterize events occurring at the R-G and G-E interface.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CELLULAR & MOLEC RES LAB,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital			COUPRY, Isabelle/L-4900-2014	Lanier, Stephen/0000-0002-2740-7607	FOGARTY INTERNATIONAL CENTER [F05TW004313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; FIC NIH HHS [3 FO5 TW4313] Funding Source: Medline; NINDS NIH HHS [NS-24821] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, FASEB J, V4, P3068; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DUZIC E, 1992, J BIOL CHEM, V267, P9844; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1986, J BIOL CHEM, V261, P133; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1985, J BIOL CHEM, V260, P864; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KUROSE H, 1986, J BIOL CHEM, V261, P6423; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LONGABAUGH JP, 1988, J CLIN INVEST, V81, P420, DOI 10.1172/JCI113335; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MILLIGAN G, 1990, BIOCHEM J, V270, P521; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEGISHI M, 1988, J BIOL CHEM, V263, P6893; OHARA K, 1988, MOL PHARMACOL, V33, P290; PARKER EM, 1991, J BIOL CHEM, V266, P519; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P187; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRASSHEIM D, 1990, BIOCHEM J, V266, P521, DOI 10.1042/bj2660521; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SUSANNI EE, 1989, CIRC RES, V65, P1145, DOI 10.1161/01.RES.65.4.1145; THOMSEN WJ, 1988, MOL PHARMACOL, V34, P6301; UEDA H, 1989, J BIOL CHEM, V264, P3732; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9852	9857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349607				2022-12-27	WOS:A1992HT96500065
J	XU, GQ; HUAN, LJ; KHATRI, IA; WANG, DH; BENNICK, A; FAHIM, REF; FORSTNER, GG; FORSTNER, JF				XU, GQ; HUAN, LJ; KHATRI, IA; WANG, DH; BENNICK, A; FAHIM, REF; FORSTNER, GG; FORSTNER, JF			CDNA FOR THE CARBOXYL-TERMINAL REGION OF A RAT INTESTINAL MUCIN-LIKE PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOBLET-CELL MUCIN; PUTATIVE LINK GLYCOPEPTIDE; VONWILLEBRAND-FACTOR; POLYMERIC STRUCTURE; MOLECULAR-CLONING; MULTIDOMAIN PROTEIN; MUCUS GLYCOPROTEIN; DISULFIDE BRIDGES; CYSTIC-FIBROSIS; RNA ISOLATION	When subjected to thiol reduction, purified intestinal mucins have been shown to undergo a decrease in molecular mass and to liberate a 118-kDa glycopeptide (Roberton, A. M., Mantle, M., Fahim, R. E. F., Specian, R., Bennick, A., Kawagishi, S., Sherman, P., and Forstner, J. F. (1989) Biochem. J. 261, 637-647). The latter has been called a putative "link" component because it is assumed to be important for disulfide bond-mediated mucin polymerization. Controversy exists as to whether the putative link is an integral mucin component or a separate mucin-associated glycopeptide. In the present study both NH2-terminal and internal amino acid sequences of the 118-kDa glycopeptide of rat intestinal mucin were used to generate opposing oligonucleotide primers for polymerase chain reaction. A specific 1.2-kilobase (kb) product was obtained, from which a 0.5-kb HindIII fragment was used as a probe to screen a lambda-ZAP II cDNA library of rat intestine. A 2.6-kb cDNA (designated MLP 2677) was sequenced and revealed an open reading frame of 2.5 kb encoding 837 amino acids. The deduced amino acid sequence showed that the putative link peptide is equivalent to the carboxyl-terminal 689 amino acids of a larger peptide. Northern blots revealed a mRNA size of approximately 9 kb. Computer searches revealed no sequence homology with other proteins, but similarities were seen in the alignment of cysteine residues in the link and in several domains of human von Willebrand factor, as well as cysteine-rich areas of bovine and porcine submaxillary mucins and a frog skin mucin designated FIM-B.1. In keeping with earlier demonstrations of the presence of mannose in the 118-kDa glycopeptide, there were several (13) consensus sequences for attachment of N-linked oligosaccharides within the link domain. Further sequencing of MLP 2677 in a direction 5' to the codon specifying the NH2-terminal proline of the link has revealed a coding region for 148 amino acids, including a unique 75-amino acid domain rich in cysteine and proline, and a region containing 4.5-variable tandem repeats (each 11-12 amino acids) rich in serine, threonine, and proline. The presence of mucin-like tandem repeats suggests that the entire cysteine-rich link peptide represents the carboxyl-terminal region (75.5 kDa) of a mucin-like peptide (MLP). The latter is estimated to have a molecular mass of approximately 300 kDa.	HOSP SICK CHILDREN,RES INST,DEPT BIOCHEM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								Allen A., 1981, PHYSL GASTROINTESTIN, P617; BELL AE, 1985, GASTROENTEROLOGY, V88, P269, DOI 10.1016/S0016-5085(85)80180-3; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CREETH JM, 1977, BIOCHEM J, V167, P557, DOI 10.1042/bj1670557; CREPIN M, 1990, BIORHEOLOGY, V27, P471; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FAHIM REF, 1987, BIOCHEM J, V243, P631, DOI 10.1042/bj2430631; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; FORSYTHE KH, 1989, TRANSPORT Q, V43, P259; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JABBAL I, 1976, CAN J BIOCHEM CELL B, V54, P707, DOI 10.1139/o76-102; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MANTLE M, 1984, BIOCHEM J, V217, P159, DOI 10.1042/bj2170159; MANTLE M, 1981, BIOCHEM J, V195, P277, DOI 10.1042/bj1950277; MANTLE M, 1978, Biochemical Society Transactions, V6, P607; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; MANTLE M, 1989, BIOCHEM J, V259, P243, DOI 10.1042/bj2590243; MANTLE M, 1991, BIOCHEM J, V274, P679, DOI 10.1042/bj2740679; MASSON PL, 1973, CERVICAL MUCUS HUMAN, P82; MUSKAL SM, 1990, PROTEIN ENG, V3, P667, DOI 10.1093/protein/3.8.667; NAZIRUDDIN B, 1990, BIOCHIM BIOPHYS ACTA, V1041, P164, DOI 10.1016/0167-4838(90)90061-J; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PEARSON JP, 1981, BIOCHEM J, V197, P155, DOI 10.1042/bj1970155; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; ROSE MC, 1989, J BIOL CHEM, V264, P8193; SAJJAN SU, 1990, INFECT IMMUN, V58, P868, DOI 10.1128/IAI.58.4.868-873.1990; SAMBROOK J, 1989, MOL CLONING, V1, P743; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; XU G, 1991, GLYCOCONJ J, V8, P209	53	101	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5401	5407						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371999				2022-12-27	WOS:A1992HH74700062
J	SHIMABUKU, AM; NISHIMOTO, T; UEDA, K; KOMANO, T				SHIMABUKU, AM; NISHIMOTO, T; UEDA, K; KOMANO, T			P-GLYCOPROTEIN - ATP HYDROLYSIS BY THE N-TERMINAL NUCLEOTIDE-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIDRUG-RESISTANCE; GENE; CELLS; PURIFICATION; MUTATIONS; F1-ATPASE; PROTEINS; SUBUNITS; SITE; DNA	Two ATP-binding domains are found in members of the family of ATP-dependent transport proteins, which includes P-glycoprotein and cystic fibrosis transmembrane conductance regulator. To investigate the involvement of the two ATP-binding domains in the ATPase activity of P-glycoprotein, full-length and the 5'-half of human MDR1 cDNA, which encodes P-glycoprotein, were fused with the Escherichia coli lacZ gene and expressed in NIH3T3 cells. Immunoprecipitated full-length P-glycoprotein beta-galactosidase showed ATPase activity with apparent specific activity of 180 nmol/mg/min, a value higher than previously reported, in the presence of phospholipids, suggesting that stabilization of the transmembrane domains is necessary for ATP hydrolysis. N-terminal half P-glycoprotein-beta-galactosidase also showed ability to hydrolyze ATP but with slightly lower specific activity. Both ATPase activities showed similar characteristics when the effect of several inhibitors was analyzed, indicating that the N-terminal ATP-binding domain contains all residues necessary to hydrolyze ATP without interacting with the C-terminal ATP-binding domain.	KYOTO UNIV,DEPT AGR CHEM,BIOCHEM LAB,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Ueda, Kazumitsu/0000-0003-2980-6078				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMADA H, 1988, CANCER RES, V48, P4296; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Miller J. H, 1972, EXPT MOL GENETICS; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHIMABUKU AM, 1991, AGR BIOL CHEM TOKYO, V55, P1075, DOI 10.1080/00021369.1991.10870709; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	26	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4308	4311						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347041				2022-12-27	WOS:A1992HF64200009
J	BAJT, ML; GINSBERG, MH; FRELINGER, AL; BERNDT, MC; LOFTUS, JC				BAJT, ML; GINSBERG, MH; FRELINGER, AL; BERNDT, MC; LOFTUS, JC			A SPONTANEOUS MUTATION OF INTEGRIN-ALPHA-IIB-BETA-3 (PLATELET GLYCOPROTEIN-IIB-IIIA) HELPS DEFINE A LIGAND-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN GAMMA-CHAIN; GPIIB-IIIA; GLANZMANNS THROMBASTHENIA; MONOCLONAL-ANTIBODIES; ADHESION RECEPTOR; RECOGNITION SITE; CELL-SURFACE; EXPRESSION; COMPLEX; LOCALIZATION	This work characterizes a mutant integrin alpha(IIb)beta-3 (glycoprotein (GP) IIb-IIIa) from a thrombasthenic patient, ET, whose platelets fail to aggregate in response to stimuli. The nature of the defect was defined by the reduced ability of synthetic peptide ligands, corresponding to the carboxyl terminus of the fibrinogen-gamma chain (gamma-402-411) and Arg-Gly-Asp (RGD), to increase the binding of the occupancy-dependent anti-LIBS1 antibody to mutant alpha(IIb)beta-3 and the reduced binding of mutant alpha(IIb)beta-3 to an immobilized RGD peptide. In addition, ET's platelets failed to bind the ligand-mimetic monoclonal anti-alpha(IIb)beta-3, PAC1. DNA sequence analysis of amplified ET genomic DNA revealed a single G --> A base change which encoded substitution of R214 by Q in mature beta-3. Introduction of this point mutation into recombinant wild type alpha(IIb)beta-3 expressed in Chinese hamster ovary cells reproduced the ET platelet alpha(IIb)beta-3 deficits in binding of fibrinogen, mAb PAC1, and synthetic peptide ligands. Furthermore, substitution of R214 by Q in the synthetic peptide containing the sequence of beta-3(211-222) resulted in decreased ability of this peptide to block fibrinogen binding to purified alpha(IIb)beta-3. These findings suggest that substitution of beta-3 R214 by Q is responsible for the functional defect in alpha-(IIb)beta-3 and that R214 is proximal to or part of a ligand binding domain in alpha-(IIb)beta-3.	UNIV SYDNEY, WESTMEAD HOSP, DEPT MED, THROMBOSIS & CARDIOVASC DIS RES CTR, WESTMEAD, NSW 2145, AUSTRALIA	University of Sydney	BAJT, ML (corresponding author), Scripps Clinic, COMM VASCULAR BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Berndt, Michael C/D-5580-2012	Frelinger, Andrew/0000-0002-6871-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042977, R29HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008172] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42977] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [T32GM08172-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN ML, 1987, SEMIN THROMB HEMOST, V13, P307, DOI 10.1055/s-2007-1003506; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COURTOIS G, 1986, EUR J BIOCHEM, V159, P61, DOI 10.1111/j.1432-1033.1986.tb09833.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1990, BLOOD, V76, P2017; GINSBERG MH, 1980, BLOOD, V55, P661; HERRMANN BG, 1987, GUIDE MOL CLONING TE, P180; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1986, BLOOD, V68, P1224; TAUB R, 1989, J BIOL CHEM, V264, P259; XIAOPING D, 1991, CELL, V65, P409; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	35	157	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3789	3794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371279				2022-12-27	WOS:A1992HE60700040
J	GUY, GR; CAO, X; CHUA, SP; TAN, YH				GUY, GR; CAO, X; CHUA, SP; TAN, YH			OKADAIC ACID MIMICS MULTIPLE CHANGES IN EARLY PROTEIN-PHOSPHORYLATION AND GENE-EXPRESSION INDUCED BY TUMOR-NECROSIS-FACTOR OR INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; MOLECULAR-CLONING; FACTOR RECEPTOR; CELL-CYCLE; KINASE; PHOSPHATASE; ACTIVATION; CYTOKINES; PROMOTER; LINE	Okadaic acid, a phosphatase inhibitor from a marine organism, mimics tumor necrosis factor/interleukin-1 (TNF/IL-1) in inducing changes in early cellular protein phosphorylation. A total of approximately 116 proteins exhibit significant and concordant changes in phosphorylation or dephosphorylation within 15 min in human fibroblasts activated by either okadaic acid, TNF, or IL-1. The fidelity of this mimicry by okadaic acid extends to the phosphorylation of the 27 hsp complex, stathmin, eIF-4E, myosin light chain, nucleolin, epidermal growth factor receptor, and other cdc2-kinase substrates (c-abl, RB, and p53). The okadaic acid-induced pattern of protein phosphorylation is distinct from that observed in cells treated with phorbol 12-myristate 13-acetate or with ligands like epidermal growth factor, cyclic AMP agonists, bradykinin, or interferons. Like TNF, okadaic acid also induces the transcription of immediate early response genes like c-jun and Egr-1 as well as the interleukin-6 genes. The overall early effects of okadaic acid uniquely parallel those of TNF/IL-1 and not those of other cytokines or ligands. Regulation of protein phosphatase inhibition is discussed as a mechanism for TNF/IL-1 signal transduction.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DINARELLO CA, 1984, TRENDS PHARMACOL SCI, V5, P420, DOI 10.1016/0165-6147(84)90491-7; DINARELLO CA, 1990, LYMPHOKINES IMMUNE R, P146; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P2555, DOI 10.1073/pnas.87.7.2555; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; GOH C R, 1990, Annals Academy of Medicine Singapore, V19, P235; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GUY GR, 1991, J BIOL CHEM, V266, P14343; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUSCHER B, 1991, J IMMUNOL, V10, P865; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; THOMAS NSB, 1991, ONCOGENE, V6, P317; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	40	164	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1846	1852						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370482				2022-12-27	WOS:A1992HA48500070
J	KURODA, S; OTAKA, S; MIYAZAKI, T; NAKAO, M; FUJISAWA, Y				KURODA, S; OTAKA, S; MIYAZAKI, T; NAKAO, M; FUJISAWA, Y			HEPATITIS-B VIRUS ENVELOPE L-PROTEIN PARTICLES - SYNTHESIS AND ASSEMBLY IN SACCHAROMYCES-CEREVISIAE, PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-ANTIGEN PARTICLES; HUMAN-LYSOZYME; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SIGNAL SEQUENCE; P-31 GENE; YEAST; EXPRESSION; SECRETION; ACID	The hepatitis B virus envelope gene encodes three transmembrane proteins in frame; S, the product of S gene; M, the product of M (pre-S2 + S) gene; and L, the product of L (pre-S1 + pre-S2 + S) gene. Unlike the S and M proteins, attempts to efficiently synthesize L proteins and assemble them into L protein particles in various eukaryotic cells have been unsuccessful, probably because of the presence of the pre-S1 peptide with an unknown function which appears to be inhibitory to the host secretory apparatus. To investigate the role of the pre-S1 peptide, we constructed an L gene fused with a synthetic gene for chicken-lysozyme signal peptide (C-SIG) at the 5'-terminal and placed the resultant gene under the control of the yeast glyceraldehyde-3-phosphate dehydrogenase gene promoter. After the fused-C-SIG peptide was correctly processed by the yeast secretory apparatus, a yeast transformant synthesized a protein with a molecular mass of approximately 52 kDa at a level of 42% of the total soluble protein. Electron micrographic observation showed that the gene products assembled into 23-nm spherical and filamentous particles. The pre-S peptide of the gene product was deposited into the endoplasmic reticulum (ER) lumen and well-glycosylated. It seemed that the gene products were accumulated as particles in certain specific membrane structures of the yeast secretory apparatus. Moreover, both the amount of mRNAs specific for the L gene and the in vivo stability of the synthesized L proteins did not change significantly by the addition of the C-SIG gene. These findings indicated that, if the pre-S1 peptide penetrates the ER membrane efficiently, the L proteins can be synthesized cotranslationally, translocate across the ER membrane with its S region, and then assemble by themselves into the particle form. Therefore, the pre-S1 peptide may involve weak or reduced signal peptide activity for recognition by the secretory apparatus and/or for the transport of the pre-S peptide into the ER lumen.	TAKEDA CHEM IND LTD, BIOL RES LABS, OSAKA 532, JAPAN	Takeda Chemical Industries	KURODA, S (corresponding author), TAKEDA CHEM IND LTD, BIOTECHNOL RES LABS, OSAKA 532, JAPAN.							BACH ML, 1979, P NATL ACAD SCI USA, V76, P386, DOI 10.1073/pnas.76.1.386; BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BUDKOWSKA A, 1982, J IMMUNOL METHODS, V51, P341, DOI 10.1016/0022-1759(82)90401-X; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1986, MOL CELL BIOL, V6, P1454, DOI 10.1128/MCB.6.5.1454; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUJISAWA Y, 1985, GENE, V40, P23, DOI 10.1016/0378-1119(85)90020-4; FUJISAWA Y, 1990, VACCINE, V8, P192, DOI 10.1016/0264-410X(90)90044-M; GERBER MA, 1974, AM J PATHOL, V75, P489; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; HAZAMA M, 1989, VACCINE, V7, P567, DOI 10.1016/0264-410X(89)90285-5; HEERMANN KH, 1987, INTERVIROLOGY, V28, P14, DOI 10.1159/000149993; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HITZEMAN RA, 1983, NUCLEIC ACIDS RES, V11, P2745, DOI 10.1093/nar/11.9.2745; IMAMURA T, 1987, J VIROL, V61, P3543, DOI 10.1128/JVI.61.11.3543-3549.1987; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V138, P268, DOI 10.1016/0006-291X(86)90275-5; ITOH Y, 1986, BIOCHEM BIOPH RES CO, V141, P942, DOI 10.1016/S0006-291X(86)80134-6; JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0; JIGAMI Y, 1986, GENE, V43, P273, DOI 10.1016/0378-1119(86)90216-7; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURODA S, 1991, VACCINE, V9, P163, DOI 10.1016/0264-410X(91)90148-Y; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; KUROKI K, 1990, VIROLOGY, V78, P297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1988, GENE, V67, P229, DOI 10.1016/0378-1119(88)90400-3; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILICH DR, 1986, J IMMUNOL, V137, P313; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; NARITA K, 1966, J BIOCHEM-TOKYO, V59, P170, DOI 10.1093/oxfordjournals.jbchem.a128278; Neurath A R, 1988, Adv Virus Res, V34, P65, DOI 10.1016/S0065-3527(08)60516-3; NEURATH AR, 1989, VACCINE, V7, P234; OBERTO J, 1985, GENE, V40, P57, DOI 10.1016/0378-1119(85)90024-1; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PATZER EJ, 1986, J VIROL, V58, P884, DOI 10.1128/JVI.58.3.884-892.1986; PERSING DH, 1987, J VIROL, V61, P1672, DOI 10.1128/JVI.61.5.1672-1677.1987; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIMON K, 1988, J CELL BIOL, V107, P2163, DOI 10.1083/jcb.107.6.2163; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSUGITA A, 1982, EUR J BIOCHEM, V124, P585, DOI 10.1111/j.1432-1033.1982.tb06634.x; VALENZUELA P, 1985, BIO-TECHNOL, V3, P317, DOI 10.1038/nbt0485-317; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; WINGFIELD PT, 1987, YEAST, V3, P43, DOI 10.1002/yea.320030107; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0; [No title captured]	53	86	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1953	1961						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370486				2022-12-27	WOS:A1992HA48500085
J	DUEWEKE, TJ; KEZDY, FJ; WASZAK, GA; DEIBEL, MR; TARPLEY, WG				DUEWEKE, TJ; KEZDY, FJ; WASZAK, GA; DEIBEL, MR; TARPLEY, WG			THE BINDING OF A NOVEL BISHETEROARYLPIPERAZINE MEDIATES INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; ZIDOVUDINE AZT; DOUBLE-BLIND; HIV; 3'-AZIDO-3'-DEOXYTHYMIDINE; REPLICATION; EFFICACY	The bisheteroarylpiperazines (BHAPs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and specifically block HIV-1 replication (Romero, D. L., Busso, M., Tan, C.-K., Reusser, F., Palmer, J. R., Poppe, S. M., Aristoff, P. A., Downey, K. M., So, A. G., Resnick, L., and Tarpley, W. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8806-8810). Here we show that the radiolabeled BHAP [H-3]U-88204 binds specifically to HIV-1 RT with high affinity (K(D) of 50 nm) and a stoichiometry of 1 mol of U-88204 per 1 mol of p66/p51 RT heterodimer. Binding of [H-3]U-88204 to RT is unaffected by the presence of saturating poly(rC).oligo (dG)12-18 template-primer. Direct measurement of competition between [H-3]U-88204 and other RT inhibitors for binding to RT reveals mutually exclusive competition between [H-3]U-88204 and the non-nucleoside RT inhibitor BI-RG-587 (Kopp, E. B., Miglietta, J. J., Shrutkowski, A. G., Shih, C.-K., Grob, P. M. and Skoog, M.T. (1991) Nucleic Acids Res. 19, 3035-3039), indicating that both share the same binding site. Phosphonoformate in concentrations up to 50-mu-M shows no competition with [H-3]U-88204 for binding to RT either alone or in the presence of template-primer. Dideoxynucleotide RT inhibitors affect the binding of [H-3]U-88204 to RT when complementary template-primer is present. [H-3]U-88204 and the dideoxynucleotide ddGTP can bind RT simultaneously, but the presence of one ligand decreases the affinity of RT for the second. Inasmuch as ddGTP approximates the nucleotide substrate of RT, the direct demonstration of an RT-dideoxynucleotide-[H-3]U-88204 complex validates the use of indirect kinetic methods to assess the strength of BHAP interaction with RT and suggests that RT inhibition by U-88204 is achieved via effects on nucleotide substrate binding.			DUEWEKE, TJ (corresponding author), UPJOHN CO,KALAMAZOO,MI 49001, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CH, 1989, J BIOL CHEM, V264, P11934; COHEN KA, 1991, J BIOL CHEM, V266, P14670; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1989, ANTIVIR RES, V12, P1, DOI 10.1016/0166-3542(89)90064-8; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRANK KB, 1991, J BIOL CHEM, V266, P14232; HAO Z, 1988, MOL PHARMACOL, V34, P431; HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045; JACOBS S, 1975, J PHARM COMMUN, V66, P687; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SARIN PS, 1985, BIOCHEM PHARMACOL, V34, P4075, DOI 10.1016/0006-2952(85)90392-2; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	26	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					27	30						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370445				2022-12-27	WOS:A1992GY43900008
J	GREENHALGH, DA; SUBRAMANIAM, S; ALEXIEV, U; OTTO, H; HEYN, MP; KHORANA, HG				GREENHALGH, DA; SUBRAMANIAM, S; ALEXIEV, U; OTTO, H; HEYN, MP; KHORANA, HG			EFFECT OF INTRODUCING DIFFERENT CARBOXYLATE-CONTAINING SIDE-CHAINS AT POSITION-85 ON CHROMOPHORE FORMATION AND PROTON TRANSPORT IN BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC ACID-96; SCHIFF-BASE; PURPLE MEMBRANE; TRANSLOCATION; SUBSTITUTIONS; PHOTOCYCLE; PUMP; SPECTROSCOPY; RESIDUES; MUTANTS	During the initial stages of the bacteriorhodopsin photocycle, a proton is transferred from the Schiff base to the deprotonated carboxylate of Asp85. Earlier studies have shown that replacement of Asp85 by Asn completely abolishes proton transport activity, whereas extension of the side chain by an additional carbon-carbon bond (Asp85 --> Glu) results in a functional proton pump. Here we show that extension of the Asp85 side chain by two additional bond lengths also results in a functional proton pump as long as the terminal group is a carboxylate moiety. These side chains were created by modification of the cysteine residue in the Asp85 --> Cys mutant with either iodoacetic acid or iodoacetamide. In vitro chromophore formation studies show that the rate of Schiff base protonation in mutants that contain a carboxylate at residue 85 is invariably faster than in mutants that contain neutral substitutions at this position. We conclude that in bacteriorhodopsin, there is considerable tolerance in the volume of the side chain that can be accommodated at position 85 and that the presence of a carboxylate at residue 85 is important both for proton pumping and for stabilizing the protonated Schiff base.	MIT,DEPT BIOL,RM 18-511,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; FREE UNIV BERLIN,DEPT PHYS,W-1000 BERLIN 33,GERMANY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin	KHORANA, HG (corresponding author), MIT,DEPT BIOL,RM 18-511,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Alexiev, Ulrike/L-8478-2016	Subramaniam, Sriram/0000-0003-4231-4115	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; EGGLESTON DS, 1981, ACTA CRYSTALLOGR B, V37, P1430, DOI 10.1107/S056774088100616X; EGGLESTON DS, 1981, ACTA CRYSTALLOGR B, V37, P1428, DOI 10.1107/S0567740881006158; FISCHER UC, 1980, BIOPHYS J, V31, P139, DOI 10.1016/S0006-3495(80)85045-4; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; HEBERLE J, 1991, BIOPHYS J, V59, P327; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; LANYI JK, 1992, BIOCHIM BIOPHYS ACTA, V1099, P102, DOI 10.1016/0167-4838(92)90458-P; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; LUKAC M, 1988, J BIOL CHEM, V263, P6146; MARTI T, 1992, J BIOL CHEM, V267, P16922; MARTI T, 1991, J BIOL CHEM, V266, P18674; MIGHELL AD, 1979, ACTA CRYSTALLOGR B, V35, P1258, DOI 10.1107/S0567740879006117; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOGI T, 1989, J BIOL CHEM, V264, P14197; MULLER KH, 1991, EUR BIOPHYS J, V19, P241, DOI 10.1007/BF00183531; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; STERN LJ, 1989, BIOCHEMISTRY-US, V28, P10035, DOI 10.1021/bi00452a023; STERN LJ, 1989, J BIOL CHEM, V264, P14202; STOECKENIUS W, 1979, BIOCHIM BIOPHYS ACTA, V505, P215, DOI 10.1016/0304-4173(79)90006-5; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013	30	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25734	25738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361187				2022-12-27	WOS:A1992KD07300024
J	KELLENBERGER, S; MALHERBE, P; SIGEL, E				KELLENBERGER, S; MALHERBE, P; SIGEL, E			FUNCTION OF THE ALPHA-1-BETA-2-GAMMA-2S GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR IS MODULATED BY PROTEIN-KINASE-C VIA MULTIPLE PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-BRAIN; GABAA RECEPTOR; ALPHA-SUBUNIT; CYCLIC-AMP; XENOPUS-OOCYTES; BETA-SUBUNIT; 2 FORMS; EXPRESSION; ACTIVATION; CAMP	Activation of protein kinase C (PKC) results in down-modulation of the gamma-aminobutyric acid type A (GABA(A)) receptor. In this study, the recombinant subunit combination alpha1beta2gamma2S was expressed in Xenopus oocytes. The resulting channel was shown to be modulated by 2 muM oleoylacetylglycerol or, stereo-specifically, by low concentrations (10 nM) of the phorbol ester 4beta-phorbol 12-myristate 13-acetate. By site-specific mutagenesis, we altered the serine or threonine residues of consensus phosphorylation sites for PKC in the large, intracellular domain of alpha1, beta2, and gamma2S. Mutant subunits were co-expressed with wild type subunits to yield alpha1beta2gamma2S combinations. All of the tested 14 mutations did not affect the level of expression of GABA current. Two of these mutations, Ser-410 in beta2 and Ser-327 in gamma2S, resulted in a significant reduction of the effect of the activator of PKC, 4beta-phorbol 12-myristate 13-acetate, on the GABA current amplitude. Thus, we have identified two single serine residues, Ser-410 in the subunit beta2 and Ser-327 in gamma2S, as phosphorylation sites of a PKC endogenous to Xenopus oocytes. Co-expression of the mutant subunits suggests that phosphorylation of both sites is required for a full, PKC-mediated down-regulation of GABA currents.	UNIV BERN, INST PHARMAKOL, DEPT PHARMACOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMA PRECLIN RES, CH-4002 BASEL, SWITZERLAND	University of Bern; Roche Holding	SIGEL, E (corresponding author), UNIV BERN, INST PHARMAKOL, DEPT PHARMACOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND.		Sigel, Erwin/F-7736-2015	Kellenberger, Stephan/0000-0003-1755-6198				BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TEHRANI MHJ, 1989, SYNAPSE, V4, P126, DOI 10.1002/syn.890040206; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966	30	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25660	25663						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334482				2022-12-27	WOS:A1992KD07300011
J	HOJ, PB; CONDRON, R; TRAEGER, JC; MCAULIFFE, JC; STONE, BA				HOJ, PB; CONDRON, R; TRAEGER, JC; MCAULIFFE, JC; STONE, BA			IDENTIFICATION OF GLUTAMIC-ACID 105 AT THE ACTIVE-SITE OF BACILLUS-AMYLOLIQUEFACIENS 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE USING EPOXIDE-BASED INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GLUCOPYRANOSIDE; SOYBEAN BETA-AMYLASE; CONDURITOL-B-EPOXIDE; NUCLEOTIDE-SEQUENCE; CLOSTRIDIUM-THERMOCELLUM; MOLECULAR-CLONING; DIRECTED INACTIVATION; ESSENTIAL CARBOXYLATE; GLUCAN HYDROLASES; ESCHERICHIA-COLI	Bacillus amyloliquefaciens 1,3-1,4-beta-D-glucan 4-glucanohydrolase (EC 3.2.1.73) was modified by the mechanism-based, affinity-labeling reagent [C-14](3,4)-epoxybutyl beta-D-cellobioside. Following partial inactivation a completely inactivated enzyme preparation containing 1.1 mol of covalently bound inhibitor/mol of protein was obtained by chromatography on a cellulosic matrix. The inactivated enzyme was digested with endoproteinase Glu-C and radioactive peptides purified by reversed-phase high performance liquid chromatography (HPLC) . The affinity label was esterified exclusively to the gamma-carboxylate of Glu105 in the sequence Gly-Thr-Pro-Trp-Asp-Glu-Ile-Asp-Ile-Glu109. The sequence motif Glu-(Ile/Leu)-Asp-Ile is found in many glucanases and xylanases and may therefore serve to identify the catalytic nucleophile in beta-glycanases, which otherwise exhibit a low degree of sequence identity. The esterification of Glu105 by the affinity label abolished endoproteinase Glu-C-mediated hydrolysis of the Glu-Ile106 peptide bond. Identification of phenylthiohydantoin-Glu105 during automated sequence analysis was not possible unless the affinity label was liberated by prior base hydrolysis. These observations formed the basis for the development of a highly sensitive approach for the identification of catalytic carboxylates in polysaccharide hydrolases employing non-radioactive inhibitors, comparative HPLC mapping, electrospray mass spectrometry, and Edman degradation.	UNIV WESTERN AUSTRALIA,SCH CHEM,NEDLANDS,WA 6009,AUSTRALIA; LA TROBE UNIV,DEPT CHEM,BUNDOORA,VIC 3083,AUSTRALIA	University of Western Australia; La Trobe University	HOJ, PB (corresponding author), LA TROBE UNIV,DEPT BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA.		Hoj, Peter B/E-8526-2011					ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BAIRD SD, 1990, J BACTERIOL, V172, P1576, DOI 10.1128/jb.172.3.1576-1586.1990; BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; BOUCHER F, 1988, NUCLEIC ACIDS RES, V16, P9874, DOI 10.1093/nar/16.20.9874; BUENO A, 1990, NUCLEIC ACIDS RES, V18, P4248, DOI 10.1093/nar/18.14.4248; CLARKE AJ, 1988, BIOCHEM CELL BIOL, V66, P871, DOI 10.1139/o88-099; DATEMA R, 1982, P NATL ACAD SCI-BIOL, V79, P6787, DOI 10.1073/pnas.79.22.6787; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; ERFLE JD, 1988, BIOCHEM J, V255, P833, DOI 10.1042/bj2550833; ESHDAT Y, 1973, J BIOL CHEM, V248, P5892; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; FUKUMORI F, 1986, J GEN MICROBIOL, V132, P2329; GRABOWSKI GA, 1986, J BIOL CHEM, V261, P8263; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HOJ PB, 1989, J BIOL CHEM, V264, P4939; HUBER DJ, 1977, PLANT PHYSIOL, V60, P300, DOI 10.1104/pp.60.2.300; ISODA Y, 1987, AGR BIOL CHEM TOKYO, V51, P3223; ISODA Y, 1988, AGR BIOL CHEM TOKYO, V52, P271; ISODA Y, 1986, J BIOCHEM-TOKYO, V99, P1631, DOI 10.1093/oxfordjournals.jbchem.a135637; JEFFCOAT R, 1987, J BIOL CHEM, V262, P1088; KEITEL T, 1991, J MOL BIOL, V218, P703, DOI 10.1016/0022-2836(91)90259-9; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEGLER G, 1973, CARBOHYD RES, V28, P45, DOI 10.1016/S0008-6215(00)82855-4; LEGLER G, 1968, Z. Physiol. Chem., V349, P767; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOO JA, 1989, ANAL BIOCHEM, V179, P404, DOI 10.1016/0003-2697(89)90153-X; MARLETTA MA, 1979, J BIOL CHEM, V254, P1879; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MCCLEAR BV, 1985, J I BREWING, V91, P285, DOI 10.1002/j.2050-0416.1985.tb04345.x; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; NEWBURG DS, 1986, BIOCHIM BIOPHYS ACTA, V877, P121, DOI 10.1016/0005-2760(86)90126-8; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; QUARONI A, 1976, J BIOL CHEM, V251, P3250; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; RODRIGUEZ EB, 1989, THESIS U W AUSTR NED; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SCHWARZ WH, 1988, GENE, V63, P23, DOI 10.1016/0378-1119(88)90542-2; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; SNITEATH W, 1986, BERGEYS MANUAL SYSTE, V2, P1236; STONE BA, 1993, IN PRESS CHEM BIOL 1; TEATHER RM, 1990, J BACTERIOL, V172, P3837, DOI 10.1128/jb.172.7.3837-3841.1990; THOMAS EW, 1969, NATURE, V222, P485, DOI 10.1038/222485a0; TOMME P, 1991, J BIOL CHEM, V266, P10313; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TULL D, 1991, J BIOL CHEM, V266, P12621; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WHITE WJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P198, DOI 10.1016/0167-4838(86)90046-4; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WOODWARD JR, 1982, CARBOHYD RES, V106, P111, DOI 10.1016/S0008-6215(00)80737-5; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	65	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25059	25066						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1360982				2022-12-27	WOS:A1992KB60300025
J	RUBARTELLI, A; BAJETTO, A; ALLAVENA, G; WOLLMAN, E; SITIA, R				RUBARTELLI, A; BAJETTO, A; ALLAVENA, G; WOLLMAN, E; SITIA, R			SECRETION OF THIOREDOXIN BY NORMAL AND NEOPLASTIC-CELLS THROUGH A LEADERLESS SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR; PROTEIN; EXPORT; LEUKEMIA; SIGNAL; CDNA	Thioredoxin, despite its function as an intracellular disulfide reducing enzyme and its lack of a signal sequence, has been found to play some roles extracellularly. Here we show that thioredoxin is actively secreted by a variety of normal and transformed cells, including fibroblasts, airway epithelial cells, and activated B and T lymphocytes. Neither brefeldin A nor dinitrophenol, two drugs that block transport through the exocytic pathway, inhibit secretion of thioredoxin, indicating that the latter does not follow the classical ER-Golgi route. The secretory mechanism for thioredoxin shares several features with the alternative pathway described for interleukin-1beta, such as the potentiating effect on secretion of several unrelated drugs and the sensitivity to methylamine. However, unlike interleukin-1beta, thioredoxin is not detected in membrane-bound compartments of secreting cells. In addition, when COS7 are transfected with plasmids encoding pro-interleukin-1beta or thioredoxin, only the latter is detectable extracellularly.	INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; IST SCI SAN RAFFAELE,I-20132 MILAN,ITALY	UNICANCER; Gustave Roussy; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	RUBARTELLI, A (corresponding author), IST NAZL RIC CANC,PATOL CLIN,VIALE BENEDETTO 15 10,I-16132 GENOA,ITALY.		Rubartelli, Anna/AAA-1259-2021	Sitia, Roberto/0000-0001-7086-4152				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; GUAZZI S, 1989, LEUKEMIA RES, V13, P1105, DOI 10.1016/0145-2126(89)90156-2; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sambrook J, 1989, MOL CLONING LABORATO; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	24	407	425	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24161	24164						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332947				2022-12-27	WOS:A1992KA26300004
J	JAKOBI, R; TRAUGH, JA				JAKOBI, R; TRAUGH, JA			CHARACTERIZATION OF THE PHOSPHOTRANSFERASE DOMAIN OF CASEIN KINASE-II BY SITE-DIRECTED MUTAGENESIS AND EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; CAENORHABDITIS-ELEGANS; CONSERVED FEATURES; MOLECULAR-CLONING; CDNA; IDENTIFICATION; SEQUENCE	The catalytic alpha subunit of casein kinase II contains the 11 conserved domains characteristic of all protein kinases. Domain II and VII are involved in nucleotide binding and phosphotransfer. Two residues of the alpha subunit, Val-66 (in domain II) and Trp- 176 (in domain VII), were changed to Ala-66 and Phe-176, the residues present in more than 95% of the identified protein kinase sequences. These changes altered the selectivity of the alpha subunit for ATP and GTP. The Ala-66 mutant showed an increase in the K(m) value for GTP from 45 to 71 muM, while the K(m) value for ATP decreased from 13 to 9 muM. The K(m) value for ATP with the Phe-176 mutant showed a decrease from 13 to 7 muM. A double mutant of Ala-66/Phe-176 showed the combined effects, with a K(m) of 6 muM for ATP and 70 muM for GTP. Alteration of Trp-176 to Lys- 176, an amino acid which is not present in the corresponding position of any known protein kinase, resulted in a lack of phosphotransferase activity. The mutations, Val-66 to Ala-66 and Trp-176 to Phe-176, also altered the interaction of the alpha subunit with the regulatory beta subunit. In contrast to the wild-type alpha subunit, which was stimulated 4-fold by addition of the beta subunit, the Ala-66 and Ala-66/Phe-176 mutants were not stimulated by the beta subunit, while the Phe-176 mutant was stimulated only 2.5-fold. All of the reconstituted holoenzymes were similar in molecular weight to the native holoenzyme. The stimulation of the phosphotransferase activity toward beta-casein B by spermine and polylysine, which is mediated by the beta subunit, was similar for holoenzymes reconstituted with either wild-type or mutant alpha subunits. Therefore, binding of the beta subunit appears to alter the active site of the a subunit directly or indirectly by inducing a conformational change. Ala-66 and Phe-176 mutations appear to change the structure of the alpha subunit sufficiently so that interaction of the subunits is altered and the stimulatory effect of the beta subunit is reduced or eliminated.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside					NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BIRNBAUM MJ, 1991, BIOCHEM BIOPH RES CO, V181, P524, DOI 10.1016/0006-291X(91)91220-7; BOLDYREFF B, 1991, BIOCHIM BIOPHYS ACTA, V1088, P439, DOI 10.1016/0167-4781(91)90140-H; BOLLER MJ, 1981, J BIOL CHEM, V256, P10837; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; COCHET C, 1983, J BIOL CHEM, V258, P1403; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hathaway G M, 1979, Methods Enzymol, V60, P495; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOPATZ I, 1990, NUCLEIC ACIDS RES, V18, P3639, DOI 10.1093/nar/18.12.3639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN PM, 1983, ELECTROPHORESIS, V4, P247, DOI 10.1002/elps.1150040313; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LIN WJ, 1992, FASEB J, V6, pA1853; LIN WJ, 1992, IN PRESS 1 WORLD C C; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1765, DOI 10.1093/nar/14.4.1765; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYERIN W, 1988, BIOL CHEM H-S, V369, P896; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123	47	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23894	23902						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331104				2022-12-27	WOS:A1992JZ23900070
J	ZANG, LY; MISRA, HP				ZANG, LY; MISRA, HP			EPR KINETIC-STUDIES OF SUPEROXIDE RADICALS GENERATED DURING THE AUTOXIDATION OF 1-METHYL-4-PHENYL-2,3-DIHYDROPYRIDINIUM, A BIOACTIVATED INTERMEDIATE OF PARKINSONIAN-INDUCING NEUROTOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NIGROSTRIATAL TOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; TRAP 5,5-DIMETHYL-1-PYRROLINE-1-OXIDE DMPO; CUTANEOUS PHOTOSENSITIZING AGENTS; MONOAMINE-OXIDASE; MOLECULAR MECHANISM; MELANIN PRECURSORS; LIPID-PEROXIDATION; HYDROXYL RADICALS; SUBSTANTIA NIGRA	1-Methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), a metabolic product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has been shown to generate superoxide radicals during its autoxidation process. The generation of superoxide radicals was detected as a 5,5-dimethyl-1-pyrroline-N-oxide (DMPO).O2- spin adduct by spin trapping in combination with EPR techniques. The rate of formation of spin adduct was dependent not only on the concentrations of MPDP+ and oxygen but also on the pH of the system. Superoxide dismutase inhibited the spin adduct formation in a dose-dependent manner. The ability of DMPO to trap superoxide radicals, generated during the autoxidation of MPDP+, and of superoxide dismutase to effectively compete with this reaction for the available O2-, has been used as a convenient competition reaction to quantitatively determine various kinetic parameters. Thus, using this technique the rate constant for scavenging of superoxide radical by superoxide dismutase was found to be 7.56 x 10(9) M-1 s-1. The maximum rate of superoxide generation at a fixed spin trap concentration using different amounts of MPDP+ was found to be 4.48 x 10(-10) M s-1. The rate constant (K1) for MPDP+ making superoxide radical was found to be 3.97 x 10(-6) s-1. The secondary order rate constant (K(DMPO)) for DMPO-trapping superoxide radicals was found to be 10.2 M-1 s-1. The lifetime of superoxide radical at pH 10.0 was calculated to be 1.25 s. These values are in close agreement to the published values obtained using different experimental techniques. These results indicate that superoxide radicals are produced during spontaneous oxidation of MPDP+ and that EPR spin trapping can be used to determine the rate constants and lifetime of free radicals generated in aqueous solutions. It appears likely that the nigrostriatal toxicity of MPTP/MPDP+ leading to Parkinson's disease may largely be due to the reactivity of these radicals.	VIRGINIA POLYTECH INST & STATE UNIV, VIRGINIA MARYLAND REG COLL VET MED, DEPT BIOMED SCI, BLACKSBURG, VA 24061 USA; ACAD SINICA, INST BIOPHYS, BEIJING 100080, PEOPLES R CHINA	Virginia Polytechnic Institute & State University; Chinese Academy of Sciences; Institute of Biophysics, CAS								ARROYO CM, 1990, FREE RADICAL BIO MED, V9, P191, DOI 10.1016/0891-5849(90)90027-G; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; BENHUR E, 1985, INT J RADIAT BIOL, V48, P837, DOI 10.1080/09553008514551931; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CARMICHAEL AJ, 1985, PHOTOCHEM PHOTOBIOL, V41, P635, DOI 10.1111/j.1751-1097.1985.tb03616.x; CHEVALET J, 1972, J ELECTROANAL CHEM, V39, P201, DOI 10.1016/S0022-0728(72)80488-1; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; FARHATAZIZ E, 1977, NATL STAND REF DATA, V59, P37; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FRIDOVICH I, 1977, SUPEROXIDE SUPEROXID, P551; GESSNER W, 1985, FEBS LETT, V183, P345, DOI 10.1016/0014-5793(85)80807-3; GORDON S, 1963, J AM CHEM SOC, V85, P1375, DOI 10.1021/ja00893a002; HARBOUR JR, 1978, J PHYS CHEM-US, V82, P1397, DOI 10.1021/j100501a015; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; JAMESON DM, 1984, FLUORESCEIN HAPTEN I, P23; JANZEN EG, 1984, METHOD ENZYMOL, V105, P188; JANZEN EG, 1973, J MAGN RESON, V9, P510, DOI 10.1016/0022-2364(73)90194-7; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; KALYANARAMAN B, 1982, PHOTOCHEM PHOTOBIOL, V36, P5, DOI 10.1111/j.1751-1097.1982.tb04332.x; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KORTYTOWSKI W, 1987, BIOCHEM BIOPH RES CO, V144, P692, DOI 10.1016/S0006-291X(87)80020-7; KORYTOWSKI W, 1986, BIOCHIM BIOPHYS ACTA, V882, P145, DOI 10.1016/0304-4165(86)90149-2; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LEUNG L, 1989, J ORG CHEM, V54, P1052, DOI 10.1021/jo00266a011; LEWIN R, 1984, SCIENCE, V225, P1460, DOI 10.1126/science.6433484; MAKINO K, 1986, BIOCHEM BIOPH RES CO, V141, P381, DOI 10.1016/S0006-291X(86)80380-1; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MONTE DD, 1988, DRUG METAB DISPOS, V16, P250; MOTTEN AG, 1985, PHOTOCHEM PHOTOBIOL, V42, P9, DOI 10.1111/j.1751-1097.1985.tb03540.x; PETERSON LA, 1985, J MED CHEM, V28, P1432, DOI 10.1021/jm00148a010; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; RESZKA K, 1983, PHOTOCHEM PHOTOBIOL, V38, P281, DOI 10.1111/j.1751-1097.1983.tb02673.x; TREVOR AJ, 1987, LIFE SCI, V40, P713, DOI 10.1016/0024-3205(87)90298-0; TREVOR AJ, 1988, TOXICOLOGY, V49, P513, DOI 10.1016/0300-483X(88)90037-6; TURNER MJ, 1986, J MED CHEM, V29, P2439, DOI 10.1021/jm00162a004; WU E, 1988, CHEM RES TOXICOL, V1, P186, DOI 10.1021/tx00003a010; WU EY, 1986, LIFE SCI, V39, P1695, DOI 10.1016/0024-3205(86)90167-0; YONG VW, 1986, NEUROSCI LETT, V63, P56, DOI 10.1016/0304-3940(86)90012-1; ZANG LY, 1992, J BIOL CHEM, V267, P17547; ZANG LY, 1992, IN PRESS PHOTOCHEM P, V54	45	51	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23601	23608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331093				2022-12-27	WOS:A1992JZ23900030
J	CHILDS, TJ; WATSON, MH; SANGHERA, JS; CAMPBELL, DL; PELECH, SL; MAK, AS				CHILDS, TJ; WATSON, MH; SANGHERA, JS; CAMPBELL, DL; PELECH, SL; MAK, AS			PHOSPHORYLATION OF SMOOTH-MUSCLE CALDESMON BY MITOGEN-ACTIVATED PROTEIN (MAP) KINASE AND EXPRESSION OF MAP KINASE IN DIFFERENTIATED SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; F-ACTIN; CHICKEN GIZZARD; P34CDC2 KINASE; BINDING; PURIFICATION; CALMODULIN; MYOSIN; TROPOMYOSIN; MECHANISM	Smooth muscle caldesmon was phosphorylated in vitro by sea star p44mpk up to 2.0 mol of phosphate/mol of protein at both Ser and Thr residues. The phosphorylation sites were contained mainly in the COOH-terminal 10-kDa cyanogen bromide fragment which houses the binding sites for calmodulin, tropomyosin, and F-actin. Tryptic peptide maps of P-32-labeled caldesmon by p44mpk and p34cdc2 showed that while both enzymes recognized similar sites of phosphorylation, they have different preferred sites. Phosphorylation of caldesmon attenuated slightly its interaction with actin and had no effect on its binding to calmodulin and tropomyosin. Smooth muscle cell extracts from chicken gizzard and rat aorta contained 42- and 44-kDa proteins, respectively, which were cross-reactive with an antibody to Sea star p44mpk. Immunoprecipitates from gizzard and aorta cell extracts, generated with the p44mpk antibody, possessed kinase activities toward myelin basic protein as well as caldesmon. These results suggest that MAP kinase may have functions in the differentiated smooth muscle cells distinct from those involved in the cell cycle.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; KINETEK BIOTECHNOL CORP,BIOMED RES LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	Queens University - Canada; University of British Columbia								ADAM LP, 1992, FEBS LETT, V302, P2223; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAYASHI K, 1991, J BIOL CHEM, V266, P355; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ISHIKAWA R, 1992, FEBS LETT, V299, P54, DOI 10.1016/0014-5793(92)80099-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARSTON SB, 1991, BIOCHEM J, V279, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NGAI PK, 1984, J BIOL CHEM, V259, P3656; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SANDERS C, 1984, CAN J BIOCHEM CELL B, V62, P443, DOI 10.1139/o84-060; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WATSON MH, 1990, J BIOL CHEM, V265, P18860; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103	34	140	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22853	22859						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331069				2022-12-27	WOS:A1992JY16300025
J	GANTZ, I; DELVALLE, J; WANG, LD; TASHIRO, T; MUNZERT, G; GUO, YJ; KONDA, Y; YAMADA, T				GANTZ, I; DELVALLE, J; WANG, LD; TASHIRO, T; MUNZERT, G; GUO, YJ; KONDA, Y; YAMADA, T			MOLECULAR-BASIS FOR THE INTERACTION OF HISTAMINE WITH THE HISTAMINE-H2-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; CLONING; IDENTIFICATION; GENE; ACTIVATION; EXPRESSION; AGONISTS; ROLES	We undertook these studies to characterize the molecular basis of the interaction of histamine with the H2 receptor. Key areas of homology in the structures of the histamine H2 and beta2 adrenergic receptor suggested specific transmembrane amino acids that might be important for binding of histamine. A third transmembrane aspartic acid of the histamine receptor (Asp98), thought to serve as a counter anion that interacts with the cationic amine moiety of histamine, was mutated to Asn98, and the mutated receptor was expressed in Hepa cells. Removal of the negatively charged amino acid abolished both binding of the H2 receptor antagonist [methyl-H-3]tiotidine and histamine stimulated increases in cellular cAMP content. Mutation of a fifth transmembrane aspartic acid (Asp186) to Ala186 or Asn186 by itself or in conjunction with mutation of another fifth transmembrane amino acid (Thr190 to Ala190 ) resulted in a loss of [methyl-H-3] tiotidine binding, although the generation of cAMP in response to histamine was maintained. The histamine receptor with only a Thr190 to Ala190 or Cys190 mutation retained the ability to bind [methyl-H-3]tiotidine, but both the affinity and efficacy of binding were reduced. These data lead us to propose a model for histamine binding in which Asp98 is essential for histamine binding and action, Asp186 defines H2 selectivity, and Thr190 is important in establishing the kinetics of histamine binding, but is not essential for H2 selectivity.	UNIV MICHIGAN,MED CTR,DEPT SURG,3101 TAUBMAN CTR,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIDDK NIH HHS [P30DK34933, R01DK33500, R01DK34306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK033500, R01DK034306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DURANT GJ, 1975, J MED CHEM, V18, P905, DOI 10.1021/jm00243a009; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANTIATIS T, 1989, MOL CLONING LABORATO; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RISING TJ, 1985, FRONTIERS HISTAMINE, V51, P61; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; WANG CD, 1991, MOL PHARMACOL, V40, P168; WEINSTEIN H, 1976, MOL PHARMACOL, V12, P738; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	17	122	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20840	20843						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356984				2022-12-27	WOS:A1992JT97800053
J	MENDOZA, JA; LORIMER, GH; HOROWITZ, PM				MENDOZA, JA; LORIMER, GH; HOROWITZ, PM			CHAPERONIN CPN60 FROM ESCHERICHIA-COLI PROTECTS THE MITOCHONDRIAL ENZYME RHODANESE AGAINST HEAT INACTIVATION AND SUPPORTS FOLDING AT ELEVATED-TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; SMALL STOICHIOMETRY; PROTEINS; GROEL; SHOW; ATP	The chaperonin protein cpn60 from Escherichia coli protects the monomeric, mitochondrial enzyme rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) against heat inactivation. The thermal inactivation of rhodanese was studied for four different states of the enzyme: native, refolded, bound to cpn60 in the form of a binary complex formed from unfolded rhodanese, and a thermally perturbed state. Thermal stabilization is observed in a range of temperatures from 25 to 48-degrees-C. Rhodanese that had been inactivated by incubation at 48-degrees-C, in the presence of cpn60 can be reactivated at 25-degrees-C, upon addition of cpn10, K+, and MgATP. A recovery of about 80% was achieved after 1 h of the addition of those components. Thus, the enzyme is protected against heat inactivation and kept in a reactivable form if inactivation is attempted using the binary complex formed between rhodanese folding intermediate(s) and cpn60. The chaperonin-assisted refolding of urea-denatured rhodanese is dependent on the temperature of the refolding reaction. However, optimal chaperonin assisted refolding of rhodanese observed at 25-degrees-C, which is achieved upon addition of cpn10 and ATP to the cpn60-rhodanese complex, is independent of the temperature of preincubation of the complex, that was formed previously at low temperature. The results are in agreement with a model in which the chaperonin cpn60 interacts with partly folded intermediates by forming a binary complex which is stable to elevated temperatures. In addition, it appears that native rhodanese can be thermally perturbed to produce a state different from that achieved by denaturation that can interact with cpn60.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880	University of Texas System; University of Texas Health San Antonio; DuPont					NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HOROWITZ P, 1987, J BIOL CHEM, V262, P5587; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KLIBANOV AM, 1983, ADV APPL MICROBIOL, V29, P1, DOI 10.1016/S0065-2164(08)70352-6; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1991, J CELL BIOCH SG, V15, P160; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Ploegman J.H., 1978, NATURE, V273, P1245; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	23	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17631	17634						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355476				2022-12-27	WOS:A1992JM22300026
J	BORCHELT, DR; TARABOULOS, A; PRUSINER, SB				BORCHELT, DR; TARABOULOS, A; PRUSINER, SB			EVIDENCE FOR SYNTHESIS OF SCRAPIE PRION PROTEINS IN THE ENDOCYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; ASPARAGINE-LINKED GLYCOSYLATION; INFECTED CULTURED-CELLS; INCUBATION PERIOD MICE; SEMLIKI FOREST VIRUS; BREFELDIN-A; TRANSGENIC MICE; RAT HEPATOCYTES; EARLY ENDOSOMES; GOLGI PROTEINS	Infectious scrapie prions are composed largely, if not entirely, of an abnormal isoform of the prion protein (PrP) which is designated PrP(Sc). A chromosomal gene encodes both the cellular prion protein (PrP(C)) as well as PrP(Sc). Pulse-chase experiments with scrapie-infected cultured cells indicate that PrP(Sc) is formed by a post-translational process. PrP is translated in the endoplasmic reticulum, modified as it passes through the (Golgi, and is transported to the cell surface. Release of nascent PrP from the cell surface by phosphatidylinositol-specific phospholipase C or hydrolysis with dispase prevented PrP(Sc) synthesis. At 18-degrees-C, the synthesis of PrP(Sc) was inhibited under conditions that other investigators report a blockage of endosomal fusion with lysosomes. Our results suggest that PrP(Sc) synthesis occurs after PrP transits from the cell surface. Whether all of the PrP molecules have an equal likelihood to be converted into PrP(Sc) or only a distinct subset is eligible for conversion remains to be established. Identifying the subcellular compartment(s) of PrP(Sc) synthesis should be of considerable importance in defining the molecular changes that distinguish PrP(Sc) from PrP(C).	UNIV CALIF SAN FRANCISCO, DEPT NEUROL, HSE-781, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132, R35AG008967] Funding Source: NIH RePORTER; NIA NIH HHS [AG08967, AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON RG, 1991, SCIENCE, V255, P410; BARRY RA, 1988, J IMMUNOL, V140, P1188; BARRY RA, 1986, J INFECT DIS, V153, P848, DOI 10.1093/infdis/153.5.848; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHANDLER RL, 1961, LANCET, V1, P1378; CLARKE MC, 1979, SLOW TRANSMISSIBLE D, V2, P225; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUNN WA, 1980, J BIOL CHEM, V255, P5971; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARE JF, 1984, ARCH BIOCHEM BIOPHYS, V233, P547, DOI 10.1016/0003-9861(84)90478-8; HARE JF, 1988, J BIOL CHEM, V263, P8759; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARKOVITS P, 1981, CR ACAD SCI III-VIE, V293, P413; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MCKINLEY MP, 1991, J VIROL, V65, P1440; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1990, CELL, V1, P101; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1991, FASEB J, V5, pA1177; TARABOULOS A, 1991, 1991 PRION DIS HUM A; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; WEIGEL PH, 1981, J BIOL CHEM, V256, P2615; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	64	436	447	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16188	16199						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1353761				2022-12-27	WOS:A1992JJ45800034
J	JENNINGS, ML; SMITH, JS				JENNINGS, ML; SMITH, JS			ANION-PROTON COTRANSPORT THROUGH THE HUMAN RED-BLOOD-CELL BAND-3 PROTEIN - ROLE OF GLUTAMATE-681	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; BINDING-SITE; TRANSPORT PROTEIN; EXCHANGE PROTEIN; PROTEOLYTIC DISSECTION; CYTOPLASMIC DOMAIN; LOCALIZATION; CLEAVAGE	The band 3 protein of the human red blood cell membrane contains a glutamate residue that must be protonated in order for divalent (SO4=) anion transport to take place at an appreciable rate. The carboxyl side chain on this glutamate residue can be converted to the primary alcohol by treatment of intact cells with Woodward's reagent K (N-ethyl-5-phenylisoxazolium 3'-sulfonate) followed by reductive cleavage with BH4-. Edman degradation of CNBr fragments from band 3 labeled in intact cells with Woodward's reagent K and [H-3]BH4- showed that Glu681 is heavily labeled under conditions in which Cl- exchange is inhibited, SO4= exchange is accelerated, and Cl- conductance is accelerated. No other glutamate residue in band 3 is detectably labeled under the conditions of these experiments, as demonstrated either by Edman degradation or by the lack of label in major known proteolytic fragments. It is concluded that Glu681 is the binding site for the H+ that is transported with SO4= during band 3-catalyzed H+/SO4= cotransport. This residue is conserved among all species of red cell band 3 (AE1) as well as the related proteins AE2 and AE3. Glu681 is the first amino acid residue in band 3 which has been identified as a binding site for a transported substrate (H+). The functional characteristics of this residue suggest that it lies within the transport pathway and can be alternately exposed to the intracellular and extracellular media.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	JENNINGS, ML (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,BASIC SCI BLDG,RT F-41,GALVESTON,TX 77550, USA.				NIGMS NIH HHS [GM26861] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BARTEL D, 1989, BIOCHIM BIOPHYS ACTA, V985, P355, DOI 10.1016/0005-2736(89)90427-6; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BJERRUM PJ, 1983, J GEN PHYSIOL, V81, P453, DOI 10.1085/jgp.81.4.453; BROCK CJ, 1983, BIOCHEM J, V213, P577, DOI 10.1042/bj2130577; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; DUNN BM, 1974, J BIOL CHEM, V249, P3717; EIDELMAN O, 1991, AM J PHYSIOL, V260, pC1094, DOI 10.1152/ajpcell.1991.260.5.C1094; FALKE JJ, 1985, J BIOL CHEM, V260, P3294; FROHLICH O, 1986, BIOCHIM BIOPHYS ACTA, V864, P169, DOI 10.1016/0304-4157(86)90010-9; FROHLICH O, 1984, J GEN PHYSIOL, V84, P877, DOI 10.1085/jgp.84.6.877; FROLICH O, 1983, J GEN PHYSIOL, V81, P127; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; GUNN RB, 1978, MEMBRANE TRANSPORT P, V1, P61; JENNINGS ML, 1990, J GEN PHYSIOL, V96, P991, DOI 10.1085/jgp.96.5.991; JENNINGS ML, 1976, J MEMBRANE BIOL, V28, P187, DOI 10.1007/BF01869697; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1988, CELL PHYSL BLOOD SOC, V41, P163; JULIEN T, 1990, BIOCHIM BIOPHYS ACTA, V1026, P43, DOI 10.1016/0005-2736(90)90330-Q; KAPLAN JH, 1983, FEBS LETT, V156, P175, DOI 10.1016/0014-5793(83)80272-5; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KNAUF PA, 1983, J GEN PHYSIOL, V81, P95, DOI 10.1085/jgp.81.1.95; KNAUF PA, 1984, J GEN PHYSIOL, V83, P693; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPKE S, 1976, BIOCHIM BIOPHYS ACTA, V455, P353, DOI 10.1016/0005-2736(76)90311-4; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MATSUYAMA H, 1985, J BIOCH, V99, P495; MILANICK MA, 1984, AM J PHYSIOL, V247, pC247, DOI 10.1152/ajpcell.1984.247.3.C247; MUELLER TJ, 1979, J BIOL CHEM, V254, P8103; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; PASSOW H, 1986, REV PHYSL BIOCH PHAR, V103, P62; RAMJEESINGH M, 1984, BIOCHIM BIOPHYS ACTA, V769, P381, DOI 10.1016/0005-2736(84)90321-3; RUDLOFF V, 1983, FEBS LETT, V163, P14, DOI 10.1016/0014-5793(83)81152-1; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; WIETH JO, 1982, J GEN PHYSIOL, V79, P253, DOI 10.1085/jgp.79.2.253; WIETH JO, 1985, KIDNEY PHYSL PATHOPH, P49; ZAKI L, 1981, BIOCHEM BIOPH RES CO, V99, P243, DOI 10.1016/0006-291X(81)91738-1	52	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13964	13971						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352774				2022-12-27	WOS:A1992JD32500031
J	YU, DH; MATIN, A; HUNG, MC				YU, DH; MATIN, A; HUNG, MC			THE RETINOBLASTOMA GENE-PRODUCT SUPPRESSES NEU ONCOGENE-INDUCED TRANSFORMATION VIA TRANSCRIPTIONAL REPRESSION OF NEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUSCEPTIBILITY GENE; CELL-CYCLE; EXPRESSION; ELEMENTS; PROTEIN; CANCER; SEQUENCE; ENCODES; BINDING; CLONING	The retinoblastoma susceptibility gene (Rb) is a tumor suppressor gene involved in the etiology of many types of human cancers. However, the molecular mechanisms involved in tumor suppression by Rb are largely unknown. The neu gene is a dominant transforming oncogene and a member of the growth factor receptor tyrosine kinase gene family. Both inactivation of the Rb gene and overexpression of the neu gene are involved in human breast and lung cancers. Therefore, it is of interest and importance to investigate the potential interactions between Rb and neu. Here we show that Rb suppresses neu-induced transformation by focus formation assays. This transformation suppression by Rb was further shown to be due to transcriptional repression of neu using Rb expressing effector plasmid and neu promoter-chloramphenicol acetyltransferase reporter gene. The cis-acting element conferring Rb-mediated repression was mapped to a recently identified novel enhancer in the neu promoter. The data indicate that the growth factor receptor neu is a target for the Rb gene product and transcriptional repression of a dominant oncogene expression may be one of the molecular mechanisms of Rb-mediated tumor suppression.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R03CA054989] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CA-54989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUPE R, 1990, SCIENCE, V249, P1552; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHAO XY, 1992, IN PRESS MOL CELL BI	30	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10203	10206						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350277				2022-12-27	WOS:A1992HV09000002
J	THEROUX, SJ; TAGLIENTISIAN, C; NAIR, N; COUNTAWAY, JL; ROBINSON, HL; DAVIS, RJ				THEROUX, SJ; TAGLIENTISIAN, C; NAIR, N; COUNTAWAY, JL; ROBINSON, HL; DAVIS, RJ			INCREASED ONCOGENIC POTENTIAL OF ERBB IS ASSOCIATED WITH THE LOSS OF A COOH-TERMINAL DOMAIN SERINE PHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; TISSUE-SPECIFIC TRANSFORMATION; C-ERBB; KINASE-ACTIVITY; TYROSINE; VIRUS; EXPRESSION; SEQUENCES; DNA	The erbB oncogene encodes an altered form of the epidermal growth factor (EGF) receptor that lacks the extracellular ligand binding domain. This oncogene is exclusively leukemogenic. However, an increase in oncogenic potential and a broadening of the tissue specificity of tumor formation occurs after retroviral transduction of erbB. The increased oncogenic potential correlates with structural alterations within the erbB gene. One common event is the deletion of a serine phosphorylation site located within the COOH-terminal domain. This site of phosphorylation has been demonstrated to be required for EGF-induced desensitization of signaling by the EGF receptor (Countaway, J. L., Nairn, A. C., and Davis, R. J. (1992) J. Biol. Chem. 267, 1129-1140). Here we show that the mutation of erbB at this negative regulatory serine phosphorylation site causes fibroblast transformation in vitro and is associated with an increased oncogenic potential in vivo.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT PATHOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA27223, CA53396, CA39240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027223, P01CA039240, R03CA053396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; ISRAEL MA, 1979, J VIROL, V29, P990, DOI 10.1128/JVI.29.3.990-996.1979; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; THEROUX SJ, 1992, NUCLEIC ACIDS RES, V20, P915, DOI 10.1093/nar/20.4.915; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7967	7970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349014				2022-12-27	WOS:A1992HQ18500003
J	TOWLE, CA; TREADWELL, BV				TOWLE, CA; TREADWELL, BV			IDENTIFICATION OF A NOVEL MAMMALIAN ANNEXIN - CDNA CLONING, SEQUENCE-ANALYSIS, AND UBIQUITOUS EXPRESSION OF THE ANNEXIN-XI GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR KINASE; DEPENDENT 35-KILODALTON SUBSTRATE; PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID-BINDING-PROTEINS; AMINO-ACID-SEQUENCE; LIGHT-CHAIN BINDING; CALPACTIN-I; LIPOCORTIN-I; HEAVY-CHAIN; DIFFERENTIAL EXPRESSION	Annexins (or lipocortins) are a family of at least 10 structurally related calcium- and phospholipid-binding proteins. Each protein consists of a conserved core domain having four (or eight) repeats of a segment approximately 70 amino acids in length and a nonconserved, usually short, amino-terminal domain. To date, amino acid sequences for eight distinct mammalian annexins have been predicted from cDNAs. This report describes an additional member of this family, bovine annexin XI, identified by cDNA cloning and sequence analysis. The 503-amino acid deduced protein consists of a core domain of four annexin repeats and a long amino-terminal domain rich in glycine, proline, and tyrosine. This novel annexin gene is expressed in a wide variety of tissues and isolated cells in culture.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TOWLE, CA (corresponding author), MASSACHUSETTS GEN HOSP, ORTHOPAED RES LABS, BOSTON, MA 02114 USA.				NIAMS NIH HHS [2R01AR16265-17A3] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016265] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BARALLE FE, 1978, NATURE, V274, P84, DOI 10.1038/274084a0; BLAY J, 1989, BIOCHEM J, V259, P577, DOI 10.1042/bj2590577; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DE BK, 1986, J BIOL CHEM, V261, P3784; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWLING LG, 1985, BIOCHEM BIOPH RES CO, V132, P382, DOI 10.1016/0006-291X(85)91033-2; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERNANDEZ MP, 1988, J BIOL CHEM, V263, P5921; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FUNAKOSHI T, 1990, BIOCHEM BIOPH RES CO, V168, P125, DOI 10.1016/0006-291X(90)91683-J; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1991, J BIOL CHEM, V266, P1697; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; GRUNDMANN U, 1988, BEHRING I MITT, V82, P59; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HAMMAN HC, 1988, BIOCHEM BIOPH RES CO, V156, P660, DOI 10.1016/S0006-291X(88)80893-3; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HUANG KS, 1987, J BIOL CHEM, V262, P7639; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; ODENWALD WF, 1983, BIOCHEM BIOPH RES CO, V112, P147, DOI 10.1016/0006-291X(83)91809-0; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; Sambrook J, 1989, MOL CLONING LABORATO; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SMALLWOOD M, 1990, BIOCHEM J, V270, P157, DOI 10.1042/bj2700157; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TAYLOR WR, 1987, PROTEIN ENG, V1, P183, DOI 10.1093/protein/1.3.183; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; TREADWELL BV, 1986, ARCH BIOCHEM BIOPHYS, V251, P724, DOI 10.1016/0003-9861(86)90382-6; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WIRL G, 1990, J CELL PHYSIOL, V144, P511, DOI 10.1002/jcp.1041440320; WU LNY, 1991, J BIOL CHEM, V266, P1195; ZHUANG Q, 1989, BIOCHEM BIOPH RES CO, V159, P236, DOI 10.1016/0006-291X(89)92428-5	72	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5416	5423						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372001				2022-12-27	WOS:A1992HH74700064
J	WONG, M; LAWTON, T; GOETINCK, PF; KUHN, JL; GOLDSTEIN, SA; BONADIO, J				WONG, M; LAWTON, T; GOETINCK, PF; KUHN, JL; GOLDSTEIN, SA; BONADIO, J			AGGRECAN CORE PROTEIN IS EXPRESSED IN MEMBRANOUS BONE OF THE CHICK-EMBRYO - MOLECULAR AND BIOMECHANICAL STUDIES OF NORMAL AND NANOMELIA EMBRYOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; MESSENGER-RNA; CARTILAGE; COLLAGEN; SULFATE; PROTEOGLYCANS; GENE; CHONDROCYTES; SYNTHESIZE; SEQUENCE	The recessive mutation nanomelia blocks the synthesis of a large aggregating proteoglycan (aggrecan) by avian embryo chondrocytes. Lack of aggrecan is associated with short stature, multiple morphological defects in cartilage, and embryo lethality. Bony defects have also been described, but were assumed to be a secondary consequence of the cartilage defect. However, two lines of evidence presented in this paper indicate that the aggrecan deficiency directly affects intramembranous bone. First, the morphology (i.e. projected area and shape) of certain membranous bones of nanomelia embryos was abnormal. Second, membranous bone from nanomelia embryos proved to be significantly stiffer in biomechanical tests that measured functional properties of the extracellular matrix. These findings were unexpected because intramembranous bones normally develop from mesenchyme and not from a cartilage intermediate, and they prompted a search for evidence of aggrecan expression in the bone of normal chick embryos. We report that: 1) aggrecan mRNA was identified by PCR analysis of total RNA isolated from day- 13 chick embryo calvarium, 2) the PCR method successfully amplified aggrecan mRNA from primary chick embryo osteoblasts in culture, 3) in situ hybridization of membranous bone tissue sections demonstrated aggrecan expression by chick embryo osteoblasts in vivo, and 4) the aggrecan message was identified in Northern blots of calvarial mRNA probed at high stringency. The results of the molecular and biomechanical studies provide evidence that aggrecan is indeed expressed in membranous bone as well as cartilage. Altogether, these results suggest that aggrecan may contribute to the functional properties and the normal growth and development of avian membranous bone.	UNIV MICHIGAN,DEPT SURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,PROGRAM BIOENGN,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	WONG, M (corresponding author), UNIV MICHIGAN,ORTHOPAED RES LABS,ORTHOPAED SURG SECT,ANN ARBOR,MI 48109, USA.		Zenobi-Wong, Marcy/J-5398-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557, R29AR038473] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20557, AR-38473] Funding Source: Medline; NICHD NIH HHS [HD-22016] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1979, STEREOLOGICAL METHOD; BARRY F, 1990, BIOCHEM SOC T, V18, P197, DOI 10.1042/bst0180197; BERESFORD JN, 1987, J BIOL CHEM, V262, P17164; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; CHOI K, 1990, J BIOMECH, V23, P1103, DOI 10.1016/0021-9290(90)90003-L; CHOI K, 1992, IN PRESS J BIOMECH; CHRISTNER JE, 1978, ANAL BIOCHEM, V90, P22, DOI 10.1016/0003-2697(78)90004-0; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FITCH JM, 1989, DEVELOPMENT, V105, P85; GOETINCK PF, 1988, PATHOL IMMUNOPATH R, V7, P73, DOI 10.1159/000157097; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; KOSHER RA, 1986, DEV BIOL, V118, P112, DOI 10.1016/0012-1606(86)90078-3; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KUHN JL, 1989, J ORTHOPAED RES, V7, P876, DOI 10.1002/jor.1100070614; LANDAUER W, 1965, J HERED, V56, P131, DOI 10.1093/oxfordjournals.jhered.a107392; MAJMUDAR G, 1991, J BONE MINER RES, V6, P869; Maroudas, 1979, ADULT ARTICULAR CART, P219; MARTIN RB, 1989, STRUCTURE FUNCTION A; Mow V.C., 1989, BASIC BIOMECHANICS M, V2nd, P31; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; ODONNELL CM, 1988, J BIOL CHEM, V263, P17749; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PENNYPACKER JP, 1976, DEV BIOL, V50, P35, DOI 10.1016/0012-1606(76)90065-8; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; STIRPE NS, 1987, DEV BIOL, V124, P77, DOI 10.1016/0012-1606(87)90461-1; STIRPE NS, 1990, DEV BIOL, V137, P419, DOI 10.1016/0012-1606(90)90266-L; STIRPE NS, 1989, DEVELOPMENT, V107, P22; TANAKA T, 1988, J BIOL CHEM, V263, P15831	33	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5592	5598						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372006				2022-12-27	WOS:A1992HH74700088
J	EBERLEIN, GA; EYSSELEIN, VE; DAVIS, MT; LEE, TD; SHIVELY, JE; GRANDT, D; NIEBEL, W; WILLIAMS, R; MOESSNER, J; ZEEH, J; MEYER, HE; GOEBELL, H; REEVE, JR				EBERLEIN, GA; EYSSELEIN, VE; DAVIS, MT; LEE, TD; SHIVELY, JE; GRANDT, D; NIEBEL, W; WILLIAMS, R; MOESSNER, J; ZEEH, J; MEYER, HE; GOEBELL, H; REEVE, JR			PATTERNS OF PROHORMONE PROCESSING - ORDER REVEALED BY A NEW PROCHOLECYSTOKININ-DERIVED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLECYSTOKININ MESSENGER-RNA; CANINE CHOLECYSTOKININ; MOLECULAR-FORMS; SEQUENCE; BRAIN; PREPROCHOLECYSTOKININ; CLONING; PLASMA; CDNA; GASTRINOMA	An 83-amino acid cholecystokinin peptide with a sulfated tyrosine and an amidated carboxyl terminus (CCK-83) was purified from human intestinal mucosa. The purified peptide was chemically characterized, and its bioactivity was compared to CCK-8. Several post-translational processing steps such as cleavage at basic residues, sulfation, and amidation are necessary to form biologically active cholecystokinin from its nascent prepropeptide. The discovery of CCK-83 gives new insight into the order of preprohormone processing. The processing of prepro-CCK appears to be in the order of: 1) signal peptidase cleavage, 2) tyrosine sulfation, 3) cleavage after a carboxyl-terminal pair of basic residues, 4) carboxypeptidase B-like cleavage of these basic residues, 5) amidation (which results in the formation of CCK-83), and 6) cleavage at monobasic residues by endopeptidases (which results in the smaller molecular forms of cholecystokinin). The characterization of biologically active CCK-83 with a sulfated tyrosine and an amidated carboxyl terminus establishes the site of signal peptidase action and suggests an order of post-translational modifications that give rise to the various molecular forms of cholecystokinin.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,CTR INFLAMMATORY BOWEL DIS,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,CTR INFLAMMATORY BOWEL DIS,DEPT SURG,TORRANCE,CA 90509; UNIV ESSEN GESAMTHSCH,DEPT GASTROENTEROL & SURG,W-4300 ESSEN 1,GERMANY; CITY HOPE NATL MED CTR,BECKMAN RES INT,DUARTE,CA 91010; UNIV WURZBURG,MED POLIKLIN,W-8700 WURZBURG,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM 1,W-4630 BOCHUM,GERMANY; VET ADM MED CTR BRENTWOOD,CTR ULCER RES & EDUC,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Duisburg Essen; City of Hope; Beckman Research Institute of City of Hope; University of Wurzburg; Ruhr University Bochum; University of California System; University of California Los Angeles	EBERLEIN, GA (corresponding author), CALIF BIOTECHNOL INST,MT VIEW,CA 94043, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036200, R01DK033850] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33850, DK 36200, DK 41031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; DEPAUW E, 1984, BIOCHEM BIOPH RES CO, V123, P27, DOI 10.1016/0006-291X(84)90375-9; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DESMOND H, 1987, FEBS LETT, V210, P185, DOI 10.1016/0014-5793(87)81334-0; EBERLEIN GA, 1987, AM J PHYSIOL, V253, pG477, DOI 10.1152/ajpgi.1987.253.4.G477; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ENG J, 1984, PEPTIDES, V5, P1203, DOI 10.1016/0196-9781(84)90188-8; EYSSELEIN VE, 1988, REGUL PEPTIDES, V22, P205, DOI 10.1016/0167-0115(88)90033-X; EYSSELEIN VE, 1984, REGUL PEPTIDES, V9, P173, DOI 10.1016/0167-0115(84)90070-3; EYSSELEIN VE, 1990, AM J PHYSIOL, V258, pG253, DOI 10.1152/ajpgi.1990.258.2.G253; EYSSELEIN VE, 1982, PEPTIDES, V3, P687, DOI 10.1016/0196-9781(82)90171-1; EYSSELEIN VE, 1987, J BIOL CHEM, V262, P214; GUBLER U, 1987, J BIOL CHEM, V262, P15242; GUBLER U, 1984, P NATL ACAD SCI-BIOL, V81, P4307, DOI 10.1073/pnas.81.14.4307; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUEBNER VD, 1991, J BIOL CHEM, V266, P12223; JUNG DH, 1980, CLIN CHIM ACTA, V100, P7, DOI 10.1016/0009-8981(80)90179-5; KREIL G, 1973, EUR J BIOCHEM, V33, P556; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; MOESSNER J, 1989, Z GASTROENTEROL, V27, P94; MUTT V, 1976, CLIN ENDOCRINOL, V5, pS175, DOI 10.1111/j.1365-2265.1976.tb03825.x; REEVE JR, 1983, J BIOL CHEM, V258, P5582; REEVE JR, 1984, BIOCHEM BIOPH RES CO, V123, P404, DOI 10.1016/0006-291X(84)90428-5; REEVE JR, 1991, J BIOL CHEM, V266, P13770; REEVE JR, 1986, J BIOL CHEM, V261, P6392; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; REHFELD JF, 1972, BIOCHIM BIOPHYS ACTA, V285, P364, DOI 10.1016/0005-2795(72)90321-2; RODRIGUEZ C, 1989, J BIOL CHEM, V264, P5988; STEINER DF, 1975, PROTEASES BIOL CONTR, P531; TAKAHASHI Y, 1985, P NATL ACAD SCI USA, V82, P1931, DOI 10.1073/pnas.82.7.1931; TATEMOTO K, 1984, FEBS LETT, V174, P289, DOI 10.1016/0014-5793(84)81175-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITTEN JL, 1984, BIOCHEM BIOPH RES CO, V124, P350, DOI 10.1016/0006-291X(84)91560-2	35	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1517	1521						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370477				2022-12-27	WOS:A1992HA48500022
J	FISHER, MT; STADTMAN, ER				FISHER, MT; STADTMAN, ER			OXIDATIVE MODIFICATION OF ESCHERICHIA-COLI GLUTAMINE-SYNTHETASE - DECREASES IN THE THERMODYNAMIC STABILITY OF PROTEIN-STRUCTURE AND SPECIFIC CHANGES IN THE ACTIVE-SITE CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; LIMITED PROTEOLYSIS; BINDING-SITE; DIVALENT CATIONS; OXYGEN RADICALS; DEGRADATION; INACTIVATION; TURNOVER; MODEL	Metal catalyzed oxidation of specific amino acid residues has been proposed to be an important physiological mechanism of marking proteins for proteolytic degradation. After initial oxidative inactivation of dodecameric Escherichia coli glutamine synthetase (GS), the integrity of the GS active site and protein structure was assessed by monitoring ATP binding, observing a susceptibility of GS to tryptic cleavage, and comparative thermodynamic analysis. The tryptic cleavage rates of an active site linked central loop were significantly accelerated for the oxidized conformer. This tryptic cleavage was essentially prevented in the presence of glutamate for native GS but not for the oxidized conformer. The integrity of the ATP binding site in the oxidized GS was substantially altered as indicated by the reduction in fluorescence enhancement associated with ATP binding. Decreases in the free energies of quaternary protein structure and subunit interactions due to oxidative modification were determined by temperature and urea induced unfolding equilibrium measurements. Comparative thermal stability measurements of a partial unfolding transition indicated that the loss in stabilization free energy for the oxidized GS conformer was 1.3 kcal/mol dodecamer. Under alkaline conditions, the urea-induced disruption of quaternary and tertiary structures of oxidized and native GS were examined. This comparative analysis revealed that the free energies of the subunit interactions and unfolding of the dissociated monomers for oxidized GS were decreased by 1.5 and 1.7 kcal/mol, respectively. Our results suggest that small free energy decreases in GS protein structural stability of only 1-2 kcal/mol may be responsible for the selective proteolytic turnover of the oxidized GS.	NHLBI, BIOCHEM LAB, ENZYMES SECT, BLDG 3, RM 222, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ABELL LM, 1989, BIOCHEMISTRY-US, V28, P1940; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; ATKINS WM, 1991, BIOCHEMISTRY-US, V30, P3406, DOI 10.1021/bi00228a008; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; CIARDI JE, 1973, BIOCHEMISTRY-US, V12, P4321, DOI 10.1021/bi00746a004; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; DAUTRYVARSAT A, 1979, J BIOL CHEM, V254, P3124; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELGADO CJ, 1972, BIOCHIM BIOPHYS ACTA, V268, P121, DOI 10.1016/0005-2744(72)90205-7; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FISHER MT, 1990, FASEB J, V4, P1996; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FULKS RM, 1985, BIOCHIM BIOPHYS ACTA, V843, P214, DOI 10.1016/0304-4165(85)90142-4; GINSBURG A, 1991, BIOCHEMISTRY-US, V30, P9421, DOI 10.1021/bi00103a005; Ginsburg A., 1972, ADV PROTEIN CHEM, V26, P1; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HUNT JB, 1972, BIOCHEMISTRY-US, V11, P3723, DOI 10.1021/bi00770a010; HUNT JB, 1975, ARCH BIOCHEM BIOPHYS, V166, P102, DOI 10.1016/0003-9861(75)90370-7; HUNT JB, 1980, J BIOL CHEM, V255, P590; LEE YS, 1988, J BIOL CHEM, V263, P6643; LEI M, 1979, J BIOL CHEM, V254, P3129; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; MERKLER DJ, 1987, BIOCHEMISTRY-US, V26, P7805, DOI 10.1021/bi00398a041; MILLER RE, 1974, ARCH BIOCHEM BIOPHYS, V163, P155, DOI 10.1016/0003-9861(74)90465-2; MONROE DM, 1984, BIOCHEMISTRY-US, V23, P4565, DOI 10.1021/bi00315a009; MOSS J, 1990, J BIOL CHEM, V265, P21056; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; Oliver CN, 1982, EXPERIENCES BIOCH PE, P233; OLIVER CN, 1981, THESIS J HOPKINS U B; PINKOFSKY HB, 1984, J BIOL CHEM, V259, P9616; POLLACK S, 1977, BIOCHIM BIOPHYS ACTA, V497, P481, DOI 10.1016/0304-4165(77)90205-7; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; SEGAL A, 1972, ARCH BIOCHEM BIOPHYS, V152, P367, DOI 10.1016/0003-9861(72)90226-3; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; SHRAKE A, 1989, BIOCHEMISTRY-US, V28, P6281, DOI 10.1021/bi00441a021; SPENCER RD, 1970, J CHEM PHYS, V52, P1654, DOI 10.1063/1.1673201; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TIMMONS RB, 1974, BIOCHEMISTRY-US, V13, P4479, DOI 10.1021/bi00719a002; WOOLFOLK CA, 1966, ARCH BIOCHEM BIOPHYS, V116, P177, DOI 10.1016/0003-9861(66)90026-9; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V122, P174, DOI 10.1016/0003-9861(67)90137-3; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1872	1880						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346137				2022-12-27	WOS:A1992HA48500074
J	CHOUDHURY, K; SUNDARAMOORTHY, M; MAURO, JM; POULOS, TL				CHOUDHURY, K; SUNDARAMOORTHY, M; MAURO, JM; POULOS, TL			CONVERSION OF THE PROXIMAL HISTIDINE LIGAND TO GLUTAMINE RESTORES ACTIVITY TO AN INACTIVE MUTANT OF CYTOCHROME-C PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELECTRON-TRANSFER; RADICAL SITE; COMPOUND-I; TRYPTOPHAN-51; MUTAGENESIS; REDUCTION; KINETICS; ES	Using site-directed mutagenesis, a double mutant in yeast cytochrome c peroxidase (CCP) has been constructed where the proximal ligand, His175, has been converted to glutamine and the neighboring Trp191 has been converted to phenylalanine. The refined 2.4-angstrom crystal structure of the double mutant shows that the Gln175 side chain is within coordination distance of the heme iron atom and that Phe191 occupies the same position as Trp191 in the native enzyme with very little rearrangement outside the immediate vicinity of the mutations. Consistent with earlier work, we find that the single mutant, His175 --> Gln, is fully active under steady state assay conditions and that as reported earlier (Mauro et al., 1988), the Trp191 --> Phe mutant exhibits only <0.05% activity. However, the double mutant, His175 --> Gln/Phe191 --> Phe, exhibits 20% wild type activity. Since it is known that the Trp191 --> Phe mutant is inactive because it can no longer transfer electrons from ferrocytochrome c, changing the nature of the proximal ligand is able to restore this activity. These results raise interesting questions regarding the mechanism of interprotein electron transfer reactions.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT BIOCHEM & MOLEC BIOL,IRVINE,CA 92717; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; GEORGE WASHINGTON UNIV,DEPT GENET,WASHINGTON,DC 20052	University of California System; University of California Irvine; University of California System; University of California Irvine; George Washington University	POULOS, TL (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.				NIGMS NIH HHS [GM 42614] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEUNG E, 1986, P NATL ACAD SCI USA, V83, P1330, DOI 10.1073/pnas.83.5.1330; CONKLIN KT, 1988, J AM CHEM SOC, V110, P3345, DOI 10.1021/ja00219a001; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; EDWARDS SE, 1991, J BIOL CHEM, V265, P2588; ERMAN JE, 1975, BIOCHIM BIOPHYS ACTA, V393, P343, DOI 10.1016/0005-2795(75)90060-4; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HAZZARD JT, 1991, J AM CHEM SOC, V113, P3856; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MCLENDON G, 1985, J AM CHEM SOC, V107, P7811, DOI 10.1021/ja00312a002; PURCELL WL, 1976, J AM CHEM SOC, V98, P7033, DOI 10.1021/ja00438a049; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; SUNDARAMOORTHY M, 1991, J AM CHEM SOC, V113, P7755, DOI 10.1021/ja00020a044; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Yonetani T., 1976, ENZYMES, P345; [No title captured]	21	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25656	25659						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334481				2022-12-27	WOS:A1992KD07300010
J	YOKOTA, I; SAIJO, T; VOCKLEY, J; TANAKA, K				YOKOTA, I; SAIJO, T; VOCKLEY, J; TANAKA, K			IMPAIRED TETRAMER ASSEMBLY OF VARIANT MEDIUM-CHAIN ACYL-COENZYME-A DEHYDROGENASE WITH A GLUTAMATE OR ASPARTATE SUBSTITUTION FOR LYSINE-304 CAUSING INSTABILITY OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COA DEHYDROGENASE; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PREVALENT MUTATION; ESCHERICHIA-COLI; MCAD DEFICIENCY; GENE; IDENTIFICATION; BIOSYNTHESIS	Ninety percent of variant medium-chain acyl-CoA dehydrogenase (MCAD) alleles in patients with MCAD deficiency carry a 985A-->G transition which causes glutamate substitution for lysine 329 in precursor (p) MCAD (K-304 in mature MCAD). We have used site-directed mutagenesis to produce three variant cDNAs encoding variant pMCAD with glutamate (Kp329E2), aspartate (Kp329D), or arginine (Kp329R) substitution for Kp329. We carried out in vitro expression of cDNAs, and incubated the translation products with isolated rat liver mitochondria. Kp329E was imported into mitochondria and processed into the mature subunit as efficiently as wild-type. Gel filtration analysis of the mitochondria revealed that at 10 min after import, markedly more K304E eluted as a monomer than did wild-type, and the amount of K304E tetramer formed was distinctly less than wild-type at any point up to 60 min after import, indicating that the assembly of K304E is defective. After further incubation, K304E decayed more rapidly than did wild-type, indicating a reduced stability. In similar studies, K304R behaved like the wild-type, while K304D closely resembled K304E, indicating that the presence of a basic residue at 304 is essential for tetramer formation and intramitochondrial stability of mature MCAD.	YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, POB 3333, NEW HAVEN, CT 06510 USA	Yale University	TANAKA, K (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, POB 3333, NEW HAVEN, CT 06510 USA.		Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NIDDK NIH HHS [DK38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAKEMORE AIF, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90907-7; BROSS P, 1992, PROG CLIN BIOL RES, V375, P473; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COATES PM, 1992, PEDIATR RES, V31, P34, DOI 10.1203/00006450-199201000-00006; CONBOY JG, 1981, P NATL ACAD SCI-BIOL, V78, P3073, DOI 10.1073/pnas.78.5.3073; GREGERSEN N, 1991, HUM GENET, V86, P545; GREGERSEN N, 1992, PROG CLIN BIOL RES, V375, P441; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA Y, 1986, PEDIATR RES, V20, P843, DOI 10.1203/00006450-198609000-00007; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; INAGAKI T, 1990, J CLIN BIOCHEM NUTR, V8, P1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; KIM JJP, 1992, NEW DEV FATTY ACID O, V111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWENSTEIN J, 1970, Biochimica et Biophysica Acta, V223, P432, DOI 10.1016/0005-2728(70)90201-X; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MATSUBARA Y, 1991, LANCET, V338, P552, DOI 10.1016/0140-6736(91)91110-G; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MATSUBARA Y, 1986, P NATL ACAD SCI USA, V83, P6543, DOI 10.1073/pnas.83.17.6543; OGILVIE I, 1991, BIOCHEM MED METAB B, V46, P373, DOI 10.1016/0885-4505(91)90085-Y; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROE CR, 1988, METABOLIC BASIS INHE, P889; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4530; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALDINGER D, 1988, BIOL CHEM H-S, V369, P1185, DOI 10.1515/bchm3.1988.369.2.1185; YOKOTA I, 1991, AM J HUM GENET, V49, P1280; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; 1992, NEW DEV FATTY ACID O, P499	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26004	26010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361190				2022-12-27	WOS:A1992KD07300063
J	SETH, A; GONZALEZ, FA; GUPTA, S; RADEN, DL; DAVIS, RJ				SETH, A; GONZALEZ, FA; GUPTA, S; RADEN, DL; DAVIS, RJ			SIGNAL TRANSDUCTION WITHIN THE NUCLEUS BY MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; C-MYC ONCOGENE; MYELIN BASIC-PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTOR; MESSENGER-RNA; PHOSPHORYLATION SITE; TYROSINE KINASE; GENE-PRODUCT	The nucleus is an important target of signal transduction by growth factor receptors that stimulate mitogen-activated protein (MAP) kinases. We tested the hypothesis that MAP kinases have a signaling role within the nucleus by examining the effect of the expression of a human MAP kinase isoform (p41mapk) in tissue culture cells. The expressed p41mapk was found to be localized in both the cytoplasmic and nuclear compartments of the cells. Significantly, the expression of p41mapk caused an increase in the phosphorylation of a nuclear substrate: Ser62 of c-Myc. Phosphorylation at Ser62 stimulated the activity of the NH2-terminal transactivation domain of c-Myc. Thus, p41mapk causes the phosphorylation and regulation of a physiologically significant nuclear target of signal transduction. These data establish that at least one MAP kinase isoform has a nuclear role during signal transduction.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Penn L J, 1990, Semin Cancer Biol, V1, P69; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SYMONDS G, 1989, ONCOGENE, V4, P285; THEROUX SJ, 1992, NUCLEIC ACIDS RES, V20, P915, DOI 10.1093/nar/20.4.915; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAITZ W, 1991, ONCOGENE, V6, P29; WATERS CM, 1991, ONCOGENE, V6, P797; WELLS KS, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P27; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	89	322	322	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24796	24804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332967				2022-12-27	WOS:A1992KA26300096
J	YEO, EJ; WAGNER, C				YEO, EJ; WAGNER, C			PURIFICATION AND PROPERTIES OF PANCREATIC GLYCINE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE BINDING-PROTEIN; RAT-LIVER CYTOSOL; METABOLISM; CDNA	Glycine N-methyltransferase (GNMT) regulates the ratio of S-adenosylmethionine to S-adenosylhomocysteine. It is very abundant in liver cytosol and earlier studies have shown it to be present in high concentrations in the pancreas. We have previously reported that liver GNMT is allosterically inhibited by 5-methyltetrahydrofolate pentaglutamate (5-CH3-H4PteGlu5), and proposed that this represents a metabolic control mechanism which links the de novo synthesis of methyl groups to the methylating ability of the liver. We now report that pancreatic GNMT also contains bound folate in vivo. Purified pancreatic GNMT is inhibited by reduced folate polyglutamates in vitro. The K(I) for the synthetic (R,S)5-CH3-H4PteGlu5 is 2.4 x 10(-7) M. The natural (S) form of 5-CH3-H4PteGlu5 is tightly bound and has a K(d) of 1.3 x 10(-7) M. One mole is bound per enzyme tetramer. These studies suggest that GNMT is important in the regulation of methyl group metabolism in the pancreas as well as in the liver.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37212 USA; VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NIDDK NIH HHS [DK15289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALAGHI M, 1992, J NUTR, V122, P1391, DOI 10.1093/jn/122.7.1391; BALINSKY BI, 1970, INTRO EMBRYOLOGY, P528; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1989, J NUTR, V119, P612, DOI 10.1093/jn/119.4.612; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HOOVER KL, 1986, J NUTR, V116, P1569, DOI 10.1093/jn/116.8.1569; KERR SJ, 1972, J BIOL CHEM, V247, P4248; KRUMDIECK CL, 1983, VITAM HORM, V40, P45, DOI 10.1016/S0083-6729(08)60432-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; OGAWA H, 1984, BIOCHEM BIOPH RES CO, V124, P44, DOI 10.1016/0006-291X(84)90913-6; PARSA I, 1970, AM J PATHOL, V59, P1; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WAGNER C, 1985, NUTR REV, V43, P293; WAGNER C, 1984, P NATL ACAD SCI USA, V81, P3631; WALZEM RL, 1988, J NUTR, V118, P1343, DOI 10.1093/jn/118.11.1343; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAPPIA V, 1983, METHOD ENZYMOL, V94, P57	27	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24669	24674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332963				2022-12-27	WOS:A1992KA26300078
J	MATSUMURA, M; SAITO, Y; JACKSON, MR; SONG, ES; PETERSON, PA				MATSUMURA, M; SAITO, Y; JACKSON, MR; SONG, ES; PETERSON, PA			INVITRO PEPTIDE BINDING TO SOLUBLE EMPTY CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES ISOLATED FROM TRANSFECTED DROSOPHILA-MELANOGASTER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA MOLECULES; IMMUNOGENIC PEPTIDES; ANTIGENIC PEPTIDES; SELF-PEPTIDES; MHC MOLECULES; HEAVY-CHAIN; T-CELLS; BETA-2-MICROGLOBULIN; REGION; GENE	A soluble form of a mouse class I major histocompatibility antigen (H-2K(b)) has been expressed in transfected Drosophila melanogaster cells. These molecules were efficiently secreted (up to 4 mg/liter) as noncovalent heterodimers and purified to homogeneity from cell supernatants. The isolated soluble K(b) molecules were devoid of endogenous peptides. Using these molecules, we have characterized the K(b) heavy chain-beta2-microglobulin (beta2m) assembly as well as peptide binding in vitro. In detergent-free solution the heavy chains readily re-assembled with beta2m even in the absence of peptides. Kinetic analyses showed that the peptide binding is rapid and reversible and dependent on the heavy chains being assembled with beta2m. Likewise, peptide dissociated from K(b) molecules without the displacement of beta2m. Equilibrium binding experiments using various peptides confirmed that octapeptides bind to K(b) molecules with the highest affinity and form the most stable complexes. However, in contrast to earlier studies, the amino-terminal positioning of peptide to K(b) molecules was more crucial than the carboxyl-terminal positioning and amidation of the peptide carboxylate did not affect the binding. Soluble K(b) molecules could selectively bind allele-specific peptides among a mixture of randomly synthesized octapeptides in vitro; however, no dominant residue was observed at the carboxyl terminus of bound peptides. This suggests that the previously observed hydrophobic residues at the carboxyl terminus of peptides may reflect the specificity of enzyme(s) or protein(s) involved in peptide processing in vivo.			MATSUMURA, M (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA97489] Funding Source: Medline; NIAID NIH HHS [AI31965] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031965] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY F, 1990, INT IMMUNOL, V2, P995, DOI 10.1093/intimm/2.10.995; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; PARKER KC, 1992, J BIOL CHEM, V267, P5451; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002	48	135	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23589	23595						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331092				2022-12-27	WOS:A1992JZ23900028
J	DUZIC, E; COUPRY, I; DOWNING, S; LANIER, SM				DUZIC, E; COUPRY, I; DOWNING, S; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .1. COUPLING OF ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES TO DISTINCT G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; HIGH-AFFINITY; ALPHA-2B-ADRENERGIC RECEPTOR; CELL LINE; EXPRESSION; CLONING; IDENTIFICATION; SYSTEMS; BRAIN	Alpha-2-adrenergic receptor (alpha-2-AR) subtypes couple to pertussis toxin (PT)-sensitive G-proteins to elicit both stimulatory and inhibitory cell responses. Signal specificity may be generated by the ability of the receptor subtypes to "recognize" distinct G-proteins with different affinity. To address this issue we stably expressed three alpha-2-AR subtypes, RNG-alpha-2 (alpha-2B-AR), RG10 (alpha-2C-AR), and RG20 (alpha-2D-AR), in NIH-3T3 fibroblasts, which express two PT-sensitive G-proteins (G(i-alpha-2), G(i-alpha-3), and analyzed receptor/G-protein interactions by determining: 1) functional coupling to adenylylcyclase and 2) the ability of the receptors to exist in a high affinity state for agonist. In alpha-2D-AR transfectants expressing 200 or 2,200 fmol of receptor/mg of protein, epinephrine (10-mu-M) inhibited forskolin-induced elevation of cellular cAMP by 26 +/- 4.8% and 72 +/- 6.2%, respectively. Similar results were obtained in alpha-2B-AR transfectants. However, in alpha-2C-AR transfectants (200 fmol/mg) the forskolin-induced elevation of cellular cAMP was not altered by agonist treatment. In alpha-2C-AR transfectants expressing higher receptor densities (650-1,200 fmol/mg), epinephrine inhibited the effect of forskolin by 30 +/- 3.2%. This difference in functional coupling among the alpha-2-AR subtypes is reflected at the receptor/G-protein interface. In membrane preparations of alpha-2B and alpha-2D-AR but not alpha-2c-AR transfectants, agonist competition curves were biphasic, indicating high and low affinity states of the receptor for agonist. The high affinity state was guanyl-5'-yl imidodiphosphate- and PT-sensitive, indicative of receptor/G-protein coupling. These data suggest that the alpha-2c-AR differs from the alpha-2B and alpha-2D-AR subtypes in its ability to recognize PT-sensitive G-proteins expressed in NIH-3T3 fibroblasts. The alpha-2c-AR may couple preferentially to PT-sensitive G-proteins (G(i1), G(o1,2) not expressed in NIH-3T3 fibroblasts and thereby elicit different cellular responses.	MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CELLULAR & MOLEC RES LAB,BOSTON,MA 02114	Medical University of South Carolina; Harvard University; Harvard Medical School; Massachusetts General Hospital			COUPRY, Isabelle/L-4900-2014	Lanier, Stephen/0000-0002-2740-7607	FIC NIH HHS [3 FO5 TW4313-02] Funding Source: Medline; NINDS NIH HHS [NS-24821] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CALTABIANO MM, 1990, GENE AMST, V85, P479; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CARPENE C, 1990, BIOCHEM PHARMACOL, V40, P437, DOI 10.1016/0006-2952(90)90541-R; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COUPRY I, 1992, J BIOL CHEM, V267, P9852; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN C, 1986, DNA CLONING PRACTICA, V2, P152; GRAHAM RM, 1986, HEART CARDIOVASCULAR, V2, P1059; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LANIER SM, 1988, J BIOL CHEM, V263, P14491; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LORENZ W, 1990, MOL PHARMACOL, V38, P599; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MCKENZIE FR, 1990, BIOCHEM J, V267, P371; MICHEL AD, 1989, BRIT J PHARMACOL, V98, P890, DOI 10.1111/j.1476-5381.1989.tb14618.x; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; PARIS H, 1990, J PHARMACOL EXP THER, V254, P888; REGAN JW, 1986, J BIOL CHEM, V261, P3894; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P187; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMMONEAUX V, 1991, MOL PHARMACOL, V40, P235; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STARKE K, 1989, PHYSIOL REV, V69, P900; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; THOMSEN WJ, 1988, MOL PHARMACOL, V34, P814; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	51	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9844	9851						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349606				2022-12-27	WOS:A1992HT96500064
J	KWON, HM; YAMAUCHI, A; UCHIDA, S; PRESTON, AS; GARCIAPEREZ, A; BURG, MB; HANDLER, JS				KWON, HM; YAMAUCHI, A; UCHIDA, S; PRESTON, AS; GARCIAPEREZ, A; BURG, MB; HANDLER, JS			CLONING OF THE CDNA FOR A NA+/MYO-INOSITOL COTRANSPORTER, A HYPERTONICITY STRESS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL TRANSPORT; NUCLEOTIDE-SEQUENCE; SYMPORT CARRIER; NA+/GLUCOSE; GLUCOSE; CELLS; GENE	Kidney medullary cells in situ, as well as kidney-derived Madin-Darby canine kidney (MDCK) cells accumulate nonperturbing, small organic solutes (osmolytes), including myo-inositol, when bathed in hypertonic media. Accumulation of osmolytes balances the osmolality of extracellular fluid without raising intracellular salts that would perturb cellular functions. In hypertonic media, increased myo-inositol accumulation is the result of increased activity of a Na+/myo-inositol cotransporter. We have isolated a cDNA encoding a Na+/myo-inositol cotransporter from MDCK cells using expression in Xenopus oocytes. The cDNA sequence predicts a protein of 718 amino acids with a significant amino acid sequence similarity to the Na+/D-glucose cotransporters of absorbing epithelia. Transporter mRNA is present in kidney and brain and is markedly induced in MDCK cells by medium hypertonicity, demonstrating that adaptation to hypertonic stress involves up-regulation of transporter mRNA accumulation.	JOHNS HOPKINS UNIV, SCH MED,DIV NEPHROL,ROSS BLDG,9TH FLOOR S, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA; NHLBI, KIDNEY & ELECTROLYTE METAB LAB, BETHESDA, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Uchida, Shinichi/D-1111-2013; Lee-Kwon, Whaseon/D-6021-2011		NIDDK NIH HHS [DK42479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGNASCO S, 1986, J BIOL CHEM, V261, P5872; CASPARY WF, 1970, BIOCHIM BIOPHYS ACTA, V203, P308, DOI 10.1016/0005-2736(70)90145-8; COADY MJ, 1990, AM J PHYSIOL, V259, pC605, DOI 10.1152/ajpcell.1990.259.4.C605; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; HAMMERMAN MR, 1980, AM J PHYSIOL, V239, pF113, DOI 10.1152/ajprenal.1980.239.2.F113; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEILIG CW, 1989, AM J PHYSIOL, V257, pF1108, DOI 10.1152/ajprenal.1989.257.6.F1108; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KWON HM, 1991, AM J PHYSIOL, V260, pF258, DOI 10.1152/ajprenal.1991.260.2.F258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; MORIYAMA T, 1991, AM J PHYSIOL, V260, pF494, DOI 10.1152/ajprenal.1991.260.4.F494; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; STRANGE K, 1991, AM J PHYSIOL, V260, pC784, DOI 10.1152/ajpcell.1991.260.4.C784; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; UCHIDA S, 1991, J CLIN INVEST, V88, P656, DOI 10.1172/JCI115350; VEIS JH, 1991, AM J PHYSIOL, V260, pF619, DOI 10.1152/ajprenal.1991.260.5.F619; WHITESIDE CI, 1991, AM J PHYSIOL, V260, pF138, DOI 10.1152/ajprenal.1991.260.1.F138; YAMATO I, 1990, J BIOL CHEM, V265, P2450; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	27	323	327	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6297	6301						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372904				2022-12-27	WOS:A1992HK31800087
J	OGATA, Y; ENGHILD, JJ; NAGASE, H				OGATA, Y; ENGHILD, JJ; NAGASE, H			MATRIX METALLOPROTEINASE-3 (STROMELYSIN) ACTIVATES THE PRECURSOR FOR THE HUMAN MATRIX METALLOPROTEINASE-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RHEUMATOID SYNOVIAL FIBROBLASTS; IV COLLAGENASE; DEGRADING METALLOPROTEINASE; ALVEOLAR MACROPHAGES; V COLLAGEN; GELATINASE; PURIFICATION; TISSUE; CELLS	Matrix metalloproteinase 9 (MMP-9), also known as 92-kDa gelatinase/type IV collagenase, is secreted from neutrophils, macrophages, and a number of transformed cells in zymogen form. Here we report that matrix metalloproteinase 3 (MMP-3/stromelysin) is an activator of the precursor of matrix metalloproteinase 9 (proMMP-9). MMP-3 initially cleaves proMMP-9 at the Glu40-Met41 bond located in the middle of the propeptide to generate an 86-kDa intermediate. Cleavage of this bond triggers a change in proMMP-9 that renders the Arg87-Phe88 bond susceptible to the second cleavage by MMP-3, resulting in conversion to an 82-kDa form alpha-2-Macroglobulin binding studies of partially activated MMP-9 demonstrate that the 82-kDa species is proteolytically active, but not the initial intermediate of 86 kDa. This stepwise activation mechanism of proMMP-9 is analogous to those of other members of the MMP family, but the action of MMP-3 on proMMP-9 is the first example of zymogen activation that can be triggered by another member of the MMP family. The results imply that MMP-3 may be an effective activator of proMMP-9 in vivo.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,3901 RAINBOW BLVD,KANSAS CITY,KS 66103; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	University of Kansas; University of Kansas Medical Center; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; DAVIS GE, 1990, CANCER RES, V50, P1113; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; LYONS IG, 1991, BIOCHEMISTRY-US, V30, P1449; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1989, J CELL SCI, V92, P487; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1989, FEBS LETT, V249, P353, DOI 10.1016/0014-5793(89)80657-X; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SALAMONSEN LA, 1991, J CELL SCI, V100, P381; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SOPATA I, 1974, BIOCHIM BIOPHYS ACTA, V370, P510, DOI 10.1016/0005-2744(74)90112-0; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	42	585	603	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3581	3584						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371271				2022-12-27	WOS:A1992HE60700008
J	LOUIS, NA; WITTERS, LA				LOUIS, NA; WITTERS, LA			GLUCOSE REGULATION OF ACETYL-COA CARBOXYLASE IN HEPATOMA AND ISLET CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A CARBOXYLASE; STIMULATED INSULIN-SECRETION; FATTY-ACID SYNTHESIS; MALONYL-COA; REVERSIBLE PHOSPHORYLATION; TISSUE DISTRIBUTION; GLYCOGEN-SYNTHASE; RAT-LIVER; ENZYMES	The regulation of acetyl-CoA carboxylase (ACC) by glucose and other fuel molecules has been examined in Fao Reuber hepatoma cells and Syrian hamster insulin tumor (HIT) cells in order to determine whether lipogenic substrates acutely alter ACC activity and to examine the mechanism of such regulation. In Fao cells, preincubated in simple medium without substrates, glucose addition results in a rapid activation of ACC. This effect, mimicked by other fuels such as lactate, is characterized by an increase in enzyme V(max) and a decrease in the activation constant for citrate. Several lines of evidence indicate that this activation of ACC is due to enzyme dephosphorylation, including the kinetic changes observed, the persistence of enzyme activation through ACC isolation, the necessity of inclusion of sodium fluoride/EDTA in the cell lysis buffer for preservation of the glucose-induced change, and the direct demonstration of diminished P-32-labeling of ACC after glucose exposure. Identical effects of glucose are also observed in HIT cells, although the ACC activation is smaller in magnitude and less sensitive than that observed in Fao cells. Other insulin secretagogues such as glutamine, lactate, and isobutylmethylxanthine are also found to activate HIT ACC. Others have suggested that glucose-induced changes in malonyl-CoA in beta-cells may be linked to glucose-induced insulin secretion. However, studies conducted in late passage HIT cells, which fail to secrete insulin in response to glucose stimulation, reveal the same glucose-induced activation seen in early passage, secretion-competent HIT cells, suggesting that glucose-induced ACC activation is not by itself sufficient to provoke insulin secretion. Taken together, these findings indicate that glucose and other fuel molecules can play a major role in the rapid regulation of the fatty acid synthesis pathway. The activation of fatty acid synthesis by substrate-induced ACC dephosphorylation insures ultimate fuel storage of glucose-derived carbon as fatty acid, while substrate-induced increases in the ACC product, malonyl CoA, would serve to simultaneously limit the rate of fatty acid oxidation through its allosteric regulation of carnitine palmitoyltransferase I.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,DIV ENDOCRINE METAB,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Dartmouth College; Dartmouth College			Louis, Nancy/G-5163-2011	Louis, Nancy/0000-0001-7092-8136	NIDDK NIH HHS [DK 35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; EASOM RA, 1984, BIOCHEM J, V220, P733, DOI 10.1042/bj2200733; EVANS JL, 1989, BIOCHEM J, V259, P821, DOI 10.1042/bj2590821; GIFFHORN S, 1984, BIOCHEM J, V221, P343, DOI 10.1042/bj2210343; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JAMIL H, 1987, J BIOL CHEM, V262, P638; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MOIR AMB, 1990, BIOCHEM J, V272, P511, DOI 10.1042/bj2720511; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SPENCE JT, 1985, BIOCHEM J, V227, P939, DOI 10.1042/bj2270939; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VAGELOS PR, 1963, J BIOL CHEM, V238, P533; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; WINDER WW, 1989, J APPL PHYSIOL, V67, P2230, DOI 10.1152/jappl.1989.67.6.2230; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; WITTERS LA, 1978, BIOCHEMISTRY-US, V17, P406, DOI 10.1021/bi00596a004; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	35	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2287	2293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346395				2022-12-27	WOS:A1992HB53200029
J	PARK, DJ; MIN, HK; RHEE, SG				PARK, DJ; MIN, HK; RHEE, SG			INHIBITION OF CD3-LINKED PHOSPHOLIPASE-C BY PHORBOL ESTER AND BY CAMP IS ASSOCIATED WITH DECREASED PHOSPHOTYROSINE AND INCREASED PHOSPHOSERINE CONTENTS OF PLC-GAMMA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CALCIUM; COMPLEX; PATHWAY; TURNOVER	The mechanisms by which phorbol 12-myristate 13-acetate (PMA) and cAMP attenuate the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P2) induced by ligation of the T-cell antigen receptor complex (TCR) was studied in the human Jurkat T-cell line. It has previously been shown that stimulation of Jurkat cells with antibodies to CD3, components of the TCR, elicits a rapid and transient phosphorylation of phospholipase C (PLC)-gamma-1, the predominant PLC isozyme in Jurkat cells, at multiple tyrosine residues and that such tyrosine phosphorylation leads to activation of PLC-gamma-1. Prior incubation of Jurkat cells with PMA or forskolin, which increases intracellular cAMP concentrations, prevented tyrosine phosphorylation of PLC-gamma-1 as well as the hydrolysis of PtdIns 4,5-P2 induced by ligation of CD3. Dose-response curves of PMA and of forskolin for the inhibition of PLC-gamma-1 tyrosine phosphorylation and of PtdIns 4,5-P2 hydrolysis were similar. These results suggest that the inhibition of PtdIns 4,5-P2 hydrolysis by PMA and cAMP is attributable to reduced tyrosine phosphorylation of PLC-gamma-1. Treatment of Jurkat cells with PMA or forskolin stimulated the phosphorylation of PLC-gamma-1 at serine 1248. PMA treatment also elicited the phosphorylation of PLC-gamma-1 at an unidentified serine site. Phosphopeptide map analysis indicated that the sites of PLC-gamma-1 phosphorylated in Jurkat cells treated with PMA and forskolin are the same as those phosphorylated in vitro by protein kinase C (PKC) and cAMP-dependent protein kinase (PKA), respectively. Stimulation of Jurkat cells with antibodies to CD3 also elicited phosphorylation of PLC-gamma-1 at serine 1248 and at the unidentified serine site phosphorylated in PLC-gamma-1 from PMA-treated cells. Thus, phosphorylation of PLC-gamma-1 by PKC or PKA at serine 1248 may modulate the interaction of PLC-gamma-1 with the protein tyrosine kinase or the protein tyrosine phosphatase; this altered interaction may, at least in part, be responsible for the decreased tyrosine phosphorylation of PLC-gamma-1 seen in PMA- and forskolin-treated Jurkat cells. Furthermore, in the absence of PMA, activation of PKC by diacylglycerol provides a negative feedback signal responsible for reducing the phosphotyrosine contents of PLC-gamma-1.	NHLBI,BIOCHEM LAB,BLDG 3,RM 122,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Park, Do-Joon/J-2736-2012					ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; ALBERT F, 1985, J IMMUNOL, V134, P3649; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHOUAIB S, 1987, J CLIN INVEST, V80, P333, DOI 10.1172/JCI113077; DOSREIS GA, 1986, CELL IMMUNOL, V101, P213, DOI 10.1016/0008-8749(86)90199-1; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HIS ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; ISAKOV N, 1987, J IMMUNOL, V138, P3100; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1989, J BIOL CHEM, V264, P20167; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LERNER A, 1988, J IMMUNOL, V140, P936; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MCATEE P, 1989, J BIOL CHEM, V264, P11193; MEISENHELDER J, 1989, CELL, V57, P1108; MILLS GB, 1989, J IMMUNOL, V142, P1995; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; SOMMERMEYER H, 1990, EUR J IMMUNOL, V20, P1881, DOI 10.1002/eji.1830200902; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TOMITAYAMAGUCHI M, 1990, J IMMUNOL, V144, P3946; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG T, 1978, SCIENCE, V201, P155, DOI 10.1126/science.208147; WARD SG, 1990, J IMMUNOL, V144, P3523; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	43	146	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1496	1501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370476				2022-12-27	WOS:A1992HA48500019
J	MONNIER, D; COLAS, JF; ROSAY, P; HEN, R; BORRELLI, E; MAROTEAUX, L				MONNIER, D; COLAS, JF; ROSAY, P; HEN, R; BORRELLI, E; MAROTEAUX, L			NKD, A DEVELOPMENTALLY REGULATED TACHYKININ RECEPTOR IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SUBSTANCE-P-LIKE; IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; FMRFAMIDE-LIKE; NEUROPEPTIDES; EXPRESSION; CLONING; GENE; LOCALIZATION	A number of neuropeptides have been described which are present in the insect nervous system. The physiological role of these neuropeptides has not yet been clarified. We have characterized a Drosophila melanogaster cDNA coding for a protein, NKD, whose sequence resembles that of mammalian G protein-coupled neuropeptide receptors. This protein shows 38% homology with the mammalian tachykinin NK3 receptor within the transmembrane domain region. Stable cell lines expressing this cDNA are responsive to Locusta migratoria tachykinin but not to other peptides of the tachykinin family. The expression of this gene is detected principally in adult fly heads, but also in the adult body and in embryos. Interestingly, NKD mRNA is detected at very early stages of Drosophila embryonic development (3 h) and reaches the highest level of expression at 12-16 h, a time which correlates with the period of major neuronal development. In situ hybridization experiments demonstrate that NKD is expressed in the central nervous system, as well as in subsets of neurons in each segment of the developing ventral ganglia. The cytological localization of this gene is at position 86C on the Drosophila third chromosome.	FAC MED STRASBOURG,CNRS,GENET EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Maroteaux, Luc/H-4585-2019	Maroteaux, Luc/0000-0002-9499-8603				ARAKAWA S, 1990, NEURON, V4, P343, DOI 10.1016/0896-6273(90)90047-J; BROADIE KS, 1990, DEVELOPMENT, V108, P59; COPENHAVER PF, 1989, DEV BIOL, V131, P70, DOI 10.1016/S0012-1606(89)80039-9; FOLKERS K, 1984, BRIT J PHARMACOL, V83, P449, DOI 10.1111/j.1476-5381.1984.tb16506.x; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P396; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HOFFMANN JA, 1991, NEW BIOL, V3, P336; KESHISHIAN H, 1985, J NEUROSCI, V5, P1005; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MUDGE AW, 1989, NATURE, V339, P663, DOI 10.1038/339663a0; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; NASSEL DR, 1990, BRAIN RES, V507, P225, DOI 10.1016/0006-8993(90)90276-H; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONAI T, 1989, FEBS LETT, V255, P219, DOI 10.1016/0014-5793(89)81095-6; Sambrook J, 1989, MOL CLONING LABORATO; SAUDOU F, 1990, EMBO J, V9, P3611, DOI 10.1002/j.1460-2075.1990.tb07572.x; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1990, FEBS LETT, V261, P397, DOI 10.1016/0014-5793(90)80601-E; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANBRUNT J, 1987, BIO-TECHNOL, V5, P31; VERHAERT P, 1985, HISTOCHEMISTRY, V86, P501; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WHITE K, 1986, J COMP NEUROL, V247, P430, DOI 10.1002/cne.902470403; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	29	125	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1298	1302						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370464				2022-12-27	WOS:A1992GY96000096
J	XI, D; VANDOLAH, FM; RAMSDELL, JS				XI, D; VANDOLAH, FM; RAMSDELL, JS			MAITOTOXIN INDUCES A CALCIUM-DEPENDENT MEMBRANE DEPOLARIZATION IN GH4C1 PITUITARY-CELLS VIA ACTIVATION OF TYPE-L VOLTAGE-DEPENDENT CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE BREAKDOWN; GAMBIERDISCUS-TOXICUS; CA-2+ TRANSPORT; BETA-SUBUNIT; DINOFLAGELLATE; MECHANISMS; RELEASE; SYNAPTOSOMES; CURRENTS; AGONIST	Maitotoxin (MTX) is a water-soluble polyether, isolated from the marine dinoflagellate Gambierdiscus toxicus, that stimulates hormone release and Ca2+ influx. We have investigated the action by which MTX induces Ca2+ influx and stimulates prolactin (PRL) release from GH4C1 rat pituitary cells. PRL release elicited by MTX is abolished in a concentration-dependent manner by nimodipine, a dihydropyridine (DHP) antagonist of type L voltage-dependent calcium channels (L-VDCC), indicating that MTX-enhanced PRL release occurs via activation of type L-VDCC. As an initial approach to determine whether MTX interacts directly with VDCC, we examined whether MTX affects the binding of [H-3]PN 200-110, a DHP class antagonist, in intact GH4C1 cells. MTX increased the B(max) of [H-3]PN 200-110 binding to intact GH4C1 cells from 4.6 +/- 0.03 to 12.5 +/- 2.2 fmol/10(6) cells, without changing the K(d). This indicates that MTX does not bind to the DHP site, but rather suggests that MTX may have an allosteric interaction with the DHP binding site. The effect of MTX on DHP binding was largely (65%) calcium-dependent. We next examined whether MTX alters the membrane potential of GH4C1 cells using the potential sensitive fluorescent dye bisoxonol. Addition of 100 ng/ml MTX to GH4C1 cells caused a membrane depolarization within 2.5 min which reached a plateau at 5 min. The MTX-induced depolarization was not prevented by substitution of impermeant choline ions for Na+. It was similarly unaffected by K+ channel blockers or by depleting the K+ chemical concentration gradient with gramicidin, a monovalent cation pore-forming agent. By contrast, low extracellular Ca2+ totally abolished the depolarization response, and nimodipine at 100 nM substantially reduced the MTX-induced membrane depolarization. These results indicate that the predominant effect of MTX on depolarization is Ca2+ influx through L-VDCC. Taken together, our results indicate that MTX-enhanced PRL release occurs exclusively via activation of type L-VDCC in GH4C1 Cells. We suggest that MTX induces an initial slow calcium conductance, possibly via an allosteric interaction with a component of the VDCC complex, which, in turn, initiates a positive feedback mechanism involving calcium-dependent membrane depolarization and voltage-dependent activation of calcium channels.	MED UNIV S CAROLINA,221 FT JOHNSON RD,CHARLESTON,SC 29412; NATL MARINE FISHERIES SERV,CHARLESTON LAB,CHARLESTON,SC 29412	Medical University of South Carolina; National Oceanic Atmospheric Admin (NOAA) - USA					NIDDK NIH HHS [DK 43107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; BARROS F, 1984, J BIOL CHEM, V259, P9404; CONN PM, 1987, MOL ENDOCRINOL, V1, P154, DOI 10.1210/mend-1-2-154; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; GUSOVSKY F, 1989, FEBS LETT, V243, P307, DOI 10.1016/0014-5793(89)80151-6; GUSOVSKY F, 1990, J PHARMACOL EXP THER, V252, P466; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; HAMILTON SL, 1985, SCIENCE, V229, P182, DOI 10.1126/science.3160111; HOLMES MJ, 1990, TOXICON, V28, P1159, DOI 10.1016/0041-0101(90)90116-O; KACZOROWSKI GJ, 1984, J BIOL CHEM, V259, P9395; KOBAYASHI M, 1987, BRIT J PHARMACOL, V92, P665, DOI 10.1111/j.1476-5381.1987.tb11370.x; KOCH BD, 1988, J BIOL CHEM, V263, P216; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEGRAND AM, 1984, J MOL CELL CARDIOL, V16, P663, DOI 10.1016/S0022-2828(84)80630-6; LOGIN IS, 1990, ENDOCRINOLOGY, V127, P1948, DOI 10.1210/endo-127-4-1948; MCPHERSON GA, 1985, J PHARMACOL METHOD, V13, P125, DOI 10.1016/0160-5402(85)90056-7; MURATA M, 1991, TOXICON, V29, P1085, DOI 10.1016/0041-0101(91)90206-7; SCHETTINI G, 1984, AM J PHYSIOL, V247, pE520, DOI 10.1152/ajpendo.1984.247.4.E520; SLADECZEK F, 1988, EUR J BIOCHEM, V174, P663, DOI 10.1111/j.1432-1033.1988.tb14149.x; SOERGEL DG, 1990, J PHARMACOL EXP THER, V255, P1360; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; TAGLIALATELA M, 1990, BIOCHIM BIOPHYS ACTA, V1026, P126, DOI 10.1016/0005-2736(90)90342-L; TAKAHASHI M, 1982, J BIOL CHEM, V257, P7287; TAN KN, 1984, J BIOL CHEM, V259, P418; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; UEDA H, 1986, NEUROSCI LETT, V67, P141, DOI 10.1016/0304-3940(86)90387-3; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WU CH, 1988, ANNU REV PHARMACOL, V28, P141; YASUMOTO T, 1988, J SYNTH ORG CHEM JPN, V40, P478; YOKOYAMA A, 1988, J BIOCHEM-TOKYO, V104, P184, DOI 10.1093/oxfordjournals.jbchem.a122438; YOSHII M, 1987, BRAIN RES, V424, P119, DOI 10.1016/0006-8993(87)91200-5	32	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25025	25031						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334077				2022-12-27	WOS:A1992KB60300020
J	SAIDO, TC; SHIBATA, M; TAKENAWA, T; MUROFUSHI, H; SUZUKI, K				SAIDO, TC; SHIBATA, M; TAKENAWA, T; MUROFUSHI, H; SUZUKI, K			POSITIVE REGULATION OF MU-CALPAIN ACTION BY POLYPHOSPHOINOSITIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALMODULIN-BINDING PROTEIN; PHOSPHATIDYLINOSITOL KINASE; CA-2+-DEPENDENT PROTEASE; ACIDIC PHOSPHOLIPIDS; PLASMA-MEMBRANE; PHORBOL ESTER; CALCIUM; FODRIN; NEOMYCIN	Whether calcium is the only major intracellular activator of calpain has not yet been established. Here we demonstrate that polyphosphoinositides may play critical roles in the activation process of mu-calpain. Experiments with purified enzyme, substrate (fodrin), and phospholipids show that only polyphosphoinositides but not other lipids significantly promote calpain action in the physiological intracellular calcium range of 10(-7) to 10(-6) M. The effect of polyphosphoinositide is exerted through both a reduction in the calcium concentration required for calpain autolysis and an increase in the V(max) of the proteolytic reaction. Neomycin, a polyphosphoinositide-binding antibiotic, inhibits both polyphosphoinositide-assisted proteolysis in test tubes and calcium-induced calpain activation coupled with substrate proteolysis in intact cells. This implies that the presence of polyphosphoinositides may actually be a prerequisite for calpain activation inside cells.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,TOKYO 173,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Gerontology; University of Tokyo	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BURGOYNE RD, 1987, NATURE, V326, P448, DOI 10.1038/326448a0; BURNS NR, 1985, NATURE, V313, P178, DOI 10.1038/313178b0; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHOWDHURY MIH, 1990, VIROLOGY, V176, P126; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; COLLICAN SA, 1986, J BIOL CHEM, V261, P4170; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; CROALL ED, 1990, INTRACELLULAR CALCIU, P103; Dixon M., 1979, ENZYMES, P47; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOX JEB, 1987, BLOOD, V69, P537; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GOLL ED, 1990, INTRACELLULAR CALCIU, P103; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HATHAWAY DR, 1990, INTRACELLULAR CALCIU, P91; HENDRICKSON H S, 1971, Biochemical and Biophysical Research Communications, V44, P1258; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; INOMATA M, 1983, J BIOCHEM-TOKYO, V93, P291, DOI 10.1093/oxfordjournals.jbchem.a134166; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KOSOWER NS, 1990, INTRACELLULAR CALCIU, P163; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; MATSUOKA K, 1988, SCIENCE, V239, P640; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; PALMER FBSC, 1981, J LIPID RES, V22, P1296; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V128, P331, DOI 10.1016/0006-291X(85)91683-3; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; Shoeman RL, 1990, INTRACELLULAR CALCIU, P191; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SIMAN R, 1990, J NEUROSCI, V10, P2400; SIMAN R, 1990, FID RES FDN, V4, P145; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TYSNES OB, 1988, EUR J BIOCHEM, V177, P219, DOI 10.1111/j.1432-1033.1988.tb14365.x; WANG CY, 1988, BIOCHEMISTRY-US, V27, P1254, DOI 10.1021/bi00404a027; WANG CY, 1987, J BIOL CHEM, V262, P14716; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	67	216	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24585	24590						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332961				2022-12-27	WOS:A1992KA26300066
J	WU, QY; TSIANG, M; SADLER, JE				WU, QY; TSIANG, M; SADLER, JE			LOCALIZATION OF THE SINGLE-STRANDED-DNA BINDING-SITE IN THE THROMBIN ANION-BINDING EXOSITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HEPARIN COFACTOR-II; PROTEIN-C; BLOOD-COAGULATION; ANTICOAGULANT ACTIVITY; HUMAN THROMBOMODULIN; CRYSTAL-STRUCTURE; LYSYL RESIDUES; HIRUDIN; ACTIVATION	Single-stranded DNA molecules containing a 15-nucleotide consensus sequence have been reported to inhibit thrombin activity. The mechanism of the inhibition was studied using a consensus 15-mer oligonucleotide and two recombinant mutant thrombins: the anion-binding exosite mutant thrombin R70E, and thrombin K154A, in which the mutation was located in a surface loop outside of the exosite. The consensus 15-mer oligonucleotide inhibited both fibrinogen-clotting and platelet-activation activities of plasma-derived thrombin, recombinant wild type thrombin, and mutant thrombin K154A in a sequence-specific and dose-dependent manner, whereas it did not inhibit either activity of mutant thrombin R70E. The 15-mer oligonucleotide also inhibited thrombomodulin-dependent protein C activation by plasma-derived thrombin. In competition equilibrium binding experiments, binding of I-125-labeled diisopropyl phosphoryl-thrombin to thrombomodulin was completely inhibited by the consensus 15-mer oligonucleotide with a K(d) value of 2.68 +/- 0.16 nM. These results suggest that Arg-70 in the anion-binding exosite of thrombin is a key determinant for interaction with specific single-stranded DNA molecules, and that binding of single-stranded DNA molecules to the exosite prevents the interaction of thrombin with fibrinogen, the platelet thrombin receptor, and thrombomodulin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	WU, QY (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED, HOWARD HUGHES MED INST,660 S EUCLID AVE, BOX 8022, ST LOUIS, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X; Wu, Qingyu/0000-0003-0561-9315	NHLBI NIH HHS [HLBI14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baenziger N L, 1974, Methods Enzymol, V31, P149; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; DITTMAN WA, 1990, BLOOD, V75, P329; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; MANN KG, 1990, BLOOD, V76, P1; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; NOE G, 1988, J BIOL CHEM, V263, P11729; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SHEEHAN JP, 1991, BLOOD S, V78, pA277; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1992, J BIOL CHEM, V267, P7083; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	41	73	74	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24408	24412						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332957				2022-12-27	WOS:A1992KA26300043
J	HAHN, TJ; GOOCHEE, CF				HAHN, TJ; GOOCHEE, CF			GROWTH-ASSOCIATED GLYCOSYLATION OF TRANSFERRIN SECRETED BY HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM TRANSFERRIN; HAMSTER-KIDNEY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGLUCOSAMINYLTRANSFERASE-V; CONCANAVALIN-A-SEPHAROSE; TRANSFORMED-CELLS; DEPENDENT CHANGES; SUGAR CHAINS; OVARY CELLS; GLYCOPEPTIDES	Growth-associated alterations in the oligosaccharide structures of transferrin secreted by HepG2 cells were examined by concanavalin A-crossed affinoimmunoelectrophoresis. Slowly dividing, confluent cultures produced transferrin with a approximately 4.5-fold greater proportion of biantennary complex-type oligosaccharides than rapidly dividing, subconfluent cultures. The activity of N-acetylglucosaminyltransferase V (GlcNAc-T V) and galactosyltransferase were measured in cell extracts from subconfluent and confluent cultures. While the activity of galactosyltransferare remained relatively constant, the activity of GIcNAc-T V was approximately 3.2-fold lower in confluent cultures than in subconfluent cultures. These results suggest that the growth-associated alteration in the oligosaccharides of transferrin is due, at least in part, to the regulation of GlcNAc-T V activity.	STANFORD UNIV, DEPT CHEM ENGN, STAUFFER BLDG 3, STANFORD, CA 94305 USA	Stanford University								BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BATES GW, 1967, J BIOL CHEM, V242, P2810; BUCK CA, 1971, BIOCHEMISTRY-US, V10, P2176, DOI 10.1021/bi00787a034; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; BUCK CA, 1970, BIOCHEMISTRY-US, V9, P4567, DOI 10.1021/bi00825a016; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; CECCARINI C, 1975, P NATL ACAD SCI USA, V72, P3139, DOI 10.1073/pnas.72.8.3139; CECCARINI C, 1975, P NATL ACAD SCI USA, V72, P2687, DOI 10.1073/pnas.72.7.2687; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; Freshney R. I., 1987, CULTURE ANIMAL CELLS, P137; GREEN ED, 1988, J BIOL CHEM, V263, P25; HAHN TJ, 1991, ANAL BIOCHEM, V199, P243, DOI 10.1016/0003-2697(91)90097-D; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HEEGAARD NHH, 1989, ELECTROPHORESIS, V10, P836, DOI 10.1002/elps.1150101207; IBER H, 1990, EUR J CELL BIOL, V52, P236; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; LO JT, 1979, J BIOL CHEM, V254, P6710; MACDONALD DJ, 1978, CLIN CHIM ACTA, V87, P367, DOI 10.1016/0009-8981(78)90180-8; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MATLIN KS, 1988, J BIOL CHEM, V263, P11478; MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MONTREUIL J, 1975, PROTEINS IRON STORAG, P27; MURAMATSU T, 1973, J MOL BIOL, V80, P781, DOI 10.1016/0022-2836(73)90210-6; MUSGROVE E, 1987, EXP CELL RES, V172, P65, DOI 10.1016/0014-4827(87)90093-0; NILSSON LA, 1983, SCAND J IMMUNOL S, V10, P57; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OGATA SI, 1976, NATURE, V259, P580, DOI 10.1038/259580a0; ONEIL P, 1983, ADV ENG MATH, P1054; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PAUL B, 1984, CARBOHYD RES, V126, P27, DOI 10.1016/0008-6215(84)85124-1; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PIERCE M, 1986, J BIOL CHEM, V261, P772; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; POTVIN B, 1990, J BIOL CHEM, V265, P1615; SALIER JP, 1980, ELECTROPHORESIS, V1, P193; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; WARREN L, 1972, NATURE, V235, P276, DOI 10.1038/235275a0; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; YAKIN HM, 1982, ELECTROPHORESIS, V3, P244, DOI 10.1002/elps.1150030503; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	53	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23982	23987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331106				2022-12-27	WOS:A1992JZ23900082
J	MISHIMA, K; PRICE, SR; NIGHTINGALE, MS; KOUSVELARI, E; MOSS, J; VAUGHAN, M				MISHIMA, K; PRICE, SR; NIGHTINGALE, MS; KOUSVELARI, E; MOSS, J; VAUGHAN, M			REGULATION OF ADP-RIBOSYLATION FACTOR (ARF) EXPRESSION - CROSS-SPECIES CONSERVATION OF THE DEVELOPMENTAL AND TISSUE-SPECIFIC ALTERNATIVE POLYADENYLATION OF ARF-4 MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-BINDING-PROTEINS; AMINO-ACID SEQUENCE; CHOLERA-TOXIN; MOLECULAR-CLONING; HUMAN TESTIS; ADENYLATE-CYCLASE; CDNA STRUCTURE; CODING REGION; BOVINE BRAIN	ADP-ribosylation factors (ARFs), approximately 20-kDa guanine nucleotide-binding proteins, are involved in protein trafficking and enhance cholera toxin ADP-ribosyltransferase activity. Expression of six ARF genes was examined in mammalian tissues; only ARF 4 mRNA was detected in rat testis in forms considerably shorter than those in other tissues. Testis-specific expression of short forms of ARF 4 mRNA was observed in several mammalian species. On Northern analysis of the developmental expression of rat ARF 4 mRNA, appearance of the shorter species was consistent with its involvement in a late stage of spermatogenesis. Sequences of products of rapid amplification of cDNA ends (RACE-polymerase chain reaction) of rat ARF 4 mRNA revealed that different mRNAs resulted from the use of three polyadenylation signals, one AUUAAA and two AAUAAA. Sequences of 3'-untranslated regions of rat and human ARF 4 mRNA were very similar with identical polyadenylation signals at similar positions. Of the ARF 4 mRNAs identified by RACE-PCR, with sizes of 1.1, 1.3, and 1.8 kb, the 1.1-kb mRNA was predominant in adult testis. By in situ hybridization, the 1.1-kb mRNA was identified primarily in mature sperm, consistent with the developmental studies. Shorter mRNAs, thought to be more stable, may compensate for cessation of transcription at late stages of spermatogenesis.	NIDR, PATIENT CARE BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	MISHIMA, K (corresponding author), NHLBI, CELLULAR METAB LAB, BETHESDA, MD 20892 USA.							BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BRAUN RE, 1990, ENZYME, V44, P120, DOI 10.1159/000468752; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE KD, 1986, J BIOL CHEM, V261, P7178; Cooper TG, 1986, EPIDIDYMIS SPERM MAT; de Kretser D.M., 1988, P837; DOBNER PR, 1987, NUCLEIC ACIDS RES, V15, P199, DOI 10.1093/nar/15.1.199; DOUGLASS J, 1991, ANN NY ACAD SCI, V637, P384, DOI 10.1111/j.1749-6632.1991.tb27324.x; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P337; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HENNIG B, 1975, EUR J BIOCHEM, V55, P167, DOI 10.1111/j.1432-1033.1975.tb02149.x; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIERSZENBAUM AL, 1975, J CELL BIOL, V65, P258, DOI 10.1083/jcb.65.2.258; KITAGAWA Y, 1990, BIOCHEM BIOPH RES CO, V171, P230, DOI 10.1016/0006-291X(90)91381-2; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; OYEN O, 1988, FEBS LETT, V229, P391, DOI 10.1016/0014-5793(88)81163-3; PENG Z, 1989, Biofactors, V2, P45; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERBANY AA, 1987, DNA-J MOLEC CELL BIO, V6, P267, DOI 10.1089/dna.1987.6.267; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SODERSTROM KO, 1976, MOL CELL ENDOCRINOL, V5, P181, DOI 10.1016/0303-7207(76)90082-4; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1991, BIOCHEMISTRY-US, V30, P3697, DOI 10.1021/bi00229a015; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	59	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24109	24116						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358888				2022-12-27	WOS:A1992JZ23900102
J	FOUFELLE, F; GOUHOT, B; PEGORIER, JP; PERDEREAU, D; GIRARD, J; FERRE, P				FOUFELLE, F; GOUHOT, B; PEGORIER, JP; PERDEREAU, D; GIRARD, J; FERRE, P			GLUCOSE STIMULATION OF LIPOGENIC ENZYME GENE-EXPRESSION IN CULTURED WHITE ADIPOSE-TISSUE - A ROLE FOR GLUCOSE-6-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYL-COA CARBOXYLASE; FATTY-ACID SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PYRUVATE-KINASE GENE; RAT HEPATOCYTES; MESSENGER-RNA; DEPENDENT INDUCTION; POSTTRANSCRIPTIONAL REGULATION; INSULIN; LIVER	The expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) is low in the adipose tissue of suckling rats and increases markedly at weaning to a high carbohydrate diet. We have studied in vitro the factors regulating this phenomenon. Inguinal adipose tissue pieces from 19-day-old suckling rats were cultured for 6 or 24 h in minimal essential medium. Insulin (100 nM) added in the presence of lactate and pyruvate did not stimulate the expression of FAS and ACC. Glucose (20 mM) alone resulted in a 5-7-fold increase of FAS and ACC mRNA. Insulin potentiated the effect of glucose. 3-O-Methylglucose, a glucose analog that is transported into the cell but not metabolized, had no effect on FAS and ACC mRNA accumulation. However, 2-deoxyglucose (1 mM), a glucose analog which is phosphorylated to 2-deoxyglucose 6-phosphate, stimulated the expression of FAS and ACC to the same extent as 20 mM glucose. Glucose 6-phosphate concentrations in adipose tissue pieces cultured in various conditions changed in parallel with the FAS and ACC mRNA levels. We conclude that glucose 6-phosphate could be the metabolite involved in the stimulation of lipogenic enzyme gene expression in response to glucose.	HOP ST VINCENT DE PAUL,INSERM,U342,82 AV DENFERT ROCHEREAU,F-75674 PARIS 14,FRANCE; CNRS,CTR RECH ENDOCRINOL MOLEC & DEV,F-92190 MEUDON,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)			Ferré, Pascal/K-1250-2013	Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; GIFFHORN S, 1984, BIOCHEM J, V221, P343, DOI 10.1042/bj2210343; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; Girard J., 1977, GLUCAGON ITS ROLE PH, P563, DOI DOI 10.1007/978-1-4612-6366-1-36; GOODRIDGE AG, 1986, FASEB J, V45, P2399; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KATZ NR, 1983, BIOCHEM J, V212, P65, DOI 10.1042/bj2120065; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LETURQUE A, 1991, AM J PHYSIOL, V260, pE588, DOI 10.1152/ajpendo.1991.260.4.E588; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1983, METABOLISM, V33, P545; MEYER S, 1991, EUR J BIOCHEM, V202, P985, DOI 10.1111/j.1432-1033.1991.tb16460.x; MEYUHAS O, 1976, BIOCHEM J, V158, P9, DOI 10.1042/bj1580009; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; NEPOKROEFF CM, 1984, EUR J BIOCHEM, V140, P441, DOI 10.1111/j.1432-1033.1984.tb08122.x; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Romsos D R, 1974, Adv Lipid Res, V12, P97; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; SPENCE JT, 1985, BIOCHEM J, V227, P939, DOI 10.1042/bj2270939; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; TSUJIKAWA M, 1980, J NUTR SCI VITAMINOL, V26, P367, DOI 10.3177/jnsv.26.367; VERNON RG, 1981, BIOCHEM J, V200, P307, DOI 10.1042/bj2000307; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	36	168	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20543	20546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356982				2022-12-27	WOS:A1992JT97800006
J	HARWERTH, IM; WELS, W; MARTE, BM; HYNES, NE				HARWERTH, IM; WELS, W; MARTE, BM; HYNES, NE			MONOCLONAL-ANTIBODIES AGAINST THE EXTRACELLULAR DOMAIN OF THE ERBB-2 RECEPTOR FUNCTION AS PARTIAL LIGAND AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST CANCER; NEU ONCOGENE PRODUCT; BETA-CASEIN GENE; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; PROTEIN EXPRESSION; C-ERBB-2 PROTEIN; CELL-LINE; KINASE	In this paper we describe the isolation and characterization of four monoclonal antibodies (FRP5, FSP16, FWP51, and FSP77) which specifically recognize the human erbB-2 protein. All of the antibodies recognize epitopes on the extracellular domain of the receptor protein. FRP5 and FSP16 compete with one another for binding while FWP51 and FSP77 each recognize a different epitope. The effects of the antibodies on the erbB-2 receptor protein have been analyzed. Two different erbB-2-expressing cell lines, SKBR3 breast tumor cells and HC11 R111 cells, were examined. The SKBR3 cells express approximately 1 x 10(6) molecules of the erbB-2 protein/cell; HC11 R111 cells, a clone of mouse mammary epithelial cells derived by transfection of a human erbB-2 expression plasmid, contain 10-fold less erbB-2 protein than the SKBR3 cells. Treatment of the two cell lines with FRP5, FSP16, and FWP51 led to a rapid increase in the phosphotyrosine content of the erbB-2 protein. Three of the antibodies, FRP5, FSP16, and FSP77, stimulated the turnover of the erbB-2 protein. Binding of the antibodies did not stimulate DNA synthesis in HC11 R111 cells. Thus, the erbB-2-specific monoclonal antibodies behave as partial ligand agonists. The antibodies were examined for their effects upon the growth of SKBR3 and HC11 R111 cells. The growth of SKBR3 cells was inhibited by 90% following long term treatment of the cells with FSP77.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Wels, Winfried/0000-0001-9858-3643				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BERGER MS, 1988, CANCER RES, V48, P1238; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DREBIN JA, 1988, ONCOGENE, V2, P387; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FERNANDEZPOL JA, 1985, J BIOL CHEM, V260, P5003; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HARLOW E, 1988, ANTIBODIES LABORATOR, P330; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOEHLER G, 1975, NATURE, V256, P495; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LANGTON BC, 1991, CANCER RES, V51, P2593; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATO JD, 1987, METHOD ENZYMOL, V146, P63; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; VARLEY JM, 1987, ONCOGENE, V1, P423; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	51	120	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15160	15167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353079				2022-12-27	WOS:A1992JF08800096
J	MENETSKI, JP; VARGHESE, A; KOWALCZYKOWSKI, SC				MENETSKI, JP; VARGHESE, A; KOWALCZYKOWSKI, SC			THE PHYSICAL AND ENZYMATIC-PROPERTIES OF ESCHERICHIA-COLI RECA PROTEIN DISPLAY ANION-SPECIFIC INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POTASSIUM GLUTAMATE; NUCLEIC-ACIDS; BINDING; POLYNUCLEOTIDE; BACTERIA; EXCHANGE; LIGANDS; INVITRO; ATPASE	The enzymatic activities of Escherichia coli recA protein are sensitive to ionic composition. Here we report that sodium glutamate (NaGlu) is much less inhibitory to the DNA strand exchange, DNA-dependent ATPase, and DNA binding activities of the recA protein than is NaCl. Both joint molecule formation and complete exchange of DNA strands occur (albeit at reduced rates) at NaGlu concentrations as high as 0.5 M whereas concentrations of NaCl greater than 0.2 M are sufficient for complete inhibition. The single-stranded DNA (ssDNA)-dependent ATPase activity is even less sensitive to inhibition by NaGlu; ATP hydrolysis stimulated by M13 ssDNA is unaffected by 0.5 M NaGlu and is further stimulated by E. coli ssDNA binding protein approximately 2-fold. Finally, NaGlu has essentially no effect on the stability of recA protein-epsilon-M13 DNA complexes, with concentrations of NaGlu as high as 1.5 m failing to dissociate the complexes. Surprisingly, NaGlu also has little effect on the concentration of NaCl required to disrupt the recA protein-epsilon-EM13 DNA complex, demonstrating that destabilization is dependent on both the concentration and type of anionic rather than cationic species. Quantitative analysis of DNA binding isotherms establishes that the intrinsic binding affinity of recA protein is affected by the anionic species present and that the cooperativity parameter is relatively unaffected. Consequently, the sensitivity of recA protein-ssDNA complexes to disruption by NaCl does not result from the competitive effects associated with cation displacement from the ssDNA upon protein binding but rather results from anion displacement upon complex formation. The magnitude of this anion-specific effect on ssDNA binding is large relative to that of other nucleic acid binding proteins.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611; UNIV CALIF DAVIS,DIV BIOL SCI,MICROBIOL SECT,DAVIS,CA 95616	Northwestern University; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN D, V1, P244; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEBOWITZ JH, 1985, THESIS J HOPKINS U; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; PUGH BF, 1988, J BIOL CHEM, V263, P76; Record M T Jr, 1985, Adv Biophys, V20, P109; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	32	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10400	10404						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350278				2022-12-27	WOS:A1992HV09000033
J	BANGS, JD; CRAIN, PF; HASHIZUME, T; MCCLOSKEY, JA; BOOTHROYD, JC				BANGS, JD; CRAIN, PF; HASHIZUME, T; MCCLOSKEY, JA; BOOTHROYD, JC			MASS-SPECTROMETRY OF MESSENGER-RNA CAP-4 FROM TRYPANOSOMATIDS REVEALS 2 NOVEL NUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; DISCONTINUOUS TRANSCRIPTION; LIQUID-CHROMATOGRAPHY; SPLICED LEADER; BRUCEI; DERIVATIVES; CONTAINS; SEQUENCE; DNA	Synthesis of mRNA in kinetoplastid protozoa involves the process of trans-splicing, in which an identical 39-41-nucleotide (depending on the species) mini-exon is placed at the 5' end of mature mRNAs. The mini-exon sequence is highly conserved among all members of the Kinetoplastida, nucleotides 1-6 being identical in the four genera so far examined. Prior to trans-splicing, the mini-exon donor RNA is capped by the addition of a (5'-5') triphosphate-linked 7-methylguanosine, followed by modification of the first four transcribed nucleotides. Partial structures have been Previously deduced for this cap 4 moiety from Trypanosoma brucei and Leptomonas collosoma. We have Purified enough cap 4 from T. brucei and Crithidia fasciculata to allow definitive structural analysis by combined liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry. The results, together with the known mini-exon sequence, show that cap 4 in both species has the structure m7G(5')ppp(5')m2(6)AmpAmpCmpm3Ump. The presence of N6,N6,2'-O-trimethyladenosine and 3,2'-O-dimethyluridine, nucleosides previously unknown in nature, were confirmed by rigorous comparison with synthetic standards. The conservation of cap 4 between these divergent genera suggests that this structure may be common to most if not all Kinetoplastida.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Stanford University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Boothroyd, John C./0000-0001-9719-745X	NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [2T32CA09302-13] Funding Source: Medline; NIAID NIH HHS [AI21025] Funding Source: Medline; NIGMS NIH HHS [GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1990, TETRAHEDRON LETT, V31, P5507, DOI 10.1016/S0040-4039(00)97884-5; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BJORK GR, 1984, PROCESSING RNA, P291; BOOTHROYD JC, 1989, NUCL ACIDS MOL BIOL, V3, P216; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CORDINGLEY JS, 1980, MOL BIOCHEM PARASIT, V1, P91, DOI 10.1016/0166-6851(80)90003-1; CRAIN PF, 1983, ANAL BIOCHEM, V132, P124, DOI 10.1016/0003-2697(83)90434-7; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DUNN DB, 1975, HDB BIOCH MOL BIOL, P127; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; GABRIEL A, 1987, J BIOL CHEM, V262, P16192; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, pA3; GREENBERG JR, 1988, NUCLEIC ACIDS RES, V16, P3437, DOI 10.1093/nar/16.8.3437; HALL R, 1971, MODIFIED NUCLEOSIDES, P96; HALL RH, 1971, MODIFIED NUCLEOSIDES, P160; HOLMES JL, 1985, ORG MASS SPECTROM, V20, P169, DOI 10.1002/oms.1210200302; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Maniatis T, 1989, DECONTAMINATION DILU; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P825, DOI 10.1016/0076-6879(90)93453-R; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P771, DOI 10.1016/0076-6879(90)93449-U; MCCLOSKEY JA, 1974, BASIC PRINCIPLES NUC, V1, pCH3; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MUHICH ML, 1987, NUCLEIC ACIDS RES, V15, P3141, DOI 10.1093/nar/15.7.3141; PANG H, 1982, J ORG CHEM, V47, P3923, DOI 10.1021/jo00141a023; PANG H, 1982, J ORG CHEM S, V47; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; ROTTMAN FM, 1978, INT REV BIOCH BIOCH, V17, P45; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TAKEDA N, 1991, J CHROMATOGR-BIOMED, V562, P225, DOI 10.1016/0378-4347(91)80580-6; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VESTAL ML, 1990, METHOD ENZYMOL, V193, P107, DOI 10.1016/0076-6879(90)93413-F; VONMINDEN DL, 1974, J ORG CHEM, V39, P285; WAGNER D, 1974, J ORG CHEM, V39, P24, DOI 10.1021/jo00915a005	42	151	154	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9805	9815						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1349605				2022-12-27	WOS:A1992HT96500058
J	BERSTEIN, G; BLANK, JL; SMRCKA, AV; HIGASHIJIMA, T; STERNWEIS, PC; EXTON, JH; ROSS, EM				BERSTEIN, G; BLANK, JL; SMRCKA, AV; HIGASHIJIMA, T; STERNWEIS, PC; EXTON, JH; ROSS, EM			RECONSTITUTION OF AGONIST-STIMULATED PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS USING PURIFIED M1 MUSCARINIC RECEPTOR, GQ/11, AND PHOSPHOLIPASE C-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE ACTIVITY; REGULATORY COMPONENT; G-PROTEIN; ALPHA-SUBUNITS; BOVINE BRAIN; ACETYLCHOLINE-RECEPTOR; GTPASE ACTIVITY; PURIFICATION	We describe the reconstitution using purified proteins of the m1 muscarinic cholinergic pathway that activates phosphatidylinositol 4,5-bisphosphate-specific phospholipase C via the G protein G(q/11). Recombinant m1 muscarinic receptor was co-reconstituted in lipid vesicles with either hepatic G(q/11) or with cerebral alpha(q/11) and beta-gamma-subunits. The rate of [S-35]GTP-gamma-S binding to the reconstituted vesicles was stimulated 20-50-fold by agonist. Maximal receptor-catalyzed binding was 7 mol of GTP-gamma-S bound per mol of receptor. The m2 muscarinic receptor was a poor activator of G(q/11). The binding of [alpha-P-32]GTP and [gamma-P-32]GTP to m1/G(q/11) vesicles indicated that the receptor could maintain up to 40% of the total coupled G(q/11) in the GTP bound state. The rate of hydrolysis of bound GTP, 0.8 min-1, is consistent with the rate predicted from the GTP binding data but is 3-5-fold lower than rates reported for other trimeric G proteins. Agonist-stimulated photoaffinity labeling with gamma-(4-azidoanilido)-[alpha-P-32]GTP indicated that the receptor catalyzed binding to both alpha(q) and alpha-11 with about equal efficiency. Receptor-catalyzed activation of G(q/11) by GTP-gamma-S, measured as the ability to activate purified phospholipase C-beta-1, paralleled receptor-catalyzed [S-35]GTP-gamma-S binding. Co-reconstitution of receptor, G(q/11), and phospholipase C-beta-1 restored GTP-gamma-S-dependent carbachol-stimulated hydrolysis of phosphatidylinositol 4,5-bisphosphate. The m1 receptor, G(q/11), and phospholipase C-beta-1 are thus sufficient to initiate the hormonal inositol trisphosphate/diacylglycerol signaling pathway without additional proteins.	UNIV TEXAS, SW MED CTR, SW GRAD SCH BIOMED SCI, DEPT PHARMACOL, DALLAS, TX 75235 USA; VANDERBILT UNIV, MED CTR,SCH MED,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Vanderbilt University					FOGARTY INTERNATIONAL CENTER [F05TW004475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, F32GM014489] Funding Source: NIH RePORTER; FIC NIH HHS [F05-TW04475] Funding Source: Medline; NIGMS NIH HHS [S32-GM14489, R01-GM30355] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1984, J BIOL CHEM, V259, P9351; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERSTEIN G, 1990, CURRENT ASPECTS NEUR, V1, P245; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUJO H, 1988, FEBS LETT, V240, P95, DOI 10.1016/0014-5793(88)80346-6; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CERIONE RA, 1986, J BIOL CHEM, V261, P9514; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLEMING JW, 1980, J CYCLIC NUCL PROT, V6, P407; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAGA K, 1985, J BIOL CHEM, V260, P7927; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MAY DC, 1985, J BIOL CHEM, V260, P5829; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; THOMAS R, 1991, METHOD ENZYMOL, V195, P280; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	58	291	293	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8081	8088						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1341877				2022-12-27	WOS:A1992HQ18500021
J	ALAM, T; AN, MR; PAPACONSTANTINOU, J				ALAM, T; AN, MR; PAPACONSTANTINOU, J			DIFFERENTIAL EXPRESSION OF 3 C/EBP ISOFORMS IN MULTIPLE TISSUES DURING THE ACUTE PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENHANCER-BINDING-PROTEIN; SERUM-ALBUMIN GENE; HEPATOMA-CELLS; RAT-LIVER; TRANSCRIPTIONAL REGULATION; ANGIOTENSINOGEN GENE; LEUCINE ZIPPER; FAMILY; GLUCOCORTICOIDS; TRANSACTIVATION	Eucaryotic organisms possess natural defense processes triggered by stress factors such as injury, infection, and inflammation. The acute phase response is an early defense mechanism during which striking changes in protein synthesis occur in the liver and other tissues. The altered expression of many acute phase protein genes is at the transcriptional level. Some of these genes have DNA binding sites for the CCAAT/enhancer binding protein (C/EBP) family of transcription factors. We report here that in vivo expression of three isoforms of C/EBP is dramatically changed during the acute phase response. The steady-state mRNA levels of C/EBP-alpha decreased significantly in the liver, lung, and fat tissues of lipopolysaccharide (LPS)-treated mice; moreover, nuclear run-off transcription assays indicated a decrease in the rate of C/EBP-alpha gene transcription in isolated liver nuclei. The steady-state levels of C/EBP-beta and a new isoform, C/EBP-delta, were dramatically increased in many tissues within 4 h following LPS treatment. The rates of transcription of these two genes were only minimally altered in liver but significantly increased in kidney nuclei isolated from stimulated animals. Thus, the C/EBP isoforms exhibit differential mechanisms in their responses to LPS in various tissues and are likely to play an important role in mediating the transcriptional activation of genes involved in the acute phase response.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,613 BASIC SCI BLDG,RT F-43,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, IN PRESS BIOCHEMISTR; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTER KC, 1989, J BIOL CHEM, V264, P4112; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EVERS BM, 1991, SURGERY, V110, P247; FEY G, 1990, PROGR LIVER DIS, P89; FEY GH, 1987, MOL BIOL MED, V4, P323; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOJ A, 1974, STRUCTURE FUNCTION P, V1, P73; KOJ A, 1985, ACUTE PHASE RESPONSE, P00145; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T, 1982, MOL CLONING LABORATO; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NORTHEMANN W, 1989, BIOCHEMISTRY-US, V28, P84, DOI 10.1021/bi00427a013; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SCHREIBER G, 1987, PLASMA PROTEINS STRU, V5, P293; THOMAS T, 1989, J BIOL CHEM, V264, P5784; THOMPSON WL, 1976, BIOCHEM J, V156, P25, DOI 10.1042/bj1560025; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	38	289	290	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5021	5024						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371993				2022-12-27	WOS:A1992HH74700002
J	HUANG, MM; INDIK, Z; BRASS, LF; HOXIE, JA; SCHREIBER, AD; BRUGGE, JS				HUANG, MM; INDIK, Z; BRASS, LF; HOXIE, JA; SCHREIBER, AD; BRUGGE, JS			ACTIVATION OF FC-GAMMA-RII INDUCES TYROSINE PHOSPHORYLATION OF MULTIPLE PROTEINS INCLUDING FC-GAMMA-RII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN-PLATELETS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; GLYCOPROTEIN-IIB; IMMUNOGLOBULIN-G; EXPRESSION; THROMBIN; KINASE; CLONING	Platelets provide a useful system for studying Fc-gamma receptor-mediated signaling events because these cells express only a single class of Fc-gamma receptors and because platelet aggregation and secretion can be activated through Fc-gamma receptor stimulation. We report here that stimulation of platelets by cross-linking antibodies to Fc-gamma-RII or by treatment with an anti-CD9 monoclonal antibody, which acts through Fc-gamma-RII, causes an induction of tyrosine phosphorylation of multiple platelet proteins. Although the profile of tyrosine-phosphorylated proteins induced by stimulation of this Fc receptor was similar to that induced by thrombin, an additional 40-kDa phosphorylated protein was also detected. This protein co-migrated with Fc-gamma-RII and was immunoprecipitated with a monoclonal antibody to Fc-gamma-RII. In addition, after the cross-linking of Fc-gamma-RII in HEL cells or in COS-1 cells transfected with Fc-gamma-RII cDNA, the 40-kDa protein immunoprecipitated with anti-Fc-gamma-RII was also phosphorylated on tyrosine. These data strongly suggest that Fc-gamma-RII itself is a substrate for a tyrosine kinase(s) activated when Fc-gamma-RII is stimulated. Fc-gamma-RII was phosphorylated by the Src protein in vitro, suggesting that this kinase may be responsible for phosphorylation of Fc-gamma-RII in vivo. These studies establish that activation of platelets and human erythroleukemia cells through Fc-gamma-RII and CD9 involves an induction of tyrosine phosphorylation of multiple proteins including Fc-gamma-RII itself and suggest that these phosphorylation events may be involved in Fc-gamma-RII-mediated cell signaling.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA27951] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NIAID NIH HHS [AI22193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027951, R01CA027951] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON GP, 1990, BLOOD, V76, P1165; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014-5793(83)81027-8; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRASS LF, 1991, J BIOL CHEM, V266, P958; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EISENMAN E, 1992, IN PRESS NATURE; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3606; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GORMAN DJ, 1985, NOUV REV FR HEMATOL, V27, P255; HENSON PM, 1973, J CLIN INVEST, V52, P1282, DOI 10.1172/JCI107296; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HORSEWOOD P, 1991, BLOOD, V78, P1019; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; ISRAELS ED, 1973, THROMB DIATH HAEMOST, V29, P434; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KARAS SP, 1982, BLOOD, V60, P1277; KELTON JG, 1988, BLOOD, V72, P925; KELTON JG, 1987, AM J HEMATOL, V25, P299, DOI 10.1002/ajh.2830250310; KING M, 1990, CELL IMMUNOL, V128, P462, DOI 10.1016/0008-8749(90)90041-O; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MODDERMAN PW, 1988, THROMB HAEMOSTASIS, V60, P68; MOREL MC, 1989, BRIT J HAEMATOL, V71, P57, DOI 10.1111/j.1365-2141.1989.tb06275.x; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PAOLINI R, 1992, IN PRESS NATURE; RAPPAPORT EF, 1991, CLIN RES, V39, P151; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RENDU F, 1987, BIOCHEM BIOPH RES CO, V146, P1397, DOI 10.1016/0006-291X(87)90805-9; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIVIER E, 1991, J IMMUNOL, V146, P206; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x	51	185	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5467	5473						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372004				2022-12-27	WOS:A1992HH74700071
J	ADAN, RAH; COX, JJ; VANKATS, JP; BURBACH, JPH				ADAN, RAH; COX, JJ; VANKATS, JP; BURBACH, JPH			THYROID-HORMONE REGULATES THE OXYTOCIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; CANCER CELL-LINE; VASOPRESSIN GENE; RESPONSE ELEMENT; MESSENGER-RNA; EXPRESSION; RAT; PROMOTER; IDENTIFICATION; LACTATION	Endocrine factors involved in the transcriptional regulation of the oxytocin (OT) gene were investigated in heterologous expression systems. Plasmids having a 5'-flanking region of the rat OT gene (-363/+16) or the human OT gene (-382/+41) cloned in front of the firefly luciferase gene were co-transfected with an expression vector for the rat thyroid hormone receptor-alpha in P19 embryonal carcinoma (EC) cells. Thyroid hormone (T3) stimulated the activity of the rat and human OT promoters about 10-fold. In MCF-7 breast tumor cells transfected with the human OT promoter-luciferase fusion gene, T3 stimulation through endogenous thyroid hormone receptors was about 5-fold. Co-transfection experiments in P19EC cells using 5' deletion mutants of the rat OT gene showed that thyroid hormone responsiveness was located in two regions, one located between nucleotides -195 and -172, the other between nucleotides -172 and -148. Each region accounted for about 3-fold T3 stimulation. Gel retardation analysis using extracts from HeLa cells overproducing the c-erbA/TR-alpha protein showed specific binding to the -172/-148 element, while no binding occurred on the -195/-172 element. The -172/-148 element which contains the imperfect estrogen response element, GGTGACCTTGACC, has inverted as well as direct repeats of the TGACC motif. Mutagenesis of TGACC motifs separately reduced thyroid hormone responsiveness by about 50%. However, simultaneous mutation of two TGACC motifs abolished the responsiveness to T3 completely. There was no cooperativity between the activated thyroid hormone and estrogen receptors in transfected MCF-7 cells nor in thyroid hormone receptor and estrogen receptor co-transfected P19EC cells. Negative interactions between these two receptors were observed and gel retardation assays showed interaction between the two receptors proteins. It was shown in an in vivo experiment that treatment of rats with thyroid hormone increased hypothalamic OT mRNA levels, the pituitary OT content, as well as OT levels in blood. The results reveal thyroid hormone as a physiological regulator of OT gene expression, which stimulates OT promoter activity directly through interaction with a thyroid hormone-response element in the OT gene.	UNIV UTRECHT, FAC MED,DEPT PHARMACOL,RUDOLF MAGNUS INST, VONDELLAAN 6, 3521 GD UTRECHT, NETHERLANDS	Utrecht University			van Kats, Jorge/A-8284-2008					ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ALMAZAN G, 1989, DEV BRAIN RES, V45, P69, DOI 10.1016/0165-3806(89)90008-4; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURBACH JPH, 1990, J NEUROENDOCRINOL, V2, P633; BURBACH JPH, 1989, METHOD ENZYMOL, V168, P385; DALMAN FC, 1990, J BIOL CHEM, V265, P1615; DAY RN, 1989, MOL ENDOCRINOL, V3, P931, DOI 10.1210/mend-3-6-931; DELEAUNOIT Y, 1989, IN VITRO CELL DEV, V25, P585; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6882; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUCHS AR, 1986, OXYTOCIN CLIN LABORA, P207; FUKUDA T, 1988, ENDOCRINOLOGY, V123, P2646, DOI 10.1210/endo-123-6-2646; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RICHARD S, 1990, J BIOL CHEM, V265, P6098; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554, DOI 10.1210/endo-119-2-554; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SOLOFF MS, 1985, OXYTOCIN CLIN LABORA, P259; TALANTI S, 1972, LIFE SCI, V11, P49, DOI 10.1016/0024-3205(72)90162-2; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDEHEIJNING BJM, 1991, J NEUROENDOCRINOL, V3, P57, DOI 10.1111/j.1365-2826.1991.tb00239.x; VANTOL HHM, 1988, MOL BRAIN RES, V4, P303, DOI 10.1016/0169-328X(88)90039-3; VANTOL HHM, 1987, ENDOCRINOLOGY, V120, P71, DOI 10.1210/endo-120-1-71; VANTOL HHM, 1988, ENDOCRINOLOGY, V122, P945, DOI 10.1210/endo-122-3-945; VANTOL HHM, 1990, NEUROSCI RES COMMUN, V7, P25; VANTOL HHM, 1987, METHOD ENZYMOL, V168, P398; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; ZINGG HH, 1988, MOL BRAIN RES, V4, P1, DOI 10.1016/0169-328X(88)90011-3	48	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3771	3777						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371278				2022-12-27	WOS:A1992HE60700037
J	KIM, YK; LEE, AS				KIM, YK; LEE, AS			IDENTIFICATION OF A PROTEIN-BINDING SITE IN THE PROMOTER OF THE HUMAN THYMIDINE KINASE GENE REQUIRED FOR THE G1-S-REGULATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; CYCLE; GROWTH	When quiescent cells are stimulated to enter the cell cycle, the thymidine kinase (TK) gene is transcriptionally activated at the border of G1 and S. In this report we show that the human TK promoter contains multiple protein-binding sites. By site-directed mutagenesis, we identified a protein-binding site on the human TK promoter required for conferring G1-S-regulated transcription to a heterologous promoter and dissociated it functionally from an adjacent protein-binding domain containing an inverted CCAAT motif required for high basal level expression. Substitution-mutation of this site results in constitutive expression of the neo reporter gene in serum-stimulated fibroblasts, as well as in cells arrested in mid-G1 by a temperature-sensitive mutation. The regulatory domains for the human TK promoter exhibit interesting symmetrical features, including a set of CCAAT motifs and sites similar to the novel Yi protein-binding site recently discovered in the mouse TK promoter.	UNIV SO CALIF, SCH MED, NORRIS CANC RES INST, LOS ANGELES, CA 90033 USA	University of Southern California	KIM, YK (corresponding author), UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA.			Lee, Amy/0000-0002-0378-5443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCOT SS, 1989, J BIOL CHEM, V264, P2343; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BASERGA R, 1985, BIOL CELL REPRODUCTI, P134; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; ITO M, 1990, J BIOL CHEM, V265, P6954; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MELERO JA, 1978, J CELL PHYSIOL, V95, P295, DOI 10.1002/jcp.1040950307; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUDZINSKI GP, 1989, CELL TISSUE KINET, V22, P405, DOI 10.1111/j.1365-2184.1989.tb00226.x; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; YONG KK, 1988, P NATL ACAD SCI USA, V85, P5894, DOI 10.1073/pnas.85.16.5894	27	42	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2723	2727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370831				2022-12-27	WOS:A1992HB53200092
J	STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J				STRITTMATTER, P; KITTLER, JM; COGHILL, JE; OZOLS, J			CHARACTERIZATION OF LYSYL RESIDUES OF NADH-CYTOCHROME-B5 REDUCTASE IMPLICATED IN CHARGE-PAIRING WITH ACTIVE-SITE CARBOXYL RESIDUES OF CYTOCHROME-B5 BY SITE-DIRECTED MUTAGENESIS OF AN EXPRESSION VECTOR FOR THE FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; LECITHIN LIPOSOMES; B5 REDUCTASE; ACID; PARTICIPATION; DESATURATION; INVOLVEMENT; SEQUENCE; FORM	An expression vector for bovine NADH-cytochrome b5, reductase was constructed from two DNA fragments that were derived from beef liver poly(A+) RNA using the polymerase chain reaction. Site-directed mutagenesis of the 3 lysine residues of the reductase, previously implicated in the formation of active-site charge pairs with carboxylate residues of cytochrome b5, was then used to obtain the purified catalytic domains of flavoproteins modified at each of these sites. The observed marked decreases in catalytic efficiencies of substitutions of a negative charge at the normally positively charged residues with the catalytic domain of cytochrome b5, are consistent with their participation in the formation of charge pairs with carboxylate groups of the hemeprotein to optimize rapid electron transfer from the reductase flavin to the heme of the cytochrome.			STRITTMATTER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015924] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15924] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAILEY HA, 1979, J BIOL CHEM, V254, P5388; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KEYES SR, 1979, J BIOL CHEM, V254, P7778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVERDE A, 1968, J BIOL CHEM, V243, P5779; MATHEWS FS, 1976, ENZYMES BIOL MEMBR, V4, P143; MIKI K, 1987, J BIOL CHEM, V262, P11801; OKAYASU T, 1977, LIPIDS, V12, P267, DOI 10.1007/BF02533345; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; ROGERS MJ, 1975, J BIOL CHEM, V250, P5713; ROGERS MJ, 1973, J BIOL CHEM, V248, P800; ROGERS MJ, 1974, J BIOL CHEM, V249, P895; SALEMME FR, 1976, J MOL BIOL, V102, P563, DOI 10.1016/0022-2836(76)90334-X; Sambrook J, 1989, MOL CLONING, V3; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; SPATZ L, 1973, J BIOL CHEM, V248, P793; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2661; Strittmatter P, 1978, Methods Enzymol, V52, P97; STRITTMATTER P, 1958, J BIOL CHEM, V233, P748; STRITTMATTER P, 1975, P NATL ACAD SCI USA, V72, P2658, DOI 10.1073/pnas.72.7.2658; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; STRITTMATTER P, 1962, J BIOL CHEM, V237, P3250; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1991, J BIOL CHEM, V266, P66	32	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2519	2523						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370824				2022-12-27	WOS:A1992HB53200063
J	MACKIE, GA				MACKIE, GA			SECONDARY STRUCTURE OF THE MESSENGER-RNA FOR RIBOSOMAL-PROTEIN S20 - IMPLICATIONS FOR CLEAVAGE BY RIBONUCLEASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; POLYNUCLEOTIDE PHOSPHORYLASE; PROCESSING ENZYME; SEQUENCE; GENE; STABILIZATION; STABILITY; MUTANTS; DECAY	A synthetic RNA transcript containing the entire sequence of one of the two natural mRNAs for Escherichia richia coli ribosomal protein S20 is a substrate for specific cleavage by an endonuclease which is or depends on ribonuclease E (Mackie, G. A. (1991) J. Bacteriol. 173, 2488-2497). Partial cleavage with ribonucleases T1 or CL3 and limited modification with dimethyl sulfate have been employed to identify residues that are likely to be single stranded in the S20 mRNA's native state. The data show that the 5' one-third of the mRNA is relatively unstructured whereas the 3' one-third is extensively folded. The latter property can account for the previously observed accumulation of a 147-residue product co-terminal with the 3' end of the S20 mRNA (Mackie, G. A. (1989) J. Bacteriol. 171, 4112-4120). Sites of cleavage by the ribonuclease E-dependent activity map to single-stranded regions of the RNA. In addition, denaturation of the RNA substrate results in loss of susceptibility to the ribonuclease E-dependent activity and simultaneous loss of the single-stranded character of the two most prominent cleavage sites. It is proposed that ribonuclease E is a single-strand-specific enzyme with few primary structural constraints but a preference for an AU dinucleotide 3' to the site of cleavage.			MACKIE, GA (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ARRAIANO CM, 1988, J BACTERIOL, V170, P4625, DOI 10.1128/jb.170.10.4625-4633.1988; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRAY PN, 1973, EUR J BIOCHEM, V28, P412; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLMES WM, 1983, CELL, V32, P1029; KING TC, 1986, MICROBIOL REV, V50, P428, DOI 10.1128/MMBR.50.4.428-451.1986; KOKOSKA RJ, 1990, BIOCHIMIE, V72, P803, DOI 10.1016/0300-9084(90)90189-N; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1981, J BIOL CHEM, V256, P8177; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MACKIE GA, 1986, NUCLEIC ACIDS RES, V14, P6965, DOI 10.1093/nar/14.17.6965; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PARSONS GD, 1988, J BACTERIOL, V170, P2485, DOI 10.1128/jb.170.6.2485-2492.1988; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1054	1061						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370457				2022-12-27	WOS:A1992GY96000061
J	RAO, PV; KRISHNA, CM; ZIGLER, JS				RAO, PV; KRISHNA, CM; ZIGLER, JS			IDENTIFICATION AND CHARACTERIZATION OF THE ENZYMATIC-ACTIVITY OF ZETA-CRYSTALLIN FROM GUINEA-PIG LENS - A NOVEL NADPH-QUINONE OXIDOREDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; CARBONYL REDUCTASE; DT-DIAPHORASE; SEMI-QUINONE; PROTEIN; DEHYDROGENASES; EVOLUTION; SYSTEMS; GENE	Zeta-crystallin is a major protein in the lens of certain mammals. In guinea pigs it comprises 10% of the total lens protein, and it has been shown that a mutation in the zeta-crystallin gene is associated with autosomal dominant congenital cataract. As with several other lens crystallins of limited phylogenetic distribution, zeta-crystallin has been characterized as an "enzyme/crystallin" based on its ability to reduce catalytically the electron acceptor 2,6-dichlorophenolindophenol. We report here that certain naturally occurring quinones are good substrates for the enzymatic activity of zeta-crystallin. Among the various quinones tested, the orthoquinones 1,2-naphthoquinone and 9,10-phenanthrenequinone were the best substrates whereas menadione, ubiquinone, 9,10-anthraquinone, vitamins K1 and K2 were inactive as substrates. This quinone reductase activity was NADPH specific and exhibited typical Michaelis-Menten kinetics. Activity was sensitive to heat and sulfhydryl reagents but was very stable on freezing. Dicumarol (K(i) = 1.3 x 10(-5) M) and nitrofurantoin (K(i) = 1.4 x 10(-5) M) inhibited the activity competitively with respect to the electron acceptor, quinone. NADPH protected the enzyme against inactivation caused by heat, N-ethylmaleimide, or H2O2. Electron paramagnetic resonance spectroscopy of the reaction products showed formation of a semiquinone radical. The enzyme activity was associated with O2 consumption, generation of O2- and H2O2, and reduction of ferricytochrome c. These properties indicate that the enzyme acts through a one-electron transfer process. The substrate specificity, reaction characteristics, and physicochemical properties of zeta-crystallin demonstrate that it is an active NADPH:quinone oxidoreductase distinct from quinone reductases described previously.	NEI,MECHANISMS OCULAR DIS LAB,BETHESDA,MD 20892; NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLEN AO, 1952, J PHYS CHEM-US, V56, P576; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENAS NK, 1991, BIOCHIM BIOPHYS ACTA, V1073, P195, DOI 10.1016/0304-4165(91)90201-Q; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Estabrook R W, 1978, Methods Enzymol, V52, P43; Fridovich, 1977, SUPEROXIDE SUPEROXID, P11; GARLAND D, 1991, ARCH BIOCHEM BIOPHYS, V285, P134, DOI 10.1016/0003-9861(91)90339-K; Harding JJ, 1984, EYE B, V1b, P207; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HENDERSON GB, 1988, P NATL ACAD SCI USA, V85, P5374, DOI 10.1073/pnas.85.15.5374; HUANG QL, 1987, CURR EYE RES, V6, P725, DOI 10.3109/02713688709034836; HUANG QL, 1990, EXP EYE RES, V50, P317, DOI 10.1016/0014-4835(90)90217-I; IYANAGI T, 1987, CHEM SCRIPTA, V27A, P31; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; KEDDERIS GL, 1988, DRUG METAB REV, V19, P33, DOI 10.3109/03602538809049618; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LIND C, 1990, METHOD ENZYMOL, V186, P287; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MORENO SNJ, 1984, J BIOL CHEM, V259, P6298; PAZ MA, 1991, J BIOL CHEM, V266, P689; PEDERSEN JA, 1985, CRC HDB EPR SPECTRA, P18; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RAO PV, 1991, ARCH BIOCHEM BIOPHYS, V284, P181, DOI 10.1016/0003-9861(91)90281-M; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; ROSEN GM, 1982, ARCH BIOCHEM BIOPHYS, V215, P367, DOI 10.1016/0003-9861(82)90097-2; STEIDER CM, 1990, BIOCHEM PHARMACOL, V40, P1849; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; WERMUTH B, 1986, BIOCHEM PHARMACOL, V35, P1277, DOI 10.1016/0006-2952(86)90271-6; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; Williams CH., 1976, ENZYMES, P89; WINTERBOURN CC, 1981, ARCH BIOCHEM BIOPHYS, V209, P159, DOI 10.1016/0003-9861(81)90268-X; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	36	162	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					96	102						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370456				2022-12-27	WOS:A1992GY43900021
J	POST, SR; MIYAZAKI, H; TAGER, HS				POST, SR; MIYAZAKI, H; TAGER, HS			IDENTIFICATION OF A MG2+-DEPENDENT AND GUANYL NUCLEOTIDE-DEPENDENT GLUCAGON RECEPTOR CYCLE BY USE OF PERMEABILIZED CANINE HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SLOWLY REVERSIBLE BINDING; ADENYLATE-CYCLASE; G-PROTEINS; GUANINE-NUCLEOTIDES; PLASMA-MEMBRANES; RAT-LIVER; FUNCTIONAL INTERACTIONS; REGULATORY COMPONENT; N-ETHYLMALEIMIDE	We have investigated (by use of intact and saponin-permeabilized canine hepatocytes) the roles of Mg2+ and guanyl nucleotides in regulating glucagon-receptor interactions. In contrast to intact cells, saponin-permeabilized hepatocytes bind [[I-125]iodo-Tyr10]glucagon according to a single first-order process and exhibit a single apparent dissociation constant for glucagon binding during steady-state incubations. Further analysis of the permeabilized cell system demonstrated (a) the temperature-sensitive action of Mg2+ to enhance the extent and affinity of glucagon-receptor interactions at steady-state, (b) the conversion of Mg2+-independent hormone-receptor complexes to Mg2+-dependent complexes, (c) the effect of guanyl nucleotides to inhibit specifically the Mg2+-dependent component of glucagon-receptor interactions, (d) the more rapid association of glucagon with receptor during cell incubations occurring in the presence of guanyl nucleotides or in the absence of Mg2+, and (e) the ability of guanyl nucleotides to induce both high and low affinity states of glucagon-receptor interactions. Additional experiments identified an effect of cell incubations in the presence of glucagon to limit the subsequent binding of hormone, the ability of GDP, GTP, or guanosine-5'-3-O-(thio)triphosphate (GTP-gammaS) to dissociate previously bound glucagon, and a specific requirement for GDP to re-activate the glucagon receptor for additional cycles of hormone binding. A model is presented in which (a) glucagon binds to receptor in a Mg2+-independent fashion, (b) glucagon-receptor complexes are converted to a Mg2+-dependent state, (c) guanyl nucleotide exchange initiates both an alteration in glucagon-receptor affinity and the subsequent dissociation of hormone, and (d) in the context of the intact cell, G protein-mediated hydrolysis of GTP to GDP is required to reinitialize the system.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago	TAGER, HS (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Post, Steven/0000-0002-4711-1723	NIDDK NIH HHS [DK20595, DK18347] Funding Source: Medline; NIGMS NIH HHS [GM07183] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018347, P60DK020595, R01DK018347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BIRD SJ, 1978, J BIOL CHEM, V253, P8826; BIRNBAUMER L, 1971, J BIOL CHEM, V246, P1857; BOND M, 1987, J BIOL CHEM, V262, P15630; BONNEVIENIELSEN V, 1983, J BIOL CHEM, V258, P1313; BONNEVIENIELSEN V, 1982, P NATL ACAD SCI-BIOL, V79, P2167, DOI 10.1073/pnas.79.7.2167; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; CODINA J, 1984, J BIOL CHEM, V259, P1408; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENGLAND RD, 1983, BIOCHEMISTRY-US, V22, P1722, DOI 10.1021/bi00276a031; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FISKUM G, 1985, CELL CALCIUM, V6, P25, DOI 10.1016/0143-4160(85)90032-6; FRANDSEN EK, 1987, BIOCHIM BIOPHYS ACTA, V929, P74, DOI 10.1016/0167-4889(87)90242-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOPALAKRISHNAN V, 1988, ENDOCRINOLOGY, V123, P922, DOI 10.1210/endo-123-2-922; GRADY T, 1987, J BIOL CHEM, V262, P15514; HAGOPIAN WA, 1987, J BIOL CHEM, V262, P15506; HAGOPIAN WA, 1984, J BIOL CHEM, V259, P8986; HEIDENREICH KA, 1982, J BIOL CHEM, V257, P804; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HORWITZ EM, 1985, J BIOL CHEM, V260, P9307; IYENGAR R, 1980, J BIOL CHEM, V255, P312; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; LAD PM, 1977, J BIOL CHEM, V252, P5942; LEFKOWITZ RJ, 1976, J BIOL CHEM, V251, P4686; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MANDEL P, 1964, PROG NUCLEIC ACID RE, V3, P299, DOI 10.1016/S0079-6603(08)60744-8; MASON JC, 1985, P NATL ACAD SCI USA, V82, P6835, DOI 10.1073/pnas.82.20.6835; MICK GJ, 1988, J BIOL CHEM, V263, P10667; MUKHERJEE C, 1975, J BIOL CHEM, V250, P4869; MUKHERJEE XG, 1976, J BIOL CHEM, V251, P4686; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PADRELL E, 1987, ENDOCRINOLOGY, V120, P2316, DOI 10.1210/endo-120-6-2316; POHL SL, 1971, J BIOL CHEM, V246, P1849; RODBELL M, 1971, J BIOL CHEM, V246, P1861; RODBELL M, 1974, J BIOL CHEM, V249, P59; ROJAS FJ, 1983, ENDOCRINOLOGY, V113, P711, DOI 10.1210/endo-113-2-711; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; ROMANI A, 1991, J BIOL CHEM, V266, P24376; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SONNE O, 1978, J BIOL CHEM, V253, P3203; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WILLIAMS LT, 1978, J BIOL CHEM, V253, P2984; WILLIAMS LT, 1977, J BIOL CHEM, V252, P7207; WYBORSKI RJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P532, DOI 10.1016/0003-9861(88)90405-5; ZHAO H, 1990, J BIOL CHEM, V265, P14822	56	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25776	25785						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334486				2022-12-27	WOS:A1992KD07300032
J	GOMEZFOIX, AM; COATS, WS; BAQUE, S; ALAM, T; GERARD, RD; NEWGARD, CB				GOMEZFOIX, AM; COATS, WS; BAQUE, S; ALAM, T; GERARD, RD; NEWGARD, CB			ADENOVIRUS-MEDIATED TRANSFER OF THE MUSCLE GLYCOGEN-PHOSPHORYLASE GENE INTO HEPATOCYTES CONFERS ALTERED REGULATION OF GLYCOGEN-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; SEQUENCE-ANALYSIS; EXPRESSION; ACTIVATION; TISSUE; DNA; SYNTHASE; KINASE; TYPE-5; CELLS	The muscle isozyme of glycogen phosphorylase is potently activated by the allosteric ligand AMP, whereas the liver isozyme is not. In this study we have investigated the metabolic impact of expression of muscle phosphorylase in liver cells. To this end, we constructed a replication-defective, recombinant adenovirus containing the muscle glycogen phosphorylase cDNA (termed AdCMV-MGP) and used this system to infect hepatocytes in culture. AMP-activatable glycogen phosphorylase activity was increased 46-fold 6 days after infection of primary liver cells with AdCMV-MGP. Despite large increases in phosphorylase activity, glycogen levels were only slightly reduced in AdCMV-MGP-infected liver cells compared to uninfected cells or cells infected with wild-type adenovirus. The lack of correlation of phosphorylase activity and glycogen content suggests that the liver cell environment can inhibit the muscle phosphorylase isozyme. This inhibition can be overcome, however, by addition of carbonyl cyanide m-chlorophenylhydrazone (CCCP), which increases AMP levels by 30-fold and causes a much larger decrease in glycogen levels in AdCMV-MGP-infected cells than in uninfected or wild-type adenovirus-infected controls. CCCP treatment also caused a preferential decrease in glycogen content relative to glucagon treatment in AdCMV-MGP-infected hepatocytes (74% versus 11%, respectively), even though the two drugs caused equal increases in phosphorylase alpha activity. Introduction of muscle phosphorylase into hepatocytes therefore confers a capacity for glycogenolytic response to effectors that is not provided by the endogenous liver phosphorylase isozyme. The remarkable efficiency of adenovirus-mediated gene transfer into primary hepatocytes and the demonstration of altered regulation of glycogen metabolism as a consequence of expression of a non-cognate phosphorylase isozyme may have implications for gene therapy of glycogen storage diseases.	UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas					NIDDK NIH HHS [R29-DK40734] Funding Source: Medline; PHS HHS [FU90 37284920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040734] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CARABAZA A, 1986, ARCH BIOCHEM BIOPHYS, V250, P469, DOI 10.1016/0003-9861(86)90751-4; CARABAZA A, 1990, J BIOL CHEM, V265, P2724; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CLARK D, 1988, CURR TOP CELL REGUL, V29, P217; COATS WS, 1991, J BIOL CHEM, V266, P16113; COHEN PTW, 1973, FEBS LETT, V29, P113; FLETTERICK RJ, 1982, ACCOUNTS CHEM RES, V15, P361, DOI 10.1021/ar00083a004; GLASER T, 1989, GENOMICS, V5, P510, DOI 10.1016/0888-7543(89)90017-7; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1991, BIOCHEM J, V276, P607, DOI 10.1042/bj2760607; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KOBAYASHI M, 1982, J BIOL CHEM, V257, P4041; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LEDERER B, 1976, BIOCHEM J, V159, P689, DOI 10.1042/bj1590689; LEDLEY FD, 1990, J INHERIT METAB DIS, V13, P597, DOI 10.1007/BF01799515; LIU TJ, 1992, SOMAT CELL MOLEC GEN, V18, P89, DOI 10.1007/BF01233451; LYON JB, 1963, J BIOL CHEM, V238, P1; MADSEN NB, 1961, BIOCHEM BIOPH RES CO, V6, P310, DOI 10.1016/0006-291X(61)90385-0; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1987, AM J HUM GENET, V40, P351; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1991, BIOCHIM BIOPHYS ACTA, V1090, P333, DOI 10.1016/0167-4781(91)90198-U; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SEN A, 1988, J BIOL CHEM, V263, P19132; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; VANDEBROECK A, 1988, BIOCHEM J, V256, P685, DOI 10.1042/bj2560685; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437	40	247	317	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25129	25134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334082				2022-12-27	WOS:A1992KB60300035
J	HEIM, R; IWATA, T; ZVARITCH, E; ADAMO, HP; RUTISHAUSER, B; STREHLER, EE; GUERINI, D; CARAFOLI, E				HEIM, R; IWATA, T; ZVARITCH, E; ADAMO, HP; RUTISHAUSER, B; STREHLER, EE; GUERINI, D; CARAFOLI, E			EXPRESSION, PURIFICATION, AND PROPERTIES OF THE PLASMA-MEMBRANE CA2+ PUMP AND OF ITS N-TERMINALLY TRUNCATED 105-KDA FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; CALMODULIN-BINDING DOMAIN; ION MOTIVE ATPASES; PIG SMOOTH-MUSCLE; CALCIUM-PUMP; CA-2+ PUMP; MOLECULAR-CLONING; FUNCTIONAL DOMAINS; CA-2+-TRANSPORTING ATPASE; DIRECTED MUTAGENESIS	Isoform 4b of the human plasma membrane Ca2+ pump was expressed in COS cells and in the baculovirus system (Sf9 cells). A 105-kDa pump fragment lacking the first two transmembrane domains and the so-called transduction domain was also expressed. The expression level was 2-4 times the background in COS cells and at least 7 times in the baculovirus system. Tests on membranes from both systems showed that the expressed pump was active. The expressed pump and the 105-kDa fragment were isolated from Sf9 cell membranes by calmodulin affinity chromatography. The pump had Ca2+-dependent ATPase activity with a calmodulin stimulation factor of 3, formed a La3+-stabilized phosphoenzyme, and had a K(M) (Ca2+) in the presence of calmodulin of about 1 muM. The 105-kDa fragment, assayed by the phosphoenzyme test on COS or Sf9 cell membranes or by ATPase measurements after isolation from Sf9 cells, pro-ed inactive. Laser confocal microscopy on Sf9 cells showed that both the pump and the 105-kDa fragment were apparently associated with the plasma membrane. The expressed pump in COS and Sf9 cells and the endogenous pump in a number of other cell lines had a slower gel mobility (i.e. a higher apparent molecular mass) than the erythrocyte pump.	SWISS FED INST TECHNOL,INST BIOCHEM,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND; MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55901; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	ETH Zurich; Mayo Clinic; ETH Zurich			Adamo, Hugo Pedro/ABB-8338-2021; Carafoli, Ernesto/K-5192-2016	Adamo, Hugo Pedro/0000-0002-1712-8049; Carafoli, Ernesto/0000-0002-7826-0094				BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CURRIE JR, 1991, J NEUROSCI RES, V30, P687, DOI 10.1002/jnr.490300413; DEJAEGERE S, 1990, BIOCHEM J, V271, P655, DOI 10.1042/bj2710655; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREEN NM, 1989, BIOCHEM SOC T, V17, P819, DOI 10.1042/bst0170819; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HOLZER KP, 1989, J BIOL CHEM, V264, P14389; JAMES P, 1989, J BIOL CHEM, V264, P8289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; NIGGLI V, 1987, METHOD ENZYMOL, V139, P791; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; SCULLY SP, 1982, CELL CALCIUM, V3, P515, DOI 10.1016/0143-4160(82)90042-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Summers MD, 1987, TEXAS AGR EXPT STATI; SZASZ I, 1978, BIOCHIM BIOPHYS ACTA, V512, P331, DOI 10.1016/0005-2736(78)90257-2; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	47	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24476	24484						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332959				2022-12-27	WOS:A1992KA26300053
J	ORNING, L; GIERSE, J; DUFFIN, K; BILD, G; KRIVI, G; FITZPATRICK, FA				ORNING, L; GIERSE, J; DUFFIN, K; BILD, G; KRIVI, G; FITZPATRICK, FA			MECHANISM-BASED INACTIVATION OF LEUKOTRIENE-A4 HYDROLASE AMINOPEPTIDASE BY LEUKOTRIENE-A4 - MASS-SPECTROMETRIC AND KINETIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HUMAN-ERYTHROCYTES; ZINC METALLOENZYME; MOLECULAR-CLONING; EPOXIDE HYDROLASE; BIOSYNTHESIS; PURIFICATION; INHIBITION; METABOLISM; LEUKOCYTES	"Suicide" inactivation of leukotriene (LT) A4 hydrolase/aminopeptidase occurs via an irreversible mechanism-based process which is saturable, of pseudo first-order, and dependent upon catalysis. Data obtained with either recombinant enzyme or enzyme purified from human leukocytes were similar. Apparent binding constants and inactivation rate constants are equivalent, compatible with a single type of substrate-enzyme complex which partitions between two fates, turnover and inactivation. Both catalytic functions are inactivated, consistent with an overlapping active site for this bifunctional enzyme. The partition ratio (turnover/inactivation) for the LTA4-enzyme complex is 129 +/- 16 for LTA4 hydrolase activity and 124 +/- 10 for aminopeptidase activity. The pH dependence for turnover and inactivation are indistinguishable with a maximum at pH 8. L-Proline p-nitroanilide, a weak substrate with a high K(m) for the aminopeptidase affords only partial protection against inactivation by LTA4. However, two potent competitive inhibitors, bestatin and captopril, protect both catalytic processes from inactivation, consistent with an active-site specificity for the suicide event. Electrospray ionization mass spectrometry indicates that the molecular weight of pure recombinant enzyme is 69,399 +/- 4 and that covalent modification accompanies catalysis, producing an LTA4:enzyme adduct with a molecular weight 69,717 +/- 4 and a 1:1 stoichiometry. In agreement with kinetic data, electrospray ionization mass spectrometry shows that bestatin inhibits the covalent modification of enzyme by LTA4 and that the extent of modification is proportional to the loss of enzymatic activity.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; MONSANTO CO,CORP RES,ST LOUIS,MO 63167	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Monsanto					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLB PO1 34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRENNER DG, 1981, BIOCHEMISTRY-US, V20, P3682; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; EVANS JF, 1985, J BIOL CHEM, V260, P966; EVANS JF, 1992, FEBS LETT, V297, P139, DOI 10.1016/0014-5793(92)80345-H; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; JAKSCHIK BA, 1983, PROSTAG OTH LIPID M, V25, P767, DOI 10.1016/0090-6980(83)90002-3; KITZ R, 1962, J BIOL CHEM, V237, P3245; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MATHEWS WR, 1988, ANAL CHEM, V60, P349, DOI 10.1021/ac00155a016; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MEDINA JF, 1990, EUR J BIOCHEM, V191, P27, DOI 10.1111/j.1432-1033.1990.tb19089.x; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; ORNING L, 1990, J BIOL CHEM, V265, P14911; ORNING L, 1991, J BIOL CHEM, V266, P16507; ORNING L, 1991, J BIOL CHEM, V266, P1375; ORNING L, 1992, BIOCHEMISTRY-US, V31, P4218, DOI 10.1021/bi00132a010; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RADMARK O, 1990, ADV PROSTAG THROMB L, V20, P35; RAJASHEKHAR B, 1984, J BIOL CHEM, V259, P6925; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TOH H, 1990, BIOCHEM BIOPH RES CO, V171, P216, DOI 10.1016/0006-291X(90)91379-7; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L	32	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22733	22739						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331064				2022-12-27	WOS:A1992JY16300009
J	WILLIAMS, SF; PALMER, MAJ; PEOPLES, OP; WALSH, CT; SINSKEY, AJ; MASAMUNE, S				WILLIAMS, SF; PALMER, MAJ; PEOPLES, OP; WALSH, CT; SINSKEY, AJ; MASAMUNE, S			BIOSYNTHETIC THIOLASE FROM ZOOGLOEA-RAMIGERA - MUTAGENESIS OF THE PUTATIVE ACTIVE-SITE BASE CYS-378 TO SER-378 CHANGES THE PARTITIONING OF THE ACETYL S-ENZYME INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-KETOACYL THIOLASE; PROTON-TRANSFER	The proposed active-site base Cys-378 of thiolase, responsible for deprotonation of acetyl-CoA, has been converted to a less acidic residue Ser-378 by mutagenesis. Comparison of the CD spectra and dimethyl suberimidate cross-linking experiments of the wild type, mutant Ser-378, and Gly-378 enzymes indicated that there have been no major conformational changes. The Ser-378 enzyme retains 0.1% of the V(max) of wild type in the direction of acetoacetyl-CoA thiolytic cleavage and 0.07% of the V(max) in the Claisen condensation direction. Analysis of the acetyl S-enzyme intermediate partitioning, that is capture of the acetyl enzyme by 1) the thiolate of coenzyme A relative to 2) the C-2 carbanion of acetyl-CoA, is changed to favor reaction 2 in the case of the Ser-378 mutant enzyme.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	WILLIAMS, SF (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DAVIS JT, 1987, J BIOL CHEM, V262, P82; GEHRING U, 1972, ENZYMES, V7, P391; GILBERT HF, 1981, BIOCHEMISTRY-US, V20, P5643, DOI 10.1021/bi00523a001; HILLEL Z, 1977, BIOCHEMISTRY-US, V16, P3334, DOI 10.1021/bi00634a008; MASAMUNE S, 1989, J AM CHEM SOC, V111, P1879, DOI 10.1021/ja00187a053; MASAMUNE S, 1989, PURE APPL CHEM, V61, P303, DOI 10.1351/pac198961030303; PALMER MAJ, 1991, J BIOL CHEM, V266, P8369; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006	9	36	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16041	16043						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1353760				2022-12-27	WOS:A1992JJ45800010
J	LANGE, AJ; ESPINET, C; HALL, R; ELMAGHRABI, MR; VARGAS, AM; MIKSICEK, RJ; GRANNER, DK; PILKIS, SJ				LANGE, AJ; ESPINET, C; HALL, R; ELMAGHRABI, MR; VARGAS, AM; MIKSICEK, RJ; GRANNER, DK; PILKIS, SJ			REGULATION OF GENE-EXPRESSION OF RAT SKELETAL-MUSCLE LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - ISOLATION AND CHARACTERIZATION OF A GLUCOCORTICOID RESPONSE ELEMENT IN THE 1ST INTRON OF THE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; CELL LINE; RECEPTOR; DNA; ENHANCER; BINDING; IDENTIFICATION; INDUCTION; PROTEINS; SEQUENCE	At least two genes encode isoenzymes of rat 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Alternative splicing of one of these genes generates a skeletal muscle-specific transcript from an upstream promoter and a liver-specific transcript from a downstream promoter. A potent glucocorticoid response element was identified in the first intron of the gene, i.e. between liver exon I and exon II. The element is approximately 3.5 kilobase pairs (kb) downstream of the liver isoenzyme transcription start site and 13 kb upstream of exon II of the gene and confers dexamethasone-sensitive expression of chloramphenicol acetyltransferase (CAT) activity from a heterologous thymidine kinase promoter and from both homologous 5'-flanking regions of the gene. This glucocorticoid response element also exhibits androgen- but not estrogen-sensitive expression of CAT activity in HeLa cells cotransfected with the appropriate receptor expression vector. DNase footprint and sequence analysis revealed that the element is comprised minimally of two adjacent 15-mer glucocorticoid receptor dimer binding sites situated in opposite orientations. Glucocorticoid regulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in liver and skeletal muscle is mediated by a single complex glucocorticoid response element located in the first intron of the skeletal muscle/liver gene.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL,STONY BROOK,NY 11794; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vanderbilt University	LANGE, AJ (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.		Miksicek, Richard/AAC-7319-2020; Vargas, Ana/GSE-1963-2022; Espinet, Carme/A-7950-2010	EspinetMestre, Carme/0000-0001-7172-3407	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43384] Funding Source: Medline; NIDDK NIH HHS [DK-38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P5643; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ELMAGHRABI MR, 1990, LIVER 6 PHOSPHOFRUCT, P87; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GEY GO, 1952, CANCER RES, V12, P264; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IVARIE RD, 1978, CELL, V13, P41, DOI 10.1016/0092-8674(78)90136-8; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; Maxam A M, 1980, Methods Enzymol, V65, P499; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOORE EE, 1982, J CELL PHYSIOL, V111, P1, DOI 10.1002/jcp.1041110102; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NITSCH D, 1991, HORMONAL CONTROL REG, P223; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PRESTRIDGE DS, 1991, SIGNALSCAN VERSION 2; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TSAI MJ, 1991, HORMONAL REGULATION, P101; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P205	45	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15673	15680						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1339434				2022-12-27	WOS:A1992JG11300065
J	SVINARICH, DM; TWOMEY, TA; MACAULEY, SP; KREBS, CJ; YANG, TP; KRAWETZ, SA				SVINARICH, DM; TWOMEY, TA; MACAULEY, SP; KREBS, CJ; YANG, TP; KRAWETZ, SA			CHARACTERIZATION OF THE HUMAN LYSYL OXIDASE GENE LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ELASTIN GENE; 5'-FLANKING REGION; DNA; SEQUENCE; ACID; HYBRIDIZATION; AMPLIFICATION; PURIFICATION; DELINEATION; POLYMERASE	Lysyl oxidase (EC 1.4.3.13) is a copper-dependent enzyme acting principally on collagen and elastin catalyzing the formation of aldehyde cross-links. It is also believed to possess a tumor suppressor activity as the anti-oncogene of ras. While rat, human, and mouse lysyl oxidase cDNAs have been cloned, little is known about the structure of the gene, its organization, or regulation. This paper describes the cloning of an intronic segment of the human lysyl oxidase gene. Sequence analysis defined the location of an intron that separates the prepro-coding segments from the segment encoding the catalytic domain. Genomic restriction mapping and gene copy number data established that multiple lysyl oxidase mRNA transcripts originate from a single gene and thus are products of alternative splicing. Northern analysis of adult and fetal fibroblast RNA showed a dominant approximately 4.3-kilobase lysyl oxidase mRNA transcript that varied in abundance as a function of cell line. These data are consistent with a complex mechanism regulating the expression of the lysyl oxidase gene.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,540 E CANFIELD AVE,DETROIT,MI 48201; UNIV FLORIDA,HLTH SCI CTR,CTR MAMMALIAN GENET,DIV PEDIAT GENET,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	Wayne State University; State University System of Florida; University of Florida			krawetz, stephen/GQQ-3308-2022					BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HARRIS ED, 1979, SCIENCE, V208, P55; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; KRAWETZ SA, 1988, J BIOL CHEM, V263, P321; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI WH, 1987, J MOL EVOL, V25, P330, DOI 10.1007/BF02603118; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIRELMAN D, 1979, J BIOL CHEM, V254, P571; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OLSEN BR, 1988, COLLAGEN, V4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINNEL SR, 1968, P NATL ACAD SCI USA, V61, P707; Rucker R B, 1977, Int Rev Exp Pathol, V17, P1; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLOS D, 1990, EUR J BIOCHEM, V190, P21, DOI 10.1111/j.1432-1033.1990.tb15540.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHEHEE WR, 1987, J MOL BIOL, V196, P757, DOI 10.1016/0022-2836(87)90402-5; SIEGEL RC, 1976, J BIOL CHEM, V251, P5779; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; SVINARICH D M, 1991, Methods in Molecular and Cellular Biology, V2, P134; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TWOMEY TA, 1990, BIOTECHNIQUES, V8, P478; WAKASAKI H, 1990, BIOCHEM BIOPH RES CO, V166, P1201, DOI 10.1016/0006-291X(90)90993-W	38	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14382	14387						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352776				2022-12-27	WOS:A1992JD32500090
J	HO, KC; QUARMBY, VE; FRENCH, FS; WILSON, EM				HO, KC; QUARMBY, VE; FRENCH, FS; WILSON, EM			MOLECULAR-CLONING OF RAT PROSTATE TRANSGLUTAMINASE COMPLEMENTARY-DNA - THE MAJOR ANDROGEN-REGULATED PROTEIN-DP1 OF RAT DORSAL PROSTATE AND COAGULATING GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; STEROID-BINDING PROTEIN; VENTRAL PROSTATE; ERYTHROCYTE-MEMBRANE; MR=14,000 SUBUNIT; C-MYC; RNA; SEQUENCES; GENES; TRANSCRIPTION	Complementary DNA (cDNA) that codes for a major androgen-dependent secretory protein of rat coagulating gland and dorsal prostate, dorsal protein 1 (DP1), was isolated by molecular cloning. Recombinant DP1 cDNA clones were identified from a bacteriophage lambda-gt11 rat coagulating gland expression library using an affinity purified polyclonal antibody. Amino acid sequence deduced from DNA contained sequences identical with several DP1 cyanogen bromide cleavage fragments. Northern blot hybridization of poly(A) RNA isolated from intact rat dorsal prostate and coagulating gland revealed a predominant messenger RNA (mRNA) species of approximately 3200 nucleotides. Tissue-specific expression of DP1 mRNA was indicated by the absence of DP1 mRNA in ventral prostate and other tissues of the rat. Expression of DP1 mRNA was androgen-dependent, decreasing approximately 80% 7 days after castration and increasing rapidly following androgen replacement. Southern blot analysis of restriction enzyme-digested rat DNA indicated that DP1 is encoded by a single gene and that no major genomic rearrangements accounted for its lack of expression in the dorsal prostate-derived rat Dunning tumor. Sequence comparisons revealed that rat prostate DP1 shares sequence identity with Factor XIIIa and tissue transglutaminase, including the active center, GQCWVF, indicating that DP1 is a member of the transglutaminase gene family.	UNIV N CAROLINA,REPROD BIOL LABS,CB 7500 MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004466, R37HD016910, R37HD004466, P30HD018968, R01HD016910] Funding Source: NIH RePORTER; NICHD NIH HHS [HD04466, HD16910, P30-HD18968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT RJ, 1984, PROSTATE, V5, P75, DOI 10.1002/pros.2990050108; BLATTNER FR, 1978, SCIENCE, V202, P1279, DOI 10.1126/science.725603; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHAN SJ, 1979, P NATL ACAD SCI USA, V76, P5036, DOI 10.1073/pnas.76.10.5036; CHEN C, 1979, J STEROID BIOCHEM, V11, P401, DOI 10.1016/0022-4731(79)90058-X; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FORSGREN B, 1979, P NATL ACAD SCI USA, V76, P3149, DOI 10.1073/pnas.76.7.3149; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOTTERER GS, 1957, P SOC EXP BIOL MED, V94, P60, DOI 10.3181/00379727-94-22855; GRANDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAYASHI N, 1991, BIOL REPROD, V45, P308, DOI 10.1095/biolreprod45.2.308; HEYNS W, 1977, BIOCHEM BIOPH RES CO, V77, P1492, DOI 10.1016/S0006-291X(77)80147-2; HEYNS W, 1977, EUR J BIOCHEM, V78, P221, DOI 10.1111/j.1432-1033.1977.tb11733.x; HO KC, 1985, GENE, V39, P49, DOI 10.1016/0378-1119(85)90106-4; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; ISAACS JT, 1982, CANCER RES, V42, P2352; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEA OA, 1979, J BIOL CHEM, V254, P6196; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OHARE K, 1979, NUCLEIC ACIDS RES, V7, P321, DOI 10.1093/nar/7.2.321; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8818; PARKER MG, 1983, J BIOL CHEM, V258, P12; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PARKER MG, 1978, EUR J BIOCHEM, V85, P399, DOI 10.1111/j.1432-1033.1978.tb12252.x; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PORTA R, 1990, INT J PEPT PROT RES, V35, P117; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; SAMBROOK J, 1989, MOL CLONING LAB MANU, P779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P173; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEERS E, 1965, J BIOL CHEM, V240, P2478; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; THOMAS P, 1980, P NATL ACAD SCI USA, V74, P5201; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEAVER CA, 1981, P NATL ACAD SCI-BIOL, V78, P4073, DOI 10.1073/pnas.78.7.4073; Williams-Ashman H G, 1980, Adv Enzyme Regul, V18, P239, DOI 10.1016/0065-2571(80)90018-7; WILLIAMSASHMAN HG, 1977, BIOCHEM BIOPH RES CO, V79, P1192, DOI 10.1016/0006-291X(77)91132-9; WILLIAMSASHMAN HG, 1984, MOL CELL BIOCHEM, V58, P51, DOI 10.1007/BF00240604; WILSON EM, 1980, J BIOL CHEM, V255, P946; WILSON EM, 1981, PROSTATIC CELL STR A, P351; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZKURA K, 1987, AGR BIOL CHEM TOKYO, V51, P957; [No title captured]	57	87	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12660	12667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352290				2022-12-27	WOS:A1992HZ48300045
J	BEGGS, AH; BYERS, TJ; KNOLL, JHM; BOYCE, FM; BRUNS, GAP; KUNKEL, LM				BEGGS, AH; BYERS, TJ; KNOLL, JHM; BOYCE, FM; BRUNS, GAP; KUNKEL, LM			CLONING AND CHARACTERIZATION OF 2 HUMAN SKELETAL-MUSCLE ALPHA-ACTININ GENES LOCATED ON CHROMOSOME-1 AND CHROMOSOME-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; MUSCULAR-DYSTROPHY; BETA-SPECTRIN; DMD GENE; SEQUENCE; PROTEIN; CDNA; EXPRESSION; LOCALIZATION; MOUSE	Conserved sequences of dystrophin, beta-spectrin, and alpha-actinin were used to plan a set of degenerate oligonucleotide primers with which we amplified a portion of a human alpha-actinin gene transcript. Using this short clone as a probe, we isolated and characterized full-length cDNA clones for two human alpha-actinin genes (ACTN2 and ACTN3). These genes encode proteins that are structurally similar to known alpha-actinins with approximately 80% amino acid identity to each other and to the previously characterized human nonmuscle gene. ACTN2 is the human homolog of a previously characterized chicken gene while ACTN3 represents a novel gene product. Northern blot analysis demonstrated that ACTN2 is expressed in both skeletal and cardiac muscle, but ACTN3 expression is limited to skeletal muscle. As with other muscle-specific isoforms, the EF-hand domains in ACTN2 and ACTN3 are predicted to be incapable of binding calcium, suggesting that actin binding is not calcium sensitive. ACTN2 was mapped to human chromosome 1q42-q43 and ACTN3 to 11q13-q14 by somatic cell hybrid panels and fluorescent in situ hybridization. These results demonstrate that rome of the isoform diversity of alpha-actinins is the result of transcription from different genetic loci.	HARVARD UNIV,SCH MED,DIV GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	BEGGS, AH (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,BOSTON,MA 02115, USA.			Beggs, Alan/0000-0001-8818-0568; Knoll, Joan/0000-0001-6691-1710	NICHD NIH HHS [HD18658] Funding Source: Medline; NINDS NIH HHS [NS23740] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD018658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; BARON MD, 1987, J BIOL CHEM, V262, P17623; BARON MD, 1987, J BIOL CHEM, V262, P2558; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BEGGS AH, 1990, HUM GENET, V86, P45; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BRUNS G, 1987, HUM GENET, V76, P58; BRUNS GAP, 1979, BIOCHEM GENET, V17, P1031, DOI 10.1007/BF00504344; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEGROUCHY J, 1978, ANNU REV GENET, V12, P289; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; EBASHI S, 1965, J BIOCHEM-TOKYO, V58, P7, DOI 10.1093/oxfordjournals.jbchem.a128167; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; GEIGER B, 1981, J CELL BIOL, V91, P614, DOI 10.1083/jcb.91.3.614; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1989, J CELL BIOL, V108, P503, DOI 10.1083/jcb.108.2.503; HUEBNER K, 1985, P NATL ACAD SCI USA, V82, P3790, DOI 10.1073/pnas.82.11.3790; JOCKUSCH BM, 1980, EXP CELL RES, V127, P409, DOI 10.1016/0014-4827(80)90445-0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOBAYASHI R, 1983, EUR J BIOCHEM, V133, P607, DOI 10.1111/j.1432-1033.1983.tb07505.x; KOBAYASHI R, 1989, EUR J BIOCHEM, V185, P297, DOI 10.1111/j.1432-1033.1989.tb15115.x; KOBAYASHI R, 1984, EUR J BIOCHEM, V143, P125, DOI 10.1111/j.1432-1033.1984.tb08351.x; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LAING NG, 1992, AM J HUM GENET, V50, P576; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIMURA N, 1987, J BIOL CHEM, V262, P4717; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; OLSEN DR, 1989, AM J HUM GENET, V44, P876; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHAT FH, 1985, J CELL BIOL, V101, P1001, DOI 10.1083/jcb.101.3.1001; SINGH I, 1977, BIOCHIM BIOPHYS ACTA, V491, P29, DOI 10.1016/0005-2795(77)90038-1; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; SUZUKI A, 1973, BIOCHIM BIOPHYS ACTA, V295, P188, DOI 10.1016/0005-2795(73)90087-1; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	55	246	259	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9281	9288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1339456				2022-12-27	WOS:A1992HR85400088
J	LEROUX, C; MAZURE, N; MARTIN, P				LEROUX, C; MAZURE, N; MARTIN, P			MUTATIONS AWAY FROM SPLICE SITE RECOGNITION SEQUENCES MIGHT CIS-MODULATE ALTERNATIVE SPLICING OF GOAT ALPHA-S1-CASEIN TRANSCRIPTS - STRUCTURAL ORGANIZATION OF THE RELEVANT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN MULTIGENE FAMILY; PRE-MESSENGER RNA; COMPLETE NUCLEOTIDE-SEQUENCE; BETA-TROPOMYOSIN GENE; SECONDARY STRUCTURE; NONSENSE MUTATIONS; EXON SEQUENCES; KAPPA-CASEIN; CDNAS; ACID	Alpha(s1)-casein variants F and D, synthesized in goat milk at lower levels than variant A, essentially differ from it by internal deletions of 37 and 11 amino acid residues, respectively. Northern blot analysis of mRNAs encoding alpha(s1)-casein F and A and sequencing of the relevant cloned cDNAs, as well as sequencing of in vitro amplified genomic fragments, revealed multiple alternatively processed transcripts, from the F allele. Although correctly spliced messengers were identified, most of the FmRNAs lacked three exons. There exons, further identified as exons 9, 10, and 11, together encode the 37 amino acid residues present in alpha(s1)-casein variant A but missing in variant F. Exon 9 codes for the sequence present in variant A but deleted in variant D. A single nucleotide deletion in exon 9 and two insertions, 11 and 3 base pairs in length, in the downstream intron, were identified as mutations potentially responsible for the alternative skipping of these 3 exons. From a computer-predicted secondary structure it appeared that the 11-base pair insertion might be involved in base-pairing interactions with the intron 5' splice site which might consequently be less accessible to U1 snRNA. We also report here the complete structural organization of the goat alpha(s1)-casein transcription unit, deduced from polymerase chain reaction experiments. It contains 19 exons scattered within a nucleotide stretch nearly 17-kilobase pairs long.	INRA, GENET BIOCHIM LAB, DOMAINE VILVERT, F-78350 JOUY EN JOSAS, FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Mazure, Nathalie/0000-0003-1350-7161; Leroux, Christine/0000-0001-6835-3978				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BOISNARD M, 1991, EUR J BIOCHEM, V201, P633, DOI 10.1111/j.1432-1033.1991.tb16324.x; BOISNARD M, 1985, BIOCHIMIE, V67, P1043, DOI 10.1016/S0300-9084(85)80299-6; BONSING J, 1988, AUST J BIOL SCI, V41, P527, DOI 10.1071/BI9880527; BRIGNON G, 1989, Protein Sequences and Data Analysis, V2, P181; BRIGNON G, 1990, EUR J BIOCHEM, V193, P237, DOI 10.1111/j.1432-1033.1990.tb19328.x; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; ERSTER SH, 1988, NUCLEIC ACIDS RES, V16, P5999, DOI 10.1093/nar/16.13.5999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAYE P, 1977, BIOCHEM BIOPH RES CO, V79, P903, DOI 10.1016/0006-291X(77)91196-2; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GROSCLAUDE F, 1987, GENET SEL EVOL, V19, P399, DOI 10.1186/1297-9686-19-4-399; GROSCLAUDE F, 1978, ANN GENET SEL ANIM, V10, P313, DOI 10.1186/1297-9686-10-3-313; GRUSBY MJ, 1990, P NATL ACAD SCI USA, V87, P6897, DOI 10.1073/pnas.87.17.6897; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOBBS AA, 1982, NUCLEIC ACIDS RES, V10, P8079, DOI 10.1093/nar/10.24.8079; JONES WK, 1985, J BIOL CHEM, V260, P7042; LEROUX C, 1990, ANIM GENET, V21, P341, DOI 10.1111/j.1365-2052.1990.tb01979.x; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; MAHE MF, 1989, GENET SEL EVOL, V21, P127, DOI 10.1051/gse:19890202; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MCKNIGHT RA, 1989, J DAIRY SCI, V72, P2464, DOI 10.3168/jds.S0022-0302(89)79386-3; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERCIER JC, 1990, GENOME ANALYSIS IN DOMESTIC ANIMALS, P233; MERCIER JC, 1971, EUR J BIOCHEM, V23, P41, DOI 10.1111/j.1432-1033.1971.tb01590.x; MERCIER JC, 1985, BIOCHIMIE, V67, P959, DOI 10.1016/S0300-9084(85)80291-1; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PROVOT C, 1989, BIOCHIMIE, V71, P827, DOI 10.1016/0300-9084(89)90046-1; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Rosen J. M., 1987, The mammary gland. Development, regulation, and function., P301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART AF, 1984, NUCLEIC ACIDS RES, V12, P3895, DOI 10.1093/nar/12.9.3895; STEWART AF, 1987, MOL BIOL EVOL, V4, P231; Swaisgood H. E., 1982, Developments in Dairy Chemistry, V1, P1; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; YULEE LY, 1986, NUCLEIC ACIDS RES, V14, P1883, DOI 10.1093/nar/14.4.1883; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	50	116	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6147	6157						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372900				2022-12-27	WOS:A1992HK31800066
J	KIM, H; PATEL, MS				KIM, H; PATEL, MS			CHARACTERIZATION OF 2 SITE-SPECIFICALLY MUTATED HUMAN DIHYDROLIPOAMIDE DEHYDROGENASES (HIS-452-]GLN AND GLU-457-]GLN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; LIPOAMIDE DEHYDROGENASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; PIG HEART; RESOLUTION; COMPLEXES; ENZYME	Two site-specifically mutated human dihydrolipoamide dehydrogenases (His-452 --> Gln and Glu-457 --> Gln) were expressed in pyruvate dehydrogenase complex-deletion mutant Escherichia coli JRG1342. The expressed mutant E3s were purified to near homogeneity using DEAE-Sephacel and hydroxyapatite columns. The initial velocity measurements in the absence of products for the Gln-452 mutant E3 in the direction of NAD+ reduction showed parallel lines in double-reciprocal plots, indicating that the mutant E3, like wild-type enzyme, catalyzed E3 reaction via a ping-pong mechanism. The specific activity of the Gln-452 mutant E3 was about 0.2% of that of wild-type enzyme. Its K(m) for dihydrolipoamide was dramatically increased by 63-fold. The substitution of His-452 to Gln resulted in a destabilization of the transition state of human E3 catalysis by about 6.4 kcal mol-1. The Gln-457 mutant E3, unlike wild-type enzyme, catalyzed E3 reaction via a sequential mechanism in the direction of NAD+ reduction based on the intersecting lines shown on double-reciprocal plots. Its specific activity decreased to 28% of that of wild-type enzyme. Its K(m) for dihydrolipoamide increased about 4.3-fold. The substitution of Glu-457 to Gln resulted in a destabilization of the transition state by about 1.7 kcal mol-1. These results indicate that His-452, which is a possible proton acceptor/donor in human E3 reaction, is critical to human E3 catalysis and that the local environment around His-452 and Glu-457, which are suggested to be hydrogen-bonded, is important in the binding of dihydrolipoamide to the enzyme.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, 2109 ABINGTON RD, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK20478, DK42885] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478, R01DK042885] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON N, 1988, BIOCHEM J, V256, P741, DOI 10.1042/bj2560741; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KIM HJ, 1991, J BIOL CHEM, V266, P9367; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MANNERVIK B, 1973, BIOCHEM BIOPH RES CO, V53, P1151, DOI 10.1016/0006-291X(73)90585-8; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATTHEWS RG, 1977, J BIOL CHEM, V252, P3199; PAI EF, 1983, J BIOL CHEM, V258, P1752; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P49, DOI 10.1016/0005-2744(69)90281-2; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V573, P113, DOI 10.1111/j.1749-6632.1989.tb14990.x; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; WALKER JL, 1986, J BIOL CHEM, V261, P2214; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Williams CH., 1976, ENZYMES, P89; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55; YOUNG JF, 1983, P NATL ACAD SCI-BIOL, V80, P6105, DOI 10.1073/pnas.80.19.6105	24	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5128	5132						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347528				2022-12-27	WOS:A1992HH74700022
J	XU, RX; ANTHOLINE, WE; PETERING, DH				XU, RX; ANTHOLINE, WE; PETERING, DH			REACTION OF CO(II)BLEOMYCIN WITH DIOXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BLEOMYCIN; DEOXYRIBONUCLEIC-ACID; ACTIVATED BLEOMYCIN; OXYGEN; DNA; COBALT; SYSTEM; DRUG; O2	The reaction of Co(II)bleomycin with dioxygen has been investigated. Dioxygen binds to the Co(II) complex within the time of mixing according to electron spin resonance and uv-visible spectroscopy and dioxygen analysis. Then, two dioxygenated cobalt centers react, releasing 1 mol of O2 and forming an intermediate characterized by a few highly shifted H-1 NMR resonances and loss of the ESR spectrum. This is thought to be a dioxygen-bridged dimer of cobalt bleomycin molecules. Time-dependent absorbance and dioxygen measurements yield the same second order rate constant for this step of the reaction. According to uv-visible and NMR spectral analysis, the intermediate decays into diamagnetic products in a first order rate process. High performance liquid chromatography and H-1 NMR studies demonstrate that the product contains two bleomycin species of equal concentration. One component is Co(III)bleomycin, designated Form II. The other is the peroxide adduct of Co(III)bleomycin, Form 1, as determined by direct determination of hydrogen peroxide, which is slowly released from the product at low pH. In contrast, hydrogen peroxide is readily detected during the reaction of Co(II)Blm with O2. In isolation, Form I is unstable at pH 7 and is converted within 24 h into a mixture of Form I and Form II.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201; MED COLL WISCONSIN,DEPT RADIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,NATL BIOMED ESR CTR,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Milwaukee; Medical College of Wisconsin; Medical College of Wisconsin					NCI NIH HHS [CA-22184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBEN JO, 1968, BIOCHEMISTRY-US, V7, P624, DOI 10.1021/bi00842a018; ALBERTINI JP, 1982, BIOCHEMISTRY-US, V21, P6777, DOI 10.1021/bi00269a025; BARHAM D, 1972, ANALYST, V97, P142, DOI 10.1039/an9729700142; BARR JR, 1990, J AM CHEM SOC, V112, P4058, DOI 10.1021/ja00166a064; BASOLO F, 1967, MECHANISMS INORGANIC, P158; BURGER RM, 1983, J BIOL CHEM, V258, P1559; BURGER RM, 1979, J BIOL CHEM, V254, P2299; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; BYRNES RW, 1990, CANCER RES, V50, P5275; CHANG CH, 1982, BIOCHEMISTRY-US, V21, P6332, DOI 10.1021/bi00268a001; CHANG CH, 1983, BIOCHEM BIOPH RES CO, V110, P959; CHIKIRA M, 1989, J BIOL CHEM, V264, P21478; FUJII A, 1973, J ANTIBIOT, V26, P396, DOI 10.7164/antibiotics.26.396; JONES RD, 1979, CHEM REV, V79, P139, DOI 10.1021/cr60318a002; NAKAMURA M, 1988, J ANTIBIOT, V41, P638, DOI 10.7164/antibiotics.41.638; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2740, DOI 10.1021/bi00607a007; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2476; SUGIURA Y, 1978, J ANTIBIOT, V31, P1206, DOI 10.7164/antibiotics.31.1206; VOS CM, 1981, J INORG BIOCHEM, V12, P45; 1972, WORTHINGTON ENZYME M, P43	23	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					944	949						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370470				2022-12-27	WOS:A1992GY96000043
J	PIPAON, C; SANTOS, A; PEREZCASTILLO, A				PIPAON, C; SANTOS, A; PEREZCASTILLO, A			Thyroid Hormone Up-regulates NGFI-A Gene Expression in Rat Brain during Development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAINS; GROWTH-FACTORS; RECEPTOR; TRANSCRIPTION; ENCODES; TRIIODOTHYRONINE; PROTEIN	NGFI-A is an immediate-early response gene induced by signals that initiate growth and differentiation. Its mRNA encodes a sequence-specific transcriptional activator possibly implicated in the control of brain developmental processes. Due to the essential role of thyroid hormone for a correct brain development, we have now investigated the possible regulation by 3,5,3'-triiodo-L-thyronine (T3) of NGFI-A gene expression during maturation of the central nervous system. Our results indicate that expression of mRNA encoding NGFI-A transcription factor is about 8-fold decreased in the brain of neonatal hypothyroid rats. No changes were seen when hypothyroidism was induced in adult life. T3 treatment increased NGFI-A mRNA within 1 h, suggesting that thyroid hormone effect is likely to be a direct one. These data indicate a strong regulation by thyroid hormone of the expression of the growth factor inducible gene NGFI-A during brain development, making this gene a suitable model to study T3 action in the early developing nervous system.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC MED,DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid			Santos, Angel/K-3744-2014; Pipaon, Carlos/L-4922-2014; Perez-Castillo, Ana/A-9505-2015	Santos, Angel/0000-0002-7551-8483; Pipaon, Carlos/0000-0002-3851-6710; Perez-Castillo, Ana/0000-0002-2632-5853				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HAN EB, 1976, AM J OBSTET GYNECOL, V125, P949; JUMP DB, 1984, J BIOL CHEM, V259, P2789; Klein RZ., 1980, NEONATAL THYROID SCR, P51; KOENIG MP, 1981, FETAL BRAIN DISORDER, P229; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MELLSTROM B, 1991, IN PRESS MOL ENDOCRI; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; RABIE A, 1973, BRAIN RES, V61, P267, DOI 10.1016/0006-8993(73)90532-5; SAMUELS HH, 1983, MOL BASIS THYROID HO, P35; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; WOLFF EC, 1964, THYROID GLAND, V1, P237; YAFFE BM, 1984, J BIOL CHEM, V259, P6284	27	56	57	2	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					21	23		10.1016/S0021-9258(18)48449-9	http://dx.doi.org/10.1016/S0021-9258(18)48449-9			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370444	hybrid			2022-12-27	WOS:A1992GY43900006
J	ARTEMYEV, NO; RARICK, HM; MILLS, JS; SKIBA, NP; HAMM, HE				ARTEMYEV, NO; RARICK, HM; MILLS, JS; SKIBA, NP; HAMM, HE			SITES OF INTERACTION BETWEEN ROD G-PROTEIN ALPHA-SUBUNIT AND CGMP-PHOSPHODIESTERASE GAMMA-SUBUNIT - IMPLICATIONS FOR THE PHOSPHODIESTERASE ACTIVATION MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; AMINO-ACID SEQUENCE; OUTER SEGMENTS; INHIBITORY SUBUNIT; CDNA SEQUENCE; RETINAL RODS; TRANSDUCIN; BOVINE; CASCADE	In photoreceptor cells of vertebrates light activates a series of protein-protein interactions resulting in activation of a cGMP-phosphodiesterase (PDE). Interaction between the GTP-bound form of rod G-protein alpha-subunit (alpha(t)) and PDE inhibitory gamma-subunit (Pgamma) is a key event for effector enzyme activation. This interaction has been studied using Pgamma labeled with the fluorescent probe, lucifer yellow vinyl sulfone, at Cys-68 (PgammaLY) and sites of interaction on alpha(t) and Pgamma have been investigated. Addition of alpha(t)GTPgammaS to PgammaLY produced a 3.2-fold increase in the fluorescence of PgammaLY. The K(d) for alpha(t)GTPgammaS.PgammaLY interaction was 36 nM. Addition of 1 muM alpha(t)GDP had no effect, but in the presence of AlF4-, alpha(t)GDP increased PgammaLY fluorescence by 85%. When PgammaLY was reconstituted with Palphabeta to form fluorescent holo-PDE, alpha(t)GTPgammaS increased the fluorescence of holo-PDE with a K0.5 = 0.7 muM. Also, alpha(t)GTPgammaS stimulated the activity of this PDE over an identical range of concentrations with a similar K0.5 (0.6 muM). alpha(t)GTPgammaS enhanced the fluorescence of a COOH-terminal Pgamma fragment, PgammaLY-46-87, as well (K(d) = 1.5 muM). We demonstrate that an alpha(t) peptide, alpha(t)-293-314, which activated PDE (Rarick, H. M., Artemyev, N. O., and Hamm, H. E. (1992) Science 256, 1031-1033), mediates PDE activation by interacting with the Pgamma-46-87 region. Peptide alpha(t)-293-314 bound to PgammaLY (K0.5 = 1.2 muM) as well as to the carboxyl-terminal Pgamma fragment, PgammaLY-46-87 (K0.5 = 1.7 muM) as measured by fluorescence increase, while other alpha(t) peptides had no effect. A peptide from the Pgamma central region, Pgamma-24-46, blocked the interaction between alpha(t)GTPgammaS and PgammaLY. The K(d) for alpha(t)GTPgammaS.Pgamma-24-46 interaction was 0.7 muM. On the other hand, Pgamma-24-46 had no effect on alpha(t)-293-314 interaction with PgammaLY. Our data suggest that there are at least two distinct sites of interaction between alpha(t)GTPgammaS and Pgamma. The interaction between alpha(t)-293-314 and Pgamma-46-87 is important for PDE activation. A second site of interaction involves the Pgamma-24-46 region and an as yet unknown region on the alpha(t) subunit. We suggest that the initial step of PDE activation by alpha(t) includes the binding of alpha(t) to the COOH-terminal region of Pgamma with the formation of an intermediate complex, alpha(t)-Pgamma-Palphabeta in which Pgamma is still bound to Palphabeta through its central region. An alpha(t)-induced conformational change in the Pgamma-24-46 region may result in a decreased affinity of Pgamma for Palphabeta and an increased affinity for alpha(t).	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-06062] Funding Source: Medline; NHLBI NIH HHS [T32HL07692] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; HINGORANI VN, 1988, J BIOL CHEM, V263, P19804; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KROLL S, 1989, J BIOL CHEM, V264, P4490; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MALINSKI JA, 1992, IN PRESS BIOCHEMISTR; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; STEWART WW, 1981, J AM CHEM SOC, V103, P7615, DOI 10.1021/ja00415a033; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	34	75	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25067	25072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334079				2022-12-27	WOS:A1992KB60300026
J	ASTROM, A; PETTERSSON, U; VOORHEES, JJ				ASTROM, A; PETTERSSON, U; VOORHEES, JJ			STRUCTURE OF THE HUMAN CELLULAR RETINOIC ACID-BINDING PROTEIN-II GENE - EARLY TRANSCRIPTIONAL REGULATION BY RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT TERATOCARCINOMA CELLS; CHAIN-TERMINATING INHIBITORS; PROMOTER-SPECIFIC ACTIVATION; SELECTIVE RESPONSE ELEMENTS; COMPLEMENTARY-DNA SEQUENCE; CARCINOMA PCC4.AZA1R CELLS; MESSENGER-RNA EXPRESSION; SKIN FIBROBLASTS INVITRO; GROWTH-POTENTIAL INVITRO; RECEPTOR-BETA GENES	The gene for human cellular retinoic acid-binding protein II (CRABP-II) has been cloned. It was isolated from a human placenta genomic library and is contained within one bacteriophage clone. The gene spans 6 kilobases and consists of 4 exons. One major transcription initiation site was mapped to an A residue 137 nucleotides upstream of the ATG initiation codon. The upstream region contains a TATA box and potential AP2, Sp1, and Krox-24 binding sites, as well as a direct repeat with homology to a retinoic acid-responsive element. The CRABP-II mRNA was rapidly induced within 2-6 h in cultured human skin fibroblasts by retinoic acid, reaching a plateau after 6 h of treatment. The rapid increase of CRABP-II message was mainly due to an increased rate of transcription as determined by nuclear run-on experiments. Increased transcription could be detected as early as 1 h after addition of retinoic acid, peaked at 2 h, and returned to basal levels within 6 h. On-going protein synthesis was required for this transient increase of transcription, since the induction was blocked by cycloheximide. These data suggest that the human CRABP-II gene is transcriptionally regulated by a newly synthesized regulatory protein.			ASTROM, A (corresponding author), UNIV MICHIGAN,DEPT DERMATOL,KRESGE I,R6558,ANN ARBOR,MI 48109, USA.							ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CLEVELAND D W, 1989, New Biologist, V1, P121; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; EWARDS SA, 1991, DEV BIOL, V148, P165; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARPER RA, 1979, SCIENCE, V204, P526, DOI 10.1126/science.432659; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NERVI C, 1990, CELL GROWTH DIFFER, V1, P535; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPORN MB, 1983, CANCER RES, V43, P3034; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25251	25255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334086				2022-12-27	WOS:A1992KB60300053
J	KOSUGI, S; OKAJIMA, F; BAN, T; HIDAKA, A; SHENKER, A; KOHN, LD				KOSUGI, S; OKAJIMA, F; BAN, T; HIDAKA, A; SHENKER, A; KOHN, LD			MUTATION OF ALANINE 623 IN THE 3RD CYTOPLASMIC LOOP OF THE RAT THYROTROPIN (TSH) RECEPTOR RESULTS IN A LOSS IN THE PHOSPHOINOSITIDE BUT NOT CAMP SIGNAL INDUCED BY TSH AND RECEPTOR AUTOANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; THYROID-CELLS; CYCLIC-AMP; STIMULATION; ASSIGNMENT; DOMAINS; BINDING; REGIONS; GENE	Thyrotropin (TSH) and IgG preparations from patients with Graves' disease increase inositol phosphate as well as cAMP formation in Cos-7 cells transfected with rat TSH receptor cDNA. Mutation of alanine 623 in the carboxyl end of the third cytoplasmic loop of the TSH receptor, to lysine or glutamic acid, results in the loss of TSH- and Graves' IgG-stimulated inositol phosphate formation but not in stimulated cAMP formation. There is no effect of the mutations on basal or P2-purinergic receptor-mediated inositol phosphate formation. The mutations do not affect transfection efficiency or the synthesis, processing, or membrane integration of the receptor, as evidenced by the unchanged amount and composition of the TSH receptor forms on Western blots of membranes from transfected cells. The mutations increase the affinity of the TSH receptor for [I-125]TSH and decrease B(max); however, cells with an equivalently decreased B(max) as a result of transfection with lower levels of wild type receptor do not lose either TSH-induced inositol phosphate formation or cAMP signaling activity. Thus, in addition to discriminating between ligand-induced phosphatidylinositol bisphosphate and cAMP signals, the mutation appears to cause an altered receptor conformation which affects ligand binding to its large extracellular domain.	NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	KOSUGI, S (corresponding author), NIDDKD,CELL REGULAT SECT,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.		KOSUGI, Shinji/GYR-2946-2022					AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CORDA D, 1985, J BIOL CHEM, V260, P9230; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; JI IH, 1991, J BIOL CHEM, V266, P14953; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1992, MOL ENDOCRINOL, V6, P166; LAURENT E, 1991, J CLIN INVEST, V87, P1634, DOI 10.1172/JCI115178; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ROUSSEAUMERCK MF, 1990, GENOMICS, V8, P233, DOI 10.1016/0888-7543(90)90276-Z; SHO K, 1991, J BIOL CHEM, V266, P12180; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; TAHARA K, 1991, J BIOL CHEM, V266, P440; THOMPSON EB, 1992, MOL ENDOCRINOL, V6, P501, DOI 10.1210/me.6.4.501; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	23	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24153	24156						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332945				2022-12-27	WOS:A1992KA26300002
J	DUZIC, E; LANIER, SM				DUZIC, E; LANIER, SM			FACTORS DETERMINING THE SPECIFICITY OF SIGNAL TRANSDUCTION BY GUANINE NUCLEOTIDE-BINDING PROTEIN-COUPLED RECEPTORS .3. COUPLING OF ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES IN A CELL TYPE-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENYLATE-CYCLASE; CYCLIC-AMP ACCUMULATION; HAMSTER OVARY CELLS; RAT-BRAIN; PHOSPHOLIPASE-C; ADRENERGIC-RECEPTORS; GENERATING SYSTEMS; CALCIUM CHANNELS; ACTIVATION; STIMULATION	A number of diverse signaling pathways can be activated by G-protein coupled receptors. However, the factors involved in selection of a particular transduction pathway by a single receptor are not well understood. We are attempting to address this issue utilizing the alpha2-adrenergic receptor (alpha2-AR) subfamily as a representative model system. In this report, we demonstrate that the cellular response mediated by an alpha2-AR subtype is cell-specific and thus depends on its environment. Receptor coupling to adenylylcyclase was determined following stable expression of the rat alpha2B- and alpha2D-AR subtypes in three functionally distinct cell types (NIH-3T3 fibroblasts, DDT1 MF-2 smooth muscle cells, and the pheochromocytoma cell line PC-12). When the receptor subtype gene is expressed in NIH-3T3 and DDT1 MF-2 cells, receptor activation inhibits basal and forskolin-induced increases in cellular cAMP. However, in PC-12 transfectants the same receptor subtype actually increases basal cAMP and augments the effect of forskolin. Potentiation of the forskolin effect in PC-12 cells is insensitive to pertussis toxin but is blocked by loading the cells with BAPTA (bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid) which minimizes changes in Ca2+i by calcium chelation. These data and the functional demonstration of a Ca2+/calmodulin-sensitive adenylylcyclase in PC-12 but not NIH-3T3 and DDT1MF-2 cells, suggests that the cell-specific effects of epinephrine are due to receptor coupling to both different G-proteins and types of adenylylcyclase.	MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425	Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NINDS NIH HHS [NS-24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROSTROM CO, 1977, J BIOL CHEM, V252, P5677; BROSTROM MA, 1982, BIOCHIM BIOPHYS ACTA, V721, P227, DOI 10.1016/0167-4889(82)90073-8; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CALTABIANO MM, 1990, GENE AMST, V85, P479; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COUPRY I, 1992, J BIOL CHEM, V267, P9852; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; DALY JW, 1982, J NEUROCHEM, V38, P532, DOI 10.1111/j.1471-4159.1982.tb08660.x; DALY JW, 1981, J NEUROSCI, V1, P49, DOI 10.1523/JNEUROSCI.01-01-00049.1981; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P9844; Exton J H, 1987, Kidney Int Suppl, V23, pS68; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GRAHAM RM, 1986, HEART CARDIOVASCULAR, V2, P1059; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES SB, 1991, MOL PHARMACOL, V39, P239; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUBALAK S, 1992, IN PRESS AM J PHYSL; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LeDonne N C Jr, 1980, Ann N Y Acad Sci, V356, P402, DOI 10.1111/j.1749-6632.1980.tb29647.x; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Longenecker GL., 1985, PLATELETS PHYSL PHAR, P159; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL S, 1984, BIOCHEM J, V224, P453, DOI 10.1042/bj2240453; MACNEIL S, 1985, CELL CALCIUM, V6, P213; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MALNOE A, 1982, BIOCHIM BIOPHYS ACTA, V714, P84, DOI 10.1016/0304-4165(82)90129-5; MCCLUE SJ, 1991, MOL PHARMACOL, V40, P627; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MINOCHERHOMJEE AM, 1988, CALMODULIN, P249; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PILC A, 1986, J PHARMACOL EXP THER, V237, P725; PINKASKRAMARSKI R, 1988, FEBS LETT, V239, P174, DOI 10.1016/0014-5793(88)80911-6; POBBINER BF, 1991, MOL PHARMACOL, V40, P156; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TIMMERMANS PBMWM, 1987, CAN J PHYSIOL PHARM, V65, P1649, DOI 10.1139/y87-259; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	69	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24045	24052						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358886				2022-12-27	WOS:A1992JZ23900092
J	KANAHO, Y; TAKAHASHI, K; TOMITA, U; IIRI, T; KATADA, T; UI, M; NOZAWA, Y				KANAHO, Y; TAKAHASHI, K; TOMITA, U; IIRI, T; KATADA, T; UI, M; NOZAWA, Y			A PROTEIN-KINASE-C INHIBITOR, STAUROSPORINE, ACTIVATES PHOSPHOLIPASE-D VIA A PERTUSSIS TOXIN-SENSITIVE GTP-BINDING PROTEIN IN RABBIT PERITONEAL NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 GRANULOCYTES; CHEMOTACTIC PEPTIDE; SIGNAL TRANSDUCTION; PHORBOL ESTERS; ALPHA-SUBUNITS; COMPOUND 48/80; MAST-CELLS; WASP VENOM; PHOSPHATIDYLCHOLINE; MASTOPARAN	In rabbit peritoneal neutrophils prelabeled with [H-3] lyso platelet-activating factor, a protein kinase C inhibitor, staurosporine (> 1 muM), increased [H-3]phosphatidylethanol ([H-3]PEt) level in the presence of ethanol in a concentration- and time-dependent manner, providing evidence for staurosporine activation of phospholipase D (PLD). The staurosporine activation of the enzyme absolutely required both extracellular calcium and cytochalasin B, and was almost completely inhibited by pretreatment of the cells with pertussis toxin (IAP). In a reconstituted system where the purified G(i1) had been incorporated into phospholipid vesicles, staurosporine activated GTPase activity of G(i1) in a concentration-dependent fashion, with a maximal 4-5-fold effect. ADP-ribosylation by IAP of G(i1) in vesicles significantly suppressed the staurosporine activation. As with the GTPase activity of G(i1), GTPase activities of other purified IAP-sensitive G proteins, such as G(i2)) and G(o), were significantly stimulated by staurosporine, but the cholera toxin substrate G(s) was appreciably less sensitive to the staurosporine stimulation. The staurosporine activation of GTPase was also observed in rabbit neutrophil membranes from control cells, but not in membranes from IAP-treated neutrophils. From these results, we conclude that the staurosporine activation of PLD in rabbit neutrophils is attributed to the direct activation of an IAP-sensitive G protein in a similar manner to receptors occupied by agonists. By contrast, staurosporine failed to activate phosphoinositide-specific phospholipase C (PI-PLC) under the conditions in which it activated PLD, indicating that there exists a PLD activation pathway independent of PI-PLC. Furthermore, it was found that N-acetyl-beta-glucosaminidase release from the granules of intact neutrophils was evoked by staurosporine to almost the same extent as by fMLP (100 nM), but O2- generation was not affected. These results suggest a possibility that PLD pathway plays an important role in enzyme release, but is not sufficient for O2- generation, in rabbit peritoneal neutrophils.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN	Tokyo Institute of Technology; University of Tokyo	KANAHO, Y (corresponding author), GIFU UNIV,SCH MED,DEPT BIOCHEM,TSUKASAMACHI 40,GIFU 500,JAPAN.							AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BECKER EL, 1979, AM J PATHOL, V95, P81; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CATT KJ, 1973, NATURE-NEW BIOL, V244, P219, DOI 10.1038/newbio244219a0; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DECKMYN H, 1991, G PROTEINS, P429; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUANG R, 1991, J BIOL CHEM, V266, P1652; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANAHO Y, 1989, CELL SIGNAL, V1, P553, DOI 10.1016/0898-6568(89)90063-6; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1988, J BIOL CHEM, V263, P12472; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WONG K, 1992, BIOCHEM J, V283, P499, DOI 10.1042/bj2830499; YANG SF, 1967, J BIOL CHEM, V242, P477	40	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23554	23559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331088				2022-12-27	WOS:A1992JZ23900023
J	VILEN, BJ; PENTA, JF; TING, JPY				VILEN, BJ; PENTA, JF; TING, JPY			STRUCTURAL CONSTRAINTS WITHIN A TRIMERIC TRANSCRIPTIONAL REGULATORY REGION - CONSTITUTIVE AND INTERFERON-GAMMA-INDUCIBLE EXPRESSION OF THE HLA-DRA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II GENES; INVARIANT CHAIN GENE; ACTIVATED T-CELLS; ALPHA GENE; ANTIGEN PRESENTATION; IMMUNE INTERFERON; BINDING PROTEINS; NUCLEAR PROTEINS; IA-ANTIGEN	Constitutive and inducible transcription of the major histocompatability class II HLA-DRA gene involves the upstream S element and the conserved X and Y elements. In this report we have addressed the roles of spatial constraints and stereospecific alignment between the upstream S and X elements, and the X and Y elements, in both constitutive and interferon-gamma (gamma-IFN)-induced expression. Analysis of the constitutive expression in B cell lines (B-LCL) has previously shown that the X and Y elements must be stereo-aligned. Further study reveals that any spacing changes between S and X, regardless of the helical alignment of these two elements, is not tolerated. These same restraints are involved in an inducible system, because the response to gamma-IFN treatment requires both stereo alignment between the X and Y elements and precise spacing between the S and X elements. Neither constitutive nor inducible expression can be restored by correcting the distance and spacing between only the S and Y elements with misalignment of X. These results reveal a common pathway for constitutive and inducible expression that may require either direct or indirect protein complex formation among proteins bound to three highly conserved regulatory elements. We have also evaluated the role of the A/T-rich sequence located immediately 5' of the Y element and show that it exerts little effect on constitutive and gamma-IFN induced DRA expression.	UNIV CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 48185] Funding Source: Medline; PHS HHS [P32-A1-07273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON G, 1990, J IMMUNOL, V145, P3456; BASHAM TY, 1983, J IMMUNOL, V130, P1492; BASTA PV, 1987, J IMMUNOL, V138, P1275; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BOTTAZZO GF, 1983, LANCET, V2, P1115; BROWN AM, 1991, J IMMUNOL, V146, P3183; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; COGSWELL JP, 1990, P NATL ACAD SCI USA, V87, P7703, DOI 10.1073/pnas.87.19.7703; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FIERZ W, 1985, J IMMUNOL, V134, P3785; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HAMMERLING GJ, 1976, TRANSPLANT REV, V30, P64; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P6269, DOI 10.1093/nar/19.22.6269; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KORMAN AJ, 1985, IMMUNOL REV, V85, P45, DOI 10.1111/j.1600-065X.1985.tb01130.x; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; MOSES H, 1992, J IMMUNOL, V148, P3643; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PETERLIN BM, 1990, IMMUNOL RES, V9, P164, DOI 10.1007/BF02918176; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; ROBBINS PA, 1988, J IMMUNOL, V141, P1281; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SLOAN JH, 1992, J IMMUNOL, V148, P2591; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TANESE N, 1991, ENES DEV, V5, P2212; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WAIBEL F, 1990, NATURE, V346, P199, DOI 10.1038/346199a0; WILLMAN CL, 1989, J EXP MED, V170, P1559, DOI 10.1084/jem.170.5.1559; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	56	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23728	23734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331098				2022-12-27	WOS:A1992JZ23900047
J	BRANDSCH, R; BICHLER, V; SCHMIDT, M; BUCHNER, J				BRANDSCH, R; BICHLER, V; SCHMIDT, M; BUCHNER, J			GROE DEPENDENCE OF REFOLDING AND HOLOENZYME FORMATION OF 6-HYDROXY-D-NICOTINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; ARTHROBACTER-OXIDANS; D-6-HYDROXYNICOTINE OXIDASE; PROTEINS; BINDING; CATALYSTS; PURIFICATION; APOENZYME; FAD	In Escherichia coli cells expressing 6-hydroxy-D-nicotine oxidase (6-HDNO), a flavoprotein with covalently bound FAD, approximately 40% of the polypeptide is in its apoform. We investigated whether in vivo holoenzyme formation was influenced by the association of the apoenzyme with cellular chaperones. Immunoprecipitation of apoenzyme-containing cell extract with protein-A-Separose-bound 6-HDNO- or GroEL-specific antibodies failed to reveal the formation of complexes between these proteins. The limiting factor in holoenzyme formation in vivo appeared to be the intracellular supply of phosphorylated tricarbon compounds (e.g. glycerol-3-P) acting as allosteric effectors in the flavinylation reaction. When holoenzyme formation from purified apo6-HDNO was investigated in vitro, addition of GroEL and GroES to the reaction assays increased the yield of holoenzyme formation. The observed increase in apoenzyme to holoenzyme transition was ATP independent, and the effect of GroE could be simulated by high concentrations of glycerol (40%). Apparently, a nonspecific protein-protein interaction between the GroE proteins and the apo6-HDNO favored holoenzyme formation. The refolding of guanidinium hydrochloride-unfolded holoenzyme, however, was catalyzed by GroEL and GroES in an ATP-dependent reaction. Recovery of the native, enzymatically active, conformation ranged from 30 to 40%. When apo6-HDNO was denatured and refolded, the same dependence on GroE and ATP was observed in the recovery of a conformation able to incorporate FAD and to yield holoenzyme. [C-14] FAD in the refolding assay yielded radioactively labeled 6-HDNO demonstrating the autocatalytical covalent incorporation of FAD into the polypeptide during the folding process.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	University of Regensburg	BRANDSCH, R (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,W-7800 FREIBURG,GERMANY.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BRUHMULLER M, 1972, EUR J BIOCHEM, V29, P143, DOI 10.1111/j.1432-1033.1972.tb01968.x; BRUHMULLER M, 1978, EUR J BIOCHEM, V37, P256; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GODSELL DS, 1991, TRENDS BIOCHS CI, V16, P203; HAMM HH, 1978, EUR J BIOCHEM, V93, P449; HARLOW E, 1988, ANTIBODIES, P425; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAROSSA RA, 1991, MOL MICROBIOL, V5, P529, DOI 10.1111/j.1365-2958.1991.tb00724.x; Maniatis T., 1982, MOL CLONING; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAUCH L, 1990, MOL GEN GENET, V221, P427, DOI 10.1007/BF00259408; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; NAGURSKY H, 1988, EUR J BIOCHEM, V177, P319, DOI 10.1111/j.1432-1033.1988.tb14379.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8	25	21	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20844	20849						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356985				2022-12-27	WOS:A1992JT97800054
J	HAINES, DS; SUHADOLNIK, RJ; HUBBELL, HR; GILLESPIE, DH				HAINES, DS; SUHADOLNIK, RJ; HUBBELL, HR; GILLESPIE, DH			CELLULAR AND ENZYMATIC-ACTIVITIES OF A SYNTHETIC HETEROPOLYMER DOUBLE-STRANDED-RNA OF DEFINED SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREATED HELA-CELLS; PROTEIN-SYNTHESIS; 2',5'-OLIGO(A) POLYMERASE; INTERFERON; ACTIVATION; KINASE; PPPA2'P5'A2'P5'A; EXPRESSION; INFECTION; INDUCTION	We have synthesized a novel heteropolymer double-stranded RNA (dsRNA) molecule of defined length and strandedness (dsRNA309) and evaluated its ability to induce cytokine gene expression, activate dsRNA-dependent enzymes, and inhibit both tumor cell growth and virus replication. Unlike the conventionally studied synthetic homopolymer dsRNAs, polyinosinic acid:polycytidylic acid (poly(I-C)) and its mismatched analogue polyinosinic:polycytidylic, uridylic acid (poly(I-C-12,U), dsRNA309 possessed restricted biological activity. dsRNA309 was unable to inhibit tumor cell growth or efficiently induce cytokine (i.e. interferon-beta and interleukin-1-alpha) gene expression. However, dsRNA309 was able to inhibit virus replication and activate dsRNA-dependent intracellular enzymes, 2'-5' oligoadenylate synthetase (2'-5'A synthetase) and the dsRNA-activated inhibitor kinase in in vitro assay systems. Overall, dsRNA309 provided a means for examining the mechanisms governing the dsRNA-regulated antiviral and antiproliferative responses, and studies with dsRNA309 demonstrated that the ability of a synthetic dsRNA to activate dsRNA-dependent intracellular enzymes does not necessarily predict the same gene inducing capacity.	TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	HAINES, DS (corresponding author), HAHNEMANN UNIV, DEPT NEOPLAST DIS, BROAD & VINE ST, PHILADELPHIA, PA 19102 USA.							BAGLIONI C, 1978, NATURE, V273, P684, DOI 10.1038/273684a0; CARTER WA, 1974, SCIENCE, V186, P1172, DOI 10.1126/science.186.4170.1172; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; CORY JG, 1965, BIOCHIM BIOPHYS ACTA, V103, P646, DOI 10.1016/0005-2787(65)90085-7; FARRELL PJ, 1978, P NATL ACAD SCI USA, V75, P5893, DOI 10.1073/pnas.75.12.5893; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GOLDFELD AE, 1989, P NATL ACAD SCI USA, V86, P1490, DOI 10.1073/pnas.86.5.1490; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HUBBELL HR, 1984, CANCER RES, V44, P3252; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MARCUS PI, 1977, NATURE, V266, P815, DOI 10.1038/266815a0; MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401; MINKS MA, 1980, J BIOL CHEM, V255, P6403; MINKS MA, 1979, J BIOL CHEM, V254, P180; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; TORRENCE PF, 1984, HDB EXP PHARM, V71, P233; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	29	7	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18315	18319						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356106				2022-12-27	WOS:A1992JN50200014
J	MALETTI, M; ANDERSSON, M; MARIE, JC; ROSSELIN, G; MUTT, V				MALETTI, M; ANDERSSON, M; MARIE, JC; ROSSELIN, G; MUTT, V			SOLUBILIZATION AND PARTIAL-PURIFICATION OF SOMATOSTATIN-28 PREFERRING RECEPTORS FROM HAMSTER PANCREATIC-BETA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITES; STRUCTURAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; CROSS-LINKING; RAT-BRAIN; MEMBRANES; POLYPEPTIDE; SECRETION; PROTEINS; INSULIN	Somatostatin-28 (SRIF-28) preferring receptors were solubilized from hamster beta-cell insulinoma using the zwitterionic detergent 3-[(3-cholamidopropyl) dimethylammonio]-l-propanesulfonate. The binding of the iodinated [Leu8-D-TRP22-Tyr25]SRIF-28 analog (referred to as I-125[LWY] SRIF-28) to the solubilized fraction was time-dependent, saturable, and reversible. Scatchard analysis of equilibrium binding data indicated that the solubilized extract contained two classes of SRIF-28-binding sites: a high affinity site (K(d) = 0.3 nM and B(max) = 1 pmol/mg protein) and a low affinity site (K(d) = 13 nM and B(max) = 4.7 pmol/mg protein). The binding of I-125[LWY]SRIF-28 to solubilized SRIF-28 receptors was sensitive to the GTP analog guanosine-5'-O-thiotriphosphate, suggesting that receptors are functionally linked to a G-protein. By anion-exchange chromatography of the solubilized extract followed by chromatography on wheat germ agglutinin, a 46-fold purification of SRIF-28 receptors was obtained. At this stage of purification, only high affinity sites were found (K(d) = 1 nM) and the GTP effect was not maintained. A specific protein of 37 kDa was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis after photoaffinity labeling. We suggest that this protein is the putative SRIF-28 receptor or a subunit thereof.	KAROLINSKA INST,DEPT BIOCHEM 2,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	MALETTI, M (corresponding author), HOP ST ANTOINE,INSERM,U55,F-75571 PARIS 12,FRANCE.							AMHERDT M, 1987, J CLIN INVEST, V80, P1455, DOI 10.1172/JCI113225; ANTONIOTTI H, 1984, J CHROMATOGR, V296, P181, DOI 10.1016/S0021-9673(01)96411-8; BOHLEN P, 1980, BIOCHEM BIOPH RES CO, V96, P725, DOI 10.1016/0006-291X(80)91415-1; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BROWN M, 1981, ENDOCRINOLOGY, V108, P2391, DOI 10.1210/endo-108-6-2391; BRUNO JF, 1989, ENDOCRINOLOGY, V124, P831, DOI 10.1210/endo-124-2-831; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; COTRONEO P, 1988, EUR J BIOCHEM, V174, P219, DOI 10.1111/j.1432-1033.1988.tb14085.x; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GOLDFINE ID, 1972, J BIOL CHEM, V247, P1211; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HE HT, 1990, MOL PHARMACOL, V37, P614; KNUHTSEN S, 1988, BIOCHEM J, V254, P641, DOI 10.1042/bj2540641; KNUHTSEN S, 1990, J BIOL CHEM, V265, P1129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN MJM, 1986, SCAND J GASTROENTERO, V21, P42, DOI 10.3109/00365528609087430; LOMASNEY JW, 1986, J BIOL CHEM, V261, P7710; MALETTI M, 1984, ENDOCRINOLOGY, V115, P1324, DOI 10.1210/endo-115-4-1324; MANDARINO L, 1981, NATURE, V291, P76, DOI 10.1038/291076a0; MEYERS CA, 1980, P NATL ACAD SCI-BIOL, V77, P6171, DOI 10.1073/pnas.77.10.6171; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; OKAMURA H, 1989, J BIOL CHEM, V264, P5904; PATTHI S, 1988, J BIOL CHEM, V263, P19363; PRADAYROL L, 1980, FEBS LETT, V109, P55, DOI 10.1016/0014-5793(80)81310-X; REUBI JC, 1984, NEUROSCI LETT, V49, P259, DOI 10.1016/0304-3940(84)90299-4; REUBI JC, 1982, ENDOCRINOLOGY, V110, P1049, DOI 10.1210/endo-110-3-1049; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; SAKAMOTO C, 1988, J BIOL CHEM, V263, P14441; SAKAMOTO C, 1984, J BIOL CHEM, V259, P9623; SCHALLY AV, 1980, P NATL ACAD SCI-BIOL, V77, P4489, DOI 10.1073/pnas.77.8.4489; SCHONBRUNN A, 1983, ENDOCRINOLOGY, V113, P1559, DOI 10.1210/endo-113-5-1559; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SHAPIRO S, 1975, ENDOCRINOLOGY, V97, P442, DOI 10.1210/endo-97-2-442; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRIKANT CB, 1986, BIOCHEM BIOPH RES CO, V139, P757, DOI 10.1016/S0006-291X(86)80055-9; SRIKANT CB, 1981, NATURE, V294, P259, DOI 10.1038/294259a0; SRIKANT CB, 1986, J BIOL CHEM, V261, P7690; SRIKANT CB, 1987, SOMATOSTATIN BASIC C, P89; TAPAREL D, 1983, BIOCHEM BIOPH RES CO, V115, P827, DOI 10.1016/S0006-291X(83)80009-6; THERMOS K, 1988, MOL PHARMACOL, V33, P370; THERMOS K, 1989, NEUROSCIENCE, V31, P131, DOI 10.1016/0306-4522(89)90035-3; THERMOS K, 1990, AM J PHYSIOL, V259, pE216, DOI 10.1152/ajpendo.1990.259.2.E216; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZYSK JR, 1986, J BIOL CHEM, V261, P6781	45	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15620	15625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353498				2022-12-27	WOS:A1992JG11300058
J	BANEYX, F; GATENBY, AA				BANEYX, F; GATENBY, AA			A MUTATION IN GROEL INTERFERES WITH PROTEIN FOLDING BY REDUCING THE RATE OF DISCHARGE OF SEQUESTERED POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; GENE-PRODUCTS; PURIFICATION; SUPPRESSION; EXPRESSION; EXPORT; ATP	GroEL140, a mutant Escherichia coli chaperonin unable to support bacteriophage lambda-head assembly, was purified to near homogeneity and compared to wild type GroEL (cpn60). GroEL140 exhibited a 1.5-fold lower ATPase activity relative to the wild type protein. The hydrolysis of ATP by both polypeptides was fully inhibited by an excess of ATP-gamma-S and partially inhibited by ADP and 5'-adenylylimidodiphosphate, suggesting that adenine nucleotides display different affinities for the ATP binding site of chaperonins. GroEL140 was more sensitive to trypsin digestion compared to wild type GroEL indicating that the mutation destabilized the conformation of the mutant. The proteolytic susceptibility of both chaperonins was similarly enhanced upon addition of ATP, ADP or non-hydrolyzable ATP analogs, providing evidence (i) of a conformational change in the chaperonin structure which is likely to drive the protein discharge process, and (ii) that hydrolysis of ATP is not required to achieve topological modifications. GroEL140 retained its ability to bind non-native ribulose bisphosphate carboxylase/oxygenase (Rbu-P2-carboxylase), but released bound proteins upon addition of ATP and GroES (cpn10) 6-7-fold less efficiently compared to GroEL. This functional defect was shown to be related to a suboptimal, but not an absence of, interaction with GroES since (i) GroEL140 and GroES were unable to form a complex isolatable by size exclusion chromatography, and (ii) increasing the incubation time or the concentration of GroES enhanced the amount of refolded Rbu-P2-carboxylase discharged from GroEL140-Rbu-P2-carboxylase binary complexes. Pulse-chase experiments involving a double immunoabsorption technique confirmed that Rbu-P2-carboxylase remained associated two times longer with GroEL140 than with GroEL in vivo.	DUPONT CO,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont								BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GATENBY AA, 1981, NATURE, V291, P117, DOI 10.1038/291117a0; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1977, ANAL BIOCHEM, V78, P66, DOI 10.1016/0003-2697(77)90009-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIKI T, 1988, J MOL BIOL, V201, P327, DOI 10.1016/0022-2836(88)90141-6; MORIMOTO R I, 1990, P1; NEIDHARDT FC, 1981, J BACTERIOL, V145, P513, DOI 10.1128/JB.145.1.513-520.1981; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SOMERVILLE CR, 1984, MOL GEN GENET, V193, P214, DOI 10.1007/BF00330670; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1992, IN PRESS BIOCHEMISTR; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VIITANEN PV, 1992, IN PRESS PROTEIN SCI; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	41	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11637	11644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350786				2022-12-27	WOS:A1992HX16900107
J	THOMPSON, DB; SOMMERCORN, J				THOMPSON, DB; SOMMERCORN, J			USE OF A MULTIPLE S1 NUCLEASE PROTECTION ASSAY TO MONITOR CHANGES IN RNA LEVELS FOR TYPE-1 PHOSPHATASE AND SEVERAL PROTOONCOGENES IN RESPONSE TO INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; GENE-EXPRESSION; MESSENGER-RNA; OLIGONUCLEOTIDE PROBES; NUCLEOTIDE-SEQUENCE; HEPATOMA-CELLS; FOS-PROTEIN; TRANSCRIPTION; LOCALIZATION; CLONING	Changes in insulin-regulated gene expression occur in a time- and tissue-dependent fashion. To monitor these changes we have adapted the S1 nuclease protection assay to allow simultaneous estimation of multiple RNA species in a single sample by using synthetic oligonucleotides of various lengths as probes for specific RNA species, which can then be resolved by electrophoresis. The multiple S1 nuclease protection assay was used to assess the influence of insulin on the RNA concentrations of 12 different genes in human skeletal muscle. Estimates obtained by this assay were comparable with those obtained by Northern analysis. RNA levels for proto-oncogene c-src displayed a transient 4-fold increase, whereas RNA levels for type 1 protein phosphatase were suppressed by 50% during the same time period. RNAs corresponding to known insulin-responsive genes such as c-fos, c-myc, c-Ha-ras, and c-src displayed rapid and transient 2-4-fold increases between 30 and 60 min as detected by either Northern analysis or the multiple S1 nuclease protection assay. In addition, RNA levels for the insulin receptor, Glut-4, Glut-3, and c-jun were apparently unaffected by exposure of the cells to insulin.			THOMPSON, DB (corresponding author), NIDDKD,CLIN DIABET & NUTR SECT,PHOENIX,AZ 85016, USA.							BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BECK AJ, 1977, CELL, V12, P721; BECKER-ANDRE M, 1991, Methods in Molecular and Cellular Biology, V2, P189; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1989, J BIOL CHEM, V264, P21435; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COUTLEE F, 1990, J BIOL CHEM, V265, P11601; COVERA S, 1991, J BIOL CHEM, V266, P9271; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GAI XX, 1989, ONCOGENE RES, V5, P111; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HANES BD, 1985, NUCLEIC ACID HYBRIDI; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HENDERSON GS, 1991, BIOTECHNIQUES, V10, P190; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KELLER GH, 1989, DNA PROBES, P1; KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MOORE PS, 1989, ARCH BIOCHEM BIOPHYS, V275, P486, DOI 10.1016/0003-9861(89)90395-0; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; Nei M., 1983, P165; Nei M, 1987, MOL EVOLUTIONARY GEN, P254, DOI [10.7312/nei-92038, DOI 10.7312/NEI-92038]; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Sharp P A, 1980, Methods Enzymol, V65, P750; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TORCZYNSKI RM, 1985, DNA-J MOLEC CELL BIO, V4, P283, DOI 10.1089/dna.1985.4.283; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Vogt V M, 1980, Methods Enzymol, V65, P248; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WOOD WI, 1987, METHOD ENZYMOL, V152, P443	53	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5921	5926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372896				2022-12-27	WOS:A1992HK31800034
J	FESCHENKO, MS; ZVARITCH, EI; HOFMANN, F; SHAKHPARONOV, MI; MODYANOV, NN; VORHERR, T; CARAFOLI, E				FESCHENKO, MS; ZVARITCH, EI; HOFMANN, F; SHAKHPARONOV, MI; MODYANOV, NN; VORHERR, T; CARAFOLI, E			A MONOCLONAL-ANTIBODY RECOGNIZES AN EPITOPE IN THE 1ST EXTRACELLULAR LOOP OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; AMINO-ACID SEQUENCE; CA-2+ PUMP; SARCOPLASMIC-RETICULUM; ERYTHROCYTE-MEMBRANE; FUNCTIONAL DOMAINS; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; CALCIUM-PUMP	A monoclonal antibody against the human erythrocyte Ca2+ pump (1E4) reacted with the enzyme in intact erythrocytes. Using trypsinized preparations of the pump the antibody only reacted with the N-terminal fragments of 33.5 and 35 kDa. The fragments span from the N terminus (35 kDa) or from residue 19 (33.5 kDa) to residue 314 of the hPMCA4 isoform of the pump. Exhaustive degradation with a number of agents produced smaller peptides which reacted with the antibody. Sequencing analysis on two chymotryptic fragments of 8.8 and 13.5 kDa identified the epitope in an approximately 80-residue domain beginning with Gly-81. Two peptides corresponding to the putative extramembrane portions of this region of the pump were synthesized. The antibody reacted with one of them, spanning residues Phe-121 to Gly-152 and containing the first putative external loop of the pump. Peptides corresponding to overlapping portions of this peptide were synthesized, leading to the location of the epitope in a 13-residue sequence (Glu-130 to Glu-142) in the first predicted extracellular loop (Verma, A. K., Filoteo, A. G., Stanford, D. R., Wieben, E. D., Strehler, E. E., Fischer, R., Heim, R., Vogel, G., Mathews, S., Strehler-Page, M-A., James, P., Vorherr, T., Krebs, J., Penniston, J. T., and Carafoli, E. (1988) J. Biol. Chem. 263, 14152-14159).	SWISS FED INST TECHNOL,BIOCHEM LAB,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND; MM SHEMYAKIN BIOORGAN CHEM INST,MOSCOW 117871,USSR	ETH Zurich; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BEATTY JD, 1987, J IMMUNOL METHODS, V100, P161, DOI 10.1016/0022-1759(87)90186-4; BEATTY JD, 1987, J IMMUNOL METHODS, V100, P173, DOI 10.1016/0022-1759(87)90187-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARIDE AJ, 1988, BIOCHEM J, V255, P663; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DESRGROTH SF, 1970, J IMMUNOL METHODS, V35, P1; DIANO M, 1987, ANAL BIOCHEM, V166, P224, DOI 10.1016/0003-2697(87)90568-9; ENGVALL E, 1972, J IMMUNOL, V109, P129; FESCHENKO MS, 1991, IN PRESS BIOL MEMBRA; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; GREEB J, 1989, J BIOL CHEM, V264, P18569; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHLER G, 1981, IMMUNOLOGICAL METHOD, P296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NIGGLI V, 1981, J BIOL CHEM, V256, P395; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; SACHS G, 1989, J BIOENERG BIOMEMBR, V21, P573, DOI 10.1007/BF00808114; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; VRMA AK, 1988, J BIOL CHEM, V263, P14152; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4097	4101						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371283				2022-12-27	WOS:A1992HE60700079
J	HANSON, S; ADELMAN, J; ULLMAN, B				HANSON, S; ADELMAN, J; ULLMAN, B			AMPLIFICATION AND MOLECULAR-CLONING OF THE ORNITHINE DECARBOXYLASE GENE OF LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RESISTANT LEISHMANIA; ALPHA-DIFLUOROMETHYLORNITHINE; DNA AMPLIFICATION; TRYPANOSOMA-BRUCEI; INTRACELLULAR DEGRADATION; EXTRACHROMOSOMAL CIRCLES; DIHYDROFOLATE REDUCTASE; PLASMODIUM-FALCIPARUM; MESSENGER-RNA	A strain of Leishmania donovani has been described that is resistant to DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase (ODCase) activity, and contains 15-fold greater amounts of ODCase activity and protein than the wild type strain from which it was derived (Coons, T., Hanson, S., Bitonti, A. J., McCann, P. P., and Ullman, B. (1990) Mol. Biochem. Pharmacol. 39, 77-90). From this mutant strain, another ODCase overproducing L. donovani strain, DFMO16, was generated by virtue of its ability to proliferate under even higher concentrations of DFMO. To investigate the mechanism by which DFMO-resistant cells overexpress ODCase, the leishmanial ODCase gene was isolated by hybridization to a fragment of the L. donovani ODCase gene that was generated by the polymerase chain reaction. The nucleotide sequence of a 4.5-kilobase DNA fragment encompassed an open reading frame encoding 707 amino acids (M(r) = 77,350). The leishmanial protein contained an extra approximately 200 amino acid NH2-terminal extension and lacked the COOH terminus of the mammalian ODCase. Northern blot analysis revealed two leishmanial ODCase transcripts of 4.8 and 6.5 kilobases, both of which were amplified 10-20-fold in the DFMO16 cells. Genomic Southern blot analysis established that the augmented amount of ODCase activity and ODCase mRNA in the DFMO16 strain could be attributed to a approximately 10-20-fold amplification of the ODCase gene copy number. DFMO16 cells exhibited an unstable phenotype in that the amplification of the ODCase gene, the increased amount of ODCase transcript, the overproduction of ODCase activity, and the DFMO-resistance growth phenotype all reverted synchronously in the absence of selective pressure.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R37AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALHONENHONGISTO L, 1985, BIOCHEM BIOPH RES CO, V126, P734, DOI 10.1016/0006-291X(85)90246-3; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Ausubel FM, 1988, MOL REPROD DEV; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; Battey, 1986, BASIC METHODS MOL BI; BELLOFATTO V, 1987, MOL BIOCHEM PARASIT, V25, P227, DOI 10.1016/0166-6851(87)90086-7; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; Campbell W.C., 1986, CHEMOTHERAPY PARASIT; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COOMBS GH, 1983, J ANTIMICROB CHEMOTH, V11, P151, DOI 10.1093/jac/11.2.151; COONS T, 1990, MOL BIOCHEM PARASIT, V39, P77, DOI 10.1016/0166-6851(90)90010-J; DETKE S, 1988, J BIOL CHEM, V263, P3418; DETKE S, 1989, EXP CELL RES, V180, P161, DOI 10.1016/0014-4827(89)90220-6; DOBERSTYN EB, 1984, EXPERIENTIA, V40, P1311, DOI 10.1007/BF01951884; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; FONZI WA, 1987, J BIOL CHEM, V262, P10127; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GILLIN FD, 1983, J PROTOZOOL, V31, P161; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HANSON WL, 1983, J PARASITOL, V69, P446, DOI 10.2307/3281265; HANSON WL, 1982, AM J VET RES, V43, P1651; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATAKURA K, 1989, MOL BIOCHEM PARASIT, V34, P189, DOI 10.1016/0166-6851(89)90010-8; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KAUR K, 1988, J BIOL CHEM, V263, P7020; KINK JA, 1987, P NATL ACAD SCI USA, V84, P1253, DOI 10.1073/pnas.84.5.1253; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDFEAR SM, 1985, MOL BIOCHEM PARASIT, V15, P61, DOI 10.1016/0166-6851(85)90029-5; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEINONEN P, 1987, BIOCHEM J, V242, P199, DOI 10.1042/bj2420199; LOOKER D, 1988, NUCLEIC ACIDS RES, V16, P7198, DOI 10.1093/nar/16.14.7198; McCann P. P., 1981, Advances in polyamine research., P97; MCCONLOGUE L, 1986, MOL CELL BIOL, V6, P2865, DOI 10.1128/MCB.6.8.2865; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; MURPHY WJ, 1986, CELL, V47, P515; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; PETERS W, 1985, PARASITOLOGY, V90, P705, DOI 10.1017/S003118200005232X; PHILLIPS MA, 1987, MOL BIOCHEM PARASIT, V22, P9, DOI 10.1016/0166-6851(87)90064-8; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; POHJANPELTO P, 1985, J BIOL CHEM, V260, P8532; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACK SP, 1990, MOL CELL BIOL, V10, P6788; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; WANG CC, 1982, TRENDS BIOCHEM SCI, V7, P354, DOI 10.1016/0968-0004(82)90108-6; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WILSON K, 1991, J BIOL CHEM, V266, P1665; [No title captured]; 1982, B WORLD HEALTH ORGAN, V60, P821	74	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2350	2359						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1339439				2022-12-27	WOS:A1992HB53200038
J	NAKAJIMA, Y; TSUCHIDA, K; NEGISHI, M; ITO, S; NAKANISHI, S				NAKAJIMA, Y; TSUCHIDA, K; NEGISHI, M; ITO, S; NAKANISHI, S			DIRECT LINKAGE OF 3 TACHYKININ RECEPTORS TO STIMULATION OF BOTH PHOSPHATIDYLINOSITOL HYDROLYSIS AND CYCLIC-AMP CASCADES IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; MOLECULAR CHARACTERIZATION; ADENYLATE-CYCLASE; PHOSPHOINOSITIDE METABOLISM; INOSITOL PHOSPHOLIPIDS; MAMMALIAN TACHYKININ; FUNCTIONAL CDNA; MESSENGER-RNAS; P RECEPTOR; FIBROBLASTS	The mammalian tachykinin system consists of three distinct peptides, substance P, substance K, and neuromedin K, and possesses three corresponding receptors. In this investigation we examined intracellular signal transduction of the individual tachykinin receptors by transfection and stable expression of these receptor cDNAs in Chinese hamster ovary cells. The three receptors commonly showed a rapid and marked stimulation in both phosphatidylinositol (PI) hydrolysis and cyclic AMP formation in response to tachykinin interaction. Direct linkage of the three receptors to both phospholipase C and adenylate cyclase was evidenced by the finding that tachykinin, added together with GTP, activated these enzyme activities in membrane preparations derived from tachykinin receptor-expressing cells. The stimulation of cyclic AMP formation was less efficient than that of PI hydrolysis in receptor-expressing cells as well as their membrane preparations (about 1 order of magnitude difference in the effective peptide concentrations). However, the stimulatory responses of the PI hydrolysis and cyclic AMP formation in both receptor-expressing cells and their membrane preparations were induced in complete agreement with the tachykinin binding selectivity of each subtype of the receptors. This investigation demonstrated unequivocally that the tachykinin receptors have the potential to couple directly to both phospholipase C and adenylate cyclase and to stimulate PI hydrolysis and cyclic AMP formation.	OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA,OSAKA 565,JAPAN		NAKAJIMA, Y (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; ERSPAMER CF, 1980, N-S ARCH PHARMACOL, V311, P61; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEY MR, 1980, MOL PHARMACOL, V18, P78; HENDERSON AK, 1990, LIFE SCI, V47, pPL7, DOI 10.1016/0024-3205(90)90329-P; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; LANIYONU A, 1988, FEBS LETT, V240, P186, DOI 10.1016/0014-5793(88)80365-X; LIPSKY JJ, 1982, J PHARMACOL EXP THER, V220, P287; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NAWA H, 1984, LIFE SCI, V34, P1153, DOI 10.1016/0024-3205(84)90087-0; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; SASAI Y, 1989, BIOCHEM BIOPH RES CO, V165, P695, DOI 10.1016/S0006-291X(89)80022-1; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SUGAMA K, 1989, BIOCHIM BIOPHYS ACTA, V1011, P75, DOI 10.1016/0167-4889(89)90081-5; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; UHING RJ, 1986, J BIOL CHEM, V261, P2140; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANGIERSBERGEN PLM, 1991, P NATL ACAD SCI USA, V88, P1661, DOI 10.1073/pnas.88.5.1661; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WATSON SP, 1984, BIOCHEM PHARMACOL, V33, P3733, DOI 10.1016/0006-2952(84)90033-9; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMASHITA K, 1983, LIFE SCI, V32, P2163, DOI 10.1016/0024-3205(83)90106-6; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	34	271	284	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2437	2442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370820				2022-12-27	WOS:A1992HB53200051
J	SUGAWARA, E; NIKAIDO, H				SUGAWARA, E; NIKAIDO, H			PORE-FORMING ACTIVITY OF OMPA PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE-PROTEIN; CELL-ENVELOPE MEMBRANE; PSEUDOMONAS-AERUGINOSA; TRANSPORT MUTANTS; DODECYL-SULFATE; MAJOR PROTEINS; K-12; CHANNELS; PERMEABILITY; PURIFICATION	Escherichia coli outer membrane protein OmpA was purified to homogeneity, as a monomer, from a K12 derivative deficient in both OmpF and OmpC porins. When proteoliposomes reconstituted from the purified OmpA, phospholipids, and lithium dodecyl sulfate were tested for permeability to small molecules by osmotic swelling, it was found that OmpA produced apparently nonspecific diffusion channels that allowed the penetration of various solutes. The pore-forming activity was destroyed by the heat denaturation of the OmpA protein, and the use of an OmpA-deficient mutant showed that the activity was not caused by copurifying contaminants. The size of the OmpA channel, estimated by comparison of diffusion rates of solutes of different sizes, was rather similar to that of E. coli OmpF and OmpC porins, i.e. about 1 nm in diameter. The rate of penetration of L-arabinose caused by a given amount of OmpA protein, however, was about a hundredfold lower than the rate produced by the same amount of E. coli OmpF porin. The addition of large amounts of lithium dodecyl sulfate to the reconstitution mixture increased the permeability through the OmpA channel, apparently by facilitating the correct insertion of OmpA into the bilayer.			SUGAWARA, E (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NIAID NIH HHS [AI-09644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS JC, 1985, J BACTERIOL, V161, P484, DOI 10.1128/JB.161.2.484-492.1985; BAVOIL P, 1977, MOL GEN GENET, V158, P23, DOI 10.1007/BF00455116; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; DUCHENE M, 1988, J BACTERIOL, V170, P155, DOI 10.1128/jb.170.1.155-162.1988; EYTAN GD, 1976, J BIOL CHEM, V251, P6831; FLAMMANN HT, 1984, J BACTERIOL, V159, P410, DOI 10.1128/JB.159.1.410-412.1984; GOTOH N, 1989, J BACTERIOL, V171, P983, DOI 10.1128/jb.171.2.983-990.1989; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; KLOSE M, 1988, J BIOL CHEM, V263, P13297; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MANNING PA, 1977, J MOL BIOL, V116, P285, DOI 10.1016/0022-2836(77)90217-0; MANNING PA, 1976, J BACTERIOL, V127, P1081; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; NAKAE T, 1976, J BIOL CHEM, V251, P2176; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; NIKAIDO H, 1977, BIOCHEM BIOPH RES CO, V76, P324, DOI 10.1016/0006-291X(77)90728-8; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Nikaido H., 1986, BACTERIA, V10, P145; SCHNAITMAN CA, 1984, J BACTERIOL, V159, P555, DOI 10.1128/JB.159.2.555-563.1984; SCHWEIZER M, 1977, J BACTERIOL, V129, P1651, DOI 10.1128/JB.129.3.1651-1652.1977; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SONNTAG I, 1978, J BACTERIOL, V136, P280, DOI 10.1128/JB.136.1.280-285.1978; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; VANALPHEN L, 1977, FEBS LETT, V75, P285, DOI 10.1016/0014-5793(77)80104-X; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WOODRUFF WA, 1989, J BACTERIOL, V171, P3304, DOI 10.1128/jb.171.6.3304-3309.1989; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	32	189	196	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2507	2511						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370823				2022-12-27	WOS:A1992HB53200061
J	CALALB, MB; FOX, DT; HANKS, SK				CALALB, MB; FOX, DT; HANKS, SK			MOLECULAR-CLONING AND ENZYMATIC ANALYSIS OF THE RAT HOMOLOG OF PHK-GAMMA-T, AN ISOFORM OF PHOSPHORYLASE-KINASE CATALYTIC SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PROTEIN-KINASE; MESSENGER-RNAS; CDNA CLONES; B KINASE; CALMODULIN; IDENTIFICATION; SEQUENCE; ISOENZYMES; TISSUES	Messenger RNA encoding a protein kinase closely related to the catalytic subunit of skeletal muscle phosphorylase kinase has previously been isolated from a human HeLa cell cDNA library, and cross-species Northern hybridization analysis has shown that the rat homolog of this transcript is abundant in the adult testis (Hanks, S. K. (1989) Mol. Endocrinol. 3, 110-116). We now propose that the protein encoded by this transcript be designated as "PhK-gamma-T." In this article, the primary structure of the rat homolog of PhK-gamma-T is described, as deduced from nucleotide sequences of cDNA and genomic clones. RNase protection analysis reveals that PhK-gamma-T transcripts are actually present in a wide variety of adult rat tissues, but at levels 20-100-fold less than what is observed in the testis. In the testis, transcription of the PhK-gamma-T gene is initiated at multiple sites as shown by RNase protection and primer extension. Enzymatic activity of PhK-gamma-T was demonstrated using renatured bacterially expressed protein. In the presence of Ca2+/calmodulin, PhK-gamma-T is able to efficiently phosphorylate glycogen phosphorylase and convert it from an inactive to an active form. We conclude that PhK-gamma-T represents a true isoform of phosphorylase kinase catalytic subunit.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; SALK INST BIOL STUDIES,MOLEC BIOL LAB,LA JOLLA,CA 92037	Vanderbilt University; Salk Institute					NCRR NIH HHS [RR-05424] Funding Source: Medline; NIGMS NIH HHS [GM-38793] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038793] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER PK, 1987, J BIOL CHEM, V262, P8799; BURCHELL A, 1976, FEBS LETT, V67, P17, DOI 10.1016/0014-5793(76)80861-7; CAWLEY KC, 1988, NUCLEIC ACIDS RES, V16, P2355, DOI 10.1093/nar/16.5.2355; CHAMBERLAIN JS, 1987, P NATL ACAD SCI USA, V84, P2886, DOI 10.1073/pnas.84.9.2886; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISMAN TD, 1982, J BIOL CHEM, V257, P798; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COHEN P, 1988, MOL ASPECTS CELL REG, V5, P123; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; de Kretser D.M., 1988, P837; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1989, MOL ENDOCRINOL, V3, P110, DOI 10.1210/mend-3-1-110; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HARLOW E, 1988, ANTIBODIES LABORATOR; JAMES P, 1991, J BIOL CHEM, V266, P7087; KEE SM, 1986, J BIOL CHEM, V261, P4732; KILIMANN MW, 1990, J INHERIT METAB DIS, V13, P435, DOI 10.1007/BF01799500; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MANN T, 1964, BIOCH SEMEN MALE REP, P1; Marston F. A. O., 1987, DNA CLONING, P59; ONO T, 1989, J BIOL CHEM, V264, P2081; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PICKETTGIES CA, 1986, ENZYMES, V17, P396; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PROUX D, 1974, BIOCHIMIE, V56, P1559; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J, 1989, MOL CLONING LABORATO; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; SKUSTER JR, 1980, J BIOL CHEM, V255, P2203; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO; TAIRA T, 1982, J BIOCHEM-TOKYO, V91, P883, DOI 10.1093/oxfordjournals.jbchem.a133776; ZEVGOLIS VG, 1991, BIOCHIM BIOPHYS ACTA, V1091, P222, DOI 10.1016/0167-4889(91)90065-6	37	27	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1455	1463						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370475				2022-12-27	WOS:A1992HA48500013
J	DIJESO, B; LIGUORO, D; FERRANTI, P; MARINACCIO, M; ACQUAVIVA, R; FORMISANO, S; CONSIGLIO, E				DIJESO, B; LIGUORO, D; FERRANTI, P; MARINACCIO, M; ACQUAVIVA, R; FORMISANO, S; CONSIGLIO, E			MODULATION OF THE CARBOHYDRATE MOIETY OF THYROGLOBULIN BY THYROTROPIN AND CALCIUM IN FISHER RAT-THYROID LINE-5 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI FOREST VIRUS; CHLORIDE SLOWS TRANSPORT; YEAST SECRETORY PATHWAY; VIRAL MEMBRANE-PROTEINS; GOLGI-COMPLEX; KIDNEY-CELLS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; FOLLICLES; MONENSIN	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days. Such a TSH effect is much less or not evident when secreted thyroglobulin is digested with peptide N-glycohydrolase F or when intracellular thyroglobulin is compared. Intracellular thyroglobulin migrates faster than thyroglobulin secreted either in the presence or in the absence of TSH. Evaluation of the mannose and galactose content of thyroglobulin demonstrates that intracellular thyroglobulin has more mannose and less galactose than extracellular thyroglobulin; it also shows that TSH decreases the mannose content of thyroglobulin while increasing its galactose content. Bio-Gel P6 chromatography shows that TSH increases the complex type carbohydrate chains while decreasing the high mannose chains in the secreted thyroglobulin. High mannose type oligosaccarides were characterized by fast atom bombardment-mass spectrometry analysis. Treatment with the calcium ionophore A23187 (5-mu-M) of FRTL-5 cells cultured with or without TSH causes the appearance of a "fast" migrating form of thyroglobulinin in the culture medium. Bio-Gel P6 chromatography shows that A23187 causes a dramatic decrease of the complex carbohydrate chains of the secreted thyroglobulin.	CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC LUIGI CALIFANO,I-80131 NAPLES,ITALY; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; CNR,SERV SPETTROMETRIA,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			Ferranti, Pasquale/ABF-8111-2021	di jeso, bruno/0000-0001-8713-5984; FERRANTI, Pasquale/0000-0002-6250-6512				Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBAT.FS, 1980, P NATLA CAD SCI US, V77, P4355; ARIMA T, 1972, J BIOL CHEM, V247, P1825; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1987, J BIOL CHEM, V262, P10304; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORTESE F, 1976, EUR J BIOCHEM, V68, P121, DOI 10.1111/j.1432-1033.1976.tb10770.x; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DUNN JT, 1975, J BIOL CHEM, V250, P5801; EGGO MC, 1982, ENDOCRINOLOGY, V111, P1663, DOI 10.1210/endo-111-5-1663; EKHLOM R, 1981, MOL CELL ENDOCRINOL, V24, P141; FONTANA S, 1980, AUTOIMMUNE ASPECTS E, P147; FRANC JL, 1984, BIOCHEM BIOPH RES CO, V118, P910, DOI 10.1016/0006-291X(84)91481-5; FUKUDA M, 1971, BIOCHEM J, V123, P407, DOI 10.1042/bj1230407; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLIN KS, 1988, J BIOL CHEM, V263, P11478; MATLIN KS, 1986, J BIOL CHEM, V261, P5172; MULLIN BR, 1977, ENDOCRINOLOGY, V100, P351, DOI 10.1210/endo-100-2-351; NITSCH L, 1980, P NATL ACAD SCI-BIOL, V77, P472, DOI 10.1073/pnas.77.1.472; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ODA K, 1988, J BIOL CHEM, V263, P12576; RANI CSS, 1985, BIOCHEM BIOPH RES CO, V131, P1041, DOI 10.1016/0006-291X(85)90195-0; RING P, 1987, CELL TISSUE RES, V250, P149, DOI 10.1007/BF00214666; RING P, 1987, CELL TISSUE RES, V248, P153, DOI 10.1007/BF01239976; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; RONIN C, 1986, J BIOL CHEM, V261, P7287; RONIN C, 1976, BIOCHIM BIOPHYS ACTA, V428, P445, DOI 10.1016/0304-4165(76)90053-2; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHNEIDE.AB, 1971, J BIOL CHEM, V246, P6592; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SHIFRIN S, 1983, J BIOL CHEM, V258, P3780; SPIRO MJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P35, DOI 10.1016/0003-9861(80)90403-8; SPIRO RG, 1965, J BIOL CHEM, V240, P1603; THORENS B, 1986, NATURE, V321, P618, DOI 10.1038/321618a0	46	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1938	1944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370485				2022-12-27	WOS:A1992HA48500083
J	MORLEY, GP; CALLAGHAN, JM; ROSE, JB; TOH, BH; GLEESON, PA; VANDRIEL, IR				MORLEY, GP; CALLAGHAN, JM; ROSE, JB; TOH, BH; GLEESON, PA; VANDRIEL, IR			THE MOUSE GASTRIC H,K-ATPASE BETA-SUBUNIT - GENE STRUCTURE AND COORDINATE EXPRESSION WITH THE ALPHA-SUBUNIT DURING ONTOGENY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOIMMUNE GASTRITIS; H+/K+-ATPASE; ADHESION MOLECULE; PERNICIOUS-ANEMIA; GLIA AMOG; NA,K-ATPASE; RAT; CLONING; STOMACH; DNA	The gastric H,K-ATPase (EC 3.6.1.3) is responsible for acid secretion into the stomach and is composed of two subunits, alpha and beta. The structure of the gene encoding the mouse beta-subunit and the expression of both subunits during ontogeny are reported. The gene spans approximately 12 kilobase pairs and contains 7 exons. The positions at which introns interrupt the coding regions of the mouse H,K-ATPase beta-subunit and mouse Na,K-ATPase (EC 3.6.1.37) beta-2 subunit genes are identical. The alternative beta-subunit isoform of the Na,K-ATPase, beta-1, has a similar but not identical gene structure. Primer extension and S1 nuclease analysis of RNA isolated from mouse stomachs aged between 2 and 25 days indicated that major transcription-initiation sites are between 22 and 25 base pairs 5' of the translation initiation site at all ages. The expression of the H,K-ATPase alpha and beta-subunit genes during ontogeny (day 1-40) was found to be co-ordinated. Protein levels of both the ATPase alpha and beta-subunits were very low until day 15 and then increased to adult levels by day 30. In any mucosal cell throughout ontogeny, expression. of the beta-subunit gene invariably coincided with the expression of the alpha-subunit gene. Cells detected by anti-H,K-ATPase beta-subunit antibodies in sections from 10- and 30-day-old mice all had typical morphology of parietal cells and were arranged in glandular structures. Co-ordinate expression of the two subunit genes suggest that the regulatory mechanisms will be similar and that the beta-subunit may be required for localization and function of the catalytic alpha-subunit.	MONASH UNIV, ALFRED HOSP, SCH MED, DEPT PATHOL & IMMUNOL, MELBOURNE, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503; van Driel, Ian/0000-0001-5371-120X				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; CALLAGHAN JM, 1990, J CELL SCI, V95, P563; CROTHERS JM, 1990, AM J PJHYSL, V259, pG918; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALLER LD, 1985, ENZYMES BIOL MEMBR, V3, P431; FORTE JG, 1989, HDB PHYSL, V3, P207; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLEESON PA, 1991, IMMUNOL TODAY, V12, P233, DOI 10.1016/0167-5699(91)90036-S; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GOLDKORN I, 1989, J BIOL CHEM, V264, P18768; HELANDER HF, 1969, GASTROENTEROLOGY, V56, P35; HELANDER HF, 1989, SCAND J GASTROENTERO, V24, P863, DOI 10.3109/00365528909089227; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HERVATIN F, 1989, BIOCHIM BIOPHYS ACTA, V985, P320, DOI 10.1016/0005-2736(89)90419-7; HERVATIN F, 1987, AM J PHYSIOL, V252, pG28, DOI 10.1152/ajpgi.1987.252.1.G28; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JOHNSON LR, 1985, ANNU REV PHYSIOL, V47, P199; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES CM, 1991, GASTROENTEROLOGY, V101, P287, DOI 10.1016/0016-5085(91)90002-3; JONES CM, 1991, EUR J BIOCHEM, V197, P49, DOI 10.1111/j.1432-1033.1991.tb15881.x; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAGYAR JP, 1990, NUCLEIC ACIDS RES, V18, P6695, DOI 10.1093/nar/18.22.6695; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MORI Y, 1989, GASTROENTEROLOGY, V97, P364, DOI 10.1016/0016-5085(89)90072-3; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Sambrook J, 1989, MOL CLONING LABORATO; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; THEAN ET, 1989, IMMUNOL CELL BIOL, V67, P41, DOI 10.1038/icb.1989.5; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	51	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1165	1174						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370459				2022-12-27	WOS:A1992GY96000077
J	CURRIER, SJ; KANE, SE; WILLINGHAM, MC; CARDARELLI, CO; PASTAN, I; GOTTESMAN, MM				CURRIER, SJ; KANE, SE; WILLINGHAM, MC; CARDARELLI, CO; PASTAN, I; GOTTESMAN, MM			IDENTIFICATION OF RESIDUES IN THE 1ST CYTOPLASMIC LOOP OF P-GLYCOPROTEIN INVOLVED IN THE FUNCTION OF CHIMERIC HUMAN MDR1-MDR2 TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDR GENE FAMILY; MULTIDRUG RESISTANCE GENE; SITE-SPECIFIC MUTAGENESIS; ALTERED PATTERN; FULL-LENGTH; TUMOR-CELLS; MOUSE MDR1; CDNA; EXPRESSION; PROTEINS	The human MDR1 gene encodes the multidrug transporter (P-glycoprotein), a multidrug efflux pump. The highly homologous MDR2 gene product does not appear to be a functional multidrug pump. We have constructed a chimeric protein in which the first intracytoplasmic loop and the third and fourth transmembrane domains of the MDR1 protein were replaced by the analogous region of MDR2. Substitution of the MDR2 sequences encompassing amino acid residues 140 to 229 resulted in 17 amino acid changes, 10 in the intracytoplasmic loop (amino acids 141-188) and 7 in the transmembrane regions. This chimeric protein was expressed on the surface of NIH 3T3 cells where it bound [H-3]azidopine but did not confer drug resistance. When only 4 residues, 165, 166, 168, and 169, were changed back to MDR1 amino acids, a functional drug transporter was recovered. When residues 165, 166, 168, and 169 from MDR2 were substituted into a functional MDR1 cDNA, the resulting construction was not able to confer drug resistance. These results indicate that the major functional differences between MDR1 and MDR2 in this region of P-glycoprotein reside in a small segment of the first intracytoplasmic loop. We also independently analyzed the effect of replacing Asn183 of MDR1 with Ser which occurs in MDR2. Substitution of Ser at position 183 in combination with Val at position 185 in P-glycoprotein resulted in a relative increase in resistance to actinomycin D, vinblastine, and doxorubicin in transfected NIH 3T3 cells. These results emphasize the importance of the first intracytoplasmic loop in P-glycoprotein in determining function and relative drug specificity of the transporter.	NCI,CELL BIOL LAB,9000 ROCKVILLE PIKE,BLDG 37,RM 1B22,BETHESDA,MD 20892; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P563, DOI 10.1007/BF01026439; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1991, J BIOL CHEM, V266, P4545; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HORIO M, 1989, J BIOL CHEM, V264, P14880; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAXAM AM, 1980, METHOD ENZYMOL, V65, P506; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SHEN DW, 1986, MOL CELL BIOL, V6, P4039, DOI 10.1128/MCB.6.11.4039; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SILVERMAN JA, 1991, GENE, V106, P229, DOI 10.1016/0378-1119(91)90203-N; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P505; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1	35	112	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25153	25159						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1360983				2022-12-27	WOS:A1992KB60300038
J	SATO, K; AKAIKE, T; KOHNO, M; ANDO, M; MAEDA, H				SATO, K; AKAIKE, T; KOHNO, M; ANDO, M; MAEDA, H			HYDROXYL RADICAL PRODUCTION BY H2O2 PLUS CU,ZN-SUPEROXIDE DISMUTASE REFLECTS THE ACTIVITY OF FREE COPPER RELEASED FROM THE OXIDATIVELY DAMAGED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA ALPHA-1-PROTEINASE INHIBITOR; ZINC SUPEROXIDE-DISMUTASE; HUMAN NEUTROPHIL ELASTASE; HYDROGEN-PEROXIDE; OXYGEN RADICALS; PULSE RADIOLYSIS; DNA DAMAGE; INACTIVATION; MYELOPEROXIDASE; PROTEASE	To elaborate the catalytic activity of Cu2+ of Cu,Zn-superoxide dismutase (SOD) in the generation of hydroxyl radical (.OH) from H2O2, we investigated the mechanism of inactivation of alpha1-protease inhibitor (alpha1-PI), mediated by H2O2 and Cu,Zn-SOD. When alpha1-PI was incubated with 500 units/ml Cu,Zn-SOD and 1.0 mm H2O2, 60% of anti-elastase activity of alpha1-PI was lost within 90 min. ESR spin trapping using 5,5-dimethyl-1-pyrroline N-oxide showed that free .OH was indeed generated in the reaction of Cu,Zn-SOD/H2O2; this was substantiated by the almost complete eradication of .OH by either ethanol or dimethyl sulfoxide accompanied by the generation of carbon-centered radicals. .OH production and alpha1-PI inactivation in the H2O2/SOD system became apparent at 30 min or later. Dimethyl sulfoxide and 5,5-dimethyl-1-pyrroline N-oxide protected inactivation of alpha1-PI significantly in this system, indicating that alpha1-PI inactivation was mediated by .OH. SOD activity decreased rapidly during the reaction with H2O2 for the initial 30 min. Time-dependent changes in the ESR signal of SOD showed the destruction of ligands for Cu2+ in SOD by H2O2 within this initial period. Thus we conclude that inactivation of alpha1-PI is mediated in the H2O2/Cu,Zn-SOD system via the generation of .OH by free Cu2+ released from oxidatively damaged SOD.	KUMAMOTO UNIV, SCH MED, DEPT MICROBIOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT MED, KUMAMOTO 860, JAPAN; JEOL LTD, DIV ANALYT INSTRUMENTS, ELECTRON SPIN RESONANCE APPLICAT LAB, AKISHIMA 196, JAPAN	Kumamoto University; Kumamoto University; Jeol Ltd; JEOL Japan								AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; ARUOMA OI, 1989, FEBS LETT, V244, P76, DOI 10.1016/0014-5793(89)81166-4; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; CLARK RA, 1981, J BIOL CHEM, V256, P3348; DEAN RT, 1989, BIOCHEM BIOPH RES CO, V159, P821, DOI 10.1016/0006-291X(89)90068-5; DIZDAROGLU M, 1990, BIOCHEMISTRY-US, V29, P8447, DOI 10.1021/bi00488a035; DUCHESNE J, 1977, J THEOR BIOL, V66, P137, DOI 10.1016/0022-5193(77)90316-2; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GELVAN D, 1990, BIOCHIM BIOPHYS ACTA, V1035, P353, DOI 10.1016/0304-4165(90)90100-B; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HEIDTMANN H, 1986, PROTEINASE INHIBITOR, V12, P441; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HUNT JV, 1988, BIOCHEM J, V250, P87, DOI 10.1042/bj2500087; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KAJIHARA J, 1988, BIOCH TOKYO, V104, P851; KLUG D, 1972, J BIOL CHEM, V247, P4839; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; KWON NS, 1990, AGENTS ACTIONS, V29, P388, DOI 10.1007/BF01966473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN RA, 1982, J BIOL CHEM, V257, P336; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P331, DOI 10.1021/bi00505a016; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; MATHESON NR, 1985, BIOCHEMISTRY-US, V24, P1941, DOI 10.1021/bi00329a021; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOLLA A, 1986, INFECT IMMUN, V53, P522, DOI 10.1128/IAI.53.3.522-529.1986; NOWAK D, 1990, EXP PATHOL-JENA, V38, P249, DOI 10.1016/S0232-1513(11)80236-7; ODA T, 1992, ARCH BIOCHEM BIOPHYS, V294, P38, DOI 10.1016/0003-9861(92)90133-H; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SALO DC, 1990, J BIOL CHEM, V265, P11919; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SINET PM, 1981, ARCH BIOCHEM BIOPHYS, V212, P411, DOI 10.1016/0003-9861(81)90382-9; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	48	150	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25371	25377						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334093				2022-12-27	WOS:A1992KB60300070
J	DEGRAY, JA; LASSMANN, G; CURTIS, JF; KENNEDY, TA; MARNETT, LJ; ELING, TE; MASON, RP				DEGRAY, JA; LASSMANN, G; CURTIS, JF; KENNEDY, TA; MARNETT, LJ; ELING, TE; MASON, RP			SPECTRAL-ANALYSIS OF THE PROTEIN-DERIVED TYROSYL RADICALS FROM PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION; ENZYME	We have analyzed the low temperature EPR spectra of the protein-derived tyrosyl radicals detected upon addition of arachidonic acid or 5-phenyl-4-pentenyl-1-hydroperoxide (PPHP) to prostaglandin H synthase. With either arachidonic acid or PPHP the initial radical detected is a doublet (peak-to-trough = 35 Gauss) that disappears rapidly and is replaced by a broad singlet (peak-to-trough = 30 Gauss) followed by a narrow singlet (peak-to-trough = 26.5 Gauss). The relative amounts of these signals vary with time and concentration of arachidonic acid. The three tyrosyl radical signals were subjected to computer simulation and power saturation analysis. The data establish that there are only two distinct tyrosyl radical species, the doublet and the narrow singlet. The broad singlet seen at intermediate times and at low arachidonic acid concentrations is a composite of the doublet and the narrow singlet. The composition of the broad singlet in incubations of prostaglandin H synthase with 0.5 mM arachidonic acid is approximately 40% doublet and 60% singlet. The broad singlet signal does not represent a distinct tyrosyl radical species.	NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709; VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,CTR MOLEC TOXICOL,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CHEM,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; Vanderbilt University			Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				BARRY BA, 1990, J BIOL CHEM, V265, P20139; DEGRAY JA, 1987, THESIS BROWN U PROVI; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1990, ADV PROSTAGLANDIN TH, V21, P137; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; PACEASCIAK CR, 1983, ENZYMES, V16, P544; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; TSAI AL, 1992, J BIOL CHEM, V267, P17753	15	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23583	23588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331091				2022-12-27	WOS:A1992JZ23900027
J	STELLWAGEN, RH				STELLWAGEN, RH			INVOLVEMENT OF SEQUENCES NEAR BOTH AMINO AND CARBOXYL TERMINI IN THE RAPID INTRACELLULAR DEGRADATION OF TYROSINE AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ORNITHINE DECARBOXYLASE; SHORT-LIVED PROTEIN; RAT-LIVER; ASPARTATE-AMINOTRANSFERASE; DIHYDROFOLATE-REDUCTASE; EUKARYOTIC CELLS; MAMMALIAN-CELLS; PEST HYPOTHESIS; ACID-SEQUENCE; PLASMID DNA	The degradation of rat liver tyrosine aminotransferase has been studied after transfection of suitable expression vectors into mammalian cells in culture. A normal rapid rate of degradation (half-life about 6 h) was observed in cells under stable transfection conditions. However, the higher enzyme levels produced during transient transfections or after amplification with methotrexate caused the apparent half-life of degradation to increase substantially. Analysis of expression in Chinese hamster ovary (CHO)-DG44 cells from vectors with deletions near either end of the tyrosine aminotransferase coding sequence showed that approximately the first 40 and the last 12 amino acid residues are not required to obtain normal catalytic function. When catalytically active deletion mutants were examined for effects on tyrosine aminotransferase degradation in stably transfected CHO-DG44 cell populations, short sequences near each end of the protein were found to be necessary for rapid degradation. The required sequence near the amino terminus is located between amino acids 30 and 40 and includes the highly basic region RKKGRKAR, a potential ubiquitin attachment site. The other essential sequence (EECDK) is located at the very COOH terminus of the 454-amino acid chain and is part of an acidic domain rich in cysteines and having PEST characteristics (rich in Pro, Glu, and Thr). Ser448, a potential casein kinase II phosphorylation site, is not required for activity or rapid degradation of tyrosine aminotransferase. No correlation was observed between the intracellular degradation rates of the various mutant proteins and their heat stabilities in vitro.			STELLWAGEN, RH (corresponding author), UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90033 USA.							ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; Arnone A, 1985, TRANSAMINASES, P138; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BEYNON RJ, 1986, AM J PHYSIOL, V251, pC141, DOI 10.1152/ajpcell.1986.251.2.C141; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOND JS, 1976, BIOCHIM BIOPHYS ACTA, V451, P238, DOI 10.1016/0304-4165(76)90274-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DIETRICH JB, 1988, BIOCHIMIE, V70, P673, DOI 10.1016/0300-9084(88)90252-0; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOHDA E, 1981, J BIOL CHEM, V256, P2567; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRANGE T, 1985, J MOL BIOL, V184, P347, DOI 10.1016/0022-2836(85)90386-9; GRINDE B, 1982, BIOCHEM J, V202, P191, DOI 10.1042/bj2020191; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HARGROVE JL, 1981, J BIOL CHEM, V256, P8012; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; HARGROVE JL, 1985, TRANSAMINASES, P511; HAYASHI H, 1987, BIOCH VITAMIN B6, P39; HERSHKO A, 1971, J BIOL CHEM, V246, P710; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; ISHIGURO M, 1991, BIOCHEMISTRY-US, V30, P6048, DOI 10.1021/bi00238a031; JANSONIUS JN, 1985, TRANSAMINASES, P110; JOHNSON RW, 1973, J BIOL CHEM, V248, P4528; KOHLI KK, 1988, BIOCHIM BIOPHYS ACTA, V956, P77, DOI 10.1016/0167-4838(88)90300-7; KOHLI KK, 1990, J CELL PHYSIOL, V142, P194, DOI 10.1002/jcp.1041420124; KOZAK M, 1983, MICROBIOL REV, V47, P1; LEE KL, 1971, J BIOL CHEM, V246, P7595; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LORBER B, 1991, FEBS LETT, V291, P345, DOI 10.1016/0014-5793(91)81317-2; MANN DF, 1984, BIOCHIM BIOPHYS ACTA, V788, P17, DOI 10.1016/0167-4838(84)90292-9; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MCILHINNEY A, 1974, BIOCHIM BIOPHYS ACTA, V372, P366, DOI 10.1016/0304-4165(74)90198-6; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; PAN JS, 1991, FASEB J, V5, pA1180; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; RETTENMEIER R, 1990, NUCLEIC ACIDS RES, V18, P3853, DOI 10.1093/nar/18.13.3853; Rivett A.J., 1990, Essays in Biochemistry, V25, P39; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSCOE DH, 1973, J CELL PHYSIOL, V82, P325, DOI 10.1002/jcp.1040820302; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL HL, 1963, P NATL ACAD SCI USA, V50, P912, DOI 10.1073/pnas.50.5.912; SPENCER CJ, 1978, J BIOL CHEM, V253, P7677; STELLWAGEN RH, 1977, J CELL PHYSIOL, V91, P51, DOI 10.1002/jcp.1040910106; STRINDENT ST, 1981, J CELL PHYSIOL, V108, P231, DOI 10.1002/jcp.1041080213; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1	55	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23713	23721						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358885				2022-12-27	WOS:A1992JZ23900045
J	BENLEVY, R; PELES, E; GOLDMANMICHAEL, R; YARDEN, Y				BENLEVY, R; PELES, E; GOLDMANMICHAEL, R; YARDEN, Y			AN ONCOGENIC POINT MUTATION CONFERS HIGH-AFFINITY LIGAND-BINDING TO THE NEU RECEPTOR - IMPLICATIONS FOR THE GENERATION OF SITE HETEROGENEITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; TRANSMEMBRANE DOMAIN; MONOCLONAL-ANTIBODY; SIGNAL TRANSDUCTION; LIVING CELLS; A431 CELLS; PROTEIN	The neu protooncogene encodes a receptor tyrosine kinase homologous to the receptor for the epidermal growth factor. The oncogenic potential of neu is released upon chemical carcinogenesis, which replaces a glutamic acid for a valine residue, within the single transmembrane domain. This results in constitutive receptor dimerization and activation of the intrinsic catalytic function. To study the implications of the oncogenic mutation and the consequent receptor dimerization on the interaction with the yet incompletely characterized ligand of p185neu, we constructed chimeric proteins between the ligand binding domain of the epidermal growth factor receptor and the transmembrane and cytoplasmic domains of the normal or the transforming Neu proteins. The chimeric receptors displayed cellular and biochemical differences characteristic of the normal and the transforming Neu proteins and therefore may reliably represent the ligand binding functions of the two receptor forms. Analyses of ligand binding revealed qualitative and quantitative differences that were a result of the single mutation; whereas the normal chimera (valine version) displayed two populations of binding sites with approximately 90% of the receptors in the low affinity state, the transforming receptor (glutamic acid version) showed a single population of binding sites with relatively high affinity. Kinetics measurements indicated that the difference in affinities was because of slower rates of both ligand association and ligand dissociation from the constitutively dimerized mutant receptor. It therefore appears that the oncogenic mutation, by permanently dimerizing the receptor, establishes a high affinity ligand binding state which is functionally equivalent to the ligand-occupied normal receptor. Our conclusion is further supported by the rates of endocytosis of the wild-type and the mutant receptor. Hence, these results provide the first experimental evidence from living cells which supports a model that attributes the heterogeneity of ligand binding sites to the state of oligomerization of receptor tyrosine kinases.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P1; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1989, CANCER CEL, V7, P371; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAYLOR SI, 1975, BIOCHEMISTRY-US, V14, P2357, DOI 10.1021/bi00682a013; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERHEIJDEN GF, 1990, BIOCHEM J, V271, P215, DOI 10.1042/bj2710215; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALKER F, 1991, J BIOL CHEM, V266, P2746; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1981, BIOCHIM BIOPHYS ACTA, V674, P188, DOI 10.1016/0304-4165(81)90377-9; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8	56	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17304	17313						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1355090				2022-12-27	WOS:A1992JL05300086
J	SCHWEITZ, H; VIGNE, P; MOINIER, D; FRELIN, C; LAZDUNSKI, M				SCHWEITZ, H; VIGNE, P; MOINIER, D; FRELIN, C; LAZDUNSKI, M			A NEW MEMBER OF THE NATRIURETIC PEPTIDE FAMILY IS PRESENT IN THE VENOM OF THE GREEN MAMBA (DENDROASPIS-ANGUSTICEPS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PARTICULATE GUANYLATE-CYCLASE; CYCLIC-GMP; PORCINE BRAIN; ATRIAL; RECEPTOR; RAT; SEQUENCE; CELLS; ENDOTHELIUM	This paper describes the purification, sequence, and biological properties of a 38-amino acid residue peptide from the venom of Dendroaspis angusticeps which shared important sequence homologies with natriuretic peptides. Dendroaspis natriuretic peptide (DNP) relaxed aortic strips that had been contracted by 40 mM KCl with a potency (K0.5 = 20 nM) similar to that of atrial natriuretic peptide (ANP) and larger than that of C type natriuretic peptide (CNP). The relaxing actions of ANP and DNP (both at 100 nM) were mutually exclusive. Bovine aortic endothelial cells responded to ANP (K0.5 = 3 nM) and DNP (K0.5 = 3 nM) but not to CNP by a large activation of guanylate cyclase. Rat aortic myocytes showed larger cGMP responses to CNP (K0.5 = 10 nM) than to ANP or DNP (K0.5 = 100 nM). Finally, DNP completely prevented the specific I-125-ANP binding to clearance receptors in cultured aortic myocytes with a potency (K(d) = 10 nM) that was less than that of ANP (K(d) = 0.3 nM). It is concluded that DNP is a new member of the family of natriuretic peptides and that it recognizes ANP(A) receptors and clearance, ANP(C) receptors, but not CNP-specific ANP(B) receptors.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE									ANDREWS PC, 1981, J BIOL CHEM, V256, P8267; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DINIZ CR, 1968, VENOMOUS ANIMALS THE, V1, P217; FOSSET M, 1984, P NATL ACAD SCI-BIOL, V81, P7228, DOI 10.1073/pnas.81.22.7228; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; GENEST J, 1987, CIRCULATION, V75, P118; KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; KOJIMA M, 1990, BIOCHEM BIOPH RES CO, V168, P863; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MARSAULT R, 1991, AM J PHYSIOL, V261, pC986, DOI 10.1152/ajpcell.1991.261.6.C986; MONCADA S, 1991, PHARMACOL REV, V43, P109; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TAKEI Y, 1991, FEBS LETT, V282, P317; VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661; WOLLBERG Z, 1988, TOXICON, V26, P525, DOI 10.1016/0041-0101(88)90232-2; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	31	243	273	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13928	13932						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352773				2022-12-27	WOS:A1992JD32500025
J	VALLEJO, M; PENCHUK, L; HABENER, JF				VALLEJO, M; PENCHUK, L; HABENER, JF			SOMATOSTATIN GENE UPSTREAM ENHANCER ELEMENT ACTIVATED BY A PROTEIN COMPLEX CONSISTING OF CREB, ISL-1-LIKE, AND ALPHA-CBF-LIKE TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; DNA-BINDING PROTEIN; CAMP RESPONSE ELEMENTS; CYCLIC-AMP; INSULIN GENE; PROMOTER ELEMENT; NUCLEAR FACTORS; GLUCAGON GENE; SUBUNIT GENE; SEQUENCE	The expression of the genes encoding the hormones glucagon, insulin, somatostatin, and pancreatic polypeptide in the endocrine islets of the pancreas is regulated in a cell-specific manner, defining four distinct cellular phenotypes (A-, B-, D-, and F-cells, respectively). Binding of nuclear proteins to cognate DNA sequences within cis-acting regulatory elements mediates the transcriptional events that result in the cell-specific activation or repression of gene expression. In a parallel study, we describe the functional properties of the SMS-UE, a pancreatic islet D-cell specific enhancer element that regulates the expression of the somatostatin gene and contains two interdependent domains, A and B. In the studies described herein, we have characterized the nuclear proteins that recognize the SMS-UE. Domain A of the SMS-UE is a DNA enhancer sequence that is identical to that bound by the ubiquitously distributed CCAAT box-binding protein alpha-CBF, a transcription factor that regulates the expression of the human chorionic gonadotrophin alpha-subunit gene. The B-domain, on the other hand, binds an islet cell-specific protein with characteristics similar to those of Isl-1, a transcriptional activator protein that binds to the E2 enhancer of the rat insulin-1 gene. In addition, the SMS-UE binds transcription factor CREB but not CREM, the close homolog of CREB, on a site adjacent to, or overlapping, the 3' end of domain B. We show that the carboxyl-terminal bZIP domain of CREB binds to the cAMP response element of the somatostatin gene but is not sufficient for binding to the SMS-UE, and we present evidence suggesting that CREB.SMS-UE binding requires stabilization by a region of the protein located within the transactivation domain.			VALLEJO, M (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114, USA.		Vallejo, Mario/ABG-4610-2020	Vallejo, Mario/0000-0002-6422-0323	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030457, R37DK030457] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30457] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUDEK RW, 1991, DIABETES, V40, P1041, DOI 10.2337/diabetes.40.8.1041; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUHRMANN G, 1990, NUCLEIC ACIDS RES, V18, P1287, DOI 10.1093/nar/18.5.1287; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1089; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANAK R, 1991, MOL CELL BIOL, V11, P3652; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON E, 1991, MOL ENDOCRINOL, V5, P879; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; POWERS AC, 1989, J BIOL CHEM, V264, P10048; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN LP, 1984, SCIENCE, V224, P168, DOI 10.1126/science.6142531; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STRATOWA C, 1986, P NATL ACAD SCI USA, V83, P4292, DOI 10.1073/pnas.83.12.4292; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931	73	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12876	12884						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352292				2022-12-27	WOS:A1992HZ48300074
J	FAZIOLI, F; BOTTARO, DP; MINICHIELLO, L; AURICCHIO, A; WONG, WT; SEGATTO, O; DIFIORE, PP				FAZIOLI, F; BOTTARO, DP; MINICHIELLO, L; AURICCHIO, A; WONG, WT; SEGATTO, O; DIFIORE, PP			IDENTIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF NOVEL PUTATIVE SUBSTRATES FOR THE EPIDERMAL GROWTH-FACTOR RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; EGF RECEPTOR; INSULIN-RECEPTOR; PROTEIN; DOMAINS; CELLS; GAP	To gain insight into the mechanisms which control the mitogenic response to epidermal growth factor (EGF), we have partially purified and characterized several intracellular proteins which are phosphorylated on tyrosine residues following activation of the epidermal growth factor receptor (EGFR). Partial purification was achieved by immunoaffinity chromatography using immobilized anti-phosphotyrosine antibodies. Antisera generated against the partially purified proteins were used to identify at least five novel EGFR putative substrates, designated, on the basis of their apparent molecular weight, p97, p68, p61, p56, and p23. All of these proteins became specifically phosphorylated on tyrosine after EGF treatment of intact cells, as assessed by phosphoamino acid analysis, and none of them represented an EGFR degradation product. The phosphorylation of these proteins appeared to be relatively specific for the EGFR. In particular, an EGFR-related kinase, erbB-2 was much less efficient than EGFR at phosphorylating p97, p56, and p23 and incapable of phosphorylating p68. The identification of these novel EGFR putative substrates should lead to a better understanding of the mechanisms controlling the specificity of EGFR-mediated mitogenic signaling.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1D23,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bottaro, Donald P/AAF-3853-2020; Minichiello, Liliana/AAA-7190-2022; Di Fiore, Pier Paolo/K-2130-2012; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bottaro, Donald P/0000-0002-5057-5334; Segatto, Oreste/0000-0003-2561-1142; AURICCHIO, Alberto/0000-0002-0832-2472				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LONARDO F, 1990, New Biologist, V2, P992; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	46	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5155	5161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347529				2022-12-27	WOS:A1992HH74700026
J	SARKADI, B; PRICE, EM; BOUCHER, RC; GERMANN, UA; SCARBOROUGH, GA				SARKADI, B; PRICE, EM; BOUCHER, RC; GERMANN, UA; SCARBOROUGH, GA			EXPRESSION OF THE HUMAN MULTIDRUG RESISTANCE CDNA IN INSECT CELLS GENERATES A HIGH-ACTIVITY DRUG-STIMULATED MEMBRANE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN GENE; HAMSTER OVARY CELLS; MUTANTS; BINDING; PERMEABILITY; PURIFICATION; VINBLASTINE; COLCHICINE; ANTIBODIES	Drug-resistant tumor cells actively extrude a variety of chemotherapeutic agents by the action of the multidrug resistance (MDR1) gene product, the plasma membrane P-glycoprotein. In this report we show that the expression of the human MDR1 gene in cultured Sf9 insect cells via a baculovirus vector generates a high activity vanadate-sensitive membrane ATPase. This ATPase is markedly stimulated by drugs known to interact with the P-glycoprotein, such as vinblastine and verapamil, and the ability of the various drugs to stimulate the ATPase corresponds to their previously observed affinity for this transporter. The drug-stimulated ATPase is not present in uninfected or mock-infected Sf9 cells, and its appearance correlates with the appearance of the MDR1 gene product detected with a monoclonal anti-MDR protein antibody and by labeling with 8-azido-ATP. The drug-induced ATPase requires magnesium ions, does not utilize ADP or AMP as substrates, exhibits a half-maximal activation at about 0.5 mM MgATP, and its maximal activity (about 3-5-mu-mol/mg MDR protein/min) approaches that of the well characterized ion transport ATPases. These results provide the first direct demonstration of a high capacity drug-stimulated ATPase activity of the human multidrug resistance protein and offer a new and simple assay for the investigation of functional interactions of various drugs with this clinically important enzyme.	UNIV N CAROLINA, DEPT PHARMACOL, CB 7365 FLOB, CHAPEL HILL, NC 27599 USA; NATL INST HAEMATOL & BLOOD TRANSFUS, BUDAPEST, HUNGARY; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill			Sarkadi, Balazs/I-5024-2013					BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROXTERMAN HJ, 1988, FASEB J, V2, P2278, DOI 10.1096/fasebj.2.7.3350243; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; INABA M, 1979, CANCER RES, V39, P2200; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; LING V, 1983, CANCER TREAT REP, V67, P869; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKADI B, 1977, BIOCHIM BIOPHYS ACTA, V464, P93, DOI 10.1016/0005-2736(77)90373-X; TSURUO T, 1983, CANCER RES, V43, P2905; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	36	603	621	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4854	4858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347044				2022-12-27	WOS:A1992HF64200084
J	WITTERS, LA; KEMP, BE				WITTERS, LA; KEMP, BE			INSULIN ACTIVATION OF ACETYL-COA CARBOXYLASE ACCOMPANIED BY INHIBITION OF THE 5'-AMP-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; EPIDIDYMAL ADIPOSE-TISSUE; PHASE PEPTIDE-SYNTHESIS; ISOLATED ADIPOCYTES; HEPATOMA-CELLS; POSTTRANSCRIPTIONAL REGULATION; PHOSPHORYLATION; EPINEPHRINE; SITES	The activity of acetyl-CoA carboxylase (ACC), a rate-limiting enzyme of fatty acid biosynthesis and malonyl-CoA production, can be regulated by several mechanisms, including multisite covalent phosphorylation, both in vitro and in intact cells. Evidence has been presented by others to indicate that a 5'-AMP-activated protein kinase (AMPK) is likely the major regulatory kinase active on ACC. While insulin is known to activate ACC in several cell types, accompanied by changes in ACC phosphorylation, the mechanism underlying this activation has been obscure. In the present study, we have examined, in Fao hepatoma cells, the effects of insulin on ACC and AMPK activity, the latter measured with a synthetic peptide corresponding to one of the phosphorylation sites on ACC for AMPK. Our results show that insulin leads to inhibition of kinase activity prior to the onset of ACC activation; the peak of maximal kinase inhibition (approximately 35% at 10 min) is seen to precede the onset of ACC activation (20 min). The inhibition of kinase activity due to insulin is observed both in the absence and presence of varying stimulating concentrations of added 5'-AMP. Both kinase inhibition and ACC activation display similar insulin sensitivity (A50 0.3 nM). Preservation of this insulin-induced kinase inhibition requires the presence of protein phosphatase inhibitors in the cell lysis buffer, suggesting that AMPK itself might be regulated by insulin-stimulated changes in kinase phosphorylation. Taken together, these data are consistent with the hypothesis that the 5'-AMP-activated protein kinase is a regulated component of the insulin signal transduction pathway and may be the major target for insulin regulation of ACC.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	Dartmouth College; St. Vincent's Institute of Medical Research	WITTERS, LA (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756, USA.		Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORTHWICK AC, 1990, BIOCHEM J, V270, P795, DOI 10.1042/bj2700795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSEY RW, 1984, BIOCHEM J, V218, P733, DOI 10.1042/bj2180733; BROWNSEY RW, 1982, BIOCHEM J, V202, P77, DOI 10.1042/bj2020077; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CRETTAZ M, 1988, BIOCHEMISTRY-US, V27, P495, DOI 10.1021/bi00401a071; CRETTAZ M, 1983, ENDOCRINOLOGY, V113, P1201, DOI 10.1210/endo-113-4-1201; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; HALESTRA.AP, 1973, BIOCHEM J, V132, P509, DOI 10.1042/bj1320509; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HAYSTEAD TAJ, 1986, BIOCHEM J, V234, P279, DOI 10.1042/bj2340279; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P275, DOI 10.1111/j.1432-1033.1983.tb07359.x; JAMIL H, 1987, J BIOL CHEM, V262, P638; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LEE KH, 1973, BIOCHEM BIOPH RES CO, V54, P1133, DOI 10.1016/0006-291X(73)90810-3; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MOIR AMB, 1990, BIOCHEM J, V272, P511, DOI 10.1042/bj2720511; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PARK KR, 1991, J BIOL CHEM, V266, P12249; PELECH SL, 1991, BIOCHEM J, V274, P759, DOI 10.1042/bj2740759; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; STEWART JM, 1966, SOLID PHASE PEPTIDE, P44; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; TIPPER JP, 1983, ARCH BIOCHEM BIOPHYS, V227, P386, DOI 10.1016/0003-9861(83)90468-X; WITTERS LA, 1988, J BIOL CHEM, V263, P8027; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; WITTERS LA, 1981, BIOCHEM BIOPH RES CO, V100, P872, DOI 10.1016/S0006-291X(81)80254-9; WITTERS LA, 1986, ADV PROTEIN PHOSPHAT, V3, P201	36	172	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2864	2867						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346611				2022-12-27	WOS:A1992HD15400008
J	GUADAGNO, SN; BORNER, C; WEINSTEIN, IB				GUADAGNO, SN; BORNER, C; WEINSTEIN, IB			ALTERED REGULATION OF A MAJOR SUBSTRATE OF PROTEIN-KINASE-C IN RAT 6 FIBROBLASTS OVERPRODUCING PKC-BETA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; PROMINENT CELLULAR SUBSTRATE; SUBCELLULAR-DISTRIBUTION; TRANSFORMED FIBROBLASTS; POLYACRYLAMIDE GELS; CALMODULIN-BINDING; MOLECULAR-CLONING; GENE-EXPRESSION; DOWN-REGULATION; 87-KDA PROTEIN	We have shown previously that the stable overproduction of protein kinase C beta-I (cPKC-beta-I) in rat 6 (R6) embryo fibroblasts results in multiple cellular growth abnormalities. To characterize the pathways through which cPKC-beta-I acts to exert its effects, we have undertaken a biochemical analysis of the cell line R6-PKC3. The subcellular distribution of cPKC-beta-I in unstimulated R6-PKC3 cells was approximately 80% cytosolic and approximately 20% membrane bound, and treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in translocation and down-regulation of an appreciable fraction of the cPKC-beta-I enzyme. However, long term TPA treatment was not sufficient to down-regulate all of the overproduced enzyme from both the cytosolic and membrane fractions. Two-dimensional gel analysis of P-32-labeled cellular phosphoproteins from either untreated or TPA-treated cultures revealed only minor qualitative differences between R6-PKC3 cells and a vector control cell line, R6-C1. On the other hand, several quantitative differences in the level of phosphorylation of discrete protein spots were seen. The most prominent phosphoprotein was a previously described 80/87-kDa protein designated MARCKS (myr-istoylated alanine-rich C kinase substrate). Compared with R6-C1 cells, R6-PKC3 cells exhibited a 2-3-fold increase in the basal level of phosphorylation of MARCKS and after treatment with TPA, displayed a dramatic prolongation in phosphorylation of this protein. Additionally, treatment of R6-PKC3 cells with TPA led to a prolonged increase in both the cytosolic and total cellular level of the MARCKS protein and a pronounced decrease in the level of MARCKS mRNA. Taken together, these results indicate that overproduction of cPKC-beta-I markedly alters several parameters of the MARCKS protein which may be responsible, at least in part, for the altered phenotype of these cells.	COLUMBIA UNIV,CTR COMPREHENS CANC,701 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					PHS HHS [02656] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENZEEV A, 1986, TRENDS BIOCHEM SCI, V11, P478, DOI 10.1016/0968-0004(86)90251-3; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1991, IN PRESS NATURE; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIEH LL, 1989, J CELL BIOCHEM, V41, P179, DOI 10.1002/jcb.240410403; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1989, J BIOL CHEM, V264, P20928; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAUSS RS, 1989, ONCOGENE, V4, P991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1990, J BIOL CHEM, V265, P22434; PATEL J, 1987, J BIOL CHEM, V262, P16686; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; RODRIGUEZPENA A, 1986, BIOCHEM BIOPH RES CO, V140, P379, DOI 10.1016/0006-291X(86)91101-0; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WOODGETT JR, 1987, CELL MEMBRANES METHO, V3, P215; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	69	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2697	2707						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370830				2022-12-27	WOS:A1992HB53200089
J	LUTFALLA, G; GARDINER, K; PROUDHON, D; VIELH, E; UZE, G				LUTFALLA, G; GARDINER, K; PROUDHON, D; VIELH, E; UZE, G			THE STRUCTURE OF THE HUMAN INTERFERON ALPHA-BETA-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSIGNMENT; SEQUENCE; PROTEIN; GAMMA; CHROMOSOME-21; ORGANIZATION; SUPERFAMILY; EXPRESSION; CLONING; GENOME	Using the cDNA coding for the human interferon alpha/beta-receptor (IFNAR), the IFNAR gene has been physically mapped relative to the other loci of the chromosome 21q22.1 region. 32,906 base pairs covering the IFNAR gene have been cloned and sequenced. Primer extension and solution hybridization-ribonuclease protection have been used to determine that the transcription of the gene is initiated in a broad region of 20 base pairs. Some aspects of the polymorphism of the gene, including noncoding sequences, have been analyzed; some are allelic differences in the coding sequence that induce amino acid variations in the resulting protein. The exon structure of the IFNAR gene and of that of the available genes for the receptors of the cytokine/growth hormone/prolactin/interferon receptor family have been compared with the predictions for the secondary structure of those receptors. From this analysis, we postulate a common origin and propose an hypothesis for the divergence from the immunoglobulin superfamily.	ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA		LUTFALLA, G (corresponding author), INST RECH SCI CANC, CNRS, VIRAL ONCOL LAB, 7 RUE GUY MOQUET, BP 8, F-94801 VILLEJUIF, FRANCE.		Lutfalla, Georges/AAW-9386-2021; Uzé, Gilles/O-6383-2019	Uze, Gilles/0000-0002-4150-5772; LUTFALLA, Georges/0000-0002-6591-7894	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NHGRI NIH HHS [KO1 HG00001] Funding Source: Medline; NICHD NIH HHS [P01 HD17449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX DR, 1990, CYTOGENET CELL GENET, V55, P235, DOI 10.1159/000133017; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GABORIAUD C, 1990, FEBS LETT, V269, P1, DOI 10.1016/0014-5793(90)81103-U; GARDINER K, 1990, J CELL SCI, V96, P5; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCINNIS MG, 1991, GENOMICS, V11, P573, DOI 10.1016/0888-7543(91)90064-L; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; Sambrook J, 1989, MOL CLONING LABORATO; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VIELH E, 1990, NUCLEIC ACIDS RES, V18, P5580, DOI 10.1093/nar/18.18.5580; WATKINS PC, 1987, CYTOGENET CELL GENET, V46, P712; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	30	88	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2802	2809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370833				2022-12-27	WOS:A1992HB53200103
J	KJELSBERG, MA; COTECCHIA, S; OSTROWSKI, J; CARON, MG; LEFKOWITZ, RJ				KJELSBERG, MA; COTECCHIA, S; OSTROWSKI, J; CARON, MG; LEFKOWITZ, RJ			CONSTITUTIVE ACTIVATION OF THE ALPHA-1B-ADRENERGIC RECEPTOR BY ALL AMINO-ACID SUBSTITUTIONS AT A SINGLE SITE - EVIDENCE FOR A REGION WHICH CONSTRAINS RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; BINDING; AGONIST; HYDROLYSIS; PROTEIN; DOMAINS; MUTAGENESIS; EXPRESSION; AFFINITY; GS	Mutations in an intracellular region of the alpha-1B-adrenergic receptor constitutively activate the receptor, resulting in G protein coupling in the absence of agonist, as evidenced by elevated levels of polyphosphoinositide hydrolysis. Remarkably, all 19 possible amino acid substitutions at a single site in this region (alanine 293) confer constitutive activity. This set of mutated receptors exhibits a graded range of elevated biological activities, apparently representing a spectrum of receptor conformations which mimic the "active" state of the wild type receptor. In addition to their constitutive activities, these mutated receptors all demonstrate a higher affinity for agonists, another primary characteristic of the "active" conformation of G protein-coupled receptors. The fact that all possible mutations at this particular site result in increased activity suggests that this region may function to constrain the G protein coupling of the receptor, a constraint which is normally relieved by agonist occupancy.	DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BURGISSER E, 1982, P NATL ACAD SCI-BIOL, V79, P1732, DOI 10.1073/pnas.79.6.1732; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V22, P290; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3	27	527	551	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1430	1433						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346134				2022-12-27	WOS:A1992HA48500008
J	PEREZREYES, E; CASTELLANO, A; KIM, HS; BERTRAND, P; BAGGSTROM, E; LACERDA, AE; WEI, XY; BIRNBAUMER, L				PEREZREYES, E; CASTELLANO, A; KIM, HS; BERTRAND, P; BAGGSTROM, E; LACERDA, AE; WEI, XY; BIRNBAUMER, L			CLONING AND EXPRESSION OF A CARDIAC BRAIN BETA-SUBUNIT OF THE L-TYPE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; SUBSTRATE-SPECIFICITY; SYNTHETIC PEPTIDES; COMPLEMENTARY-DNA; PURIFIED RECEPTOR; GAMMA-SUBUNIT	The skeletal muscle dihydropyridine receptor/Ca2+ channel is composed of five protein components (alpha-1, alpha-2-delta, beta, and gamma). Only two such components, alpha-1 and alpha-2, have been identified in heart. The present study reports the cloning and expression of a novel beta-gene that is expressed in heart, lung, and brain. Coexpression of this beta with a cardiac alpha-1 in Xenopus oocytes causes the following changes in Ca2+ channel activity: it increases peak currents, accelerates activation kinetics, and shifts the current-voltage relationship toward more hyperpolarized potentials. It also increases dihydropyridine binding to alpha-1 in COS cells. These results indicate that the cardiac L-type Ca2+ channel has a similar subunit structure as in skeletal muscle, and provides evidence for the modulatory role of the beta-subunit.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	PEREZREYES, E (corresponding author), BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA.		Castellano, Antonio/AAH-8829-2021; IBIS, VASCULAR/P-3934-2015; Castellano, Antonio/E-6285-2010	Castellano, Antonio/0000-0003-3955-5137; Castellano, Antonio/0000-0003-3955-5137	NHLBI NIH HHS [HL-37044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FRECH GC, 1989, GENE ANAL TECH, V6, P33, DOI 10.1016/0735-0651(89)90024-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PRAGNELL M, 1991, Biophysical Journal, V59, p390A; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI X, J BIOL CHEM, V266, P21943; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	39	375	387	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1792	1797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370480				2022-12-27	WOS:A1992HA48500061
J	YONEZAWA, K; UEDA, H; HARA, K; NISHIDA, K; ANDO, A; CHAVANIEU, A; MATSUBA, H; SHII, K; YOKONO, K; FUKUI, Y; CALAS, B; GRIGORESCU, F; DHAND, R; GOUT, I; OTSU, M; WATERFIELD, MD; KASUGA, M				YONEZAWA, K; UEDA, H; HARA, K; NISHIDA, K; ANDO, A; CHAVANIEU, A; MATSUBA, H; SHII, K; YOKONO, K; FUKUI, Y; CALAS, B; GRIGORESCU, F; DHAND, R; GOUT, I; OTSU, M; WATERFIELD, MD; KASUGA, M			INSULIN-DEPENDENT FORMATION OF A COMPLEX CONTAINING AN 85-KDA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE AND TYROSINE-PHOSPHORYLATED INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; SIGNAL TRANSDUCTION; INTACT-CELLS; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; PROTEIN; BINDING; PURIFICATION; PHOSPHOTYROSINE; PI3-KINASE	Monoclonal antibodies raised against the 85-kDa subunit (p85) of bovine phosphatidylinositol (PI) 3-kinase were found to recognize uncomplexed p85 or p85 in the active PI 3-kinase. Immunoprecipitation studies of Chinese hamster ovary cells, which overexpress the human insulin receptor when treated with insulin, showed increased amounts of p85 and PI 3-kinase activity immunoprecipitable with monoclonal anti-p85 antibody and no increase in the tyrosine phosphorylation of p85. Insulin also induced an association of p85 with the tyrosine-phosphorylated insulin receptor substrate 1 (IRS-1) and other phosphorylated proteins ranging in size from 100 to 170 kDa but not with the activated insulin receptor. In vitro reconstitution studies were used to show p85 in the active PI 3-kinase associated with the tyrosine-phosphorylated IRS-1 but not with the activated insulin receptor. Competition studies using synthetic phosphopeptides corresponding to potential tyrosine phosphorylation sites of IRS-1 revealed that phosphopeptides containing YMXM motifs inhibited this association with different potencies, whereas nonphosphorylated analogues and a phosphopeptide containing the EYYE motif had no effect. Src homology region 2 domains of p85 expressed as glutathione S-transferase fusion proteins also bound to tyrosine-phosphorylated IRS-1. These results suggest that insulin causes the association of PI 3-kinase with IRS-1 via phosphorylated YMXM motifs of IRS-1 and Src homology region 2 domains of p85.	KOBE UNIV, SCH MED,DEPT INTERNAL MED 2,7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN; CNRS, UPR8402, CRBM, F-34033 MONTPELLIER, FRANCE; INSERM, U249, F-34100 MONTPELLIER, FRANCE; HYOGO INST CLIN RES, AKASHI 673, JAPAN; UNIV TOKYO, FAC AGR, DEPT AGR CHEM, BIOCHEM LAB, BUNKYO KU, TOKYO 113, JAPAN; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Kobe University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Tokyo; Ludwig Institute for Cancer Research	KASUGA, M (corresponding author), KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, 7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN.		GRIGORESCU, FLORIN/C-2238-2013; Grigorescu, Florin/Q-3728-2019; Fukui, Yasuhisa/E-8806-2010; Chavanieu, Alain/A-2247-2013	GRIGORESCU, FLORIN/0000-0002-3095-5639; Grigorescu, Florin/0000-0002-3095-5639; Chavanieu, Alain/0000-0002-0512-5115				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BECKER AB, 1990, ANNU REV MED, V41, P99; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAVANIEU A, 1991, BIOORG MED CHEM LETT, V1, P299, DOI 10.1016/S0960-894X(01)80812-X; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KADOWAKI T, 1987, J BIOL CHEM, V262, P7324; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; YONEZAWA K, 1991, ADV EXP MED BIOL, V293, P227; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZARDENETA G, 1990, ANAL BIOCHEM, V190, P340, DOI 10.1016/0003-2697(90)90205-N	46	122	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25958	25965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334490				2022-12-27	WOS:A1992KD07300057
J	KAGAWA, N; WATERMAN, MR				KAGAWA, N; WATERMAN, MR			PURIFICATION AND CHARACTERIZATION OF A TRANSCRIPTION FACTOR WHICH APPEARS TO REGULATE CAMP RESPONSIVENESS OF THE HUMAN CYP21B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE GENES; CELL-FREE-EXTRACTS; RNA POLYMERASE-II; PROMOTER REGION; FACTOR SP1; SEQUENCE; DNA; ELEMENT; ACTIVATION; IDENTIFICATION	A unique cAMP regulatory sequence, -129/-96 base pairs (bp), associated with the gene encoding human cytochrome P450C21 (CYP21B) binds a nuclear protein designated ASP, as described previously (Kagawa, N., and Waterman, M. R. (1991) J. Biol. Chem. 266, 11199-11204). This putative transcription factor required for cAMP-dependent transcription of the human CYP21B gene has been purified from the nuclear extracts of mouse Y1 cells by using sequence-specific DNA-affinity chromatography. The purified ASP is 78 kDa as estimated by SDS-polyacrylamide gel electrophoresis and binds to its specific recognition site, -126/-113-bp CACTCTGTGGGCGG, which has been demonstrated to be the minimum cAMP regulatory sequence of the human CYP21B gene. To characterize ASP more precisely, an antibody was raised against the 78-kDa protein. This antibody led to a supershift of the DNA.ASP complex on gel shift analysis and inhibition of in vitro transcription promoted by the ASP binding sequence, thereby indicating that ASP is a 78-kDa transcription factor. Upon DNase I footprinting experiments, ASP showed a characteristic footprint which very closely resembles but is distinct from that of Sp1 which also occupies a binding site within -129/-96 bp. Furthermore, the addition of purified ASP enhanced the mRNA synthesis promoted by the minimum cAMP regulatory sequence in a cell-free transcription system using HeLa cell extracts, whereas added Sp1 does not. These results indicate that ASP is a primary transcription factor for the cAMP-dependent regulation of the human CYP21B gene.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET & GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK28350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LUND J, 1990, J BIOL CHEM, V265, P3304; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOUW AR, 1989, J BIOL CHEM, V264, P1305; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; ZANGER UM, 1991, J BIOL CHEM, V266, P11417; ZANGER UM, 1992, FASEB J, V6, P719, DOI 10.1096/fasebj.6.2.1311271	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25213	25219						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334085				2022-12-27	WOS:A1992KB60300047
J	DURAND, M; THUONG, NT; MAURIZOT, JC				DURAND, M; THUONG, NT; MAURIZOT, JC			BINDING OF NETROPSIN TO A DNA TRIPLE HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHIDIUM-BROMIDE; MINOR GROOVE; STRAND FORMATION; MAJOR GROOVE; OLIGONUCLEOTIDE; CONFORMATION; DISTAMYCIN; SEQUENCES; COMPLEXES; CLEAVAGE	The interaction of netropsin, a minor groove binding drug, with T-A-T triple helix and A-T double helix was studied using circular dichroism spectroscopy and thermal denaturation. The triple helix was made by an oligonucleotide (dA)12-x-(dT)12-x-(dT)12, where x is a hexaethylene glycol chain bridged between the 3' phosphate of one strand and the 5' phosphate of the following strand. This oligonucleotide is able to fold back on itself to form a very stable triplex. Changing the conditions allows the same oligonucleotide in a duplex form with a (dT)12 dangling arm. Circular dichroism spectroscopy demonstrates that netropsin can bind to the triple helical structure. Spectral analysis shows that the bound drug exhibits a conformation and an environment similar in double-stranded and in triple-stranded structure. However, the binding constant to the triple-stranded structure is found smaller than the binding constant to the double-stranded one. Thermal denaturation experiments demonstrate that netropsin destabilizes the triplex whereas it stabilizes the duplex.			DURAND, M (corresponding author), CTR BIOPHYS MOLEC 1A, F-45071 ORLEANS, FRANCE.							ARNOTT S, 1974, J MOL BIOL, V88, P523, DOI 10.1016/0022-2836(74)90499-9; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; CASSANI GR, 1969, BIOCHEMISTRY-US, V8, P3928, DOI 10.1021/bi00838a008; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DURAND M, 1992, BIOCHEMISTRY-US, V31, P9197, DOI 10.1021/bi00153a012; DURAND M, 1990, NUCLEIC ACIDS RES, V18, P6353, DOI 10.1093/nar/18.21.6353; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KIBLERHERZOG L, 1990, NUCLEIC ACIDS RES, V18, P3545, DOI 10.1093/nar/18.12.3545; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LATT SA, 1967, BIOCHEMISTRY-US, V6, P3293, DOI 10.1021/bi00862a040; Le Pecq J B, 1971, Methods Biochem Anal, V20, P41, DOI 10.1002/9780470110393.ch2; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; LEPECQ J, 1965, CR HEBD ACAD SCI, V260, P7033; LUCK G, 1974, NUCLEIC ACIDS RES, V1, P503, DOI 10.1093/nar/1.3.503; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MARKY LA, 1989, BIOCHEMISTRY-US, V28, P9982, DOI 10.1021/bi00452a016; MERGNY JL, 1991, NUCLEIC ACIDS RES, V19, P1521, DOI 10.1093/nar/19.7.1521; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PATEL DJ, 1985, BIOCHIMIE, V67, P887, DOI 10.1016/S0300-9084(85)80181-4; PATEL DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6424, DOI 10.1073/pnas.79.21.6424; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; POSVIC TJ, 1989, J AM CHEM SOC, V111, P3059; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; SUN JS, 1991, J BIOMOL STRUCT DYN, V9, P425, DOI 10.1080/07391102.1991.10507926; SUTHERLAND JC, 1978, BIOCHEMISTRY-US, V17, P5088, DOI 10.1021/bi00617a003; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WARING MJ, 1974, BIOCHEM J, V143, P483, DOI 10.1042/bj1430483; WARTELL RM, 1974, J BIOL CHEM, V249, P6719; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZASEDATELEV AS, 1974, MOL BIOL REP, V1, P337, DOI 10.1007/BF00309567; ZIMMER C, 1976, NUCLEIC ACIDS RES, V3, P1521, DOI 10.1093/nar/3.6.1521; ZIMMER C, 1972, EUR J BIOCHEM, V26, P81, DOI 10.1111/j.1432-1033.1972.tb01742.x; Zimmer C, 1975, Prog Nucleic Acid Res Mol Biol, V15, P285, DOI 10.1016/S0079-6603(08)60122-1; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2; ZIMMER C, 1971, J MOL BIOL, V58, P329, DOI 10.1016/0022-2836(71)90250-6	57	58	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24394	24399						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332955				2022-12-27	WOS:A1992KA26300041
J	FUNG, BKK; LIEBERMAN, BS; LEE, RH				FUNG, BKK; LIEBERMAN, BS; LEE, RH			A 3RD FORM OF THE G-PROTEIN BETA-SUBUNIT .2. PURIFICATION AND BIOCHEMICAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; AMINO-ACID SEQUENCE; GAMMA-SUBUNITS; CYCLIC-GMP; RETINAL CONES; ALPHA-SUBUNITS; TRANSDUCIN; DIVERSITY; BINDING; BRAIN	Visual excitation in cones is thought to involve a cone-specific G protein (cone transducin) that transduces the light signal detected by the cone visual pigment into an increase in the enzymatic activity of a cGMP phosphodiesterase. In the preceding paper, we have shown that the Gbeta3 isoform of G proteins is specifically localized in bovine cone photoreceptors and proposed that it might be a component of cone transducin. We reported here the purification from bovine retinal extract of a cone-specific Tbeta3gamma complex (where T is transducin), which is composed of a Gbeta3 subunit and an immunochemically distinct Ggamma subunit. Our purification of this complex is based on a two-stage procedure; the first stage consists of a series of column chromatographies that yield a mixture of purified Tbetagamma substantially enriched in Tbeta3gamma, and the second stage involves the removal of all of the rod-specific Tbeta1gamma from the mixture using an affinity column of immobilized monoclonal antibodies directed against the rod Tgamma subunit of transducin. Using this procedure, we were able to obtain sufficient amounts of Tbeta1gamma and Tbeta3gamma to begin a comparative study of their properties. We showed that Tbeta3gamma is distinguishable from Tbeta1gamma by isoelectric focusing under nondenaturing conditions. The Gbeta3 polypeptide of Tbeta3gamma also migrates slightly slower than the Gbeta1 polypeptide of Tbeta1gamma on denaturing polyacrylamide gels. Analysis of the interactions of Tbeta3gamma with other retinal proteins indicated that it has a lower affinity for the Talpha subunit of rod transducin but appears to complex with a phosducin-like protein. The differences in the intrinsic biochemical properties of Tbeta3gamma as compared to Tbeta1gamma may partially account for the lower light sensitivity of cones.	UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; VET ADM MED CTR, MOLEC NEUROL LAB, SEPULVEDA, CA 91343 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA)	FUNG, BKK (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA.				NATIONAL EYE INSTITUTE [R01EY005895] Funding Source: NIH RePORTER; NEI NIH HHS [EY00395, EY05895] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTWELL D, 1985, NATURE, V317, P14, DOI 10.1038/317014a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR BR, 1984, J IMMUNOL METHODS, V71, P265, DOI 10.1016/0022-1759(84)90073-5; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1983, J BIOL CHEM, V258, P10502; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HARWELL LW, 1984, J IMMUNOL METHODS, V66, P59, DOI 10.1016/0022-1759(84)90247-3; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HO Y-K, 1990, Investigative Ophthalmology and Visual Science, V31, P215; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE R, 1989, Investigative Ophthalmology and Visual Science, V30, P171; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1990, EXP EYE RES, V51, P325, DOI 10.1016/0014-4835(90)90029-T; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P11035; MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKATANI K, 1989, J PHYSIOL-LONDON, V409, P525, DOI 10.1113/jphysiol.1989.sp017511; NAKATANI K, 1986, Investigative Ophthalmology and Visual Science, V27, P300; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NAVON SE, 1987, EXP EYE RES, V44, P115, DOI 10.1016/S0014-4835(87)80030-1; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weizsacker E. V., 1992, BIOCHEM BIOPH RES CO, V183, P350; WOOLKALIS MJ, 1987, MOL PHARMACOL, V32, P1; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	48	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24782	24788						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332966				2022-12-27	WOS:A1992KA26300094
J	LOHSE, DL; LINHARDT, RJ				LOHSE, DL; LINHARDT, RJ			PURIFICATION AND CHARACTERIZATION OF HEPARIN LYASES FROM FLAVOBACTERIUM-HEPARINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ENZYMATIC DEGRADATION; SULFATE; HEPARITINASE; ENZYMES; BIOSYNTHESIS; PRODUCTS; PROTEINS; POLYMER; BINDING	Heparin lyase I has been purified from Flavobacterium heparinum and has been partially characterized (Yang, V. C., Linhardt, R. J., Berstein, H., Cooney, C. L., and Langer, R. (1985) J. Biol. Chem. 260, 1849-1857). There has been no report of the purification of the other polysaccharide lyases from this organism. Although all three of these heparin/heparan sulfate lyases are widely used, with the exception of heparin lyase I, there is no information on their purity or their physical and kinetic characteristics. The absence of pure heparin lyases and a lack of understanding of the optimal catalytic conditions and substrate specificity has stood in the way of the use of these enzymes as reagents for the specific depolymerization of heparin and heparan sulfate into oligosaccharides for structure and activity studies. This paper describes a single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity. Heparin lyase I (heparinase, EC 4.2.2.7), heparin lyase II (no EC number), and heparin lyase III (heparitinase, EC 4.2.2.8) have molecular weights (by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and isoelectric points (by isoelectric focusing) of M(r) 42,800, pI 9.1-9.2, M(r) 84, 100, pI 8.9-9.1, M(r) 70,800, pI 9.9-10.1, respectively. Their amino acid analyses and peptide maps demonstrate that while these proteins are different gene products they are closely related. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. These data should improve the application of these important enzymes in the study of heparin and heparan sulfate.	UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242	University of Iowa					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38060] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNICK CT, 1972, BIOCHEMISTRY-US, V11, P568; BOHMER LH, 1990, J BIOL CHEM, V265, P13609; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; COHEN DM, 1990, BIOPOLYMERS, V30, P733, DOI 10.1002/bip.360300708; DIETRICH CP, 1971, BIOCHIM BIOPHYS ACTA, V237, P430, DOI 10.1016/0304-4165(71)90260-1; DIETRICH CP, 1974, BIOCHIM BIOPHYS ACTA, V343, P34, DOI 10.1016/0304-4165(74)90237-2; DIETRICH CP, 1973, J BIOL CHEM, V248, P6408; DIETRICH CP, 1969, BIOCHEMISTRY-US, V8, P2089, DOI 10.1021/bi00833a046; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GALLIHER PM, 1982, EUR J APPL MICROBIOL, V15, P252, DOI 10.1007/BF00499966; HOVINGH P, 1970, J BIOL CHEM, V245, P6170; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER HH, 1986, ANAL CHEM, V58, P166, DOI 10.1021/ac00292a041; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1991, CHEM IND-LONDON, P45; LINHARDT RJ, 1984, APPL BIOCHEM BIOTECH, V9, P41, DOI 10.1007/BF02798373; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINHARDT RJ, 1985, INT J BIOCHEM, V17, P1179; LINKER A, 1965, J BIOL CHEM, V240, P3724; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LOHSE DL, 1992, THESIS U IOWA; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MCLEAN MW, 1985, 8TH P INT S GLYC, P73; MICHELACCI YM, 1974, BIOCHEM BIOPH RES CO, V56, P973, DOI 10.1016/S0006-291X(74)80284-6; MOFFAT CF, 1991, EUR J BIOCHEM, V197, P449, DOI 10.1111/j.1432-1033.1991.tb15931.x; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAMURA T, 1988, J CLIN MICROBIOL, V26, P1070, DOI 10.1128/JCM.26.5.1070-1071.1988; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; OTOTANI N, 1978, J BIOCHEM-TOKYO, V84, P1005, DOI 10.1093/oxfordjournals.jbchem.a132181; OTOTANI N, 1981, 6TH P INT S GLYC TOK; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAYZA AN, 1956, NATURE, V177, P88, DOI 10.1038/177088a0; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; SASISEKHARAN R, 1991, THESIS HARVARD U; SAYLERS AA, 1977, APPL ENVIRON MICROB, V33, P319; SILVA ME, 1976, BIOCHIM BIOPHYS ACTA, V437, P129, DOI 10.1016/0304-4165(76)90354-8; SILVA ME, 1974, BIOCHEM BIOPH RES CO, V56, P965, DOI 10.1016/S0006-291X(74)80283-4; YANG VC, 1985, CARBOHYD RES, V143, P294, DOI 10.1016/S0008-6215(00)90723-7; YANG VC, 1987, APPL BIOCHEM BIOTECH, V16, P35, DOI 10.1007/BF02798354; YANG VC, 1985, J BIOL CHEM, V260, P1849; YOSHIDA K, 1989, 10TH P ANN S GLYC; YOSHIDA K, 1991, 1991 INT S HEP REL P; ZIMMERMANN JJF, 1991, APPL BIOCHEM BIOTECH, V30, P137	51	196	230	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24347	24355						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332952				2022-12-27	WOS:A1992KA26300034
J	SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			RECONSTITUTION OF TRANSCRIPTION WITH 5 PURIFIED INITIATION-FACTORS AND RNA POLYMERASE-II FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TFIIE; PREINITIATION COMPLEX; LARGE SUBUNIT; YEAST; PROMOTER; PURIFICATION; GENE; SEQUENCE; INVITRO; KINASE	Yeast RNA polymerase II initiation factors a, b, e, and g were isolated from whole cell extract and found to be sufficient, when combined with bacterially expressed yeast transcription factor (TF) IID, to enable RNA polymerase II to utilize nine different eukaryotic promoters in vitro, and to initiate transcription at sites used in vivo. The purified factors did not contain the previously described transcription factor IIA (TFIIA). TFIIA failed to substitute for any purified factor or to stimulate transcription with the complete set of factors, indicating that its function in crude extracts is primarily as an anti-inhibitor.			SAYRE, MH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	52	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23376	23382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331084				2022-12-27	WOS:A1992JY16300101
J	MCMAHON, HT; FORAN, P; DOLLY, JO; VERHAGE, M; WIEGANT, VM; NICHOLLS, DG				MCMAHON, HT; FORAN, P; DOLLY, JO; VERHAGE, M; WIEGANT, VM; NICHOLLS, DG			TETANUS TOXIN AND BOTULINUM TOXINS TYPE-A AND TYPE-B INHIBIT GLUTAMATE, GAMMA-AMINOBUTYRIC-ACID, ASPARTATE, AND MET-ENKEPHALIN RELEASE FROM SYNAPTOSOMES - CLUES TO THE LOCUS OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; NEUROTOXIN TYPE-A; PROTEIN KINASE-C; PERMEABILIZED CHROMAFFIN CELLS; CEREBRAL CORTICAL SYNAPTOSOMES; CYTOSOLIC FREE CA-2+; LIGHT CHAIN; CLOSTRIDIAL NEUROTOXINS; ACETYLCHOLINE-RELEASE; TRANSMITTER RELEASE	Tetanus toxin (100 nM) when preincubated with guinea pig cerebrocortical synaptosomes for 45 min reduces the final extent of the KCl-evoked, Ca2+-dependent, glutamate transmitter release to 30% of non-intoxicated controls. Similarly, 100 nM Botulinum neurotoxins, types A and B, preincubated for 90 min inhibit release to 45-60% of non-intoxicated controls. The toxins preferentially attenuate a slow phase of KCl-evoked glutamate release which may be associated with synaptic vesicle mobilization. Tetanus toxin additionally inhibits the release of aspartate, gamma-aminobutyric acid and met-enkephalin from the same preparation. Since amino acids and neuropeptides are released by distinct mechanisms, this indicates that the toxin affects a step common to both exocytotic pathways. When Ba2+ (which does not interact with calmodulin) is substituted for Ca2+, the control KCl-evoked release of each transmitter is unaffected and tetanus toxin is still inhibitory. Taken together these results implicate a calmodulin-independent locus (or loci) of action common to small- and large-dense-core vesicles and associated with vesicle transport.	UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; UNIV UTRECHT, RUDOLF MAGNUS INST PHARMACOL, 3508 TC UTRECHT, NETHERLANDS	University of Dundee; Imperial College London; Utrecht University			NICHOLLS, DAVID G/K-4300-2012; Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; verhage, matthijs/0000-0002-6085-7503	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILERA J, 1990, FEBS LETT, V263, P61, DOI 10.1016/0014-5793(90)80705-N; AGUILERA J, 1990, J NEUROCHEM, V54, P339, DOI 10.1111/j.1471-4159.1990.tb13319.x; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; ASHTON AC, 1990, TOXICON, V28, P963, DOI 10.1016/0041-0101(90)90025-3; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; ASHTON AC, 1991, J NEUROCHEM, V56, P827, DOI 10.1111/j.1471-4159.1991.tb01998.x; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CONSIDINE RV, 1990, TOXICON, V28, P13, DOI 10.1016/0041-0101(90)90002-O; DASGUPTA BR, 1988, BIOCHIMIE, V70, P811, DOI 10.1016/0300-9084(88)90111-3; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EVANS DM, 1986, EUR J BIOCHEM, V154, P409, DOI 10.1111/j.1432-1033.1986.tb09413.x; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; FISHMAN PS, 1987, BRAIN RES, V406, P275, DOI 10.1016/0006-8993(87)90792-X; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT, P1; GREENGARD P, 1987, MOL NEUROBIOL, V1, P82; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HALPERN JL, 1990, J NEUROCHEM, V55, P2072, DOI 10.1111/j.1471-4159.1990.tb05797.x; HILGER GA, 1989, FEBS LETT, V242, P245; JANICKI PK, 1983, J NEUROCHEM, V41, P395, DOI 10.1111/j.1471-4159.1983.tb04755.x; KAUPPINEN RA, 1986, EUR J BIOCHEM, V158, P159, DOI 10.1111/j.1432-1033.1986.tb09733.x; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LAZAROVICI P, 1989, FEBS LETT, V253, P121, DOI 10.1016/0014-5793(89)80943-3; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; MATTEOLI M, 1989, CELL BIOL INT REP, V13, P981, DOI 10.1016/0309-1651(89)90014-3; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; PARTON RG, 1987, J NEUROCHEM, V49, P1057; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; POULAIN B, 1991, J BIOL CHEM, V266, P9580; RABASSEDA X, 1988, TOXICON, V26, P329, DOI 10.1016/0041-0101(88)90001-3; SANCHEZPRIETO J, 1987, J NEUROCHEM, V49, P58, DOI 10.1111/j.1471-4159.1987.tb03394.x; SANCHEZPRIETO J, 1987, EUR J BIOCHEM, V165, P675, DOI 10.1111/j.1432-1033.1987.tb11494.x; SANDBERG K, 1989, J NEUROSCI, V9, P3946; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TSE CK, 1982, EUR J BIOCHEM, V122, P493; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; VERHAGE M, 1992, IN PRESS BRAIN RES; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]	60	237	239	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21338	21343						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356988				2022-12-27	WOS:A1992JV01100015
J	BRUGGEMANN, EP; CURRIER, SJ; GOTTESMAN, MM; PASTAN, I				BRUGGEMANN, EP; CURRIER, SJ; GOTTESMAN, MM; PASTAN, I			CHARACTERIZATION OF THE AZIDOPINE AND VINBLASTINE BINDING-SITE OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; BACTERIAL TRANSPORT PROTEINS; DEPENDENT TRANSPORT; PHOTOAFFINITY PROBE; MEMBRANE-VESICLES; CYSTIC-FIBROSIS; H-3 AZIDOPINE; DRUG-BINDING; TUMOR-CELLS; KB CELLS	To determine the number of drug binding sites that exist on the multidrug transporter, P-glycoprotein, we used azidopine, a dihydropyridine photoaffinity compound that reverses multidrug resistance and labels P-glycoprotein. Azidopine labels P-glycoprotein in two distinct locations: one labeled site is within the amino half of P-glycoprotein between amino acid residues 198 and 440, and the other site is within the carboxy half of the protein. Vinblastine is a cytotoxic drug that is used in cancer chemotherapy and is a substrate for transport by P-glycoprotein. We found that vinblastine inhibits azidopine labeling to approximately the same extent at each labeled site on P-glycoprotein. Because several studies have shown that amino acid residue 185 of P-glycoprotein plays a critical role in some aspects of drug binding and transport, we also studied the effect that amino acid residue 185 has on azidopine labeling. These studies show that azidopine labels both sites equivalently in both wild-type (G185) and mutant (V185) P-glycoproteins. We conclude from our results that the two halves of P-glycoprotein approach each other to form a single binding site for these drugs.	NCI,MOLEC BIOL LAB,BLDG 37,RM 4E16,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144; AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CASTILLO G, 1990, P NATL ACAD SCI USA, V87, P4737, DOI 10.1073/pnas.87.12.4737; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; CROOP JM, 1987, CANCER RES, V47, P5982; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERRY DR, 1984, FEBS LETT, V169, P112, DOI 10.1016/0014-5793(84)80299-9; FERRY DR, 1985, EMBO J, V4, P1933, DOI 10.1002/j.1460-2075.1985.tb03873.x; FOJO A, 1985, CANCER RES, V45, P3002; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FORD JM, 1990, CANCER RES, V50, P1748; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KOIKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAFA AR, 1990, BIOCHEM BIOPH RES CO, V166, P259; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SHEN DW, 1986, J BIOL CHEM, V261, P7762; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLINGHAM MC, 1986, CANCER RES, V46, P5941; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	50	202	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21020	21026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356986				2022-12-27	WOS:A1992JT97800080
J	TABB, JS; KISH, PE; VANDYKE, R; UEDA, T				TABB, JS; KISH, PE; VANDYKE, R; UEDA, T			GLUTAMATE TRANSPORT INTO SYNAPTIC VESICLES - ROLES OF MEMBRANE-POTENTIAL, PH GRADIENT, AND INTRAVESICULAR PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; BOVINE CEREBRAL-CORTEX; FUNCTIONAL RECONSTITUTION; CATECHOLAMINE TRANSPORT; CHROMAFFIN VESICLES; ENERGY-DEPENDENCE; DELTA-PH; PROTON; GLYCINE; ATPASE	Glutamate, the major excitatory neurotransmitter in the mammalian central nervous system, is transported into bovine synaptic vesicles in a manner that is ATP dependent and requires a vesicular electrochemical proton gradient. We studied the electrical and chemical elements of this driving force and evaluated the effects of chloride on transport. Increasing concentrations of Cl- were found to increase the steady-state ATP-dependent vesicular pH gradient (DELTA-pH) and were found to concomitantly decrease the vesicular membrane potential (DELTA-PSI). Low millimolar chloride concentrations, which cause 3-6-fold stimulation of vesicular glutamate uptake, caused small but measurable increases in DELTA-pH and decreases in DELTA-PSI, when compared to control vesicles in the absence of chloride. Nigericin in potassium buffers was used to alter the relative proportions of DELTA-pH and DELTA-PSI. Compared to controls, at all chloride concentrations tested, nigericin virtually abolished DELTA-pH and increased the vesicle interior positive DELTA-PSI. Concomitantly, nigericin increased ATP-dependent glutamate uptake in 0-1 mM chloride but decreased glutamate uptake in 4 mM (45%), 20 mM (80%), and 140 mM (75%) Cl- (where DELTA-pH in the absence of nigericin was large). These findings suggest that either DELTA-PSI, DELTA-pH, or a combination can drive glutamate uptake, but to different degrees. In the presence of 4 mM Cl-, where uptake is optimal, both DELTA-PSI and DELTA-pH contribute to the driving force for uptake. When the extravesicular pH was increased from 7.4 to 8.0, more Cl- was required to stimulate vesicular glutamate uptake. In the absence of Cl-, as extravesicular pH was lowered to 6.8, uptake was over 3-fold greater than it was at pH 7.4. As extravesicular pH was reduced from 8.0 toward 6.8, less Cl- was required for maximal stimulation. Decreasing the extravesicular pH from 8.0 to 6.8 in the absence of Cl- significantly increased glutamate uptake activity, even though proton-pumping ATPase activity actually decreased about 45% under identical conditions. In the absence of chloride, nigericin increased glutamate uptake at all the pH values tested except pH 8.0. Glutamate uptake at pH 6.8 in the presence of nigericin was over 6-fold greater than uptake at pH 7.4 in the absence of nigericin. We conclude from these experiments that optimal ATP-dependent glutamate uptake requires a large DELTA-PSI and a small DELTA-pH. Chloride stimulates glutamate uptake by increasing the vesicle DELTA-pH, and we suggest that the resulting decrease in intravesicular pH at low Cl- concentrations plays an important role in stimulating vesicular glutamate uptake.	UNIV MICHIGAN,MENTAL HLTH RES INST,205 ZINA PITCHER PL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PSYCHIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Kish, Phil E/H-6051-2011		NIMH NIH HHS [MH 15794-12] Funding Source: Medline; NINDS NIH HHS [NS 26884] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026884] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; CIDON S, 1989, J BIOL CHEM, V264, P8281; FLOOR E, 1988, J NEUROCHEM, V55, P1663; FONNUM F, 1989, J NEUROCHEM, V52, P946; FYSKE EM, 1988, J NEUROCHEM, V50, P1237; HELL JW, 1990, J BIOL CHEM, V265, P2111; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOLZ RW, 1978, P NATL ACAD SCI USA, V75, P5190, DOI 10.1073/pnas.75.10.5190; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; JOHNSON RG, 1979, J BIOL CHEM, V254, P963; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KISH PE, 1989, METHOD ENZYMOL, V174, P10; LOH YP, 1984, J BIOL CHEM, V259, P8238; MAYCOX PR, 1990, EMBO J, V9, P1465, DOI 10.1002/j.1460-2075.1990.tb08263.x; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SHIOI J, 1989, BIOCHEM J, V258, P499, DOI 10.1042/bj2580499; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; TABB JS, 1991, 3RD IBRO WORLD C NEU; TOLL L, 1978, BIOCHEMISTRY-US, V17, P2517, DOI 10.1021/bi00606a010; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603	30	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15412	15418						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353494				2022-12-27	WOS:A1992JG11300026
J	GUY, PM; CARRAWAY, KL; CERIONE, RA				GUY, PM; CARRAWAY, KL; CERIONE, RA			BIOCHEMICAL COMPARISONS OF THE NORMAL AND ONCOGENIC FORMS OF INSECT CELL-EXPRESSED NEU TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN INSULIN-RECEPTOR; HUMAN MAMMARY-TUMORS; POINT MUTATION; ACTIVATION; PROTEIN; DOMAIN; OVEREXPRESSION; AMPLIFICATION; PURIFICATION	The rat neu oncogene product is a member of the epidermal growth factor (EGF) receptor subgroup of the superfamily of growth factor receptor tyrosine kinases. The oncogenic activation of the neu protein occurs by a point mutation within its transmembrane region which results in an increase in its tyrosine kinase activity. Using three different forms of neu expressed in insect cells via baculovirus infection, we have examined the biochemical differences between the normal and transforming forms of neu and investigated the role of the transmembrane domain in its tyrosine kinase activity. One form of neu which was expressed in insect cells consisted of the complete tyrosine kinase domain but lacked the extracellular and transmembrane regions (designated NTK). The other two forms consisted of the tyrosine kinase domain, the transmembrane domain, and 40 amino acids of the extracellular domain. One of these transmembrane forms of neu contained the normal valine residue at position 664 within the transmembrane region (MS-N), while the other contained the oncogenic glutamic acid residue at this position (MS-T). Direct comparisons of NTK, MS-N, and MS-T have shown that the NTK protein is capable of the highest extents of both autophosphorylation activity and the tyrosine phosphorylation of exogenous substrate, suggesting that the presence of the transmembrane region of neu suppresses the tyrosine kinase activity of this receptor. In addition, we have found that the oncogenic point mutation within the transmembrane region stimulates the tyrosine kinase activity of the neu protein by allowing it to more effectively utilize Mg2+. Overall, the results of these studies suggest that the valine to glutamic acid substitution at position 664 may at least partially relieve a negative constraint imparted by the membrane-spanning domain on the tyrosine kinase activity of neu and enables a more effective use of Mg2+ in the catalysis of tyrosine phosphorylation of exogenous substrates.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University	GUY, PM (corresponding author), CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,SHURMAN HALL,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HERRERA R, 1988, J BIOL CHEM, V263, P5560; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KOLAND JG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P489, DOI 10.1016/0167-4889(90)90160-F; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WENTE SR, 1990, P NATL ACAD SCI USA, V87, P2805, DOI 10.1073/pnas.87.7.2805	27	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13851	13856						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1352772				2022-12-27	WOS:A1992JD32500013
J	VALLEJO, M; MILLER, CP; HABENER, JF				VALLEJO, M; MILLER, CP; HABENER, JF			SOMATOSTATIN GENE-TRANSCRIPTION REGULATED BY A BIPARTITE PANCREATIC-ISLET D-CELL-SPECIFIC ENHANCER COUPLED SYNERGETICALLY TO A CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; PROTEIN-BINDING DOMAINS; CYCLIC-AMP; PROMOTER ELEMENT; CONTROL REGION; MESSENGER-RNA; GLUCAGON GENE; MAMMALIAN-CELLS; DNA ELEMENTS; EXPRESSION	The insulin-, glucagon-, and somatostatin-producing cells in the pancreatic islets derive from a common precursor stem cell and differentiate sequentially during embryonic development, thereby providing an informative model for the study of the transcriptional mechanisms involved in the control of cell-specific gene expression. Relative to the early expression of the glucagon and insulin genes on embryonic days 10 and 12, respectively, the expression of the somatostatin gene is delayed (day 17). The relatively late expression of the somatostatin gene indicates the involvement of both negative and positive transcriptional control mechanisms. We show that the expression of the somatostatin gene in pancreatic islet cells is accomplished by the interplay of both positive and negative cis-regulatory DNA elements. We have characterized the functional properties of one of these positive control elements, the somatostatin gene upstream enhancer element (SMS-UE). The SMS-UE is a pancreatic islet D-cell-specific transcriptional regulator that acts synergistically with the cyclic AMP response element. Mutation-expression and cell-free transcription analyses show that the SMS-UE is a bipartite element with two interdependent functional domains. Our results indicate that the SMS-UE is part of a functional unit that includes other transcriptional control elements of the somatostatin gene proximal promoter, and that they act together to regulate the D-cell-specific transcription of the somatostatin gene in the islet cells of the pancreas.			VALLEJO, M (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, HOWARD HUGHES MED INST, MOLEC ENDOCRINOL LAB, BOSTON, MA 02114 USA.		Vallejo, Mario/ABG-4610-2020	Vallejo, Mario/0000-0002-6422-0323	NIDDK NIH HHS [DK30457, DK30834] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030457, R01DK030834, R01DK030457] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDEK RW, 1991, DIABETES, V40, P1041, DOI 10.2337/diabetes.40.8.1041; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MONTMINY MR, 1984, P NATL ACAD SCI-BIOL, V81, P3337, DOI 10.1073/pnas.81.11.3337; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; PATEL YC, 1991, ENDOCRINOLOGY, V128, P1754, DOI 10.1210/endo-128-4-1754; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; POWERS AC, 1989, J BIOL CHEM, V264, P10048; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEAQUIST ER, 1989, DIABETES, V38, P1439, DOI 10.2337/diabetes.38.11.1439; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SINGLETON CK, 1984, J BIOL CHEM, V259, P1963; STRATOWA C, 1986, P NATL ACAD SCI USA, V83, P4292, DOI 10.1073/pnas.83.12.4292; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TAVIANINI MA, 1984, J BIOL CHEM, V259, P1798; WANG TC, 1990, J BIOL CHEM, V265, P8908; WERNER H, 1988, J BIOL CHEM, V263, P7666; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	59	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12868	12875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352291				2022-12-27	WOS:A1992HZ48300073
J	THOMAS, PM; SAMELSON, LE				THOMAS, PM; SAMELSON, LE			THE GLYCOPHOSPHATIDYLINOSITOL-ANCHORED THY-1 MOLECULE INTERACTS WITH THE P60FYN PROTEIN TYROSINE KINASE IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; CO-EXPRESSION; ACTIVATION; PHOSPHORYLATION; MEMBRANE; COMPLEX; ASSOCIATION; CHAIN	Stimulation of murine T cells by engagement of the multi-component T cell antigen receptor or by cross-linking the Thy-1 molecule leads to a similar response characterized by lymphocyte activation and lymphokine production. The early biochemical events induced by engaging these molecules also are similar and begin with activation of a tyrosine kinase pathway and tyrosine phosphorylation of a comparable set of substrates. Previous work demonstrates that the protein tyrosine kinase p60(fyn) is associated with the antigen receptor and therefore it may participate in the tyrosine phosphorylations that are observed with antigen receptor signaling. In this study we demonstrate that the Thy-1 molecule is also associated with p60(fyn) in a murine T cell hybridoma and in murine thymocytes. The interaction is independent of antigen receptor expression. Thy-1 is a member of the class of molecules anchored to the plasma membrane by a glycophosphatidylinositol (GPI) group. The association of Thy-1 with p60(fyn) is dependent on the GPI linkage, since cleavage of the GPI anchor disrupts the interaction. The association of Thy-1 and p60(fyn) suggests a means by which Thy-1 cross-linking leads to tyrosine phosphorylation and T cell activation.			THOMAS, PM (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ANDERSON GW, 1991, SCIENCE, V255, P410; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALAFAT J, 1983, J GEN VIROL, V64, P1241, DOI 10.1099/0022-1317-64-6-1241; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; NARDELLI B, 1989, J IMMUNOL METHODS, V120, P233, DOI 10.1016/0022-1759(89)90247-0; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2	31	210	215	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12317	12322						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351058				2022-12-27	WOS:A1992HY94700099
J	COGHLAN, VM; VICKERY, LE				COGHLAN, VM; VICKERY, LE			ELECTROSTATIC INTERACTIONS STABILIZING FERREDOXIN ELECTRON-TRANSFER COMPLEXES - DISRUPTION BY CONSERVATIVE MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; AMINO-ACID SEQUENCE; HUMAN PLACENTAL FERREDOXIN; ADRENODOXIN REDUCTASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; SALT BRIDGE; PROTEIN; RECOGNITION; REPLACEMENTS	Mitochondrial ferredoxins mediate electron transfer from NADPH:ferredoxin oxidoreductase to cytochrome P450 enzymes. Previous studies on human ferredoxin, in which acidic residues were replaced with neutral amino acids, established that Asp-76 and Asp-79 are are important for binding to both reductase and P450 (Coghlan, V. M., and Vickery, L. E. (1991) J. Biol. Chem. 266, 18606-18612). Here we report that replacement of Asp --> Glu at position 76 or 79, whereas maintaining negative charge at these positions also results in dramatic decreases in binding affinity for both electron transfer partners (5-100-fold, DELTA(DELTA-G) almost-equal-to 1.0-2.8 kcal/mol). These results imply that the active electron transfer complexes in these systems are dominated by a stable form which requires specific pairwise electrostatic interactions of fixed geometry for recognition and binding. This mechanism contrasts with that proposed for other electron transfer systems (as exemplified by cytochrome c) in which electrostatic interactions are believed to function primarily in precollisional orientation leading to "encounter complexes" having multiple geometries of similar free energy.	UNIV CALIF IRVINE, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM43548] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM GE, 1973, J CLIN ENDOCR METAB, V37, P40, DOI 10.1210/jcem-37-1-40; AKHREM AA, 1978, BIOORG KHIM+, V4, P462; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BAGBY S, 1990, EUR J BIOCHEM, V188, P413, DOI 10.1111/j.1432-1033.1990.tb15418.x; BURCH AM, 1990, SCIENCE, V247, P831, DOI 10.1126/science.2154849; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1988, ARCH BIOCHEM BIOPHYS, V264, P376, DOI 10.1016/0003-9861(88)90302-5; DAS G, 1988, J BIOL CHEM, V263, P18290; DUVAL JF, 1980, STEROIDS, V36, P473, DOI 10.1016/0039-128X(80)90034-3; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P4445, DOI 10.1021/bi00412a035; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; Kraut J, 1981, BIOCHEM SOC T, V9, P197, DOI 10.1042/bst0090197; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MATTHEW JB, 1983, NATURE, V301, P169, DOI 10.1038/301169a0; MAUK MR, 1982, BIOCHEMISTRY-US, V21, P1843, DOI 10.1021/bi00537a021; MCLENDON G, 1991, STRUCT BOND, V75, P159; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMURA T, 1964, J BIOL CHEM, V239, P2379; ORMEJOHNSON NR, 1979, J BIOL CHEM, V254, P2103; POULOS TL, 1987, J BIOL CHEM, V262, P13881; ROBERTS VA, 1991, J BIOL CHEM, V266, P13431; RODGERS KK, 1988, SCIENCE, V240, P1657, DOI 10.1126/science.2837825; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WEBER PC, 1985, J BIOL CHEM, V260, P5568; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387	39	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8932	8935						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1349603				2022-12-27	WOS:A1992HR85400037
J	SEN, GC; LENGYEL, P				SEN, GC; LENGYEL, P			THE INTERFERON SYSTEM - A BIRDS-EYE-VIEW OF ITS BIOCHEMISTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GAMMA-RECEPTOR CDNA; PROTEIN-KINASE; HUMAN-CELLS; MOLECULAR-CLONING; EXPRESSION; GENES; IFN; ALPHA; ACTIVATION; PURIFICATION		YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University	SEN, GC (corresponding author), CLEVEL CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195, USA.		Yang, Chen/G-1379-2010		NIAID NIH HHS [AI12320, AI22510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012320, R01AI022510, R37AI012320, R21AI012320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BANDYOPADHYAY S, 1982, IN PRESS J BIOL CHEM, V264; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHOUBEY D, 1982, IN PRESS J CELL BIOL; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; COFANO F, 1990, J BIOL CHEM, V265, P4064; CROSS JC, 1991, P NATL ACAD SCI USA, V88, P3817, DOI 10.1073/pnas.88.9.3817; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DELCAYRE AX, 1991, EMBO J, V10, P919, DOI 10.1002/j.1460-2075.1991.tb08025.x; Demaeyer E., 1988, INTERFERONS OTHER RE; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GRESSER I, 1990, J INVEST DERMATOL, V95, P665; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HERSHEY GKK, 1990, J BIOL CHEM, V265, P17868; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JUNG V, 1990, J BIOL CHEM, V265, P1827; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KARA CJ, 1991, CURR OPIN IMMUNOL, V3, P16, DOI 10.1016/0952-7915(91)90070-H; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MAO C, 1990, J IMMUNOL, V145, P4257; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PATEL RC, 1992, IN PRESS J BIOL CHEM; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1991, HORMONAL CONTROL GEN, P349; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SNAPPER CM, 1988, J IMMUNOL, V140, P2121; SPERLING J, 1991, P NATL ACAD SCI USA, V88, P10377, DOI 10.1073/pnas.88.23.10377; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VILCEK J, 1989, HDB EXPT PHARM, V95, P3; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WILLIAMS B, 1985, 2 5A SYSTEM CLIN MOL; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; YAN C, 1991, P NATL ACAD SCI USA, V88, P144, DOI 10.1073/pnas.88.1.144	76	655	682	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5017	5020						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371992				2022-12-27	WOS:A1992HH74700001
J	RITTER, JK; CHEN, F; SHEEN, YY; TRAN, HM; KIMURA, S; YEATMAN, MT; OWENS, IS				RITTER, JK; CHEN, F; SHEEN, YY; TRAN, HM; KIMURA, S; YEATMAN, MT; OWENS, IS			A NOVEL COMPLEX LOCUS UGT1 ENCODES HUMAN BILIRUBIN, PHENOL, AND OTHER UDP-GLUCURONOSYLTRANSFERASE ISOZYMES WITH IDENTICAL CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; GENE; EXPRESSION; REGION; CELLS; CDNA	Two human liver UDP-glucuronosyltransferase (transferase) cDNAs, HUG-Br1 and HUG-Br2, were previously isolated (Ritter, J. K., Crawford, J. M., and Owens, I. S. (1991) J. Biol. Chem. 266, 1043-1047), and each was shown to encode a bilirubin transferase isozyme which catalyzes the formation of all physiological conjugates of bilirubin IX-alpha following expression in COS-1 cells. Sequence data showed that the cDNAs contained identical 3' ends (1469 base pairs in length) to each other and to that of the human phenol trans rase cDNA, HLUG P1 (Harding, D., Fournel-Gigleux, S., Jackson, M. R., and Burchell, B. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8381-8385). Here we report that the two corresponding bilirubin transferases and the phenol transferase are encoded by a novel locus, UGT1, which is also predicted to encode three other bilirubin transferase-like isozymes all having identical carboxyl termini. The transcriptional arrangement utilizes six nested promoter elements, each of which is positioned upstream of a unique exon 1. Each exon 1 encodes the NH2-terminal domain (286 amino acids) and confers the substrate specificity of the isoform. The 3' end of the locus contains 4 common exons which encode the identical carboxyl termini (246 amino acids). It is predicted that six nested primary transcripts are synthesized and that each exon 1 is differentially spliced to the 4 common exons to produce six unique, mature mRNAs. Although the gene organization is present as a single copy, it provides the flexibility of independent regulation of each isoform which is known to occur in the case of bilirubin and phenol transferase activities. With an understanding of the gene structure, lethal, as well as the nonlethal defects, associated with bilirubin transferase activity can now be determined.	NCI,MOLEC CARCINOGENESIS LAB,BLDG 10,RM 95 242,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; CHOWDHURY JR, 1989, METABOLIC BASIS INHE, P1367; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HARDING D, 1990, ANN HUM GENET, V54, P17, DOI 10.1111/j.1469-1809.1990.tb00356.x; HEILIG R, 1987, NUCLEIC ACIDS RES, V15, P9129, DOI 10.1093/nar/15.22.9129; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; NEBERT DW, 1979, CRC CR REV BIOCH MOL, V6, P401, DOI 10.3109/10409237909105427; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; SCHMID R, 1966, GLUCURONIC ACID FREE, P493; VINCENT A, 1984, EMBO J, V3, P1003, DOI 10.1002/j.1460-2075.1984.tb01920.x	15	446	460	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3257	3261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1339448				2022-12-27	WOS:A1992HD15400069
J	NEGISHI, M; HASHIMOTO, H; ICHIKAWA, A				NEGISHI, M; HASHIMOTO, H; ICHIKAWA, A			TRANSLOCATION OF ALPHA-SUBUNITS OF STIMULATORY GUANINE NUCLEOTIDE-BINDING PROTEINS THROUGH STIMULATION OF THE PROSTACYCLIN RECEPTOR IN MOUSE MASTOCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DECAPEPTIDE; ADENYLATE-CYCLASE SYSTEM; PLASMA-MEMBRANE; PLATELET MEMBRANES; GS-ALPHA; ACTIVATION; MYRISTOYLATION; IDENTIFICATION; PROSTAGLANDIN; TRANSDUCERS	The translocation of the alpha-subunits of Gs from the membrane to the cytosol by iloprost, a stable prostacyclin analogue, was studied in mouse mastocytoma P-815 cells. In the presence of guanosine 5'-O-(thiotriphosphate) (GTP-gamma-S), iloprost stimulated the adenylate cyclase activity, caused the release of both 42- and 45-kDa proteins reactive with the anti Gs-alpha carboxyl-terminal antibody, RM/1, from the membrane and attenuated cholera toxin-catalyzed ADP-ribosylation of the 42- and 45-kDa proteins in the membrane. The iloprost-stimulated adenylate cyclase activity and release of Gs-alpha from the membrane were markedly suppressed by RM/1. Cholera toxin treatment also stimulated the adenylate cyclase activity and release of Gs-alpha from the membrane, and iloprost synergistically potentiated these actions of cholera toxin. In mastocytoma cells, iloprost induced the translocation of both 42- and 45-kDa Gs-alpha from the membrane to the cytosol, 45-kDa Gs-alpha remaining in the cytosol for a longer time than 42-kDa Gs-alpha. Whereas 42-kDa Gs-alpha in the cytosol was eluted at the position of M(r) = approximately 40,000, 45-kDa Gs-alpha was eluted at the position of M(r) = approximately 120,000 from a Superose 12 gel filtration column. In contrast, both 42- and 45-kDa Gs-alpha released in vitro from the membrane by iloprost plus GTP-gamma-S were eluted at the position of M(r) = approximately 40,000, but only 45-kDa Gs-alpha was eluted at the position of M(r) = approximately 120,000 when it was incubated with cytosol. These results taken together demonstrate that iloprost induces the translocation of both 42- and 45-kDa Gs-alpha from the membrane to the cytosol and that only the 45-kDa Gs-alpha released exists in the cytosol as a soluble complex with unidentified component(s) in mastocytoma cells.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN	Kyoto University			Hashimoto, Hitoshi/D-1209-2010	Hashimoto, Hitoshi/0000-0001-6548-4016				BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHANG FH, 1989, J BIOL CHEM, V264, P5352; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; JOHNSON AR, 1970, J PHARMACOL EXP THER, V175, P632; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KADOWITZ PJ, 1978, J APPL PHYSIOL, V45, P408, DOI 10.1152/jappl.1978.45.3.408; LOMBROSO M, 1984, PROSTAGLANDINS, V27, P321, DOI 10.1016/0090-6980(84)90083-2; LYNCH CJ, 1986, FEBS LETT, V200, P333, DOI 10.1016/0014-5793(86)81163-2; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLIGAN G, 1989, BIOCHEM J, V260, P837, DOI 10.1042/bj2600837; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEGISHI M, 1991, BIOCHEM BIOPH RES CO, V176, P102, DOI 10.1016/0006-291X(91)90895-E; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135	27	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2364	2369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370818				2022-12-27	WOS:A1992HB53200040
J	NUTTER, LM; NGO, EO; FISHER, GR; GUTIERREZ, PL				NUTTER, LM; NGO, EO; FISHER, GR; GUTIERREZ, PL			DNA STRAND SCISSION AND FREE-RADICAL PRODUCTION IN MENADIONE-TREATED CELLS - CORRELATION WITH CYTOTOXICITY AND ROLE OF NADPH QUINONE ACCEPTOR OXIDOREDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXICITY; INTERCALATING AGENTS; ISOLATED HEPATOCYTES; HYDROGEN-PEROXIDE; RAT HEPATOCYTES; MAMMALIAN-CELLS; TUMOR-CELLS; METABOLISM; DAMAGE; THIOL	Menadione (MD; 2-methyl-1,4-naphthoquinone), a redox cycling quinone was shown to induce single (ss)- and double (ds)-strand DNA breaks in human MCF-7 cells. This DNA damage was mediated via the hydroxyl radical as evidenced by electron spin resonance spectroscopy (ESR) studies utilizing the spin- trap, 5,5-dimethyl-1-pyrroline-1-oxide. The free radical production and DNA damage were shown to play a role in MD cytotoxicity as revealed by the reversal of MD toxicity and inhibition of hydroxyl radical production by exogeneously added catalase. The role of NADPH quinone acceptor oxidoreductase in the metabolism of MD was evaluated. Purified quinone acceptor oxidoreductase in combination with MD resulted in the production of significant levels of the hydroxyl radical as measured by ESR. Dicumarol, an inhibitor of quinone acceptor oxidoreductase, decreased the production of the hydroxyl radical and attenuated DNA strand breaks in MCF-7 cells treated with MD.	UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore	NUTTER, LM (corresponding author), UNIV MINNESOTA,DEPT PHARMACOL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NCI NIH HHS [CA33861, 1R29CA52618-O1A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1985, CANCER RES, V45, P5257; AKMAN SA, 1987, J PHARMACOL EXP THER, V240, P486; BEGLEITER A, 1988, CANCER RES, V48, P1727; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; Buettner G.R, 1982, SUPEROXIDE DISMUTASE, V2, P63; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; CHLEBOWSKI RT, 1985, CANCER TREAT REV, V12, P49, DOI 10.1016/0305-7372(85)90012-X; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4513; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FISHER GR, 1991, FREE RADICAL BIO MED, V10, P359, DOI 10.1016/0891-5849(91)90044-4; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GOLD J, 1986, CANCER TREAT REP, V70, P1433; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KEYES SR, 1985, CANCER RES, V45, P213; KOHN KW, 1979, METHOD CANCER RES, V16, P291; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; MARTINS EAL, 1990, FREE RADICAL BIO MED, V8, P433, DOI 10.1016/0891-5849(90)90056-O; MIRABELLI F, 1988, BIOCHEM PHARMACOL, V37, P3423, DOI 10.1016/0006-2952(88)90691-0; MORRISON H, 1984, BIOCHEM PHARMACOL, V33, P1763, DOI 10.1016/0006-2952(84)90347-2; MORRISON H, 1985, TOXICOL LETT, V28, P37, DOI 10.1016/0378-4274(85)90007-4; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NUTTER L M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P5; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; OLLINGER K, 1990, CHEM-BIOL INTERACT, V73, P53, DOI 10.1016/0009-2797(90)90108-Y; POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; SIEGEL D, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P558; SINHA BK, 1987, BIOCHEMISTRY-US, V26, P3776, DOI 10.1021/bi00387a006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SU YZ, 1987, CANCER TREAT REP, V71, P619; THOR H, 1982, J BIOL CHEM, V257, P2419; TSUDA H, 1990, CANCER LETT, V55, P195, DOI 10.1016/0304-3835(90)90119-I; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006	38	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2474	2479						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370822				2022-12-27	WOS:A1992HB53200056
J	PHILLIPS, MA; STEWART, BE; RICE, RH				PHILLIPS, MA; STEWART, BE; RICE, RH			GENOMIC STRUCTURE OF KERATINOCYTE TRANSGLUTAMINASE - RECRUITMENT OF NEW EXON FOR MODIFIED FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANCHORAGE REGION; AMINO-ACID-SEQUENCE; ERYTHROCYTE-MEMBRANE; EPIDERMAL-CELLS; CROSS-LINKING; GENE; DNA; FRAGMENTS	The gene for keratinocyte transglutaminase (TG(K)) spans 14 kilobase pairs and contains 15 exons. Many features of the TG(K) gene are very similar, if not identical, to those of the gene encoding the catalytic subunit of human clotting factor XIII: they have the same number of exons, corresponding introns always interrupt the coding region in the same phase of the codon, and most exons are of similar size (10 of 15 are exactly the same size). In these respects, the TG(K) and factor XIII catalytic subunit genes resemble each other more than either resembles the gene for erythrocyte band 4.2, a noncatalytic transglutaminase superfamily member. Exon II in both the TG(K) and factor XIII genes encodes an amino-terminal extension of nonhomologous sequence which in each protein confers a specialized function (membrane anchorage or activation of cross-linking, respectively). This suggests that the evolution of these genes included recruitment of a new exon to modify the enzyme action. Southern blots of genomic DNA reveal the presence of a TG(K)-like gene in birds, amphibians, and fish, but not in flies.	UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis			Rice, Robert/AAP-7813-2021		NCI NIH HHS [CA46928] Funding Source: Medline; NIAMS NIH HHS [AR27130] Funding Source: Medline; NIEHS NIH HHS [ES07059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; LI WH, 1991, FUNDAMENTALS MOL EVO, P67; LICHTI U, 1985, J BIOL CHEM, V260, P1422; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; Sambrook J, 1989, MOL CLONING LABORATO; SEITZ J, 1990, HISTOCHEMISTRY, V93, P525, DOI 10.1007/BF00266412; SIGNORINI M, 1991, J PLANT PHYSIOL, V137, P547, DOI 10.1016/S0176-1617(11)80697-8; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R	34	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2282	2286						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346394				2022-12-27	WOS:A1992HB53200028
J	SHIMIZU, H; FISHER, JH; PAPST, P; BENSON, B; LAU, K; MASON, RJ; VOELKER, DR				SHIMIZU, H; FISHER, JH; PAPST, P; BENSON, B; LAU, K; MASON, RJ; VOELKER, DR			PRIMARY STRUCTURE OF RAT PULMONARY SURFACTANT PROTEIN-D - CDNA AND DEDUCED AMINO-ACID-SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; II CELLS; LUNG SURFACTANT; BINDING PROTEIN; HIGH-AFFINITY; SP-A; LECTIN; CONGLUTININ; COMPLEMENT; MANNOSE	Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells. The complete primary structure of rat SP-D has been determined by sequencing of a cloned cDNA. The protein consists of three regions: an NH2-terminal segment of 25 amino acids, a collagen-like domain consisting of 59 Gly-X-Y repeats, and a COOH-terminal carbohydrate recognition domain of 153 amino acids. There are 6 cysteine residues present in rat SP-D: 2 in the NH2-terminal noncollagenous segment and 4 in the COOH-terminal carbohydrate-binding domain. The collagenous domain contains one possible N-glycosylation site. The protein is preceded by a cleaved, NH2-terminal signal peptide. SP-D shares considerable homology with the C-type mammalian lectins. Hybridization analysis demonstrates that rat SP-D is encoded by a 1.3-kilobase mRNA which is abundant in lung and highly enriched in alveolar type II cells. Extensive homology exists between rat SP-D and bovine conglutinin.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM MED & CRIT CARE,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; CALIF BIOTECHNOL INC,MT VIEW,CA 94043	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NHLBI NIH HHS [HL 29891, HL 41320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R01HL041320, R37HL029891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHRISTIANSEN PF, 1988, SCAND J IMMUNOL, V31, P453; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; CROUCH E, 1989, FASEB J, V3, pA1048; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ENGVALL E, 1972, J IMMUNOL, V109, P129; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GIGA Y, 1987, J BIOL CHEM, V262, P6197; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HIRANI S, 1985, J IMMUNOL, V134, P1105; HUYUH TV, 1985, DNA CLONING, V1, P49; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YM, 1991, J BIOL CHEM, V266, P2715; LERACH H, 1977, BIOCHEMISTRY-US, V16, P4743; LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; REVAK SD, 1988, J CLIN INVEST, V81, P826, DOI 10.1172/JCI113391; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; STRANG CJ, 1986, BIOCHEM J, V234, P381, DOI 10.1042/bj2340381; TAKAHASHI A, 1986, BIOCHEM BIOPH RES CO, V135, P527, DOI 10.1016/0006-291X(86)90026-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WHITSETT JA, 1986, PEDIATR RES, V20, P744, DOI 10.1203/00006450-198608000-00009; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	40	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1853	1857						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370483				2022-12-27	WOS:A1992HA48500071
J	KONRAD, M				KONRAD, M			CLONING AND EXPRESSION OF THE ESSENTIAL GENE FOR GUANYLATE KINASE FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLATE KINASE; SACCHAROMYCES-CEREVISIAE; X-RAY; PURIFICATION; DISRUPTION; SEQUENCE; PROTEINS; GTP	Guanylate kinase catalyzes the reversible transfer of the terminal phosphoryl group of ATP to the acceptor molecule GMP. Detailed analysis of the in vivo function of this enzyme has been limited by the lack of any genetic data. Using oligonucleotides based on amino acid sequence information of the yeast enzyme, the Saccharomyces cerevisiae gene, GUK1, was isolated and characterized. The gene is present in single copy and maps to chromosome IV. Insertional mutagenesis of the GUK1 locus caused recessive lethality, indicating that this enzyme is necessary for vegetative cell growth. Using inducible expression systems, guanylate kinase was produced in large amounts both in S. cerevisiae and in Escherichia coli.			KONRAD, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, POB 2841, W-3400 GOTTINGEN, GERMANY.							Agarwal K C, 1978, Methods Enzymol, V51, P483; Anderson E. P., 1973, ENZYMES, V8, P49; ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BESSMAN MJ, 1959, J BIOL CHEM, V234, P2735; Boyer P.D, 1973, ENZYMES, P279; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; BUCCINO RJ, 1969, ARCH BIOCHEM BIOPHYS, V132, P49, DOI 10.1016/0003-9861(69)90337-3; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; ITO Y, 1980, EUR J BIOCHEM, V105, P85, DOI 10.1111/j.1432-1033.1980.tb04477.x; KONRAD M, 1990, NUCLEIC ACIDS RES, V18, P5320, DOI 10.1093/nar/18.17.5320; KONRAD M, 1988, J BIOL CHEM, V263, P19468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIECH RP, 1965, J BIOL CHEM, V240, P351; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OESCHGER MP, 1966, J BIOL CHEM, V241, P5452; PALL ML, 1988, J BIOL CHEM, V263, P11168; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VETTER IR, 1991, BIOCHEMISTRY-US, V30, P4137, DOI 10.1021/bi00231a005; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	33	49	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25652	25655						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334480				2022-12-27	WOS:A1992KD07300009
J	MASIAKOWSKI, P; CARROLL, RD				MASIAKOWSKI, P; CARROLL, RD			A NOVEL FAMILY OF CELL-SURFACE RECEPTORS WITH TYROSINE KINASE-LIKE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CILIARY NEUROTROPHIC FACTOR; TRK PROTOONCOGENE PRODUCT; DEPENDENT PROTEIN-KINASE; SIGNAL TRANSDUCTION; CONSERVED FEATURES; MOLECULAR-CLONING; CATALYTIC SUBUNIT; EXPRESSION; SEQUENCE	Human cDNA clones encoding two novel proteins with a region strongly homologous to the tyrosine kinase domain of growth factor receptors, in particular of the Trk family, were obtained by a polymerase chain reaction-based approach. These proteins, Ror1 and Ror2, share 58% overall amino acid identity and a structure indicative of cell surface molecules. A secretion signal sequence and a transmembrane domain delimit the extracellular portion, which contains immunoglobulin-like, cysteine-rich, and kringle domains. The cytoplasmic portion contains the tyrosine kinase-like domain which (in Ror2) appears to be associated with protein kinase activity in vitro, followed by serine/threonine- and proline-rich motifs. Partial nucleotide sequences of the rat genes reveal striking evolutionary conservation of the proteins between human and rat. The level of expression of the rat genes is high in the head and body of early embryo and decreases dramatically after embryonic day 16. Based on these data, Ror1 and Ror2 appear to define a new developmentally regulated family of cell surface receptors for unidentified ligands.			MASIAKOWSKI, P (corresponding author), REGENERON PHARMACEUT, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUNRO S, 1987, CELL, V48, P8899; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	57	213	242	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26181	26190						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334494				2022-12-27	WOS:A1992KD07300088
J	SHENG, ZL; PAN, BS; MILLER, TE; POTTER, JD				SHENG, ZL; PAN, BS; MILLER, TE; POTTER, JD			ISOLATION, EXPRESSION, AND MUTATION OF A RABBIT SKELETAL-MUSCLE CDNA CLONE FOR TROPONIN-I - THE ROLE OF THE NH2 TERMINUS OF FAST SKELETAL-MUSCLE TROPONIN-I IN ITS BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CROSS-LINKING; RELATIVE REACTIVITIES; REGULATORY DOMAIN; INHIBITORY REGION; ACETIC-ANHYDRIDE; CONTRACTION; CALCIUM; TROPOMYOSIN; COMPONENTS	A cDNA for rabbit fast skeletal muscle troponin I (TnI) was isolated and sequenced. The clone contains a coding sequence predicting a 182-amino-acid protein with a molecular mass of 21,162 daltons. The translated sequence is different from that reported by Wilkinson and Grand (Wilkinson, J. M., and Grand, R. J. A. (1978) Nature 271, 31-35) in that Arg-153, Asp-154, and Leu-155 must be inserted into their original sequence. Amino acid sequencing of adult rabbit TnI confirmed this result. In order to investigate the role of the NH2 terminus of TnI in its biological activity, we have expressed a recombinant deletion mutant (TnI(d57)), which lacks residues 1-57, in a bacterial expression system. Both wild type TnI (WTnI) and TnI(d57) inhibited acto-S1-ATPase activity and this inhibition could be fully reversed by troponin C (TnC) in the presence of Ca2+. Additionally both WTnI and TnI(d57) bound to an actin affinity column. Thus, both inhibitory actin binding and Ca2+-dependent neutralization by TnC were retained in TnI(d57). TnC affinity chromatography was used to compare the binding of TnI and TnI(d57) to TnC. Using this method, two types of interaction between TnC and TnI were observed: 1) one which is metal independent (or structural) and 2) one dependent on Ca2+ or Mg2+ binding to the Ca2+-Mg2+ sites of TnC. The same experiments with TnI(d57) demonstrated that the type 1 interaction was weakened, and type 2 binding was lost. This method also revealed an interaction between TnC and TnI which is dependent upon Ca2+ binding to the Ca2+-specific sites of TnC and which is retained in TnI(d57). Taken together, these results suggest that the NH2 terminus of TnI may constitute a Ca2+-Mg2+-dependent interaction site between TnC and TnI and play, in part, a structural role in maintaining the stability of the troponin complex while the COOH terminus of TnI contains a Ca2+-specific site-dependent interaction site for TnC as well as the previously demonstrated Ca2+-sensitive inhibitory and actin binding activities.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701, R01AR040727] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37701, AR40727] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; CHONG PCS, 1983, FEBS LETT, V153, P372, DOI 10.1016/0014-5793(83)80646-2; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HARTSHOR.DJ, 1968, BIOCHEM BIOPH RES CO, V31, P647, DOI 10.1016/0006-291X(68)90610-4; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HITCHCOCK SE, 1981, J MOL BIOL, V147, P153, DOI 10.1016/0022-2836(81)90083-8; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; NGAI SM, 1991, BIOPHYS J, V59, P586; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; PARDER JD, 1982, METHOD ENZYMOL, V85, P234; PEARLSTONE JR, 1978, CAN J BIOCHEM, V55, P1032; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; PUTNEY SD, 1983, NATURE, V302, P718, DOI 10.1038/302718a0; RUEGG JC, 1989, PFLUG ARCH EUR J PHY, V414, P430, DOI 10.1007/BF00585053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUB MC, 1969, BIOCHEM J, V115, P993, DOI 10.1042/bj1150993; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILKINSON JM, 1972, BIOCHEM J, V127, P215, DOI 10.1042/bj1270215; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	48	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25407	25413						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1339446				2022-12-27	WOS:A1992KB60300076
J	PETRASH, JM; HARTER, TM; DEVINE, CS; OLINS, PO; BHATNAGAR, A; LIU, SQ; SRIVASTAVA, SK				PETRASH, JM; HARTER, TM; DEVINE, CS; OLINS, PO; BHATNAGAR, A; LIU, SQ; SRIVASTAVA, SK			INVOLVEMENT OF CYSTEINE RESIDUES IN CATALYSIS AND INHIBITION OF HUMAN ALDOSE REDUCTASE - SITE-DIRECTED MUTAGENESIS OF CYS-80, CYS-298, AND CYS-303	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE REDUCTASES; ESCHERICHIA-COLI; KIDNEY ALDOSE; EXPRESSION; LENS; PURIFICATION; COMPLICATIONS; PROTEINS; BINDING; CLONING	In order to study the potential role of cysteinyl residues in catalysis and inhibition of human aldose reductase, mutants containing cysteine to serine substitution at positions 80 (ALR2:C80S), 298 (ALR2:C298S), and 303 (ALR2:C303S) were constructed. Mutation of Cys-298 resulted in the most profound changes, as ALR2:C298S displayed 4- to 5-fold elevation in K'(m(NADPH)), K'(m(DL-glyceraldehyde)), and k(cat(DL-glyceraldehyde)) relative to wild type aldose reductase as well as a 10-fold higher K(i) for the aldose reductase inhibitor sorbinil. Wild type and mutant reductases were equally sensitive to tolrestat, a structurally different reductase inhibitor. Carboxymethylation of the wild type enzyme or the C80S and C303S mutants led to a modest decrease in k(cat) as well as an increase in K'(m(DL-glyceraldehyde)) and K(i(sorbinil)). These parameters were not significantly changed when ALR2:C298S was subjected to carboxymethylation. Lithium sulfate caused activation of ALR2:WT, C80S, and C303S but did not significantly affect the activity of ALR2:C298S. The differential sensitivity of wild type and mutant reductases to inhibition by sorbinil and tolrestat, before and after carboxymethylation, indicates that these inhibitors bind at different sites. These results suggest that Cys-298 is present near the active site and constitutes a regulatory group which controls the catalytic activity and inhibitor sensitivity of the enzyme.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; MONSANTO CO, CORP RES, ST LOUIS, MO 63198 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77550 USA	Washington University (WUSTL); Monsanto; University of Texas System; University of Texas Medical Branch Galveston	PETRASH, JM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 660 S EUCLID AVE, CAMPUS BOX 8096, ST LOUIS, MO 63110 USA.		Bhatnagar, Aruni/H-7791-2013	Harter, Theresa/0000-0002-7039-2236	NATIONAL EYE INSTITUTE [R01EY001677, R55EY005856, R01EY005856, R23EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NEI NIH HHS [EY01677, EY05856] Funding Source: Medline; NIDDK NIH HHS [DK36118] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGET PB, 1983, J MOL BIOL, V164, P561, DOI 10.1016/0022-2836(83)90050-5; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BHATNAGAR A, 1992, FASEB J, V6, pA1669; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANLANT G, 1982, EUR J BIOCHEM, V129, P99, DOI 10.1111/j.1432-1033.1982.tb07026.x; CARPER D, 1991, ADV EXP MED BIOL, V284, P129; CARPER DA, 1991, INVEST OPHTH VIS SCI, V32, P975; COHEN MP, 1987, POLYOL PARADIGM COMP; DAS B, 1985, BIOCHIM BIOPHYS ACTA, V840, P324, DOI 10.1016/0304-4165(85)90212-0; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DELCORSO A, 1989, J BIOL CHEM, V264, P17653; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLING ME, 1985, NUCLEIC ACIDS RES, V13, P7095; FLYNN TG, 1982, BIOCHEM PHARMACOL, V31, P2705, DOI 10.1016/0006-2952(82)90123-X; GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513; GONZALEZ RG, 1984, DIABETES, V33, P196, DOI 10.2337/diabetes.33.2.196; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P149, DOI 10.1089/dna.1990.9.149; HAYMAN S, 1965, J BIOL CHEM, V240, P877; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KADOR PF, 1983, MOL PHARMACOL, V24, P521; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU S, 1989, ARCH BIOCHEM BIOPHYS, V275, P112, DOI 10.1016/0003-9861(89)90355-X; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; NISHIMURA C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P171, DOI 10.1016/0167-4838(91)99006-E; OKA T, 1985, P NATL ACAD SCI USA, V82, P7212, DOI 10.1073/pnas.82.21.7212; OLD SE, 1990, P NATL ACAD SCI USA, V87, P4942, DOI 10.1073/pnas.87.13.4942; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PETRASH JM, 1989, CURR EYE RES, V8, P1021, DOI 10.3109/02713688908997394; PETRASH JM, 1991, ELECTROPHORESIS, V12, P84, DOI 10.1002/elps.1150120116; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; Stribling D, 1989, J Diabet Complications, V3, P139, DOI 10.1016/0891-6632(89)90036-6; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098	50	117	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24833	24840						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332968				2022-12-27	WOS:A1992KA26300101
J	PORT, JD; HUANG, LY; MALBON, CC				PORT, JD; HUANG, LY; MALBON, CC			BETA-ADRENERGIC AGONISTS THAT DOWN-REGULATE RECEPTOR MESSENGER-RNA UP-REGULATE A M(R) 35,000 PROTEIN(S) THAT SELECTIVELY BINDS TO BETA-ADRENERGIC-RECEPTOR MESSENGER-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; STABILITY INVITRO; BETA-2-ADRENERGIC RECEPTORS; ALPHA-1-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; GM-CSF; GENE	In an effort to explore the molecular basis for agonist-induced destabilization of beta-adrenergic receptor mRNA, we investigated the nature of RNA-binding proteins both in untreated and agonist-treated DDT1-MF2 smooth muscle cells. Messenger RNAs for the alpha1b-, beta1, and beta2-adrenergic receptors as well as for beta-globin were transcribed in vitro, incubated with cytosolic fractions, covalently cross-linked by short-wave UV light, and analyzed by SDS-polyacrylamide gel electrophoresis. A prominent M(r) 35,000 radiolabeled protein(s) with the following characteristics was identified: (i) binds selectively to beta1- and beta2-adrenergic receptor mRNAs, both of which undergo agonist-induced down-regulation; (ii) does not bind to either alpha1b-adrenergic receptor mRNA, which does not undergo agonist induced down-regulation, or to beta-globin mRNA; (iii) displays binding to beta2-adrenergic receptor mRNA that is selectively competed by poly(U) RNA, but not poly(A), -(C), or -(G) RNA; and (iv) displays binding to receptor mRNA that can be competed by RNA harboring destabilizer sequences that are AU-rich and AUUUA pentamer-rich. The abundance of the M(r) 35,000 RNA-binding protein selective for beta-adrenergic receptor message, a factor we term betaARB protein, varies inversely with the level of receptor mRNA, being induced by agonists that down-regulate receptor mRNA.	SUNY STONY BROOK, HLTH SCI CTR,SCH MED,DEPT PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020	Port, Jonathan D./0000-0001-7048-3544	NHLBI NIH HHS [R01 HL051239] Funding Source: Medline; NIADDK NIH HHS [K04 AM00786] Funding Source: Medline; NIDDK NIH HHS [DK25410, DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111, R01DK025410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1991, CRIT REV EUKAR GENE, V1, P99; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1988, MOL BIOL MED, V5, P1; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	48	116	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24103	24108						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358887				2022-12-27	WOS:A1992JZ23900101
J	TANG, LH; CHOKSHI, H; HU, CB; GORDON, MM; ALPERS, DH				TANG, LH; CHOKSHI, H; HU, CB; GORDON, MM; ALPERS, DH			THE INTRINSIC-FACTOR (IF)-COBALAMIN RECEPTOR-BINDING SITE IS LOCATED IN THE AMINO-TERMINAL PORTION OF IF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCOBALAMIN-I; ESCHERICHIA-COLI; RAT-KIDNEY; CDNA; VITAMIN-B12; RECOGNITION; LOCALIZATION; PURIFICATION; HAPTOCORRIN; TRANSLATION	Intrinsic factor has two binding sites, one each for cobalamin and for the ileal receptor recognizing the intrinsic factor-cobalamin complex. To obtain initial functional mapping of these domains, cDNAs encoding intact rat and human intrinsic factor or fragments thereof were expressed transiently in COS-1 cells or in an in vitro transcription/translation system. Deletion of as little as 12% of the amino acids from the carboxyl terminus resulted in loss of cobalamin binding activity. On the other hand, the receptor binding region of intrinsic factor appears localized to a restricted region in the amino-terminal portion of the protein. Only those transcription/translation fragments of rat or human intrinsic factor tested that contained amino acid residues 25 to 62 (out of 399) showed calcium-dependent binding to isolated kidney brush borders, the shortest sequence corresponding with 20 consecutive amino acids. In contrast, a 232-amino acid carboxyl-terminal fragment of rat intrinsic factor and 243- and 338-amino acid carboxyl-terminal fragments of human intrinsic factor showed no receptor binding activity.	WASHINGTON UNIV,SCH MED,DIV GASTROENTEROL,660 S EUCLID,BOX 8124,ST LOUIS,MO 63110	Washington University (WUSTL)					NIDDK NIH HHS [DK33487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS ER, 1991, FEBS LETT, V281, P90, DOI 10.1016/0014-5793(91)80365-A; BORTZ JD, 1988, J CELL BIOL, V107, P811, DOI 10.1083/jcb.107.2.811; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DIECKGRAEFE BK, 1988, P NATL ACAD SCI USA, V85, P46, DOI 10.1073/pnas.85.1.46; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GORDON M, IN PRESS BIOCH BIOPH; GORDON MM, 1991, AM J PHYSIOL, V260, pG736, DOI 10.1152/ajpgi.1991.260.5.G736; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HAGEDORN CH, 1977, GASTROENTEROLOGY, V73, P1019; HEWITT JE, 1990, EUR J BIOCHEM, V189, P125, DOI 10.1111/j.1432-1033.1990.tb15468.x; HEWITT JE, 1991, GENOMICS, V10, P432, DOI 10.1016/0888-7543(91)90329-D; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; JOHNSTON J, 1989, J BIOL CHEM, V264, P15754; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; PLATICA O, 1991, J BIOL CHEM, V266, P7860; SCHONER RG, 1985, BIO-TECHNOL, V3, P151, DOI 10.1038/nbt0285-151; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1990, HDB PHYSL INTESTINAL, P437; SMOLKA A, 1990, GASTROENTEROLOGY, V98, P607, DOI 10.1016/0016-5085(90)90279-A; STUPPERICH E, 1991, EUR J BIOCHEM, V199, P299, DOI 10.1111/j.1432-1033.1991.tb16124.x; 1989, PROMEGA PROTOCOLS AP, P42	25	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22982	22986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331073				2022-12-27	WOS:A1992JY16300044
J	SILBERRING, J; CASTELLO, ME; NYBERG, F				SILBERRING, J; CASTELLO, ME; NYBERG, F			CHARACTERIZATION OF DYNORPHIN-A-CONVERTING ENZYME IN HUMAN SPINAL-CORD - AN ENDOPROTEASE RELATED TO A DISTINCT CONVERSION PATHWAY FOR THE OPIOID HEPTADECAPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; MET-ENKEPHALIN; SPECIFICITY; PEPTIDES; NEUROPEPTIDES; BRAIN	A highly specific proteinase, converting dynorphin A (1-17) to enkephalins, was isolated from the human spinal cord and subjected to further characterization. The enzyme was found to be a thiol-dependent protein with a relative molecular mass of 50 kDa and a pH optimum between 5.0 and 5.5. This proteinase appears to exclusively convert dynorphin A (1-17) to Leu-enkephalin and its COOH-terminal extensions Leu-enkephalin-Arg6 (which was a major conversion product) and Leu-enkephalin-Arg6-Arg7 but not the other prodynorphin- or proenkephalin-derived peptides. This high specificity toward a single structure is suggested to be involved in a distinct processing pathway associated with the generation of the opioid peptides with selectivity for delta-opioid receptors.	UNIV UPPSALA,DEPT PHARMACOL,POB 591,S-75124 UPPSALA,SWEDEN	Uppsala University			Castelló, María/GRX-6490-2022; Silberring, Jerzy/AGA-5631-2022; Castelló, María/AGO-5653-2022	Silberring, Jerzy/0000-0002-4362-8362; Castelló, María/0000-0001-8669-4805				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ANDREWS PC, 1989, REGUL PEPTIDES, P193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMARGO ACM, 1987, J NEUROCHEM, V48, P1258, DOI 10.1111/j.1471-4159.1987.tb05655.x; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; FUJIMOTO JM, 1989, J PHARMACOL EXP THER, V251, P1045; FUJIMOTO JM, 1990, NEUROPHARMACOLOGY, V29, P609, DOI 10.1016/0028-3908(90)90021-I; FUJIMOTO JM, 1990, PHARMACOLOGIST, V32, P138; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; Hope D B, 1974, Methods Enzymol, V31, P403; KUMAGAI A, 1982, METHOD ENZYMOL, V86, P17; LYRENAS S, 1988, OBSTET GYNECOL, V72, P54; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NYBERG F, 1985, BIOCHEM BIOPH RES CO, V131, P1069, DOI 10.1016/0006-291X(85)90199-8; NYBERG F, 1991, BRAIN RES, V552, P129, DOI 10.1016/0006-8993(91)90670-Q; NYBERG F, 1987, HDB EXPT PHARM, V82, P227; Nyberg F, 1991, DEGRADATION BIOACTIV, P189; NYBERG F, 1990, J PROGR CLIN BIOL RE, V20, P261; PRZEWLOCKI R, 1983, BRAIN RES, V280, P95, DOI 10.1016/0006-8993(83)91177-0; ROOS P, 1979, BIOCHIM BIOPHYS ACTA, V588, P368, DOI 10.1016/0304-4165(79)90345-3; SATOH M, 1989, J NEUROCHEM, V52, P61, DOI 10.1111/j.1471-4159.1989.tb10898.x; SILBERRING J, 1991, J CHROMATOGR, V554, P83, DOI 10.1016/S0021-9673(01)88439-9; SILBERRING J, 1992, LIFE SCI, V50, P839, DOI 10.1016/0024-3205(92)90202-Z; SILBERRING J, 1990, ANAL CHIM ACTA, V238, P331, DOI 10.1016/S0003-2670(00)80555-3; SILBERRING J, 1989, BIOMED CHROMATOGR, V3, P203, DOI 10.1002/bmc.1130030506; SILBERRING J, 1989, J BIOL CHEM, V264, P11082; SILBERRING J, 1990, BIOMED ENVIRON MASS, V19, P819, DOI 10.1002/bms.1200191305; SILBERRING J, 1992, J CHROMATOGR, V50, P839; SUPATTAPONE S, 1988, MOL BRAIN RES, V3, P173, DOI 10.1016/0169-328X(88)90063-0; TURNER AJ, 1986, ESSAYS BIOCHEM, V22, P69	32	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21324	21328						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356987				2022-12-27	WOS:A1992JV01100013
J	IKEDA, RA; BAILEY, PA				IKEDA, RA; BAILEY, PA			INHIBITION OF T7 RNA-POLYMERASE BY T7 LYSOZYME INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 LYSOZYME; ESCHERICHIA-COLI; TRANSCRIPTION; EXPRESSION; DNA; PROMOTER; SYSTEM; GENES	The in vivo observation that the expression of bacteriophage T7 gene 3.5 (T7 lysozyme) inactivates T7 class II transcription and the in vitro observation that T7 lysozyme inhibits T7 RNA polymerase lead to the hypothesis that T7 lysozyme might preferentially inhibit transcription from T7 class II promoters. T7 lysozyme was cloned into a lambdap(L) expression vector, overproduced in Escherichia coli, and purified. The ability of purified T7 lysozyme to inhibit transcription from T7 DNA, the cloned T7 class II promoters, phi2.5 and phi4.7, and the cloned class III promoter, phi10, was measured in vitro. It was observed that the effectiveness of T7 lysozyme as an inhibitor of T7 RNA polymerase is inversely related to the concentration of Mg2+; T7 lysozyme inhibits T7 RNA polymerase most effectively at low Mg2+ concentrations. In addition, no preferential inhibition of transcription from cloned T7 class II promoters was observed, nor was a strong T7 class III promoter preferred when transcriptional capacity was reduced by T7 lysozyme. These observations contradict the hypotheses that the temporal control of T7 gene expression is either due to direct and selective inhibition of the T7 class II promoters by T7 lysozyme or to preferential transcription of the strong T7 class III promoters when transcriptional capacity is reduced by T7 lysozyme. It appears that alternative mechanisms such as the involvement of additional proteins and/or cellular conditions to enhance transcription from T7 class III promoters or to inhibit transcription from T7 class II promoter are necessary to explain the temporal control of transcription of bacteriophage T7.			IKEDA, RA (corresponding author), GEORGIA INST TECHNOL, SCH CHEM & BIOCHEM, ATLANTA, GA 30332 USA.			Ikeda, Richard/0000-0003-4015-5528	NIAID NIH HHS [AI-24905] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024905] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; IKEDA RA, 1992, J BIOL CHEM, V267, P11322; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; INOUYE M, 1973, J BIOL CHEM, V248, P7247; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SILBERSTEIN S, 1975, J MOL BIOL, V96, P1, DOI 10.1016/0022-2836(75)90178-3; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1982, COLD SPRING HARB SYM, V47, P999, DOI 10.1101/SQB.1983.047.01.114; SUMMERS WC, 1969, VIROLOGY, V39, P175, DOI 10.1016/0042-6822(69)90037-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAVRIEV SK, 1982, NUCLEIC ACIDS RES, V10, P1635, DOI 10.1093/nar/10.5.1635	23	12	14	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20153	20158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356974				2022-12-27	WOS:A1992JR85800065
J	TATSUTA, T; NAITO, M; OHHARA, T; SUGAWARA, I; TSURUO, T				TATSUTA, T; NAITO, M; OHHARA, T; SUGAWARA, I; TSURUO, T			FUNCTIONAL INVOLVEMENT OF P-GLYCOPROTEIN IN BLOOD-BRAIN-BARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODIES; MOLECULAR-WEIGHT; ENZYME-ACTIVITY; MDR1 GENE; EXPRESSION; TRANSPORT; MEMBRANE	P-glycoprotein, an active efflux pump of antitumor agents in multidrug-resistant tumor cells, exists in various normal tissues, including brain capillaries. To study the physiological function of P-glycoprotein expressed in brain capillary endothelium, we established nine mouse brain capillary endothelial cell (MBEC) lines and examined the transport of antitumor agents across the monolayer of MBEC epithelia. In the MBECs, the activities of alkaline phosphatase and gamma-glutamyl transpeptidase, specific markers for brain capillary endothelial cells, were about three times higher than those in other cells including human umbilical vein endothelial cells. By immunoblot analysis, P-glycoprotein was detected in all of the nine MBEC clones. The P-glycoprotein expressed in MBECs specifically bound [I-125]iodoaryl azidoprazosin as that in multidrug-resistant cells, and efflux of vincristine was observed in the MBECs. When MBECs were grown on a porous filter membrane, they formed a monolayer of epithelium. By immunoelectron microscopic analysis, P-glycoprotein in MBEC epithelia was shown to be localized to the apical surface of the cells. Moreover, the unidirectional transepithelial transport of vincristine from basal side to apical side was demonstrated in vitro. These observations indicate that P-glycoprotein in brain capillary endothelium prevents vincristine from entering the central nervous system and thus may be one of the functional components of the blood-brain barrier.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA MED COLL,DEPT PATHOL,KAWAGOE,SAITAMA 350,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Saitama Medical University; Japanese Foundation for Cancer Research								ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; AUERBACH R, 1982, P NATL ACAD SCI-BIOL, V79, P7891, DOI 10.1073/pnas.79.24.7891; BECK DW, 1986, BRAIN RES, V381, P131, DOI 10.1016/0006-8993(86)90700-6; BETZ AL, 1975, AM J PHYSIOL, V228, P895, DOI 10.1152/ajplegacy.1975.228.3.895; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; COOMBER BL, 1985, MICROVASC RES, V30, P99, DOI 10.1016/0026-2862(85)90042-1; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNFORD EM, 1992, CANCER CHEMOTH PHARM, V29, P439, DOI 10.1007/BF00684844; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEBAULT LE, 1980, SCIENCE, V207, P653, DOI 10.1126/science.6101511; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GARLACH JH, 1986, NATURE, V324, P485; GOLDSTEIN GW, 1986, SCI AM, V254, P74; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREIG NH, 1990, J CONTROL RELEASE, V11, P61, DOI 10.1016/0168-3659(90)90121-9; GREIG NH, 1984, CANCER TREAT REV, V11, P157, DOI 10.1016/0305-7372(84)90006-9; GREIG NH, 1990, CANCER CHEMOTH PHARM, V26, P263, DOI 10.1007/BF02897227; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, CANCER RES, V48, P3173; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HORIO M, 1989, J BIOL CHEM, V264, P14880; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; LISE D, 1991, BIOCHEM J, V276, P745; Maniatis T., 1982, MOL CLONING; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MOMMA S, 1987, J NEUROCHEM, V48, P1291, DOI 10.1111/j.1471-4159.1987.tb05660.x; NAITO M, 1987, CANCER IMMUNOL IMMUN, V24, P158; NAITO M, 1989, BIOCHEM BIOPH RES CO, V158, P1066, DOI 10.1016/0006-291X(89)92830-1; NAITO M, 1988, J BIOL CHEM, V263, P11887; NAKAMURA H, 1990, Japanese Journal of Clinical Electron Microscopy, V23, P393; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; SPECTOR R, 1980, J NEUROCHEM, V35, P1092, DOI 10.1111/j.1471-4159.1980.tb07863.x; SPECTOR R, 1982, J NEUROCHEM, V39, P837, DOI 10.1111/j.1471-4159.1982.tb07968.x; SUGAWARA I, 1990, JPN J CANCER RES, V81, P727, DOI 10.1111/j.1349-7006.1990.tb02636.x; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; SUGIMOTO Y, 1987, CANCER RES, V47, P2620; SUGIYAMA Y, 1990, PHARM TECH JAPAN, V6, P519; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TSURUO T, 1983, CANCER RES, V43, P5437; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLIAM FNG, 1989, MOL CELL BIOL, V9, P1224; WILLIAMS SK, 1980, J NEUROCHEM, V35, P374, DOI 10.1111/j.1471-4159.1980.tb06274.x; YANG CPH, 1989, J BIOL CHEM, V264, P782	51	324	328	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20383	20391						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356979				2022-12-27	WOS:A1992JR85800099
J	GIESELMANN, V; SCHMIDT, B; VONFIGURA, K				GIESELMANN, V; SCHMIDT, B; VONFIGURA, K			INVITRO MUTAGENESIS OF POTENTIAL N-GLYCOSYLATION SITES OF ARYLSULFATASE-A - EFFECTS ON GLYCOSYLATION, PHOSPHORYLATION, AND INTRACELLULAR SORTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE SPECIFIC RECEPTOR; LYSOSOMAL-ENZYMES; OLIGOSACCHARIDES; FIBROBLASTS; EXPRESSION	The correct intracellular sorting of lysosomal enzymes such as arylsulfatase A depends on the presence of mannose 6-phosphate residues on high mannose type oligosaccharides. The arylsulfatase A cDNA contains three potential N-glycosylation sites, two of which are utilized. We have mutated one or two of the N-glycosylation sites and analyzed the glycosylation, phosphorylation, and intracellular sorting of the mutant arylsulfatase A polypeptides. The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive. In mutants with one oligosaccharide side chain at positions I, II, or III all side chains can acquire mannose 6-phosphate residues irrespective of their location. This demonstrates spatial flexibility of the phosphotransferase, which specifically recognizes lysosomal enzymes and initiates the addition of mannose 6-phosphate residues on oligosaccharide side chains. However, these mutants have different intracellular sorting efficiencies and seem to use different (mannose 6-phosphate receptor-dependent and -independent) sorting pathways.			GIESELMANN, V (corresponding author), UNIV GOTTINGEN,BIOCHEM ABT 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.							ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; ISIDORO C, 1990, EUR J BIOCHEM, V191, P591, DOI 10.1111/j.1432-1033.1990.tb19162.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN C, 1989, J BIOL CHEM, V264, P1252; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, H-S Z PHYSIOL CHEM, V363, P425, DOI 10.1515/bchm2.1982.363.1.425; WAHEED A, 1983, AM J HUM GENET, V35, P228	15	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13262	13266						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352293				2022-12-27	WOS:A1992JB74600029
J	YAMADA, K; GONCALVES, E; KAHN, CR; SHOELSON, SE				YAMADA, K; GONCALVES, E; KAHN, CR; SHOELSON, SE			SUBSTITUTION OF THE INSULIN-RECEPTOR TRANSMEMBRANE DOMAIN WITH THE C-NEU/ERBB2 TRANSMEMBRANE DOMAIN CONSTITUTIVELY ACTIVATES THE INSULIN-RECEPTOR KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MIMICS LIGAND INDUCTION; FMS PROTO-ONCOGENE; POINT MUTATION; CYTOPLASMIC DOMAIN; TYROSINE KINASE; NEU ONCOGENE; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; BETA-SUBUNIT	To examine the role of the transmembrane domain (TM) of the insulin receptor in insulin-induced receptor kinase activation, we prepared four mutated insulin receptors: 1) a Val938 --> Asp substitution (IR/TM(V-->D)), 2) insertion of a 3-amino acid repeat (Val938-Phe939-Leu940) (IR/TM+3), or the entire TM was replaced by the corresponding domain of either the 3) platelet-derived growth factor (PDGF) receptor (IR/TM(PDGFR)) or 4) c-neu/erbB2 proto-oncogene product (IR/TM(c-neu)). Each mutant receptor was stably expressed in Chinese hamster ovary cells, assessed by fluorescence-activated cell sorting, insulin binding, and biosynthetic labeling. All mutant receptors exhibited normal affinity for insulin. Pulse-chase experiments showed that each proreceptor was processed into alpha- and beta-subunits, although the rate of IR/TM(V-->D) conversion was reduced almost-equal-to 3-fold. With IR/TM(PDGFR), IR/TM(V-->D), and IR/TM+3 basal and insulin-stimulated levels of autophosphorylation and tyrosine kinase activation were normal, both in wheat germ agglutinin (WGA)-purified receptor preparations and intact cells. By contrast, following WGA purification or isolation of crude membranes, IR/TM(c-neu) was a constitutively active autokinase and substrate kinase in vitro. However, in intact cells insulin-stimulated autophosphorylation and kinase activity appeared normal. We conclude that although there is considerable latitude in acceptable structure, residues within the insulin receptor transmembrane domain can play a functional role in regulation of insulin receptor tyrosine kinase activity.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.			Goncalves, Edison/AAR-3280-2020; Kahn, Ronald/AAY-2435-2021	Goncalves, Edison/0000-0002-7887-1231; Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031036, R37DK031036, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836, DK31036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P1; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COBB MH, 1989, J BIOL CHEM, V264, P18701; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUNNILL P, 1968, BIOPHYS J, V8, P865, DOI 10.1016/S0006-3495(68)86525-7; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; FRITZ HJ, 1978, BIOCHEMISTRY-US, V17, P1257, DOI 10.1021/bi00600a020; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; GANDERTON RH, 1989, THESIS U CAMBRIDGE; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAISER ET, 1987, TRENDS BIOCHEM SCI, V12, P305, DOI 10.1016/0968-0004(87)90147-2; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEEF JW, 1987, J BIOL CHEM, V262, P14837; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	62	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12452	12461						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352286				2022-12-27	WOS:A1992HZ48300015
J	YANG, Y; FRUH, K; CHAMBERS, J; WATERS, JB; WU, L; SPIES, T; PETERSON, PA				YANG, Y; FRUH, K; CHAMBERS, J; WATERS, JB; WU, L; SPIES, T; PETERSON, PA			MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)-ENCODED HAM2 IS NECESSARY FOR ANTIGENIC PEPTIDE LOADING ONTO CLASS-I MHC MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							H-2-DEFICIENT LYMPHOMA VARIANTS; MULTICATALYTIC PROTEINASE; REGION; TRANSPORTERS; PATHWAY; CELLS; GENE	The mutant murine lymphoma cell line RMA-S is unable to present endogenous antigens due to its inability to efficiently assemble class I major histocompatibility complex molecules and antigenic peptides. Therefore, it has been suggested that RMA-S cells are defective either in peptide generation or in peptide transport into the endoplasmic reticulum, where class I major histocompatibility complex molecule assembly is believed to occur. As proteasomes and the putative peptide transporters HAM1 and HAM2 have been implicated in class I antigen processing, we have investigated their expression in RMA-S and its wild-type counterpart RMA. Both proteasomes and HAM1 proteins are expressed at similar levels and show identical subcellular distributions in the two cell lines. However, only one copy of the HAM2 gene is present in RMA-S cells, and it contains a point mutation that leads to a premature stop codon. Thus, the HAM2 protein is absent from RMA-S cells. These data demonstrate that HAM2 is essential for peptide loading onto class I molecules.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	YANG, Y (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				AMES FLG, 1992, IN PRESS FASEB J; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOBBERSTEIN B, 1992, NATURE, V355, P109, DOI 10.1038/355109a0; GLYME R, 1991, NATURE, V353, P357; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HYDE SC, 1990, NATURE, V346, P352; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; OHLEN C, 1990, EUR J IMMUNOL, V20, P1873, DOI 10.1002/eji.1830200837; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG Y, 1992, IN PRESS P NATL ACAD	29	114	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11669	11672						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1339432				2022-12-27	WOS:A1992HY94700003
J	AHLUWALIA, N; BERGERON, JJM; WADA, I; DEGEN, E; WILLIAMS, DB				AHLUWALIA, N; BERGERON, JJM; WADA, I; DEGEN, E; WILLIAMS, DB			THE P88 MOLECULAR CHAPERONE IS IDENTICAL TO THE ENDOPLASMIC-RETICULUM MEMBRANE-PROTEIN, CALNEXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; SIGNAL-SEQUENCE RECEPTOR; CELL-SURFACE EXPRESSION; HLA-B ANTIGENS; INTRACELLULAR-TRANSPORT; LIGHT-CHAINS; BETA-2-MICROGLOBULIN; ASSOCIATION; PEPTIDE; HEAVY	We previously described a novel molecular chaperone (designated p88) that participates in the assembly of murine class I histocompatibility molecules (Degen, E., and Williams, D. B. (1991) J. Cell Biol. 112, 1099-1115). Our findings suggest that p88 may either promote proper assembly of class I molecules or retain them, probably within the endoplasmic reticulum (ER), until assembly of the ternary complex of heavy chain, beta-2-microglobulin, and peptide ligand is complete. In this report, we compare p88 to calnexin, a calcium-binding 90-kDa phosphoprotein of the ER membrane (Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J.-J., 11, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). We show that p88 and calnexin share antigenic epitopes defined by a polyclonal anti-calnexin antiserum. Furthermore, both proteins were immunoprecipitated in association with an intracellularly retained variant of the class I H-2K(b) molecule. Since p88 and calnexin were also indistinguishable by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, were resistant to digestion with endoglycosidase H, and exhibited virtually identical patterns of peptide fragments following digestion with either V8 protease or trypsin, we conclude that p88 and calnexin represent the same protein. The identification of the p88 chaperone as a phosphorylated, calcium-binding protein of the ER membrane suggests possible means whereby its interaction with class I molecules may be regulated.	UNIV TORONTO,DEPT BIOCHEM,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA; BETH ISRAEL HOSP,BOSTON,MA 02215; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 2B2,QUEBEC,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; McGill University; Harvard University; Harvard Medical School			Bergeron, John/AAW-1893-2021	Wada, Ikuo/0000-0001-5668-6994				ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BECK JC, 1986, J IMMUNOL, V137, P916; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HOCHSTENBACH F, 1992, IN PRESS P NATL ACAD; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOCH GLE, 1987, J CELL SCI, V87, P491; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NUCHTERN JG, 1989, NATURE, V339, P2223; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; SWIEDLER SJ, 1983, J BIOL CHEM, V258, P1515; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; WADA I, 1991, J BIOL CHEM, V266, P19599; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	36	112	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10914	10918						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350281				2022-12-27	WOS:A1992HV09000105
J	BERKOWITZ, EA; EVANS, MI				BERKOWITZ, EA; EVANS, MI			FUNCTIONAL-ANALYSIS OF REGULATORY REGIONS UPSTREAM AND IN THE 1ST INTRON OF THE ESTROGEN-RESPONSIVE CHICKEN VERY LOW-DENSITY APOLIPOPROTEIN-II GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-DEPENDENT INTERACTION; GROWTH-HORMONE GENE; VITELLOGENIN GENE; AVIAN LIVER; DEVELOPMENTAL REGULATION; TRANSCRIPTION FACTORS; RECEPTOR-BINDING; MESSENGER-RNA; YOLK PROTEIN; CELL-LINE	Estrogen regulates the expression of the yolk protein genes in the chicken liver during periods of egg laying. While all five of these genes, vitellogenins I, II, and III, very low density apolipoprotein II (apoVLDLII), and apolipoprotein B, respond to estrogen, individual controls are superimposed on their coordinate regulation with respect to the kinetics of induction, magnitude of response, and developmental expression. The estrogen-responsive Leghorn strain M hepatoma (LMH) cell line provides a model system for studying the molecular basis of the similarities and differences in the regulation of these genes. The apoVLDLII gene is regulated by estrogen in LMH cells in an appropriate time- and dose-dependent manner. Regulatory regions of the apoVLDLII gene have been identified by transient transfection studies in LMH cells. All four of the sequences previously shown to bind protein between the TAATA motif at -26 and proximal estrogen response element at -171 are essential in regulation of the apoVLDLII gene. Mutation, of any single binding region reduces expression by more than 80%, indicating cooperative interactions of proteins across the entire region. While these sequences will direct assembly of a functional transcription complex, we demonstrate that addition of the first intron of the apoVLDLII gene to the promoter construct results in a 4-fold increase in estrogen-dependent expression following transient transfection into LMH cells. Results of deletion analyses indicate that two distinct regions of the intron contribute to this regulation.	W VIRGINIA UNIV,MED CTR,SCH MED,DEPT BIOCHEM,MORGANTOWN,WV 26506	West Virginia University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026339, R01HD026339] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26339] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERKOWITZ EA, 1992, IN PRESS IN VITRO CE; BINDER R, 1990, MOL ENDOCRINOL, V4, P201, DOI 10.1210/mend-4-2-201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUHAT A, 1990, NUCLEIC ACIDS RES, V18, P2861, DOI 10.1093/nar/18.10.2861; BURCH JBE, 1984, NUCLEIC ACIDS RES, V12, P1117, DOI 10.1093/nar/12.2.1117; BURCH JBE, 1990, NUCLEIC ACIDS RES, V18, P4157, DOI 10.1093/nar/18.14.4157; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CATO ACB, 1988, MOL CELL BIOL, V8, P5323, DOI 10.1128/MCB.8.12.5323; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; COCHRANE AW, 1988, J MOL BIOL, V203, P555, DOI 10.1016/0022-2836(88)90192-1; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EVANS MI, 1987, P NATL ACAD SCI USA, V84, P8493, DOI 10.1073/pnas.84.23.8493; EVANS MI, 1988, GENE DEV, V2, P116, DOI 10.1101/gad.2.1.116; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KOK K, 1985, NUCLEIC ACIDS RES, V13, P5189, DOI 10.1093/nar/13.14.5189; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LIN CT, 1986, ENDOCRINOLOGY, V118, P538, DOI 10.1210/endo-118-2-538; LOWNDES NF, 1990, MOL CELL BIOL, V10, P4990, DOI 10.1128/MCB.10.9.4990; MATHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93, DOI 10.1016/0003-9861(89)90090-8; MOORE DD, 1985, P NATL ACAD SCI USA, V82, P699, DOI 10.1073/pnas.82.3.699; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PTASHNE M, 1981, NATURE, V16, P249; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RAYNAUD JP, 1973, MOL PHARMACOL, V9, P520; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHIP ADVH, 1983, NUCLEIC ACIDS RES, V11, P2529; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILKS A, 1981, GENE, V16, P249, DOI 10.1016/0378-1119(81)90081-0; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	51	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7134	7138						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372608				2022-12-27	WOS:A1992HM05300104
J	DISTEL, RJ; ROBINSON, GS; SPIEGELMAN, BM				DISTEL, RJ; ROBINSON, GS; SPIEGELMAN, BM			FATTY-ACID REGULATION OF GENE-EXPRESSION - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; BINDING-PROTEIN; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; SODIUM-BUTYRATE; C-FOS; 3T3-ADIPOCYTES; COMPLEXES; ENHANCER; INSULIN	Fatty acids are important metabolic substrates and may also be involved in pathological syndromes such as the insulin resistance of diabetes and obesity. We demonstrate here that fatty acids can regulate specific gene expression; mRNAs encoding the fatty acid binding protein adipocyte P2 (aP2) and the Fos-related transcription factor Fra1 are specifically induced at least 20-fold upon treatment of preadipocytes with oleate. For aP2, the effect requires long chain fatty acids and occurs without a generalized activation of the genes linked to adipocyte differentiation. Other fibroblastic cells without preadipocyte characteristics do not induce aP2 mRNA in response to fatty acids. Unlike aP2, Fra1 induction by fatty acids also can be detected in NIH 3T3 and 3T3-C2 fibroblasts. Nuclear transcription assays in 3T3-F442A preadipocytes demonstrate that fatty acids elicit no transcriptional increase in the aP2 gene. Fra1, on the other hand, shows a 3-4-fold increase in transcription. These results demonstrate at least two distinct mechanisms by which fatty acids may influence gene expression.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MAYER 813,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013033] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405] Funding Source: Medline; NIGMS NIH HHS [GM13033] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMRI EZ, 1991, J LIPID RES, V32, P1457; BAKER N, 1978, CANCER RES, V38, P2372; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BOND JF, 1984, MOL CELL BIOL, V4, P1313, DOI 10.1128/MCB.4.7.1313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P46; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; MATARESE V, 1988, J BIOL CHEM, V263, P14544; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TOSCANI A, 1988, ONCOGENE RES, V3, P223; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117	25	197	202	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5937	5941						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372897				2022-12-27	WOS:A1992HK31800037
J	MORRIS, AP; CUNNINGHAM, SA; BENOS, DJ; FRIZZELL, RA				MORRIS, AP; CUNNINGHAM, SA; BENOS, DJ; FRIZZELL, RA			CELLULAR-DIFFERENTIATION IS REQUIRED FOR CAMP BUT NOT CA2+-DEPENDENT CL- SECRETION IN COLONIC EPITHELIAL-CELLS EXPRESSING HIGH-LEVELS OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCYTIC DIFFERENTIATION; ELECTROLYTE TRANSPORT; CANCER-CELLS; CHLORIDE; MEMBRANE; CHANNELS; INVITRO; MOUSE; CA-2+; HT-29	The gene responsible for cystic fibrosis (CF) has recently been cloned and sequenced. When transfected into CF epithelial cells, normal transcripts of this gene correct the underlying defect in CF, i.e. cAMP-dependent Cl- secretion is restored. Thus, the protein encoded by this gene, designated "cystic fibrosis transmembrane conductance regulator" (CFTR), somehow participates in the Cl- secretory response. In this paper we have correlated CFTR gene expression with cAMP and Ca2+-dependent Cl- secretion in unpolarized (parental) and polarized (Cl.19A) clones of the human colonic adenocarcinoma cell line HT-29. These cell lines were found to express equally high levels of CFTR mRNA at 4 days post-passage. In addition, protein expression (determined by immunoprecipitation) was also identical. The cAMP-generating agonist forskolin had little effect on I-125 efflux from the unpolarized cells. In contrast, this agonist increased I-125 efflux 3-fold in polarized cells. The lack of response in the unpolarized cells was not due to the inability of forskolin to raise cAMP levels. Neurotensin, a Ca2+-mobilizing agonist, stimulated I-125 efflux from both cell lines. In the polarized cells, the magnitude of this response was attenuated at 8 days post-seeding. At this time, the undifferentiated line attained some cAMP responsiveness. This latter effect was paralleled by the appearance of monolayers within areas of the multicell layer. Cell-attached patch-clamp recording from apical membrane patches of polarized cells revealed the presence of a forskolin-stimulated 8-pS Cl- channel; no channel activity was observed in forskolin-stimulated unpolarized cells. Ca2+-activated Cl- channels were found in both cell lines. In agreement with the I-125 efflux data, the single-channel activation response to [Ca2+]i was smaller in the polarized cell line. From these studies, we can conclude that CFTR expression, measured both at the mRNA and protein level, does not correlate with the colonocyte's ability to secrete chloride ions in response to a cAMP-generating agonist. Cyclic AMP-dependent Cl- secretion requires cellular polarization; specifically, the delineation of an apical membrane. Differences in the cellular location of CFTR during differentiation are likely to explain our results. In contrast, Ca2+-stimulated Cl- secretion occurred independently of cellular polarization but was reduced when the cells formed tight junctions.			MORRIS, AP (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031091, P50DK042017, P01DK038518] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31091, DK 38518, DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUGERON C, 1984, CANCER RES, V44, P3961; AUGERON C, 1986, ION GRADIENT COUPLED, P363; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; BRINKLEY BR, 1973, TISSUE CULTURE METHO, P438; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLONY PC, 1990, CELL MOL BIOL COLON, P1; DENNING G, 1991, FASEB J, V5, pA8069; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FRIZZELL RA, 1977, J MEMBRANE BIOL, V35, P175, DOI 10.1007/BF01869948; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GREY MA, 1988, J MEMBRANE BIOL, V105, P131; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOOGEVEEN AT, 1991, EXP CELL RES, V193, P435, DOI 10.1016/0014-4827(91)90118-E; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; LABOISSE CL, 1990, MOL BIOL COLON CANCE, P27; LEBIVIC A, 1988, EUR J CELL BIOL, V46, P113; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; MORRIS AP, 1990, CELL REGUL, V1, P951, DOI 10.1091/mbc.1.12.951; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; OLOUGHLIN EV, 1991, AM J PHYSIOL, V260, P758; PHILLIPS TE, 1984, AM J PHYSIOL, V247, pG674, DOI 10.1152/ajpgi.1984.247.6.G674; PINTO M, 1982, BIOL CELL, V44, P193; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; SUNTER JP, 1979, J ANAT, V129, P833; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAYLOR CJ, 1987, LANCET, V2, P107, DOI 10.1016/S0140-6736(87)92781-4; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; ZIMMERMAN TW, 1982, AM J PHYSIOL, V242, pG116, DOI 10.1152/ajpgi.1982.242.2.G116	42	81	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5575	5583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372005				2022-12-27	WOS:A1992HH74700086
J	JURANKA, P; ZHANG, F; KULPA, J; ENDICOTT, J; BLIGHT, M; HOLLAND, IB; LING, V				JURANKA, P; ZHANG, F; KULPA, J; ENDICOTT, J; BLIGHT, M; HOLLAND, IB; LING, V			CHARACTERIZATION OF THE HEMOLYSIN TRANSPORTER, HLYB, USING AN EPITOPE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CHROMOSOMAL HEMOLYSIN; NUCLEOTIDE-SEQUENCE; PROTEIN; SECRETION; MUTAGENESIS; SIGNAL; EXPORT	The prokaryotic hlyB gene product is a member of a superfamily of ATP-binding transport proteins that include the eukaryotic multidrug-resistance P-glycoprotein, the yeast STE6, and the cystic fibrosis CFTR gene products (Juranka, P. F., Zastawny, R. L., and Ling, V. (1989) FASEB J. 3, 2583-2592). Previous genetic studies have indicated that HlyB is involved in the transport of the 107-kDa HlyA protein from Escherichia coli; however, the HlyB protein has not been purified for biochemical studies due to its low abundance. In this study, we have engineered a monoclonal antibody epitope into the C-terminal end of HlyB that did not destroy its function. This has allowed us to use immunological methods to identify and localize various molecular forms of the HlyB protein present in vivo.	ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV PARIS 11,DEPT GENET & MICROBIOL,CNRS,URA D1354,F-91405 ORSAY,FRANCE	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Endicott, Jane/0000-0003-4868-0116				CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KORONAKIS V, 1988, MOL GEN GENET, V213, P551, DOI 10.1007/BF00339631; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1988, MECHANISMS DRUG RESI, V9, P197; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKMAN N, 1986, CURR TOP MICROBIOL, V125, P159; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; MACKMAN N, 1985, MOL GEN GENET, V201, P529, DOI 10.1007/BF00331351; MACKMAN N, 1984, MOL GEN GENET, V196, P123; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER W, 1980, J BACTERIOL, V144, P53, DOI 10.1128/JB.144.1.53-59.1980; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U	29	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3764	3770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371277				2022-12-27	WOS:A1992HE60700036
J	KO, K; BORNEMISZA, O; KOURTZ, L; KO, ZW; PLAXTON, WC; CASHMORE, AR				KO, K; BORNEMISZA, O; KOURTZ, L; KO, ZW; PLAXTON, WC; CASHMORE, AR			ISOLATION AND CHARACTERIZATION OF A CDNA CLONE ENCODING A COGNATE 70-KDA HEAT-SHOCK PROTEIN OF THE CHLOROPLAST ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; TRANSIT PEPTIDE; MESSENGER-RNA; HSP70; TRANSLOCATION; POLYPEPTIDES; BINDING; IMPORT; GENES; MEMBRANES	The translocation of proteins into the endoplasmic reticulum, the mitochondrion, and the chloroplast has recently been shown to involve homologues of the highly conserved 70-kDa heat shock protein (HSP70) family. In this study, we have isolated and sequenced a full-length cDNA clone encoding a cognate 70-kDa heat shock protein of the spinach chloroplast envelope (SCE70). The cDNA insert is 2,535 base pairs long and codes for 653 amino acid residues of a protein with a predicted molecular mass of 71,731 daltons. The deduced amino acid sequence shows a high degree of homology with HSP70 proteins from other organisms. Southern genomic and RNA analyses reveal different hybridization patterns than that observed for a heat-inducible 70-kDa protein gene. The protein synthesized from the SCE70 cDNA insert co-migrates with a 70-kDa polypeptide of the chloroplast envelope following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis and import studies indicate that SCE70 is associated with the chloroplast outer envelope. The import data suggest that SCE70 is targeted to the envelope membrane via a pathway different from other plastidic precursors but similar to that recently reported for outer envelope proteins SOE1 and OM14.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	KO, K (corresponding author), QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA.		Plaxton, William C/O-3353-2013	Plaxton, William C/0000-0002-8447-7249				ALTANO C, 1989, J BIOL CHEM, V264, P10709; AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BARTLETT SG, 1982, METHODS CHLOROPLAST; BIENZ M, 1984, P NATL ACAD SCI-BIOL, V81, P3138, DOI 10.1073/pnas.81.10.3138; BIGGIN MO, 1984, P NATL ACAD SCI USA, V80, P3963; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; CASHMORE AR, 1982, METHODS CHLOROPLAST; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUA NH, 1982, METHODS CHLOROPLAST; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1985, J BIOL CHEM, V260, P3691; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; HUNYH TV, 1985, DNA CLONING PRACTICA, V1, P49; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LIN TY, 1991, PLANT MOL BIOL, V16, P475, DOI 10.1007/BF00023998; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANIATIS T, 1981, MOL CLONING; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; POWELL MJ, 1990, GENE, V95, P105, DOI 10.1016/0378-1119(90)90420-V; ROBERTS JK, 1991, PLANT MOL BIOL, V16, P671, DOI 10.1007/BF00023431; ROCHESTER DE, 1986, EMBO J, V5, P451, DOI 10.1002/j.1460-2075.1986.tb04233.x; ROGERS SG, 1988, PLANT MOL BIOL METHO; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA M, 1986, J BACTERIOL, V168, P213, DOI 10.1128/jb.168.1.213-220.1986; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WILKINSON MC, 1990, PHYTOCHEMISTRY, V10, P3073; WINTER J, 1988, MOL GEN GENET, V211, P315, DOI 10.1007/BF00330609	58	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2986	2993						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371110				2022-12-27	WOS:A1992HD15400029
J	NELSON, C; RABB, H; ARNAOUT, MA				NELSON, C; RABB, H; ARNAOUT, MA			GENETIC CAUSE OF LEUKOCYTE ADHESION MOLECULE DEFICIENCY - ABNORMAL SPLICING AND A MISSENSE MUTATION IN A CONSERVED REGION OF CD18 IMPAIR CELL-SURFACE EXPRESSION OF BETA-2 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; POLYMERASE CHAIN-REACTION; AMINO-ACID-SEQUENCE; LEU-CAM DEFICIENCY; MESSENGER-RNA; FIBRONECTIN RECEPTOR; EPITHELIAL-CELLS; SUBUNIT; LFA-1; COMMON	Patients with leukocyte adhesion molecule (CD11/CD18, beta-2 integrins) deficiency have structural defects in the common beta-subunit (CD18), which prevent heterodimer formation and normal cell surface expression' of these receptors, leading to life-threatening bacterial infections. To elucidate the nature of these defects in a patient with partial (type II) deficiency, abnormal CD18 cDNA clones were isolated, using the polymerase chain reaction to amplify the patient's B cell-derived cDNAs. Sequence analysis revealed two mutant alleles. cDNA clones, representing a maternal allele, contained both a 12-base pair insertion resulting in an in-frame addition of four amino acids between P247 and E248 and a C1756 --> T nucleotide transition, resulting in an R586 --> W substitution in the normal CD18 protein. The in-frame insertion arose by a single nucleotide C --> A transversion in the 3' terminus of an intron, generating an aberrant splice acceptor site. Other cDNA clones contained an A1052 --> G nucleotide transition not present in either parent which resulted in an N351 --> S substitution. To determine the functional importance of these changes, cDNA encoding a normal alpha-chain (CD11b) was cotransfected into COS with CD18 cDNAs encoding for wild-type, maternal mutant allele, or CD18 containing N351 --> S substitution. Immunostaining of transfectants with anti-CD18 monoclonal antibodies revealed no cell surface expression of the maternal mutant CD18, and 22% surface expression of N351 --> S CD18. Both the insertion and the N351 --> S mutations occurred in a 250 amino acid extracellular region of CD18 that is highly conserved among beta-integrins supporting a role for this region in heterodimer formation.	MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,RENAL UNIT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BEATTY PG, 1983, J IMMUNOL, V131, P2913; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; Cannady W G, 1978, Prog Clin Pathol, V7, P239; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; DANA N, 1987, J CLIN INVEST, V79, P1010, DOI 10.1172/JCI112868; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DANA N, 1988, BAILLIERE CLIN IMMUN, V2, P453; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; DIMANCHE MT, 1987, EUR J IMMUNOL, V17, P417, DOI 10.1002/eji.1830170318; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Maniatis T, 1989, DECONTAMINATION DILU; MENTZER SJ, 1987, J CELL PHYSIOL, V130, P410, DOI 10.1002/jcp.1041300314; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	38	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3351	3357						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346613				2022-12-27	WOS:A1992HD15400083
J	JOSEPH, CK; QURESHI, SA; WALLACE, DJ; FOSTER, DA				JOSEPH, CK; QURESHI, SA; WALLACE, DJ; FOSTER, DA			MARCKS PROTEIN IS TRANSCRIPTIONALLY DOWN-REGULATED IN V-SRC-TRANSFORMED BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; HERBIMYCIN-A; FPS GENE; PHOSPHORYLATION; EXPRESSION; 80-KDA; HETEROGENEITY; FIBROBLASTS	Activation of protein kinase C (PKC) by tumor-promoting phorbol esters leads to the phosphorylation of an 80-kilodalton PKC substrate (known as MARCKS) in murine fibroblasts. In BALB/c 3T3 cells stably transformed by v-Src, phorbol esters were unable to induce phosphorylation of MARCKS. Western blot analysis and in vitro kinase assays showed that both PKC protein levels and kinase activity were unchanged in v-Src-transformed relative to the parental nontransformed BALB/c 3T3 cells. However, MARCKS protein levels were reduced in v-Src-transformed cells relative to nontransformed cells. MARCKS RNA levels were also correspondingly reduced in v-Src-transformed cells. Nuclear "run-on" assays showed decreased transcription of MARCKS in v-Src-transformed cells. Thus, the absence of MARCKS in v-Src-transformed cells could be explained by a down-regulation of MARCKS transcription. Inhibiting the protein tyrosine kinase activity of v-Src with herbimycin A restored MARCKS RNA levels, MARCKS transcription, and MARCKS protein, suggesting that down-regulation of MARCKS in v-Src-transformed BALB/c 3T3 cells is a direct effect of v-Src.	CUNY HUNTER COLL,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021; CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)					NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BIEMANN HPN, 1990, MOL CELL BIOL, V10, P2122, DOI 10.1128/MCB.10.5.2122; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; NIEDEL JE, 1986, RECEPTORS PHOSPHOINO, P47; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P306; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UNGER ER, 1986, AM J SURG PATHOL, V10, P1, DOI 10.1097/00000478-198601000-00001; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YANG HC, 1987, J CELL PHYSIOL, V133, P377, DOI 10.1002/jcp.1041330224	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1327	1330						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370466				2022-12-27	WOS:A1992GY96000100
J	MARIYAMA, M; KALLURI, R; HUDSON, BG; REEDERS, ST				MARIYAMA, M; KALLURI, R; HUDSON, BG; REEDERS, ST			THE ALPHA-4(IV) CHAIN OF BASEMENT-MEMBRANE COLLAGEN - ISOLATION OF CDNAS ENCODING BOVINE ALPHA-4(IV) AND COMPARISON WITH OTHER TYPE-IV COLLAGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOODPASTURE ANTIGEN; NONCOLLAGENOUS DOMAIN; ALPHA-2(IV) CHAINS; GLOBULAR DOMAIN; ALPORT SYNDROME; X-CHROMOSOME; IDENTIFICATION; LOCALIZATION; ALPHA-1(IV); GENES	Renal basement membranes are believed to contain five distinct type IV collagens. An understanding of the specific roles of these collagens and the specificities of their interactions will be aided by knowledge of their comparative structures. Genes for alpha-1(IV), alpha-2(IV), alpha-3(IV), and alpha-5(IV) have been cloned and the deduced peptide sequences compared. A fifth chain, alpha-4(IVC been identified in glomerular and other basement membranes. Using a polymerase chain reaction-based strategy and short known peptide sequences from the noncollagenous domain (NC1), we have cloned and characterized partial bovine cDNAs of alpha-4(IV). Sequence analysis shows that this molecule has characteristic features of type IV collagens including an NH2-terminal Gly-X-Y domain which is interrupted at several points and a COOH-terminal NC1 domain with 12 cysteine residues in positions identical to those of other type IV collagens. Within the NC1 domain bovine alpha-4(IV) has 70, 59, 58, and 53% amino acid identity with human alpha-2(IV), alpha-1(IV), alpha-5(IV), and alpha-3(IV), respectively. Alignment of the peptides also shows that alpha-4(IV) is most closely related to alpha-2(IV). Nevertheless, in the extreme COOH-terminal region of the NC1 domain there are structural features that are unique to alpha-4(IV). Cloning of the region of alpha-4(IV) that encodes the NC1 domain allows comparison of all five type IV collagens and highlights certain regions that are likely to be important in the specificities of NC1-NC1 interactions and in other discriminant functions of these molecules.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66103	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Kansas; University of Kansas Medical Center			; Kalluri, Raghu/E-2677-2015	Hudson, Billy/0000-0002-5420-4100; Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUO XD, 1989, J BIOL CHEM, V264, P17574; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KIM Y, 1991, AM J PATHOL, V138, P413; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MYERS JC, 1990, AM J HUM GENET, V46, P1024; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P3838, DOI 10.1073/pnas.81.12.3838; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; YOSHIOKA K, 1985, J IMMUNOL, V134, P3831	31	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1253	1258						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370461				2022-12-27	WOS:A1992GY96000089
J	SLIGH, JE; HURWITZ, MY; ZHU, CM; ANDERSON, DC; BEAUDET, AL				SLIGH, JE; HURWITZ, MY; ZHU, CM; ANDERSON, DC; BEAUDET, AL			AN INITIATION CODON MUTATION IN CD18 IN ASSOCIATION WITH THE MODERATE PHENOTYPE OF LEUKOCYTE ADHESION DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; COMMON BETA-SUBUNIT; NON-AUG CODONS; MESSENGER-RNA; TRANSLATION INITIATION; P150,95 GLYCOPROTEINS; MAMMALIAN-CELLS; ALPHA-SUBUNIT; LFA-1; MAC-1	Leukocyte adhesion deficiency (LAD) is an autosomal recessive disease caused by mutations in the CD18 gene which codes for the beta-2 integrin subunit. We studied two patients, the first of which had a moderate LAD phenotype and expressed only 9% of CD11/CD18 on blood leukocytes. RNA from lymphoblasts was reverse-transcribed, and the cDNA was amplified, cloned, and sequenced. An ATG to AAG alteration in the initiation codon was detected in 39 of 45 (87%) cDNA clones. This mutation was detected in the father, but not in the mother. The maternal defect was shown to be a frameshift mutation with the deletion of a single T in the aspartic acid codon at position 690 (GAT), 11 amino acids N-terminal to the beginning of the transmembrane domain. This mutation predicts a polypeptide which would terminate without transmembrane or cytoplasmic domains. The frameshift mutation was also found in the second patient who had the severe phenotype of LAD (< 11% of CD11/CD18), indicating that this allele does not encode a functional protein. The partial expression in the patient with a moderate phenotype must be derived from the initiation codon mutation and may be due to a low level of initiation of translation of the CD18 mRNA at the second codon (CUG).	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,HOWARD HUGHES MED INST,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,SPEROS P MARTEL LEUKOCYTE BIOL LAB,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	SLIGH, JE (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019031, R01AI019031, R01AI023521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE009079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23521, AI 19031] Funding Source: Medline; NIDCR NIH HHS [DE09079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON DC, 1984, J CLIN INVEST, V74, P536, DOI 10.1172/JCI111451; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ATWEH GF, 1988, J CLIN INVEST, V82, P557, DOI 10.1172/JCI113632; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOJO SS, 1989, J BIOL CHEM, V264, P20839; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HO MK, 1983, J BIOL CHEM, V258, P2766; ISSEKUTZ AC, 1979, CLIN IMMUNOL IMMUNOP, V14, P1, DOI 10.1016/0090-1229(79)90119-3; JANKOVIC L, 1990, HEMOGLOBIN, V14, P169, DOI 10.3109/03630269009046958; JOHN SWM, 1989, AM J HUM GENET, V45, P905; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARLIN SD, 1986, J EXP MED, V164, P855, DOI 10.1084/jem.164.3.855; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MOI P, 1987, J CLIN INVEST, V80, P1416, DOI 10.1172/JCI113220; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NOZARI G, 1986, GENE, V43, P23, DOI 10.1016/0378-1119(86)90004-1; OLIVIERI NF, 1987, BLOOD, V70, P729; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PIRASTU M, 1984, J BIOL CHEM, V259, P2315; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SASTRE L, 1986, J IMMUNOL, V137, P1060; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; TAIRA M, 1990, J BIOL CHEM, V265, P16491; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					714	718						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1346132				2022-12-27	WOS:A1992GY96000009
J	DELAPENA, P; DELGADO, LM; DELCAMINO, D; BARROS, F				DELAPENA, P; DELGADO, LM; DELCAMINO, D; BARROS, F			2 ISOFORMS OF THE THYROTROPIN-RELEASING-HORMONE RECEPTOR GENERATED BY ALTERNATIVE SPLICING HAVE INDISTINGUISHABLE FUNCTIONAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; GTP-BINDING PROTEINS; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; XENOPUS OOCYTES; TRH RECEPTORS; TUMOR-CELLS; PITUITARY; EXPRESSION	Two cDNA clones encoding two different isoforms of the thyrotropin-releasing hormone receptor (TRH-R) from GH3 rat anterior pituitary cells have been isolated. One isoform corresponds to the TRH-R(412) receptor previously described (de la Pena, P., Delgado, L. M., del Camino, D., and Barros, F. (1992) Biochem. J. 284, 891-899). The second one, named TRH-R(387), contains a 52-base pair deletion, which yields a new variant of the receptor protein 25 amino acid shorter and which contains 12 new residues on its carboxyl terminus. This new isoform is produced by alternative splicing of a retained intron in the primary transcript of a gene represented only once in the rat genome. Furthermore, the perfect colinearity between genomic DNA and TRH-R(412) cDNA demonstrates that no other introns are present within the coding region of the TRH receptor gene. Functional expression in Xenopus laevis oocytes indicates that both cDNAs encode fully functional TRH receptors. Otherwise, indistinguishable electrophysiological responses to TRH are evoked in oocytes expressing both receptor isoforms.			DELAPENA, P (corresponding author), UNIV OVIEDO, FAC MED, DEPT BIOL FUNC, AREA BIOQUIM, E-33006 OVIEDO, SPAIN.		De-la-Pena-Cortines, Pilar/B-1453-2012; Barros, Francisco/O-6647-2019; Barros, Francisco/H-3297-2015	De-la-Pena-Cortines, Pilar/0000-0002-3915-730X; Barros, Francisco/0000-0001-9040-1948; Barros, Francisco/0000-0001-9040-1948				ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BOEGE F, 1991, EUR J BIOCHEM, V199, P1, DOI 10.1111/j.1432-1033.1991.tb16085.x; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUVIER M, 1991, FEBS LETT, V279, P243, DOI 10.1016/0014-5793(91)80159-Z; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; DANNIES PS, 1976, NATURE, V261, P707, DOI 10.1038/261707a0; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DRUMMOND AH, 1989, INOSITOL LIPIDS CELL, P355; FUNATSU K, 1985, J NEUROCHEM, V45, P390, DOI 10.1111/j.1471-4159.1985.tb04000.x; GAUTVIK KM, 1981, EUR J BIOCHEM, V116, P235, DOI 10.1111/j.1432-1033.1981.tb05324.x; GAUTVIK KM, 1983, J BIOL CHEM, V258, P304; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; JOHNSON WA, 1989, ANN NY ACAD SCI, V553, P137; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOPEZBARNEO J, 1990, P NATL ACAD SCI USA, V87, P8150, DOI 10.1073/pnas.87.20.8150; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; ROSS PC, 1990, P NATL ACAD SCI USA, V87, P3052, DOI 10.1073/pnas.87.8.3052; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SINGER D, 1990, PFLUG ARCH EUR J PHY, V416, P7, DOI 10.1007/BF00370215; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x	41	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25703	25708						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334485				2022-12-27	WOS:A1992KD07300019
J	ZHOU, GX; CHAO, L; CHAO, J				ZHOU, GX; CHAO, L; CHAO, J			KALLISTATIN - A NOVEL HUMAN TISSUE KALLIKREIN INHIBITOR - PURIFICATION, CHARACTERIZATION, AND REACTIVE CENTER SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; HUMAN URINARY KALLIKREIN; PLASMINOGEN-ACTIVATOR; BINDING PROTEIN; HUMAN-PLASMA; ALPHA-1-PROTEINASE INHIBITOR; MOLECULAR-BIOLOGY; RAT-LIVER; HEPARIN; ALPHA-1-ANTITRYPSIN	A novel human tissue kallikrein inhibitor designated as kallistatin has been purified from plasma to apparent homogeneity by polyethylene glycol fractionation and successive chromatography on heparin-Agarose, DEAE-Sepharose, hydroxylapatite, and phenyl-Superose columns. A purification factor of 4350 was achieved with a yield of approximately 1.35 mg per liter of plasma. The purified inhibitor migrates as a single band with an apparent molecular mass of 58 kDa when analyzed on SDS-polyacrylamide gel electrophoresis under reducing conditions. It is an acidic protein with pI values ranging from 4.6 to 5.2. No immunological cross-reactivity was found by Western blot analyses between kallistatin and other serpins. Kallistatin inhibits human tissue kallikrein's activity toward kininogen and tripeptide substrates. The second-order reaction rate constant (k(a)) was determined to be 2.6 x 10(4) M-1 s-1 using Pro-Phe-Arg-MCA. The inhibition is accompanied by formation of an equimolar, heat- and SDS-stable complex between tissue kallikrein and kallistatin, and by generation of a small carboxyl-terminal fragment from the inhibitor due to cleavage at the reactive site by tissue kallikrein. Heparin blocks kallistatin's complex formation with tissue kallikrein and abolishes its inhibitory effect on tissue kallikrein's activity. The amino-terminal residue of kallistatin is blocked. Sequence analysis of the carboxyl-terminal fragment generated from kallistatin reveals the reactive center sequence from P1' to P15', which shares sequence similarity with, but is different from known serpins including protein C inhibitor, alpha1-antitrypsin, and alpha1-antichymotrypsin. The results show that kallistatin is a new member of the serpin superfamily that inhibits human tissue kallikrein.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425	Medical University of South Carolina	CHAO, J (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BUCHMAN TG, 1990, SURGERY, V108, P559; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAI KX, 1991, BIOCHIM BIOPHYS ACTA, V1129, P127, DOI 10.1016/0167-4781(91)90227-D; CHAO J, 1983, J BIOL CHEM, V258, P4434; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; ECKE S, 1992, J BIOL CHEM, V267, P7048; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ESPANA F, 1989, THROMB RES, V55, P369, DOI 10.1016/0049-3848(89)90069-8; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; HIRANO K, 1984, H-S Z PHYSIOL CHEM, V365, P27, DOI 10.1515/bchm2.1984.365.1.27; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IERSEL JV, 1985, ANAL BIOCHEM, V151, P196; IWANAGA S, 1979, KININS, V2, P147; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU HS, 1989, INT J PEPT PROT RES, V33, P237; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MITAS JA, 1978, NEW ENGL J MED, V299, P162, DOI 10.1056/NEJM197807272990402; MURRAY SR, 1990, J CARDIOVASC PHARM, V15, pS7, DOI 10.1097/00005344-199000156-00003; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCHACHTER M, 1980, PHARMACOL REV, V31, P1; SCICLI AG, 1986, KIDNEY INT, V29, P120, DOI 10.1038/ki.1986.14; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; SHIMAMOTO K, 1979, JPN CIRC J, V43, P147, DOI 10.1253/jcj.43.147; STEIN PL, 1989, J BIOL CHEM, V264, P15441; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TAKAHARA H, 1982, J BIOL CHEM, V257, P2438; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; XIONG W, 1992, J LAB CLIN MED, V119, P514; YOON JB, 1987, J BIOL CHEM, V262, P4284	41	143	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25873	25880						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334488				2022-12-27	WOS:A1992KD07300045
J	MULLER, G; SCHUBERT, K; FIEDLER, F; BANDLOW, W				MULLER, G; SCHUBERT, K; FIEDLER, F; BANDLOW, W			THE CAMP-BINDING ECTOPROTEIN FROM SACCHAROMYCES-CEREVISIAE IS MEMBRANE-ANCHORED BY GLYCOSYL-PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; YEAST MITOCHONDRIA; PHOSPHOLIPASE-C; SUBMITOCHONDRIAL LOCALIZATION; INTRAMITOCHONDRIAL LOCATION; SYNERGISTIC CONTROL; PLASMA-MEMBRANE; PROTEIN; INSULIN	Saccharomyces cerevisiae contains an amphiphilic cAMP-binding glycoprotein at the outer face of the plasma membrane (M(r) = 54,000). It is converted to a hydrophilic form by treatment with glycosyl-phosphatidylinositol-specific phospholipases C and D (GPI-PLC/D), suggesting membrane anchorage by a covalently bound glycolipid. Determination of the constituents of the purified anchor by gas-liquid chromatography and amino acid analysis reveals the presence of glycerol, myo-inositol, glucosamine, galactose, mannose, ethanolamine, and asparagine (as the carboxyl-terminal amino acid of the Pronase-digested protein to which the anchor is attached). Complementary results are obtained by metabolic labeling, indicating that fatty acids and phosphorus are additional anchor constituents. The phosphorus is resistant to alkaline phosphatase, whereas approximately half is lost from the protein after treatment with GPI-PLD or nitrous acid, and all is removed by aqueous HF indicating the presence of two phosphodiester bonds. Inhibition of N-glycosylation by tunicamycin or removal of protein-bound glycan chains by N-glycanase or Pronase does not abolish radiolabeling of the anchor structure by any of the above compounds. Analysis of the products obtained after sequential enzymic and chemical degradation of the anchor agrees with the arrangement of constitutents in GPIs from higher eucaryotes. Evidence for anchorage of the yeast cAMP-binding protein by a GPI anchor is strengthened additionally by the reactivity of the GPI-PLC-cleaved anchor with antibodies directed against the cross-reacting determinant of trypanosomal variant surface glycoproteins.	UNIV MUNICH,INST GENET & MIKROBIOL,W-8000 MUNICH 19,GERMANY	University of Munich	MULLER, G (corresponding author), HOECHST AG,DIV PHARMACEUT RES,SBU METAB H825,POB 800320,W-6230 FRANKFURT 80,GERMANY.			Muller, Gunter/0000-0001-6178-8215				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ANDERSON AJ, 1977, CARBOHYD RES, V57, pC7, DOI 10.1016/S0008-6215(00)81944-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULOW R, 1986, J BIOL CHEM, V261, P1918; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; FIEDLER F, 1987, SYST APPL MICROBIOL, V9, P16, DOI 10.1016/S0723-2020(87)80050-4; FISCHER W, 1973, BIOCHIM BIOPHYS ACTA, V296, P527, DOI 10.1016/0005-2760(73)90113-6; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Heller M, 1978, Adv Lipid Res, V16, P267; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HOOPER NM, 1991, BIOCHEM J, V273, P301, DOI 10.1042/bj2730301; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KLIP A, 1988, FEBS LETT, V238, P419, DOI 10.1016/0014-5793(88)80524-6; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9974; MULLER G, 1991, BIOCHEMISTRY-US, V30, P10181; MULLER G, 1987, YEAST, V3, P161, DOI 10.1002/yea.320030304; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9968; MULLER G, 1991, EUR J BIOCHEM, V202, P299, DOI 10.1111/j.1432-1033.1991.tb16376.x; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; MULLER G, 1987, EMBO J, V6, P2199; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RODEL G, 1985, J BACTERIOL, V161, P7; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; TAGUCHI R, 1987, J BIOCHEM-TOKYO, V102, P803, DOI 10.1093/oxfordjournals.jbchem.a122119; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	51	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25337	25346						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334092				2022-12-27	WOS:A1992KB60300065
J	MURPHY, AC; ROZENGURT, E				MURPHY, AC; ROZENGURT, E			PASTEURELLA-MULTOCIDA TOXIN SELECTIVELY FACILITATES PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS BY BOMBESIN, VASOPRESSIN, AND ENDOTHELIN - REQUIREMENT FOR A FUNCTIONAL G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-C ACTIVITY; KINASE-C; ALPHA-SUBUNITS; GUANINE-NUCLEOTIDE; POTENT MITOGEN; PHORBOL ESTERS; MONOCLONAL-ANTIBODIES; DERMONECROTIC TOXIN; BACTERIAL TOXINS	Treatment of Swiss 3T3 cells with a subsaturating concentration of recombinant Pasteurella multocida toxin (rPMT) markedly potentiated the production of inositol phosphates induced by bombesin, vasopressin, and endothelin but not by platelet-derived growth factor (PDGF) (AA and BB homodimers). Similarly, the neuropeptides but not PDGF caused a shift in the dose-dependent increase in inositol phosphates induced by rPMT. The rate of accumulation of inositol phosphates induced by bombesin was increased 2-fold by rPMT treatment while that of PDGF was unaffected. rPMT treatment also enhanced bombesin-induced inositol(1,4,5)trisphosphate, the direct product of phosphatidylinositol 4,5-bisphosphate hydrolysis. In contrast, treatment of cells with rPMT had no effect on the tyrosine phosphorylation of phospholipase Cgamma. Depletion of protein kinase C increased rPMT-induced inositol phosphates in a manner similar to that observed for bombesin but not PDGF. Thus, rPMT selectively potentiates neuropeptide-mediated inositol phosphate production. The action of rPMT on phosphatidylinositol 4,5-bisphosphate hydrolysis persisted in streptolysin O-permeabilized cells. Addition of guanosine 5'-O-(beta-thiodiphosphate) to permeabilized cells markedly reduced rPMT-induced inositol phosphates in a time- and dose-dependent manner. rPMT also increased the sensitivity of phospholipase C for free calcium. Our results strongly suggest that the action of rPMT facilitates the coupling of G protein to phospholipase C.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BROWN KD, 1990, BIOCHEM J, V270, P557, DOI 10.1042/bj2700557; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BUYS WECM, 1990, NUCLEIC ACIDS RES, V18, P2815, DOI 10.1093/nar/18.9.2815; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANTER N, 1986, J GEN MICROBIOL, V132, P1089; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FOGED NT, 1988, INFECT IMMUN, V56, P1901, DOI 10.1128/IAI.56.8.1901-1906.1988; FOGED NT, 1987, FEMS MICROBIOL LETT, V43, P45, DOI 10.1111/j.1574-6968.1987.tb02095.x; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS AMIE, 1990, FEMS MICROBIOL LETT, V67, P187, DOI 10.1111/j.1574-6968.1990.tb13860.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LAX AJ, 1990, FEBS LETT, V277, P59, DOI 10.1016/0014-5793(90)80809-W; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARTIN TFJ, 1989, J BIOL CHEM, V264, P20917; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NAKAI T, 1984, INFECT IMMUN, V46, P429, DOI 10.1128/IAI.46.2.429-434.1984; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PETERSEN SK, 1989, INFECT IMMUN, V57, P3907, DOI 10.1128/IAI.57.12.3907-3913.1989; PETERSEN SK, 1990, MOL MICROBIOL, V4, P821, DOI 10.1111/j.1365-2958.1990.tb00652.x; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, J CELL SCI, P43; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHENKER A, 1991, SCIENCE, V266, P9309; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	66	58	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25296	25303						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334089				2022-12-27	WOS:A1992KB60300059
J	PERLMAN, JH; NUSSENZVEIG, DR; OSMAN, R; GERSHENGORN, MC				PERLMAN, JH; NUSSENZVEIG, DR; OSMAN, R; GERSHENGORN, MC			THYROTROPIN-RELEASING-HORMONE BINDING TO THE MOUSE PITUITARY RECEPTOR DOES NOT INVOLVE IONIC INTERACTIONS - A MODEL FOR NEUTRAL PEPTIDE BINDING TO G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; HIGH-AFFINITY; TUMOR-CELLS; GH3 CELLS; TRH; ACTIVATION; CULTURE; IDENTIFICATION; EXPRESSION	Thyrotropin-releasing hormone, TRH (<Glu-His-Proamide), and [N(tau)Me-His]TRH (MeTRH) are present as neutral and positively charged forms at physiologic pH, and it was possible that they bind to the TRH receptor (TRH-R) as charged (protonated) species. Binding affinities of TRH and MeTRH to endogenous rat TRH-Rs and to transfected wild type mouse TRH-Rs decreased below pH 7.1. Half-maximal decreases in binding occurred at the approximate pK(a) values of these ligands. Asp to Ala mutations in extracellular loop 1, TM-4, and TM-5 did not decrease binding affinity, but an Asp to Ala mutation in TM-2 caused the affinity to decrease 8-fold. The pH dependences of binding of MeTRH, however, were similar in wild type and all mutant receptors and were consistent with the protonated form of MeTRH binding less well. Thus, the binding of TRH to its receptor does not involve ionic interactions and may be a prototype for binding of neutral peptide ligands to G protein-coupled receptors.	CORNELL UNIV, MED CTR,NEW YORK HOSP,COLL MED,DEPT MED, DIV MOLEC MED,1300 YORK AVE, NEW YORK, NY 10021 USA; CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	Cornell University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK43036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; DRUMMOND AH, 1985, BIOCHEM BIOPH RES CO, V127, P63, DOI 10.1016/S0006-291X(85)80126-1; DRUMMOND AH, 1989, ANN NY ACAD SCI, V553, P197; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; GERSHENGORN MC, 1986, ENDOCRINOLOGY, V119, P833, DOI 10.1210/endo-119-2-833; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GERSHENGORN MC, 1978, J CLIN INVEST, V62, P937, DOI 10.1172/JCI109222; GERSHENGORN MC, 1983, MOL BASIS THYROID HO, P338; GOREN HJ, 1977, MOL PHARMACOL, V13, P606; GRANT G, 1972, BIOCHEMISTRY-US, V11, P3070, DOI 10.1021/bi00766a020; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HINKLE PM, 1984, J BIOL CHEM, V259, P3445; HINKLE PM, 1974, J BIOL CHEM, V249, P3085; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; IMAI A, 1987, METHOD ENZYMOL, V141, P100; JI IH, 1991, J BIOL CHEM, V266, P14953; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEVE KA, 1991, MOL PHARMACOL, V39, P733; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REYNOLDS WF, 1973, J AM CHEM SOC, V95, P328, DOI 10.1021/ja00783a006; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Sambrook J, 1989, MOL CLONING LABORATO; SHARIF NA, 1987, NEUROSCI LETT, V81, P339, DOI 10.1016/0304-3940(87)90407-1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; Vale W, 1973, Front Neuroendocrinol, V0, P375; WANG CD, 1991, MOL PHARMACOL, V40, P168; XIE YB, 1990, J BIOL CHEM, V265, P21411	31	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24413	24417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332958				2022-12-27	WOS:A1992KA26300044
J	YANG, ZH; WENSEL, TG				YANG, ZH; WENSEL, TG			INORGANIC PYROPHOSPHATASE FROM BOVINE RETINAL ROD OUTER SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; CGMP PHOSPHODIESTERASE; FREE CALCIUM; LIGHT ADAPTATION; CYCLIC-GMP; RAT-LIVER; PURIFICATION; CA-2+; PHOTORECEPTORS; ACTIVATION	Rod outer segments from bovine retina contain a higher level of intracellular inorganic pyrophosphatase (EC 3.6.1.1) activity than has been found in any other mammalian tissue; the specific activity in extracts of soluble outer segment proteins is more than 6-fold higher than in extracts from bovine liver and more than 24-fold higher than in skeletal muscle extracts. This high activity may be necessary to keep inorganic pyrophosphate concentrations low in the face of the high rates of pyrophosphate production that accompany the cGMP flux driving phototransduction. We have begun to explore the role of inorganic pyrophosphatase in photoreceptor cGMP metabolism by 1) studying the kinetic properties of this enzyme and its interactions with divalent metal ions and anionic inhibitors, 2) purifying it and studying its size and subunit composition, and 3) examining the effects of pyrophosphate on rod outer segment guanylyl cyclase. K(m) for magnesium pyrophosphate was 0.9-1.5 muM, and the purified enzyme hydrolyzed >885 mumol of PP(i) min-1 mg-1. The enzyme appears to be a homodimer of 36-kilodalton subunits when analyzed by gel electrophoresis and density gradient centrifugation, implying that k(cat) = 10(3) s-1, and k(cat)/K(m) = 0.7-1 x 10(9) M-1 s-1. The enzyme was inhibited by Ca2+ at submicromolar levels: 28% inhibition was observed at 138 nM [Ca2+], and 53% inhibition at 700 nM [Ca2+]. Imidodiphosphate acted as a competitive inhibitor, with K(i) = 1.2 muM, and fluoride inhibited half-maximally approximately 20 muM. Inhibition studies on rod outer segment guanylyl cyclase confirmed previous reports that pyrophosphate inhibits guanylyl cyclase, suggesting an essential role for inorganic pyrophosphatase in maintaining cGMP metabolism.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1986, J BIOL CHEM, V261, P3034; ANG Z, 1991, BIOPHYS J, V59, pA535; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAYKOV AA, 1989, ARCH BIOCHEM BIOPHYS, V273, P287, DOI 10.1016/0003-9861(89)90486-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER LG, 1977, BIOINORG CHEM, V7, P141; CHEN M, 1973, P SOC EXP BIOL MED, V143, P44, DOI 10.3181/00379727-143-37249; CHEUNG WY, 1966, BIOCHEM BIOPH RES CO, V23, P214, DOI 10.1016/0006-291X(66)90530-4; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; DAVIDSON AM, 1987, BIOCHEM J, V246, P715, DOI 10.1042/bj2460715; DAVIDSON AM, 1989, BIOCHEM J, V258, P817, DOI 10.1042/bj2580817; DETWILER P B, 1989, Investigative Ophthalmology and Visual Science, V30, P162; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FELIX R, 1975, BIOCHEM J, V147, P111, DOI 10.1042/bj1470111; FISHER RA, 1974, ANN HUM GENET, V37, P341, DOI 10.1111/j.1469-1809.1974.tb01841.x; FISHER RA, 1974, ANN HUM GENET, V38, P171, DOI 10.1111/j.1469-1809.1974.tb01948.x; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HACHIMORI A, 1983, J BIOCHEM, V93, P257, DOI 10.1093/oxfordjournals.jbchem.a134161; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; IRIE M, 1970, J BIOCHEM, V67, P47, DOI 10.1093/oxfordjournals.jbchem.a129233; JANSON CA, 1979, J BIOL CHEM, V254, P3743; JOHNSONRA, 1990, J BIOL CHEM, V265, P11595; KHANDELWAL RL, 1980, BIOCHIM BIOPHYS ACTA, V613, P95, DOI 10.1016/0005-2744(80)90196-5; KLEMME JH, 1976, Z NATURFORSCH C, V31, P544; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB TD, 1986, J PHYSIOL-LONDON, V372, P315, DOI 10.1113/jphysiol.1986.sp016011; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MOE OA, 1972, J BIOL CHEM, V247, P7315; MOE OA, 1972, J BIOL CHEM, V247, P7308; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PEPE IM, 1986, FEBS LETT, V203, P73, DOI 10.1016/0014-5793(86)81439-9; PRITZKER KPH, 1986, HUM PATHOL, V17, P543, DOI 10.1016/S0046-8177(86)80124-1; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; PYNES GD, 1967, J BIOL CHEM, V242, P2119; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RATTO GM, 1988, J NEUROSCI, V8, P3240; RIDLINGTON JW, 1972, J BIOL CHEM, V247, P7303; SHATTON JB, 1981, CANCER RES, V41, P1866; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; STETTEN D, 1960, AM J MED, V28, P867, DOI 10.1016/0002-9343(60)90195-9; STRYER L, 1991, J BIOL CHEM, V266, P10711; THUILLIER L, 1978, BIOCHIM BIOPHYS ACTA, V524, P198, DOI 10.1016/0005-2744(78)90118-3; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHEELER TJ, 1980, BIOCHEMISTRY-US, V19, P4564, DOI 10.1021/bi00561a004; YANG Z, 1990, Investigative Ophthalmology and Visual Science, V31, P216; YANG ZH, 1992, J BIOL CHEM, V267, P24641; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YOSHIDA C, 1982, CANCER RES, V42, P3526	61	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24634	24640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360011				2022-12-27	WOS:A1992KA26300073
J	BARON, V; KALIMAN, P; GAUTIER, N; VANOBBERGHEN, E				BARON, V; KALIMAN, P; GAUTIER, N; VANOBBERGHEN, E			THE INSULIN-RECEPTOR ACTIVATION PROCESS INVOLVES LOCALIZED CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-FREE SYSTEM; KINASE-ACTIVITY; BINDING-SITE; BETA-SUBUNIT; PHOSPHORYLATION; AUTOPHOSPHORYLATION; ATP; ANTIBODIES	The molecular process by which insulin binding to the receptor alpha-subunit induces activation of the receptor beta-subunit with ensuing substrate phosphorylation remains unclear. In this study, we aimed at approaching this molecular mechanism of signal transduction and at delineating the cytoplasmic domains implied in this process. To do this, we used antipeptide antibodies to the following sequences of the receptor beta-subunit: (i) positions 962-972 in the juxtamembrane domain, (ii) positions 1247-1261 at the end of the kinase domain, and (iii) positions 1294-1317 and (iv) positions 1309-1326, both in the receptor C terminus. We have previously shown that insulin binding to its receptor induces a conformational change in the beta-subunit C terminus. Here, we demonstrate that receptor autophosphorylation induces an additional conformational change. This process appears to be distinct from the one produced by ligand binding and can be detected in at least three different beta-subunit regions: the juxtamembrane domain, the kinase domain, and the C terminus. Hence, the cytoplasmic part of the receptor beta-subunit appears to undergo an extended conformational change upon autophosphorylation. By contrast, the insulin-induced change does not affect the juxtamembrane domain 962-972 nor the kinase domain 1247-1261 and may be limited to the receptor C terminus. Further, we show that the hormone-dependent conformational change is maintained in a kinase-deficient receptor due to a mutation at lysine 1018. Therefore, during receptor activation, the ligand-induced change could precede ATP binding and receptor autophosphorylation. We propose that insulin binding leads to a transient receptor form that may allow ATP binding and, subsequently, autophosphorylation. The second conformational change could unmask substrate-binding sites and stabilize the receptor in an active conformation.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur								BARON V, 1989, BIOCHEM J, V260, P749, DOI 10.1042/bj2600749; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DONNER DB, 1983, J BIOL CHEM, V258, P9413; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; FREYCHET P, 1976, METHODS RECEPTOR RES, P384; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEATING MT, 1988, J BIOL CHEM, V263, P12805; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1982, FEBS LETT, V143, P179, DOI 10.1016/0014-5793(82)80094-X; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052	22	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23290	23294						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331080				2022-12-27	WOS:A1992JY16300089
J	ZU, YL; TAKAMATSU, Y; ZHAO, MJ; MAEKAWA, T; HANDA, H; ISHII, S				ZU, YL; TAKAMATSU, Y; ZHAO, MJ; MAEKAWA, T; HANDA, H; ISHII, S			TRANSCRIPTIONAL REGULATION BY A POINT MUTANT OF ADENOVIRUS-2 E1A PRODUCT LACKING DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; AMP RESPONSE ELEMENT; CYCLIC-AMP; ACTIVATES TRANSCRIPTION; FUNCTIONAL DOMAINS; ESCHERICHIA-COLI; MESSENGER-RNAS; EARLY PROMOTER; PROTEIN; TRANSFORMATION	The adenovirus E1a protein (E1A) regulates transcription through interaction with transcription factors bound to DNA, like cAMP response element BP1/ATF2, or through dissociating E2F transcription factor complex. However, it was also reported that E1A can bind to DNA (Chatterjee, P. K., Bruner, M., Flint, S. J., and Harter, M. L. (1988) EMBO J. 7, 835-841), and it is not clear whether DNA binding of E1A is involved in a part of the process of transcriptional regulation by E1A. In this paper, the small region of E1A that is responsible for DNA binding was identified and a point mutant lacking DNA binding activity was constructed. Analysis of deletion mutants of E1A proteins expressed in bacteria showed that a basic region between amino acids 201 and 216 of E1A is essential for DNA binding. Point mutation of arginines at amino acid numbers 205 and 206 to aspartic acids completely abolished the DNA binding activity of E1A. Using this mutant, the requirement of the E1A DNA binding for E1A-dependent transcriptional regulation was examined. trans-Activation of the adenovirus E4 promoter and trans-repression of the human c-erbB-2 promoter by this point mutant were examined by cotransfection experiments. Mutations of the E1A DNA-binding domain affected neither the E1A-induced trans-activation nor trans-repression at all. These results give complete proof that the DNA binding activity of E1A is not required for transcriptional regulation by E1A.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA 236,JAPAN; TOKYO INST TECHNOL,FAC LIFE SCI & TECHNOL,DEPT BIOSYST,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	RIKEN; Yokohama City University; Tokyo Institute of Technology			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANAKA S, 1987, MOL CELL BIOL, V7, P2578, DOI 10.1128/MCB.7.7.2578; HANDA H, 1987, GENE, V58, P127; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KATO HT, 1983, MOL CELL BIOL, V3, P2058; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERRICAUDET M, 1979, NATURE, V218, P649; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZU YL, 1991, J BIOL CHEM, V266, P24134	55	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20181	20187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356975				2022-12-27	WOS:A1992JR85800070
J	POLLOCK, NJ; MANELLI, AM; HUTCHINS, CW; STEFFEY, ME; MACKENZIE, RG; FRAIL, DE				POLLOCK, NJ; MANELLI, AM; HUTCHINS, CW; STEFFEY, ME; MACKENZIE, RG; FRAIL, DE			SERINE MUTATIONS IN TRANSMEMBRANE-V OF THE DOPAMINE D1-RECEPTOR AFFECT LIGAND INTERACTIONS AND RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PLATELET ALPHA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; BINDING-SITE; EXPRESSION; GENE; IDENTIFICATION; AGONISTS; DOMAINS; BIOLOGY	Several serines present in transmembrane domain V are conserved among members of the G-protein-coupled receptor family that bind catecholamines. Two of these serines that are present in the beta-adrenergic receptor were previously shown by site-directed mutagenesis to affect agonist binding and receptor activation (Strader, C. D., Candelore, M. R., Hill, W. S., Sigal, 1. S., and Dixon, R. A. F. (1989) J. Biol. Chem. 264, 13572-13578). We investigated the role of the serines present in transmembrane V of another catecholamine receptor, the dopamine D 1 receptor, by site-directed mutagenesis, and the results show that mutations at serines 198, 199, and 202 affect dopamine binding. The substitution of serine 198 or serine 199 by an alanine also affects the binding of several other agonist and antagonist dopaminergic compounds while an alanine substitution at serine 202 has no effect on the binding of these compounds. Moreover, each single serine mutation decreased the maximal cAMP accumulation elicited by a dopamine D1 partial agonist. These results suggest that serines present in transmembrane V of the D1 receptor affect ligand interactions and receptor signal transduction, but not entirely in the manner that would be predicted from the model proposed for the beta-adrenergic receptor.	ABBOTT LABS,DEPT CORP MOLEC BIOL,1 ABBOTT PK RD,AP20,ABBOTT PK,IL 60064; ABBOTT LABS,COMP ASSISTED MOLEC DESIGN,N CHICAGO,IL 60064; ABBOTT LABS,DIV NEUROSCI RES,N CHICAGO,IL 60064	Abbott Laboratories; Abbott Laboratories; Abbott Laboratories								BROOKER G, 1980, CLIN CHEM, V26, P1738; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVELLI O, 1991, EUR J PHARM-MOLEC PH, V207, P277, DOI 10.1016/0922-4106(91)90001-X; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COX BA, 1991, IN PRESS J NEUROCHEM, V59; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; Sambrook J, 1989, MOL CLONING LABORATO; SEEMAN P, 1990, NATURE, V347, P19; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STEFFEY ME, 1991, EUR J PHARM-MOLEC PH, V207, P311, DOI 10.1016/0922-4106(91)90005-3; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG SKF, 1988, J BIOL CHEM, V263, P7925; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	31	105	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17780	17786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355478				2022-12-27	WOS:A1992JM22300049
J	SCHMIDT, M; BUCHNER, J				SCHMIDT, M; BUCHNER, J			INTERACTION OF GROE WITH AN ALL-BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT CHAIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CONSTANT FRAGMENT; BINDING; RECONSTITUTION; PURIFICATION; INTERMEDIATE; AGGREGATION; POLYPEPTIDE	Molecular chaperones are involved in protein folding both in vivo and in vitro. The Escherichia coli chaperone GroEL interacts with a number of nonnative proteins. A common structural motif of nonnative proteins, which is recognized by GroEL, has not yet been identified. In order to study the role of beta-sheet secondary structure on the interaction of nonnative proteins with GroEL, we used the F(ab) fragment of a monoclonal antibody as a model substrate protein. Here we show that GroEL interacts functionally with this all-beta-protein during reactivation. Antibody fragments refold spontaneously in good yield from the guanidine-denatured state. Functional refolding to the native state is inhibited transiently by GroEL, but there is no complete folding arrest in the absence of Mg-ATP and GroES. The yield of these unspecifically released GroEL-bound F(ab) fragments corresponds to that of the spontaneous reactivation in the absence of chaperones. However, the refolding kinetics in the presence of GroEL are considerably slower. The addition of Mg-ATP to the GroEL.F(ab) complex results in an immediate release of bound substrate protein and a significant increase in the amount of reconstituted antibody fragments compared to spontaneous reactivation. GroES is not essential for functional GroEL-mediated refolding of the F(ab) fragment but affects the reactivation yield to a small extent. Interestingly, stimulation of the GroEL-mediated F(ab) refolding depends primarily on the binding and not on hydrolysis of adenosine triphosphates. Previous results indicate the binding of alpha-helices to GroEL. The results presented in this paper suggest that beta-sheet secondary structural elements are recognized by GroEL. We therefore conclude that the interaction of a nonnative protein with GroEL depends mainly on the nature of the early folding intermediate but not on a specific element of secondary structure.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BALDWIN RL, 1991, CIBA F SYMP, V161, P190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY JS, 1992, NATURE, V355, P455; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	38	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16829	16833						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1355088				2022-12-27	WOS:A1992JL05300018
J	BRECHLER, V; PAVOINE, C; HANF, R; GARBARZ, E; FISCHMEISTER, R; PECKER, F				BRECHLER, V; PAVOINE, C; HANF, R; GARBARZ, E; FISCHMEISTER, R; PECKER, F			INHIBITION BY GLUCAGON OF THE CGMP-INHIBITED LOW-K(M) CAMP PHOSPHODIESTERASE IN HEART IS MEDIATED BY A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LIVER PLASMA-MEMBRANE; ADENYLATE-CYCLASE; AMP PHOSPHODIESTERASES; CALCIUM CURRENT; CA-2+ PUMP; SELECTIVE INHIBITORS; HORMONAL-REGULATION; CARDIAC-CELLS; ACTIVATION	We have recently reported that glucagon activated the L-type Ca2+ channel current in frog ventricular myocytes and showed that this was linked to the inhibition of a membrane-bound low-K(m) cAMP phosphodiesterase (PDE) (Mery, P. F., Brechler, V., Pavoine, C., Pecker, F., and Fischmeister, R. (1990) Nature 345, 158-161). We show here that the inhibition of membrane-bound PDE activity by glucagon depends on guanine nucleotides, a reproducible inhibition of 40% being obtained with 0.1-mu-M glucagon in the presence of 10-mu-M GTP, with GTP > GTP-gamma-S, while GDP and ATP-gamma-S were without effect. Glucagon had no effect on the cytosolic low-K(m) cAMP PDE, assayed with or without 10-mu-M GTP. Glucagon inhibition of membrane-bound PDE activity was not affected by pretreatment of the ventricle particulate fraction with cholera toxin. However, it was abolished after pertussis toxin pretreatment. Mastoparan, a wasp venom peptide known to activate G(i)/G(o) proteins directly, mimicked the effect of glucagon. PDE inhibition by glucagon was additive with the inhibition induced by Ro 20-1724, but was prevented by milrinone. This was correlated with an increase by glucagon of cAMP levels in frog ventricular cells which was not additive with the increase in cAMP due to milrinone. We conclude that glucagon specifically inhibits the cGMP-inhibited, milrinone-sensitive PDE (CGI-PDE). Insensitivity of adenylylcyclase to glucagon and inhibition by the peptide of a low-K(m) cAMP PDE were not restricted to frog heart, but also occurred in mouse and guinea pig heart. These results confirm that two mechanisms mediate the action of glucagon in heart: one is the activation of adenylylcyclase through G(s), and the other relies on the inhibition of the membrane-bound low-K(m) CGI-PDE, via a pertussis toxin-sensitive G-protein.	UNIV PARIS 11, INSERM, U241, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	BRECHLER, V (corresponding author), HOP HENRI MONDOR, INSERM, U99, F-94010 CRETEIL, FRANCE.		Pavoine, Catherine/N-4405-2018; Fischmeister, Rodolphe/L-6061-2018	Pavoine, Catherine/0000-0002-0598-5545; Fischmeister, Rodolphe/0000-0003-2086-9865				ARRIODUPONT M, 1985, BIOL CELL, V54, P163; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BLACHE P, 1990, J BIOL CHEM, V265, P21514; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; BUXTON ILO, 1986, AM J PHYSIOL, V251, pH307, DOI 10.1152/ajpheart.1986.251.2.H307; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHATELAIN P, 1983, PFLUG ARCH EUR J PHY, V397, P100, DOI 10.1007/BF00582046; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; GANZ MB, 1990, J BIOL CHEM, V265, P8989; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HEYWORTH CM, 1983, BIOCHEM J, V214, P99, DOI 10.1042/bj2140099; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOLMER SR, 1991, CIRCULATION, V84, P1891, DOI 10.1161/01.CIR.84.5.1891; HUGHES AR, 1984, P NATL ACAD SCI-BIOL, V81, P5680, DOI 10.1073/pnas.81.18.5680; KISS Z, 1984, EUR J BIOCHEM, V142, P323, DOI 10.1111/j.1432-1033.1984.tb08289.x; LACOMBE ML, 1979, J BIOL CHEM, V254, P3697; LOTEN EG, 1978, J BIOL CHEM, V253, P746; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MASTERS SB, 1984, MOL PHARMACOL, V26, P149; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; MERY PF, 1990, NATURE, V345, P158, DOI 10.1038/345158a0; MIOT F, 1983, FEBS LETT, V151, P273, DOI 10.1016/0014-5793(83)80085-4; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; MULLER B, 1990, J CARDIOVASC PHARM, V16, P796, DOI 10.1097/00005344-199011000-00016; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; PYNE NJ, 1989, BIOCHEM J, V261, P897, DOI 10.1042/bj2610897; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SIMMONS MA, 1988, MOL PHARMACOL, V33, P664; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISHAAR RE, 1988, DRUG DEVELOP RES, V12, P119, DOI 10.1002/ddr.430120206; WILDENTHAL K, 1976, J CLIN INVEST, V57, P551, DOI 10.1172/JCI108310	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15496	15501						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353495				2022-12-27	WOS:A1992JG11300039
J	SPIVAKKROIZMAN, T; ROTIN, D; PINCHASI, D; ULLRICH, A; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; ROTIN, D; PINCHASI, D; ULLRICH, A; SCHLESSINGER, J; LAX, I			HETERODIMERIZATION OF C-ERBB2 WITH DIFFERENT EPIDERMAL GROWTH-FACTOR RECEPTOR MUTANTS ELICITS STIMULATORY OR INHIBITORY RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; NEU ONCOGENE; SIGNAL TRANSDUCTION; POINT MUTATION; PHORBOL ESTERS; KIT RECEPTOR; PROTEIN; PHOSPHORYLATION	Ligand-induced dimerization of growth factor receptors is crucial for stimulation of their intrinsic protein tyrosine kinase activity promoting receptor autophosphorylation by an intermolecular mechanism. Moreover, the suppressive and negative dominant action of defective epidermal growth factor receptor (EGFR) was shown to be caused by formation of inactive heterodimers with normal EGFR leading to diminished biological signaling. In this report we explore the structural requirements and functional significance of heterodimerization between EGFR and HER2. HER2 (also called c-erbB-2 or neu) is a member of the EGFR family whose natural ligand is still unknown. We show that in response to EGF, wild type EGFR and various EGFR mutants were able to undergo heterodimerization with HER2. Addition of EGF to transfected cells co-expressing HER2 with a kinase negative point mutant of EGFR (K721A) stimulated heterodimer formation, tyrosine phosphorylation of K721A and HER2, and tyrosine phosphorylation of one of their known substrates, phospholipase C-gamma. However, the binding of EGF to transfected cells co-expressing HER2 together with another EGFR mutant CD533 (a deletion mutant lacking most of the cytoplasmic domain of EGFR) caused heterodimerization and inhibition of tyrosine kinase activity. It appears therefore that EGF-induced heterodimerization of EGFR and HER2 can promote either stimulatory or inhibitory influences on kinase activity. We propose that the nature of receptor interactions on the cell surface can either activate or inhibit the initiation of growth factor-controlled cellular signaling.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	SPIVAKKROIZMAN, T (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1010; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOU OK, 1987, NATURE, V328, P820; COCHET C, 1988, J BIOL CHEM, V263, P3290; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING AC, 1982, J BIOL CHEM, V257, P3053; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, MOL BIOL CELL, V2, P641; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS B, 1990, SCIENCE, V248, P435; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; REDEMANN N, 1992, IN PRESS MOL CELL BI; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTIN D, 1992, IN PRESS EMBO J; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P549; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1982, BIOPHYS METHODS EXP, V20, P197; Schlessinger J., 1979, PHYSICAL CHEM ASPECT, P89; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SKOLNIK EY, 1991, CELL, V65, P85; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	45	102	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8056	8063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349015				2022-12-27	WOS:A1992HQ18500018
J	TRACKMAN, PC; BEDELLHOGAN, D; TANG, J; KAGAN, HM				TRACKMAN, PC; BEDELLHOGAN, D; TANG, J; KAGAN, HM			POSTTRANSLATIONAL GLYCOSYLATION AND PROTEOLYTIC PROCESSING OF A LYSYL OXIDASE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE; PURIFICATION; AORTA; CULTURES; ELASTIN; CELLS; DNA	The synthesis and post-translational processing of a lysyl oxidase precursor protein predicted by the cDNA sequence of rat aorta lysyl oxidase were investigated. In vitro transcription of the cloned lysyl oxidase cDNA and cell-free translation of its mRNA transcript yielded a 47-kDa protein in the absence and a 50-kDa glycosylated protein in the presence of pancreatic membranes, each of which were immunoprecipitated with antibody against the 32-kDa bovine enzyme. Similarly, an N-glycosylated, 50-kDa protein band was synthesized by and immunoprecipitated from cultured neonatal rat aorta smooth muscle cells labeled with [S-35]methionine. Pulse-chase studies of proteins newly synthesized by these cells demonstrated that the glycosylated 50-kDa precursor is secreted and that it is processed to the 32-kDa molecular form of lysyl oxidase principally in the medium. The presence of an extracellular processing enzyme activity which converts the 50-kDa precursor to the 32-kDa species was demonstrated by incubating conditioned medium of neonatal rat aorta smooth muscle cell cultures as a source of processing activity with conditioned medium containing S-35-labeled precursor synthesized but not processed by a tumorigenic cell line transfected with a lysyl oxidase expression vector. In contrast to the 50-kDa species, the 32-kDa protein does not appear to be N-glycosylated consistent with the loss of N-linked oligosaccharide units during the processing to the smaller species. The modes of biosynthesis and secretion of lysyl oxidase are discussed in terms of other nonproteolytic activities required for activation of prolysyl oxidase.			TRACKMAN, PC (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL019717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19717, HL-13262] Funding Source: Medline; NIAMS NIH HHS [R37-AR-18880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMASSIAN B, 1991, CONNECT TISSUE RES, V25, P197, DOI 10.3109/03008209109029156; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; BURBELO PD, 1986, COLLAGEN REL RES, V6, P153; CRONLUND AL, 1986, CONNECT TISSUE RES, V15, P173, DOI 10.3109/03008208609167141; DORNER AJ, 1990, METHOD ENZYMOL, V185, P557; ENWEMEKA CS, 1991, TISSUE CELL, V23, P173, DOI 10.1016/0040-8166(91)90072-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAGAN HM, 1986, J CELL BIOL, V103, P1121, DOI 10.1083/jcb.103.3.1121; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P222; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROMEROCHAPMAN N, 1991, BIOCHEM J, V275, P657, DOI 10.1042/bj2750657; SAMBROOK J, 1989, MOL CLONING APPENDIX; SHACKLETON DR, 1990, BIOCHEM J, V266, P917; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; WAKASAKI H, 1990, LAB INVEST, V63, P377; WAKASAKI H, 1990, BIOCHEM BIOPH RES CO, V166, P1201, DOI 10.1016/0006-291X(90)90993-W; WOYNAROWSKA B, 1989, CANCER RES, V49, P5598	32	144	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8666	8671						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349020				2022-12-27	WOS:A1992HQ18500105
J	CHESSLER, SD; BYERS, PH				CHESSLER, SD; BYERS, PH			DEFECTIVE FOLDING AND STABLE ASSOCIATION WITH PROTEIN DISULFIDE ISOMERASE/PROLYL HYDROXYLASE OF TYPE-I PROCOLLAGEN WITH A DELETION IN THE PRO-ALPHA-2(I) CHAIN THAT PRESERVES THE GLY-X-Y REPEAT PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL OSTEOGENESIS IMPERFECTA; TRIPLE-HELICAL DOMAIN; ENDOPLASMIC-RETICULUM; SUBSTITUTION; SECRETION; GLYCINE; GENE	We have studied the folding, processing, and association with two endoplasmic reticulum (ER) resident proteins of the abnormal type I procollagen molecules produced by a strain of fibroblasts harboring a 4.5 kilobase deletion in an allele of COL1A2 (Willing, M. C., Cohn, D. H., Starman, B. Holbrook, K. A., Greenberg, C. R., and Byers, P. H. (1988) J. Biol. Chem. 263, 8398-8404). By sequencing cDNA, we found that the mutant allele encodes pro-alpha-2(I) chains that are shortened by 180 amino acids but retain the Gly-X-Y repeat pattern crucial for collagen triple helix formation. The type I procollagen molecules that incorporated the shortened chain were retained intracellularly and were stable. The triple helical domain in these molecules did not attain a normal conformation and remained accessible to posttranslational modifying enzymes amino-terminal to the deletion site for a prolonged period. The abnormal molecules folded into a triple helical conformation more slowly than the normal molecules, and the amino-terminal ends of the pro-alpha-1(I) chains failed to become protease-resistant. While the abnormal procollagen molecules were not bound by the ER-resident protein BiP, they stably associated with protein disulfide isomerase, the beta-subunit of prolyl-4-hydroxylase. These results indicate that some mutations in type I collagen genes both transiently delay folding and permanently disrupt the structure of the triple helix and suggest that binding to prolyl-4-hydroxylase helps to retain certain abnormal procollagen molecules within the ER.	UNIV WASHINGTON,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,CTR INHERITED DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Byers, Peter H./0000-0001-7786-7030	NIAMS NIH HHS [AR21557] Funding Source: Medline; NIGMS NIH HHS [GM07266-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSUK JA, 1989, MATRIX, V9, P244, DOI 10.1016/S0934-8832(89)80057-5; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P241; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; Gething M J, 1990, Semin Cell Biol, V1, P65; KAO WWY, 1979, J BIOL CHEM, V254, P2234; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WALLIS GA, 1990, J BIOL CHEM, V265, P18628; WARREN G, 1990, CELL, V62, P1, DOI 10.1016/0092-8674(90)90229-8; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WILLING MC, 1988, J BIOL CHEM, V263, P8398	27	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7751	7757						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1339453				2022-12-27	WOS:A1992HN48500078
J	LI, W; MACDONALD, RG; HEXUM, TD				LI, W; MACDONALD, RG; HEXUM, TD			ROLE OF SULFHYDRYL-GROUPS IN Y2 NEUROPEPTIDE-Y RECEPTOR-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; RAT-BRAIN; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CROSS-LINKING; MEMBRANES; NPY; NEURONS; SITES; IMMUNOREACTIVITY	Benextramine, a tetramine disulfide, irreversibly inhibits neuropeptide Y (NPY) binding to the 50-kDa Y2 NPY receptor in bovine hippocampus (Li, W., MacDonald, R. G., and Hexum, T. D. (1991) Eur. J. Pharmacol. 207, 89-91). Evidence is presented that this inhibition occurs through a thiol-disulfide exchange. Treatment of bovine hippocampal membranes with benextramine inhibited NPY affinity cross-linking to the 50-kDa receptor. This inhibition of labeling was not affected by washing the membranes, but could be completely reversed by the addition of several thiol reducing reagents, including reduced glutathione, beta-mercaptoethanol, and cysteine. Benextramine inhibited 70% of NPY-specific labeling and was much more effective than other sulfhydryl reactive agents, such as oxidized glutathione, cystamine, and 5,5'-dithio-bis(2-nitrobenzoic acid). Furthermore, the sulfhydryl-modifying agents N-ethylmaleimide and p-chloromercuriphenyl-sulfonic acid specifically decreased NPY affinity labeling. Finally, NPY labeling of the 50-kDa receptor was reduced by the heavy metal ions Zn2+, Cu2+, and Hg2+. Preincubation with NPY prevented Y2 receptors from being inactivated by either 400-mu-M N-ethylmaleimide or 1 mM benextramine. These results suggest that one or more benextramine-sensitive sulfhydryl groups on the Y2 receptor are important for NPY binding activity.	UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026479] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26479] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; ALLEN JM, 1985, CLIN SCI, V68, P373, DOI 10.1042/cs0680373; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; CHANG RSL, 1985, LIFE SCI, V37, P2111, DOI 10.1016/0024-3205(85)90583-1; CHERDCHU C, 1989, EUR J PHARMACOL, V173, P115, DOI 10.1016/0014-2999(89)90507-4; CHRONWALL BM, 1984, NEUROSCI LETT, V52, P213, DOI 10.1016/0304-3940(84)90164-2; DOUGHTY MB, 1990, EUR J PHARMACOL, V185, P113, DOI 10.1016/0014-2999(90)90218-U; GIMPL G, 1990, J BIOL CHEM, V265, P18142; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEXUM TD, 1989, NEUROPEPTIDES, V13, P35, DOI 10.1016/0143-4179(89)90019-X; HOKFELT T, 1983, NEUROSCI LETT, V36, P217, DOI 10.1016/0304-3940(83)90003-4; INUI A, 1989, ENDOCRINOLOGY, V124, P402, DOI 10.1210/endo-124-1-402; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, EUR J PHARM-MOLEC PH, V207, P89, DOI 10.1016/S0922-4106(05)80042-2; LI W, 1991, BRAIN RES, V553, P167, DOI 10.1016/0006-8993(91)90246-R; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P393, DOI 10.1111/j.1748-1716.1982.tb07157.x; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; MANNON PJ, 1989, AM J PHYSIOL, V256, pG637, DOI 10.1152/ajpgi.1989.256.3.G637; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MELCHIORRE C, 1981, TRENDS PHARMACOL SCI, V2, P209, DOI 10.1016/0165-6147(81)90315-1; NGUYEN TD, 1990, J BIOL CHEM, V265, P6416; POTTER EK, 1988, PHARMACOL THERAPEUT, V37, P251, DOI 10.1016/0163-7258(88)90028-9; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; SMITH Y, 1985, J COMP NEUROL, V236, P71, DOI 10.1002/cne.902360107; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TATEMOTO K, 1989, NEUROPEPTIDE Y, P13; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; WAHLESTEDT C, 1989, PROG NEURO-PSYCHOPH, V13, P31, DOI 10.1016/0278-5846(89)90003-1; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WALKER MW, 1988, MOL PHARMACOL, V34, P779; WALKER MW, 1988, J NEUROSCI, V8, P2438	35	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7570	7575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348506				2022-12-27	WOS:A1992HN48500054
J	OGISO, M; IRIE, A; KUBO, H; HOSHI, M; KOMOTO, M				OGISO, M; IRIE, A; KUBO, H; HOSHI, M; KOMOTO, M			SENILE CATARACT-RELATED ACCUMULATION OF LEWIS(X) GLYCOLIPID IN HUMAN LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN SSEA-1; CELL-ADHESION; SIALYL-LEX; GLYCOSPHINGOLIPIDS; RECOGNITION; CHROMATOGRAPHY; GANGLIOSIDES; CARBOHYDRATE; MECHANISMS; EMBRYOS	A glycosphingolipid that reacted positively to anti-stage-specific embryonic antigen-1 (SSEA-1) anti-serum accumulated in human lens in association with aging and senile cataract formation. Since this anti-serum recognizes Lewis(x) (Le(x)) structure, Gal-beta-1-4(Fuc-alpha-1-3)GlcNAc-, which is a typical tumor-associated and differentiation-related saccharide chain, the lens glycolipid was predicted to be a Le(x) antigen. The glycolipid purified from cataractous lens tissues was indeed a Le(x) glycolipid, Gal-beta-1-4(Fuc-alpha-1-3)GlcNAc-beta-1-3Gal-beta-1-4Glc-beta-1-1 ceramide. Enhanced expression of the Le(x) glycolipid may affect the organization of lens plasma membranes through Le(x)-Le(x) interactions, as suggested for compaction in mouse preimplantation embryos and embryonic teratocarcinomas, resulting in lens opacification, namely cataract.	TOHO UNIV,SCH MED,DEPT PHYSIOL & OPHTHALMOL,TOKYO 143,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	Toho University; Tokyo Institute of Technology								ANDO S, 1976, BIOCHIM BIOPHYS ACTA, V424, P98; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CHYLACK LT, 1984, OPHTHALMOLOGY, V91, P596; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; HAKOMORI S, 1981, BIOCHEM BIOPH RES CO, V100, P1578, DOI 10.1016/0006-291X(81)90699-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IRIE A, 1990, J BIOCHEM-TOKYO, V108, P531, DOI 10.1093/oxfordjournals.jbchem.a123237; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KNOWLES BB, 1980, NATURE, V288, P615, DOI 10.1038/288615a0; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LAINE RA, 1975, J LIPID RES, V16, P102; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P243; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1979, DEV BIOL, V70, P515, DOI 10.1016/0012-1606(79)90043-5; TAO R V P, 1983, Current Eye Research, V2, P427; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	31	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6467	6470						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348055				2022-12-27	WOS:A1992HM05300005
J	BACK, AL; KWOK, WW; HICKSTEIN, DD				BACK, AL; KWOK, WW; HICKSTEIN, DD			IDENTIFICATION OF 2 MOLECULAR DEFECTS IN A CHILD WITH LEUKOCYTE ADHERENCE DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; MEDIATED GENE-TRANSFER; LEU-CAM DEFICIENCY; ADHESION DEFICIENCY; MESSENGER-RNA; ENZYMATIC AMPLIFICATION; LFA-1; EXPRESSION; RECEPTOR; DIFFERENTIATION	Children with leukocyte adherence deficiency (LAD), or leukocyte cell adhesion molecule deficiency, experience recurrent, life-threatening bacterial infections related to severe deficiency in surface expression of the leukocyte integrin molecules. The leukocyte integrins consist of a common CD18 (beta) subunit and individual, noncovalently associated alpha-subunits designated CD11a, CD11b, and CD11c. Defects in the CD18 subunit prevent surface expression of the CD11/CD18 complexes in children with this disease. We investigated the molecular basis of the disease in a child with the severe deficiency form of LAD and identified two molecular defects in the CD18 subunit. The first defect is a single-base pair C --> T transposition resulting in an amino acid substitution of a leucine for a proline at amino acid 178. This amino acid substitution is located in a region that is highly conserved among the integrin beta-subunits and where two previous defects have been located in LAD. The second mutation involves a deletion of 220 base pairs in the cDNA coding for a portion of the extracellular domain and results in a frameshift into a premature stop codon. The deleted region corresponds to a single exon in the CD18 gene. Identification of these two molecular defects in a single child with this disease indicates the compound heterozygous nature of the disorder in this child and identifies regions of the CD18 subunit that may be important for CD11/CD18 heterodimer formation and surface expression.	SEATTLE VET AFFAIRS MED CTR,MED RES SERV,SEATTLE,WA 98108; VIRGINIA MASON MED CTR,SEATTLE,WA 98101; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195	Virginia Mason Medical Center; University of Washington; University of Washington Seattle								ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; BACK AL, 1990, BIOCHEM BIOPH RES CO, V171, P787, DOI 10.1016/0006-291X(90)91215-E; BEATTY PG, 1984, LANCET; BEATTY PG, 1983, J IMMUNOL, V131, P2914; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; DANA N, 1987, J CLIN INVEST, V79, P1010, DOI 10.1172/JCI112868; DIMANCHE MT, 1987, EUR J IMMUNOL, V17, P417, DOI 10.1002/eji.1830170318; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HICKSTEIN DD, 1988, J IMMUNOL, V141, P4313; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; HICKSTEIN DD, 1987, J IMMUNOL, V138, P513; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; MARLIN SD, 1986, J EXP MED, V164, P855, DOI 10.1084/jem.164.3.855; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597	35	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5482	5487						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347532				2022-12-27	WOS:A1992HH74700073
J	MARTINEZBLANCO, H; REGLERO, A; FERNANDEZVALVERDE, M; FERRERO, MA; MORENO, MA; PENALVA, MA; LUENGO, JM				MARTINEZBLANCO, H; REGLERO, A; FERNANDEZVALVERDE, M; FERRERO, MA; MORENO, MA; PENALVA, MA; LUENGO, JM			ISOLATION AND CHARACTERIZATION OF THE ACETYL-COA SYNTHETASE FROM PENICILLIUM-CHRYSOGENUM - INVOLVEMENT OF THIS ENZYME IN THE BIOSYNTHESIS OF PENICILLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ISOPENICILLIN-N SYNTHETASE; ACID TRANSPORT-SYSTEM; PHENYLACETYL-COA; ASPERGILLUS-NIDULANS; WIS 54-1255; HOMOCITRATE SYNTHASE; FATTY-ACIDS; PURIFICATION; ACYLTRANSFERASE	Acetyl-CoA synthetase (ACS) of Penicillium chrysogenum was purified to homogeneity (745-fold) from fungal cultures grown in a chemically defined medium containing acetate as the main carbon source. The enzyme showed maximal rate of catalysis when incubated in 50 mM HCl-Tris buffer, pH 8.0, at 37-degrees-C. Under these conditions, ACS showed hyperbolic behavior against acetate, CoA, and ATP; the K(m) values calculated for these substrates were 6.8, 0.18, and 17 mM, respectively. ACS recognized as substrates not only acetate but also several fatty acids ranging between C2 and Ca and some aromatic molecules (phenylacetic, 2-thiopheneacetic, and 3-thiopheneacetic acids). ATP can be replaced by ADP although, in this case, a lower activity was observed (37%). ACS is inhibited by some thiol reagents (5,5'-dithiobis(nitrobenzoic acid), N-ethylmaleimide, p-chloromercuribenzoate) and divalent cations (Zn2+, Cu2+, and Hg2+), whereas it was stimulated when the reaction mixtures contained 1 mM dithiothreitol, reduced glutathione, or 2-mercaptoethanol. The calculated molecular mass of ACS was 139 +/- 1 kDa, and the native enzyme is composed of two apparent identical subunits (70 kDa) in an alpha-2 oligomeric structure. ACS activity was regulated "in vivo" by carbon catabolite inactivation when glucose was taken up by cells in which the enzyme had been previously induced. This enzyme can be coupled "in vitro" to acyl-CoA:6-aminopenicillanic acid acyltransferase from P. chrysogenum, thus allowing the reconstitution of the functional enzymatic system which catalyzes the two latter reactions responsible for the biosynthesis of different penicillins. The ACS from Aspergillus nidulans can also be coupled to 6-aminopenicillanic acid acyltransferase to synthesize penicillins. These results strongly indicate that this enzyme can catalyze the activation (to their CoA thioesters) of some of the side-chain precursors required in these two fungi for the production of several penicillins. All these data are reported here for the first time.	UNIV LEON, FAC VET, DEPT BIOQUIM & BIOL MOLEC, E-24007 LEON, SPAIN; CONSEJO SUPER INVEST CIENTIFICAS, E-28006 MADRID, SPAIN; ANTIBIOT SA LEON, DEPT BIOQUIM, LEON, SPAIN	Universidad de Leon; Consejo Superior de Investigaciones Cientificas (CSIC)			Penalva, Miguel A/G-2295-2015; Luengo, Jose M./E-1935-2016	Penalva, Miguel A/0000-0002-3102-2806; Luengo, Jose M./0000-0002-4984-6256; Moreno Valle, Miguel Angel/0000-0002-1419-6898; Martinez Blanco, Honorina/0000-0003-4591-2321; Ferrero Garcia, Miguel Angel/0000-0002-4335-0372				ALONSO MJ, 1988, J ANTIBIOT, V41, P1074, DOI 10.7164/antibiotics.41.1074; BADOR H, 1984, BIOCHIMIE, V66, P223, DOI 10.1016/0300-9084(84)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HD, 1975, J BACTERIOL, V121, P959, DOI 10.1128/JB.121.3.959-969.1975; Brunner R, 1975, Methods Enzymol, V43, P476; BURNETT JH, 1976, FUNDAMENTALS MYCOLOG, P238; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DEMAIN AL, 1974, J GEN MICROBIOL, V82, P143, DOI 10.1099/00221287-82-1-143; DUNTZE W, 1968, EUR J BIOCHEM, V3, P326, DOI 10.1111/j.1432-1033.1968.tb19533.x; Fawcett P, 1975, Methods Enzymol, V43, P471; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1410, DOI 10.7164/antibiotics.42.1410; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1398, DOI 10.7164/antibiotics.42.1398; FLOREY HW, 1949, ANTIBIOTICS, V2; FRENKEL EP, 1977, J BIOL CHEM, V252, P504; FRIEDRICH CG, 1977, J ANTIBIOT, V30, P760, DOI 10.7164/antibiotics.30.760; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GANCEDO C, 1976, ARCH MICROBIOL, V109, P221, DOI 10.1007/BF00446632; Gancedo C., 1989, YEASTS, V3, P205; GEISSLER JF, 1988, J BACTERIOL, V170, P1709, DOI 10.1128/jb.170.4.1709-1714.1988; GORTS CPM, 1969, BIOCHIM BIOPHYS ACTA, V184, P299, DOI 10.1016/0304-4165(69)90032-4; HOLZ G, 1974, METHOD ENZYMAT AN, V3, P1528; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; JETTEN MSM, 1989, J BACTERIOL, V171, P5430, DOI 10.1128/jb.171.10.5430-5435.1989; KESTON AS, 1956, 5TH M AM CHEM SOC DA, P310; KOGEKAR RG, 1983, INDIAN J BIOCHEM BIO, V20, P208; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; LENZ AG, 1980, FEBS LETT, V109, P271, DOI 10.1016/0014-5793(80)81103-3; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUENGO JM, 1986, BIO-TECHNOL, V4, P44, DOI 10.1038/nbt0186-44; LUENGO JM, 1986, J ANTIBIOT, V39, P1565, DOI 10.7164/antibiotics.39.1565; LUENGO JM, 1986, J ANTIBIOT, V39, P1754, DOI 10.7164/antibiotics.39.1754; LUENGO JM, 1980, J BACTERIOL, V144, P869, DOI 10.1128/JB.144.3.869-876.1980; MAGASANIK B, 1961, COLD SPRING HARB SYM, V26, P249, DOI 10.1101/SQB.1961.026.01.031; MARTINEZBLANCO H, 1989, J ANTIBIOT, V42, P1416, DOI 10.7164/antibiotics.42.1416; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MARTINVILLACORTA J, 1990, J ANTIBIOT, V43, P1559, DOI 10.7164/antibiotics.43.1559; MARTINVILLACORTA J, 1989, J ANTIBIOT, V42, P1502, DOI 10.7164/antibiotics.42.1502; MASUREKAR PS, 1972, CAN J MICROBIOL, V18, P1045, DOI 10.1139/m72-162; MATERN H, 1977, J BIOL CHEM, V252, P6399; MAZON MJ, 1982, EUR J BIOCHEM, V127, P605; OSULLIVAN J, 1979, BIOCHEM J, V184, P421, DOI 10.1042/bj1840421; RAMON D, 1987, GENE, V57, P171, DOI 10.1016/0378-1119(87)90120-X; RAMOS FR, 1985, ANTIMICROB AGENTS CH, V27, P380, DOI 10.1128/AAC.27.3.380; REVILLA G, 1986, J BACTERIOL, V168, P947, DOI 10.1128/jb.168.2.947-952.1986; ROMANO AH, 1969, PROC R SOC SER B-BIO, V173, P475, DOI 10.1098/rspb.1969.0072; SANDEMAN RA, 1989, MOL GEN GENET, V218, P87, DOI 10.1007/BF00330569; SMITH DJ, 1990, BIO-TECHNOL, V8, P39, DOI 10.1038/nbt0190-39; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; WALLACH D, 1976, J BIOL CHEM, V251, P5802; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHITEMAN PA, 1990, FEBS LETT, V262, P342, DOI 10.1016/0014-5793(90)80224-7; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559	52	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5474	5481						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347531				2022-12-27	WOS:A1992HH74700072
J	STEPHAN, V; BENHAMOU, M; GUTKIND, JS; ROBBINS, KC; SIRAGANIAN, RP				STEPHAN, V; BENHAMOU, M; GUTKIND, JS; ROBBINS, KC; SIRAGANIAN, RP			FC-EPSILON-RI-INDUCED PROTEIN TYROSINE PHOSPHORYLATION OF PP72 IN RAT BASOPHILIC LEUKEMIA-CELLS (RBL-2H3) - EVIDENCE FOR A NOVEL SIGNAL TRANSDUCTION PATHWAY UNRELATED TO G-PROTEIN ACTIVATION AND PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; HISTAMINE-RELEASE; MAST-CELLS; INOSITOL TRISPHOSPHATE; SYNERGISTIC SIGNALS; MEDIATED ACTIVATION; KINASE-C; RECEPTOR; SECRETION; INHIBITION	Recently, we demonstrated that aggregation of the high affinity IgE receptor in rat basophilic leukemia (RBL-2H3) cells results in rapid tyrosine phosphorylation of a 72-kDa protein (pp72). Here we investigated the relationship of pp72 phosphorylation to guanine nucleotide-binding protein (G protein) activation and phosphatidylinositol hydrolysis. The activation of G proteins by NaF in intact cells or by guanosine 5'-O-(3-thiotriphosphate) in streptolysin 0-permeabilized cells induced both phosphatidylinositol hydrolysis and histamine release without tyrosine phosphorylation of pp72. Similarly, in RBL-2H3 cells expressing the G protein-coupled muscarinic acetylcholine receptor, carbachol activated phospholipase C and induced secretion without concomitant pp72 phosphorylation. Therefore, pp72 phosphorylation was not induced by G protein activation or as a consequence of phosphatidylinositol hydrolysis. To investigate whether pp72 tyrosine phosphorylation precedes the activation of phospholipase C, we studied the effect of the tyrosine kinase inhibitor genistein. Preincubation of cells with genistein decreased, in parallel, antigen-induced tyrosine phosphorylation of pp72 (IC50 = 34-mu-g/ml) and histamine release (IC50 = 31-mu-g/ml). However, genistein at concentrations of up to 60-mu-g/ml did not inhibit phosphatidylinositol hydrolysis nor did it change the amount of the secondary messenger inositol (1,4,5)-triphosphate. Previous observations showed that there was no pp72 tyrosine phosphorylation after activation of protein kinase C or after an increase in intracellular calcium. Taken together, these results suggest that pp72 tyrosine phosphorylation represents a distinct, independent signaling pathway induced specifically by aggregation of the Fc-epsilon-RI.	NIDR,IMMUNOL LAB,BLDG 10,RM 1N 106,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Benhamou, Marc/0000-0001-7763-3795				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P87; BALLA T, 1988, J BIOL CHEM, V263, P4083; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BEAVEN MA, 1991, FASEB J, V5, pA1676; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1986, FASEB J, V45, P2156; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANE PJL, 1991, J IMMUNOL, V146, P715; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; NARASIMHAN V, 1990, J BIOL CHEM, V264, P1459; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRIBLUDA VS, 1987, J BIOL CHEM, V262, P11449; RASHEED S, 1976, J VIROL, V19, P13, DOI 10.1128/JVI.19.1.13-18.1976; SAITO H, 1989, J IMMUNOL, V143, P250; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WILSON BS, 1989, J IMMUNOL, V143, P259	44	69	69	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5434	5441						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372002				2022-12-27	WOS:A1992HH74700066
J	EMMERICH, J; BEG, OU; PETERSON, J; PREVIATO, L; BRUNZELL, JD; BREWER, HB; SANTAMARINAFOJO, S				EMMERICH, J; BEG, OU; PETERSON, J; PREVIATO, L; BRUNZELL, JD; BREWER, HB; SANTAMARINAFOJO, S			HUMAN LIPOPROTEIN-LIPASE - ANALYSIS OF THE CATALYTIC TRIAD BY SITE-DIRECTED MUTAGENESIS OF SER-132, ASP-156, AND HIS-241	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-HEPARIN PLASMA; PANCREATIC LIPASE; MOLECULAR-CLONING; HEPATIC LIPASE; GENE FAMILY; SEQUENCE; CDNA; BINDING; INACTIVATION; DEFICIENCY	Lipoprotein lipase (LPL) plays a central role in normal lipid metabolism as the key enzyme involved in the hydrolysis of triglycerides present in chylomicrons and very low density lipoproteins. LPL is a member of a family of hydrolytic enzymes that include hepatic lipase and pancreatic lipase. Based on primary sequence homology of LPL to pancreatic lipase, Ser- 132, Asp-156, and His-241 have been proposed to be part of a domain required for normal enzymic activity. We have analyzed the role of these potential catalytic residues by site-directed mutagenesis and expression of the mutant LPL in human embryonic kidney-293 cells. Substitution of Ser- 132, Asp- 156, and His-241 by several different residues resulted in the expression of an enzyme that lacked both triolein and tributyrin esterase activities. Mutation of other conserved residues, including Ser-97, Ser-307, Asp-78, Asp-37 1, Asp-440, His-93, and His-439 resulted in the expression of active enzymes. Despite their effect on LPL activity, substitutions of Ser-132, Asp-156, and His-241 did not change either the heparin affinity or lipid binding properties of the mutant LPL. In summary, mutation of Ser-132, Asp-156, and His-241 specifically abolishes total hydrolytic activity without disrupting other important functional domains of LPL. These combined results strongly support the conclusion that Ser-132, Asp-156, and His-241 form the catalytic triad of LPL and are essential for LPL hydrolytic activity.	NHLBI,MOLEC DIS BRANCH,BLDG 10,RM 7N117,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENAVRAM CM, 1986, P NATL ACAD SCI USA, V83, P4185, DOI 10.1073/pnas.83.12.4185; BENGTSSON G, 1982, FEBS LETT, V147, P183, DOI 10.1016/0014-5793(82)81038-7; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; EMI M, 1990, J BIOL CHEM, V265, P5910; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOBAYASHI J, 1989, EUR J CLIN INVEST, V19, P424, DOI 10.1111/j.1365-2362.1989.tb00254.x; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; OSTLUNDLINDQVIST AM, 1977, FEBS LETT, V83, P231, DOI 10.1016/0014-5793(77)81011-9; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P9; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YANG CY, 1989, J BIOL CHEM, V264, P16822	35	84	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4161	4165						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371284				2022-12-27	WOS:A1992HE60700087
J	BOCHKAREVA, ES; GIRSHOVICH, AS				BOCHKAREVA, ES; GIRSHOVICH, AS			A NEWLY SYNTHESIZED PROTEIN INTERACTS WITH GROES ON THE SURFACE OF CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; ATP HYDROLYSIS; IDENTIFICATION; PURIFICATION; CARBOXYLASE; PRODUCTS; GROWTH; GENE	To facilitate folding and assembly of different proteins, chaperonin GroEL requires the presence of its helper protein GroES. Using a photochemical cross-linking approach, we show that GroES and newly synthesized pre-beta-lactamase (pre-betalac) contact with each other only within the ternary complex with GroEL. Possibly owing to this contact GroES is able to directly influence the pre-betalac/GroEL interaction. Furthermore, the cross-linking of pre-betalac to GroES suggests that the binding of the protein ligands to GroEL occurs near the GroES binding site, known to be in the central hole space of GroEL.	WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	GIRSHOVICH, AS (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							ANG D, 1991, J BIOL CHEM, V266, P24233; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	25	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25672	25675						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361186				2022-12-27	WOS:A1992KD07300014
J	KANOH, H; IMAI, S; YAMADA, K; SAKANE, F				KANOH, H; IMAI, S; YAMADA, K; SAKANE, F			PURIFICATION AND PROPERTIES OF PHOSPHATIDIC-ACID PHOSPHATASE FROM PORCINE THYMUS MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIACYLGLYCEROL KINASE; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; PHOSPHOHYDROLASE ACTIVITIES; KINETIC-ANALYSIS; MIXED MICELLES	We purified phosphatidic acid phosphatase (EC 3.1.3.4) 2300-fold from porcine thymus membranes. The enzyme was solubilized with beta-octyl glucoside and Triton X-100 and fractionated with ammonium sulfate. The purification was then achieved by chromatography in the presence of Triton X-100 with Sephacryl S-300, hydroxylapatite, heparin-Sepharose, and Affi-Gel Blue. The final enzyme preparation gave a single band of M(r) = 83,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The native enzyme, on the other hand, was eluted at M(r) = 218,000 in gel filtration chromatography with Superose 12 in the presence of Triton X-100. The enzyme was judged to be specific to phosphatidic acid, since excess amounts of dicetylphosphate or lysophosphatidic acid did not inhibit the enzyme activity. In this respect, the enzyme was inhibited by 1,2-diacylglycerol but not by 1- or 2-monoacylglycerol and triacylglycerol. The enzyme required Triton X-100 or deoxycholate for its activity. Although the enzyme appeared to be an integral membrane protein, we could not detect its phospholipid dependencies. The activity was independent of Mg2+, and other cations were strongly inhibitory. The specific enzyme activity was 15 mumol/min/mg of protein when assayed using phosphatidic acid as Triton X-100 mixed micelles. The K(m) for the surface concentration of phosphatidic acid was 0.30 mol %. The enzyme was inhibited by sphingosine and chlorpromazine, and less potently, by propranolol and NaF. The enzyme was insensitive to thio-reactive reagents like N-ethylmaleimide.			KANOH, H (corresponding author), SAPPORO MED COLL,DEPT BIOCHEM,WEST 17,SOUTH 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN.		Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, V1, P1; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; EPAND RM, 1990, BIOCHEM BIOPH RES CO, V171, P487, DOI 10.1016/0006-291X(90)91419-S; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HII CST, 1991, J BIOL CHEM, V266, P20238; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HOSAKA K, 1975, J BIOCHEM-TOKYO, V77, P501, DOI 10.1093/oxfordjournals.jbchem.a130751; IDE H, 1989, ARCH BIOCHEM BIOPHYS, V271, P177, DOI 10.1016/0003-9861(89)90268-3; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; QIAN Z, 1990, J BIOL CHEM, V265, P3607; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALTON PA, 1989, BIOCHEM J, V261, P673, DOI 10.1042/bj2610673; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA K, 1988, BIOCHEM J, V255, P601	42	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25309	25314						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334090				2022-12-27	WOS:A1992KB60300061
J	FLORIO, T; PAN, MG; NEWMAN, B; HERSHBERGER, RE; CIVELLI, O; STORK, PJS				FLORIO, T; PAN, MG; NEWMAN, B; HERSHBERGER, RE; CIVELLI, O; STORK, PJS			DOPAMINERGIC INHIBITION OF DNA-SYNTHESIS IN PITUITARY-TUMOR CELLS IS ASSOCIATED WITH PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROLACTIN SECRETION; ADENYLATE-CYCLASE; GH3 CELLS; RAT; BROMOCRIPTINE; GROWTH; SOMATOSTATIN; RECEPTOR; VANADATE; PROTEINS	Dopaminergic D2 receptor agonists, such as bromocriptine, are potent anti-proliferative agents in the treatment of human pituitary adenomas. We have reproduced the anti-proliferative effect of dopamine in an established pituitary cell line stably transfected with the rat D2 dopamine receptor cDNA. We found that dopaminergic inhibition of DNA synthesis parallels the stimulation of a phosphotyrosine phosphatase activity. Both actions are blocked by pertussis toxin and by the phosphotyrosine phosphatase inhibitor, vanadate. We suggest that the anti-proliferative action of dopamine is mediated, at least in part, by the dopaminergic stimulation of a phosphotyrosine phosphatase.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; Civelli, Olivier/A-8392-2012	Florio, Tullio/0000-0002-2394-996X; Hershberger, Ray/0000-0001-5683-6526				ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BANCROFT FC, 1969, J CELL BIOL, V43, P432, DOI 10.1083/jcb.43.3.432; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FAGIN JA, 1987, ENDOCRINOLOGY, V120, P2037, DOI 10.1210/endo-120-5-2037; FAURE N, 1980, ENDOCRINOLOGY, V107, P1022, DOI 10.1210/endo-107-4-1022; HAUG E, 1976, ENDOCRINOLOGY, V99, P1482, DOI 10.1210/endo-99-6-1482; HERSHBERGER RE, 1991, CIRCULATION, V83, P1343, DOI 10.1161/01.CIR.83.4.1343; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KROWN KA, 1992, ENDOCRINOLOGY, V131, P595, DOI 10.1210/en.131.2.595; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LIU YF, 1992, IN PRESS MOL ENDOCRI; LLOYD HM, 1975, NATURE, V255, P497, DOI 10.1038/255497a0; MALARKEY WB, 1977, NATURE, V266, P640, DOI 10.1038/266640a0; MELMED S, 1986, BRAIN RES, V369, P83, DOI 10.1016/0006-8993(86)90515-9; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; PAN MG, 1992, SCIENCE, V256, P37; PRYSORJONES RA, 1981, J ENDOCRINOL, V88, P463, DOI 10.1677/joe.0.0880463; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSENFELD RG, 1989, ENDOCRINOLOGY, V124, P2867, DOI 10.1210/endo-124-6-2867; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHALLY AV, 1988, CANCER RES, V48, P6977; SICHLEY DR, 1983, MOL PHARMACOL, V23, P585; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THORNER MO, 1975, BRIT MED J, V4, P694, DOI 10.1136/bmj.4.5998.694; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5; WASS JAH, 1982, BRIT MED J, V284, P1908, DOI 10.1136/bmj.284.6333.1908; WINKELMANN W, 1983, ACTA ENDOCRINOL-COP, V102, P37; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	38	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24169	24172						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360008				2022-12-27	WOS:A1992KA26300006
J	FOROOZAN, R; RUEDI, JM; BABIOR, BM				FOROOZAN, R; RUEDI, JM; BABIOR, BM			THE REDUCTION OF CYTOCHROME-B558 AND THE ACTIVITY OF THE RESPIRATORY BURST OXIDASE FROM HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING OXIDASE; FULLY SOLUBLE SYSTEM; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATION; PURIFICATION; GRANULOCYTES; KINETICS	It is known that in respiratory burst oxidase preparations engaged in O2- production, cytochrome b558, a characteristic oxidase component, is partly reduced. This result has been interpreted in terms of a mechanism in which cytochrome b558 functions as an electron-carrying component of the respiratory burst oxidase, its level of reduction reflecting a steady-state partitioning of the cytochrome between reduced and oxidized forms as it ferries electrons from. NADPH to oxygen. Kinetic arguments based on this interpretation have supported the proposal that the cytochrome is reduced at a rate sufficient to account for the rate of O2- production by activated neutrophils. We have confirmed the partial reduction of cytochrome b558 in neutrophil cytoplasts and in oxidase preparations exposed to NADPH, but have found that the reduction of the cytochrome bears no apparent relation to the activity of the oxidase, and can occur when NADPH is added to neutrophil membrane preparations that are unable to manufacture O2-. We therefore conclude that the NADPH-dependent reduction of cytochrome b558 seen in these preparations is unlikely to be a reflection of a catalysis-related steady state and that inferences drawn from such observations regarding the kinetic competence of the cytochrome may need to be reconsidered.			FOROOZAN, R (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024227, R37AI024227, R01AI030742, R21AI130742, R01AI028479] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24227, AI-28479, AI-30742] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1992, ADV ENZYMOL, V65, P49; BABIOR BM, 1981, LEUKOCYTE FUNCTION, P35; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; GABIG TG, 1982, J BIOL CHEM, V257, P4114; GLASS GA, 1986, J BIOL CHEM, V261, P3247; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; PICK E, 1987, J BIOL CHEM, V262, P16476; SEGAL AW, 1988, HEMATOL ONCOL CLIN N, V2, P213, DOI 10.1016/S0889-8588(18)30616-6; SEGER RA, 1983, BLOOD, V61, P423; SMITH RM, 1991, BLOOD, V77, P673; SWITZER R L, 1989, Biofactors, V2, P77; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	28	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24400	24407						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332956				2022-12-27	WOS:A1992KA26300042
J	GUPTA, M; ZHU, CX; TSEDINH, YC				GUPTA, M; ZHU, CX; TSEDINH, YC			AN ENGINEERED MUTANT OF VACCINIA VIRUS-DNA TOPOISOMERASE-I IS SENSITIVE TO THE ANTICANCER DRUG CAMPTOTHECIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVE-SITE TYROSINE; SEQUENCE SPECIFICITY; ANTITUMOR DRUGS; CLEAVAGE; IDENTIFICATION; ABSENCE	Although highly homologous to the other eukaryotic type I DNA topoisomerases, vaccinia virus DNA topoisomerase I is distinct in its resistance to the anticancer drug camptothecin. After comparison of available sequences of sensitive and resistant type I topoisomerases, the aspartic acid at position 221 of vaccinia virus topoisomerase I is mutated to a valine. The resulting mutant protein is partially active. In contrast to the wild type enzyme, the relaxation of supercoiled DNA is inhibited by camptothecin. Its cleavage reaction with DNA is enhanced by camptothecin due to inhibition of religation of DNA. This demonstrates that even though the size of vaccinia virus is only about one-third that of the other camptothecin-sensitive topoisomerases, it has a potential interaction site for camptothecin.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595	New York Medical College					NIGMS NIH HHS [GM42774] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STERNGLANZ R, 1981, P NATL ACAD SCI USA, V78, P2742; SVEJSTRUM JQ, 1991, J MOL BIOL, V230, P669; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	22	15	16	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24177	24180						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332948				2022-12-27	WOS:A1992KA26300008
J	LAHERTY, CD; HU, HM; OPIPARI, AW; WANG, F; DIXIT, VM				LAHERTY, CD; HU, HM; OPIPARI, AW; WANG, F; DIXIT, VM			THE EPSTEIN-BARR-VIRUS LMP1-GENE PRODUCT INDUCES A20-ZINC FINGER PROTEIN EXPRESSION BY ACTIVATING NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR NECROSIS FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; FACTOR-ALPHA; INTERLEUKIN-1 STIMULATE; BNLF-1 ONCOGENE; GENE-EXPRESSION; CELL LINES; INFECTION; TRANSCRIPTION; INDUCTION	A20 is an inducible zinc finger protein that confers resistance to tumor necrosis factor alpha cytotoxicity. A survey of various cell lines revealed that A20 was constitutively expressed in Epstein-Barr virus (EBV)-immortalized B-cells. Transfection experiments demonstrated that the EBV latent membrane protein LMP1 induced A20 expression. LMP1 is a transforming protein of EBV that has dramatic effects on cell growth, activation, and survival. An integral membrane phosphoprotein, LMP1 bears no homology to other recognized membrane signaling molecules, and its signal transduction pathway is not known. However, studies using the A20 promoter demonstrated that LMP1 transcriptionally activates the A20 gene through cis-acting kappaB sites. In addition, electrophoretic mobility shift assays confirmed LMP1-inducible binding of an NF-kappaB-like factor to kappaB sequences within the A20 promoter. This is the first report implicating NF-kappaB in signaling by LMP1, a fundamentally important viral transforming protein.	UNIV MICHIGAN, SCH MED, CELLULAR & MOLEC BIOL PROGRAM, ANN ARBOR, MI 48109 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOLEC GENET, BOSTON, MA 02115 USA	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	LAHERTY, CD (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Hu, Hong-Ming/0000-0002-2206-3470	NHLBI NIH HHS [HL 45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BAICHWAL VR, 1989, ONCOGENE, V4, P67; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; GAFFEY MJ, 1992, PATHOL ANNU, V27, P55; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KIEFF E, 1990, VIROLOGY, P1889; KRANSOW SW, 1991, CYTOKINE, V3, P1; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MURRAY RJ, 1988, J VIROL, V62, P894, DOI 10.1128/JVI.62.3.894-901.1988; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	33	379	388	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24157	24160						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332946				2022-12-27	WOS:A1992KA26300003
J	BUCK, E; ZIMANYI, I; ABRAMSON, JJ; PESSAH, IN				BUCK, E; ZIMANYI, I; ABRAMSON, JJ; PESSAH, IN			RYANODINE STABILIZES MULTIPLE CONFORMATIONAL STATES OF THE SKELETAL-MUSCLE CALCIUM RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; NEGATIVELY CHARGED HOMOTETRAMER; CA-2+ RELEASE; TERMINAL CISTERNAE; RECEPTOR COMPLEX; FEET STRUCTURES; CARDIAC-MUSCLE; BINDING; PURIFICATION; RECONSTITUTION	Nanomolar to micromolar ryanodine alters the gating kinetics of the Ca2+ release channel from skeletal sarcoplasmic reticulum (SR) fused with bilayer lipid membranes (BLM). In the presence of asymmetric CsCl and 100 muM CaCl2 cis, ryanodine (RY) (5-40 nM) activates the channel, increasing the open probability (p(o);maximum 300% of control) without changing unitary conductance (468 picosiemens (pS)). Statistical analyses of gating kinetics reveal that open and closed dwell times exhibit biexponential distributions and are significantly modified by nanomolar RY. Altered channel gating kinetics with low nanomolar RY is fully reversible and correlates well with binding kinetics of nanomolar [H-3]RY with its high affinity site (K(d1) = 0.7 nM) under identical experimental conditions. RY (20-50 nM) induces occasional 1/2 conductance fluctuations which correlate with [H-3]RY binding to a second site having lower affinity (K(d2) = 23 nm). RY (5-50 nM) in the presence of 500 mM CsCl significantly enhances Ca2+-induced Ca2+ release from actively loaded SR vesicles. Ryanodine greater-than-or-equal-to 50 nM stabilizes the channel in a 234-pS subconductance which is not readily reversible. RY (greater-than-or-equal-to 70 muM) produces a unidirectional transition from the 1/2 to a 1/4 conductance fluctuation, whereas RY greater-than-or-equal-to 200 muM causes complete closure of the channel. The RY required for stabilizing 1/4 conductance transitions and channel closure do not quantitatively correlate with [H-3]RY equilibrium binding constants and is attributed to significant reduction in association kinetics with >200 nM [H-3]RY in the presence of 500 mM CsCl. These results demonstrate that RY stabilizes four discrete states of the SR release channel and supports the existence of multiple interacting RY effector sites on the channel protein.	UNIV CALIF DAVIS,DEPT VET PHARMACOL & TOXICOL,DAVIS,CA 95616; PORTLAND STATE UNIV,DEPT PHYS,PORTLAND,OR 97207	University of California System; University of California Davis; Portland State University			Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIEHS NIH HHS [ES05002] Funding Source: Medline; NIGMS NIH HHS [GM 44337] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005002, R29ES005002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1979, NATURE, V280, P807, DOI 10.1038/280807a0; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P887, DOI 10.1093/oxfordjournals.jbchem.a123143; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WATERHOUSE AL, 1984, J CHEM SOC CHEM COMM, P1265, DOI 10.1039/c39840001265; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZIMANYI I, 1992, IN PRESS MOL PHARM	35	139	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23560	23567						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331089				2022-12-27	WOS:A1992JZ23900024
J	LELONGT, B; PIEDAGNEL, R; CHATELET, F; BAUDOUIN, B; BRENCHLEY, PEC; VERROUST, PJ; CASSINGENA, R; VANDEWALLE, A; RONCO, PM				LELONGT, B; PIEDAGNEL, R; CHATELET, F; BAUDOUIN, B; BRENCHLEY, PEC; VERROUST, PJ; CASSINGENA, R; VANDEWALLE, A; RONCO, PM			DRAMATIC CHANGES OF SULFATED PROTEOGLYCANS COMPOSITION IN A TUMORIGENIC SV-40-TRANSFORMED RENAL PROXIMAL-TUBULE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER HYDROLASES; HAMSTER-KIDNEY CELLS; ROUS-SARCOMA VIRUS; HEPARAN-SULFATE; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; GLYCOSAMINOGLYCAN SYNTHESIS; SKIN FIBROBLASTS; SIMIAN VIRUS-40; TRANSFORMATION	To characterize the sulfated proteoglycans (PGs) alterations associated with malignant transformation of epithelial cells in vitro, the localization, charge, size, and composition of cell-associated and secreted sulfated PGs have been compared in rabbit renal proximal-tubule cells in primary culture (Ronco et al., 1990) and in a derived SV-40 transformed cell line (RC.SV1) exhibiting a proximal phenotype and high tumor-inducing ability (Vandewalle et al., 1989). Both normal and transformed cells incorporated PGs into a thick basement membrane layer as shown by ruthenium red staining and immunodetection with a monoclonal antibody raised against the core protein of the bovine basement membrane heparan sulfate-PG (HS-PG). In primary cultures of normal cells, cell-associated PGs were almost identical to those extracted from renal tubule fractions in vivo by their size (K(av) = 0.27 vs. 0.26 on Sepharose CL-6B) and composition characterized by the exclusive presence of heparan sulfate glycosaminoglycan (HS-GAG) chains. In addition, the cells secreted a HS-PG with similar biochemical characteristics (K(av) = 0.29; 100% HS-GAG chains). The SV-40-transformed RC.SV1 cells also synthesized and secreted a unique PG with the same charge and K(av) values and apparently the same core protein (35 kDa) as in nontransformed cells, but three major differences were observed: (i) an increased proportion of PG-associated [S-35]sulfate radioactivity released into the culture medium (36 vs. 21%), (ii) the emergence of free GAG chains unincorporated into PGs and detected only in the cell-associated fraction, and (iii) a dramatic change in the composition of GAG chains in which chondroitin sulfate replaced heparan-sulfate. The latter finding is in keeping with the known chondroitin sulfate increase and heparan-sulfate decrease in epithelial tumors. The alterations of PGs observed in this study may play a role in the acquisition and/or maintenance of the malignant phenotype.	UER XAVIER BICHAT,U246,PARIS,FRANCE; HOP TENON,HISTOL & CYTOL PATHOL LAB,F-75970 PARIS 20,FRANCE; CNRS,UPR 42,F-94800 VILLEJUIF,FRANCE; ST MARYS HOSP,DEPT IMMUNOL,MANCHESTER M13 0JH,LANCS,ENGLAND	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); University of Manchester	LELONGT, B (corresponding author), HOP TENON,INSERM,U64,4 RUE CHINE,F-75970 PARIS 20,FRANCE.		Piedagnel, Remi/C-7427-2017; lelongt, brigitte/N-3746-2017; Ronco, Pierre/AAC-8390-2022	lelongt, brigitte/0000-0002-9308-8798; Piedagnel, Remi/0000-0002-5931-1271; Brenchley, Paul/0000-0003-1290-9919				BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; DAVID G, 1983, J BIOL CHEM, V258, P7338; DROZ D, 1990, AM J PATHOL, V137, P895; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; HOPWOOD JJ, 1978, PEDIATR RES, V12, P52, DOI 10.1203/00006450-197801000-00013; HOPWOOD JJ, 1977, J BIOL CHEM, V252, P4777; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IOZZO RV, 1985, LAB INVEST, V53, P373; IOZZO RV, 1988, CANCER METAST REV, V7, P39, DOI 10.1007/BF00048277; JOHNSTON LS, 1979, BIOCHIM BIOPHYS ACTA, V583, P81, DOI 10.1016/0304-4165(79)90312-X; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; KOJIMA J, 1975, CANCER RES, V35, P542; KRAEMER PM, 1972, J CELL BIOL, V55, P713, DOI 10.1083/jcb.55.3.713; LELONGT B, 1988, P NATL ACAD SCI USA, V85, P9047, DOI 10.1073/pnas.85.23.9047; LEVY P, 1990, CANCER RES, V50, P6716; LIOTTA LA, 1983, LAB INVEST, V49, P636; OHKUBO Y, 1983, CANCER RES, V43, P2712; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RONCO P, 1990, J CELL PHYSIOL, V145, P222, DOI 10.1002/jcp.1041450206; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHANLEY DJ, 1983, J BIOL CHEM, V258, P810; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; SUGAHARA K, 1985, J BIOCHEM-TOKYO, V98, P875, DOI 10.1093/oxfordjournals.jbchem.a135367; TAUC M, 1988, J HISTOCHEM CYTOCHEM, V36, P523, DOI 10.1177/36.5.2895788; UNDERHILL CB, 1975, BIOCHEM BIOPH RES CO, V63, P448, DOI 10.1016/0006-291X(75)90708-1; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2847	33	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23815	23822						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331101				2022-12-27	WOS:A1992JZ23900059
J	OU, WJ; THOMAS, DY; BELL, AW; BERGERON, JJM				OU, WJ; THOMAS, DY; BELL, AW; BERGERON, JJM			CASEIN KINASE-II PHOSPHORYLATION OF SIGNAL SEQUENCE RECEPTOR-ALPHA AND THE ASSOCIATED MEMBRANE CHAPERONE CALNEXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; ENDOPLASMIC-RETICULUM; PROTEIN-KINASE; BINDING; SUBUNIT; CELLS; CALSEQUESTRIN; TRANSLOCATION; CALRETICULIN; PURIFICATION	Signal sequence receptor alpha (SSRalpha) and calnexin are major calcium-binding proteins of the endoplasmic reticulum (ER) which are implicated in chaperone functions. They were identified as major membrane substrates after in vitro phosphorylation of ER membranes with [gamma-P-32]GTP (Wada, I., Rindress, D., Cameron, P. H., Ou, W. J., Doherty, J.-J., II, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). Using purified SSRalpha and associated calnexin as substrates, we have attempted to identify the kinase(s) responsible for their phosphorylation. A salt extract from canine pancreatic ER membranes and cytosol possessed SSRalpha kinase activity which showed identical chromatographic behavior through phosphocellulose, DEAE-Sepharose, and hydroxylapatite purification protocols. Final purification was effected from the cytosol with three polypeptides of 38, 36, and 28 kDa detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. On the basis of primary sequence analysis of the three subunits of the purified kinase and the reconstitution of phosphorylation of SSRalpha and associated calnexin in heat-inactivated ER membranes by the addition of the purified kinase we conclude that the ER-associated kinase responsible for the GTP phosphorylation of SSRalpha and associated calnexin is casein kinase II.	MCGILL UNIV,DEPT ANAT & CELL BIOL,3640 UNIV ST,MONTREAL H3A 2B2,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA; MCGILL UNIV,SHELDON BIOTECHNOL CTR,MONTREAL H3A 2B2,QUEBEC,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	McGill University; McGill University; McGill University; National Research Council Canada			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALA SE, 1991, J BIOL CHEM, V266, P391; CHENG HC, 1986, J BIOL CHEM, V261, P989; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DEPAOLIROACH AA, 1981, J BIOL CHEM, V256, P8955; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FLAMIGNI F, 1990, BIOCHIM BIOPHYS ACTA, V1052, P345, DOI 10.1016/0167-4889(90)90232-3; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; Gros E., 1967, METHOD ENZYMOL, V11, P238; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HELLERHARRISON R, 1989, BIOCHEMISTRY-US, V262, P9053; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Hoekstra M F, 1992, Trends Cell Biol, V2, P153, DOI 10.1016/0962-8924(92)90022-F; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOIX J, 1991, BIOCHEM BIOPH RES CO, V179, P463, DOI 10.1016/0006-291X(91)91393-Q; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; STETLER DA, 1982, BIOCHEMISTRY-US, V21, P3721, DOI 10.1021/bi00258a030; TUAZON P, 1989, ADV 2ND MESSENGER PH, V23, P123; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WITTERS LA, 1983, J BIOL CHEM, V258, P5643	42	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23789	23796						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331100				2022-12-27	WOS:A1992JZ23900056
J	CARDARELLI, PM; YAMAGATA, S; TAGUCHI, I; GORCSAN, F; CHIANG, SL; LOBL, T				CARDARELLI, PM; YAMAGATA, S; TAGUCHI, I; GORCSAN, F; CHIANG, SL; LOBL, T			THE COLLAGEN RECEPTOR-ALPHA-2-BETA-1, FROM MG-63 AND HT1080-CELLS, INTERACTS WITH A CYCLIC RGD PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; CELL-ADHESION; ALPHA-2-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; BINDING-SPECIFICITY; DEPENDENT ADHESION; LAMININ RECEPTOR; DIVALENT-CATIONS; IDENTIFICATION	Several receptors for the extracellular matrix protein collagen have been described which belong to the superfamily of receptors collectively known as integrins. Although several integrins have been shown to interact with extracellular matrix molecules via a common recognition site, arginine-glycine-aspartic Acid (RGD), within the beta1 integrin subfamily, only the fibronectin receptor (alpha5beta1) has been convincingly shown to interact with RGD. In the present study, we tested whether a collagen receptor could interact with RGD. Adhesion of an osteosarcoma cell line, MG-63, to immobilized collagen I was inhibited by the cyclic RGD-containing peptide, C*GRGDSPC* (where C* indicates that Cys participates in disulfide), and not by the linear GRGDSP or the non-RGD-containing cyclic peptide, C*GKGESPC*. Similarly, using collagen-Sepharose affinity chromatography, a heterodimeric protein could be specifically eluted from the column by the cyclic RGD peptide. Immunoprecipitations of the eluted material with monoclonal antibodies showed reactivity with the collagen receptor alpha2beta1 and not alpha3beta1. Our data demonstrate that RGD peptides can interact with the collagen receptor, and the differences seen with the linear and cyclic peptide suggest that the cyclic C*GRGDSPC* has a higher avidity for the receptor than the more flexible linear GRGDSP. In this paper, we provide supportive evidence that one possible mode of collagen interaction with alpha2beta1 is via the RGD recognition sequence.	TANABE SEIYAKU CO LTD,APPL BIOCHEM RES LAB,OSAKA 532,JAPAN	Mitsubishi Tanabe Pharma Corporation	CARDARELLI, PM (corresponding author), TANABE RES LABS,SAN DIEGO,CA 92121, USA.							ADAMSON ED, 1983, COLLAGEN HLTH DISEAS, P218; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BARANY G, 1980, PEPTIDES ANAL SYNTHE, P3; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; Hay E.D., 1981, CELL BIOL EXTRACELLU, P379, DOI [10.1007/978-1-4613-0881-2_13, DOI 10.1007/978-1-4613-0881-2_13]; HRUBY VJ, 1982, LIFE SCI, V31, P189, DOI 10.1016/0024-3205(82)90578-1; HRUBY VJ, 1983, DESIGN SYNTHESIS ORG, P269; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; MILLER EJ, 1983, CONNECTIVE TISSUE BI, P41; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; VONKAMBER B, 1971, HELV CHIM ACTA, V54, P927; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965	38	81	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23159	23164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331077				2022-12-27	WOS:A1992JY16300070
J	FACCHIANO, F; LUINI, A				FACCHIANO, F; LUINI, A			TETANUS TOXIN POTENTLY STIMULATES TISSUE TRANSGLUTAMINASE - A POSSIBLE MECHANISM OF NEUROTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; INHIBITS EXOCYTOSIS; STRUCTURAL FEATURES; INSULIN RELEASE; LIGHT CHAIN; PROTEIN; GTP; SYNAPTOSOMES; HOMOLOGY; ENZYME	The observation that tetanus toxin (TT) contains two sequences that show homology to known transglutaminase (TGase) substrate sites suggested that the toxin and TGase might interact. This prediction was confirmed by two pieces of evidence. First, TT potently stimulated the enzymatic activity of TGase. The effect was maximal at physiological (micromolar) concentrations of the endogenous TGase regulators calcium and GTP. Second, TT and TGase displayed marked variations of their intrinsic fluorescence properties when they were coincubated, indicating the occurrence of binding between them. TT-TGase binding and TGase activation occurred at similar concentrations of TT and are probably causally related. The activation of TGase, an enzyme present in nerve endings that, when activated, can irreversibly cross-link cellular proteins, might mediate the neurotoxic action of TT.			FACCHIANO, F (corresponding author), CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY.		Luini, Alberto/L-1372-2013; Facchiano, Francesco/K-8716-2016	Luini, Alberto/0000-0002-8729-2549; Facchiano, Francesco/0000-0003-4313-0617				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BERGAMINI CM, 1987, BIOCHIM BIOPHYS ACTA, V916, P149, DOI 10.1016/0167-4838(87)90222-6; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; CHEN RF, 1976, BIOCH FLUORESCENCE S, V2, P410; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FACCHIANO A, 1989, COMPUT APPL BIOSCI, V5, P299; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; HAND D, 1985, BIOSCIENCE REP, V5, P1079, DOI 10.1007/BF01119629; ISRAEL M, 1987, J NEUROCHEM, V49, P975, DOI 10.1111/j.1471-4159.1987.tb00989.x; KATZ B, 1969, J PHYSIOL-LONDON, V203, P459, DOI 10.1113/jphysiol.1969.sp008875; LAZAROVICI P, 1987, J BIOL CHEM, V262, P2645; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; METAFORA S, 1987, J PROTEIN CHEM, V6, P353; NURY S, 1989, EUR J BIOCHEM, V180, P161, DOI 10.1111/j.1432-1033.1989.tb14627.x; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P203; RAGONE R, 1989, PROTEIN ENG, V2, P497, DOI 10.1093/protein/2.7.497; SENER A, 1985, ENDOCRINOLOGY, V117, P237, DOI 10.1210/endo-117-1-237; SENER A, 1985, BIOCHEM PHARMACOL, V34, P2495, DOI 10.1016/0006-2952(85)90532-5; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1983, J PHARMACOL EXP THER, V225, P546; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; UDENFRIEND S, 1962, FLUORESCENCE ASSAY B, P108	35	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13267	13271						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352294				2022-12-27	WOS:A1992JB74600030
J	DAUBNER, SC; LAURIANO, C; HAYCOCK, JW; FITZPATRICK, PF				DAUBNER, SC; LAURIANO, C; HAYCOCK, JW; FITZPATRICK, PF			SITE-DIRECTED MUTAGENESIS OF SERINE-40 OF RAT TYROSINE-HYDROXYLASE - EFFECTS OF DOPAMINE AND CAMP-DEPENDENT PHOSPHORYLATION ON ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLIC-AMP; END PRODUCT; ACTIVATION; PH; PHEOCHROMOCYTOMA; CELLS; 3-MONOOXYGENASE; PURIFICATION; MECHANISM	Rat tyrosine hydroxylase expressed with a baculovirus expression system contains covalent phosphate and has kinetic parameters consistent with those expected of phosphorylated enzyme (Fitzpatrick, P. F., Chlumsky, L. J., Daubner, S. C., and O'Malley, K. L. (1990) J. Biol. Chem. 265, 2042-2047). The phosphorylation site was identified as serine 40, by purifying the enzyme from cells grown in the presence of [P-32]phosphate. Replacement of serine 40 with alanine by site-directed mutagenesis prevented phosphorylation but had little effect on the steady-state kinetic parameters at pH 7. Both wild type and S40A tyrosine hydroxylase were expressed in Escherichia coli; the kinetic parameters of the enzymes purified from bacteria were nearly identical to those of the enzymes expressed with the baculovirus system, although the bacterially expressed enzyme contained no covalent phosphate. Treatment of this wild type enzyme with cAMP-dependent protein kinase decreased the K(BH4) value about 2-fold but had no effect on the V(max) value at pH 7. Treatment with a stoichiometric amount of dopamine decreased the V(max) value 15-fold and increased the K(BH4) value 2-3-fold. Phosphorylation of the dopamine-bound enzyme increased the V(max)value 10-fold and decreased the K(BH4)value 2-fold. The kinetic parameters of the dopamine-bound recombinant enzyme were identical to those of enzyme purified from PC12 cells. In contrast, the S40A enzyme was converted to a less active form by treatment with dopamine but was not affected by phosphorylating conditions. These results are consistent with a model in which the major effect of phosphorylation of serine 40 is to relieve tyrosine hydroxylase from the inhibitory effects of catecholamines.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70119	Texas A&M University System; Texas A&M University College Station; Louisiana State University System					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025134, R29NS025134] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25134] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1991, J MOL NEUROSCI, V2, P203; AMES MM, 1978, J BIOL CHEM, V253, P27; ANDERSSON KK, 1989, FEBS LETT, V258, P9, DOI 10.1016/0014-5793(89)81603-5; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ANDERSSON KK, 1989, J INORG BIOCHEM, V36, P323; Arnow LE, 1937, J BIOL CHEM, V118, P531; ATKINSON J, 1987, J NEUROCHEM, V49, P1241, DOI 10.1111/j.1471-4159.1987.tb10016.x; BAILEY SW, 1989, BIOCHEMISTRY-US, V28, P494, DOI 10.1021/bi00428a013; BENSON SA, 1984, BIOTECHNIQUES, V66, P64; BONNEFOY E, 1988, EUR J BIOCHEM, V174, P685, DOI 10.1111/j.1432-1033.1988.tb14152.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; Cleland W W, 1979, Methods Enzymol, V63, P103; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P3658, DOI 10.1021/bi00229a010; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; FUJISAWA H, 1982, OXYGENASES OXYGEN ME, P281; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAGIWARA T, 1991, J BIOL CHEM, V266, P16401; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1982, J BIOL CHEM, V257, P2641; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; HAYCOCK JW, 1982, J BIOL CHEM, V257, P13699; HOSS A, 1990, J VIROL, V64, P4799; JOH TH, 1978, P NATL ACAD SCI USA, V75, P4744, DOI 10.1073/pnas.75.10.4744; KATZ IR, 1976, BIOCHIM BIOPHYS ACTA, V429, P84, DOI 10.1016/0005-2744(76)90032-2; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAR MA, 1982, J NEUROCHEM, V39, P409, DOI 10.1111/j.1471-4159.1982.tb03962.x; LOVENBERG W, 1975, P NATL ACAD SCI USA, V72, P2955, DOI 10.1073/pnas.72.8.2955; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MILLER LP, 1985, NEUROCHEM INT, V7, P689, DOI 10.1016/0197-0186(85)90067-1; OKUNO S, 1985, J BIOL CHEM, V260, P2633; POLLOCK RJ, 1981, J NEUROCHEM, V37, P855, DOI 10.1111/j.1471-4159.1981.tb04471.x; RICHTAND NM, 1985, J BIOL CHEM, V260, P8465; ROSKOSKI R, 1987, J NEUROCHEM, V48, P840, DOI 10.1111/j.1471-4159.1987.tb05593.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STULL JT, 1977, J BIOL CHEM, V252, P851; TACHIKAWA E, 1986, MOL PHARMACOL, V30, P476; VIGNY A, 1982, BIOCHEM BIOPH RES CO, V106, P1, DOI 10.1016/0006-291X(82)92049-6; VIGNY A, 1981, J NEUROCHEM, V36, P483, DOI 10.1111/j.1471-4159.1981.tb01618.x; VRANA KE, 1981, J NEUROCHEM, V36, P92, DOI 10.1111/j.1471-4159.1981.tb02382.x; VULLIET PR, 1980, P NATL ACAD SCI-BIOL, V77, P92, DOI 10.1073/pnas.77.1.92; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WAYMIRE JC, 1972, J CLIN INVEST, V51, P1798, DOI 10.1172/JCI106981; YAMAUCHI T, 1979, J BIOL CHEM, V254, P503; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	55	145	147	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12639	12646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352289				2022-12-27	WOS:A1992HZ48300042
J	FOUNTOULAKIS, M				FOUNTOULAKIS, M			UNFOLDING INTERMEDIATES OF THE EXTRACELLULAR DOMAIN OF THE INTERFERON GAMMA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-BINDING; PROTEIN; THIOREDOXIN; TRANSLOCATION; MECHANISM	Reduction of proteins which require disulfide bonds to be stable in the folded state is accompanied by stepwise unfolding. A soluble human interferon gamma-receptor produced in Escherichia coli was used to investigate the kinetics of formation of unfolding intermediates. The protein includes 8 cysteine residues forming four disulfide bonds. It was reduced by using either dithiothreitol or the thioredoxin reduction system. Reduction with dithiothreitol resulted in formation of mainly four monomeric unfolding species as visualized by sodium dodecyl sulfate-polyacrylamide gels. The enzymatically catalyzed reaction produced only small amounts of two monomeric products and mostly delivered oligomeric and polymeric forms. In both cases, the ligand binding capacity of the receptor was significantly reduced immediately after appearance of the first intermediate. The intermediates involved interchange of disulfide bonds and did not show ligand binding capacity. Some of them were recognized by specific antibodies which detect conformational epitopes on the native interferon gamma-receptor. On the basis of the antibody binding, a preliminary characterization of the formed intermediates was attempted. When the soluble receptor was reduced in the presence of denaturing agents, the reduction products were different from the unfolding intermediates generated in the absence of denaturants.			FOUNTOULAKIS, M (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,BLDG 15-16,CH-4002 BASEL,SWITZERLAND.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KING J, 1989, CHEM ENG NEWS, V67, P32, DOI 10.1021/cen-v067n015.p032; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MOULT J, 1991, BIOCHEMISTRY-US, V30, P3816, DOI 10.1021/bi00230a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001	32	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7095	7100						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372607				2022-12-27	WOS:A1992HM05300098
J	JIN, H; OKSENBERG, D; ASHKENAZI, A; PEROUTKA, SJ; DUNCAN, AMV; ROZMAHEL, R; YANG, Y; MENGOD, G; PALACIOS, JM; ODOWD, BF				JIN, H; OKSENBERG, D; ASHKENAZI, A; PEROUTKA, SJ; DUNCAN, AMV; ROZMAHEL, R; YANG, Y; MENGOD, G; PALACIOS, JM; ODOWD, BF			CHARACTERIZATION OF THE HUMAN 5-HYDROXYTRYPTAMINE-1B RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOCUS; DNA; AMPLIFICATION; POLYMORPHISM; FAMILY; BRAIN; GENE	We report the cloning of a human gene encoding the 5-hydroxytryptamine1B receptor. The receptor has the characteristics of a G-protein-linked receptor and is most homologous to the human 5-HT1D receptor. This human 5-HT receptor gene, most abundantly expressed in striatum, is localized on chromosome 6, at 6q13, and the gene encoding the 5-HT1D receptor is localized on chromosome 1. Radioligand studies indicate that the affinity of [H-3]5-HT is 16 +/- 2 nM. Drug competition studies indicate that the receptor displays high affinity (i.e. < 40 nM) for 5-HT, 5-carboxyamidotryptamine, methiothepin, and metergoline.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL,STANFORD,CA 94305; GENENTECH INC,S SAN FRANCISCO,CA 94080; KINGSTON GEN HOSP,KINGSTON K7L 2V7,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; CTR INVEST DESARROLLO,E-08034 BARCELONA,SPAIN; CSIC,BARCELONA,SPAIN; ADDICT RES FDN,TORONTO M5S 2S1,ONTARIO,CANADA	University of Toronto; Stanford University; Roche Holding; Genentech; Queens University - Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Consejo Superior de Investigaciones Cientificas (CSIC); University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada			Ashkenazi, Avi/ABG-2712-2020; Mengod, Guadalupe/K-5391-2014	Ashkenazi, Avi/0000-0002-6890-4589; Mengod, Guadalupe/0000-0001-7223-7873	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER; NIDA NIH HHS [1 RO1-DA07223-01] Funding Source: Medline; NINDS NIH HHS [NS 23506-04] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAAS F, 1984, HUM GENET, V67, P301, DOI 10.1007/BF00291357; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; DEMARTINVILLE B, 1982, AM J HUM GENET, V34, P216; DUNCAN AMV, 1988, CYTOGENET CELL GENET, V49, P309, DOI 10.1159/000132684; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HARTIG P, 1990, NEUROPSYCHOPHARMACOL, V3, P335; HEURING RE, 1987, J NEUROSCI, V7, P894; HOYER D, 1989, TRENDS PHARMACOL SCI, V10, P130, DOI 10.1016/0165-6147(89)90159-4; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Maniatis T, 1989, DECONTAMINATION DILU; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENGOD G, 1991, MOL BRAIN RES, V10, P185, DOI 10.1016/0169-328X(91)90110-J; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGUYEN T, 1991, GENE, V109, P211, DOI 10.1016/0378-1119(91)90611-E; ODOWD BF, 1991, ENCY HUM BIOL, V1, P81; Osborne N.N., 1982, P7; PALACIOS JM, 1991, SEROTONIN MOL BIOL R, P107; PRICHETT DB, 1988, EMBO J, V7, P4135; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; VOGT M, 1982, BIOL SEROTONERGIC TR, P299; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	28	174	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5735	5738						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348246				2022-12-27	WOS:A1992HK31800004
J	MARSHALL, LB; FIGLER, NL; GONIAS, SL				MARSHALL, LB; FIGLER, NL; GONIAS, SL			IDENTIFICATION OF ALPHA-2-MACROGLOBULIN CONFORMATIONAL INTERMEDIATES BY ELECTRON-MICROSCOPY AND IMAGE-ANALYSIS - COMPARISON OF ALPHA-2-MACROGLOBULIN-THROMBIN AND ALPHA-2-MACROGLOBULIN REACTED WITH CIS-DICHLORODIAMMINEPLATINUM(II) AND TRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED HUMAN ALPHA-2-MACROGLOBULIN; HUMAN-PLASMA; FAST FORMS; PROTEINASE; METHYLAMINE; COMPLEX; MACROMOLECULES; BINDING	Human alpha-2-macroglobulin (alpha-2M) exists in two well defined, highly distinct conformations and in less well described intermediate conformations. In this study, previously characterized reactions were used to partially or completely transform the conformation of alpha-2M. Electron micrographs of each preparation were subjected to image analysis. TernarY alpha-2M-trypsin (2 mol of trypsin/mol of alpha-2M) was analyzed as a control for the fully transformed state. Correspondence analysis (CORAN) and hierarchical ascendant classification (HAC) generated five image clusters from 330 aligned alpha-2M-trypsin complexes. Average images of each cluster resembled the letter "H" with four nearly equivalent lateral arms. Abnormally shaped lateral arms were not demonstrated by HAC, using a variety of factor sets. In a native polyacrylamide gel electrophoresis system, alpha-2M-thrombin migrated in a diffuse band partially behind alpha-2M-trypsin, suggesting conformational heterogeneity. CORAN and HAC of 733 alpha-2M-thrombin complexes identified two neighboring clusters, the average images of which showed an H-like structure in which one arm was replaced by a globular stain-excluding body. The two alpha-2M-thrombin clusters included 125 images (17.1 % of image population). The complete absence of atypical lateral arm structure in the alpha-2M-trypsin clusters suggests that this variation is not the result of orientation or staining artifact. Native alpha-2M was reacted with cis-dichlorodiammineplatinum(II) and then with trypsin to form alpha-2M-Pt-trypsin, a preparation that includes partially transformed alpha-2M structures. CORAN and HAC of 580 alpha-2M-Pt-trypsin complexes generated five clusters, the average images of which showed atypical lateral arm structure equivalent to that demonstrated with alpha-2M-thrombin. The five alpha-2M-Pt-trypsin clusters accounted for 15.2% of the image population. These studies suggest that alpha-2M conformational change intermediates demonstrate common structural characteristics, permitting an elucidation of the steps involved in this complex transformation.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BOX 214,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NHLBI NIH HHS [HL-02272] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BOISSET N, 1988, BIOL CELL, V64, P45, DOI 10.1016/0248-4900(88)90092-5; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DELAIN E, 1988, J BIOL CHEM, V263, P2981; FIGLER NL, 1991, J STRUCT BIOL, V106, P237, DOI 10.1016/1047-8477(91)90073-6; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1989, ELECTRON MICROSC REV, V2, P53, DOI 10.1016/0892-0354(89)90010-5; FRANK J, 1978, ULTRAMICROSCOPY, V3, P282; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; NISHIGAI M, 1985, BIOCHIM BIOPHYS ACTA, V831, P236, DOI 10.1016/0167-4838(85)90040-8; PIZZO SV, 1984, RECEPTORS, V1, P178; POCHON F, 1983, FEBS LETT, V161, P51, DOI 10.1016/0014-5793(83)80728-5; ROCHE PA, 1988, ARCH BIOCHEM BIOPHYS, V267, P285, DOI 10.1016/0003-9861(88)90034-3; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1981, FEBS LETT, V127, P167, DOI 10.1016/0014-5793(81)80197-4; STEINER JP, 1985, BIOCHEMISTRY-US, V24, P2993, DOI 10.1021/bi00333a028; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369	31	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6347	6352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372906				2022-12-27	WOS:A1992HK31800093
J	FORD, VA; STRINGER, C; KENNEL, SJ				FORD, VA; STRINGER, C; KENNEL, SJ			THROMBOMODULIN IS PREFERENTIALLY EXPRESSED IN BALB-C LUNG MICROVESSELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY ASSAY; HUMAN-PLACENTA; PROTEIN-C; NATURAL ANTICOAGULANT; FACTOR-V; THROMBIN; ENDOTHELIUM; ANTIGEN; LOCALIZATION; ACTIVATION	Previously, two rat monoclonal antibodies where developed which bind distinct epitopes on a murine glycoprotein, P112, which is expressed primarily in lung capillary endothelium. In this paper we show that P112 is identical to the endothelial anticoagulant protein, thrombomodulin (TM). Several lines of evidence support this conclusion. First, amino acid analysis of P112 shows a high degree of homology to TM, and both molecules exhibit the same mobility in gel electrophoresis. Second, P112 and TM share reactivity for two different monoclonal antibodies. Third, purified P112, like TM, acts as a cofactor for protein C activation. Finally, two cDNA clones identified with P112 polyclonal antiserum contain sequence identity with the known TM cDNA sequence. Quantitative analysis of TM (P112) expression using a two-site monoclonal antibody assay demonstrates that significantly higher levels of TM are found in lung in comparison with other highly vascularized organs, i.e. the kidney and liver. Quantitative Northern blot data coincides with the two-site assay data and demonstrates that the high level of TM expression in lung is not due to preferential binding of the monoclonal antibodies to lung TM but rather to increased production of TM mRNA in the lung relative to other highly vascularized organs. It is suggested that expression of TM is highest in cells from continuous endothelium.	OAK RIDGE NATL LAB, DIV BIOL SCI, OAK RIDGE, TN 37831 USA; UNIV TENNESSEE, OAK RIDGE GRAD SCH BIOMED SCI, OAK RIDGE, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville					NCI NIH HHS [CA 09104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSINGT.JB, 1974, MICROVASC RES, V7, P229, DOI 10.1016/0026-2862(74)90008-9; Berlilner RW., 1973, HDB PHYSL, P185; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRONE C, 1963, P SOC EXP BIOL MED, V112, P453; CRONE C, 1984, HDB PHYSL CARDIOVASC, P435; DEBAULT LE, 1986, LAB INVEST, V54, P172; DEBAULT LE, 1986, LAB INVEST, V54, P179; DITTMAN WA, 1988, J BIOL CHEM, V263, P15815; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; FULCHER CA, 1984, BLOOD, V63, P486; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HUGHES BJ, 1989, CANCER RES, V49, P6214; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KENNEL SJ, 1988, LAB INVEST, V59, P692; KENNEL SJ, 1987, EXP MOL PATHOL, V47, P110, DOI 10.1016/0014-4800(87)90012-8; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; KENNEL SJ, 1981, CANCER RES, V41, P3465; KENNEL SJ, 1986, CANCER RES, V46, P707; KENNEL SJ, 1990, NUCL MED BIOL, V17, P193, DOI 10.1016/0883-2897(90)90147-S; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, V1; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOLLAR P, 1980, J CLIN INVEST, V66, P1222, DOI 10.1172/JCI109973; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; MARUYAMA K, 1990, J PHARM SCI, V79, P978, DOI 10.1002/jps.2600791107; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORELLE G, 1989, FOCUS, V11, P77; PALADE GE, 1979, ACTA PHYSIOL SCAND, P11; PAWLIK G, 1981, BRAIN RES, V208, P35, DOI 10.1016/0006-8993(81)90619-3; PINO RM, 1989, PROGR HISTOCHEMISTRY; RORVIK MC, 1988, J HISTOCHEM CYTOCHEM, V36, P741, DOI 10.1177/36.7.3290332; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SAMBROOK J, 1989, MOL CLONING LABORATO, P2118; THOMPSON EA, 1986, J CLIN INVEST, V78, P13, DOI 10.1172/JCI112541; WEIBEL ER, 1973, PHYSIOL REV, V53, P419, DOI 10.1152/physrev.1973.53.2.419; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	43	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5446	5450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372003				2022-12-27	WOS:A1992HH74700068
J	LEE, SC; OLINS, PO				LEE, SC; OLINS, PO			EFFECT OF OVERPRODUCTION OF HEAT-SHOCK CHAPERONES GROESL AND DNAK ON HUMAN PROCOLLAGENASE PRODUCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; CLONING VEHICLES; PROTEINS; GENE; MUTATIONS; SEQUENCE; EXPORT; LAMBDA; CONSTRUCTION; REPLICATION	The effect of overexpression of the heat shock chaperone genes dnaK and groESL on heterologous protein production in Escherichia coli was examined, using a set of related human procollagenase proteins. A diverse range of effects on protein solubility, secretion, and accumulation was observed, and these effects were highly dependent on the particular chaperone/procollagenase pairing involved. Both chaperones caused a large increase in the apparent solubility of a fusion of the LamB signal peptide to procollagenase. GroESL had no effect on the accumulation of mature (secreted) procollagenase, while DnaK suppressed secretion considerably. In the absence of a signal peptide, overexpression of either chaperone resulted in a dramatic increase in both solubility and accumulation of procollagenase. The 10-fold increase in accumulation was associated with an increase in in vivo protein half-life.			LEE, SC (corresponding author), MONSANTO CO, MONSANTO CORP RES, 700 CHESTERFIELD VILLAGE PKWY, ST LOUIS, MO 63198 USA.		Lee, Stephen/C-2394-2011					BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; ELLIS RJ, 1990, ANNU REV BIOCHEM, V61, P321; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GREENFIELD L, 1978, P NATL ACAD SCI USA, V75, P4724, DOI 10.1073/pnas.75.10.4724; KLEIN BK, 1991, BIO-TECHNOL, V9, P869, DOI 10.1038/nbt0991-869; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MALKI A, 1991, MOL GEN GENET, V225, P420, DOI 10.1007/BF00261682; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILIPS GJ, 1990, NATURE, V344, P44; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; STADER JA, 1990, METHOD ENZYMOL, V185, P166; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	111	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2849	2852						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346610				2022-12-27	WOS:A1992HD15400004
J	YEM, AW; TOMASSELLI, AG; HEINRIKSON, RL; ZURCHERNEELY, H; RUFF, VA; JOHNSON, RA; DEIBEL, MR				YEM, AW; TOMASSELLI, AG; HEINRIKSON, RL; ZURCHERNEELY, H; RUFF, VA; JOHNSON, RA; DEIBEL, MR			THE HSP56 COMPONENT OF STEROID-RECEPTOR COMPLEXES BINDS TO IMMOBILIZED FK506 AND SHOWS HOMOLOGY TO FKBP-12 AND FKBP-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; 59-KILODALTON PROTEIN; FK506-BINDING PROTEIN	Extracts from human Jurkat cells or from calf thymus contain a 60-kDa protein that is bound to immobilized FK506. As expected, the NH2-terminal sequences of the 60-kDa protein from these two species were found to be nearly the same. We were surprised to discover, however, that the sequence of the human protein was identical to that of Hsp56, a heat shock protein of unknown function that has been shown to be a component of several steroid receptor complexes. Further analysis of the calf thymus protein revealed a peptide with homology to a region near the COOH terminus of both FKBP-12 and FKBP-13. It would appear, therefore, that this 60-kDa protein, or as we refer to it provisionally, ''Hsp56,'' could have the capacity to bind FK506 directly. These observations lead us to speculate that ''Hsp56'' may mediate immunosuppression and inhibition of T-cell proliferation by FK506 and may do so via a cytosolic signal transduction pathway separate, but not necessarily exclusive, from that of FKBP-12 and FKBP-13.	UPJOHN CO,DEPT BIOCHEM,301 HENRIETTA ST,KALAMAZOO,MI 49001; UPJOHN CO,DEPT CELL BIOL,KALAMAZOO,MI 49001; UPJOHN CO,DEPT MED CHEM,KALAMAZOO,MI 49001	Pfizer; Pfizer; Pfizer								FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0	17	182	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2868	2871						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371107				2022-12-27	WOS:A1992HD15400009
J	AZUMA, T; LIU, WG; VANDERLAAN, DJ; BOWCOCK, AM; TAGGART, RT				AZUMA, T; LIU, WG; VANDERLAAN, DJ; BOWCOCK, AM; TAGGART, RT			HUMAN GASTRIC CATHEPSIN-E GENE - MULTIPLE TRANSCRIPTS RESULT FROM ALTERNATIVE POLYADENYLATION OF THE PRIMARY TRANSCRIPTS OF A SINGLE GENE LOCUS AT 1Q31-Q32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW-MOVING PROTEINASE; HUMAN RENIN GENE; MULTILOCUS LINKAGE ANALYSIS; ACID PROTEINASE; ASPARTIC PROTEINASES; IMMUNOCHEMICAL SIMILARITY; PEPSINOGEN-II; RAT SPLEEN; E CTSE; MUCOSA	Genomic clones containing portions of the human cathepsin E (CTSE) gene were isolated from cosmid and lambda-recombinant libraries. The regions corresponding to coding, the 5'- and 3'-untranslated, and the exon-intron boundaries of the CTSE gene were identified by sequence and hybridization analysis. The size and placement of the nine exons found in the 17.5-kilobase CTSE gene was highly conserved relative to other aspartic proteinases and provided additional evidence that these proteinases are derived from a common ancestral gene. Segregation and linkage analysis of two informative restriction fragment length polymorphisms (MspI and DraI) indicated that there is a single human CTSE locus located at chromosome 1q31-q32 which is closely linked to the renin gene. Three CTSE transcripts (3.6, 2.6, and 2.1 kilobases) were identified in gastric fundic and antral mucosa poly(A+) RNA, and these appeared identical in size and relative abundance to those contained in poly(A+) RNA from cultured gastric adenocarcinoma cell lines containing CTSE. Sequence analysis of cDNA clones and comparison with the 3'-flanking untranslated region in genomic clones provided evidence that alternative polyadenylation of the primary transcript resulted in the 2.6- and 2.1-kilobase transcripts which constituted greater than 95% of CTSE transcripts found in the stomach.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,3216 SCOTT HALL,540 E CANFIELD,DETROIT,MI 48201; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KYOTO 602,JAPAN; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235	Wayne State University; Kyoto Prefectural University of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Barranco S C, 1983, Invest New Drugs, V1, P117; BARRANCO SC, 1983, CANCER RES, V43, P1703; BLUNDELL T, 1983, NATURE, V304, P273, DOI 10.1038/304273a0; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; COUVREUR JM, 1990, CYTOGENET CELL GENET, V53, P137, DOI 10.1159/000132914; DOOLITTLE RF, 1986, URFS ORFS, P3; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HARDMAN JA, 1984, DNA-J MOLEC CELL BIO, V3, P457, DOI 10.1089/dna.1.1984.3.457; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; JOHNSON MP, 1989, NUCLEIC ACIDS RES, V17, P10147, DOI 10.1093/nar/17.23.10147; JUPP RA, 1988, BIOCHEM J, V254, P895, DOI 10.1042/bj2540895; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MIYAZAKI H, 1984, P NATL ACAD SCI-BIOL, V81, P5999, DOI 10.1073/pnas.81.19.5999; MUTO N, 1987, J BIOCHEM-TOKYO, V101, P1069, DOI 10.1093/oxfordjournals.jbchem.a121971; MUTO N, 1983, BIOCHIM BIOPHYS ACTA, V745, P61, DOI 10.1016/0167-4838(83)90170-X; MUTO N, 1988, J BIOCHEM-TOKYO, V103, P629, DOI 10.1093/oxfordjournals.jbchem.a122318; MUTO N, 1985, BIOCHIM BIOPHYS ACTA, V843, P114, DOI 10.1016/0304-4165(85)90057-1; OTT J, 1985, ANAL HUMAN GENETIC L; PALS G, 1989, GENOMICS, V4, P137, DOI 10.1016/0888-7543(89)90292-9; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PUIZDAR V, 1985, FEBS LETT, V185, P236, DOI 10.1016/0014-5793(85)80913-3; RALL LB, 1987, METHOD ENZYMOL, V147, P239; SAMLOFF IM, 1987, GASTROENTEROLOGY, V93, P77, DOI 10.1016/0016-5085(87)90317-9; SAMLOFF IM, 1969, GASTROENTEROLOGY, V57, P659; SAMLOFF IM, 1982, GASTROENTEROLOGY, V82, P26; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIRAISHI T, 1988, DIGEST DIS SCI, V33, P1466, DOI 10.1007/BF01537004; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TARASOVA NI, 1986, BIOCHIM BIOPHYS ACTA, V880, P96, DOI 10.1016/0304-4165(86)90124-8; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI, P139; YAMAMOTO K, 1978, EUR J BIOCHEM, V92, P499, DOI 10.1111/j.1432-1033.1978.tb12772.x; YAMAMOTO K, 1987, BIOCHEM BIOPH RES CO, V148, P267, DOI 10.1016/0006-291X(87)91105-3; YONEZAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P1251, DOI 10.1016/0006-291X(87)91445-8; YONEZAWA S, 1987, ARCH BIOCHEM BIOPHYS, V256, P499, DOI 10.1016/0003-9861(87)90607-2	43	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1609	1614						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370478				2022-12-27	WOS:A1992HA48500035
J	MAENZ, DD; CHENU, C; BRETON, S; BERTELOOT, A				MAENZ, DD; CHENU, C; BRETON, S; BERTELOOT, A			PH-DEPENDENT HETEROGENEITY OF ACIDIC AMINO-ACID-TRANSPORT IN RABBIT JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-GLUTAMATE; SYSTEM; COTRANSPORT; SERVICE; K+	Initial rates of Na+-dependent L-glutamic and D-aspartic acid uptake were determined at various substrate concentrations using a fast sampling, rapid filtration apparatus, and the resulting data were analyzed by nonlinear computer fitting to various transport models. At pH 6.0, L-glutamic acid transport was best accounted for by the presence of both high (K(m) = 61-mu-M) and low (K(m) = 7.0 mM) affinity pathways, whereaS D-aspartic acid transport was restricted to a single high affinity route (K(m) = 80-mu-M). Excess D-aspartic acid and L-phenylalanine served to isolate L-glutamic acid flux through the remaining low and high affinity systems, respectively. Inhibition studies of other amino acids and analogs allowed us to identify the high affinity pathway as the X(AG)-. system and the low affinity one as the intestinal NBB system. The pH dependences of the high and low affinity pathways of L-glutamic acid transport also allowed us to establish some relationship between the NBB and the more classical ASC system. Finally, these studies also revealed a heterotropic activation of the intestinal X(AG)- transport system by all neutral amino acids but glycine through an apparent activation of V(max).	UNIV MONTREAL,FAC MED,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,CP 6128,SUCCURSALE A,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V857, P180, DOI 10.1016/0005-2736(86)90346-9; BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V861, P447, DOI 10.1016/0005-2736(86)90453-0; BERTELOOT A, 1984, BIOCHIM BIOPHYS ACTA, V775, P129, DOI 10.1016/0005-2736(84)90163-9; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BERTELOOT A, 1990, COMP PHYSL, V7, P130; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CORCELLI A, 1982, BIOCHIM BIOPHYS ACTA, V689, P97, DOI 10.1016/0005-2736(82)90193-6; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GIBSON QH, 1951, BIOCHEM J, V48, P426, DOI 10.1042/bj0480426; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KOEPSELL H, 1984, J BIOL CHEM, V259, P6548; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LERNER J, 1977, COMP BIOCHEM PHYS A, V57, P11, DOI 10.1016/0300-9629(77)90340-1; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; SCOTT DM, 1978, BIOCHIM BIOPHYS ACTA, V508, P379, DOI 10.1016/0005-2736(78)90340-1; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; WEISS SD, 1978, J MEMBRANE BIOL, V43, P91, DOI 10.1007/BF01869043; WINGROVE TG, 1987, AM J PHYSIOL, V252, pC105, DOI 10.1152/ajpcell.1987.252.1.C105	28	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1510	1516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346136				2022-12-27	WOS:A1992HA48500021
J	IMBODEN, MA; MATTHEWS, JL; LOFQUIST, AK; PAULE, MR				IMBODEN, MA; MATTHEWS, JL; LOFQUIST, AK; PAULE, MR			AN EXONUCLEASE REQUIRING AN INTACT HELICAL STEM FOR SPECIFICITY PRODUCES THE 3' END OF ACANTHAMOEBA-CASTELLANII 5-S RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; TRANSCRIPTION TERMINATION; NUCLEOTIDE-SEQUENCES; RIBOSOMAL-RNA; 5S; INVITRO; MUTANT; GENE; MATURATION; PRECURSOR	A nuclear extract from Acanthamoeba castellanii which contains all of the components necessary for specific transcription of a 5 S RNA gene was separated into fractions required for specific transcription initiation and an additional fraction needed in the reconstituted system to produce the 3' end characteristic of mature 5 S RNA. The latter fraction contained a novel processing activity characterized by an exonuclease specific for highly structured RNAs, including 5 S RNA. An intact helical stem formed between the 5' and 3' ends of the 5 S RNA precursor determines the 3' nucleotide. In addition, the presence of ATP is required for specific processing. However, the possibility has not been ruled out that ATP inhibits a nonspecific ribonuclease in the extract since processing proceeds into the helical stem in its absence.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; COLORADO STATE UNIV,CELL & MOLEC BIOL PROGRAM,FT COLLINS,CO 80523	Colorado State University; Colorado State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026059] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26059] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; Detke S., 1976, Molecular mechanisms in the control of gene expression. ICN-UCLA symposia on molecular and cellular biology, Volume 5., P261; DETKE S, 1975, BIOCHIM BIOPHYS ACTA, V383, P67, DOI 10.1016/0005-2787(75)90246-4; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; IMBODEN M, 1986, J MOL BIOL, V188, P393, DOI 10.1016/0022-2836(86)90163-4; JAMES P, 1990, GENETICS, V125, P293; JAMES P, 1991, J BIOL CHEM, V266, P5616; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKAY RM, 1981, NUCLEIC ACIDS RES, V9, P3321, DOI 10.1093/nar/9.14.3321; Maniatis T., 1982, MOL CLONING; PACE NR, 1980, TRANSFER RNA BIOL AS, P155; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER PR, 1991, J BIOL CHEM, V266, P7509; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; SPINDLER SR, 1978, J BIOL CHEM, V253, P6242; TELFORD JL, 1979, P NATL ACAD SCI USA, V76, P2590, DOI 10.1073/pnas.76.6.2590; WALDSCHMIDT R, 1990, EUR J BIOCHEM, V194, P167, DOI 10.1111/j.1432-1033.1990.tb19441.x; WATSON JB, 1984, NUCLEIC ACIDS RES, V12, P5369, DOI 10.1093/nar/12.13.5369; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WIGGS MY, 1983, 5 S RNA SEQUENCE ACA; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZWICK MG, 1991, GENE, V101, P153, DOI 10.1016/0378-1119(91)90239-8; ZWICK MG, 1991, NUCLEIC ACIDS RES, V19, P1681, DOI 10.1093/nar/19.7.1681; ZWICK MG, 1989, THESIS COLORADO STAT	32	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24601	24610						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332962				2022-12-27	WOS:A1992KA26300069
J	ZHANG, BX; MUALLEM, S				ZHANG, BX; MUALLEM, S			FEEDBACK INHIBITION OF CA2+ RELEASE BY CA2+ IS THE UNDERLYING MECHANISM OF AGONIST-EVOKED INTRACELLULAR CA2+ OSCILLATIONS IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; INOSITOL TRISPHOSPHATE; CA-2+ RELEASE; AR42J CELLS; GENERATION; 1,4,5-TRISPHOSPHATE; MOBILIZATION; ACTIVATION; HYDROLYSIS; STORES	Oscillations of free intracellular Ca2+ concentration ([Ca2+]i) are known to occur in many cell types during physiological cell signaling. To identify the basis for the oscillations, we measured both [Ca2+]i and extracellular Ca2+ concentration ([Ca2+]o) to follow the fate of Ca2+ during stimulation of [Ca2+]i oscillations in pancreatic acinar cells. [Ca2+]i oscillations were initiated by either t-butyloxycarbonyl-Tyr(SO3)-Nle-Gly-Tyr-Nle-Asp-2-phenylethyl ester (CCK-J), which mobilized Ca2+ from the inositol 1,4,5-trisphosphate (IP3)-insensitive pool, or low concentration of cholecystokinin octapeptide (CCK-OP), which mobilized Ca2+ from the IP3-sensitive internal pool. Little Ca2+ efflux occurred during the oscillations triggered by CCK-J or CCK-OP in spite of a large average increase in [Ca2+]i. When internal store Ca2+ pumps were inhibited with thapsigargin (Tg) during [Ca2+]i oscillations, a rapid Ca2+ efflux occurred similar to that measured in intensely stimulated, nonoscillatory cells. Tg also stimulated Ca-45 efflux from internal pools of cells stimulated with CCK-J or a low concentration of CCK-OP. Hence, a large fraction of the Ca2+ released during each spike is reincorporated by the internal store Ca2+ pumps. Surprisingly, when the increase in [Ca2+]i during stimulation of oscillations was prevented by loading the cells with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid, a persistent activation of Ca2+ release and Ca2+ efflux occurred. This was reflected as a persistent increase in [Ca2+]o in cells suspended at low [Ca2+]o or persistent efflux of Ca-45 from internal stores of cells maintained at high [Ca2+]o. Since agonist-stimulated Ca2+ release evidently remains activated when [Ca2+]i is highly buffered, the primary mechanism determining Ca2+ oscillations must include an inhibition of Ca2+ release by [Ca2+]i. Loading the cells with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid had no apparent effect on the levels or kinetics of IP3 formation in agonist-stimulated cells. This suggests that [Ca2+]i regulated the oscillation by inhibition of Ca2+ release independent of its possible effects on cellular levels of IP3.			ZHANG, BX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHUCK SH, 1986, J BIOL CHEM, V261, P13883; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; FOHR KJ, 1991, J NEUROCHEM, V56, P665, DOI 10.1111/j.1471-4159.1991.tb08201.x; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LYTON J, 1991, J BIOL CHEM, V266, P17067; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MAYER T, 1988, P NATL ACAD SCI USA, V85, P5051; MAYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; Muallem S, 1990, Semin Cell Biol, V1, P305; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; OTTO FW, 1984, AM J PHYSIOL, V246, pR847; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROSS J, 1987, ANNU REV BIOPHYS BIO, V16, P401; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; STUENKEL EL, 1989, BIOCHEM BIOPH RES CO, V158, P863, DOI 10.1016/0006-291X(89)92802-7; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHAO H, 1990, J BIOL CHEM, V265, P20856	44	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24387	24393						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332954				2022-12-27	WOS:A1992KA26300040
J	PRONK, GJ; MEDEMA, RH; BURGERING, BMT; CLARK, R; MCCORMICK, F; BOS, JL				PRONK, GJ; MEDEMA, RH; BURGERING, BMT; CLARK, R; MCCORMICK, F; BOS, JL			INTERACTION BETWEEN THE P21(RAS) GTPASE ACTIVATING PROTEIN AND THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GAP-ASSOCIATED PROTEINS; TYROSINE PHOSPHORYLATION; PHENYLARSINE OXIDE; P21RAS ACTIVATION; 3T3-L1 ADIPOCYTES; SH2 DOMAINS; RAS P21; BINDING; CELLS	We investigated the involvement of the p21ras-GTPase activating protein (GAP) in insulin-induced signal transduction. In cells overexpressing the insulin receptor, we did not observe association between GAP and the insulin receptor after insulin treatment nor the phosphorylation of GAP on tyrosine residues. However, after insulin treatment in the presence of the phosphotyrosine phosphatase inhibitor phenylarsine oxide (PAO), 5-10% of GAP was found to be associated with the insulin receptor, and, in addition, a fraction of total GAP was phosphorylated on tyrosine. Using in vitro binding we showed that the N-terminal part of GAP containing the src-homology domains 2 and 3 (SH2-SH3-SH2 region) is involved in binding to the autophosphorylated insulin receptor beta-chain. In vitro binding between GAP and the autophosphorylated insulin receptor occurred independently of PAO pretreatment. These results suggest that GAP can transiently interact with the insulin receptor after insulin treatment, and this interaction is arrested after PAO pretreatment.	UNIV UTRECHT, PHYSIOL CHEM LAB, VONDELLAAN 24A, 3521 GG UTRECHT, NETHERLANDS; ONYX PHARMACEUT, DEPT MOLEC BIOL, RICHMOND, CA 94806 USA	Utrecht University				Medema, Rene/0000-0002-6754-0381				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FROST SC, 1987, J BIOL CHEM, V262, P9872; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LIAO K, 1991, J BIOL CHEM, V266, P6544; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PRONK GJ, 1992, ONCOGENE, V7, P389; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	40	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24058	24063						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331107				2022-12-27	WOS:A1992JZ23900094
J	TAKAGAKI, Y; MANLEY, JL				TAKAGAKI, Y; MANLEY, JL			A HUMAN POLYADENYLATION FACTOR IS A G-PROTEIN BETA-SUBUNIT HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRE-MESSENGER-RNA; POLYVINYLIDENE DIFLUORIDE MEMBRANES; NUCLEAR RIBONUCLEOPROTEIN PARTICLE; POLY(A) POLYMERASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; AAUAAA SEQUENCE; SHOWS HOMOLOGY; GAMMA-SUBUNIT; GENE-PRODUCT	Cleavage stimulation factor (CstF) is one of the multiple factors required for polyadenylation of mammalian pre-mRNAs in vitro. We have shown previously that this factor is composed of three distinct subunits of 77, 64, and 50 kDa, and that the 64-kDa subunit can be UV-cross-linked to RNA in a polyadenylation signal (AAUAAA)-dependent manner. By molecular cloning, the 64-kDa subunit was shown to contain a ribonucleoprotein-type RNA binding domain and a novel repeat structure. To study the functions of the other subunits, we have now isolated cDNAs encoding the 50-kDa subunit of human CstF. This subunit shares extensive homology with mammalian G protein beta-subunits and has a characteristic repeat structure (transducin repeat), in which an approximately 44-amino acid-long sequence is repeated seven times. To our knowledge, the 50-kDa subunit is the first example of a functional beta-subunit-like protein in vertebrates. Possible roles of the transducin repeat, both in CstF function specifically and in other beta-subunit homologues more generally, are discussed.			TAKAGAKI, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459	NIGMS NIH HHS [GM-28983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUJITA A, 1990, GENE, V89, P93, DOI 10.1016/0378-1119(90)90210-I; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEARSEY S, 1991, GENE, V98, P147, DOI 10.1016/0378-1119(91)90118-U; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RUBY SW, 1991, TRENDS GENET, V7, P79; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317	52	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23471	23474						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1358884				2022-12-27	WOS:A1992JZ23900010
J	CANTOR, AB; KORNFELD, S				CANTOR, AB; KORNFELD, S			PHOSPHORYLATION OF ASN-LINKED OLIGOSACCHARIDES LOCATED AT NOVEL SITES ON THE LYSOSOMAL-ENZYME CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; PHOSPHOMANNOSYL RECEPTORS; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; LIGAND INTERACTIONS; PROTEINASE-A; BINDING; CELLS; PURIFICATION; RECOGNITION	We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues. The glycosylation sites were introduced into the cathepsin D cDNA by site-directed mutagenesis and were selected to be widely distributed over the surface of the molecule. When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus <0.4% for the secretory protein glycopepsinogen). However, oligosaccharides located closer to the essential components of the phosphotransferase recognition domain (lysine 203 and amino acids 265-292) were phosphorylated better than oligosaccharides located further away. Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower. These results demonstrate that there is considerable flexibility in the placement of glycosylation sites on cathepsin D in terms of the ability of the oligosaccharides to serve as substrates for phosphotransferase, although oligosaccharides located closer to the phosphotransferase recognition determinant are preferentially phosphorylated.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOEL E, 1986, Proteins Structure Function and Genetics, V1, P363, DOI 10.1002/prot.340010409; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, IN PRESS ANAL BIOCH; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FISCHER HD, 1982, J BIOL CHEM, V257, P9938; FRITZ LC, 1986, P NATL ACAD SCI USA, V83, P4114, DOI 10.1073/pnas.83.12.4114; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; GRAY GL, 1986, GENE, V48, P41, DOI 10.1016/0378-1119(86)90350-1; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Maniatis T., 1982, MOL CLONING; MECHLER B, 1982, J BIOL CHEM, V257, P1203; MEUSSDOERFFER F, 1980, J BIOL CHEM, V255, P2087; PINET F, 1985, P NATL ACAD SCI USA, V82, P8503, DOI 10.1073/pnas.82.24.8503; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; WEITZ G, 1992, J BIOL CHEM, V267, P10039; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23357	23363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331083				2022-12-27	WOS:A1992JY16300099
J	CARTER, RS; BHAT, NK; BASU, A; AVADHANI, NG				CARTER, RS; BHAT, NK; BASU, A; AVADHANI, NG			THE BASAL PROMOTER ELEMENTS OF MURINE CYTOCHROME-C-OXIDASE SUBUNIT-IV GENE CONSIST OF TANDEMLY DUPLICATED ETS MOTIFS THAT BIND TO GABP-RELATED TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATION SITE; RNA POLYMERASE-II; STRUCTURAL ORGANIZATION; DNA-BINDING; NUCLEOTIDE-SEQUENCE; MITOCHONDRIAL-DNA; NUCLEAR FACTOR; EXPRESSION; PROTEIN; YEAST	DNA sequences required for expression of the mouse cytochrome c oxidase subunit IV (COXIV) promoter were identified by transient expression of recombinant COXIV-chloramphenicol acetyltransferase constructs in COS and NIH-3T3 cells. Activity of the COXIV promoter is shown to depend upon upstream Sp1 binding sequences and two tandemly repeated 21-base pair sequence elements each mapping to sites of mRNA initiation. Each initiation region repeat contains a binding site for an ets-related transcription factor which demonstrates specificity for the characteristic GGAA ets sequence motif and reactivity with an ets domain-directed monoclonal pan ets antibody. The two 21-base pair repeats are sufficient for transcriptional activity suggesting that the ets-related factor may be involved in both transcriptional activation and start site positioning. The ets-related protein found in COS nuclear extracts is shown to be identical or closely related to the GA-binding protein (GABP) by comparison of electrophoretic mobilities and immunological reactivities of DNA-protein complexes formed with purified recombinant expressed GABP alpha and beta subunits. Sp1 and the GABP-related factors also bind to another mouse cytochrome oxidase subunit gene COXVb. The similar promoter features of these two genes suggests a possible means of coordinate transcriptional regulation among such respiratory proteins.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, BIOCHEM LABS, PHILADELPHIA, PA 19104 USA; NCI, PROGRAM RESOURCES INC,DYNCORP, FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB, FREDERICK, MD 21702 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NIGMS NIH HHS [GM-29037] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029037] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BASU A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P98, DOI 10.1016/0167-4781(90)90128-O; BASU A, 1991, J BIOL CHEM, V266, P15450; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BHAT KS, 1989, BIOCHEMISTRY-US, V28, P763, DOI 10.1021/bi00428a052; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHAT NK, 1992, HYBRIDOMA, V11, P277, DOI 10.1089/hyb.1992.11.277; CAO X, 1988, ANN NY ACAD SCI, V550, P337, DOI 10.1111/j.1749-6632.1988.tb35348.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LOMAX MI, 1984, P NATL ACAD SCI-BIOL, V81, P6295, DOI 10.1073/pnas.81.20.6295; MARAGOS C, 1989, J BIOL CHEM, V264, P12294; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMURA H, 1990, J BIOL CHEM, V265, P6525; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YAMADA M, 1990, J BIOL CHEM, V265, P7687; ZEVIANI M, 1988, GENE, V65, P1, DOI 10.1016/0378-1119(88)90411-8	51	78	78	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23418	23426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331086				2022-12-27	WOS:A1992JY16300107
J	KOYAMA, N; MORISAKI, N; SAITO, Y; YOSHIDA, S				KOYAMA, N; MORISAKI, N; SAITO, Y; YOSHIDA, S			REGULATORY EFFECTS OF PLATELET-DERIVED GROWTH FACTOR-AA HOMODIMER ON MIGRATION OF VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; CHAIN GENE-EXPRESSION; FACTOR MESSENGER-RNA; B-CHAIN; ENDOTHELIAL-CELLS; FACTOR-BETA; PDGF-AA; ARTERIAL INJURY; DNA-SYNTHESIS; PROTEIN	Migration of medial smooth muscle cells (SMC) into the intima is important in intimal thickening of atherosclerotic tissues. To study the functions of three isoforms of platelet-derived growth factor (PDGF) in atherosclerosis, we investigated their effects on SMC migration by Boyden's chamber method. Although PDGF-AB and PDGF-BB enhanced SMC migration dose-dependently, PDGF-AA did not enhance SMC migration, but instead inhibited SMC migration induced by PDGF-AB or PDGF-BB. PDGF-AA also inhibited SMC migration induced by two other migration factors, fibronectin and SMC-derived migration factor. PDGF-AA is considered to be coexpressed with transforming growth factor (TGF)-beta1 in atherosclerotic tissues. Treatment of SMC with TGF-beta1 reduced an autocrine migration activity from SMC. Studies using anti-PDGF antibody revealed that an increased secretion of PDGF-AA by TGF-beta1 caused the reduced migration activity. cAMP increase by forskolin and dibutyryl cAMP suppressed SMC migration, whereas cAMP decrease by pertussis toxin had no effects on PDGF-AA-suppressed migration. In contrast, staurosporine, an inhibitor of protein kinase C, enhanced SMC migration and neutralized the inhibitory effect of PDGF-AA. These findings suggest that PDGF-AA regulates SMC migration in intimal thickening in atheroma formation and that protein kinase C may play an important role in the inhibitory mechanism of PDGF-AA.			KOYAMA, N (corresponding author), CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,1-8-1 INOHANA,CHUO KU,CHIBA 260,JAPAN.			Koyama, Noriyuki/0000-0002-7509-6583				AU YPT, 1992, J BIOL CHEM, V267, P3438; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FISCHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162; GAY CG, 1990, J BIOL CHEM, V265, P3284; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HELDIN CH, 1990, J CELL SCI, V96, P193; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; JONZON B, 1985, J CELL PHYSIOL, V124, P451, DOI 10.1002/jcp.1041240314; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KOYAMA N, 1991, ATHEROSCLEROSIS, V86, P219, DOI 10.1016/0021-9150(91)90218-R; KOYAMA N, 1990, BIOCHEM BIOPH RES CO, V169, P725, DOI 10.1016/0006-291X(90)90391-Y; LIAU G, 1991, J BIOL CHEM, V266, P18819; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1990, J BIOL CHEM, V265, P1082; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MATUI T, 1989, P NATL ACAD SCI USA, V86, P8314; MORISAKI N, 1991, ATHEROSCLEROSIS, V88, P227, DOI 10.1016/0021-9150(91)90085-H; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOMOTO A, 1988, ATHEROSCLEROSIS, V72, P213, DOI 10.1016/0021-9150(88)90083-4; OOYAMA T, 1987, ARTERIOSCLEROSIS, V7, P593, DOI 10.1161/01.ATV.7.6.593; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAO GN, 1991, J BIOL CHEM, V266, P8604; RESINK TJ, 1990, CELL REGUL, V1, P821, DOI 10.1091/mbc.1.11.821; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1990, FEBS LETT, V275, P95, DOI 10.1016/0014-5793(90)81447-V; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P1009, DOI 10.1093/oxfordjournals.jbchem.a122956; SCHEID CR, 1984, AM J PHYSIOL, V246, pC431, DOI 10.1152/ajpcell.1984.246.5.C431; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; SUSUKI H, 1989, AM J PATHOL, V134, P35; TAGAMI M, 1986, CELL TISSUE RES, V245, P261; WELSH M, 1990, P NATL ACAD SCI USA, V87, P5807, DOI 10.1073/pnas.87.15.5807; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WOODS A, 1992, J CELL SCI, V101, P277	58	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22806	22812						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331068				2022-12-27	WOS:A1992JY16300019
J	MCKENZIE, FR; SEUWEN, K; POUYSSEGUR, J				MCKENZIE, FR; SEUWEN, K; POUYSSEGUR, J			STIMULATION OF PHOSPHATIDYLCHOLINE BREAKDOWN BY THROMBIN AND CARBACHOL BUT NOT BY TYROSINE KINASE RECEPTOR LIGANDS IN CELLS TRANSFECTED WITH M1 MUSCARINIC RECEPTORS - RAPID DESENSITIZATION OF PHOSPHOCHOLINE-SPECIFIC (PC) PHOSPHOLIPASE-D BUT SUSTAINED ACTIVITY OF PC-PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ALPHA-THROMBIN; HAMSTER FIBROBLASTS; HL-60 GRANULOCYTES; DOWN-REGULATION; 2ND MESSENGER; DNA-SYNTHESIS; GROWTH-FACTOR	In order to evaluate the possible contribution of phospholipase D (PLD) stimulation to the mitogenic response, a screening of a variety of different compounds, some of which are known to be potent mitogens, was performed using the well characterized Chinese hamster lung fibroblast (CCL39) cell line. In wild type CCL39 cells, or derivatives expressing high levels of either the human M1 muscarinic receptor (Hm1) or the human epidermal growth factor (EGF) receptor (39M1-81 and 39ER22 clones, respectively), thrombin, a potent mitogen for all three cell types, elicited the rapid activation of PLD (t1/2 activation, 30 s). Carbachol-mediated activation of the Hm1 receptor in the 39M1-81 clone, which is not a mitogenic signal, produced a similarly rapid although greater activation of PLD. Addition of EGF to the 39ER22 clone was able to provoke both a mitogenic response and stimulate PLD, albeit a comparatively small effect. In each case, the stimulation of PLD correlated closely with the ability to stimulate inositol phospholipid breakdown and was entirely dependent on the activation of protein kinase C. Moreover, the ability of both thrombin and carbachol to stimulate PLD was found to be rapidly desensitized, with a similar time course of desensitization (t1/2 desensitization, 90 s). It has recently been reported that an increase in phospholipase C (PLC)-mediated phosphocholine (PC) hydrolysis by either addition of agonist or by extracellular addition of PC-specific PLC enzyme constitutes a mitogenic signal. In this regard, in addition to stimulation of PLD, thrombin and carbachol were both able to stimulate the activity of a phosphocholine-specific phospholipase C (PC-PLC), which did not appear to desensitize within the time course employed. By contrast, EGF was unable to elicit the stimulation of PC-PLC. Ligands such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF), which bind to and activate receptors with intrinsic tyrosine kinase activity, are potent mitogens for CCL39 cells but were unable to stimulate either PLD or PC-PLC activity. Furthermore, exogenous addition of purified PC-PLC enzyme, although able to induce a strong and lasting hydrolysis of PC, was unable to produce a mitogenic signal on its own. On the basis of these results, we conclude that the activation of both PLD and PC-PLC is neither sufficient nor required to produce a mitogenic response.			MCKENZIE, FR (corresponding author), CTR BIOCHIM,UMR 134,PARC VALROSE,F-06108 NICE,FRANCE.							AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, CELL SIGNAL, V3, P273, DOI 10.1016/0898-6568(91)90055-Y; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CF, 1990, J BIOL CHEM, V265, P17468; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KAHAN K, 1992, J BIOL CHEM, V267, P13369; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; L'allemain G, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000255; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAI JK, 1988, J BIOL CHEM, V263, P12474; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PARIS S, 1988, J BIOL CHEM, V263, P11250; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	59	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22759	22769						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331066				2022-12-27	WOS:A1992JY16300013
J	MUNDSCHAU, LJ; FALLER, DV				MUNDSCHAU, LJ; FALLER, DV			ONCOGENIC RAS INDUCES AN INHIBITOR OF DOUBLE-STRANDED RNA-DEPENDENT EUKARYOTIC INITIATION FACTOR-2-ALPHA-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							68,000-MR PROTEIN-KINASE; ADENOVIRUS VA RNA1; GROWTH-FACTOR; SIGNAL TRANSDUCTION; EIF-2-ALPHA KINASE; 3T3 CELLS; C-FOS; RECEPTOR AUTOPHOSPHORYLATION; SELECTIVELY BLOCKS; 3T3-F442A CELLS	The interferon-inducible 68-kDa dsRNA-dependent eIF2alpha-kinase (dsI) is a potent cellular antiviral enzyme which is activated by autophosphorylation in response to double-stranded RNA (dsRNA). Activated dsI has also been implicated as a second messenger for gene induction by platelet-derived growth factor (PDGF) and interferon (IFN). We have shown previously that introduction of a transforming ras gene into BALB/c-3T3 fibroblasts blocks induction of responsive genes by PDGF and IFN. We therefore investigated the effect of transforming ras genes on dsI activity in these cells. We report here that dsRNA-mediated activation of dsI is blocked in v-ras-containing cells in a manner specific to ras and not attributable to the transformed phenotype since: 1) a dexamethasone-inducible v-Haras gene produced the effect within 18 h of induction; 2) morphologic reversion of ras-transformed cells with cAMP or the Krev-1 gene restored potential for dsI activation; and 3) transformation by v-mos or v-abl had no effect on dsI activation. Latent dsI levels were unaffected by v-ras. A heat-sensitive dsI inhibitory activity could be demonstrated in v-ras-containing cells which functioned in trans when mixed with untransformed cell extracts prior to stimulation with dsRNA. The inhibitory activity, which was destroyed by phenol-chloroform extraction, did not bind dsRNA.	BOSTON UNIV,SCH MED,CANC RES CTR,80 E CONCORD ST,E124,BOSTON,MA 02118	Boston University				Kasman, Laura/0000-0002-8661-2918				ALEXANDER D R, 1990, New Biologist, V2, P1049; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEDID M, 1991, J IMMUNOL, V147, P867; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEGON S, 1974, BIOCHEM BIOPH RES CO, V56, P745, DOI 10.1016/0006-291X(74)90668-8; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; OFFERMANN MK, 1989, MOL CELL BIOL, V9, P1969, DOI 10.1128/MCB.9.5.1969; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RANSONE LJ, 1988, J VIROL, V62, P3551, DOI 10.1128/JVI.62.10.3551-3557.1988; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAMSTAG Y, 1991, J IMMUNOL, V147, P788; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	44	89	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23092	23098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358881				2022-12-27	WOS:A1992JY16300061
J	PELES, E; LAMPRECHT, R; BENLEVY, R; TZAHAR, E; YARDEN, Y				PELES, E; LAMPRECHT, R; BENLEVY, R; TZAHAR, E; YARDEN, Y			REGULATED COUPLING OF THE NEU RECEPTOR TO PHOSPHATIDYLINOSITOL 3'-KINASE AND ITS RELEASE BY ONCOGENIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; EGF RECEPTOR; MIDDLE-T; SIGNAL TRANSDUCTION; CHIMERIC RECEPTOR; POINT MUTATION; PROTEIN; TRANSFORMATION	The neu protooncogene encodes a tyrosine kinase receptor that is involved in the regulation of normal growth and malignant transformation. To circumvent the use of the incompletely characterized ligand of Neu, we constructed a chimeric protein composed of the ligand-binding domain of the epidermal growth factor receptor and the transmembrane and cytoplasmic portions of Neu. By expressing this Neu-epidermal growth factor receptor chimera (termed NEC), we found that following stimulation by the heterologous ligand, the tyrosine kinase of Neu became associated with a phosphatidylinositol (PI) kinase activity. The association was dependent on the concentration of the ligand and was almost maximal within 30 s after ligand binding. The lipid kinase was identified as a type I PI 3'-kinase on the basis of its inhibition by Nonidet P-40 and high pressure liquid chromatography of the phosphorylated product. To confirm the identification of PI 3'-kinase as an effector of Neu, we raised antibodies to the a-isoform of the regulatory subunit of PI 3'-kinase (p85). Using these antibodies, it was possible to directly demonstrate ligand-dependent formation of a tyrosine-phosphorylated complex of NEC and PI 3'-kinase. Apparently, both PI 3'-kinase and phospholipase C(gamma), another substrate of the Neu kinase, simultaneously associated with the same activated NEC molecule. Nevertheless, immunofluorescence localization of PI 3'-kinase revealed no significant cellular redistribution of the enzyme after activation of the Neu kinase. Interestingly, PI 3'-kinase was localized primarily to the cell nucleus and to confined regions of the plasma membrane. Analysis of mutants of the Neu protein indicated that the oncogenic point-mutated Neu (Glu664) was permanently coupled to PI 3'-kinase; but two nontransforming versions of the oncoprotein, a kinase-defective protein and a carboxyl-terminally deleted Neu, were devoid of the constitutive association with PI 3'-kinase. Hence, we concluded that phosphatidylinositol 3'-kinase is a physiological substrate of the Neu receptor, but the regulation of this coupling is released upon oncogenic activation.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NCI NIH HHS [CA-51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11156; COCHET C, 1991, J BIOL CHEM, V266, P637; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HAZAN R, 1989, CELL GROWTH DIFFER, V1, P3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MATSUI H, 1984, CANCER RES, V44, P1002; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, CANCER CELLS MOL DIA, V7; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STANCOVSKI L, 1991, P NATL ACAD SCI USA, V88, P8691; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	62	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12266	12274						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351056				2022-12-27	WOS:A1992HY94700092
J	SCHLAEPFER, DD; FISHER, DA; BRANDT, ME; BODE, HR; JONES, JM; HAIGLER, HT				SCHLAEPFER, DD; FISHER, DA; BRANDT, ME; BODE, HR; JONES, JM; HAIGLER, HT			IDENTIFICATION OF A NOVEL ANNEXIN IN HYDRA-VULGARIS - CHARACTERIZATION, CDNA CLONING, AND PROTEIN-KINASE-C PHOSPHORYLATION OF ANNEXIN-XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING-PROTEIN; FACTOR RECEPTOR-KINASE; CALCIUM-CHANNEL ACTIVITY; LIPOCORTIN-I; TYROSINE PHOSPHORYLATION; ENDONEXIN-II; CALPACTIN-I; DEVELOPMENTAL REGULATION; ANTICOAGULANT PROTEIN; BILAYER-MEMBRANES	As a first step toward the elucidation of a simple animal model in which to investigate annexin function, we identified, isolated, and characterized a novel annexin from Hydra vulgaris, annexin XII. A hydra cDNA library was screened using a probe generated by polymerase chain reaction from primers based on the partial amino acid sequence of annexin XII. Annexin XII cDNA was cloned and the functional protein was expressed in high yields in Escherichia coli. The annexin XII cDNA sequence predicted a 316-amino acid protein that had between 44 and 54% sequence identity with the Ca2+-binding core domains of previously characterized vertebrate and Drosophila annexins. The amino-terminal domain of annexin XII did not have sequence similarity with other known annexins except at and around a site that resembled known protein kinase C (PKC) phosphorylation sites in other annexins. As anticipated from its sequence, annexin XII was a high affinity substrate for purified rat brain PKC; half-maximal phosphorylation occurred below 0.1-mu-M annexin XII, and incorporation of up to 0. 8 mol of phosphate/mol of annexin XII was observed. A PKC-like activity in hydra extracts also phosphorylated annexin XII. In summary, hydra promises to be a valuable model system for investigating the biological function of annexins and for determining how this function is modulated by PKC phosphorylation.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine			Haigler, Harry/C-3788-2011		NICHD NIH HHS [HD24511] Funding Source: Medline; NIGMS NIH HHS [GM13942, GM357844] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013942] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BRANDT ME, 1991, GENE, V97, P113, DOI 10.1016/0378-1119(91)90017-6; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CARTER VC, 1986, J CELL BIOL, V103, P2017, DOI 10.1083/jcb.103.5.2017; CHOEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CROMPTON MJ, 1990, NATURE, V345, P212; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; DE BK, 1986, J BIOL CHEM, V261, P3784; DORING V, 1991, J BIOL CHEM, V266, P17509; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FISHER DA, 1989, GENE, V84, P55, DOI 10.1016/0378-1119(89)90139-X; GEISOW MJ, 1987, BIOSCIENCE REP, V7, P289, DOI 10.1007/BF01121450; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1991, J BIOL CHEM, V266, P1697; GERKE V, 1989, FEBS LETT, V258, P259, DOI 10.1016/0014-5793(89)81668-0; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HORSEMAN ND, 1989, MOL ENDOCRINOL, V3, P773, DOI 10.1210/mend-3-5-773; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; ISACKE CM, 1989, MOL CELL BIOL, V9, P232, DOI 10.1128/MCB.9.1.232; IZANT JG, 1991, J BIOL CHEM, V266, P18560; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KAETZEL MA, 1989, BIOCHEM BIOPH RES CO, V160, P1233, DOI 10.1016/S0006-291X(89)80135-4; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KOZAK M, 1966, CELL, V44, P284; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHOFF HM, 1983, HYDRA RES METHOD; LOZANO JJ, 1989, J CELL PHYSIOL, V138, P503, DOI 10.1002/jcp.1041380309; MARRIOTT G, 1990, BIOCHEMISTRY-US, V29, P7004, DOI 10.1021/bi00482a008; MCKANNA JA, 1989, SCIENCE, V243, P1477, DOI 10.1126/science.2928781; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; MULLER WA, 1989, DEVELOPMENT, V105, P309; MULLER WA, 1990, DIFFERENTIATION, V42, P131, DOI 10.1111/j.1432-0436.1990.tb00754.x; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGATA S, 1987, EXP HEMATOL, V15, P461; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAINTEAU DP, 1988, J BIOL CHEM, V263, P12844; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1987, P NATL ACAD SCI USA, V84, P6078, DOI 10.1073/pnas.84.17.6078; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; THEIL C, 1991, J BIOL CHEM, V266, P14732; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WILLIAM F, 1988, J CELL PHYSIOL, V137, P402, DOI 10.1002/jcp.1041370303; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J	74	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9529	9539						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1339458				2022-12-27	WOS:A1992HT96500016
J	SHARMA, RC; INOUE, S; ROITELMAN, J; SCHIMKE, RT; SIMONI, RD				SHARMA, RC; INOUE, S; ROITELMAN, J; SCHIMKE, RT; SIMONI, RD			PEPTIDE-TRANSPORT BY THE MULTIDRUG RESISTANCE PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCOPROTEIN MEDIATED MECHANISM; GENE CONFERS RESISTANCE; HAMSTER OVARY CELLS; FULL-LENGTH CDNA; CLASS-II REGION; K562 ADM CELLS; P-GLYCOPROTEIN; DOXORUBICIN RESISTANCE; DIHYDROFOLATE-REDUCTASE; POLARIZED EXPRESSION	The membrane P-glycoprotein (P170) is an ATP-hydrolyzing transmembrane pump, and elevated levels of P170, due to higher expression with or without amplification of the multidrug resistance gene (mdr1), result in resistance to a variety of chemotherapeutic agents in mammalian cells. The function of the P170 pump has been proposed as a protection against toxic substances present in animal diets. Here we describe a Chinese hamster ovary cell line that was selected for resistance to a synthetic tripeptide, N-acetyl-leucyl-leucyl-norleucinal (ALLN). This ALLN-resistant variant shows the classical multidrug resistance (MDR) phenotype, including overexpression and amplification of the mdr1 gene. Additionally, a mouse embryo cell line overexpressing the transfected mdr1 gene is likewise resistant to ALLN. Our results demonstrate that P170 is capable of transporting peptides and raise the possibility that the mdr1 gene product or other MDR-like genes, present in the genome of mammalian cells, may be involved in secretion of peptides or cellular proteins as is the case with the structurally similar hylB and ste6 gene products of Escherichia coli and yeast, respectively.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA016318] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16318] Funding Source: Medline; NHLBI NIH HHS [HL 26502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; BAAS F, 1990, CANCER RES, V50, P5392; BECHHANSEN NT, 1976, J CELL PHYSIOL, V88, P23, DOI 10.1002/jcp.1040880104; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; BRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717; CHUN KT, 1990, J BIOL CHEM, V265, P22004; COLE PCS, 1991, CANCER RES, V51, P3345; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DAOUD SS, 1989, CANCER RES, V49, P2661; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO A, 1985, CANCER RES, V45, P3002; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HISAWA T, 1990, CARCINOGENESIS LONDO, V11, P75; INOUE S, 1991, J BIOL CHEM, V266, P13311; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SHARMA RC, 1991, CANCER RES, V51, P2949; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SUGAWARA I, 1988, CANCER RES, V48, P1926; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; YUSA K, 1989, CANCER RES, V49, P5002	35	157	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5731	5734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348245				2022-12-27	WOS:A1992HK31800003
J	STEPHENS, CM; BAUERLE, R				STEPHENS, CM; BAUERLE, R			ESSENTIAL CYSTEINES IN 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE FROM ESCHERICHIA-COLI - ANALYSIS BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS OF THE PHENYLALANINE-SENSITIVE ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID 7-PHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; PURIFICATION; ISOENZYME; KINETICS; GENE	The phenylalanine-sensitive isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Escherichia coli was inactivated by the sulfhydryl modifying reagents 5,5-dithiobis-(2-nitrobenzoate), bromopyruvate, and N-ethylmaleimide and protected from inactivation by the presence of its metal activator, Mn2+, and substrate, phosphoenolpyruvate. Inactivation by 5,5-dithiobis-(2-nitrobenzoate) was correlated with modification of two of the seven cysteine sulfhydryls of the enzyme monomer. The kinetics of 5,5-dithiobis-(2-nitrobenzoate) modification were altered significantly and distinctively by both substrates (phosphoenolpyruvate and erythrose 4-phosphate), by Mn2+, and by L-phenylalanine, suggesting that ligand binding has significant effects on the conformation of the enzyme. Site-directed mutagenesis was used to create multiple substitutions at the two invariant cysteine residues of the polypeptide, Cys-61 and Cys-328. Analysis of purified mutant enzymes indicated that Cys-61 is essential for catalytic activity and for metal binding. Cys-328 was found to be nonessential for catalytic activity, although mutations at this position had significant negative effects on V(max), K(m)Mn, and K(m)PEP.	UNIV VIRGINIA,DEPT BIOL,GILMER HALL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,INST EXTRATERR PHYS,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia; University of Virginia					NIGMS NIH HHS [GM35889, GM07082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035889] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARDEMIL E, 1990, BIOCHIM BIOPHYS ACTA, V1040, P71, DOI 10.1016/0167-4838(90)90147-8; DAVIES WD, 1982, NUCLEIC ACIDS RES, V10, P4045, DOI 10.1093/nar/10.13.4045; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOY CH, 1967, BIOCHEM BIOPH RES CO, V26, P187, DOI 10.1016/0006-291X(67)90232-X; DYER WE, 1990, J BIOL CHEM, V265, P1608; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GANEM B, 1978, TETRAHEDRON, V34, P3353, DOI 10.1016/0040-4020(78)80222-1; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HUISMAN OC, 1974, J BIOL CHEM, V249, P6842; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANDLISS RJ, 1978, J BIOL CHEM, V253, P4259; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MUDAY GK, 1990, J BACTERIOL, V172, P2259, DOI 10.1128/jb.172.5.2259-2266.1990; NAGANO H, 1970, ARCH BIOCHEM BIOPHYS, V138, P58, DOI 10.1016/0003-9861(70)90284-5; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; PARAVICINI G, 1989, EUR J BIOCHEM, V186, P361, DOI 10.1111/j.1432-1033.1989.tb15217.x; RAY JM, 1988, J BACTERIOL, V170, P5500, DOI 10.1128/jb.170.12.5500-5506.1988; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER R, 1976, J BIOL CHEM, V251, P5440; SIMPSON RJ, 1976, EUR J BIOCHEM, V70, P509, DOI 10.1111/j.1432-1033.1976.tb11042.x; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P599, DOI 10.1016/0005-2744(69)90228-9; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P588, DOI 10.1016/0005-2744(69)90227-7; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; SUGIMOTO S, 1980, J BIOCHEM-TOKYO, V87, P881, DOI 10.1093/oxfordjournals.jbchem.a132818; VEIRA J, 1987, METHOD ENZYMOL, V153, P67; WELTMAN JK, 1973, J BIOL CHEM, V248, P3173; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5762	5767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348247				2022-12-27	WOS:A1992HK31800010
J	FLETCHER, BS; KUJUBU, DA; PERRIN, DM; HERSCHMAN, HR				FLETCHER, BS; KUJUBU, DA; PERRIN, DM; HERSCHMAN, HR			STRUCTURE OF THE MITOGEN-INDUCIBLE TIS10 GENE AND DEMONSTRATION THAT THE TIS10-ENCODED PROTEIN IS A FUNCTIONAL PROSTAGLANDIN G/H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; TETRADECANOYL PHORBOL ACETATE; ENDOPEROXIDE SYNTHASE; COMPLEMENTARY-DNA; GROWTH-FACTOR; OSTEOBLASTIC CELLS; ARACHIDONIC-ACID; C-FOS; CYCLOOXYGENASE; MOUSE	The TIS10 cDNA was cloned as a primary response gene transcript whose mRNA rapidly accumulates in 3T3 cells treated with serum, polypeptide growth factors, or phorbol esters. The sequence of the TIS10 cDNA suggested that the gene encodes a protein with strong similarities to prostaglandin G/H synthase/cyclooxygenase (EC 1.14.99.1). Transient transfection into COS-1 cells of an expression vector driving the TIS10 cDNA leads to production and secretion of prostaglandin E2. Microsomes prepared from COS-1 cells transfected with this construct demonstrate both hydroperoxidase and cyclooxygenase activities similar to that demonstrated by cells transfected with a vector encoding the ovine prostaglandin G/H synthase. These data demonstrate that the TIS10 gene encodes a functional prostaglandin synthase/cyclooxygenase distinct from the prostaglandin synthase/cyclooxygenase whose cDNAs and/or genes have previously been cloned from sheep, mouse, and man. The structure of the TIS10 gene, determined by a combination of sequencing of genomic clones and polymerase chain reactions from genomic clones, demonstrates remarkable exon-intron conservation with the human prostaglandin synthase/cyclooxygenase gene. A 1-kilobase sequence located immediately proximal to the start site of transcription of the TIS10 gene can confer phorbol ester and serum inducibility to a luciferase reporter gene following transient transfection into NIH 3T3 cells, suggesting that this region of the gene is responsible for transcriptional regulation of the TIS10 gene by mitogens in fibroblasts.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV NEPHROL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM24797, GM0 8042-08] Funding Source: Medline; PHS HHS [1K11 01815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797, T32GM008042] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HONG SCL, 1976, J BIOL CHEM, V251, P776; KUJUBU DA, 1987, ONCOGENE, V1, P257; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIM RW, 1987, ONCOGENE, V1, P263; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SAMBROOK J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, ONCOGENE, V4, P1263; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOUNG MR, 1984, J NATL CANCER I, V72, P919	38	507	519	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4338	4344						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1339449				2022-12-27	WOS:A1992HF64200015
J	BOSCH, F; RODRIGUEZGIL, JE; HATZOGLOU, M; GOMEZFOIX, AM; HANSON, RW				BOSCH, F; RODRIGUEZGIL, JE; HATZOGLOU, M; GOMEZFOIX, AM; HANSON, RW			LITHIUM INHIBITS HEPATIC GLUCONEOGENESIS AND PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-REGULATORY REGION; ISOLATED RAT ADIPOCYTES; GLYCOGEN-SYNTHASE; FRUCTOSE 2,6-BISPHOSPHATE; ADENYLATE-CYCLASE; CHIMERIC GENES; GTP GENE; INSULIN; CELLS; IDENTIFICATION	Incubation of isolated hepatocytes from fasted rats with 20 mM LiCl for 1 h decreased glucose production from lactate, pyruvate, and alanine. In addition, phosphoenolpyruvate carboxykinase (PEPCK) gene expression in FTO-2B rat hepatoma cells was inhibited by treatment with LiCl. Lithium was also able to counteract the increased PEPCK mRNA levels caused by both Bt2cAMP and dexamethasone, in a concentration-dependent manner. A chimeric gene containing the PEPCK promoter (-550 to +73) linked to the amino-3-glycosyl phosphotransferase (neo) structural gene was transduced into FTO-2B cells using a Moloney murine leukemia virus-based retrovirus. In these infected cells, 20 mM LiCl decreased both the concentration of neo mRNA transcribed from the PEPCK-neo chimeric gene and MRNA from the endogenous PEPCK gene. Lithium also inhibited the stimulatory effect of Bt2cAMP and dexamethasone on both genes. The stability of neo mRNA was not altered by lithium, since in cells infected with retrovirus containing only the neo gene transcribed via the retroviral 5'-LTR and treated with 20 mM LiCl, no change in neo mRNA levels was observed. The intraperitoneal administration of LiCl to rats caused a decrease in hepatic PEPCK mRNA, indicating that lithium could also modify gene expression in vivo. The effects of lithium were not due to an increase in the concentration of insulin in the blood but were correlated with an increase in hepatic glycogen and fructose 2,6-bisphosphate levels. These results indicate that lithium ions, at concentrations normally used therapeutically for depression in humans, can inhibit glucose synthesis in the liver by a mechanism which can selectively modify the expression of hepatic phosphoenolpyruvate carboxykinase.	CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	BOSCH, F (corresponding author), AUTONOMOUS UNIV BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN.		Rodriguez-Gil, Joan E./F-8748-2016	Rodriguez-Gil, Joan E./0000-0002-1112-9884; BOSCH, FATIMA/0000-0002-7705-5515	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, R37DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21859, DK 24451] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; Battey, 1986, BASIC METHODS MOL BI; BELMAKER RH, 1981, BIOL PSYCHIAT, V16, P333; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BEYAERT R, 1989, P NATL ACAD SCI USA, V86, P9494, DOI 10.1073/pnas.86.23.9494; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOSCH F, 1986, J BIOL CHEM, V261, P6927; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; CHENG K, 1983, MOL CELL BIOCHEM, V56, P177; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P66, DOI 10.1016/0005-2736(68)90009-6; DOBNER PR, 1988, J BIOL CHEM, V263, P13983; DOUSA TP, 1974, ENDOCRINOLOGY, V95, P1359, DOI 10.1210/endo-95-5-1359; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; EBSTEIN R, 1976, NATURE, V259, P411, DOI 10.1038/259411a0; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; FONTELA T, 1987, DIABETOLOGIA, V30, P183, DOI 10.1007/BF00274225; FONTELA T, 1986, ACTA ENDOCRINOL-COP, V111, P342, DOI 10.1530/acta.0.1110342; FORN J, 1975, LITHIUM RES THERAPY, P487; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HAUGAARD ES, 1974, BIOCHEM PHARMACOL, V23, P1675, DOI 10.1016/0006-2952(74)90394-3; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; NEWMAN ME, 1987, NEUROPHARMACOLOGY, V26, P211, DOI 10.1016/0028-3908(87)90211-5; NYFELER F, 1979, FEBS LETT, V108, P197, DOI 10.1016/0014-5793(79)81209-0; NYFELER F, 1981, BIOCHIM BIOPHYS ACTA, V675, P17, DOI 10.1016/0304-4165(81)90064-7; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROSSETTI L, 1989, DIABETES, V38, P648, DOI 10.2337/diabetes.38.5.648; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; VANDEWERVE G, 1977, BIOCHEM J, V162, P135, DOI 10.1042/bj1620135; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2888	2893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371108				2022-12-27	WOS:A1992HD15400014
J	LAHERTY, CD; OROURKE, K; WOLF, FW; KATZ, R; SELDIN, MF; DIXIT, VM				LAHERTY, CD; OROURKE, K; WOLF, FW; KATZ, R; SELDIN, MF; DIXIT, VM			CHARACTERIZATION OF MOUSE THROMBOSPONDIN-2 SEQUENCE AND EXPRESSION DURING CELL-GROWTH AND DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL DISULFIDE EXCHANGE; CONSERVED LINKAGE GROUP; MESSENGER-RNA LEVELS; C-FOS; PLATELET THROMBOSPONDIN; 3T3 CELLS; CIRCUMSPOROZOITE PROTEIN; ADHESIVE GLYCOPROTEIN; EXTRACELLULAR-MATRIX; SULFATED GLYCOLIPIDS	Thrombospondin (TSP) is an extracellular matrix glycoprotein whose expression has been associated with a variety of cellular processes including growth and embryogenesis. The recent discovery of the existence of a second mouse TSP gene necessitates careful examination of the discrete biochemical and functional properties associated with each molecule. In this report, the primary structures of human TSP, mouse TSP1 (mTSP1), mouse TSP2 (mTSP2), and chicken TSP are compared; and the expression of mTSP1 and mTSP2 during embryogenesis and growth factor-mediated cell proliferation is examined. The cloning and sequencing of the entire coding regions of mTSP1 and mTSP2 revealed considerable conservation of residues critical for TSP structure and function; these data suggest that TSP2 is capable of trimer formation and many of the same cell-surface and ligand interactions that mediate TSP function. Comparison of the various TSP sequences also allowed the assignment based on sequence homology of previously reported human TSP as TSP1 and chicken TSP as TSP2. mTSP2, like mTSP1, was shown to be a primary response gene when quiescent Swiss 3T3 cells were stimulated with serum, platelet-derived growth factor BB, basic fibroblast growth factor, or interleukin-1-beta. Interestingly, TSP1 and TSP2 exhibited markedly different tissue- and stage-specific patterns of mRNA expression during mouse embryogenesis, implying that the two TSP molecules possess discrete functional properties important for development. Additionally, the TSP genes (Thbs1 and Thbs2) were mapped to single loci on mouse chromosomes 2 and 17, respectively.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, BOX 0602, ANN ARBOR, MI 48109 USA; UNIV NANCY 1, CELLULAR & MOLEC BIOL PROGRAM, F-54506 Vandoeuvre Les Nancy, FRANCE; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; Universite de Lorraine; Duke University; Duke University			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHGRI NIH HHS [HG-00101] Funding Source: Medline; NHLBI NIH HHS [HL-39037] Funding Source: Medline; NIDCR NIH HHS [DE-00301-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K11DE000301] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BROWNE PC, 1988, ARCH BIOCHEM BIOPHYS, V265, P534, DOI 10.1016/0003-9861(88)90158-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CURRAN T, 1985, CANCER SURV, V4, P655; DANISHEFSKY KJ, 1984, BIOCHEMISTRY-US, V23, P4984, DOI 10.1021/bi00316a024; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DONOVIEL D B, 1988, Journal of Cell Biology, V107, p596A; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GREEN EL, 1990, GENETICS PROBABILITY, V8, P524; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; JAFFE E, 1990, GENOMICS, V7, P123, DOI 10.1016/0888-7543(90)90528-3; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P555; LAWLER J, 1986, BLOOD, V67, P1197; LAWRE J, 1991, J BIOL CHEM, V266, P8039; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LONG MW, 1990, BLOOD, V75, P2311; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; Maniatis T., 1982, MOL CLONING; MOSELEY WS, 1989, GENOMICS, V5, P899, DOI 10.1016/0888-7543(89)90132-8; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NADEAU JH, 1991, GENOMICS, V9, P78, DOI 10.1016/0888-7543(91)90223-2; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PROCHOWNIK EV, 1984, J BIOL CHEM, V259, P5386; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHIMENTI J, 1988, CELL, V55, P71, DOI 10.1016/0092-8674(88)90010-4; SELDIN MF, 1989, GENOMICS, V5, P24, DOI 10.1016/0888-7543(89)90082-7; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SLANE JMK, 1988, FEBS LETT, V229, P363, DOI 10.1016/0014-5793(88)81157-8; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; STEINMETZ M, 1982, NATURE, V300, P35, DOI 10.1038/300035a0; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; VANZOELEN EJJ, 1985, J CELL PHYSIOL, V123, P151, DOI 10.1002/jcp.1041230202; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; YABKOWITZ R, 1991, CANCER RES, V51, P1645; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	65	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3274	3281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371115				2022-12-27	WOS:A1992HD15400072
J	MURRAYWHELAN, R; SCHLEGEL, W				MURRAYWHELAN, R; SCHLEGEL, W			BRAIN SOMATOSTATIN RECEPTOR-G PROTEIN-INTERACTION - G-ALPHA C-TERMINAL ANTIBODIES DEMONSTRATE COUPLING OF THE SOLUBLE RECEPTOR WITH GI(1-3) BUT NOT WITH G(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; PITUITARY CELL-MEMBRANES; RAT CEREBRAL-CORTEX; ADENYLATE-CYCLASE; ADRENERGIC-RECEPTOR; CALCIUM CURRENT; TUMOR CELLS; K+ CHANNELS; GH3 CELLS; IDENTIFICATION	Somatostatin (SST) receptors activate potassium channels, stimulate protein phosphatases, inhibit adenylate cyclase and close calcium channels. These multiple effects are controlled by guanine nucleotide binding (G) proteins of the pertussis toxin-sensitive G(i) and G(o) types. In the present study we have identified the G proteins coupling with brain SST receptors. To this end, brain SST receptors were solubilized in G-protein coupled form. Binding of the SST analogue MK 678 to the solubilized receptor was completely inhibited by guanosine 5'-O-thiotriphosphate (IC50 = 100 nM), reflecting decreased receptor affinity for agonist following uncoupling of the receptor and G protein(s). Antibodies raised against specific COOH-terminal peptides of the G proteins Gi(1-3), G(o), and G(z) were used to probe for SST receptor-G protein coupling in this system. Antibodies binding to the COOH-terminal regions of G(i1) and G(i2) (antibody AS) and G(i3) (antibody EC) inhibited binding of I-125-MK 678 (75 pM) by 57 +/- 4% and 48 +/- 5%, respectively. The effects of these antibodies were concentration-dependent and additive, such that in combination AS and EC completely inhibited binding. Antibodies binding to the COOH-terminal region of G(o) (GO) and G(z) (QN) did not affect binding of I-125-MK 678, indicating that neither G(o) nor G(z) are associated with the brain SST receptor. Prelabeling of the receptor with I-125-MK 678 prior to addition of antibody induced the formation of a ''locked conformation'' of the agonist-bound receptor-G protein complex which was insensitive to antibody. In conclusion, G(il) and/or G(i2) and G(i3) are coupled in approximately equal proportions to the brain I-125-MK 678-binding SST receptor, accounting for all of the G protein coupling of this receptor.			MURRAYWHELAN, R (corresponding author), UNIV GENEVA,DEPT MED,FDN RECH MED,64 AV ROSERAIE,CH-1211 GENEVA 4,SWITZERLAND.							BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CODINA J, 1988, J BIOL CHEM, V263, P6746; CZERNIK AJ, 1983, J BIOL CHEM, V258, P5525; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HE HT, 1990, MOL PHARMACOL, V37, P614; HEISLER S, 1982, P NATL ACAD SCI-BIOL, V79, P6502, DOI 10.1073/pnas.79.21.6502; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; KILPATRICK BF, 1983, J BIOL CHEM, V258, P3528; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MARIE JC, 1989, EUR J BIOCHEM, V186, P181, DOI 10.1111/j.1432-1033.1989.tb15193.x; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAIR BG, 1990, J BIOL CHEM, V265, P21317; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAYNOR K, 1989, J PHARMACOL EXP THER, V510, P251; SCHLEGEL W, 1984, CELL CALCIUM, V5, P223, DOI 10.1016/0143-4160(84)90038-1; SCHLEGEL W, 1985, FEBS LETT, V189, P27, DOI 10.1016/0014-5793(85)80835-8; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TANAKA S, 1981, BRAIN RES, V208, P219, DOI 10.1016/0006-8993(81)90636-3; TATSUMI H, 1990, J NEUROSCI, V10, P1675; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YAMASHITA N, 1987, AM J PHYSIOL, V253, pE28, DOI 10.1152/ajpendo.1987.253.1.E28; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	42	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2960	2965						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1346612				2022-12-27	WOS:A1992HD15400025
J	HIZI, A; SHAHARABANY, M; TAL, R; HUGHES, SH				HIZI, A; SHAHARABANY, M; TAL, R; HUGHES, SH			THE EFFECTS OF CYSTEINE MUTATIONS ON THE REVERSE TRANSCRIPTASES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-H; DNA-POLYMERASE; ESCHERICHIA-COLI; DOMAIN; MUTAGENESIS; RIBONUCLEASE; ORGANIZATION; EXPRESSION	Chemical modification of HIV-1 and HIV-2 (human immunodeficiency virus, types 1 and 2) reverse transcriptases (RT) with three thiol reactive compounds selectively inhibits the RNase H function of the enzyme. HIV-1 RT has 2 cysteines (at positions 38 and 280); HIV-2 RT has 3 (38, 280, 445). Both of the cysteines in HIV-1 RT are in the polymerase domain. To investigate the role of the cysteines in the structure and function of the HIV RTs, we have converted each cysteine to serine and made combinations of the mutations. Since HIV-1 RT has alanine at position 445, we have also substituted alanine for serine at this position in HIV-2 RT. Neither of the single mutations in HIV-1 RT nor the double mutation mimics the effects of the chemical modification. The serine 280 mutation has little effect on either polymerase or RNase H; the serine 38 mutation affects both activities, as does the 38/280 double mutant. The 38 and 280 serine mutations in HIV-2 RT resemble the equivalent mutations in HIV-1 RT. Substitution of serine or alanine at position 445 (which lies in the RNase H domain) diminishes, but does not abolish, the RNase H activity of HIV-2 without affecting polymerase activity. The RNase H activity of a mutant HIV-1 RT with serine at position 280 is completely resistant to inactivation by the three thiol reactive compounds we tested, which demonstrates that cysteine 280 is the critical residue. We suggest that the reason the mutation (cysteine 280 to serine) does not mimic the chemical modification is because the chemical modification produces a greater change in the structure of the protein. We also suggest that position 280 lies at or near the important points of contact between the RNase H and polymerase domains, so that chemical modification of this position, which lies within the polymerase domain, distorts the RNase H domain.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	HIZI, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,BLDG 539,FREDERICK,MD 21702, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [R01-AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; MYERS G, 1989, HUMAN RETROVIRUSES A; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RUCHETON M, 1979, VIROLOGY, V97, P221, DOI 10.1016/0042-6822(79)90392-1; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; Weiss R, 1985, RNA TUMOR VIRUSES	22	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1293	1297						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370463				2022-12-27	WOS:A1992GY96000095
J	LI, SJ; CRONAN, JE				LI, SJ; CRONAN, JE			THE GENE ENCODING THE BIOTIN CARBOXYLASE SUBUNIT OF ESCHERICHIA-COLI ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DEHYDROGENASE MULTIENZYME COMPLEX; BACTERIOPHAGE-T7 DNA-POLYMERASE; AMINO-ACID SEQUENCE; CARRIER PROTEIN; RECOMBINANT CLONES; CODING SEQUENCE; ALPHA-SUBUNIT; CLONING; EXPRESSION	We report the molecular cloning and DNA sequence of the gene encoding the biotin carboxylase subunit of Escherichia coli acetyl-CoA carboxylase. The biotin carboxylase gene encodes a protein of 449 residues that is strikingly similar to amino-terminal segments of two biotin-dependent carboxylase proteins, yeast pyruvate carboxylase and the alpha-subunit of rat propionyl-CoA carboxylase. The deduced biotin carboxylase sequence contains a consensus ATP binding site and a cysteine-containing sequence preserved in all sequenced bicarbonate-dependent biotin carboxylases that may play a key catalytic role. The gene encoding the biotin carboxyl carrier protein (BCCP) subunit of acetyl-CoA carboxylase is located upstream of the biotin carboxylase gene and the two genes are cotranscribed. As previously reported by others, the BCCP sequence encoded a protein of 16,688 molecular mass. However, this value is much smaller than that (22,500 daltons) obtained by analysis of the protein. Amino-terminal amino acid sequencing of the purified BCCP protein confirmed the deduced amino acid sequence indicating that BCCP is a protein of atypical physical properties. Northern and primer extension analyses demonstrate that BCCP and biotin carboxylase are transcribed as a single mRNA species that contains an unusually long untranslated leader preceding the BCCP gene. We have also determined the mutational alteration in a previously isolated acetyl-CoA carboxylase (fabE) mutant and show the lesion maps within the BCCP gene and results in a BCCP species defective in acceptance of biotin. Translational fusions of the carboxyl-terminal 110 or 84 (but not 76) amino acids of BCCP to beta-galactosidase resulted in biotinated beta-galactosidase molecules and production of one such fusion was shown to result in derepression of the biotin biosynthetic operon.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	LI, SJ (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; ALIX JH, 1989, DNA-J MOLEC CELL BIO, V8, P779, DOI 10.1089/dna.1989.8.779; ARPS PJ, 1987, J BACTERIOL, V169, P1061, DOI 10.1128/jb.169.3.1061-1070.1987; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V1, pCH4; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROWNER MF, 1989, J BIOL CHEM, V264, P12680; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; DEVEAUX LC, 1986, J BACTERIOL, V167, P920, DOI 10.1128/jb.167.3.920-927.1986; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; EASOM RA, 1989, PROTEINS, V5, P224, DOI 10.1002/prot.340050306; FALL RR, 1973, J BIOL CHEM, V248, P2078; FALL RR, 1972, J BIOL CHEM, V247, P8005; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HAASE FC, 1982, J BIOL CHEM, V257, P1994; HARDER ME, 1972, P NATL ACAD SCI USA, V69, P3105, DOI 10.1073/pnas.69.11.3105; HILL ROBERT L., 1965, ADVANCE PROTEIN CHEM, V20, P37, DOI 10.1016/S0065-3233(08)60388-5; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBLUM JS, 1988, GENE, V63, P75, DOI 10.1016/0378-1119(88)90547-1; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; LIM F, 1988, J BIOL CHEM, V263, P11493; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LYNEN F, 1972, BIOCH SOC S, V35, P5; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P3982, DOI 10.1093/nar/17.10.3982; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; NYUNOYA H, 1983, P NATL ACAD SCI USA, V77, P2119; OGITA T, 1988, BIOCHEMISTRY-US, V27, P8028, DOI 10.1021/bi00421a009; POLAKIS SE, 1974, J BIOL CHEM, V244, P6657; POST LE, 1990, J BIOL CHEM, V265, P7742; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REED KE, 1991, J BIOL CHEM, V266, P11425; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SILBERT DF, 1976, J BACTERIOL, V126, P1351, DOI 10.1128/JB.126.3.1351-1354.1976; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; SWACK JA, 1978, ANAL BIOCHEM, V87, P114, DOI 10.1016/0003-2697(78)90575-4; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4325, DOI 10.1021/bi00412a020; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4317, DOI 10.1021/bi00412a019; WEI YG, 1986, GENE, V48, P251, DOI 10.1016/0378-1119(86)90083-1	62	209	243	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					855	863						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370469				2022-12-27	WOS:A1992GY96000029
J	BEAULIEU, AD; PAQUIN, R; RATHANASWAMI, P; MCCOLL, SR				BEAULIEU, AD; PAQUIN, R; RATHANASWAMI, P; MCCOLL, SR			NUCLEAR SIGNALING IN HUMAN NEUTROPHILS - STIMULATION OF RNA-SYNTHESIS IS A RESPONSE TO A LIMITED NUMBER OF PROINFLAMMATORY AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; NUCLEOTIDE REGULATORY PROTEINS; PERTUSSIS TOXIN; MOLECULAR-CLONING; TYROSINE KINASE; CALCIUM MOBILIZATION; SELECTIVE SYNTHESIS; RABBIT NEUTROPHILS; MESSENGER-RNA	At inflammatory sites, neutrophils are stimulated by a range of proinflammatory molecules which elicit a number of cellular responses. Considerable information on the cytoplasmic events that occur following activation of neutrophils at the cell membrane level already exists. In this study, we have focused on the ability of neutrophil agonists to initiate nuclear signaling events by investigating the induction of de novo RNA synthesis. Of a total of 14 different known potent leukocyte agonists, only three had a significant effect on the induction of RNA synthesis in neutrophils; the formylated oligopeptide formyl-methionyl-leucyl-phenylalanine (fMet-Leu-Phe), granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. All three agonists induced de novo RNA synthesis in neutrophils at concentrations known to be optimal for the activation of a number of other cellular responses occurring in inflammation. Of significance was the observation that activation of RNA synthesis in neutrophils is a G-protein-mediated event, is also dependent on tyrosine phosphorylation, but is not influenced by cAMP. Finally, we have demonstrated that all three agonists also induce de novo synthesis of a limited number of proteins, with granulocyte-macrophage colony-stimulating factor and fMet-Leu-Phe having the most potent effect. These studies define the effects of neutrophil agonists on de novo RNA and protein synthesis in a proinflammatory context and suggest that these events in neutrophils occur in a restricted fashion, highly dependent on the stimuli present at sites of inflammation.			BEAULIEU, AD (corresponding author), CHU LAVAL,CTR RECH,CTR RECH INFLAMMAT IMMUNOL & RHUMATOL,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.		Rathanaswami, Palaniswami/AAL-3979-2021; Rathanaswami, Palaniswami/AAL-7192-2021					BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BEAULIEU AD, 1987, J RHEUMATOL, V14, P656; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCO NA, 1990, BLOOD, V75, P2049; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COREY SJ, 1989, J BIOL CHEM, V264, P14165; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EID NS, 1987, J EXP MED, V165, P1448, DOI 10.1084/jem.165.5.1448; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GRANELLIPIPERNO A, 1979, J EXP MED, V149, P284, DOI 10.1084/jem.149.1.284; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IMOTO M, 1987, J ANTIBIOT, V40, P1471, DOI 10.7164/antibiotics.40.1471; JACK RM, 1988, J IMMUNOL, V140, P4286; KRAFT AS, 1987, BLOOD, V70, P356; KREIS C, 1989, J IMMUNOL, V143, P1961; LAFLEUR M, 1987, J BIOL CHEM, V262, P2111; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maniatis T., 1982, MOL CLONING; MCCOLL SR, 1990, BIOCHEM BIOPH RES CO, V172, P1209, DOI 10.1016/0006-291X(90)91577-F; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCOLL SR, 1989, BLOOD, V73, P588; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NACCACHE PH, 1990, BLOOD, V76, P2098; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHIRAFUJI N, 1990, BLOOD, V75, P17; TIKU K, 1986, J IMMUNOL, V136, P3677; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; UMEZAWA K, 1988, HORIZONS ANTIBIOTIC, P74; VARTIO T, 1982, J BIOL CHEM, V257, P8862; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WAKSMAN Y, 1990, J IMMUNOL, V144, P3437	44	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					426	432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370448				2022-12-27	WOS:A1992GY43900069
J	NEVE, KA; KOZLOWSKI, MR; ROSSER, MP				NEVE, KA; KOZLOWSKI, MR; ROSSER, MP			DOPAMINE D2 RECEPTOR STIMULATION OF NA+/H+ EXCHANGE ASSESSED BY QUANTIFICATION OF EXTRACELLULAR ACIDIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; ARACHIDONIC-ACID RELEASE; PROLACTIN SECRETION; SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; GROWTH-FACTORS; CELLS; RAT; INHIBITION; ACTIVATION	A microphysiometer was used to quantify the rate of extracellular acidification by C6 glioma cells and L fibroblasts expressing recombinant dopamine D2 receptors. The dopamine D2 receptor agonist, quinpirole, accelerated the rate of acidification of the medium by C6 cells expressing either the short or long form of D2 receptors, D2(415) and D2(444), but not by wild-type cells that were not transfected with a D2 receptor cDNA. The rate of acidification increased with increasing concentrations of quinpirole up to 100 nM. Inhibition of the response by the dopamine D2 antagonist, spiperone, provided additional evidence that the enhanced extracellular acidification resulted from stimulation of D2 receptors. To test the hypothesis that D2 receptor-stimulated extracellular acidification was due to transport of protons by a Na+/H+ antiporter and reflected intracellular alkalinization, the effect of two inhibitors of Na+/H+ exchange, amiloride and methyl-isobutyl-amiloride, was determined. Both compounds inhibited quinpirole-induced extracellular acidification at concentrations that did not alter D2 receptor-mediated inhibition of adenylylcyclase or radioligand binding to D2 receptors. In addition, quinpirole-induced extracellular acidification was greatly inhibited by removal of sodium from the extracellular medium, confirming the participation of Na+/H+ exchange in the extrusion of acid. Quinpirole (100 nM) also increased the rate of extracellular acidification by L cells expressing D2(415), LZR1 cells. Treatment with pertussis toxin (100 ng/ml for 18 h) had no effect on the quinpirole-induced acid extrusion by C6D2(415) and LZR1 cells, although the same pertussis toxin treatment regimen completely prevented inhibition of adenylylcyclase. We conclude that recombinant D2 receptors accelerate Na+/H+ exchange in C6 cells and L fibroblasts by a pathway that does not involve inhibition of adenylylcyclase or pertussis toxin-sensitive G proteins.	OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT SCREENING & BIOCHEM RES,WALLINGFORD,CT 06492	Oregon Health & Science University; Bristol-Myers Squibb	NEVE, KA (corresponding author), OREGON HLTH SCI UNIV,VET AFFAIRS MED CTR,PORTLAND,OR 97201, USA.			Kozlowski, Michael/0000-0003-1213-7015	NIMH NIH HHS [MH45372] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045372] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERT PR, 1990, J BIOL CHEM, V265, P2098; AMOROSO S, 1991, BIOCHEM PHARMACOL, V41, P1279, DOI 10.1016/0006-2952(91)90098-P; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; DAVIES C, 1974, J ENDOCRINOL, V61, P411, DOI 10.1677/joe.0.0610411; DIXON SJ, 1987, J BIOL CHEM, V262, P3626; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GANZ MB, 1990, J BIOL CHEM, V265, P8989; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; JOYCE JN, 1991, J PHARMACOL EXP THER, V257, P1253; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MALGAROLI A, 1987, J BIOL CHEM, V262, P13920; MASSERANO JM, 1983, MOL CELL BIOCHEM, V53-4, P129; MELLER E, 1987, MOL PHARMACOL, V31, P592; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1981, CELL, V23, P789, DOI 10.1016/0092-8674(81)90443-8; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1991, MOL PHARMACOL, V39, P570; NEVE KA, 1989, MOL PHARMACOL, V36, P446; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAPIRSTEIN VS, 1984, J NEUROCHEM, V43, P1098, DOI 10.1111/j.1471-4159.1984.tb12849.x; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TALOR Z, 1989, LIFE SCI, V45, P517, DOI 10.1016/0024-3205(89)90102-1; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5	39	64	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25748	25753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361188				2022-12-27	WOS:A1992KD07300027
J	LEE, RH; TING, TD; LIEBERMAN, BS; TOBIAS, DE; LOLLEY, RN; HO, YK				LEE, RH; TING, TD; LIEBERMAN, BS; TOBIAS, DE; LOLLEY, RN; HO, YK			REGULATION OF RETINAL CGMP CASCADE BY PHOSDUCIN IN BOVINE ROD PHOTORECEPTOR CELLS - INTERACTION OF PHOSDUCIN AND TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; BETA-GAMMA; MOLECULAR MECHANISM; VISUAL EXCITATION; CDNA SEQUENCE; ALPHA-SUBUNIT; CYCLIC-GMP; AMINO-ACID; PROTEINS; PHOSPHOPROTEIN	Photoexcitation of retinal rod photoreceptor cells involves the activation of a cGMP enzyme cascade in which sequential activation of rhodopsin, transducin, and the cGMP phosphodiesterase in the rod outer segment constitutes the signal amplification mechanism. Phosducin, a 33-kDa phosphoprotein, has been shown to form a tight complex with the Tbetagamma subunit of transducin. In this study, we examined the interaction of phosducin-Tbetagamma and the possible regulatory role of phosducin on the cGMP cascade. Addition of phosducin to photolyzed rod outer segment (ROS) membrane reduced the GTP hydrolysis activity of transducin as well as the subsequent activation of the cGMP phosphodiesterase. Phosducin also inhibited the pertussis toxin-catalyzed ADP-ribosylation of transducin, indicating that the interaction between the Talpha and Tbetagamma subunits of transducin was interrupted upon binding of phosducin. The inhibitory effects of phosducin were reversed by the addition of exogenous Tbetagamma. These results suggest that phosducin is capable of regulating the amount of Tbetagamma available to interact with Talpha to form the active transducin complex and thereby functions as a negative regulator of the cGMP cascade. The phosducin-induced alteration of the subunit organization of transducin was examined by chemical cross-linking method using para-phenyl dimaleimide as cross-linker. It was found that the cross-linking among Talpha and Tbetagamma was blocked in the presence of phosducin. This result implies that Tbetagamma may undergo a conformational change upon phosducin binding which leads to the release of Talpha. Since phosducin is a soluble protein, the interaction with transducin only occurs when transducin is dissociated from ROS disc membrane. Indeed, phosducin failed to dissociate membrane-bound transducin and did not inhibit the initial cycle of transducin activation as measured by the presteady state GTP hydrolysis. However, phosducin interacts effectively with transducin released into solution after the initial activation and blocks the re-binding of Talpha. Tbetagamma to ROS membrane by forming a tight complex with Tbetagamma. This interaction may play an important role in regulating the turnover of the cGMP cascade in photoreceptor cells.	UNIV ILLINOIS, HLTH SCI CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA; VET ADM MED CTR, DEV NEUROL LAB, SEPULVEDA, CA 91343 USA; UNIV ILLINOIS, HLTH SCI CTR, DEPT OPHTHALMOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL EYE INSTITUTE [R01EY005788, R01EY007890, R23EY005788] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05788, EY-07890] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HO YK, 1989, CURR TOP CELL REGUL, V30, P171; HO YK, 1984, J BIOL CHEM, V259, P6694; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KATADA T, 1987, J BIOL CHEM, V262, P11897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, EXP EYE RES, V51, P325, DOI 10.1016/0014-4835(90)90029-T; LEE RH, 1991, INVEST OPHTH VIS SCI, V32, P1054; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1981, BIOCHEMISTRY-US, V20, P7532, DOI 10.1021/bi00529a031; LEE RH, 1992, IN PRESS METHODS NEU, V10; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NAVON SE, 1987, J BIOL CHEM, V262, P15746; REIG JA, 1990, J BIOL CHEM, V265, P5816; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; YEE R, 1978, J BIOL CHEM, V253, P8902	33	138	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25104	25112						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334080				2022-12-27	WOS:A1992KB60300032
J	ARSHAVSKY, VY; DUMKE, CL; BOWNDS, MD				ARSHAVSKY, VY; DUMKE, CL; BOWNDS, MD			NONCATALYTIC CGMP-BINDING SITES OF AMPHIBIAN ROD CGMP PHOSPHODIESTERASE CONTROL INTERACTION WITH ITS INHIBITORY GAMMA-SUBUNITS - A PUTATIVE REGULATORY MECHANISM OF THE ROD PHOTORESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER-SEGMENT PHOSPHODIESTERASE; FROG PHOTORECEPTOR-MEMBRANES; LIGHT-SENSITIVE CURRENT; VERTEBRATE PHOTORECEPTORS; ACTIVATION MECHANISM; MOLECULAR MECHANISM; RETINAL TRANSDUCIN; SYNTHETIC PEPTIDES; VISUAL EXCITATION	The cGMP phosphodiesterase (PDE) of retinal rods plays a central role in phototransduction. Illumination leads to its activation by a rod G-protein (G(t), transducin), thus causing a decrease in intracellular cGMP concentration, closure of plasma membrane cationic channels gated by cGMP, and development of the photoresponse. The PDE holoenzyme is an alphabetagamma2 tetramer. The alpha- and beta-subunits each contain one catalytic and one, or possibly two, noncatalytic cGMP-binding sites. Two identical gamma-subunits serve as protein inhibitors of the enzyme. Their inhibition is removed when they bind to G(t)-GTP during PDE activation. Here we report that the noncatalytic cGMP-binding sites regulate the binding of PDE(alphabeta) with PDE(gamma) and as a result determine the mechanism of PDE activation by G(t). If the noncatalytic sites are empty, G(t)-GTP physically removes PDE(gamma) from PDE(alphabeta) upon activation. Alternatively, if the noncatalytic sites are occupied by cGMP, G(t)-GTP releases PDE(gamma) inhibitory action but remains bound in a complex with the PDE heterotetramer. The kinetic parameters of activated PDE in these two cases are indistinguishable. This mechanism appears to have two implications for the physiology of photoreceptor cells. First, the tight binding of PDE(gamma) with PDE(alphabeta) when the noncatalytic sites are occupied by cGMP may be responsible for the low level of basal PDE activity observed in dark-adapted cells. Second, occupancy of the noncatalytic sites ultimately controls the rate of PDE inactivation (cf. Arshavsky, V. Yu., and Bownds, M. D. (1992) Nature 357, 416-417), for the GTPase activity that terminates PDE activity is slower when these sites are occupied and G(t) stays in a complex with PDE holoenzyme. In contrast GTPase acceleration is maximal when the noncatalytic sites are empty and G(t)-PDE(gamma) dissociates from PDE(alphabeta). Because cGMP levels are known to decrease upon illumination over a concentration range corresponding to the binding constants of the noncatalytic sites, the binding might be involved in determining the lifetime of activated PDE, after a single flash and/or during dark adaptation.	UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA; UNIV WISCONSIN, NEUROSCI TRAINING PROGRAM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NEI NIH HHS [EY 00463] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000463] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGELSONJK, 1992, INVEST OPHTH VIS SCI, V33, P1103; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHUMAKOV KM, 1982, EUR J BIOCHEM, V127, P309, DOI 10.1111/j.1432-1033.1982.tb06871.x; CLERC A, 1992, J BIOL CHEM, V267, P6620; COBBS WH, 1985, NATURE, V313, P585, DOI 10.1038/313585a0; COTE RH, 1989, J BIOL CHEM, V264, P15384; CUNNICK JM, 1990, BIOCHEM J, V271, P721, DOI 10.1042/bj2710721; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P61; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NICOL GD, 1989, J GEN PHYSIOL, V94, P233, DOI 10.1085/jgp.94.2.233; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; STRYER L, 1987, CHEM SCRIPTA, V27B, P161; STRYER L, 1991, J BIOL CHEM, V266, P10711; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P103; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	67	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24501	24507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332960				2022-12-27	WOS:A1992KA26300055
J	HOSLER, JP; FETTER, J; TECKLENBURG, MMJ; ESPE, M; LERMA, C; FERGUSONMILLER, S				HOSLER, JP; FETTER, J; TECKLENBURG, MMJ; ESPE, M; LERMA, C; FERGUSONMILLER, S			CYTOCHROME-AA3 OF RHODOBACTER-SPHAEROIDES AS A MODEL FOR MITOCHONDRIAL CYTOCHROME-C-OXIDASE - PURIFICATION, KINETICS, PROTON PUMPING, AND SPECTRAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; MAGNETIC CIRCULAR-DICHROISM; PARACOCCUS-DENITRIFICANS; HEME-A; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RAMAN-SPECTRA; RESOLUTION; COMPLEXES; PROTEIN	Aerobically grown Rhodobacter sphaeroides synthesizes a respiratory chain similar to that of eukaryotes. We describe the purification of the aa3-type cytochrome c oxidase of Rb. sphaeroides as a highly active (V(max) greater-than-or-equal-to 1800 s-1), three-subunit enzyme from isolated, washed cytoplasmic membranes by hydroxylapatite chromatography and anion exchange fast protein liquid chromatography. The purified oxidase exhibits biphasic kinetics of oxidation of mammalian cytochrome c, similar to mitochondrial oxidases, and pumps protons efficiently (H+/e- = 0.7) following reconstitution into phospholipid vesicles. A membrane-bound cytochrome c is associated with the aa3-type oxidase in situ, but is removed during purification. The EPR spectra of the Rb. sphaeroides enzyme suggest the presence of a strong hydrogen bond to one or both of the histidine ligands of heme a. In other respects, optical, EPR, and resonance Raman analyses of the metal centers and their protein environments demonstrate a close correspondence between the bacterial enzyme and the structurally more complex bovine cytochrome c oxidase. The results establish this bacterial oxidase as an excellent model system for the mammalian enzyme and provide the basis for site-directed mutational analysis of its energy transducing function.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University			Tecklenburg, Mary/L-9714-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037300, R37GM026916, R01GM026916, F32GM013047] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13047, GM37300, GM26916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; ALBRACHT SPJ, 1980, BIOCHIM BIOPHYS ACTA, V593, P173, DOI 10.1016/0005-2728(80)90055-9; BABCOCK GT, 1983, BIOCHEMISTRY-US, V22, P2314, DOI 10.1021/bi00279a002; BABCOCK GT, 1979, BIOCHEMISTRY-US, V18, P2493, DOI 10.1021/bi00579a009; BABCOCK GT, 1988, BIOL APPLICATIONS RA, P293; BABCOCK GT, 1979, CYTOCHROME OXIDASE, P105; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BLUMBERG WE, 1971, ADV CHEM, V100, P271; BOLGIANO B, 1988, BIOCHIM BIOPHYS ACTA, V933, P341, DOI 10.1016/0005-2728(88)90041-2; BOLLI R, 1986, J BIOENERG BIOMEMBR, V18, P277, DOI 10.1007/BF00743048; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Brautigan D L, 1978, Methods Enzymol, V53, P128; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CALLAHAN PM, 1983, BIOCHEMISTRY-US, V22, P452, DOI 10.1021/bi00271a031; CAO J, 1992, J BIOL CHEM, V267, P24273; CAO JL, 1991, GENE, V101, P133, DOI 10.1016/0378-1119(91)90235-4; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CASEY RP, 1980, J BIOL CHEM, V255, P3994; CASEY RP, 1986, METHOD ENZYMOL, V126, P13; CASEY RP, 1979, BIOCHEM J, V182, P149, DOI 10.1042/bj1820149; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHING YC, 1985, BIOCHEMISTRY-US, V24, P4938, DOI 10.1021/bi00339a032; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; DEPAULA JC, 1990, BIOCHEMISTRY-US, V29, P8702, DOI 10.1021/bi00489a028; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; ERECINSKA M, 1979, BIOCHIM BIOPHYS ACTA, V545, P352, DOI 10.1016/0005-2728(79)90212-3; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FETTER J, 1992, BIOPHYS J, V61; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FUKUMORI Y, 1984, FEBS LETT, V170, P301, DOI 10.1016/0014-5793(84)81332-0; GADSBY PMA, 1982, FEBS LETT, V150, P59, DOI 10.1016/0014-5793(82)81304-5; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GENNIS RB, 1982, EUR J BIOCHEM, V125, P189, DOI 10.1111/j.1432-1033.1982.tb06667.x; HALTIA T, 1992, BIOCHIM BIOPHYS ACTA, V1098, P343, DOI 10.1016/S0005-2728(09)91016-7; HOSLER JP, 1992, BIOPHYS J, V61; ISHIBE N, 1991, J BIOL CHEM, V266, P23916; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; LANDRUM JT, 1980, J AM CHEM SOC, V102, P6729, DOI 10.1021/ja00542a011; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATHER MW, 1990, 41ST P MOSB C, P94; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MYER YP, 1978, BIOCHEMISTRY-US, V17, P3723, DOI 10.1021/bi00611a008; NUMATA M, 1989, J BIOCHEM-TOKYO, V105, P245, DOI 10.1093/oxfordjournals.jbchem.a122647; OHNISHI T, 1982, J BIOL CHEM, V257, P4821; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PEIFFER WE, 1990, BIOCHEMISTRY-US, V29, P8696, DOI 10.1021/bi00489a027; PEISACH J, 1973, ANN NY ACAD SCI, V206, P310, DOI 10.1111/j.1749-6632.1973.tb43219.x; PIERROT M, 1982, J BIOL CHEM, V257, P4341; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SALEMME FR, 1973, J BIOL CHEM, V248, P3910; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SASAKI T, 1970, BIOCHIM BIOPHYS ACTA, V197, P284, DOI 10.1016/0005-2728(70)90039-3; SAUNDERS VA, 1974, BIOCHIM BIOPHYS ACTA, V333, P439, DOI 10.1016/0005-2728(74)90128-5; SEELIG A, 1981, BIOCHIM BIOPHYS ACTA, V636, P162, DOI 10.1016/0005-2728(81)90089-X; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; SHAPLEIGH JP, 1992, J BACTERIOL, V174, P2338, DOI 10.1128/JB.174.7.2338-2343.1992; SHAPLEIGH JP, 1992, IN PRESS P NATL ACAD; SIEVERS G, 1983, BIOCHIM BIOPHYS ACTA, V742, P637, DOI 10.1016/0167-4838(83)90283-2; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; SMITH L, 1991, J BIOENERG BIOMEMBR, V23, P303, DOI 10.1007/BF00762224; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONE N, 1984, BIOCHEM J, V223, P809, DOI 10.1042/bj2230809; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; STEINRUCKE P, 1991, J BIOENERG BIOMEMBR, V23, P227, DOI 10.1007/BF00762219; STEVENS TH, 1982, J BIOL CHEM, V257, P2106; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; THOMPSON DA, 1983, BIOCHEMISTRY-US, V22, P3178, DOI 10.1021/bi00282a022; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; WALKER FA, 1984, J AM CHEM SOC, V106, P6888, DOI 10.1021/ja00335a003; WHATLEY FR, 1981, ANN NY ACAD SCI, V361, P330, DOI 10.1111/j.1749-6632.1981.tb46529.x; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V230, P466, DOI 10.1016/0003-9861(84)90427-2	86	116	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24264	24272						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332949				2022-12-27	WOS:A1992KA26300022
J	YANG, ZH; WENSEL, TG				YANG, ZH; WENSEL, TG			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF CDNA-ENCODING A MAMMALIAN INORGANIC PYROPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENZYMATIC-ACTIVITY; PLASMID DNA; YEAST; SEQUENCE; GENE; PURIFICATION; CEREVISIAE; PROTEINS	Extracts of soluble proteins from bovine retina contain multiple species of inorganic pyrophosphatase (PPase) that can be resolved by hydroxylapatite or ion exchange chromatography. We have purified one of these isoforms by a combination of chromatography and electrophoresis under denaturing conditions and have partially sequenced four peptides generated from it by CNBr digestion. This sequence information was used to clone PPase cDNA from a retinal cDNA library. Of five cDNA inserts, three were 1.3 kilobase pairs in length and two of these contained a complete open reading frame that was 867 base pairs long and encoded a 289-amino acid protein of 33 kDa. The deduced amino acid sequence is 49.5% identical to that of PPase from Saccharomyces cerevisiae, and contains identical amino acid residues at all of the positions previously identified as essential for catalytic activity in that enzyme. When the bovine PPase cDNA was expressed in Escherichia coli, catalytically active PPase was produced that comigrated with bovine retinal PPase in a nondenaturing gel and was clearly distinguishable from the host PPase. Northern analysis of poly(A)+ RNA from human, canine, and bovine retinas revealed that each contained a single major band of 1.4 kilobases that hybridized strongly with a pyrophosphatase cDNA probe. Southern analysis of bovine genomic DNA was consistent with the existence of one PPase gene. Thus, the multiple forms separated by chromatography may be derived from a common precursor or from mRNAs of very similar size.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER; NEI NIH HHS [EY07981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOND MW, 1980, BIOCHEMISTRY-US, V19, P94, DOI 10.1021/bi00542a015; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; COHEN SA, 1978, J BIOL CHEM, V253, P889; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHER RA, 1974, ANN HUM GENET, V37, P341, DOI 10.1111/j.1469-1809.1974.tb01841.x; FISHER RA, 1976, CYTOGENET CELL GENET, V16, P129, DOI 10.1159/000130572; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GONZALEZ MA, 1986, BIOCHEMISTRY-US, V25, P7179, DOI 10.1021/bi00370a062; HERBOMEL P, 1980, CR ACAD SCI D NAT, V291, P881; ICHIBA T, 1990, J BIOCHEM-TOKYO, V108, P572, DOI 10.1093/oxfordjournals.jbchem.a123244; Jenner HD, 1931, J BIOL CHEM, V93, P733; KAWASAKI I, 1990, NUCLEIC ACIDS RES, V18, P5888, DOI 10.1093/nar/18.19.5888; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; Kornberg A., 1962, HORIZONS BIOCH, P251; KURANOVA IP, 1987, BIOKHIMIYA, V53, P1821; LAHTI R, 1990, BIOCHEMISTRY-US, V29, P5761, DOI 10.1021/bi00476a017; LAHTI R, 1990, BIOCHIM BIOPHYS ACTA, V1038, P338, DOI 10.1016/0167-4838(90)90246-C; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PITTLER SJ, 1976, GENOMICS, V16, P201; PYNES GD, 1967, J BIOL CHEM, V242, P2119; Roche J, 1931, BIOCHEM J, V25, P1724, DOI 10.1042/bj0251724; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHATTON JB, 1981, CANCER RES, V41, P1866; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERZYAN SS, 1984, BIOORG KHIM+, V10, P1469; THUILLIER L, 1978, BIOCHIM BIOPHYS ACTA, V524, P198, DOI 10.1016/0005-2744(78)90118-3; YANG Z, 1992, Biophysical Journal, V61, pA468; YANG ZH, 1992, J BIOL CHEM, V267, P24634	38	23	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24641	24647						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1339444				2022-12-27	WOS:A1992KA26300074
J	CAMERON, CE; GRINDE, B; JENTOFT, J; LEIS, J; WEBER, IT; COPELAND, TD; WLODAWER, A				CAMERON, CE; GRINDE, B; JENTOFT, J; LEIS, J; WEBER, IT; COPELAND, TD; WLODAWER, A			MECHANISM OF INHIBITION OF THE RETROVIRAL PROTEASE BY A ROUS-SARCOMA VIRUS PEPTIDE SUBSTRATE REPRESENTING THE CLEAVAGE SITE BETWEEN THE GAG P2 AND P10 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; MURINE LEUKEMIA-VIRUS; POL POLYPROTEINS; HIV-1 PROTEASE; AVIAN-SARCOMA; TYPE-1 PROTEASE; VIRAL-RNA; SPECIFICITY; RESOLUTION; COMPLEX	The activity of the avian myeloblastosis virus (AMV) or the human immunodeficiency virus type 1 (HIV-1) protease on peptide substrates which represent cleavage sites found in the gag and gag-pol polyproteins of Rous sarcoma virus (RSV) and HIV-1 has been analyzed. Each protease efficiently processed cleavage site substrates found in their cognate polyprotein precursors. Additionally, in some instances heterologous activity was detected. The catalytic efficiency of the RSV protease on cognate substrates varied by as much as 30-fold. The least efficiently processed substrate, p2-p10, represents the cleavage site between the RSV p2 and p10 proteins. This peptide was inhibitory to the AMV as well as the HIV-1 and HIV-2 protease cleavage of other substrate peptides with K(i) values in the 5-20 muM range. Molecular modeling of the RSV protease with the p2-p10 peptide docked in the substrate binding pocket and analysis of a series of single-amino acid-substituted p2-p10 peptide analogues suggested that this peptide is inhibitory because of the potential of a serine residue in the P1' position to interact with one of the catalytic aspartic acid residues. To open the binding pocket and allow rotational freedom for the serine in P1', there is a further requirement for either a glycine or a polar residue in P2' and/or a large amino acid residue in P3'. The amino acid residues in P1-P4 provide interactions for tight binding of the peptide in the substrate binding pocket.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,2119 ABINGTON RD,CLEVELAND,OH 44106; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Case Western Reserve University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [R01CA052047, R01CA038046] Funding Source: NIH RePORTER; NCI NIH HHS [CA52047, CA38046] Funding Source: Medline; PHS HHS [N01 C01 74101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; ALLEN G, 1983, LABORATORY TECHNIQUE, V9, P135; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FU XD, 1988, J BIOL CHEM, V263, P2140; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRINDE B, 1992, J BIOL CHEM, V267, P9491; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8441, DOI 10.1021/bi00098a023; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KOHL N, 1988, P NATL ACAD SCI USA, V85, P4185; KOTLER M, 1989, J BIOL CHEM, V264, P3428; KOTLER M, 1988, P NATL ACAD SCI USA, V85, P4185, DOI 10.1073/pnas.85.12.4185; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; MAIBAUM J, 1988, J MED CHEM, V31, P625, DOI 10.1021/jm00398a022; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; PEPINSKY RB, 1984, J VIROL, V52, P145, DOI 10.1128/JVI.52.1.145-153.1984; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; STEEG CM, 1990, J VIROL, V64, P847, DOI 10.1128/JVI.64.2.847-855.1990; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; WILLS JW, 1991, J VIROL, V65, P3804, DOI 10.1128/JVI.65.7.3804-3812.1991	34	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23735	23741						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331099				2022-12-27	WOS:A1992JZ23900048
J	CANTOR, AB; BARANSKI, TJ; KORNFELD, S				CANTOR, AB; BARANSKI, TJ; KORNFELD, S			LYSOSOMAL-ENZYME PHOSPHORYLATION .2. PROTEIN RECOGNITION DETERMINANTS IN EITHER LOBE OF PROCATHEPSIN-D ARE SUFFICIENT FOR PHOSPHORYLATION OF BOTH THE AMINO AND CARBOXYL LOBE OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-TYPE OLIGOSACCHARIDES; HUMAN CATHEPSIN-D; N-ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; AFFINITY-CHROMATOGRAPHY; CELLS	Cathepsin D is a bilobed lysosomal aspartyl protease that contains one Asn-linked oligosaccharide/lobe. Each lobe also contains protein determinants that serve as recognition domains for binding of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, the first enzyme in the biosynthesis of the mannose 6-phosphate residues on lysosomal enzymes. In this study we examined whether the location of the protein recognition domain influences the relative phosphorylation of the amino and carboxyl lobe oligosaccharides. To do this, chimeric proteins containing either amino or carboxyl lobe sequences of cathepsin D substituted into a glycosylated form of the homologous secretory protein pepsinogen were expressed in Xenopus oocytes. The amino and carboxyl lobe oligosaccharides were then isolated from the various chimeric proteins and independently analyzed for their mannose 6-phosphate content. This analysis has shown that a phosphotransferase recognition domain located on either lobe of a cathepsin D/glycopepsinogen chimeric molecule is sufficient to allow phosphorylation of oligosaccharides on both lobes. However, phosphorylation of the oligosaccharide on the lobe containing the recognition domain is favored. We also found that the majority of the carboxyl lobe oligosaccharides of cathepsin D acquire two phosphates, whereas the amino lobe oligosaccharides only acquire one phosphate.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen G, 1986, LAB TECHNIQUES BIOCH, P30; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CANTOR AB, 1992, ANAL BIOCHEM, V205, P23357; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DONG JM, 1990, J BIOL CHEM, V265, P4210; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GEISELMANN V, 1992, J BIOL CHEM, V267, P13262; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LANG L, 1984, J BIOL CHEM, V259, P4663; LAZZARINO DA, 1989, J BIOL CHEM, V264, P5015; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MONTREUIL J, 1984, PURE APPL CHEM, V56, P859, DOI 10.1351/pac198456070859; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; WEITZ G, 1992, J BIOL CHEM, V267, P10039	32	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23349	23356						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331082				2022-12-27	WOS:A1992JY16300098
J	DWYER, LD; CROCKER, PJ; WATT, DS; VANAMAN, TC				DWYER, LD; CROCKER, PJ; WATT, DS; VANAMAN, TC			THE EFFECTS OF CALCIUM SITE OCCUPANCY AND REAGENT LENGTH ON REACTIVITY OF CALMODULIN LYSYL RESIDUES WITH HETEROBIFUNCTIONAL ARYL AZIDES - MAPPING INTERACTION DOMAINS WITH SPECIFIC CALMODULIN PHOTOPROBE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HELIX; BINDING-SITES; BOVINE BRAIN; TROPONIN-C; CA-2+ PUMP; PROTEINS; TRIFLUOPERAZINE; PHOSPHODIESTERASE; PHOTOCHEMISTRY; MUTATIONS	The relationship of structural and functional moieties on calmodulin is important in all venues of cell activity. In this study, we investigate the effect of lysine modification on calmodulin function. Azidosalicylate reagents containing different "linker arm" lengths, between the photoactive terminus and an amine-reactive N-hydroxysuccinimidyl ester moiety were used to modify calmodulin lysines at three different positions in a calcium-dependent manner. The short cross-linker, (ASNE-2 (where ASNE represents azidosalicylate N-hydroxysuccinimidyl ester), modifies Lys-75, whereas the longer reagent, ASNE-6, modifies lysines 21, 75, and 94. The modification of these different lysines is shown to be calcium-dependent. At 1-100 muM levels of calcium, only Lys-94 is modified, suggesting that modification of this residue is directed by both the binding of calcium to calcium-binding loops III and IV and the hydrophobic pocket exposed between these two loops as a result of calcium binding. At higher calcium concentrations (>200 muM), where sites I and II become filled, modification of Lys-21 or Lys-75 also was observed. All the modified calmodulins were able to stimulate 3',5'-cyclic-nucleotide phosphodiesterase fully although the K(act) for the Lys-75 and Lys-21 derivatives increased 10- and 50-fold, respectively. None of the modifications affected the activation of erythrocyte plasma membrane Ca2+-ATPase. Only the ASNE-6 Lys-75 derivative showed efficient (40%) photocross-linking to the Ca2+-ATPase. The ASNE-2 Lys-75 derivative as well as the ASNE-6 Lys-21 and Lys-94 derivatives did not show efficient calcium-dependent photocross-linking to this enzyme.	UNIV KENTUCKY,MED CTR,COLL MED,DEPT BIOCHEM,MS607,800 ROSE ST,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT CHEM,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-21868] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON A, 1983, EUR J BIOCHEM, V134, P459, DOI 10.1111/j.1432-1033.1983.tb07589.x; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; Crocker PJ, 1990, BIOCONJUGATE CHEM, V1, P419, DOI 10.1021/bc00006a008; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DALGARNO DC, 1984, BIOCHIM BIOPHYS ACTA, V791, P164, DOI 10.1016/0167-4838(84)90006-2; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GIEDROC DP, 1985, J BIOL CHEM, V260, P3406; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; IMAI N, 1990, BIOCONJUGATE CHEM, V2, P144; JAFFE CL, 1980, BIOCHEMISTRY-US, V19, P4423, DOI 10.1021/bi00560a007; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMIESON GA, 1979, BIOCHEM BIOPH RES CO, V90, P1048, DOI 10.1016/0006-291X(79)91932-6; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEYVA E, 1986, J AM CHEM SOC, V108, P3783, DOI 10.1021/ja00273a037; LINSE S, 1991, J BIOL CHEM, V266, P8050; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MANN DM, 1988, J BIOL CHEM, V263, P11284; MANN DM, 1989, J BIOL CHEM, V264, P2373; MANN DM, 1987, THESIS U KENTUCKY; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1983, BIOCHEMISTRY-US, V22, P5472, DOI 10.1021/bi00293a003; NIGGLI V, 1987, METHOD ENZYMOL, V139, P791; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS2; SCHUSTER GB, 1987, J AM CHEM SOC, V109, P7803; SHIELDS CJ, 1987, J AM CHEM SOC, V109, P4723, DOI 10.1021/ja00249a047; TORRES MJ, 1986, TETRAHEDRON LETT, V27, P791, DOI 10.1016/S0040-4039(00)84102-7; VANAMAN TC, 1983, METHOD ENZYMOL, V102, P296; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WEISS W, 1982, BIOCHEM PHARMACOL, V31, P2217	44	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22606	22615						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1343568				2022-12-27	WOS:A1992JW71900096
J	METZ, SA; RABAGLIA, ME; PINTAR, TJ				METZ, SA; RABAGLIA, ME; PINTAR, TJ			SELECTIVE INHIBITORS OF GTP SYNTHESIS IMPEDE EXOCYTOTIC INSULIN RELEASE FROM INTACT RAT ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PANCREATIC-ISLETS; PROTEIN-KINASE-C; GUANINE-NUCLEOTIDES; ADENYLATE-CYCLASE; MYCOPHENOLIC-ACID; LIPOXYGENASE INHIBITORS; ARACHIDONIC-ACID; MAMMALIAN-CELLS; PHOSPHOLIPASE-C; HUMAN-PLATELETS	To investigate whether GTP concentrations can be a regulatory step in exocytotic hormone secretion, we treated isolated rat islets with mycophenolic acid (MPA) or mizoribine, two selective inhibitors of de novo GTP synthesis. When islets were cultured over-night in purine-free medium containing the drug, MPA reduced GTP levels by up to 81 +/- 1%; guanine circumvented this block via the nucleotide "salvage" pathway. MPA concomitantly inhibited glucose (16.7 mM)-induced insulin secretion in batch-type incubations (or perifusions), by up to 68% at 50-mu-g/ml. Although the inhibition of secretion occurred over a similar concentration range as the reduction in total GTP content, the two variables were not directly correlated. However, the secretory effects also were prevented by adding guanine, but not hypoxanthine or xanthine, to the culture medium. Similar results for GTP content and insulin release were seen using mizoribine. Insulin content was modestly (-18%) reduced by MPA but indices of fractional release (release/insulin content) were also markedly impaired. Although MPA also reduced ATP levels more modestly (-39%) and increased UTP (+87%), these were not the cause of the secretory defect since adenine restored ATP and UTP nearly to normal, but did not alter the reduction in GTP content or insulin secretion. MPA also inhibited secretion induced by amino acid or by a phorbol ester but had virtually no effect on release induced by a depolarizing concentration of K+, suggesting that GTP depletion does not merely impede Ca+ influx or directly block Ca2+-activated exocytosis. However, a severe reduction of GTP content did not prevent the pertussis toxin-sensitive inhibition of insulin release induced by epinephrine, suggesting that the function of heterotrimeric GTP-binding proteins is not limited by ambient GTP concentrations. Although these studies do not elucidate the exact site(s) in the exocytotic cascade which depend on intact GTP stores, they do provide the first direct evidence that GTP is required (and can be rate limiting) for insulin release.	UNIV WISCONSIN,ENDOCRINOL SECT,MADISON,WI 53792; UNIV WISCONSIN,DEPT MED,MADISON,WI 53792; WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007389, R01DK037312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37312, DK-HL07389-11] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMSON SB, 1991, J IMMUNOL, V147, P231; ANDERSON WB, 1974, J BIOL CHEM, V249, P7041; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAPITO K, 1976, BIOCHEM J, V158, P335, DOI 10.1042/bj1580335; CARLIER MF, 1991, J BIOL CHEM, V266, P12361; COHEN MB, 1983, CANCER RES, V43, P1587; COHEN MB, 1981, J BIOL CHEM, V256, P8713; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DUNNE MJ, 1986, PFLUG ARCH EUR J PHY, V407, P564, DOI 10.1007/BF00657518; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EUGUI EM, 1991, TRANSPLANT P, V23, P15; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FRANKLIN TJ, 1977, EUR J BIOCHEM, V77, P113, DOI 10.1111/j.1432-1033.1977.tb11648.x; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEISBUHLER T, 1984, CIRC RES, V54, P536, DOI 10.1161/01.RES.54.5.536; GOLD G, 1982, J CLIN INVEST, V69, P554, DOI 10.1172/JCI110481; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRANDT R, 1986, BIOCHEM J, V237, P669, DOI 10.1042/bj2370669; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HARTMAN NR, 1991, MOL PHARMACOL, V40, P118; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HOENIG M, 1987, METABOLISM, V36, P295, DOI 10.1016/0026-0495(87)90192-2; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; JACKSON RC, 1977, BIOCHEM J, V166, P1; JOHNSON GS, 1979, J BIOL CHEM, V254, P95; JONES PM, 1988, BIOCHEM J, V254, P397, DOI 10.1042/bj2540397; KATADA T, 1981, J BIOL CHEM, V256, P8310; KIMURA N, 1979, J BIOL CHEM, V254, P3451; KIMURA N, 1980, FEBS LETT, V117, P172, DOI 10.1016/0014-5793(80)80938-0; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; KOYAMA H, 1983, BIOCHEM PHARMACOL, V32, P3547, DOI 10.1016/0006-2952(83)90301-5; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEE HJ, 1985, CANCER RES, V45, P5512; LUMPERT CJ, 1990, BIOCHEM J, V269, P639, DOI 10.1042/bj2690639; MARYNISSEN G, 1990, METABOLISM, V39, P87, DOI 10.1016/0026-0495(90)90153-4; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEHLER PS, 1980, J CLIN INVEST, V66, P1334, DOI 10.1172/JCI109986; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; METZ SA, 1989, BIOCHEM PHARMACOL, V38, P1849, DOI 10.1016/0006-2952(89)90421-8; METZ SA, 1988, DIABETES, V37, P65, DOI 10.2337/diabetes.37.1.65; METZ SA, 1990, ARCH BIOCHEM BIOPHYS, V283, P417, DOI 10.1016/0003-9861(90)90663-J; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; METZ SA, 1985, P NATL ACAD SCI USA, V82, P198, DOI 10.1073/pnas.82.1.198; MORGAN A, 1990, BIOCHEM J, V269, P521, DOI 10.1042/bj2690521; MORRIS RE, 1991, TRANSPLANT P, V23, P19; NGUYEN BT, 1984, CANCER RES, V44, P2272; NGUYEN BT, 1986, BIOCHEM J, V234, P263, DOI 10.1042/bj2340263; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; RIZZO MT, 1990, CELL SIGNAL, V2, P509, DOI 10.1016/0898-6568(90)90073-J; ROBERTSON RP, 1991, DIABETES, V40, P1, DOI 10.2337/diabetes.40.1.1; RODWELL VW, 1988, HARPERS BIOCH, P344; ROSENBERG EM, 1987, DIABETES, V36, P37, DOI 10.2337/diabetes.36.1.37; SAKAGUCHI K, 1975, CANCER RES, V35, P1643; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SIRCAR JC, 1983, PROSTA LEUKOTR MED, V11, P373, DOI 10.1016/0262-1746(83)90089-6; SMITH CM, 1977, J CYCLIC NUCL PROT, V3, P347; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; SRIBNEY M, 1977, BIOCHEM BIOPH RES CO, V79, P749, DOI 10.1016/0006-291X(77)91175-5; STOEHR SJ, 1990, BLOOD, V75, P479; SWEENEY MJ, 1972, CANCER RES, V32, P1803; THAMS P, 1986, DIABETOLOGIA, V29, P888, DOI 10.1007/BF00870145; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; ULLRICH S, 1989, FEBS LETT, V247, P401, DOI 10.1016/0014-5793(89)81379-1; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; ULLRICH S, 1990, BIOCHEM J, V270, P273, DOI 10.1042/bj2700273; WELSH N, 1991, BIOCHEM J, V275, P23, DOI 10.1042/bj2750023; WILSON BS, 1989, J IMMUNOL, V143, P259; WOLF BA, 1987, BIOCHEM J, V242, P137, DOI 10.1042/bj2420137; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507; ZUNKLER BJ, 1986, IRCS MED SCI-BIOCHEM, V14, P354	75	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12517	12527						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352288				2022-12-27	WOS:A1992HZ48300025
J	HARTMAN, J; HUANG, Z; RADO, TA; PENG, SY; JILLING, T; MUCCIO, DD; SORSCHER, EJ				HARTMAN, J; HUANG, Z; RADO, TA; PENG, SY; JILLING, T; MUCCIO, DD; SORSCHER, EJ			RECOMBINANT SYNTHESIS, PURIFICATION, AND NUCLEOTIDE BINDING CHARACTERISTICS OF THE 1ST NUCLEOTIDE BINDING DOMAIN OF THE CYSTIC-FIBROSIS GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; IDENTIFICATION; TRANSPORT; PROTEINS	The majority of mutations which lead to clinical cystic fibrosis are located within the two predicted nucleotide binding domains of the cystic fibrosis gene product. We have used a prokaryotic expression system to synthesize and purify the first nucleotide binding domain (NBD-1, amino acids 426-588) with and without the most common mutation associated with the disease (the deletion of phenylalanine at position 508, DELTA-F508). Both wild type and DELTA-F508 NBD-1 bind ATP-agarose in a quantitatively comparable manner; this binding was inhibited by excess Na2ATP, trinitrophenol-ATP, or 8-azido-ATP. Irreversible NBD-1 labeling by an ATP analog was demonstrated using [P-32]8-azido-ATP. This covalent labeling was inhibited by preincubation with Na2ATP, with half-maximal inhibition for Na2ATP occurring at approximately 5 mM for both the wild type and DELTA-F508 nucleotide binding domain. These experiments are among the first to confirm the expectation that the cystic fibrosis transmembrane conductance regulator NBD-1 binds nucleotide. Since, under the conditions used in our study, NBD-1 without phenylalanine 508 displays very similar nucleotide binding characteristics to the wild type protein, our results support previous structural models which predict that the DELTA-F508 mutation should not cause an alteration in ATP binding.	UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Jilling, Tamas/0000-0002-6200-3851; Hartman, John/0000-0003-1176-6469; Sorscher, Eric J./0000-0001-9341-3354				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; HALEY B, 1988, BIOLINE ICN BIOCHEMI, V2, P6; HARTMAN J, 1991, PEDIATR PULMONOLOG S, V6, pA39; HUANG Z, 1991, LANCET, V337, P1115; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KAREM BS, 1990, P NATL ACAD SCI USA, V87, P8447; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	20	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6455	6458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372605				2022-12-27	WOS:A1992HM05300002
J	NAKAYAMA, K; KIM, WS; TORII, S; HOSAKA, M; NAKAGAWA, T; IKEMIZU, J; BABA, T; MURAKAMI, K				NAKAYAMA, K; KIM, WS; TORII, S; HOSAKA, M; NAKAGAWA, T; IKEMIZU, J; BABA, T; MURAKAMI, K			IDENTIFICATION OF THE 4TH MEMBER OF THE MAMMALIAN ENDOPROTEASE FAMILY HOMOLOGOUS TO THE YEAST KEX2 PROTEASE - ITS TESTIS-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FUR GENE; SPERMATOGENIC CELLS; PROCESSING ENZYME; SERINE PROTEASE; CDNA SEQUENCE; MESSENGER-RNA; ENDOPEPTIDASE; PITUITARY; MOUSE; RAT	We used the polymerase chain reaction to identify a mouse testis cDNA that represented another member of a growing class of mammalian endoproteases involved in the processing of precursor proteins. This cDNA encoded a 655-residue protein, designated PC4, containing a bacterial subtilisin-like catalytic domain closely related to those of the recently characterized precursor-processing endoproteases, furin, PC1/PC3, PC2, and Kex2. Within this domain, the amino acid sequence of PC4 was 70, 58, 55, and 45% identical with those of mouse furin, mouse PC1/PC3, mouse PC2, and yeast Kex2, respectively. Northern blot analysis indicated that the PC4 mRNA was detectable only in the testes after the 20th day of postnatal development. Moreover, this message was mainly expressed in the round spermatids. These data suggest that PC4 represents a prime candidate for a precursor-processing endoprotease in the testicular germ cells and that its gene expression is regulated during spermatogenesis.	UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba	NAKAYAMA, K (corresponding author), UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN.		Nakayama, Kazuhisa/ABF-2924-2020	Hosaka, Masahiro/0000-0002-1422-1774; Nakayama, Kazuhisa/0000-0001-7701-7183				BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHIRWIN JM, 1979, BIOCHEMISTRY-US, V81, P5294; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DESCHEPPER CF, 1986, P NATL ACAD SCI USA, V83, P7552, DOI 10.1073/pnas.83.19.7552; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; EIPPER BA, 1987, PSYCHOPHARMACOLOGY 3, P385; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KIM WS, 1990, J BIOL CHEM, V265, P5930; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1985, J BIOL CHEM, V260, P7194; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; PANDEY KN, 1984, ENDOCRINOLOGY, V115, P1753, DOI 10.1210/endo-115-5-1753; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P7101, DOI 10.1093/nar/17.17.7101; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	45	258	265	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5897	5900						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372895				2022-12-27	WOS:A1992HK31800030
J	VONZASTROW, M; KOBILKA, BK				VONZASTROW, M; KOBILKA, BK			LIGAND-REGULATED INTERNALIZATION AND RECYCLING OF HUMAN BETA-2-ADRENERGIC RECEPTORS BETWEEN THE PLASMA-MEMBRANE AND ENDOSOMES CONTAINING TRANSFERRIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; DOWN-REGULATION; A431 CELLS; BINDING; PROTEINS; DESENSITIZATION; AGONIST; SEQUESTRATION; LOCALIZATION; RECOGNITION	Agonist-regulated redistribution of human beta-2-adrenergic receptors was examined in 293 cells. A specific antiserum recognizing the carboxyl-terminal hydrophilic domain of the receptor was developed, characterized, and used for immunocytochemical localization of receptors in fixed cells by conventional fluorescence and confocal fluorescence microscopy. The beta-adrenergic agonist isoproterenol induced redistribution of receptors from the surface of cells into small (< 1-mu-m diameter) punctate accumulations which were detected in cells within 2 min of agonist addition. The time course of receptor redistribution paralleled that of receptor sequestration measured by ligand binding, and receptor redistribution was reversible in the presence of the beta-adrenergic antagonist alprenolol. Optical sections imaged through cells by confocal microscopy localized receptor accumulations within the cytoplasm. To address the question of receptor internalization further, a mutant receptor possessing an engineered antigenic epitope in the amino-terminal hydrophilic domain was constructed, transfected into cells, and localized using both a monoclonal antibody recognizing the epitope tag (receptor ectodomain) and an antiserum recognizing the carboxyl terminus (receptor endodomain). In untreated cells most receptor antigen was detected at the cell surface, as assessed by accessibility to ectodomain antibodies in unpermeabilized specimens. In isoproterenol-treated cells, however, little receptor antigen was detected at the cell surface. Punctate receptor accumulations present in isoproterenol-treated cells were labeled by antibodies only following permeabilization of cells, as expected if these receptor accumulations were intracellular. Finally, internalized beta-adrenergic receptors colocalized with transferrin receptors, which are markers of endosomal membranes. These data provide several lines of evidence establishing that beta-adrenergic receptors undergo ligand-regulated internalization, they suggest that internalized receptors may be recycled back to the cell surface, and they provide the first direct indication that these processes involve the same endosomal membrane system passaged by constitutively recycling receptors.	STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT PSYCHIAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CARDIOVASC MED, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHUANG DM, 1979, P NATL ACAD SCI USA, V76, P3024, DOI 10.1073/pnas.76.6.3024; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; CLARK RB, 1985, J CYCLIC NUCL PROT, V10, P97; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; DOSS RC, 1981, J BIOL CHEM, V256, P2281; FREDERICK RC, 1985, J CELL BIOL, V29, P127; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HERTEL C, 1983, J CYCLIC NUCL PROT, V9, P119; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; KAVERI SV, 1987, EUR J BIOCHEM, V167, P449, DOI 10.1111/j.1432-1033.1987.tb13358.x; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; MARSHEMA I, 1980, MOL PHARMACOL, V18, P370; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; STILES GL, 1984, J BIOL CHEM, V259, P8655; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALDO GL, 1983, J BIOL CHEM, V258, P3900; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WOODS JW, 1989, EUR J CELL BIOL, V50, P132; ZEMCIK BA, 1988, BIOCHEM J, V251, P333, DOI 10.1042/bj2510333	41	328	338	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3530	3538						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371121				2022-12-27	WOS:A1992HD15400107
J	LINN, T; GREENBLATT, J				LINN, T; GREENBLATT, J			THE NUSA AND NUSG PROTEINS OF ESCHERICHIA-COLI INCREASE THE INVITRO READTHROUGH FREQUENCY OF A TRANSCRIPTIONAL ATTENUATOR PRECEDING THE GENE FOR THE BETA-SUBUNIT OF RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-DEPENDENT TERMINATION; BACTERIOPHAGE-LAMBDA; RIBOSOMAL-PROTEINS; NUCLEOTIDE-SEQUENCE; TRYPTOPHAN OPERON; MESSENGER-RNA; DNA; SITES; GROWTH; REGION	The genes for the beta (rpoB) and beta' (rpoC) subunits of Escherichia coli RNA polymerase are the distal members of a complex transcriptional unit that contains four upstream ribosomal protein genes. The RNA polymerase subunit genes are transcribed at a lower frequency than the ribosomal protein genes as a result of termination at an attenuator preceding rpoB. A purified in vitro transcription system was developed using linear DNA templates that carry the attenuator. The ability of known termination and antitermination proteins to modulate termination at the attenuator was tested. Both NusA and NusG increase the frequency of transcriptional readthrough at the attenuator whereas NusB, S10, and Rho had no significant effect in this system.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	LINN, T (corresponding author), UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON N6A 5C1,ONTARIO,CANADA.							AXELROD VD, 1978, NUCLEIC ACIDS RES, V10, P3549; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BARRY G, 1979, P NATL ACAD SCI USA, V76, P4922, DOI 10.1073/pnas.76.10.4922; BLUMENTHAL RM, 1980, J BACTERIOL, V142, P1049, DOI 10.1128/JB.142.3.1049-1054.1980; BRUCKNER R, 1981, MOL GEN GENET, V183, P277, DOI 10.1007/BF00270629; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; DAS A, 1976, MOL BASIS HOST VIRUS, P459; DENNIS PP, 1977, J MOL BIOL, V115, P603, DOI 10.1016/0022-2836(77)90105-X; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; FARNHAM PJ, 1982, CELL, V29, P945, DOI 10.1016/0092-8674(82)90457-3; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; GRAYHACK EJ, 1982, CELL, V51, P631; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; HAYWARD RS, 1978, MOL GEN GENET, V159, P89, DOI 10.1007/BF00401752; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; LITTLE DL, 1980, J BIOL CHEM, V255, P3536; MAHER DL, 1977, MOL GEN GENET, V155, P203, DOI 10.1007/BF00393161; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MORGAN BA, 1984, NUCLEIC ACIDS RES, V12, P5465, DOI 10.1093/nar/12.13.5465; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; NODWELL JR, 1991, IN PRESS GENES DEV; PEACOCK S, 1985, GENE, V33, P227, DOI 10.1016/0378-1119(85)90097-6; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; RALLING G, 1987, J BACTERIOL, V169, P2277, DOI 10.1128/jb.169.5.2277-2280.1987; RALLING G, 1984, J BACTERIOL, V158, P279, DOI 10.1128/JB.158.1.279-285.1984; RALLING G, 1985, MOL GEN GENET, V201, P379, DOI 10.1007/BF00331327; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Sambrook J, 1989, MOL CLONING LABORATO; SCAIFE J, 1976, RNA POLYMERASE, P207; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SIGMUND CD, 1988, BIOCHEMISTRY-US, V27, P5622, DOI 10.1021/bi00415a034; STEWARD KL, 1991, J MOL BIOL, V218, P23, DOI 10.1016/0022-2836(91)90870-C; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; TAYLOR WE, 1979, GENE, V6, P331, DOI 10.1016/0378-1119(79)90073-8; WARD DF, 1981, NATURE, V292, P212, DOI 10.1038/292212a0; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423; ZARUCKISCHULZ T, 1979, P NATL ACAD SCI USA, V76, P6115, DOI 10.1073/pnas.76.12.6115; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675	56	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1449	1454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370474				2022-12-27	WOS:A1992HA48500012
J	LORIES, V; CASSIMAN, JJ; VANDENBERGHE, H; DAVID, G				LORIES, V; CASSIMAN, JJ; VANDENBERGHE, H; DAVID, G			DIFFERENTIAL EXPRESSION OF CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS IN HUMAN MAMMARY EPITHELIAL-CELLS AND LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN-SULFATE; CORE PROTEINS; EXTRACELLULAR-MATRIX; DISTINCT MEMBRANE; HUMAN SYNDECAN; RECEPTOR; CLONING; FORMS	Treating the liposome-intercalatable heparan sulfate proteoglycans from human lung fibroblasts and mammary epithelial cells with heparitinase and chondroitinase ABC revealed different core protein patterns in the two cell types. Lung fibroblasts expressed heparan sulfate proteoglycans with core proteins of approximately 35, 48/90 (fibroglycan), 64 (glypican), and 125 kDa and traces of a hybrid proteoglycan which carried both heparan sulfate and chondroitin sulfate chains. The mammary epithelial cells, in contrast, expressed large amounts of a hybrid proteoglycan and heparan sulfate proteoglycans with core proteins of approximately 35 and 64 kDa, but the fibroglycan and 125-kDa cores were not detectable in these cells. Phosphatidylinositol-specific phospholipase C and monoclonal antibody (mAb) S1 identified the 64-kDa core proteins as glypican, whereas mAb 2E9, which also reacted with proteoglycan from mouse mammary epithelial cells, tentatively identified the hybrid proteoglycans as syndecan. The expression of syndecan in lung fibroblasts was confirmed by amplifying syndecan cDNA sequences from fibroblastic mRNA extracts and demonstrating the cross-reactivity of the encoded recombinant core protein with mAb 2E9. Northern blots failed to detect a message for fibroglycan in the mammary epithelial cells and in several other epithelial cell lines tested, while confirming the expression of both glypican and syndecan in these cells. Confluent fibroblasts expressed higher levels of syndecan mRNA than exponentially growing fibroblasts, but these levels remained lower than observed in epithelial cells. These data formally identify one of the cell surface proteoglycans of human lung fibroblasts as syndecan and indicate that the expression of the cell surface proteoglycans varies in different cell types and under different culture conditions.	CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, CAMPUS GASTHUISBERG O&N, HEREST 49, B-3000 LOUVAIN, BELGIUM	KU Leuven								Bernfield M, 1989, CURR OPIN CELL BIOL, V1, P953, DOI 10.1016/0955-0674(89)90064-1; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTER L, 1986, J BIOL CHEM, V261, P2079; DAVID G, 1989, EUR J BIOCHEM, V178, P609, DOI 10.1111/j.1432-1033.1989.tb14489.x; DAVID G, 1985, J BIOL CHEM, V260, P1067; DAVID G, 1989, J CELL BIOL, V108, P1165, DOI 10.1083/jcb.108.3.1165; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HAYASHI K, 1988, LAB INVEST, V58, P68; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LORIES V, 1987, J BIOL CHEM, V262, P854; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945	30	105	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1116	1122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1339431				2022-12-27	WOS:A1992GY96000071
J	LI, XJ; WU, YN; NORTH, RA; FORTE, M				LI, XJ; WU, YN; NORTH, RA; FORTE, M			CLONING, FUNCTIONAL EXPRESSION, AND DEVELOPMENTAL REGULATION OF A NEUROPEPTIDE-Y RECEPTOR FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							I-125 PEPTIDE-YY; RAT-BRAIN; PANCREATIC-POLYPEPTIDE; BINDING SITES; K RECEPTOR; CDNA; NEURONS	Neuropeptide Y, peptide YY, and pancreatic polypeptide are homologous 36-amino acid peptides that differ from most other peptide transmitters by having a relatively rigid conformation in aqueous solutions, defined as the pancreatic polypeptide fold, and a critical C-terminal tyrosine amide. These peptides serve as gastrointestinal hormones and neurotransmitters. A cDNA encoding a novel G protein-coupled receptor activated by neuropeptide Y was cloned from Drosophila by use of degenerate oligonucleotide primers and polymerase chain reaction amplification of cDNA prepared from transcripts expressed early in embryogenesis. The cDNA encodes a protein of 449 amino acids with the characteristics of a G protein-coupled receptor and shares significant amino acid identity with mammalian tachykinin receptors. When expressed in Xenopus oocytes, the PR4 protein is activated by mammalian neuropeptides in the order: peptide YY > neuropeptide Y >> pancreatic polypeptide. Northern analysis showed that PR4 receptor is expressed at equivalent levels in adult Drosophila head and body and that the expression of the PR4 receptor is regulated during development. The molecular characterization of this receptor should lead to a better understanding of the functional role of this important family of hormone receptors in adult organisms and during development.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PHARMACOL, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022					CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FLOOD JF, 1987, BRAIN RES, V421, P280, DOI 10.1016/0006-8993(87)91297-2; HOKFELT T, 1983, NEUROSCI LETT, V29, P217; KINSON J, 1988, BRAIN RES, V446, P379; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; LUNDBERG JM, 1983, NEUROSCI LETT, V42, P167, DOI 10.1016/0304-3940(83)90401-9; LYNCH DR, 1989, J NEUROSCI, V9, P2607; MARTEL JC, 1990, NEUROSCIENCE, V36, P255, DOI 10.1016/0306-4522(90)90367-D; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; OTDONOHUE TL, 1985, PEPTIDES, V6, P755; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; SAUDOU F, 1990, EMBO J, V9, P3611, DOI 10.1002/j.1460-2075.1990.tb07572.x; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2514, DOI 10.1073/pnas.79.8.2514; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WITZ P, 1990, P NATL ACAD SCI USA, V87, P8940, DOI 10.1073/pnas.87.22.8940; WOLFGANG W, 1991, IN PRESS DEVELOPMENT; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	26	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370455				2022-12-27	WOS:A1992GY43900003
J	LEVY, JR; HUG, V				LEVY, JR; HUG, V			REGULATION OF INSULIN-RECEPTOR GENE-EXPRESSION - CELL CYCLE-MEDIATED EFFECTS ON INSULIN-RECEPTOR MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER REGION; DEGRADATION; MECHANISMS; SEQUENCES; POLY(A); GROWTH; CDNA	Posttranscriptional mechanisms play important roles in insulin receptor gene regulation; variability in cellular insulin receptor number and the growth arrest-mediated increases in insulin receptor mRNA are secondary to changes in insulin receptor mRNA stability. Therefore, further characterization of the pathways and kinetics of insulin receptor mRNA degradation were investigated. The insulin receptor mRNA in the insulin receptor-rich Hep G2 cells is more stable compared with the insulin receptor-sparse MCF-7 cells. Growth arrest results in a significant rise in insulin receptor mRNA in both cell lines. The increase in mRNA is caused by changes in mRNA stability. The half-life of the insulin receptor mRNA in growth-arrested cells is approximately three times that of proliferating cells. The insulin receptor gene contains four polyadenylation sites that produce four species of mRNA of 5.4, 6.9, 8.0, and 9.4 kilobases (kb). The mRNA species are not coordinately regulated. The ratio of the most abundant species (9.4/6.9) is significantly larger in growth-arrested cells compared with proliferating cells. By utilizing a specific cDNA probe for the 9.4-kb mRNA species, it was determined that the diminished 9.4/6.9 ratio in proliferating cells was caused by a more rapid rate of the 9.4-kb mRNA degradation. The kinetics of insulin receptor mRNA degradation were investigated. Insulin receptor mRNA levels were reduced to 56% of their base line within 6 h when growth-arrested cells were stimulated to proliferate; protein inhibition with cycloheximide completely inhibited the decline in insulin receptor mRNA.			LEVY, JR (corresponding author), MCGUIRE VET AFFAIRS MED CTR,DEPT RES,MED SERV 111-P,1201 BROAD ROCK BLVD,RICHMOND,VA 23249, USA.							ARAKI E, 1987, J BIOL CHEM, V262, P16186; CHENG GH, 1989, P NATL ACAD SCI USA, V86, P7002, DOI 10.1073/pnas.86.18.7002; CLEVELAND D W, 1989, New Biologist, V1, P121; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HATADA EN, 1989, J BIOL CHEM, V264, P6741; KAHN CR, 1985, ANNU REV MED, V36, P429; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; KIM YK, 1992, J BIOL CHEM, V267, P2723; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEVY JR, 1991, DIABETES, V40, P58, DOI 10.2337/diabetes.40.1.58; LUSCHER B, 1985, P NATL ACAD SCI USA, V82, P4389, DOI 10.1073/pnas.82.13.4389; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MCDONALD AR, 1987, DIABETES, V36, P779, DOI 10.2337/diabetes.36.6.779; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MUSCHEL R, 1986, MOL CELL BIOL, V6, P337, DOI 10.1128/MCB.6.1.337; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; THEIL EC, 1990, J BIOL CHEM, V265, P4771; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25289	25295						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334088				2022-12-27	WOS:A1992KB60300058
J	JANASWAMI, PM; KALVAKOLANU, DVR; ZHANG, YH; SEN, GC				JANASWAMI, PM; KALVAKOLANU, DVR; ZHANG, YH; SEN, GC			TRANSCRIPTIONAL REPRESSION OF INTERLEUKIN-6 GENE BY ADENOVIRAL E1A PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; NUCLEAR FACTOR; INTERFERON; EXPRESSION; BINDING; DNA; TRANSFORMATION; PRODUCTS; TYPE-5; DIFFERENTIATION	Transcription of interleukin-6 (IL-6) gene in human HepG2 and HeLa cells was induced by treatment with interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), phorbol 12-myristate 13-acetate, or dibutyryl cyclic AMP. These agents enhanced the expression of chloramphenicol acetyltransferase (CAT) activity in cells transfected with chimeric CAT genes driven by the transcriptional regulatory regions of human IL-6 gene. Both induced and basal levels of CAT expression were severely repressed upon co-transfection of expression vectors encoding the adenoviral E1A289R or E1A243R protein. The conserved region 1 of E1A proteins was required for this activity. IL-6-CAT expression could also be induced by co-transfecting expression vectors containing cDNAs of the catalytic subunit of protein kinase A or c-jun. E1A repressed transcriptional induction by these agents as well. Similar inhibition was observed when a CAT gene driven by the NFkappaB element of the IL-6 gene was used as a reporter plasmid. In a cell line stably transfected with the E1A gene, IL-1 or TNF-alpha failed to induce IL-6 mRNA. Electrophoretic mobility shift assays were carried out with nuclear extracts of these cells using, as probes, the NFkappaB element or the multiple regulatory element of the IL-6 gene. With either probe, additional faster migrating DNA-protein complexes were formed in the extracts of E1A-expressing cells as compared with the extracts of the corresponding control cells. Experiments with NFkappaB antibody revealed differences between the different DNA-protein complexes formed in the extract of E1A-expressing cells. These observations suggest that E1A represses IL-6 gene transcription by interfering with the formation of appropriate DNA-protein complexes.	CLEVELAND CLIN FDN, RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2-104, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIAID NIH HHS [AI-22510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1988, BIOESSAYS, V9, P11, DOI 10.1002/bies.950090104; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SHENK T, 1991, ADV CANCER RES, V57, P47; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; SPERGEL JM, 1991, P NATL ACAD SCI USA, V88, P6472, DOI 10.1073/pnas.88.15.6472; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TANABE O, 1988, J IMMUNOL, V141, P3875; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; VANDAM H, 1989, ONCOGENE, V4, P1207; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	44	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24886	24891						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332971				2022-12-27	WOS:A1992KA26300108
J	MENENDEZARIAS, L; YOUNG, M; OROSZLAN, S				MENENDEZARIAS, L; YOUNG, M; OROSZLAN, S			PURIFICATION AND CHARACTERIZATION OF THE MOUSE MAMMARY-TUMOR VIRUS PROTEASE EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GLUTATHIONE-S-TRANSFERASE; DEFICIENCY SYNDROME AIDS; CELL LEUKEMIA-VIRUS; HIV-1 PROTEASE; NUCLEOTIDE-SEQUENCE; ASPARTIC PROTEASE; CRYSTAL-STRUCTURE; PROTEINS; GAG	The mouse mammary tumor virus (MMTV) protease gene was cloned into pGEX-2T, an Escherichia coli expression vector containing the glutathione S-transferase coding region of Schistosoma japonicum. The chimeric protein was formed by fusion of the glutathione S-transferase with a hexapeptide which contains a thrombin cleavage site, followed by the MMTV protease. Affinity chromatography on a glutathione-Sepharose 4B column was used to isolate the chimeric protein. After thrombin cleavage, the glutathione S-transferase and the protease were separated by gel filtration chromatography on a Sephadex G-75 column. The overall yield of the protease purification procedure was about 1 mg of protease/liter of culture, and the specific activity was 380 pmol/min.mug of enzyme. Like other retroviral proteases, the MMTV enzyme was active as a dimer, showed maximum activity at pH between 4 and 6, and could be inhibited by pepstatin A and a phosphinic acid derivative HIV-1 protease inhibitor. Enzymatic characterization of this protease reveals its broad specificity, showing a clear preference for the oligopeptide substrate mimicking the cleavage site at the amino-terminal end of the capsid protein (k(cat)/K(m) = 9725.5 M-1.s-1). The chimeric protein was also an active dimer and showed a similar K(m) (17 muM) for such an oligopeptide, although its k(cat) was about 10 times smaller. Autocatalytic processing of the MMTV protease was observed after expression of clones containing the natural cleavage site, as it occurs at the amino-terminal end of the viral protease, instead of the thrombin-sensitive sequence.			MENENDEZARIAS, L (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA.		Arias, Luis Menendez/N-7447-2016; Menendez Arias, Luis/G-2436-2016	Arias, Luis Menendez/0000-0002-1251-6640; 	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENNETT RP, 1991, J VIROL, V65, P272, DOI 10.1128/JVI.65.1.272-280.1991; BILLICH S, 1988, J BIOL CHEM, V263, P17905; BOUTELJE J, 1990, ARCH BIOCHEM BIOPHYS, V283, P141, DOI 10.1016/0003-9861(90)90624-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GIAM CZ, 1988, J BIOL CHEM, V263, P14617; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; KOBAYASHI M, 1991, FEBS LETT, V293, P106, DOI 10.1016/0014-5793(91)81162-2; KRAUSSLICH HG, 1989, CURRENT COMMUNICATIO; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P11392; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y; [No title captured]	40	28	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24134	24139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331110				2022-12-27	WOS:A1992JZ23900105
J	ZHANG, XM; WEBER, I; CHEN, MJ				ZHANG, XM; WEBER, I; CHEN, MJ			SITE-DIRECTED MUTATIONAL ANALYSIS OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA RECEPTOR-BINDING SITE AND STRUCTURE-FUNCTIONAL RELATIONSHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE SEQUENCE; EXPRESSION; CDNA; IDENTIFICATION; DOMAINS; FORM	In order to define the receptor binding site and the structure-functional relationship of tumor necrosis factor (TNF), single amino acid substitutions were made by site-directed mutagenesis at selected residues of human tumor necrosis factor, using a phagemid mutagenesis/expression vector. The recombinant TNF mutants were compared to the wild type TNF in assays using crude bacterial lysates, for protein yield, solubility, subunit trimerization, receptor binding inhibition activity, and in vitro cytotoxic activity. All mutants which did not form cross-linkable trimer also showed little cytotoxic activity or receptor binding inhibition activity, indicating that trimer formation is obligatory for TNF-alpha activity. Most mutations of internal residues yielded no cross-linkable trimer, while most mutations of surface residues yielded cross-linkable trimer. Mutations at surface residues Leu29, Arg31, and Ala35 yielded cross-linkable trimers with good activities, except proline substitutions which may cause conformational changes in the polypeptide chain. This suggested that these residues are near the receptor binding site. Mutations at other strictly conserved internal residues such as Ser60, His78, and Tyr119 form cross-linkable trimer with little activity. These mutations may indirectly affect the receptor binding site by forming trimers with undetectable abnormalities. Mutants of surface residues Tyr87, Ser95, Ser133, and Ser147 affect receptor binding and cytotoxic activity but not trimer formation, suggesting that these residues are involved directly in receptor binding. The fact that residues Arg31, Ala35, Tyr87, Ser95, and Ser147, located on the opposite sides of a monomer, are clustered at the intersubunit grooves of TNF trimer supports the current notion that TNF receptor binding sites are trivalent and are located at the three intersubunit grooves. However, our finding that Ser133, which is outside the groove, can also be involved directly in receptor binding suggested that the receptor binding sites of TNF may not be confined to the intersubunit grooves, but extended to include additional surface residues.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; SK&F LABS,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406	Jefferson University; Jefferson University; Jefferson University								ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHAN JYC, 1990, NUCLEIC ACIDS RES, V18, P6723; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHEN MJ, 1988, MONOKINES OTHER NONL, P243; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DREWS RT, 1990, NUCLEIC ACIDS RES, V18, P5564, DOI 10.1093/nar/18.18.5564; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FRANSEN L, 1985, NUCLEIC ACIDS RES, V12, P9323; GOH CR, 1991, PROTEIN ENG, V4, P385, DOI 10.1093/protein/4.4.385; GOH CR, 1991, PROTEIN ENG, V4, P785; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; GRAY PW, 1984, NATURE, V312, P712; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITO H, 1986, DNA-J MOLEC CELL BIO, V5, P149, DOI 10.1089/dna.1986.5.149; JONES EY, 1990, USE OF X-RAY CRYSTALLOGRAPHY IN THE DESIGN OF ANTIVIRAL AGENTS, P345; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KUNITANI MG, 1988, J CHROMATOGR, V443, P205, DOI 10.1016/S0021-9673(00)94794-0; LAM KS, 1988, J BIOL RESP MODIF, V7, P267; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MCGRAW RA, 1990, NUCLEIC ACIDS RES, V18, P5563, DOI 10.1093/nar/18.18.5563; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PORTEU F, 1991, J BIOL CHEM, V266, P18846; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEMON D, 1987, NUCLEIC ACIDS RES, V15, P9083, DOI 10.1093/nar/15.21.9083; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHIRAI T, 1989, AGR BIOL CHEM TOKYO, V53, P1733, DOI 10.1080/00021369.1989.10869529; SIDHU RS, 1989, ANTICANCER RES, V9, P1569; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SU XZ, 1991, GENE, V107, P319, DOI 10.1016/0378-1119(91)90333-7; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VIERA J, 1987, METHOD ENZYMOL, V153, P3; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	39	68	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24069	24075						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331108				2022-12-27	WOS:A1992JZ23900096
J	TERCERO, JC; RILES, LE; WICKNER, RB				TERCERO, JC; RILES, LE; WICKNER, RB			LOCALIZED MUTAGENESIS AND EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION OF MAK3 - A PUTATIVE N-ACETYLTRANSFERASE REQUIRED FOR DOUBLE-STRANDED-RNA VIRUS PROPAGATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACETYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CHORISMATE MUTASE; LACZ FUSIONS; CELL-GROWTH; YEAST; GENE; PROTEIN; DNA	The MAK3 gene of Saccharomyces cerevisiae is necessary for the propagation of the L-A double-stranded RNA virus and its satellites, such as M1 that encodes a killer toxin. We cloned the MAK3 gene based on its genetic map position using physically mapped lambda-clones covering nearly all of the yeast genome. The minimal sequence necessary to complement the mak3-1 mutation contained 3 open reading frames (ORFs). Only one (ORF3) was necessary to complement mak3-1. A deletion insertion mutant of ORF3 grew slowly on nonfermentable carbon sources, an effect not due simply to its loss of L-A. Although ORF3 alone is sufficient for MAK3 activity when expressed from an expression vector, in its native context an additional 669 base pairs 3' to the ORF and complementary to the gene for a non-histone protein are necessary for expression, but not for normal steady state transcript levels. This suggests a posttranscriptional control of MAK3 expression by the 3' region. The MAK3 protein has substantial homology with several N-acetyltransferases with consensus patterns h..h.h...Y..[HK]GI[AG][KR].Lh...h and h.h[DE] ....N..A...Y...GF.........Y...[DE]G, (h = hydrophobic). Mutation of any of the underlined conserved residues (94GI --> AA, 123N --> A, 130Y --> A, 134GF --> SL, 144Y --> A, and 149G --> A) inactivated the gene, supporting the hypothesis that MAK3 encodes an N-acetyltransferase.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	TERCERO, JC (corresponding author), NIDDKD, GENET SIMPLE EUKARYOTES SECT, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA.		Bueren, Juan/L-6112-2014	Bueren, Juan/0000-0002-3228-7013				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; BALL SG, 1986, MOL GEN GENET, V205, P326, DOI 10.1007/BF00430446; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; COHN MS, 1978, J BIOL CHEM, V253, P5225; DIHANICH M, 1989, MOL CELL BIOL, V9, P1100, DOI 10.1128/MCB.9.3.1100; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HITZEMAN RA, 1983, SCIENCE, V219, P620, DOI 10.1126/science.6186023; HONJO M, 1990, J BACTERIOL, V172, P1783, DOI 10.1128/jb.172.4.1783-1790.1990; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; ICHO T, 1988, J BIOL CHEM, V263, P1467; ICHO T, 1989, J BIOL CHEM, V264, P6716; ISONO K, 1980, MOL GEN GENET, V177, P645; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LEE FJS, 1989, J BIOL CHEM, V264, P12339; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHEINI T, 1989, J BACTERIOL, V171, P1245, DOI 10.1128/jb.171.3.1245-1253.1989; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAPIRO M, 1990, BINARY, V2, P187; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SOMMER SS, 1982, J BACTERIOL, V150, P545, DOI 10.1128/JB.150.2.545-551.1982; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; STILES JI, 1983, METHOD ENZYMOL, V101, P290; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TENOVER FC, 1988, J BACTERIOL, V170, P471, DOI 10.1128/jb.170.1.471-473.1988; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1988, ANAL BIOCHEM, V174, P128, DOI 10.1016/0003-2697(88)90526-X; THRASH C, 1984, J BIOL CHEM, V259, P1375; TYAGI AK, 1984, P NATL ACAD SCI-BIOL, V81, P1149, DOI 10.1073/pnas.81.4.1149; WCKNER RB, 1988, P NATL ACAD SCI USA, V85, P6007; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1976, J MOL BIOL, V105, P427, DOI 10.1016/0022-2836(76)90102-9; WICKNER RB, 1976, GENETICS, V82, P429; WICKNER RB, 1982, P NATL ACAD SCI-BIOL, V79, P4706, DOI 10.1073/pnas.79.15.4706; WICKNER RB, 1991, MOL CELLULAR BIOL YE; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	54	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20270	20276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1339437				2022-12-27	WOS:A1992JR85800082
J	ASTROM, J; ASTROM, A; VIRTANEN, A				ASTROM, J; ASTROM, A; VIRTANEN, A			PROPERTIES OF A HELA CELL-3' EXONUCLEASE SPECIFIC FOR DEGRADING POLY(A) TAILS OF MAMMALIAN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL EXORIBONUCLEASE; BINDING-PROTEIN; RAT-LIVER; POLYADENYLATION; TRANSLATION; POLYMERASE; CLEAVAGE; SITE; DEADENYLATION; PURIFICATION	A HeLa cell 3'-exonuclease with properties of a mammalian mRNA poly(A) tail-removing enzyme has been characterized. The exonuclease shows high specificity for the poly(A) tail, and it is single strand-specific and requires a 3'-hydroxyl group for its activity. During degradation 5'-AMP is liberated as a product, and a 3'-OH group is left on the last adenosine residue of the remaining poly(A) tail. The activity is inhibited by 5'-AMP and can be competed by poly(A)-containing mRNA or poly(A). Based on these findings we propose a reaction pathway for poly(A) tail removal catalyzed by the HeLa cell poly(A) tail-specific 3' exonuclease.			ASTROM, J (corresponding author), UNIV UPPSALA, CTR BIOMED, DEPT MED GENET, BOX 589, S-75123 UPPSALA, SWEDEN.							ABRAHAM AK, 1978, P NATL ACAD SCI USA, V75, P2085, DOI 10.1073/pnas.75.5.2085; ABRAHAM AK, 1980, EUR J BIOCHEM, V110, P1, DOI 10.1111/j.1432-1033.1980.tb04836.x; ASTROM A, 1991, EUR J BIOCHEM, V202, P765, DOI 10.1111/j.1432-1033.1991.tb16431.x; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; FARNUM SM, 1990, GENE DEV, V4, P2278; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KUMAGAI H, 1985, BIOCHIM BIOPHYS ACTA, V827, P431, DOI 10.1016/0167-4838(85)90229-8; KUMAGAI H, 1979, BIOCHIM BIOPHYS ACTA, V566, P192, DOI 10.1016/0005-2744(79)90261-4; KWAN CN, 1977, BIOCHIM BIOPHYS ACTA, V479, P322, DOI 10.1016/0005-2787(77)90114-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARUS HM, 1967, P NATL ACAD SCI USA, V57, P1386, DOI 10.1073/pnas.57.5.1386; LAZARUS HM, 1968, P NATL ACAD SCI USA, V60, P1503, DOI 10.1073/pnas.60.4.1503; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; MULLER WE, 1980, H-S Z PHYSIOL CHEM, V361, P469; MULLER WEG, 1978, EUR J BIOCHEM, V86, P283, DOI 10.1111/j.1432-1033.1978.tb12309.x; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHRODER HC, 1980, J BIOL CHEM, V255, P4535; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SPORN MB, 1969, BIOCHEMISTRY-US, V8, P1698, DOI 10.1021/bi00832a053; TARUI Y, 1989, EUR J BIOCHEM, V186, P591, DOI 10.1111/j.1432-1033.1989.tb15249.x; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	34	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18154	18159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355481				2022-12-27	WOS:A1992JM22300103
J	EPPLER, CM; ZYSK, JR; CORBETT, M; SHIEH, HM				EPPLER, CM; ZYSK, JR; CORBETT, M; SHIEH, HM			PURIFICATION OF A PITUITARY RECEPTOR FOR SOMATOSTATIN - THE UTILITY OF BIOTINYLATED SOMATOSTATIN ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NUCLEOTIDE-BINDING-PROTEIN; PERTUSSIS TOXIN BLOCKS; ANTERIOR-PITUITARY; AFFINITY-CHROMATOGRAPHY; INSULIN-RECEPTOR; CELL-LINE; D2-DOPAMINE RECEPTOR; POLYACRYLAMIDE GELS; ADENYLATE-CYCLASE	A somatostatin (SRIF) receptor and its associated G(i) regulatory proteins was purified from GH4C1 rat pituitary cells by: 1) saturation of the membrane-bound receptor with biotinyl-NH-[Leu8,D-Trp22,Tyr25] SRIF28 (bio-S28); 2) solubilization of receptor-ligand (R.L) complex with deoxycholate-lysophosphatidylcholine (D.L); 3) adsorption of solubilized receptor-ligand complex to immobilized streptavidin; and 4) elution of receptor and G-protein by GTP. The receptor, a glycoprotein with an average M(r) of 85,000, was then purified to substantial homogeneity on immobilized wheat germ agglutinin. The 85-kDa glycoprotein was identified as a SRIF receptor by several criteria. (a) It had the same size as the chemically cross-linked R.[I-125]L complex. (b) Yield of the purified protein increased and plateaued in the same range of bio-S28 concentrations where specific high affinity binding reached saturation. (c) It was copurified with appropriate G-protein subunits. The 85-kDa receptor and two other proteins with M(r) values of 35,000 and 40,000, the sizes of G(beta) and G(alpha), did not appear in eluates from control streptavidin columns done with SRIF receptors loaded with nonbiotinylated S14. The 40-kDa protein was identified as a G(i-alpha) by ADP-ribosylation from [P-32]NAD catalyzed by pertussis toxin. (d) Both the chemically cross-linked R.[I-125]L complex and SRIF receptor purified from [S-35]methionine-labeled GH4C1 cells were reduced in size to about 38 kDa by endoglycosidase F. (e) Amino acid sequence from the purified receptor was nearly identical with that of a recently cloned SRIF receptor subtype.			EPPLER, CM (corresponding author), AMER CYANAMID CO,DEPT BIOCHEM & PHYSIOL,DIV AGR RES,POB 400,PRINCETON,NJ 08540, USA.							AMHARDT M, 1987, J CLIN INVEST, V80, P1455; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLOOM SR, 1975, GUT, V16, P834; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRAZEAU P, 1972, SCIENCE, V129, P77; BRENNAN DP, 1987, J BIOL CHEM, V262, P14795; BROWN M, 1981, ENDOCRINOLOGY, V108, P2391, DOI 10.1210/endo-108-6-2391; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; CUBERO A, 1984, J BIOL CHEM, V259, P1344; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FINN FM, 1984, P NATL ACAD SCI-BIOL, V81, P7328, DOI 10.1073/pnas.81.23.7328; FINN FM, 1990, METHOD ENZYMOL, V184, P244; FISHMAN JB, 1987, J BIOL CHEM, V262, P14049; GHEBREHIWET B, 1988, J IMMUNOL METHODS, V110, P251, DOI 10.1016/0022-1759(88)90111-1; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAZUM E, 1986, J BIOL CHEM, V261, P3043; HE HT, 1989, P NATL ACAD SCI USA, V86, P1480, DOI 10.1073/pnas.86.5.1480; HE HT, 1990, MOL PHARMACOL, V37, P614; HEIMAN ML, 1987, NEUROENDOCRINOLOGY, V45, P429, DOI 10.1159/000124788; HOFFMAN K, 1976, P NATL ACAD SCI USA, V73, P3516; HULMES JD, 1992, BIOCHEM BIOPH RES CO, V184, P131, DOI 10.1016/0006-291X(92)91168-P; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; KNUHTSEN S, 1988, BIOCHEM J, V254, P641, DOI 10.1042/bj2540641; KNUHTSEN S, 1990, J BIOL CHEM, V265, P1129; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOCH BD, 1984, ENDOCRINOLOGY, V114, P1784, DOI 10.1210/endo-114-5-1784; KOHANSKI RA, 1985, J BIOL CHEM, V260, P5014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; LIMBURD LE, 1976, J BIOL CHEM, V252, P799; LOMASNEY JW, 1986, J BIOL CHEM, V261, P7710; MAGUIRE ME, 1976, MOL PHARMACOL, V12, P335; MARIE J, 1990, BIOCHEMISTRY-US, V29, P8943, DOI 10.1021/bi00490a009; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOREL A, 1983, J BIOL CHEM, V258, P8273; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; PATEL YC, 1986, ANNU REV PHYSIOL, V48, P551; PAUL S, 1986, PEPTIDES, V7, P147, DOI 10.1016/0196-9781(86)90177-4; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REGAN JW, 1986, J BIOL CHEM, V261, P3894; REISINE T, 1985, J PHARMACOL EXP THER, V235, P551; REISINE T, 1985, J PHARMACOL EXP THER, V232, P275; REISINE T, 1990, J PHARMACOL EXP THER, V254, P646; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; SENOGLES SE, 1988, J BIOL CHEM, V263, P18996; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHORR RGL, 1982, P NATL ACAD SCI-BIOL, V79, P2778, DOI 10.1073/pnas.79.9.2778; SRIKANT CB, 1981, NATURE, V294, P259, DOI 10.1038/294259a0; SRIKANT CB, 1981, ENDOCRINOLOGY, V108, P341, DOI 10.1210/endo-108-1-341; SZECOWKA J, 1989, REGUL PEPTIDES, V24, P215, DOI 10.1016/0167-0115(89)90218-8; THERMOS K, 1990, AM J PHYSIOL, V259, pE216, DOI 10.1152/ajpendo.1990.259.2.E216; TRAN VT, 1985, SCIENCE, V228, P492, DOI 10.1126/science.2858917; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WATSON S, 1990, TRENDS PHARM SCI S, V12, P1; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZEGGARI M, 1987, EUR J BIOCHEM, V164, P667, DOI 10.1111/j.1432-1033.1987.tb11178.x	69	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15603	15612						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353497				2022-12-27	WOS:A1992JG11300056
J	KIM, IG; MCBRIDE, OW; WANG, M; KIM, SY; IDLER, WW; STEINERT, PM				KIM, IG; MCBRIDE, OW; WANG, M; KIM, SY; IDLER, WW; STEINERT, PM			STRUCTURE AND ORGANIZATION OF THE HUMAN TRANSGLUTAMINASE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BLOOD-COAGULATION FACTOR; HUMAN FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; GUINEA-PIG; ERYTHROCYTE-MEMBRANE; INSITU HYBRIDIZATION; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; EPIDERMAL-CELLS	Membrane-associated transglutaminases (TGase1) have recently been found to be common in mammalian cells, but it is not clear whether these derive from the same or different genes. In order to determine the complexity of this system, we have isolated and characterized the human gene (TGM1). The gene of 14,133 base pairs was found to contain 15 exons spliced by 14 introns. Interestingly, the positions of these introns have been conserved in comparison with the genes of two other transglutaminase-like activities described in the literature, but the TGM1 gene is by far the smallest characterized to date because its introns are relatively smaller. On the other hand, the TGase1 enzyme is the largest known transglutaminase (about 90 kDa), apparently because its gene acquired tracts that encode additional sequences on its amino and carboxyl termini that confer its unique properties. Southern blot analyses of total human genomic DNA cut with several restriction enzymes reveal only one band. Use of human-rodent cell hybrid panels and chromosomal in situ hybridization with biotin-labeled probes revealed that the human TGM1 gene maps to chromosome position 14q11.2-13. Such data suggest there is a single gene copy per haploid human genome. Comparisons of sequence identities and homologies indicate that the transglutaminase family of genes arose by duplications and subsequent divergent evolution from a common ancestor but later became scattered in the human genome. Although our present Southern blot and chromosomal localization studies revealed no restriction fragment length polymorphisms, comparisons of published sequences and our genomic clone indicate there are two sequence variants for TGase1 within the human population. The rare smaller variant contains a two-nucleotide deletion near the 5'-end, uses an alternate initiation codon, and differs from the common larger variant only in the first 15 amino acids. Furthermore, the DNA sequences of intron 14 possess several tracts of dinucleotide repeats that by polymerase chain reaction analysis show wide size polymorphism within the human population. Accordingly, this gene system constitutes a useful polymorphic marker for genetic linkage analyses.	NIAMSD,SKIN BIOL LAB,BLDG 10,RM 9N228,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; CARDINALI M, 1990, CANCER RES, V50, P8010; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEYOUNG L, 1984, J INVEST DERMATOL, V82, P275, DOI 10.1111/1523-1747.ep12260366; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENTILE V, 1991, J BIOL CHEM, V266, P478; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOLBROOK KA, 1991, J INVEST DERMATOL, V96, P542; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDEGENT JE, 1985, NATURE, V317, P175, DOI 10.1038/317175a0; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1990, BIOCHEM J, V271, P305, DOI 10.1042/bj2710305; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; ROTHNAGEL JA, 1984, MOL CELL BIOCHEM, V58, P113, DOI 10.1007/BF00240610; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	47	99	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7710	7717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348508				2022-12-27	WOS:A1992HN48500073
J	KAUMAYA, PTP; VANBUSKIRK, AM; GOLDBERG, E; PIERCE, SK				KAUMAYA, PTP; VANBUSKIRK, AM; GOLDBERG, E; PIERCE, SK			DESIGN AND IMMUNOLOGICAL PROPERTIES OF TOPOGRAPHIC IMMUNOGENIC DETERMINANTS OF A PROTEIN ANTIGEN (LDH-C4) AS VACCINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SYNTHETIC PEPTIDES; LACTATE DEHYDROGENASE-C4; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; ANTIBODY; COMPLEX; SITES; RESOLUTION; SEQUENCE	Antibodies elicited by immunization with short peptides containing antigenic determinants have been shown, in general, to bind with greatly reduced affinity to the corresponding region in the native proteins. Thus, contiguous linear peptides have not proven to be effective immunogens in generating high affinity neutralizing or protective antibodies and consequently appear to be poor prospects for vaccines. The molecular basis for such reduced reactivity is clear from the crystal structure determination of antibody Fabs bound to protein antigens, which showed the complementarity between interfaces to be lock-and-key-like and extending over a large area (750 angstrom2) involving discontinuous segments of the polypeptide chain. Thus, small perturbations in the secondary and tertiary structure of the antigen have profound effects on the fit of the antigen and its corresponding antibody. Because short peptides are unlikely to assume any particular conformation in solution, the fit is likely to be poor. New strategies are therefore required to produce conformationally stable peptides that mimic the critical structural features of the protein antigenic site. Here we show that a putative topographic determinant of the testis-specific isozyme of lactate dehydrogenase C4 (LDH-C4), designed and synthesized to adopt a well defined alpha-helical secondary and tertiary structure (four-helix bundle motif) in aqueous solutions, is highly immunogenic in both rabbits and mice, inducing IgG antibodies that bind to native LDH-C4. This engineered conformational 40-residue peptide is considerably more effective in inducing antibodies, as compared with the corresponding linear peptide. The antibody response is obtained without coupling the peptide to a carrier protein, suggesting that the peptide contains a T-cell antigenic determinant. The strategy described here to produce a conformationally stable peptide that mimics the native structure may have general applications in vaccine design.	OHIO STATE UNIV,COLL MED,DEPT OBSTET & GYNECOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED BIOCHEM,COLUMBUS,OH 43210; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,EVANSTON,IL 60201	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Northwestern University	KAUMAYA, PTP (corresponding author), OHIO STATE UNIV,COLL MED,CTR COMPREHENS CANC,SUITE 302,410 W 12TH AVE,COLUMBUS,OH 43210, USA.		Kaumaya, Pravin T. P/E-3354-2011		NIAID NIH HHS [AI25790] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025790] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BORRASCUESTA F, 1988, EUR J IMMUNOL, V18, P199, DOI 10.1002/eji.1830180203; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DRYBERG T, 1986, J EXP MED, V164, P1344; DYSON HJ, 1985, NATURE, V318, P480; EFIMOV AV, 1984, FEBS LETT, V166, P33, DOI 10.1016/0014-5793(84)80039-3; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FRANCIS MJ, 1987, NATURE, V330, P168, DOI 10.1038/330168a0; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; GOLDBERG E, 1981, FERTIL STERIL, V35, P214; GOLDBERG E, 1908, ISOZYES CURRENT TOPI, V14, P103; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HOGREFE HH, 1987, J BIOL CHEM, V262, P13155; HOGREFE HH, 1989, J BIOL CHEM, V264, P10513; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JEMMERSON R, 1990, EUR J IMMUNOL, V20, P579, DOI 10.1002/eji.1830200318; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KAUMAYA PTP, 1991, PEPTIDES 1990, P611; KAUMAYA PTP, 1990, PEPTIDES CHEM STRUCT, P709; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LAU SY, 1984, J BIOL CHEM, V239, P13253; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0; MULLER S, 1990, VACCINE, V8, P308, DOI 10.1016/0264-410X(90)90086-2; MUTTER M, 1986, Z NATURFORSCH B, V41, P1315, DOI 10.1515/znb-1986-1020; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMOLENSKI LA, 1990, EUR J IMMUNOL, V20, P953, DOI 10.1002/eji.1830200502; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWARD MW, 1987, IMMUNOL TODAY, V8, P51, DOI 10.1016/0167-5699(87)90239-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TULIP WR, 1989, COLD SH Q B, V54, P257; VANREGENMORTEL MHV, 1987, TRENDS BIOCHEM SCI, V12, P237, DOI 10.1016/0968-0004(87)90117-4	44	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6338	6346						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372905				2022-12-27	WOS:A1992HK31800092
J	IRONS, CE; SEI, CA; HIDAKA, H; GLEMBOTSKI, CC				IRONS, CE; SEI, CA; HIDAKA, H; GLEMBOTSKI, CC			PROTEIN-KINASE-C AND CALMODULIN KINASE ARE REQUIRED FOR ENDOTHELIN-STIMULATED ATRIAL-NATRIURETIC-FACTOR SECRETION FROM PRIMARY ATRIAL MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE SECRETION; VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; RAT CARDIOCYTES; PHORBOL ESTERS; GROWTH-FACTORS; CELLS; EXPRESSION; CALCIUM; RELEASE	Endothelin (ET), a potent stimulator of atrial natriuretic factor (ANF) secretion in atrial myocyte cultures, has been hypothesized to act via the stimulation of protein kinase C (PKC). This study was carried out in order to determine if ET activates PKC in atrial cultures and whether this activation fully accounts for the effects of ET on ANF secretion. By monitoring the phosphorylation of p80 upon exposure to phorbol ester or ET, it was shown that ET activated PKC in atrial cultures, but to a lesser extent than phorbol ester. In contrast, ET stimulated ANF secretion to a level five times greater than phorbol ester, indicating that PKC activation alone does not fully account for the effects of ET on ANF secretion. Down-regulation of PKC or exposure to the PKC inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H7) resulted in a 50% decrease in ET-stimulated ANF secretion. Interestingly, increasing calcium influx with BAY K 8644 stimulated ANF secretion but did not effect the phosphorylation of p80, indicating a PKC-independent pathway of ANF secretion. Similarly, a component of ET-stimulated secretion that required calcium influx was independent of PKC activation but was sensitive to the Ca2+/calmodulin kinase (CaMK) inhibitor KN-62. Complete inhibition of ET-mediated ANF secretion was obtained only in the presence of both H7 and KN-62. These results demonstrate that ET activates PKC in atrial myocyte cultures and that the full effects of ET on ANF secretion require both PKC and Ca2+/calmodulin kinase activities.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN	California State University System; San Diego State University; California State University System; San Diego State University; Nagoya University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERS DM, 1991, EXCITATION CONTRACTI, P143; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; ETSCHEID BG, 1991, CELL REGUL, V2, P229, DOI 10.1091/mbc.2.3.229; FABIATO A, 1986, BIOPHYS J, V49, pA190; FEARON CW, 1987, J BIOL CHEM, V262, P9515; FUKUDA Y, 1989, BIOCHEM BIOPH RES CO, V164, P1431, DOI 10.1016/0006-291X(89)91830-5; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; IIDA H, 1989, AM J PHYSIOL, V256, pC608, DOI 10.1152/ajpcell.1989.256.3.C608; ISHIKAWA N, 1990, J PHARMACOL EXP THER, V254, P598; JEFFERSON AB, 1991, J BIOL CHEM, V266, P1484; JETT MF, 1987, ARCH BIOCHEM BIOPHYS, V255, P354, DOI 10.1016/0003-9861(87)90403-6; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER MR, 1989, CIRCULATION S2, V80, P194; LEDSOME JR, 1985, CAN J PHYSIOL PHARM, V63, P739, DOI 10.1139/y85-121; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANNING PT, 1985, SCIENCE, V229, P395, DOI 10.1126/science.2990050; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SCHIEBINGER RJ, 1986, AM J PHYSIOL, V251, P1095; SCHLENDER KK, 1991, J BIOL CHEM, V266, P2811; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWARTZ D, 1985, SCIENCE, V229, P397, DOI 10.1126/science.3160114; SEI CA, 1990, J BIOL CHEM, V265, P7166; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	51	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5211	5216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371996				2022-12-27	WOS:A1992HH74700035
J	TURNER, SR; IRELAND, R; RAWSTHORNE, S				TURNER, SR; IRELAND, R; RAWSTHORNE, S			CLONING AND CHARACTERIZATION OF THE P-SUBUNIT OF GLYCINE DECARBOXYLASE FROM PEA (PISUM-SATIVUM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CLEAVAGE SYSTEM; LEAF MITOCHONDRIA; MULTIENZYME COMPLEX; H-PROTEIN; LIVER-MITOCHONDRIA; PURIFICATION; COMPONENT; SERINE; MATRIX	A pea leaf cDNA library constructed in lambda-gt11 was screened with an antibody raised to the P subunit of glycine decarboxylase. One of the positive clones isolated was sequenced and shown to contain an open reading frame, which encoded the entire P subunit polypeptide. Aligning the deduced amino acid sequence with the amino acid sequence determined directly from the NH2 terminus of the mature P subunit shows the presence of a putative 86 amino acid leader sequence, presumably required for import into the mitochondria, and gives a M(r) of the mature protein of 105,000. Comparison of this deduced amino acid sequence with the sequence of a pyridoxal phosphate-containing peptide isolated from the P subunit of chicken liver glycine decarboxylase shows remarkable conservation. The P subunit, however, shows little sequence homology with other published amino acid decarboxylases. Expression of the P subunit mRNA shows a pattern very similar to that of the corresponding polypeptide: it is strongly light induced and is expressed at a much higher level in leaves than in other tissues. Southern blot analysis suggests that the P subunit is encoded by a small multigene family.	JOHN INNES CTR,INST PLANT SCI RES,AFRC,CAMBRIDGE LAB,COLNEY LANE,NORWICH NR4 7UJ,ENGLAND; MT ALLISON UNIV,DEPT BIOL,SACKVILLE E0A 3C0,NB,CANADA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Mount Allison University			Turner, Simon/K-7580-2012	Turner, Simon/0000-0003-4859-1068				BLACKWELL RD, 1990, PLANT PHYSIOL, V94, P1316, DOI 10.1104/pp.94.3.1316; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; CLANDININ MT, 1975, BIOCHEMISTRY-US, V14, P387; DAY DA, 1985, AUST J PLANT PHYSIOL, V12, P219, DOI 10.1071/PP9850219; de Vries S, 1988, PLANT MOL BIOL MANUA; DELUCA V, 1989, P NATL ACAD SCI USA, V86, P2582; DOMONEY C, 1983, NUCLEIC ACIDS RES, V3, P687; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FREUDENBERG W, 1989, J BACTERIOL, V171, P2209, DOI 10.1128/jb.171.4.2209-2215.1989; FUJIWARA K, 1987, BIOCHEM BIOPH RES CO, V149, P621, DOI 10.1016/0006-291X(87)90413-X; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; GARDESTROM P, 1980, PLANT PHYSIOL, V65, P387; GARIBOLDI RT, 1984, J BIOL CHEM, V259, P6085; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HIRAGA K, 1980, J BIOL CHEM, V255, P1664; HIRAGA K, 1980, J BIOL CHEM, V255, P1671; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KIM Y, 1991, PHYSIOL PLANTARUM, V81, P501, DOI 10.1111/j.1399-3054.1991.tb05091.x; KIM YH, 1990, J BIOL CHEM, V265, P848; KUME A, 1991, J BIOL CHEM, V266, P3323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHEREL D, 1990, BIOCHEM J, V268, P783, DOI 10.1042/bj2680783; MOORE RC, 1990, J BACTERIOL, V172, P4631, DOI 10.1128/jb.172.8.4631-4640.1990; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOTOKAWA Y, 1974, ARCH BIOCHEM BIOPHYS, V164, P624, DOI 10.1016/0003-9861(74)90074-5; MURPHY G, 1988, NUCLEIC ACIDS RES, V16, P5198, DOI 10.1093/nar/16.11.5198; NEUBURGER M, 1986, FEBS LETT, V207, P18, DOI 10.1016/0014-5793(86)80005-9; OKUMARAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; ROSIE D, 1986, EMBO J, V5, P1327; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VONHEINJE G, 1985, J MOL BIOL, V184, P1327; WALKER JL, 1986, ARCH BIOCHEM BIOPHYS, V248, P626, DOI 10.1016/0003-9861(86)90517-5; WALKER JL, 1986, J BIOL CHEM, V261, P2214; WHITE BA, 1982, J BIOL CHEM, V257, P8569	39	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5355	5360						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347530				2022-12-27	WOS:A1992HH74700055
J	CHOU, CF; SMITH, AJ; OMARY, MB				CHOU, CF; SMITH, AJ; OMARY, MB			CHARACTERIZATION AND DYNAMICS OF O-LINKED GLYCOSYLATION OF HUMAN CYTOKERATIN-8 AND CYTOKERATIN-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE RESIDUES; INTERMEDIATE FILAMENTS; EPIDERMAL KERATINS; GLYCOPROTEINS; EXPRESSION; CELLS; PHOSPHORYLATION; PROTEINS; POLYPEPTIDES; HEPATOCYTES	The glycosylation of human cytokeratin (CK) 8 and 18 was studied after metabolic labeling of HT29 colonic cells with [H-3]glucosamine. Labeling of CK8/18 was not inhibited by tunicamycin, suggesting that glycosylation was not N-linked. Acid hydrolysis of CK8 and CK18, purified from [H-3]glucosamine-labeled cells, generated free glucosamine. In the presence of UDP-[H-3]galactose, galactosyltransferase catalyzed the labeling of cytokeratin 8 and 18. Beta-Elimination of t he [H-3]galactose- labeled CK8/18 generated the disaccharide N-acetyllactosaminitol, indicating that cytokeratin 8 and 18 contain single O-linked N-acetylglucosamine residues. Using chemical analysis, the stoichiometry of glycosylation was found to be 1.5 and 2 molecules of N-acetylglucosamine/protein molecule of CK8 and CK18, respectively. Peptide maps of [H-3] glucosamine-labeled CK8/18 showed that multiple peptides were labeled with the amino sugar. The biosynthetic and degradation rates of the carbohydrate moiety were faster than the protein core as determined by metabolic radiolabeling or pulse-chase experiments, respectively. Our results show that CK8 and 18 are glycosylated at multiple sites with a single O-linked N-acetylglucosamine. Furthermore, CK8/18 glycosylation is a dynamic process which is likely to have functional relevance.	VET ADM MED CTR, DEPT MED, DIV GASTROENTEROL, PALO ALTO, CA 94304 USA; BECKMAN CTR, PROGRAM MOLEC & GENET MED, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHOU, CF (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL, RM 51069, STANFORD, CA 94305 USA.			Omary, Bishr/0000-0002-8624-2347				BLOEMENDAL H, 1989, BIOCHIM BIOPHYS ACTA, V1007, P245, DOI 10.1016/0167-4781(89)90144-9; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DENK H, 1987, EXP CELL RES, V173, P137, DOI 10.1016/0014-4827(87)90339-9; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; GILMARTIN ME, 1984, J CELL BIOL, V98, P1144, DOI 10.1083/jcb.98.3.1144; HART GW, 1989, CIBA F SYMP, V145, P102; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KING IA, 1989, J BIOL CHEM, V264, P14022; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; MCTAVISH CF, 1983, FEBS LETT, V154, P251, DOI 10.1016/0014-5793(83)80159-8; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MULLIS KG, 1990, J VIROL, V64, P5317, DOI 10.1128/JVI.64.11.5317-5323.1990; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OMARY MB, 1991, AIDS, V5, P275, DOI 10.1097/00002030-199103000-00005; PEREZ MS, 1989, J IMMUNOL, V142, P3662; QUARONI A, 1991, J BIOL CHEM, V266, P11923; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; ROBERTS GP, 1983, BIOCHEM J, V212, P355, DOI 10.1042/bj2120355; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; YEAGLE PL, 1990, BIOCHEMISTRY-US, V29, P1508, DOI 10.1021/bi00458a023	36	191	196	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3901	3906						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371281				2022-12-27	WOS:A1992HE60700056
J	BO, M; BOIME, I				BO, M; BOIME, I			IDENTIFICATION OF THE TRANSCRIPTIONALLY ACTIVE GENES OF THE CHORIONIC GONADOTROPIN-BETA GENE-CLUSTER INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; SUBUNIT GENES; EXPRESSION; ALPHA; TISSUE; CELLS	The chorionic gonadotropin beta (CG-beta) subunit is encoded by a multigene cluster composed of six homologous sequences (genes or pseudogenes). They are primarily distinguished by sequences in the 5' nontranslated region of the first exon. To determine which CG-beta genes are active in vivo, we employed the reverse transcription-polymerase chain reaction technique. DNA complementary to RNA from placenta tissue and a choriocarcinoma cell line was subjected to polymerase chain reaction with CG-beta-specific primers. The amplified DNA was cloned into M13 and sequenced. Most of steady-state CG-beta mRNAs are transcribed from CG-beta genes, 5, 3, and 8. The level of expression is beta-5 > beta-3 = beta-8 > beta-7, beta-1/2. Transcripts from the CG-beta-1 and CG-beta-2 genes, which were previously considered pseudogenes because of their noncanonical splice site, were detected. These CG-beta transcripts arising from alternative splicing sites in the CG-beta-1/2 genes were also detected in polysomes which suggests they are translation-competent. Northern blotting with a CG-beta-1/2 probe revealed low amounts of CG-beta-1/2 transcripts which were smaller than the transcripts of the other genes. The results indicate that at least five, and possibly all six, CG-beta genes are transcribed in vivo, and at least one of them (CG-beta-1 and/or CG-beta-2) undergoes alternative splicing.			BO, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110, USA.							BOIME I, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1322, DOI 10.1073/pnas.71.4.1322; BOORSTEIN WR, 1982, NATURE, V300, P419, DOI 10.1038/300419a0; BOOTHBY M, 1981, J BIOL CHEM, V256, P5121; DARNELL RB, 1984, MOL CELL BIOL, V4, P829, DOI 10.1128/MCB.4.5.829; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GRAHAM MY, 1987, NUCLEIC ACIDS RES, V15, P4437, DOI 10.1093/nar/15.11.4437; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OTANI T, 1988, J BIOL CHEM, V263, P7322; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; POLICASTRO PF, 1986, J BIOL CHEM, V261, P5907; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TALMADGE K, 1984, NUCLEIC ACIDS RES, V12, P8415, DOI 10.1093/nar/12.22.8415; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TALMADGE K, 1983, DNA-J MOLEC CELL BIO, V2, P281, DOI 10.1089/dna.1983.2.281; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WONG M, 1989, J BIOL CHEM, V264, P12867; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	21	120	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3179	3184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371113				2022-12-27	WOS:A1992HD15400057
J	BOULANGER, P; LETELLIER, L				BOULANGER, P; LETELLIER, L			ION CHANNELS ARE LIKELY TO BE INVOLVED IN THE 2 STEPS OF PHAGE-T5 DNA PENETRATION INTO ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE; COLIPHAGE-T5 DNA; TRANSPORT; INJECTION; INFECTION; PROTEIN; FLUXES	Phage T5 injects its DNA into Escherichia coli cells in two steps; 8% of the chromosome is first injected, and then there is a pause during which proteins encoded by this DNA fragment are synthesized allowing the remaining DNA to be injected. Using a potassium-selective electrode, we show that the injection of the two DNA fragments is associated with an efflux in two steps, of cytoplasmic potassium. The rate of efflux is linearly related to the number of added phages suggesting that each phage induces the formation of at least one channel in the inner membrane. The first efflux occurs even in depolarized cells suggesting that the insertion and the opening of the channel can take place in the absence of the electrochemical gradient of protons (DELTA-mu(H)+). The channel is in a closed configuration during the time required for the synthesis of the phage-encoded proteins; this closing and the second efflux are prevented by the depolarization of the cell. The insertion of the channel in the inner membrane requires a fluid membrane. The results obtained suggest that the function of this channel is to translocate phage T5 DNA.	UNIV PARIS 11, BIOMEMBRANES LAB, CNRS, UA 1116, BAT 433, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOOTH IR, 1979, BIOCHEM J, V182, P687, DOI 10.1042/bj1820687; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BRADLEY DE, 1967, BACTERIOL REV, V31, P230, DOI 10.1128/MMBR.31.4.230-314.1967; BRAUN V, 1973, BIOCHIM BIOPHYS ACTA, V323, P87, DOI 10.1016/0005-2736(73)90433-1; DUCKWORTH DH, 1976, ARCH BIOCHEM BIOPHYS, V172, P319, DOI 10.1016/0003-9861(76)90083-7; GLENN J, 1980, ARCH BIOCHEM BIOPHYS, V201, P576, DOI 10.1016/0003-9861(80)90547-0; HEUTERSPREUTE M, 1987, GENE, V52, P155; Hille B, 1984, IONIC CHANNELS EXCIT; LABEDAN B, 1980, BIOCHEM BIOPH RES CO, V93, P625, DOI 10.1016/0006-291X(80)91124-9; LABEDAN B, 1973, J MOL BIOL, V75, P213, DOI 10.1016/0022-2836(73)90017-X; LABEDAN B, 1976, VIROLOGY, V75, P368, DOI 10.1016/0042-6822(76)90035-0; LABEDAN B, 1981, P NATL ACAD SCI-BIOL, V78, P215, DOI 10.1073/pnas.78.1.215; LABEDAN B, 1984, J VIROL, V49, P273, DOI 10.1128/JVI.49.1.273-275.1984; LANNI YT, 1960, VIROLOGY, V10, P501, DOI 10.1016/0042-6822(60)90132-X; LANNI YT, 1968, BACTERIOL REV, V32, P227, DOI 10.1128/MMBR.32.3.227-242.1968; LANNI YT, 1965, P NATL ACAD SCI USA, V53, P969, DOI 10.1073/pnas.53.5.969; LETELLIER L, 1989, BIOCHIMIE, V71, P167, DOI 10.1016/0300-9084(89)90147-8; MALTOUF AF, 1983, J BACTERIOL, V153, P124, DOI 10.1128/JB.153.1.124-133.1983; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCCORQUODALE D J, 1975, Critical Reviews in Microbiology, V4, P101, DOI 10.3109/10408417509111574; McCorquodale D. J., 1988, BACTERIOPHAGES, V1, P439; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; RHOADS DB, 1976, J GEN PHYSIOL, V49, P221; SHECHTER E, 1974, EUR J BIOCHEM, V49, P61, DOI 10.1111/j.1432-1033.1974.tb03811.x; SHECHTER E, 1985, MOL CYTOLOGY ESCHERI; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	32	53	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3168	3172						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371112				2022-12-27	WOS:A1992HD15400055
J	CHADWICK, CC; TIMERMAN, AP; SAITO, A; MAYRLEITNER, M; SCHINDLER, H; FLEISCHER, S				CHADWICK, CC; TIMERMAN, AP; SAITO, A; MAYRLEITNER, M; SCHINDLER, H; FLEISCHER, S			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF AN INOSITOL POLYPHOSPHATE RECEPTOR FROM CEREBELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; 1,4,5-TRISPHOSPHATE RECEPTOR; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; SMOOTH-MUSCLE; BRAIN; SOLUBILIZATION; PURIFICATION; PROTEIN; 1,3,4,5-TETRAKISPHOSPHATE	An inositol polyphosphate receptor has been purified from bovine cerebellum which consists of three different polypeptides with M(r) of 111,000, 102,000, and 52,000. Negative staining electron microscopy reveals globular-like structures 10-13 nm in diameter. The receptor has a Stokes radius of 400,000 daltons as determined by molecular sieve high performance liquid chromatography. The receptor preparation binds inositol 1,3,4,5-tetrakisphosphate, inositol hexaphosphate (or phytol), and inositol 1,4,5-trisphosphate (IP4, IP6, and IP3, respectively) with submicromolar affinity (0.19, 0.15, and 0.54-mu-M, respectively) at conditions approximating physiological ionic strength and pH. The purified receptor preparation, when reconstituted into planar bilayers, displays ion channel activity, preferentially permeable to K+. Permeability ratios of the channel are P(K+)/PN(Na+) approximately 5 and P(K+)/P(Cl) approximately 19. In symmetrical 100 mM KCl, the channel is characterized by long open times (minutes) with a conductance of 7.2 picosiemens. The channel is selectively modulated by IP4. That is, at 1-mu-M IP4, the mean open time decreased substantially to rapid flicker behavior and the channel is completely closed at 10-mu-M IP4. IP6 and IP3 did not modulate the channel under similar conditions. Thus, the channel appears to be an IP4-modulated K+ channel.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA; JOHANNES KEPLER UNIV, INST BIOPHYS, A-4040 LINZ, AUSTRIA	Vanderbilt University; Johannes Kepler University Linz					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHADWICK C C, 1991, Biophysical Journal, V59, p525A; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DONIE F, 1990, FEBS LETT, V268, P194, DOI 10.1016/0014-5793(90)81006-A; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; IRVINE RF, 1989, INOSITOL LIPIDS CELL, P135; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1989, MOL PHARMACOL, V36, P391; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P105; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MAYRLEITNER M, 1991, Biophysical Journal, V59, p525A; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOLLEMAN A, 1991, J BIOL CHEM, V266, P5658; OROURKE FA, 1985, J BIOL CHEM, V260, P956; PALADE P, 1989, MOL PHARMACOL, V36, P664; PETERSEN OH, 1989, CELL CALCIUM, V10, P375, DOI 10.1016/0143-4160(89)90063-8; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8	32	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3473	3481						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371119				2022-12-27	WOS:A1992HD15400100
J	ABRAMS, CS; RUGGERI, ZM; TAUB, R; HOXIE, JA; NAGASWAMI, C; WEISEL, JW; SHATTIL, SJ				ABRAMS, CS; RUGGERI, ZM; TAUB, R; HOXIE, JA; NAGASWAMI, C; WEISEL, JW; SHATTIL, SJ			ANTIIDIOTYPIC ANTIBODIES AGAINST AN ANTIBODY TO THE PLATELET GLYCOPROTEIN (GP) IIB-IIIA COMPLEX MIMIC GP IIB-IIIA BY RECOGNIZING FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR RECOGNITION DOMAIN; GAMMA-CHAIN; ALPHA-CHAIN; ACTIVATED PLATELETS; BINDING-SITE; VONWILLEBRAND-FACTOR; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; RNA-POLYMERASE; LIGAND-BINDING	Binding of the adhesive ligand fibrinogen and the monoclonal antibody PAC1 to platelet glycoprotein (GP) IIb-IIIa is dependent on cell activation and inhibited by Arg-Gly-Asp (RGD)-containing peptides. Previously, we identified a sequence in a hypervariable region of PACI (mu-CDR3) that mimics the activity of the antibody. Here we examine whether monoclonal antibodies to this idiotypic determinant in PAC1 can mimic GP IIb-IIIa by binding to fibrinogen. Mice were immunized with a peptide derived from the mu-CDR3 of PAC1. Four antibodies were obtained that recognized fibrinogen as well as a recombinant form of the variable region of PAC1. However, they did not bind to other RGD-containing proteins, including von Willebrand factor, fibronectin, and vitronectin. Several studies suggested that these anti-PAC1 peptide antibodies were specific for GP IIb-IIIa recognition sites in fibrinogen. Three such sites have been proposed: two RGD-containing regions in the A-alpha-chain, and the COOH terminus of the gamma-chain (gamma-400-411). Two of the antibodies inhibited fibrinogen binding to activated platelets, and all four antibodies bound to the fibrinogen A-alpha-chain on immunoblots. Antibody binding to immobilized fibrinogen was partially inhibited by monoclonal antibodies specific for the two A-alpha-chain RGD regions. However, the anti-PAC1 peptide antibodies also bound to plasmin-derived fibrinogen fragments X and D100, which contain gamma-400-411 but lack one or both A-alpha(RGD) regions. This binding was inhibited by an antibody specific for gamma-400-411. When fragment D100 was converted to D80, which lacks gamma-400-411, antibody binding was reduced significantly (p < 0.01). Electron microscopy of fibrinogen-antibody complexes confirmed that each antibody could bind to sites on the A-alpha and gamma-chains. These studies demonstrate that certain anti-PAC1 peptide antibodies mimic GP IIb-IIIa by binding to platelet recognition sites in fibrinogen. Furthermore, they suggest that the gamma-400-411 region of fibrinogen may exist in a conformation similar to that of an A-alpha(RGD) region of the molecule.	UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT HUMAN GENET, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT ANAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Scripps Research Institute; Scripps Research Institute; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL 30954, HL 31950, HL 40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL030954, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BONA C, 1984, RECEPTOR BIOCH METHO, V4, P141; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; ERLANGER BF, 1991, BIOCHEM SOC T, V19, P138, DOI 10.1042/bst0190138; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GELIEBTER J, 1987, FOCUS, V9, P5; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KENNETT RH, 1982, MONOCLONAL ANTIBODIE, P365; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MARSTON FAO, 1989, DNA CLONING PRACTICA, P59; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; NIEWIAROWSKI S, 1977, BLOOD, V49, P635; PEERSCHKE EIB, 1986, BLOOD, V67, P385; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; REES AR, 1987, IMMUNOL TODAY, V8, P44, DOI 10.1016/0167-5699(87)90237-4; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUDEE ML, 1981, ULTRAMICROSCOPY, V7, P193, DOI 10.1016/0304-3991(81)90010-3; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SLAYTER HS, 1983, ANN NY ACAD SCI, V408, P131, DOI 10.1111/j.1749-6632.1983.tb23241.x; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUB R, 1989, J BIOL CHEM, V264, P259; THORSEN LI, 1987, THROMB RES, V47, P315, DOI 10.1016/0049-3848(87)90145-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WILLIAMS JF, 1989, BIOTECHNIQUES, V7, P762; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZIBLER B, 1990, BIOCHEMISTRY-US, V29, P10032	70	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2775	2785						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370832				2022-12-27	WOS:A1992HB53200099
J	CREIGHTON, S; HUANG, MM; CAI, H; ARNHEIM, N; GOODMAN, MF				CREIGHTON, S; HUANG, MM; CAI, H; ARNHEIM, N; GOODMAN, MF			BASE MISPAIR EXTENSION KINETICS - BINDING OF AVIAN-MYELOBLASTOSIS REVERSE-TRANSCRIPTASE TO MATCHED AND MISMATCHED BASE PAIR TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-ALPHA; SPONTANEOUS MUTATION; ENZYMATIC AMPLIFICATION; INSERTION FIDELITY; ESCHERICHIA-COLI; CHAIN-REACTION; MECHANISM	We investigate the enzymatic basis for the inefficient extension of single base mismatches by DNA polymerase compared with the extension of correct base pairs. Inefficient mismatch extension could result from either a reduced binding of the enzyme to mispaired versus correctly paired DNA template-primer termini, or from a lowered intrinsic rate of extension of mispairs by a bound enzyme, or from a combination of both factors. Avian myeloblastosis reverse transcriptase is used to measure the affinities (equilibrium dissociation constants) for the four matched and twelve mismatched base pair configurations situated at a primer 3'-terminus. The binding affinities are analyzed by two different assays employing polyacrylamide gels. The first assay uses steady-state kinetics to measure the efficiency of elongating correct and incorrect base pairs and to evaluate the enzyme's dissociation constants for matched and mismatched termini. The estimated K(D) values obtained in the steady-state analysis fall within a range of approximately 0.1-20 nM. The efficiencies of extending two of the mispairs, G.G and C.C, are too low to allow a determination of K(D) by the kinetics method. The second assay uses equilibrium binding to measure the ratio of polymerase bound to matched compared with mismatched termini, K(D(right))/K(D(wrong). The affinity ratios, including values for G.G and C.C mispairs, are in the range of about 0.4-4.2. While around 1 order of magnitude difference is observed in the relative binding affinities of the polymerase for matched and mismatched primer termini, the relative extension efficiencies vary over more than 5 orders of magnitude. Therefore, it appears that inefficient mismatch extension is caused primarily by a kinetic block inhibiting elongation from mispaired primer 3'-termini rather than to a difference in binding.			CREIGHTON, S (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,MOLEC BIOL SECT,LOS ANGELES,CA 90089, USA.			Arnheim, Norman/0000-0003-1247-1347	NIGMS NIH HHS [GM21422, GM36745, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R01GM042554, R37GM036745, R01GM036745, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BURTALG D, 1972, J BIOL CHEM, V247, P241; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; DELSAL G, 1980, NUCLEIC ACIDS RES, V15, P10047; DETERA SD, 1981, J BIOL CHEM, V256, P6933; DRAKE JW, 1969, NATURE, V221, P1132, DOI 10.1038/2211132a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1983, J MOL BIOL, V165, P669, DOI 10.1016/S0022-2836(83)80273-3; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; GELFAND DN, 1989, PRC PROTOCOLS GUIDE, P129; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SEGAL IH, 1975, ENZYME KINETICS, P325; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	35	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2633	2639						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370828				2022-12-27	WOS:A1992HB53200081
J	TEDIN, K; BREMER, H				TEDIN, K; BREMER, H			TOXIC EFFECTS OF HIGH-LEVELS OF PPGPP IN ESCHERICHIA-COLI ARE RELIEVED BY RPOB MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; GUANOSINE TETRAPHOSPHATE; STRINGENT CONTROL; PROMOTER SELECTIVITY; SYNTHESIS INVITRO; RIBONUCLEIC-ACID; OMEGA SUBUNIT; BETA-SUBUNIT; RELA GENE; POLYMERASE	A controversy has surrounded the questions of whether or not guanosine tetraphosphate (ppGpp) is a specific inhibitor of bacterial rRNA and tRNA synthesis, especially during normal exponential growth, and whether the RNA polymerase is the target of ppGpp action. To answer these questions, a pBR322-derived plasmid, pKT28, was constructed that carries the Escherichia coli relA gene encoding a ppGpp synthetase under control of the lacUV5 promoter. The plasmid was used to transform the ppGpp reporter strain VH271 in which expression of beta-galactosidase from an rrnB P1 promoter is inhibited by ppGpp. In the presence of high concentrations of lac inducer, bacteria of the transformed strain accumulate ppGpp with the result that synthesis of rRNA and beta-galactosidase is inhibited and growth ceases. At low concentrations of inducer, growth is only reduced and cells form small white colonies on X-gal indicator plates. After continued incubation, these colonies form blue sectors of faster growing mutant cells. Phage P1 transduction experiments showed that these mutants have mutations cotransducing with rpoB, the gene encoding the beta-subunit of RNA polymerase. One particular mutant strain, KT13, had acquired partial resistance to ppGpp inhibition of rRNA synthesis. The mutation in this strain was cloned by in vivo recombination into an rpoB plasmid. The presence of this plasmid conferred increased resistance to overproduction of ppGpp. These results suggest that ppGpp is a specific inhibitor of rRNA synthesis, even in the absence of amino acid starvation, and that RNA polymerase is involved as the target of ppGpp action.	UNIV TEXAS,MOLEC & CELL BIOL PROGRAM,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas				Tedin, Karsten/0000-0003-2109-0730				ALFOLDI L, 1962, J MOL BIOL, V5, P348, DOI 10.1016/S0022-2836(62)80077-1; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BREEDEN L, 1980, MOL GEN GENET, V179, P119, DOI 10.1007/BF00268453; BREEDEN L, 1980, MOL GEN GENET, V179, P125, DOI 10.1007/BF00268454; BREMER H, 1987, NATO ASI SER, V14, P63; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHURCHWARD G, 1983, MOL GEN GENET, V192, P506, DOI 10.1007/BF00392197; COLLINS J, 1976, 9 A BENZ S CONTR RIB, P356; FRIESEN JD, 1974, P NATL ACAD SCI USA, V71, P3465, DOI 10.1073/pnas.71.9.3465; GENTRY D, 1991, J BACTERIOL, V173, P3901, DOI 10.1128/JB.173.12.3901-3903.1991; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GENTRY DR, 1989, J BACTERIOL, V171, P1271, DOI 10.1128/jb.171.3.1271-1277.1989; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GLASS RE, 1986, MOL GEN GENET, V203, P265, DOI 10.1007/BF00333964; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HELMSTETTER CE, 1967, J MOL BIOL, V24, P417, DOI 10.1016/0022-2836(67)90228-8; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; HUYNH TV, 1985, DNA CLONING, V1, P56; IGARASHI K, 1989, NUCLEIC ACIDS RES, V17, P8755, DOI 10.1093/nar/17.21.8755; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LITTLE R, 1983, J BACTERIOL, V155, P1426, DOI 10.1128/JB.155.3.1426-1428.1983; METZGER S, 1988, J BIOL CHEM, V263, P15699; Miller J.H., 1972, EXPT MOL GENETICS; NENE V, 1983, FEBS LETT, V153, P307, DOI 10.1016/0014-5793(83)80630-9; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OOSTRA BA, 1981, MOL GEN GENET, V183, P54, DOI 10.1007/BF00270138; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; PEDERSEN FS, 1977, EUR J BIOCHEM, V76, P91, DOI 10.1111/j.1432-1033.1977.tb11573.x; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SILVERSTONE AE, 1972, MOL GEN GENET, V118, P223, DOI 10.1007/BF00333459; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; XIAO H, 1991, J BIOL CHEM, V266, P5980; YOSHINAGA K, 1977, BIOCHIM BIOPHYS ACTA, V479, P172, DOI 10.1016/0005-2787(77)90137-X	56	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2337	2344						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370817				2022-12-27	WOS:A1992HB53200036
J	EASON, MG; LIGGETT, SB				EASON, MG; LIGGETT, SB			SUBTYPE-SELECTIVE DESENSITIZATION OF ALPHA-2-ADRENERGIC RECEPTORS - DIFFERENT MECHANISMS CONTROL SHORT AND LONG-TERM AGONIST-PROMOTED DESENSITIZATION OF ALPHA-2C10, ALPHA-2C4, AND ALPHA-2C2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; INDUCED DOWN-REGULATION; DISTINCT PATHWAYS; ADENYLATE-CYCLASE; CYTOPLASMIC DOMAIN; PHOSPHORYLATION; KINASE; CLONIDINE; BINDING	We have recently shown that the alpha2C10 adrenergic receptor (AR) undergoes short term agonist-promoted desensitization, mediated by phosphorylation of sites in the third intracellular loop. There is significant divergence in the third loop amino acid sequences between alpha2C10 and the other subtypes, alpha2C4 and alpha2C2. We therefore explored the mechanisms of alpha2AR subtype desensitization by expressing each human subtype in Chinese hamster ovary cells and subjecting them to short and long term epinephrine exposures. After 30 min of agonist exposure, alpha2C10 and a2C2 displayed desensitization characterized by rightward shifts in the curves for epinephrine-mediated inhibition of adenylyl cyclase (EC50 = alpha2C10, 0.24 +/- 0.02 muM increasing to 1.1 +/- 0.1 muM; alpha2C2, 1.3 +/- 0.3 increasing to 2.6 +/- 0.3 muM). Coincident with alpha2C10 and alpha2C2 desensitizations were decreases in agonist high affinity binding. In contrast, alpha2C4 underwent no functional desensitization after short term agonist exposure, nor were there any changes in agonist high affinity binding. Agonist-promoted receptor sequestration was clearly greater with alpha2C10 (approximately 26%) and alpha2C2 (approximately 35%) as compared to alpha2C4 (approximately 12%), but such sequestration did not play a significant role in short term desensitization, as blockade with concanavalin A had no effect on desensitization patterns. In contrast to these findings, all alpha2AR subtypes underwent desensitization after prolonged (24 h) agonist exposure. However, alpha2C10 and alpha2C2 displayed substantially more desensitization (approximately 20-fold increase in EC50) as compared to alpha2C4 (approximately 5-fold increase). The primary mechanism of desensitization during long term agonist exposure was found to be a decrease in the amount of cellular G(i), which was equivalent in magnitude in cells expressing all three subtypes. However, in addition to a decrease in G(i), alpha2C10 and alpha2C2 underwent down-regulation of receptor levels during long term agonist exposure, while alpha2C4 did not. Given that all three subtypes bind endogenous catecholamines with high affinity and inhibit adenylyl cyclase efficiently, the significance of multiple subtypes has heretofore been obscure. Our results show that alpha2AR undergo subtype-selective desensitization to agonists and suggest that alpha2AR subtypes may have evolved to meet differing needs for adaptive regulation.	UNIV CINCINNATI,COLL MED,DEPT MED PULM,231 BETHESDA AVE,MSB RM 7511,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Duke University			liggett, stephen b/E-7453-2012		NHLBI NIH HHS [HL45977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON BN, 1992, MOL PHARMACOL, V41, P688; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRODDE OE, 1982, EUR J CLIN PHARMACOL, V23, P403, DOI 10.1007/BF00605989; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GREENE S, 1992, MOL PHARMACOL, V41, P898; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HERTEL C, 1990, J BIOL CHEM, V265, P17988; INSEL PA, 1988, ALPHA 2 ADRENERGIC R, P281; ISHII K, 1984, J PHARMACOL EXP THER, V231, P685; JONES SB, 1987, P NATL ACAD SCI USA, V84, P1294, DOI 10.1073/pnas.84.5.1294; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIGGETT SB, 1991, PHARMACOL RES, V24, P29, DOI 10.1016/1043-6618(91)90119-I; LIMBIRD LE, 1985, RECEPTORS, V2, P281; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MCKERNAN RM, 1987, MOL PHARMACOL, V32, P258; MIKUNI M, 1983, EUR J PHARMACOL, V89, P313, DOI 10.1016/0014-2999(83)90513-7; MOTULSKY HJ, 1986, MOL PHARMACOL, V29, P1; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PERKINS JP, 1991, BETA ADRENERGIC RECE, P125; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SNAVELY MD, 1983, ENDOCRINOLOGY, V113, P354, DOI 10.1210/endo-113-1-354; THOMAS JM, 1986, ENDOCRINOLOGY, V119, P1305, DOI 10.1210/endo-119-3-1305; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VILLENEUVE A, 1985, J PHARMACOL EXP THER, V233, P433	37	122	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25473	25479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334095				2022-12-27	WOS:A1992KB60300085
J	BRZESKA, H; KULESZALIPKA, D; KORN, ED				BRZESKA, H; KULESZALIPKA, D; KORN, ED			INHIBITION OF ACANTHAMOEBA MYOSIN-I HEAVY-CHAIN KINASE BY CA2+-CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; ACTIN-BINDING; BRUSH-BORDER; DICTYOSTELIUM-DISCOIDEUM; MG2+-ATPASE ACTIVITY; COFACTOR PROTEIN; PLASMA-MEMBRANE; 3RD ISOFORM; C SUBSTRATE; AMINO-ACID	The actin-activated Mg2+-ATPase activity of Acanthamoeba myosins I depends on phosphorylation of their single heavy chains by myosin I heavy chain kinase. Kinase activity is enhanced >50-fold by autophosphorylation at multiple sites. The rate of kinase autophosphorylation is increased approximately 20-fold by acidic phospholipids independent of the presence of Ca2+ and diglycerides. We show in this paper that Ca2+-calmodulin inhibits phospholipid-stimulated autophosphorylation of myosin I heavy chain kinase and hence also inhibits the catalytic activity of unphosphorylated kinase in the presence of phospholipid. Ca2+-calmodulin does not inhibit kinase activity in the absence of phospholipid. Micromolar Ca2+-calmodulin also inhibits binding of myosin I heavy chain kinase to phospholipid vesicles and purified plasma membranes. Proteolytic removal of a 7-kDa NH2-terminal segment from the 97-kDa kinase prevents binding of both calmodulin and phospholipid; therefore, we propose that they bind to the same or overlapping sites. These data provide a mechanism by which Ca2+ could inhibit the actin-activated Mg2+-ATPase activity of the myosin I isozymes in vivo and thus regulate myosin I-dependent motile activities.			BRZESKA, H (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ATKINSON M A, 1991, Journal of Cell Biology, V115, p331A; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BAINES IC, 1992, IN PRESS J CELL BIOL; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BARYLKO B, 1991, Journal of Cell Biology, V115, p331A; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BONI LT, 1985, J BIOL CHEM, V260, P819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1989, J BIOL CHEM, V264, P10243; BRZESKA H, 1983, BIOCHEM BIOPH RES CO, V115, P87, DOI 10.1016/0006-291X(83)90972-5; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; BRZESKA H, 1988, J BIOL CHEM, V263, P427; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CLARKE BJ, 1988, J PROTOZOOL, V35, P408, DOI 10.1111/j.1550-7408.1988.tb04118.x; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1991, EUR J CELL BIOL, V56, P286; COTE GP, 1985, J BIOL CHEM, V260, P4543; DANDREA L, 1991, J CELL BIOL, V115, pA331; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GADASI H, 1980, NATURE, V286, P452, DOI 10.1038/286452a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOODSON H V, 1990, Journal of Cell Biology, V111, p168A; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KELLERMAN K, 1991, Journal of Cell Biology, V115, p330A; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KULESZALIPKA D, 1991, J CELL BIOL, V115, P109, DOI 10.1083/jcb.115.1.109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH TJ, 1990, BIOPHYS J, V57, pA536; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; MARUTA H, 1979, J BIOL CHEM, V254, P3624; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MCCUBBIN WD, 1979, CAN J BIOCHEM CELL B, V57, P15, DOI 10.1139/o79-002; MCDONALD JR, 1987, BIOCHEM J, V242, P695, DOI 10.1042/bj2420695; MCDONALD JR, 1985, BIOCHEM J, V232, P559, DOI 10.1042/bj2320559; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHERR E H, 1991, Journal of Cell Biology, V115, p331A; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SPUDICH JA, 1989, CELL REGUL, V1, P1; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; ULSAMER AG, 1971, J CELL BIOL, V51, P193, DOI 10.1083/jcb.51.1.193; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WYLIE DC, 1987, METHOD ENZYMOL, V139, P50; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	70	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23870	23875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331103				2022-12-27	WOS:A1992JZ23900066
J	LI, SJ; CRONAN, JE				LI, SJ; CRONAN, JE			THE GENES ENCODING THE 2 CARBOXYLTRANSFERASE SUBUNITS OF ESCHERICHIA-COLI ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE-DIHYDROFOLATE SYNTHETASE; COENZYME-A CARBOXYLASE; AMINO-ACID SEQUENCE; CODING SEQUENCE; BIOTIN ENZYMES; FOLC GENE; PROTEIN; IDENTIFICATION; CHROMOSOME; TRANSPORT	We report characterization of the component proteins and molecular cloning of the genes encoding the two subunits of the carboxyltransferase component of the Escherichia coli acetyl-CoA carboxylase. Peptide mapping of the purified enzyme component indicates that the carboxyltransferase component is a complex of two nonidentical subunits, a 35-kDa alpha-subunit and a 33-kDa beta-subunit. The alpha-subunit gene encodes a protein of 319 residues and is located immediately downstream of the polC gene (min 4.3 of the E. coli genetic map). The deduced amino acid composition, molecular mass, and amino acid sequence match those determined for the purified alpha-subunit. Six sequenced internal peptides also match the deduced sequence. The amino-terminal sequence of the beta-subunit was found within a previously identified open reading frame of unknown function called dedB and usg (min 50 of the E. coli genetic map) which encodes a protein of 304 residues. Comparative peptide mapping also indicates that the dedB/usg gene encodes the beta-subunit. Moreover, the deduced molecular mass and amino acid composition of the dedB/usg-encoded protein closely match those determined for the beta-subunit. The deduced amino acid sequences of alpha and beta-subunits show marked sequence similarities to the COOH-terminal half and the NH2-terminal halves, respectively, of the rat propionyl-CoA carboxylase, a biotin-dependent carboxylase that catalyzes a similar carboxyltransferase reaction reaction. Several conserved regions which may function as CoA-binding sites are noted.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	LI, SJ (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; ALBERTS AW, 1968, P NATL ACAD SCI USA, V59, P561, DOI 10.1073/pnas.59.2.561; ALBERTS AW, 1971, P NATL ACAD SCI USA, V68, P1259, DOI 10.1073/pnas.68.6.1259; ALBERTS AW, 1972, ENZYMES, V6, P37; ANDREWS AT, 1986, ELECTROPHORESIS THEO, P93; BOGNAR A, 1989, J BACTERIOL, V171, P1854, DOI 10.1128/jb.171.4.1854-1861.1989; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; DAKSHINAMURTI K, 1985, ANN NY ACAD SCI, V447, P1; DEVEAUX LC, 1986, J BACTERIOL, V167, P920, DOI 10.1128/jb.167.3.920-927.1986; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; LI SJ, 1992, J BIOL CHEM, V267, P855; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEDIGUE C, 1991, MOL MICROBIOL, V5, P2629, DOI 10.1111/j.1365-2958.1991.tb01972.x; NONET ML, 1987, J BIOL CHEM, V262, P12209; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; RILEY M, 1978, ANNU REV MICROBIOL, V32, P519, DOI 10.1146/annurev.mi.32.100178.002511; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; VUORIO R, 1991, FEBS LETT, V292, P90, DOI 10.1016/0014-5793(91)80841-P; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125	29	130	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16841	16847						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1355089				2022-12-27	WOS:A1992JL05300020
J	COOK, RK; BLAKE, WT; RUBENSTEIN, PA				COOK, RK; BLAKE, WT; RUBENSTEIN, PA			REMOVAL OF THE AMINO-TERMINAL ACIDIC RESIDUES OF YEAST ACTIN - STUDIES INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABEL FINGERPRINTINGS SHOW; RABBIT SKELETAL-MUSCLE; SACCHAROMYCES-CEREVISIAE; DICTYOSTELIUM-DISCOIDEUM; BINDING SITES; SEQUENCE; MYOSIN; CELLS; GENE; PROTEINS	We have examined the role of the acidic residues Asp2 and Glu4 at the NH2 terminus of Saccharomyces cerevisiae actin through site-directed mutagenesis. In DNEQ actin, these residues have been changed to Asn2 and Gln4, whereas in DELTA-DSE actin, the Asp2-Ser-Glu tripeptide has been deleted. Both mutant actins can replace wild type yeast actin. Peptide mapping studies reveal that DNEQ, like wild type actin, retains the initiator Met and is NH2 terminally acetylated, whereas DELTA-DSE has a free NH2 terminus and has lost the initiator Met. Interestingly, microscopic examination of filaments of these two actins reveal the appearance of bundled filaments. The DNEQ bundles are smaller and more ordered, whereas the DELTA-DSE bundles are larger and more loosely organized. Additionally both mutant actins activate the ATPase activity of rabbit muscle myosin S1 fragment to a lesser extent than wild type. We have also developed a sensitive assay for actin function in vivo that enabled us to detect a slight defect in the ability of these mutant actins to support secretion, an important function in yeast. Thus, although the mutant actins resulted in no gross phenotypic changes, we were able to detect a defect in actin function through this assay. From these studies we can conclude that 1) although NH2-terminal negative charges are not essential to yeast life, the loss of such charges does result in a slight defect in the actins' ability to support secretion, 2) removal of the NH2-terminal negative charges promotes the bundling of actin filaments, and 3) actins lacking NH2-terminal negative charges are unable to activate the myosin S1 ATPase activity as well as wild type actin.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS S, 1990, J BIOL CHEM, V265, P19652; ASPENSTROM P, 1991, EUR J BIOCHEM, V200, P35, DOI 10.1111/j.1432-1033.1991.tb21045.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CLEEVES AE, 1989, J CELL BIOL, V109, P2939; COOK RK, 1991, J BIOL CHEM, V266, P16825; DASGUPTA G, 1991, BIOCHEMISTRY-US, V30, P9961, DOI 10.1021/bi00105a021; DOI Y, 1987, EUR J BIOCHEM, V164, P89, DOI 10.1111/j.1432-1033.1987.tb10997.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; ELZINGA M, 1986, METHODS PROTEIN SCI, P615; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Goldstein A, 1975, Methods Enzymol, V42, P504; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GREER C, 1982, MOL CELL BIOL, V2, P1279, DOI 10.1128/MCB.2.10.1279; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; REDMAN K, 1981, J BIOL CHEM, V256, P3226; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0	42	121	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9430	9436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1349604				2022-12-27	WOS:A1992HR85400109
J	DANESCH, U; HOECK, W; RINGOLD, GM				DANESCH, U; HOECK, W; RINGOLD, GM			CLONING AND TRANSCRIPTIONAL REGULATION OF A NOVEL ADIPOCYTE-SPECIFIC GENE, FSP27 - CAAT-ENHANCER-BINDING PROTEIN (C/EBP) AND C/EBP-LIKE PROTEINS INTERACT WITH SEQUENCES REQUIRED FOR DIFFERENTIATION-DEPENDENT EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; GROWTH-FACTOR; DEVELOPMENTAL REGULATION; ADIPOSE CONVERSION; MOLECULAR-CLONING; NUCLEAR FACTORS; FAMILY; CELLS; DNA; IDENTIFICATION	We have reported previously the cloning of several cDNAs whose mRNAs are induced during differentiation of the adipogenic cell line TA1. Here we characterize an adipocyte-specific gene, which we refer to as FSP27 (formerly clone 47), that encodes a protein of 27 kDa, the sequence of which is unrelated to any in the current data banks. The FSP27 promoter confers adipocyte-specific expression to a heterologous reporter gene in transfected adipogenic cell lines, e.g. TA1 and 3T3-L1. Analysis of regulatory elements in the FSP27 promoter region indicates the presence of (a) a proximal palindromic sequence that is necessary for adipocyte-specific expression; and (b) a distal differentiation-independent enhancer-like element. The palindromic sequence TTCGAAA is protected from digestion by DNase I using nuclear extracts from TA1 preadipocytes and adipocytes. Heated rat liver nuclear extract, a very abundant source of the transcription factor CAAT-enhancer-binding protein (C/EBP) and related proteins, generates an equivalent footprint over the palindrome. However, C/EBP can account for only a portion of the protein-DNA complexes in TA1 cells because preadipocytes as well as adipocytes contain proteins distinct from C/EBP which interact with the same sequence. We suggest that C/EBP and other C/EBP-like proteins play a critical role in regulating the transcription of the fat-specific gene FSP27.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; SYNTEX INC,INST CANC & DEV BIOL,PALO ALTO,CA 94304	Stanford University; Syntex Corporation				Hoeck, Wolfgang/0000-0001-9142-7103	NIGMS NIH HHS [GM 25821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DANI C, 1990, J CELL BIOCHEM, V43, P103, DOI 10.1002/jcb.240430202; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOECK W, 1989, J BIOL CHEM, V264, P14396; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RINGOLD GM, 1986, J STEROID BIOCHEM, V24, P69, DOI 10.1016/0022-4731(86)90034-8; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629	52	108	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7185	7193						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1339452				2022-12-27	WOS:A1992HM05300111
J	ASSARAF, YG; FEDER, JN; SHARMA, RC; WRIGHT, JE; ROSOWSKY, A; SHANE, B; SCHIMKE, RT				ASSARAF, YG; FEDER, JN; SHARMA, RC; WRIGHT, JE; ROSOWSKY, A; SHANE, B; SCHIMKE, RT			CHARACTERIZATION OF THE COEXISTING MULTIPLE MECHANISMS OF METHOTREXATE RESISTANCE IN MOUSE 3T6-R50 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENES; SQUAMOUS-CELL CARCINOMA; HAMSTER OVARY CELLS; FLOW-CYTOMETRY; MESSENGER-RNA; AMPLIFICATION; TRIMETREXATE; TRANSPORT; LINE; HEAD	We have studied the discrepancy in the degree of methotrexate (MTX) resistance that exists between two clonal cell lines, mouse 3T6 R50 cells and Chinese hamster ovary B11 0.5 cells that overexpress comparable levels of dihydrofolate reductase, yet exhibit a 100-fold difference in MTX resistance while maintaining similar sensitivity to the lipophilic antifolates trimetrexate and piritrexim. These data suggested that R50 cells may possess additional mechanism(s) of antifolate resistance, such as MTX transport alteration. Flow cytometric analysis using fluorescein methotrexate revealed comparable levels of fluorescein MTX displacement with lipophilic antifolates in viable R50 and B11 0.5 cells, but marked insensitivity of R50 cells to MTX competition, thus suggesting a poor uptake of MTX into R50 cells. Analysis of the kinetic parameters of dihydrofolate reductase from R50 cells neither showed alterations in enzyme affinities for various antifolates nor in the Michaelis constant for folic acid and NADPH nor a change in the pH activity optimum. R50 cell-free extracts contained wild-type levels of folylpoly-gamma-glutamyl synthetase activity. However, following metabolic labeling with [H-3]MTX, no MTX polyglutamates could be detected in R50 cells. We conclude that the high level of MTX resistance in R50 cells is multifactorial, including overexpression of dihydrofolate reductase, reduced MTX transport, and possibly altered formation of MTX polyglutamates. The potential interactions between the different modalities of MTX resistance in R50 cells are being discussed.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOCHEM,SAN FRANCISCO,CA 94143; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Berkeley	ASSARAF, YG (corresponding author), TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL.		rosowsky, andre/N-6602-2017		NATIONAL CANCER INSTITUTE [R01CA041991, P01CA019589, R01CA016318] Funding Source: NIH RePORTER; NCI NIH HHS [CA16318, CA19589, CA41991] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1978, J BIOL CHEM, V253, P1357; ASSARAF YG, 1989, CYTOMETRY, V10, P50, DOI 10.1002/cyto.990100109; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1989, ANAL BIOCHEM, V178, P287, DOI 10.1016/0003-2697(89)90640-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P21; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; COWAN KH, 1984, J BIOL CHEM, V259, P793; DUCH DS, 1982, CANCER RES, V42, P3987; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1988, CANCER RES, V48, P6986; GEYER PK, 1984, J BIOL CHEM, V259, P7206; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; HABER DA, 1981, J BIOL CHEM, V256, P9501; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; JONES PP, 1980, SELECTED METHODS CEL, P398; KAMEN BA, 1984, BIOCHEM PHARMACOL, V33, P1697, DOI 10.1016/0006-2952(84)90298-3; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; KELLEMS RE, 1979, J BIOL CHEM, V254, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MELERA PW, 1984, MOL CELL BIOL, V4, P38, DOI 10.1128/MCB.4.1.38; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P5924, DOI 10.1073/pnas.76.11.5924; NAKAMURA H, 1972, J BIOL CHEM, V247, P179; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PIZZORNO G, 1988, CANCER RES, V48, P2149; ROSOWSKY A, 1985, CANCER RES, V45, P6205; ROTHENBE.SP, 1966, ANAL BIOCHEM, V16, P176, DOI 10.1016/0003-2697(66)90095-9; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SETZER DR, 1980, CELL, V22, P361, DOI 10.1016/0092-8674(80)90346-3; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1979, METHOD CANCER RES, V16, P382; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; WRIGHT JE, 1987, BIOCHEM PHARMACOL, V36, P2209, DOI 10.1016/0006-2952(87)90152-3	42	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5776	5784						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372892				2022-12-27	WOS:A1992HK31800012
J	PUOPOLO, K; KUMAMOTO, C; ADACHI, I; MAGNER, R; FORGAC, M				PUOPOLO, K; KUMAMOTO, C; ADACHI, I; MAGNER, R; FORGAC, M			DIFFERENTIAL EXPRESSION OF THE B-SUBUNIT OF THE VACUOLAR H+-ATPASE IN BOVINE-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; NEUROSPORA-CRASSA CONTAINS; MESSENGER-RNAS; ALPHA-SUBUNIT; BETA-SUBUNIT; SULFOLOBUS-ACIDOCALDARIUS; F1-LIKE STRUCTURE; CDNA SEQUENCE; VIMENTIN GENE	The B subunit is one of two nucleotide-binding polypeptides found in all members of the vacuolar class of H+-translocating ATPases. We have isolated a cDNA clone encoding the bovine brain B (58 kDa) subunit and have deduced its amino acid sequence. The bovine brain amino acid sequence is 99% identical to a partial cDNA reported from human brain. Northern blot analysis of RNA isolated from bovine tissues and a bovine kidney cell line reveals that two messages of approximately 3.2 and 2.0 kilobases (kb) are expressed in all tissues examined except brain, where only the 3.2-kb message can be detected. Northern blotting of RNA isolated from human fibroblast and human lung tumor cell lines reveals that three messages of approximately 6.0, 3.2, and 2.0 kb are expressed, whereas only the 3.2-kb message is expressed in a human brain tumor cell line. This is the first demonstration of tissue-specific expression of multiple forms of a vacuolar H+ATPase subunit. We have also isolated a partial cDNA clone from bovine brain which appears to encode an isoform of the B subunit. The deduced amino acid sequence is 82% identical to the major bovine brain B subunit sequence; it does not hybridize with either the 3.2- or 2.0-kb message on Northern blot. Southern blot analysis of bovine genomic DNA with probes derived from both isolated cDNAs indicates that the bovine B subunit is encoded by a multigene family.	TUFTS UNIV, SCH MED, DEPT PHYSIOL & MOLEC BIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University			Puopolo, Karen/AAY-7748-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOLOGY G; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRIEDMAN KD, 1990, PCR PROTOCOLS GUIDE, P253; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HEILIG R, 1980, CELL, V20, P625, DOI 10.1016/0092-8674(80)90309-8; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIRATA R, 1990, J BIOL CHEM, V265, P6726; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, J BIOL CHEM, V264, P1775; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS; SETZER DR, 1982, J BIOL CHEM, V257, P5143; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Watson J.D., 1987, MOL BIOL GENE, V1; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	56	118	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3696	3706						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371275				2022-12-27	WOS:A1992HE60700026
J	REINES, D				REINES, D			ELONGATION FACTOR-DEPENDENT TRANSCRIPT SHORTENING BY TEMPLATE-ENGAGED RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; FACTOR-SII; DROSOPHILA-MELANOGASTER; PREMATURE TERMINATION; REPLICATION PROTEINS; LATE PROMOTERS; C-MYC; GENE; INVITRO; PURIFICATION	In addition to polynucleotide polymerization, DNA polymerases and bacterial RNA polymerase can also remove nucleotides from the growing end of nucleic acid chains. For DNA polymerases this activity is an important factor in establishing fidelity in DNA synthesis. This report describes a novel in vitro activity of RNA polymerase II whereby it cleaves an RNA chain contained within an active elongation complex. These elongation complexes are arrested at a previously identified, naturally occurring transcriptional pause site in a human gene. The new 3'-end revealed by this cleavage remains associated with an active elongation complex and is capable of being extended by RNA polymerase II. Nascent RNA cleavage is evident after removal of free nucleotides and is dependent upon a divalent metal cation and transcription elongation factor SII. This function of SII could be important in its function as an activator of transcription elongation. It is also possible that the transcript cleavage activity of RNA polymerase II represents a proofreading function of the enzyme.			REINES, D (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM-46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FLORES O, 1989, J BIOL CHEM, V264, P8913; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUANG CC, 1981, J BIOL CHEM, V256, P4087; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; KAHN JD, 1989, J MOL BIOL, V205, P291, DOI 10.1016/0022-2836(89)90342-2; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KORNBERG A, 1980, DNA REPLICATION, P127; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MAITRA U, 1967, J BIOL CHEM, V242, P4897; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REEMS JA, 1991, J BIOL CHEM, V266, P4878; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1991, J BIOL CHEM, V266, P10510; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SKARNES WC, 1988, J MOL BIOL, V203, P153, DOI 10.1016/0022-2836(88)90099-X; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509	54	185	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3795	3800						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371280				2022-12-27	WOS:A1992HE60700041
J	MCDONALD, TV; NGHIEM, PT; GARDNER, P; MARTENS, CL				MCDONALD, TV; NGHIEM, PT; GARDNER, P; MARTENS, CL			HUMAN-LYMPHOCYTES TRANSCRIBE THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE AND EXHIBIT CF-DEFECTIVE CAMP-REGULATED CHLORIDE CURRENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL-LINE T84; CYCLIC-AMP; CHANNEL; IDENTIFICATION; EXPRESSION; TRANSPORT; MUTATIONS; CA-2+; ACID	Cystic fibrosis (CF) is the most common lethal genetic disease among Caucasians, primarily affecting epithelial tissues of the lung and gut. Mutations in a single gene, the cystic fibrosis transmembrane conductance regulator (CFTR), are responsible for this disease. Whether a physiological defect exists in the immune system of CF patients has remained controversial. A chloride ion transport defect has been described in human CF-derived lymphocytes; however, it has not been possible to detect CFTR mRNA in lymphocytes. We report here that normal human B-lymphoblasts display whole cell Cl- conductances induced by calcium-mediated pathways, volume regulation, and cAMP which are equivalent to currents described in epithelial cells. B-lymphoblasts from CF-affected humans demonstrated defective Cl- conductance regulation by cAMP but preserved regulation by calcium-mediated and volume regulation mechanisms. CFTR involvement in cAMP regulation of Cl- conductance in lymphocytes is further supported by our demonstration of the presence of appropriately spliced CFTR mRNA segments in human B and T lymphocytes as detected by an optimized reverse-transcription and polymerase chain reaction approach. The identity of the amplified products was confirmed by hybridization to CFTR-specific probes and DNA sequencing. Furthermore, the 3'-end of the gene was found in a T cell cDNA library. We conclude that CFTR mRNA is expressed in lymphocytes, consistent with the cAMP regulation of chloride transport present in normal lymphocytes but defective in CF-derived lymphocytes.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,FALK CURC,STANFORD,CA 94305; DNAX RES INST MOLEC & CELLULAR BIOL INC,RES INST,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER; NCI NIH HHS [CA09302] Funding Source: Medline; NHLBI NIH HHS [2HLC470] Funding Source: Medline; NIDDK NIH HHS [DK41324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P6799; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Frizzell R A, 1987, Prog Clin Biol Res, V254, P101; GRAY LS, 1986, J IMMUNOL, V136, P3032; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAGIWARA G, 1989, SCIENCE, V246, P1049, DOI 10.1126/science.2479979; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNUTSEN AP, 1988, INT ARCH ALLER A IMM, V85, P208, DOI 10.1159/000234504; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LAHAT N, 1989, J CLIN IMMUNOL, V9, P287, DOI 10.1007/BF00918660; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MATTHEWS WJ, 1980, NEW ENGL J MED, V302, P245, DOI 10.1056/NEJM198001313020501; MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PROCHAZKA G, 1988, J IMMUNOL, V141, P1288; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LABORATO; SCHOUMACHER RA, 1987, SCIENCE, V248, P1416; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRONG TV, 1990, PED PULMONOL S, V5, pA195; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WARD CL, 1990, PED PULMONOL S, V5, pA215; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3242	3248						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371114				2022-12-27	WOS:A1992HD15400067
J	PARKER, TG; CHOW, KL; SCHWARTZ, RJ; SCHNEIDER, MD				PARKER, TG; CHOW, KL; SCHWARTZ, RJ; SCHNEIDER, MD			POSITIVE AND NEGATIVE CONTROL OF THE SKELETAL ALPHA-ACTIN PROMOTER IN CARDIAC-MUSCLE - A PROXIMAL SERUM RESPONSE ELEMENT IS SUFFICIENT FOR INDUCTION BY BASIC FIBROBLAST GROWTH-FACTOR (FGF) BUT NOT FOR INHIBITION BY ACIDIC FGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; TRANSCRIPTIONAL ACTIVATION; REGULATORY SEQUENCES; MOLECULAR-CLONING; GENE-EXPRESSION; XENOPUS EMBRYOS; MESSENGER-RNA; HIGH-AFFINITY; BINDING-SITE; DNA-BINDING	Like mechanical load in vivo, basic fibroblast growth factor (bFGF) selectively provokes cardiac expression of ''fetal'' genes including skeletal alpha-actin (SkA). Antithetically, acidic FGF (aFGF) suppresses SkA transcription. To define sites controlling SkA transcription in cardiac muscle cells, rat cardiac myocytes were transfected with internal-deletion and block-substitution mutations in the SkA promoter, including three motifs resembling the fos serum response element (SRE). The upstream, central, and proximal SREs each contributed to basal expression in cardiac myocytes. To determine whether identical elements mediate induction by bFGF versus inhibition by aFGF, the proximal SRE (SRE1) and fos SRE were positioned upstream from a neutral promoter. In cardiac myocytes, both the SRE1 and fos SRE were expressed at levels up to one-third that of the SkA promoter (nucleotides -202 to -11). Neither was expressed in quiescent cardiac fibroblasts. bFGF augmented SRE1-CAT activity, whereas aFGF produced no change; the fos SRE was induced by both. The transcriptional and mitogenic actions of aFGF were contingent on the presence of a putative nuclear translocation motif. Thus 1) the SkA SRE1 and fos SRE each suffice for tissue specificity in cardiac myocytes; 2) unlike the c-fos SRE, the SkA SRE1 is induced selectively by bFGF yet not aFGF; 3) sequences alternative or in addition to the SRE1 are obligatory for aFGF to suppress the SkA promoter; and 4) possible differences in intracellular localization are one basis for divergent actions of aFGF and bFGF in cardiac muscle cells.	BAYLOR COLL MED,MOLEC CARDIOL UNIT,ONE BAYLOR PLAZA,RM 506C,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [P50-HL42267, R01-HL38401, R01-HL39141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039141, P50HL042267, R01HL038401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BAIRD A, 1991, FIBROBLAST GROWTH FA; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BISHOPRIC NH, 1991, J CELL BIOCHEM, V15, P192; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHIBA M, 1990, CIRCULATION, V82, P761; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1004; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOMURO I, 1989, J CLIN INVEST, V83, P1102, DOI 10.1172/JCI113989; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURABAYASHI M, 1988, J BIOL CHEM, V263, P13930; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LIU L, 1991, J CELL BIOCHEM     S, V15, P171; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MULVAGH SL, 1987, BIOCHEM BIOPH RES CO, V147, P627, DOI 10.1016/0006-291X(87)90977-6; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARLOW MH, 1991, DEV BIOL, V146, P139, DOI 10.1016/0012-1606(91)90454-B; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VILLAREAL FJ, 1991, J CELL BIOCHEM, V15, P174; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	77	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3343	3350						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371118				2022-12-27	WOS:A1992HD15400082
J	BRONNIKOV, G; HOUSTEK, J; NEDERGAARD, J				BRONNIKOV, G; HOUSTEK, J; NEDERGAARD, J			BETA-ADRENERGIC, CAMP-MEDIATED STIMULATION OF PROLIFERATION OF BROWN FAT-CELLS IN PRIMARY CULTURE - MEDIATION VIA BETA-1 BUT NOT VIA BETA-3 ADRENOCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN THERMOGENIN; HIGH-AFFINITY BINDING; ADIPOSE-TISSUE; DNA-SYNTHESIS; CYCLIC-AMP; MONOLAYER-CULTURE; MESSENGER-RNA; RIBONUCLEOTIDE REDUCTASE; MICROGRAM QUANTITIES; ADENYLATE-CYCLASE	The ability of adrenergic stimulation to affect the rate of DNA synthesis in mouse brown adipocyte precursor cells proliferating in primary culture was investigated. Addition of 1-mu-M norepinephrine to the cells at day 4 in culture (proliferating cells) significantly increased the rate of DNA synthesis, whereas no significant effect was seen at day 9 (confluent cells). The effect of norepinephrine could be mimicked by forskolin, cholera toxin, and by cAMP analogues. Specific [H-3]thymidine incorporation (per unit of DNA) was reduced by norepinephrine stimulation, indicating saturation of the salvage pathway for dTTP synthesis already in unstimulated cells and implying a beta-adrenergic stimulation of dTTP synthesis. Pharmacological characterization of this effect indicated it was mediated by beta-1 receptors, with alpha-2 receptors exerting an opposing effect. Notably, the stimulation of DNA synthesis was not observed with the beta-3-specific agonist CGP-12177. In contrast, both norepinephrine and CGP-12177 were able to induce the expression of the uncoupling protein thermogenin in the confluent cultured cells. This coincided with a shift in the cAMP-elevating potential of CGP-12177, from being antagonistic to norepinephrine stimulation in proliferating cells to being itself a full agonist in confluent cells, implying occurrence of coupled beta-3 receptors as part of the differentiation process. It was concluded that brown fat precursor cells respond directly to norepinephrine stimulation with an increased DNA synthesis, and that this response is mediated via the classical beta-1 receptors. This probably represents the cellular basis for the hyperplasia observed in the tissue in physiologically recruited states.	UNIV STOCKHOLM, WENNER GREN INST, ARRHENIUS LABS F3, S-10691 STOCKHOLM, SWEDEN; ACAD SCI USSR, INST BIOL PHYS, PUSHCHINO, MOSCOW 142292, USSR; CZECHOSLOVAK ACAD SCI, INST PHYSIOL, CS-14220 PRAGUE, CZECHOSLOVAKIA	Stockholm University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS; Czech Academy of Sciences			Houstek, Josef/C-5019-2012; Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010	Houstek, Josef/0000-0002-8413-4772; Nedergaard, Jan/0000-0003-2070-1587				AFANE M, 1989, CLIN EXP RHEUMATOL, V7, P603; ALBERT DA, 1989, J CELL PHYSIOL, V138, P129, DOI 10.1002/jcp.1041380118; ALBERT DA, 1990, J CELL PHYSIOL, V143, P251, DOI 10.1002/jcp.1041430208; ALEKSIUK M, 1971, COMP BIOCHEM PHYSIOL, V38, P723, DOI 10.1016/0300-9629(71)90213-1; ALEKSIUK M, 1971, CAN J ZOOLOG, V49, P1143, DOI 10.1139/z71-174; ARCH JRS, 1989, P NUTR SOC, V48, P215, DOI 10.1079/PNS19890032; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SL, 1982, Q J EXP PHYSIOL CMS, V67, P259; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; BUKOWIECKI L, 1978, EUR J BIOCHEM, V92, P189, DOI 10.1111/j.1432-1033.1978.tb12737.x; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; BUKOWIECKI L, 1980, AM J PHYSIOL, V238, pE552, DOI 10.1152/ajpendo.1980.238.6.E552; BUKOWIECKI LJ, 1986, AM J PHYSIOL, V250, pC880, DOI 10.1152/ajpcell.1986.250.6.C880; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; CANNON B, 1989, LIVING COLD, V2, P359; CANNON B, 1985, CIRCULATION RESPIRAT, P502; CANNON B, 1986, 13TH P INT C NUTR, P315; CONNOLLY E, 1986, J BIOL CHEM, V261, P4377; CONNOLLY E, 1988, J BIOL CHEM, V263, P10574; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; DRACH JC, 1981, SCIENCE, V212, P549, DOI 10.1126/science.7209549; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; GRANNEMAN JG, 1991, J PHARMACOL EXP THER, V256, P421; HERRON D, 1989, AM J PHYSIOL, V257, pC920, DOI 10.1152/ajpcell.1989.257.5.C920; HERRON D, 1990, FEBS LETT, V268, P296, DOI 10.1016/0014-5793(90)81031-I; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HIMMSHAGEN J, 1981, AM J PHYSIOL, V241, pE116, DOI 10.1152/ajpendo.1981.241.2.E116; HOUSTEK J, 1990, FEBS LETT, V274, P185, DOI 10.1016/0014-5793(90)81360-Z; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P441, DOI 10.1016/0005-2728(90)90077-H; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1018, P243, DOI 10.1016/0005-2728(90)90258-6; HUNT TE, 1967, ANAT REC, V157, P537, DOI 10.1002/ar.1091570313; KISSANE JM, 1958, J BIOL CHEM, V233, P184; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KUUSELA P, 1986, LIFE SCI, V38, P589, DOI 10.1016/0024-3205(86)90052-4; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIN BE, 1986, J PHARMACOL EXP THER, V236, P681; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; Miura Y, 1973, Adv Enzyme Regul, V11, P105, DOI 10.1016/0065-2571(73)90011-3; MOHELL N, 1989, COMP BIOCHEM PHYS C, V94, P229, DOI 10.1016/0742-8413(89)90171-0; MOHELL N, 1989, BIOCHEM J, V261, P401, DOI 10.1042/bj2610401; MORY G, 1980, J PHYSIOL-PARIS, V76, P859; MORY G, 1982, AM J PHYSIOL, V242, pC159, DOI 10.1152/ajpcell.1982.242.3.C159; MUZZIN P, 1989, BIOCHEM J, V261, P721, DOI 10.1042/bj2610721; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; NAKATA R, 1985, EUR J PHARMACOL, V114, P355, DOI 10.1016/0014-2999(85)90380-2; NARAYANSINGH T, 1972, COMP BIOCHEM PHYSIOL, V42, P889, DOI 10.1016/0300-9629(72)90395-7; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; NECHAD M, 1983, EXP CELL RES, V149, P119, DOI 10.1016/0014-4827(83)90385-3; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; Nedergaard J., 1986, BROWN ADIPOSE TISSUE, P152; Nicholls, 1986, BROWN ADIPOSE TISSUE, P214; NUSETTI OA, 1975, J MAMMAL, V56, P770, DOI 10.2307/1379652; OLASHAW NE, 1988, ADV SEC MESS PHOSPH, V22, P139; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PETTERSSON B, 1976, EUR J BIOCHEM, V62, P383, DOI 10.1111/j.1432-1033.1976.tb10170.x; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; RANNELS DE, 1982, FED PROC, V41, P2833; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REHNMARK S, 1986, 5TH INT C OB, P89; REHNMARK S, 1986, 9TH INT S BIOL REG C, P31; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; ROTHWELL NJ, 1985, AM J PHYSIOL, V248, pE397, DOI 10.1152/ajpendo.1985.248.4.E397; ROTHWELL NJ, 1986, BROWN ADIPOSE TISSUE, P269; SCARPACE PJ, 1987, AM J PHYSIOL, V253, pE629, DOI 10.1152/ajpendo.1987.253.6.E629; SCARPACE PJ, 1991, AM J PHYSIOL, V260, pE226, DOI 10.1152/ajpendo.1991.260.2.E226; SENAULT C, 1981, AM J PHYSIOL, V240, pE379, DOI 10.1152/ajpendo.1981.240.4.E379; SETARO F, 1976, ANAL BIOCHEM, V71, P313, DOI 10.1016/0003-2697(76)90043-9; SIMNETT JD, 1973, J CELL PHYSIOL, V81, P171, DOI 10.1002/jcp.1040810206; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; SVOBODA P, 1979, EUR J BIOCHEM, V102, P203, DOI 10.1111/j.1432-1033.1979.tb06281.x; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; THOMSON JF, 1969, J CELL BIOL, V41, P312, DOI 10.1083/jcb.41.1.312; THOMSON JF, 1969, RADIAT RES, V38, P55, DOI 10.2307/3572710; WEST DC, 1985, ANAL BIOCHEM, V147, P289, DOI 10.1016/0003-2697(85)90274-X; Whitfield J F, 1980, Ann N Y Acad Sci, V339, P216, DOI 10.1111/j.1749-6632.1980.tb15980.x; WILCKE M, 1989, BIOCHEM BIOPH RES CO, V163, P292, DOI 10.1016/0006-291X(89)92134-7; WILLEY JC, 1985, J CELL PHYSIOL, V124, P207, DOI 10.1002/jcp.1041240206; WOODCOCKMITCHELL J, 1982, INT J BIOCHEM, V14, P757, DOI 10.1016/0020-711X(82)90013-1; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306	86	179	184	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2006	2013						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346138				2022-12-27	WOS:A1992HA48500092
J	WILSON, JM; GROSSMAN, M; WU, CH; CHOWDHURY, NR; WU, GY; CHOWDHURY, JR				WILSON, JM; GROSSMAN, M; WU, CH; CHOWDHURY, NR; WU, GY; CHOWDHURY, JR			HEPATOCYTE-DIRECTED GENE-TRANSFER INVIVO LEADS TO TRANSIENT IMPROVEMENT OF HYPERCHOLESTEROLEMIA IN LOW-DENSITY-LIPOPROTEIN RECEPTOR-DEFICIENT RABBITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; LIVER-TRANSPLANTATION; PLASMA-EXCHANGE; WHHL-RABBIT; EXPRESSION; ATHEROSCLEROSIS; HYPERLIPIDEMIA; DELIVERY; SYSTEM	Familial hypercholesterolemia is an inherited disease in humans, caused by a deficiency of low density lipoprotein (LDL) receptors, that we have used as a model for developing liver-directed gene therapies. Our strategy is to reconstitute hepatic LDL receptor expression in vivo by administering a DNA-protein complex that is capable of targeting the delivery of functional LDL receptor genes to hepatocytes. Infusion of this DNA-protein complex into the peripheral circulation of a rabbit animal model for familial hypercholesterolemia resulted in hepatocyte-specific gene transfer and a temporary amelioration of hypercholesterolemia. This noninvasive approach to gene therapy should have applications in the treatment of a wide spectrum of human diseases.	UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV CONNECTICUT,SCH MED,DEPT INTERNAL MED,FARMINGTON,CT 06030; YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,DEPT INTERNAL MED,BRONX,NY 10461	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Connecticut; Yeshiva University; Albert Einstein College of Medicine	WILSON, JM (corresponding author), UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.							BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DOBBINS WO, 1978, DIAGNOSTIC ELECTRON, V1, P253; FINER MH, 1990, METHODS MOL BIOL GEN, V7, P1; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; KANO M, 1987, ARTERIOSCLEROSIS, V7, P256, DOI 10.1161/01.ATV.7.3.256; KOCHRAN WG, 1957, EXPT DESIGNS, P127; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; STARZL TE, 1984, LANCET, V1, P1382; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; TRINDER P, 1974, ANN CLIN BIOCHEM, V12, P226; VANBEVEREN C, 1985, RNA TUMOR VIRUSES; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	21	203	303	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					963	967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370472				2022-12-27	WOS:A1992GY96000046
J	WU, DQ; KATZ, A; LEE, CH; SIMON, MI				WU, DQ; KATZ, A; LEE, CH; SIMON, MI			ACTIVATION OF PHOSPHOLIPASE-C BY ALPHA-1-ADRENERGIC RECEPTORS IS MEDIATED BY THE ALPHA-SUBUNITS OF GQ FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; EXPRESSION; SUBTYPES; DIVERSITY; CDNA; CHLORETHYLCLONIDINE; HETEROGENEITY; PHOSPHATE	High efficiency transient transfection of Cos-7 cells was previously used to establish the functional coupling between Galphaq/Galpha11 and phospholipase C beta1 (Wu, D., Lee, C-H., Rhee, S. G., and Simon, M. I. (1992) J. Biol. Chem. 267, 1811-1817). Here the same system was used to study the functional coupling between other guanine nucleotide-binding regulatory protein (G-protein) alpha subunits and phospholipases and to study which Galpha subunits mediate the activation of phospholipase C by the alpha1-adrenergic receptor subtypes, alpha1A, alpha1beta, and alpha1C. We found that Galpha14 and Galpha16 behaved like Galpha11 or Galphaq, i.e. they could activate endogenous phospholipases in Cos-7 cells in the presence of AIFn. The synergistic increase in inositol phosphate release in Cos-7 cells after they were cotransfected with cDNAs encoding Galpha subunits and phospholipase C beta1 indicates that both Galpha16 and Galpha14 can activate phospholipase C beta1. The activation of phospholipase C beta1 was restricted to members of the Gq subfamily of alpha subunits. They activated phospholipase C beta1 but not phospholipase C gamma1, gamma2, or phospholipase C delta3. The cotransfection of Cos-7 cells with cDNAs encoding three different alpha1-adrenergic receptors and Galphaq or Galpha11 leads to an increase in norepinephrine-dependent inositol phosphate release. This indicates that Galphaq or Galpha11 can mediate the activation of phospholipase C by all three subtypes of alpha1-adrenergic receptors. With the same assay system, Galpha16 and Galpha14 appear to be differentially involved in the activation of phospholipase C by the alpha1-adrenergic receptors. The alpha1B subtype receptor gave a ligand-mediated synergistic response in the cells cotransfected with either Galpha14 or Galpha16. However, the alpha1C receptor responded in cells cotransfected with Galpha14 but not Galpha16, and the alpha1A receptor showed little synergistic response in cells transfected with either Galpha14 or Galpha16. The ability of the alpha1A and alpha1C receptors to activate phospholipase C through Galphaq and Galpha11 was also demonstrated in a cell-free system. Clearly Galphaq and Galpha11 can couple all three of the alpha1-adrenergic receptors to activate phospholipase C beta1, however, there are differences in the relative coupling of the Galpha14 and Galpha16 subunits to these receptors.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology	SIMON, MI (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Katz, Arieh/F-5836-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V267, P1430; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAN C, 1987, MOL PHARMACOL, V32, P505; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MORROW AL, 1986, MOL PHARMACOL, V29, P321; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUZUKI E, 1990, MOL PHARMACOL, V38, P725; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WU DQ, 1992, J BIOL CHEM, V267, P1811	32	267	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25798	25802						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334487				2022-12-27	WOS:A1992KD07300035
J	BAULDRY, SA; ELSEY, KL; BASS, DA				BAULDRY, SA; ELSEY, KL; BASS, DA			ACTIVATION OF NADPH OXIDASE AND PHOSPHOLIPASE-D IN PERMEABILIZED HUMAN NEUTROPHILS - CORRELATION BETWEEN OXIDASE ACTIVATION AND PHOSPHATIDIC-ACID PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEIN-KINASE-C; GTP-BINDING PROTEIN; FMET-LEU-PHE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FLUORIDE-TREATED NEUTROPHILS; SUPEROXIDE-GENERATING SYSTEM; STIMULATED HUMAN-NEUTROPHILS; STAPHYLOCOCCAL ALPHA-TOXIN; SODIUM DODECYL-SULFATE	A major function of human neutrophils (PMN) during inflammation is formation of oxygen radicals through activation of the respiratory burst enzyme, NADPH oxidase. Stimulus-induced production of both phosphatidic acid (PA) and diglyceride (DG) has been suggested to mediate oxidase activity; however, transductional mechanisms and cofactor requirements necessary for activation are poorly defined. We have utilized PMN permeabilized with Staphylococcus aureus alpha-toxin to elucidate the signal pathway involved in eliciting oxidase activity and to investigate whether PA or DG act as second messengers. PMN were permeabilized in cytoplasmic buffer supplemented with ATP and EGTA for 15 min before addition of NADPH and various cofactors. Oxidase activation was assessed by superoxide dismutase inhibitable reduction of ferricytochrome C; PA and DG levels were measured by radiolabeled product formation or by metabolite mass formation. Both superoxide (O2-) and PA formation were initiated by 10 muM GTPgammaS; addition of cytosolic levels of calcium ions (Ca2+, 120 nM) enhanced O2- and PA formation 1.5-2 fold. DG levels showed little change during these treatments. PA formation preceded O2- production and varying GTPgammaS levels had parallel effects on O2- and PA formation. However, while PA formation and oxidase activation occurred in tandem at Ca2+ levels of <1 muM, higher calcium enhanced PA formation but inhibited O2- production. Removal of ATP completely blocked O2- production but had little effect on PA formation; in contrast, if ATP was replaced with ATPgammaS, parallel production of PA and O2- occurred in the absence of other cofactors. Finally, while inhibition of PA production by ethanol pretreatment led to inhibition of O2- formation in PMN treated with GTPgammaS alone, in cells stimulated with a combination of GTPgammaS and Ca2+, ethanol continued to inhibit PA formation but had no effect on O2- production. Our results do not support a role for DG in the signal transduction path leading to oxidase activation and, while we show a close correlation between oxidase activation and PA production under many physiologic conditions, we also demonstrate that PA is not sufficient to induce oxidase activation and O2- formation can occur when PA production is inhibited.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA	Wake Forest University; Wake Forest Baptist Medical Center					NIAID NIH HHS [AI-30142, AI-14929, AI-10732] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030142, R01AI030142, R01AI014929, R01AI010732] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; AVIRAM I, 1989, BIOCHEM BIOPH RES CO, V161, P712, DOI 10.1016/0006-291X(89)92658-2; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADER MF, 1986, J BIOL CHEM, V261, P5777; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BASS DA, 1988, J BIOL CHEM, V263, P19610; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAUDRY SA, 1988, J BIOL CHEM, V263, P16787; BAUDRY SA, 1991, J IMMUNOL, V146, P1277; BAUDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; BAULDRY SA, 1992, J BIOL CHEM, V267, P323; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1981, BIOCHEM J, V200, P501, DOI 10.1042/bj2000501; COHEN HJ, 1978, J CLIN INVEST, V61, P1088, DOI 10.1172/JCI109008; COX CC, 1986, J IMMUNOL, V136, P4611; COX JA, 1987, J IMMUNOL, V138, P1884; CURNUTTE JT, 1975, BLOOD, V45, P851; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DALE MM, 1987, BRIT J PHARMACOL, V92, P63, DOI 10.1111/j.1476-5381.1987.tb11296.x; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; ENGLISH D, 1991, BLOOD, V77, P2746; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; ENGLISH D, 1989, J IMMUNOL, V143, P1685; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FUJITA I, 1984, BIOCHEM BIOPH RES CO, V120, P318, DOI 10.1016/0006-291X(84)91256-7; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1989, BIOCHEM J, V261, P755, DOI 10.1042/bj2610755; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GRZESKOWIAK M, 1986, BIOCHEM BIOPH RES CO, V135, P785, DOI 10.1016/0006-291X(86)90997-6; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; LU DJ, 1990, J BIOL CHEM, V265, P13721; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1984, REGULATION LEUKOCYTE, P247; MILLER RT, 1991, KIDNEY INT, V39, P421, DOI 10.1038/ki.1991.53; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NAKASHIMA S, 1987, J BIOCHEM-TOKYO, V101, P1055, DOI 10.1093/oxfordjournals.jbchem.a121948; NAKASHIMA S, 1988, ARCH BIOCHEM BIOPHYS, V261, P375, DOI 10.1016/0003-9861(88)90353-0; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; OLSON SC, 1991, J BIOL CHEM, V266, P17236; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RIDER LG, 1987, J BIOL CHEM, V262, P5603; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1989, J IMMUNOL, V142, P1652; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SPARKMAN TB, 1985, BIOCHIM BIOPHYS ACTA, V846, P8, DOI 10.1016/0167-4889(85)90103-X; THOMPSON NT, 1990, BIOCHEM J, V271, P209, DOI 10.1042/bj2710209; TRAYNOR AE, 1989, BLOOD, V73, P296; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; WALKER BAM, 1991, J IMMUNOL, V146, P3124; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	84	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25141	25152						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334083				2022-12-27	WOS:A1992KB60300037
J	ENDO, F; AWATA, H; TANOUE, A; ISHIGURO, M; EDA, Y; TITANI, K; MATSUDA, I				ENDO, F; AWATA, H; TANOUE, A; ISHIGURO, M; EDA, Y; TITANI, K; MATSUDA, I			PRIMARY STRUCTURE DEDUCED FROM COMPLEMENTARY-DNA SEQUENCE AND EXPRESSION IN CULTURED-CELLS OF MAMMALIAN 4-HYDROXYPHENYLPYRUVIC ACID DIOXYGENASE - EVIDENCE THAT THE ENZYME IS A HOMODIMER OF IDENTICAL SUBUNITS HOMOLOGOUS TO RAT LIVER-SPECIFIC ALLOANTIGEN-F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYPHENYLPYRUVATE HYDROXYLASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; ALPHA-KETOACID DEHYDROGENASE; PROLIDASE DEFICIENCY; AVIAN LIVER; PURIFICATION; PROTEIN; ANTIGEN; HYPERTYROSINEMIA; DERIVATIZATION	4-Hydroxyphenylpyruvic acid dioxygenase is an important enzyme in tyrosine catabolism in most organisms. From porcine and human liver cDNA libraries we isolated complementary DNA inserts for the enzyme. Protein sequence analysis of the porcine enzyme revealed a block of the amino terminus of the mature enzyme. Comparison of the amino acid sequence determined by Edman degradation of peptides derived from porcine liver 4-hydroxyphenylpyruvic acid dioxygenase with the nucleotide sequences revealed the primary structure of the porcine and human enzymes. The mature human and porcine enzymes have an 89% amino acid sequence identity in amino acid residues and are composed of 392 amino acid residues. A computer-assisted homology search revealed that the enzyme is 88% identical in amino acid sequence to rat liver-specific alloantigen F. A monoclonal antibody (mob 51), which can immunoprecipitate both the human and porcine enzymes, was developed. Cultured BMT-10 cells transfected with the cDNA insert of the human enzyme, using the expression vector pCAGGSneodE, produced a polypeptide with an M(r) of 43,000, which was immunoprecipitated with mob 51. Enzymic activity of the enzyme was detected in the transfected cells but not in the mock transfected cells. These findings suggest that the human 4-hydroxyphenylpyruvic acid dioxygenase is a homodimer of two identical subunits with an M(r) of 43,000. Liver-specific alloantigen F seems to be closely related to the enzyme or possibly to the subunit of the enzyme itself. Elucidation of the complete amino acid sequence of the enzyme is expected to reveal structure-function relationships of this metabolically important enzyme and to shed light on inherited disorders related to tyrosine metabolism, especially tyrosinemia types 1 and 3.	KUMAMOTO UNIV, SCH MED, DEPT PEDIAT, HONJO 1-1-1, KUMAMOTO 860, JAPAN; FUJITA HLTH UNIV, SCH MED, INST COMPREHENS MED SCI, DIV BIOMED POLYMER SCI, TOYOAKE, AICHI 47011, JAPAN; CHEMO SERO THERAPEUT INST, DIV IMMUNOL & BIOL, KUMAMOTO 85115, JAPAN	Kumamoto University; Fujita Health University								BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BUCKTHAL DJ, 1987, METHOD ENZYMOL, V142, P132; ENDO F, 1989, J BIOL CHEM, V264, P4476; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; ENDO F, 1990, J CLIN INVEST, V85, P162, DOI 10.1172/JCI114407; ENDO F, 1987, PEDIATR RES, V22, P627, DOI 10.1203/00006450-198712000-00002; ENDO F, 1991, AM J HUM GENET, V48, P704; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELLMAN JH, 1987, METHOD ENZYMOL, V142, P148; FELLMAN JH, 1972, BIOCHIM BIOPHYS ACTA, V284, P90, DOI 10.1016/0005-2744(72)90048-4; FRAVI G, 1968, NATURE, V218, P141, DOI 10.1038/218141a0; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GERSHWIN ME, 1987, J IMMUNOL, V139, P3828; GROSS E, 1967, METHOD ENZYMOL, V11, P232; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYAKAWA J, 1987, IMMUNOGENETICS, V26, P366, DOI 10.1007/BF00343706; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KOIKE K, 1988, P NATL ACAD SCI USA, V85, P41, DOI 10.1073/pnas.85.1.41; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1976, EUR J IMMUNOL, V6, P480, DOI 10.1002/eji.1830060707; LINDBLAD B, 1971, CLIN CHIM ACTA, V34, P113, DOI 10.1016/0009-8981(71)90074-X; LINDBLAD B, 1977, J BIOL CHEM, V252, P5073; LINDSTEDT S, 1982, BIOCHIM BIOPHYS ACTA, V704, P66, DOI 10.1016/0167-4838(82)90133-9; LINDSTEDT S, 1987, METHOD ENZYMOL, V142, P139; LINDSTEDT S, 1987, METHOD ENZYMOL, V142, P143; LINDSTEDT S, 1982, J BIOL CHEM, V257, P1922; LINDSTEDT S, 1982, COMP BIOCHEM PHYS B, V72, P537, DOI 10.1016/0305-0491(82)90502-8; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; Maniatis T., 1982, MOL CLONING; MIHAS AA, 1976, J IMMUNOL, V116, P1228; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOBUKUNI Y, 1990, BIOCHEMISTRY-US, V29, P1154, DOI 10.1021/bi00457a009; ROCHE PA, 1982, ARCH BIOCHEM BIOPHYS, V216, P62, DOI 10.1016/0003-9861(82)90188-6; Ruegg U T, 1977, Methods Enzymol, V47, P111; RUNDGREN M, 1977, J BIOL CHEM, V252, P5085; RUNDGREN M, 1977, J BIOL CHEM, V252, P5094; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER DM, 1981, IMMUNOGENETICS, V12, P237, DOI 10.1007/BF01561667; SUGAMURA K, 1976, CLIN EXP IMMUNOL, V26, P28; TANOUE A, 1991, J CLIN INVEST, V87, P1171, DOI 10.1172/JCI115115; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; WADA GH, 1975, J BIOL CHEM, V250, P6720; WEDDERBURN L, 1984, MOL IMMUNOL, V21, P979, DOI 10.1016/0161-5890(84)90156-1; ZHANG B, 1988, GENE, V69, P159, DOI 10.1016/0378-1119(88)90390-3	48	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24235	24240						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1339442				2022-12-27	WOS:A1992KA26300017
J	KHOSRAVIFAR, R; CLARK, GJ; ABE, K; COX, AD; MCLAIN, T; LUTZ, RJ; SINENSKY, M; DER, CJ				KHOSRAVIFAR, R; CLARK, GJ; ABE, K; COX, AD; MCLAIN, T; LUTZ, RJ; SINENSKY, M; DER, CJ			RAS (CXXX) AND RAB (CC/CXC) PRENYLATION SIGNAL SEQUENCES ARE UNIQUE AND FUNCTIONALLY DISTINCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MONOCLONAL-ANTIBODIES; VESICULAR TRANSPORT; CARBOXYL TERMINUS; ALPHA-SUBUNIT; METHYL-ESTER; C-TERMINUS; P21; YEAST; FARNESYLTRANSFERASE	Rab proteins typically lack the consensus carboxyl-terminal CXXX motif that signals isoprenoid modification of Ras and other isoprenylated proteins and, instead, terminate in either CC or CXC sequences (C = cysteine, X = any amino acid). To compare the functional relationship between the Ras CXXX and the Rab CC/CXC motifs, we have generated chimeric Ras proteins terminating in Rab carboxyl-terminal CC or CXC sequences. These mutant Ras proteins were not isoprenylated in vitro or in vivo, demonstrating that the CC and CXC sequences alone are not sufficient to replace a CXXX sequence to signal Ras isoprenoid modification. Surprisingly, chimeric Ras/Rab proteins terminating in significant lengths of carboxyl-terminal sequences from Rab1b (7-139 residues), Rab2 (5-151 residues), or Rab3a (12 residues) were also not isoprenylated. These results demonstrate that the sequence requirements for isoprenoid modification of Rab proteins are more complex than the simple tetrapeptide CXXX sequence for isoprenoid modification of Ras proteins and suggest that the Rab geranylgeranyl transferase(s) requires recognition of protein conformation to signal the addition of geranylgeranyl groups. Finally, competition studies demonstrate that a common geranylgeranyl transferase activity is responsible for the modification of Rab proteins terminating in CC or CXC motifs.	UNIV N CAROLINA,LINEBERGER CAN CTR,DEPT PHARMACOL,CHAPEL HILL,NC 27599; ELEANOR ROOSEVELT INST CANC RES,DENVER,CO 80206	University of North Carolina; University of North Carolina Chapel Hill			Khosravi-Far, Roya/C-3789-2008	Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA055008, R01CA052072] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA55008, CA52072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P469; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brake A. J., 1984, PROTEIN TRANSPORT SE, P103; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMER PJ, 1990, HYBRIDOMA, V9, P573, DOI 10.1089/hyb.1990.9.573; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; JONES TLZ, 1990, J BIOL CHEM, V265, P19389; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEI C, 1992, ONCOGENE, V7, P467; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	55	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24363	24368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332953				2022-12-27	WOS:A1992KA26300036
J	MATSUSHITA, K; EBISUYA, H; ADACHI, O				MATSUSHITA, K; EBISUYA, H; ADACHI, O			HOMOLOGY IN THE STRUCTURE AND THE PROSTHETIC GROUPS BETWEEN 2 DIFFERENT TERMINAL UBIQUINOL OXIDASES, CYTOCHROME-ALPHA(1) AND CYTOCHROME-O, OF ACETOBACTER-ACETI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; THERMOPHILE THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; GLUCONOBACTER-SUBOXYDANS; C-OXIDASE; HEME-A; PURIFICATION; COMPLEX; SEQUENCE; COPPER	Acetobacter aceti produces two different terminal oxidases dependent on the culture conditions, shaking and static cultures. Cells grown on shaking culture contain cytochrome a1, while cytochrome o is present in cells grown on static culture. Cytochrome a1 and cytochrome o of A. aceti were compared especially with respect to the protein structure and the prosthetic groups. Cytochrome a1 exhibited lower CN sensitivity and higher affinity for O2 than cytochrome o. Both terminal oxidases consisted of four nonidentical polypeptides of which the molecular sizes were identical between both enzymes. Cytochrome a1 cross-reacted with an antibody raised against cytochrome o at the same level as cytochrome o did, and an antibody elicited against cytochrome a1 cross-reacted with both cytochrome o and cytochrome a1 at the same intensity, which indicates that both oxidases are indistinguishable immunochemically. Furthermore, almost the same peptide mapping pattern with chymotrypsin was observed in subunit I and in subunit II between both terminal oxidases, and the amino-terminal sequences in the subunit II of both oxidases were identical at least in their 10 amino acids. As for the prosthetic groups, both oxidases were shown to contain two heme-irons and one copper atom. Further, high performance liquid chromatography analysis of the heme moieties extracted from both the purified enzymes indicated that cytochrome a1 contains hemes b and a at a ratio of 1 to 1, whereas cytochrome o contains the same amounts of hemes b and o. Thus, data indicate that cytochrome a1 and cytochrome o of A. aceti are cytochrome ba and cytochrome bo ubiquinol oxidases, respectively, and that both oxidases have a closely similar protein structure and prosthetic groups, in which only heme a in the heme/copper binuclear center of cytochrome a1 is replaced by heme o in that of cytochrome o.	YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,YAMAGUCHI 753,JAPAN	Yamaguchi University								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMEYAMA M, 1987, AGR BIOL CHEM TOKYO, V51, P2943; ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; Asai T, 1968, ACETIC ACID BACTERIA, P124; BACHI B, 1974, INT J SYST BACTERIOL, V24, P215, DOI 10.1099/00207713-24-2-215; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; FROUD SJ, 1984, J GEN MICROBIOL, V130, P2201; GARCIAHORSMAN JA, 1991, EUR J BIOCHEM, V199, P761, DOI 10.1111/j.1432-1033.1991.tb16181.x; GEORGIOU CD, 1987, BIOCHEMISTRY-US, V26, P5621; JURTSHUK P, 1981, BIOCHIM BIOPHYS ACTA, V637, P374, DOI 10.1016/0005-2728(81)90176-6; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; KRANZ RG, 1983, J BIOL CHEM, V258, P614; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA K, 1990, P NATL ACAD SCI USA, V87, P9863, DOI 10.1073/pnas.87.24.9863; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, BIOCHIM BIOPHYS ACTA, V894, P304, DOI 10.1016/0005-2728(87)90200-3; MATSUSHITA K, 1992, J BACTERIOL, V174, P122, DOI 10.1128/jb.174.1.122-129.1992; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MATSUSHITA K, 1982, FEBS LETT, V139, P255, DOI 10.1016/0014-5793(82)80864-8; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1982, BIOCHIM BIOPHYS ACTA, V682, P216, DOI 10.1016/0005-2728(82)90101-3; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; WEINSTEIN JD, 1983, J BIOL CHEM, V258, P6799; YAMANAKA T, 1981, J BIOCHEM, V89, P265, DOI 10.1093/oxfordjournals.jbchem.a133190; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	38	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24748	24753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332965				2022-12-27	WOS:A1992KA26300089
J	UEDA, K; OKAMURA, N; HIRAI, M; TANIGAWARA, Y; SAEKI, T; KIOKA, N; KOMANO, T; HORI, R				UEDA, K; OKAMURA, N; HIRAI, M; TANIGAWARA, Y; SAEKI, T; KIOKA, N; KOMANO, T; HORI, R			HUMAN P-GLYCOPROTEIN TRANSPORTS CORTISOL, ALDOSTERONE, AND DEXAMETHASONE, BUT NOT PROGESTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE LLC-PK1; MULTIDRUG-RESISTANCE GENE; EPITHELIAL TRANSPORT; ADRENAL-CORTEX; MDR1 CDNA; MEMBRANE; BINDING; LOCALIZATION; EXPRESSION; TISSUES	We expressed human MDR1 cDNA isolated from the human adrenal gland in porcine LLC-PK1 cells. A highly polarized epithelium formed by LLC-GA5-COL300 cells that expressed human P-glycoprotein specifically on the apical surface showed a multidrug-resistant phenotype and had 8.3-, 3.4-, and 6.5-fold higher net basal to apical transport of H-3-labeled cortisol, aldosterone, and dexamethasone, respectively, compared with host cells. But progesterone was not transported, although it inhibited azidopine photoaffinity labeling of human P-glycoprotein and increased the sensitivity of multidrug-resistant cells to vinblastine. An excess of progesterone inhibited the transepithelial transport of cortisol by P-glycoprotein. These results suggest that cortisol and aldosterone are physiological substrates for P-glycoprotein in the human adrenal cortex and that substances that efficiently bind to P-glycoprotein are not necessarily transported by P-glycoprotein.	KYOTO UNIV HOSP,FAC MED,DEPT PHARM,KYOTO 60601,JAPAN	Kyoto University	UEDA, K (corresponding author), KYOTO UNIV,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,KYOTO 60601,JAPAN.			Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; CARMICHAEL J, 1987, CANCER RES, V47, P936; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAUTH C, 1988, AM J PHYSIOL, V254, pF341; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORIO M, 1989, J BIOL CHEM, V264, P14880; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; MISFELDT DS, 1981, J MEMBRANE BIOL, V59, P13, DOI 10.1007/BF01870816; NAITO M, 1989, BIOCHEM BIOPH RES CO, V158, P1066, DOI 10.1016/0006-291X(89)92830-1; NAITO M, 1989, CANCER RES, V49, P1452; NISHIKAWA T, 1984, ENDOCRINOLOGY, V114, P486, DOI 10.1210/endo-114-2-486; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; QIAN XD, 1990, J BIOL CHEM, V265, P18753; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SUGAWARA I, 1988, CANCER RES, V48, P4611; TAIT S A S, 1970, Endocrinology, V86, P360; TAKAYAMA A, 1991, J PHARMACOL EXP THER, V257, P200; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, J BIOL CHEM, V262, P505; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282	28	610	630	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24248	24252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360010				2022-12-27	WOS:A1992KA26300019
J	BOUTILLIER, AL; BARTHEL, F; ROBERTS, JL; LOEFFLER, JP				BOUTILLIER, AL; BARTHEL, F; ROBERTS, JL; LOEFFLER, JP			BETA-ADRENERGIC STIMULATION OF CFOS VIA PROTEIN-KINASE A IS MEDIATED BY CAMP REGULATORY ELEMENT BINDING-PROTEIN (CREB)-DEPENDENT AND TISSUE-SPECIFIC CREB-INDEPENDENT MECHANISMS IN CORTICOTROPE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROOPIOMELANOCORTIN GENE-TRANSCRIPTION; ANTERIOR-PITUITARY CELLS; C-FOS; RESPONSIVE ELEMENT; HORMONAL-REGULATION; MESSENGER-RNA; TUMOR-CELLS; CYCLIC-AMP; EXPRESSION; GLUCOCORTICOIDS	Catecholamines stimulate proopiomelanocortin (POMC) gene expression in corticotrope cells, but the molecular mechanisms of these effects are not known. While beta-adrenergic receptors stimulate the protein kinase A (PKA) system, the POMC promoter does not have classical cAMP-response elements (CREs). Therefore, we investigated the induction of the c-fos protooncogene, previously shown to increase POMC transcription in AtT20 cells. In this corticotrope-derived cell line, we show that activation of beta-receptors with isoprenalin (Iso) induces a transient rise in c-fos mRNA levels. Gel mobility shift assays with a labeled AP1 consensus sequence (TGACTCA) showed induction of specific binding activity after Iso treatment. Cotransfection experiments with dominant inhibitory PKA mutants and reporter genes containing c-fos promoter sequences showed that c-fos induction by Iso is entirely dependent on a functional PKA activity. Furthermore, we show that beta-receptor induction of c-fos in corticotrophs is mediated by at least two distinct cAMP-responsive sequences. cAMP regulatory element binding (CREB)-dependent induction is observed on the CRE located at -60 bp on the c-fos promoter. A region located in the vicinity of the dyad symetry element (-290) is also found to mediate tissue-specific cAMP induction. Transcriptional activation by this site, although sensitive to PKA antagonism, is not blocked by CREB mutants.	INST PHYSIOL & CHIM BIOL, 21 RUE RENE DESCARTES, F-67084 STRASBOURG, FRANCE; MT SINAI MED CTR, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai			LOEFFLER, Jean-Philippe/AAS-4401-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2086, DOI 10.1073/pnas.80.7.2086; AFFOLTER HU, 1985, J BIOL CHEM, V260, P5477; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUTELITANO DJ, 1989, ANNU REV PHYSIOL, V51, P715, DOI 10.1146/annurev.physiol.51.1.715; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1985, FEBS LETT, V193, P54, DOI 10.1016/0014-5793(85)80078-8; EBERWINE JH, 1987, DNA-J MOLEC CELL BIO, V6, P483, DOI 10.1089/dna.1987.6.483; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; LOEFFLER JP, 1986, ENDOCRINOLOGY, V119, P2840, DOI 10.1210/endo-119-6-2840; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MIYAZAKI K, 1984, ENDOCRINOLOGY, V115, P1933, DOI 10.1210/endo-115-5-1933; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; REISINE TD, 1982, P NATL ACAD SCI USA, V3, P725; ROBERTS JL, 1987, ANN NY ACAD SCI, V512, P275, DOI 10.1111/j.1749-6632.1987.tb24966.x; SABOL SL, 1980, ARCH BIOCHEM BIOPHYS, V203, P37, DOI 10.1016/0003-9861(80)90151-4; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VONDREDEN G, 1988, NEUROENDOCRINOLOGY, V47, P32, DOI 10.1159/000124887; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG SL, 1989, MOL ENDOCRINOL, V3, P15, DOI 10.1210/mend-3-1-15	35	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23520	23526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331087				2022-12-27	WOS:A1992JZ23900019
J	CAO, HN; BANGALORE, L; DOMPE, C; BORMANN, BJ; STERN, DF				CAO, HN; BANGALORE, L; DOMPE, C; BORMANN, BJ; STERN, DF			AN EXTRA CYSTEINE PROXIMAL TO THE TRANSMEMBRANE DOMAIN INDUCES DIFFERENTIAL CROSS-LINKING OF P185(NEU) AND P185(NEU)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; POINT MUTATION; SENSORY RECEPTOR; CELL-SURFACE; PROTEIN; AGGREGATION; ACTIVATION; P185	The neu proto-oncogene encodes a receptor tyrosine kinase (p185) that is closely related to the epidermal growth factor receptor. It has been proposed that receptor tyrosine kinases are activated through oligomerization. Because this clustering model predicts that oligomerization of receptors is sufficient to activate them, we determined if p185 can be activated by introducing an extra cysteine proximal to the transmembrane domain. This should induce inter-receptor disulfide bonding and, according to the clustering model, activate the receptor. This amino acid substitution enhanced recovery of both normal and transforming neu proteins as dimers, with normal p185 recovered predominantly as monomers and transforming p185* as dimers. However, the cysteine substitution did not affect the transforming activity of the two proteins.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Yale University; Boehringer Ingelheim					NCI NIH HHS [CA45708] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO HN, 1991, ONCOGENE, V6, P705; CARRAWAY KL, 1991, J BIOL CHEM, V266, P8899; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOBASHI Y, 1991, ONCOGENE, V6, P1151; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FLANAGAN JG, 1988, P NATL ACAD SCI USA, V85, P8057, DOI 10.1073/pnas.85.21.8057; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAMPS MP, 1988, ONCOGENE, V2, P305; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	27	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20489	20492						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356980				2022-12-27	WOS:A1992JR85800114
J	FUKUI, K; MIYAKE, Y				FUKUI, K; MIYAKE, Y			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF A HUMAN GENE ENCODING D-AMINO-ACID OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; NUCLEOTIDE-SEQUENCE; CATALYTIC FUNCTION; MESSENGER-RNA; KIDNEY; DNA; EXPRESSION; RATS; PROPARGYLGLYCINE; PURIFICATION	Genomic clones covering the entire sequence of the gene encoding human D-amino-acid oxidase (DAO) (EC 1.4.3.3), one of the principal and characteristic flavoenzymes of peroxisomes, were isolated from human placental genomic libraries with the aid of a previously cloned cDNA for human DAO as a probe. Nucleotide sequence analysis revealed that the gene, present as a single copy in the human genome, comprises 11 exons and spans 20 kilobase pairs. The protein sequences containing the catalytically important residues, Tyr-228 and His-307, are coded for by separate exons. Heterologous transcription initiation sites were identified by primer extension analysis, and the sequence of the 5'-flanking region of the DAO gene was found to show some features common to other mammalian genes, such as those of glucocorticoid and the cAMP-responsive element. An additional noteworthy feature is the presence of promoter-like sequences in the first intron of the gene. In addition, two sequences of alternating pyrimidine and purine nucleotides, (CA)20 and (CA)17, are also present in the first intron. Such sequences may play some role in the expression of the DAO gene in human tissues. With the use of genomic DNAs prepared from human and Chinese hamster somatic hybrid cells as templates for the polymerase chain reaction, the gene for DAO was localized to human chromosome 12.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,5-7-1 FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan				Fukui, Kiyoshi/0000-0002-7438-4938				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHAN AWK, 1979, J HISTOCHEM CYTOCHEM, V27, P751, DOI 10.1177/27.3.39098; COCHET M, 1982, NATURE, V297, P335, DOI 10.1038/297335a0; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; FUKUI K, 1986, BIOCHEM BIOPH RES CO, V141, P1222, DOI 10.1016/S0006-291X(86)80175-9; FUKUI K, 1988, BIOCHEMISTRY-US, V27, P6693, DOI 10.1021/bi00418a008; FUKUI K, 1991, FLAVINS AND FLAVOPROTEINS 1990, P143; GOLDFISCHER S, 1986, J PEDIATR-US, V108, P25, DOI 10.1016/S0022-3476(86)80764-8; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HAMILTON GA, 1979, P NATL ACAD SCI USA, V76, P2625, DOI 10.1073/pnas.76.6.2625; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HONJO T, 1979, CELL, V18, P559, DOI 10.1016/0092-8674(79)90072-2; HORIIKE K, 1975, J BIOCHEM-TOKYO, V78, P57; HORIIKE K, 1985, ACTA HISTOCHEM CYTOC, V18, P539, DOI 10.1267/ahc.18.539; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JACOBS P, 1987, GENE, V59, P55, DOI 10.1016/0378-1119(87)90266-6; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1620; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MARCOTTE P, 1976, BIOCHEMISTRY-US, V15, P3070, DOI 10.1021/bi00659a021; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; MIYAKE Y, 1987, FLAVINS FLAVOPROTEIN, P501; MIYANO M, 1991, J BIOCHEM-TOKYO, V109, P171, DOI 10.1093/oxfordjournals.jbchem.a123340; MOMOI K, 1990, J BIOCHEM-TOKYO, V108, P406, DOI 10.1093/oxfordjournals.jbchem.a123214; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; NAKAJIMA H, 1981, BIOMED RES-TOKYO, V2, P154, DOI 10.2220/biomedres.2.154; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TADA M, 1990, GENE, V90, P293, DOI 10.1016/0378-1119(90)90193-U; WATANABE F, 1989, BIOCHEM BIOPH RES CO, V165, P1422, DOI 10.1016/0006-291X(89)92762-9; WATANABE F, 1988, FEBS LETT, V238, P269, DOI 10.1016/0014-5793(88)80494-0; WATANABE F, 1989, J BIOCHEM-TOKYO, V105, P1024, DOI 10.1093/oxfordjournals.jbchem.a122760; WEBER JL, 1989, AM J HUM GENET, V44, P388	41	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18631	18638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356107				2022-12-27	WOS:A1992JN50200059
J	MIZOBATA, T; AKIYAMA, Y; ITO, K; YUMOTO, N; KAWATA, Y				MIZOBATA, T; AKIYAMA, Y; ITO, K; YUMOTO, N; KAWATA, Y			EFFECTS OF THE CHAPERONIN GROE ON THE REFOLDING OF TRYPTOPHANASE FROM ESCHERICHIA-COLI - REFOLDING IS ENHANCED IN THE PRESENCE OF ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ATP HYDROLYSIS; PROTEIN; BINDING; PURIFICATION; MECHANISM; ASSAY; GENE	The refolding of the tetrameric enzyme tryptophanase was facilitated by the chaperonin GroE. Maximum refolding yield of tryptophanase molecules (about 80%) was attained in the presence of a 15-fold excess of GroE 21-mer over tryptophanase monomer. The GroEL subunit was required for this improvement in refolding yield, whereas the GroES subunit was not. Light scattering experiments of the refolding reaction revealed that GroE bound to tryptophanase folding intermediates and suppressed their aggregation. The presence of ATP was required for the efficient dissociation of tryptophanase from GroEL. However, our experiments indicated that tryptophanase dissociated readily from GroEL in the presence of not only ATP, but also in the presence of non-hydrolyzable ATP analogues such as ATP-gamma-S (adenosine 5'-O-(3-thiotriphosphate)) and AMP-PNP (adenyl-5'-yl imidodiphosphate) as well. Surprisingly, the release of tryptophanase from GroEL was facilitated in the presence of ADP as well. We concluded that the binding of nucleotides such as ATP and ADP changed the conformation of GroEL and facilitated the dissociation of tryptophanase molecules. The conformation formed in the presence of ADP was distinct from the conformation formed in the presence of ATP, as shown by the selective dissociation of various folding proteins from the two conformations.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University; Kyoto University			Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KAWATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P756, DOI 10.1016/S0006-291X(05)80100-7; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; SUELTER CH, 1976, FEBS LETT, V66, P230, DOI 10.1016/0014-5793(76)80510-8; TANI S, 1990, BIOTECHNOL APPL BIOC, V12, P28; TOKUSHIGE M, 1989, BIOCHIMIE, V71, P711, DOI 10.1016/0300-9084(89)90087-4; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	34	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17773	17779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355477				2022-12-27	WOS:A1992JM22300048
J	SINGH, TKA; SCRABA, DG; RYAN, RO				SINGH, TKA; SCRABA, DG; RYAN, RO			CONVERSION OF HUMAN LOW-DENSITY-LIPOPROTEIN INTO A VERY LOW-DENSITY LIPOPROTEIN-LIKE PARTICLE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PARTICLE; MANDUCA-SEXTA; APOLIPOPHORIN-III; TRANSFER PROTEIN; TOBACCO HORNWORM; INSECT; HEMOLYMPH; INTERCONVERSIONS; DIACYLGLYCEROL; LIPOPHORIN	The lipid substrate specificity of Manduca sexta lipid transfer particle (LTP) was examined in in vitro lipid transfer assays employing high density lipophorin and human low density lipoprotein (LDL) as donor/acceptor substrates. Unesterified cholesterol was found to exchange spontaneously between these substrate lipoproteins, and the extent of transfer/exchange was not affected by LTP. By contrast, transfer of labeled phosphatidylcholine and cholesteryl ester was dependent on LTP in a concentration-dependent manner. Facilitated phosphatidylcholine transfer occurred at a faster rate than facilitated cholesteryl ester transfer; this observation suggests that either LTP may have an inherent preference for polar lipids or the accessibility of specific lipids in the donor substrate particle influences their rate of transfer. The capacity of LDL to accept exogenous lipid from lipophorin was investigated by increasing the high density lipophorin:LDL ratio in transfer assays. At a 3:1 (protein) ratio in the presence of LTP, LDL became turbid (and aggregated LDL were observed by electron microscopy) indicating LDL has a finite capacity to accept exogenous lipid while maintaining an overall stable structure. When either isolated human non B very low density lipoprotein (VLDL) apoproteins or insect apolipophorin III (apoLp-III) were included in transfer experiments, the sample did not become turbid although lipid transfer proceeded to the same extent as in the absence of added apolipoprotein. The reduction in sample turbidity caused by exogenous apolipoprotein occurred in a concentration-dependent manner, suggesting that these proteins associate with the surface of LDL and stabilize the increment of lipid/water interface created by LTP-mediated net lipid transfer. The association of apolipoprotein with the surface of modified LDL was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, and scanning densitometry revealed that apoLp-III bound to the surface of LDL in a 1:14 apoB:apoLp-III molar ratio. Electron microscopy showed that apoLp-III-stabilized modified LDL particles have a larger diameter (29.2 +/- 2.6 nm) than that of control LDL (22.7 +/- 1.9 nm), consistent with the observed changes in particle density, lipid, and apolipoprotein content. Thus LTP-catalyzed vectorial lipid transfer can be used to introduce significant modifications into isolated LDL particles and provides a novel mechanism whereby VLDL-LDL interrelationships can be studied.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE BLDG,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta; University of Alberta					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 34786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1976, J BIOL CHEM, V251, P3823; ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BISGAIER CL, 1991, J LIPID RES, V32, P21; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; GRANOT E, 1985, BIOCHIM BIOPHYS ACTA, V833, P308, DOI 10.1016/0005-2760(85)90203-6; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KEZDY FJ, 1978, LIPOPROTEIN MOL, P83; KLEINMAN Y, 1988, J LIPID RES, V29, P729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P112, DOI 10.1016/0005-2760(91)90238-D; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; PRASAD SV, 1986, J BIOL CHEM, V261, P558; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1990, J BIOL CHEM, V265, P546; RYAN RO, 1990, FEBS LETT, V267, P305, DOI 10.1016/0014-5793(90)80950-N; RYAN RO, 1986, J BIOL CHEM, V261, P563; RYAN RO, 1990, J LIPID RES, V31, P871; RYAN RO, 1988, J BIOL CHEM, V263, P14140; RYAN RO, 1986, BIOCHEM BIOPH RES CO, V136, P260, DOI 10.1016/0006-291X(86)90903-4; SCHONFELD G, 1985, METABOLISM, V34, P45, DOI 10.1016/S0026-0495(85)80009-3; SILVER ET, 1990, J BIOL CHEM, V265, P22487; SINGH TKA, 1991, ARCH BIOCHEM BIOPHYS, V286, P376, DOI 10.1016/0003-9861(91)90054-M; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TALL AR, 1986, J LIPID RES, V27, P361; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; VAKAKIS N, 1983, BIOCHIM BIOPHYS ACTA, V751, P280, DOI 10.1016/0005-2760(83)90285-0; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; VANHEUSDEN MC, 1989, J BIOL CHEM, V264, P17287; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	37	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9275	9280						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1343558				2022-12-27	WOS:A1992HR85400087
J	SUBBARAMAIAH, K; SIMMS, SA				SUBBARAMAIAH, K; SIMMS, SA			PHOTOLABELING OF CHER METHYLTRANSFERASE WITH S-ADENOSYL-L-METHIONINE (ADOMET) - STUDIES ON THE ADOMET BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-MODIFICATION SYSTEM; TARGET-RECOGNIZING DOMAINS; II DNA METHYLTRANSFERASES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CYTOSINE METHYLTRANSFERASES; CATALYTIC MECHANISM; MODIFICATION ENZYME; PROTEIN; ADENOSYLMETHIONINE	CheR methyltransferase from Salmonella typhimurium was directly photolabeled with S-adenosyl-L-[methyl-H-3]methionine. The labeled protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then was detected by fluorography. The methylase-S-adenosyl-L-methionine adduct was found to be stable under the experimental conditions employed. Labeling was found to be a function of the concentration of enzyme, S-adenosyl-L-methionine (AdoMet), and the intensity and time of UV irradiation. The extent of labeling and protein methylation was found to be inhibited by S-adenosyl-L-homocysteine, S-adenosyl-L-ethionine, and sinefungin, which are known to compete with AdoMet for the same binding site on the enzyme. Our earlier data showed that the enzyme has 2 cysteine residues and that these are important for enzyme activity. Here, we show that sulfhydryl reagents inhibit the photolabeling of the substrate to the enzyme, indicating the presence of cysteine in the vicinity of the substrate-binding site. We also found that when Cys31 was modified to Ser, no photolabeling of CheR was observed, whereas a modification of Cys229 to Ser had little effect on the ability of AdoMet to label the enzyme. This suggests that Cys31 is located at or near AdoMet-binding site. The labeled protein was cleaved at tryptophan residues, generating two major fragments, each containing 1 cysteine residue. SDS-PAGE and fluorography of the cleaved products indicated the presence of the label being associated with the Cys31 fragment. Similar results were obtained when the labeled protein was cleaved at glutamic acid residues using V8 protease. A tryptic digest of the labeled protein showed two radioactive peptide peaks when subjected to separation on reverse phase high pressure liquid chromatography. The labeled peptides were further digested to free amino acids, and the labeled amino acid was identified as S-methylcysteine by thin layer chromatography. These results indicate that Cys31 may be involved with substrate binding, as well as with catalysis.	CUNY CITY COLL, DEPT CHEM, CONVENT AVE 138TH ST, NEW YORK, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)								BOUGUELERET L, 1984, NUCLEIC ACIDS RES, V12, P3659, DOI 10.1093/nar/12.8.3659; BOYD A, 1982, ANNU REV PHYSIOL, V44, P501, DOI 10.1146/annurev.ph.44.030182.002441; CHANDRASEGARAN S, 1987, STRUCTURE EXPRESSION, P149; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COX R, 1980, CANCER RES, V40, P61; HATTMAN S, 1985, J BACTERIOL, V164, P932, DOI 10.1128/JB.164.2.932-937.1985; HURT JH, 1984, BIOCHEM BIOPH RES CO, V122, P499; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KEALEY JT, 1991, BIOCHEMISTRY-US, V30, P9724, DOI 10.1021/bi00104a022; KISS A, 1985, NUCLEIC ACIDS RES, V13, P6403, DOI 10.1093/nar/13.18.6403; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LAUSTER R, 1987, FEBS LETT, V220, P167, DOI 10.1016/0014-5793(87)80897-9; LAUSTER R, 1989, J MOL BIOL, V206, P313, DOI 10.1016/0022-2836(89)90481-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNARELLI BM, 1985, P NATL ACAD SCI USA, V82, P4468, DOI 10.1073/pnas.82.13.4468; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; PAJARES MA, 1984, BIOCHEM J, V223, P61, DOI 10.1042/bj2230061; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; REICH NO, 1990, J BIOL CHEM, V265, P8929; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SCHONER B, 1983, GENE, V24, P227, DOI 10.1016/0378-1119(83)90083-5; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SOM S, 1991, J BIOL CHEM, V266, P2937; SOM S, 1990, J BIOL CHEM, V265, P4278; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SRPINGER WR, 1977, P NATL ACAD SCI USA, V74, P533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; SUBBARAMAIAH K, 1991, J BIOL CHEM, V266, P19023; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; THERIAULT G, 1985, NUCLEIC ACIDS RES, V13, P8441, DOI 10.1093/nar/13.23.8441; VIDGREN J, 1991, PROTEINS, V11, P233, DOI 10.1002/prot.340110309; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WU JC, 1987, J BIOL CHEM, V262, P4778; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930; YU PH, 1984, CAN J BIOCHEM CELL B, V62, P964, DOI 10.1139/o84-123; YU PH, 1983, BIOCHIM BIOPHYS ACTA, V742, P517, DOI 10.1016/0167-4838(83)90269-8	45	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8636	8642						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1349019				2022-12-27	WOS:A1992HQ18500101
J	FIELD, MC; MENON, AK; CROSS, GAM				FIELD, MC; MENON, AK; CROSS, GAM			DEVELOPMENTAL VARIATION OF GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS IN TRYPANOSOMA-BRUCEI - INVITRO BIOSYNTHESIS OF INTERMEDIATES IN THE CONSTRUCTION OF THE GPI ANCHOR OF THE MAJOR PROCYCLIC SURFACE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; PHOSPHATIDYLINOSITOL; PROTEINS; CLEAVAGE	The African trypanosome, Trypanosoma brucei, expresses two abundant stage-specific glycosylphosphatidylinositol (GPI)-anchored glycoproteins, the procyclic acidic repetitive protein (PARP or procyclin) in the procyclic form, and the variant surface glycoprotein (VSG) in the mammalian bloodstream form. The GPI anchor of VSG can be readily cleaved by phosphatidylinositol (PI)-specific phospholipase C (PI-PLC), whereas that of PARP cannot, due to the presence of a fatty acid esterified to the inositol. In the bloodstream form trypanosome, a number of GPIs which are structurally related to the VSG GPI anchor have been identified. In addition, several structurally homologous GPIs have been described, both in vivo and in vitro, that contain acyl-inositol. In vivo the procyclic stage trypanosome synthesizes a GPI that is structurally homologous to the PARP GPI anchor, i.e. contains acylinositol. No PI-PLC-sensitive GPIs have been detected in the procyclic form. Using a membrane preparation from procyclic trypanosomes which is capable of synthesizing GPI lipids upon the addition of nucleotide sugars we find that intermediate glycolipids are predominantly of the acylinositol type, and the mature ethanolamine-phosphate-containing precursors are exclusively acylated. We suggest that the differences between the bloodstream and procyclic form GPI biosynthetic intermediates can be accounted for by the developmental regulation of an inositol acylhydrolase, which is active only in the bloodstream form, and a glyceride fatty acid remodeling system, which is only partially functional in the procyclic form.			FIELD, MC (corresponding author), ROCKEFELLER UNIV, MOLEC PARASITOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Field, Mark/AAD-6455-2021; Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Menon, Anant Kumar/0000-0001-6924-2698; Field, Mark/0000-0002-4866-2885	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUN R, 1979, ACTA TROP, V36, P289; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGSTLER M, 1991, GLYCOCONJUGATE J, V8, P269; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1991, TRENDS GLYCOSCI GLYC, V3, P107; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SADEGHI H, 1988, P NATL ACAD SCI USA, V85, P5512, DOI 10.1073/pnas.85.15.5512; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; WALTER EI, 1990, J IMMUNOL, V144, P1030	30	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5324	5329						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371998				2022-12-27	WOS:A1992HH74700051
J	WU, CA; ZECHNER, EL; HUGHES, AJ; FRANDEN, MA; MCHENRY, CS; MARIANS, KJ				WU, CA; ZECHNER, EL; HUGHES, AJ; FRANDEN, MA; MCHENRY, CS; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .4. RECONSTITUTION OF AN ASYMMETRIC, DIMERIC DNA POLYMERASE-III HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION COMPLEX; GAMMA-SUBUNIT; GENE-PRODUCT; BETA-SUBUNIT; PROTEIN MACHINES; EPSILON-SUBUNIT; PRIMED TEMPLATE; SIZE CLASSES; IDENTIFICATION; PURIFICATION	Individually purified subunits have been used to reconstitute the action of the Escherichia coli DNA polymerase III holoenzyme (Pol III HE) at a replication fork formed in the presence of the primosome, the single-stranded DNA binding protein, and a tailed form II DNA template. Complete activity, indistinguishable from that of the intact DNA Pol III HE, could be reproduced with a combination of the DNA polymerase III core (Pol III core), the gamma.delta-complex, and the beta-subunit. Experiments where the Pol III core in reaction mixtures containing active replication forks was diluted suggested that the lagging-strand Pol III core remained associated continuously with the replication fork through multiple cycles of Okazaki fragment synthesis. Since the lagging-strand Pol III core must dissociate from the 3' end of the completed Okazaki fragment, this suggests that its association with the fork is via protein-protein interactions, lending credence to the idea that it forms a dimeric complex with the leading-strand Pol III core. An asymmetry in the action of the subunits was revealed under conditions (high ionic strength) that were presumably destabilizing to the integrity of the replication fork. Under these conditions, tau acted to stimulate DNA synthesis only when the primase was present (i.e. when lagging-strand DNA synthesis was ongoing). This stimulation was reflected by an inhibition of the formation of small Okazaki fragments, suggesting that, within the context of the model developed to account for the temporal order of steps during a cycle of Okazaki fragment synthesis, the presence of tau-accelerated the transit of the lagging-strand Pol III core from the 3' end of the completed Okazaki fragment to the 3' end of the new primer.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WU, CA (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Zechner, Ellen L./0000-0003-2035-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HENSON JM, 1979, GENETICS, V92, P1041; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KOADIRA M, 1983, MOL GEN GENET, V192, P80; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; MAKI H, 1985, J BIOL CHEM, V260, P2982; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MCHENRY CS, 1987, ICN UCLA S MOL CELLU, V47, P47; MCHENRY CS, 1989, ICN UCLA S MOL CELLU, V127, P115; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P1053, DOI 10.1073/pnas.73.4.1053; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZECKNER EL, 1909, J BIOL CHEM, V267, P4054	49	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4064	4073						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1346785				2022-12-27	WOS:A1992HE60700076
J	HSIEH, JT; ZHAU, HE; WANG, XH; LIEW, CC; CHUNG, LWK				HSIEH, JT; ZHAU, HE; WANG, XH; LIEW, CC; CHUNG, LWK			REGULATION OF BASAL AND LUMINAL CELL-SPECIFIC CYTOKERATIN EXPRESSION IN RAT ACCESSORY SEX-ORGANS - EVIDENCE FOR A NEW CLASS OF ANDROGEN-REPRESSED GENES AND INSIGHT INTO THEIR PAIRWISE CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; EPIDERMAL GROWTH-FACTOR; VENTRAL PROSTATE; MESSENGER-RNA; TERMINAL DIFFERENTIATION; KERATIN EXPRESSION; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS; FACTOR-BETA; C-MYC	Co-expression of cytokeratin (CK) pairs has been found to be associated with specific epithelial cell types whose expressions are developmentally regulated. In the prostate, CK 8 and 18 have been identified as luminal cell-specific markers, and CK 5 and 15 have been identified as basal cell-specific markers. In this study, we report the cloning and sequencing of a full-length CK 8 cDNA (1.9 kilobases) from a rat ventral prostate (VP) cDNA library. Although the open reading frame shares 90% homology with mouse CK 8 sequences, nucleotide comparison revealed that rat CK 8 cDNA comprises a species-specific sequence on both 5' and 3' ends. The steady-state levels of CK 8 mRNA were elevated in VP, seminal vesicle (SV), and liver of a castrated rat but not in the other organs such as the coagulating gland, bladder, and thymus. Unlike the other androgen-repressed genes, elevated CK 8 mRNA levels persisted even after the glandular involution was completed, indicating that CK 8 is a new class of androgen-repressed gene. The regression of CK 8 expression may be androgen receptor-mediated, since androgen but not estrogen administration to castrated hosts repressed the CK 8 mRNA levels, and this effect can be antagonized by the simultaneous administration of an antiandrogen (4-hydroxyflutamide). Immunohistochemical staining of prostatic tissues reveals that the CK 8 filamentous structure is shifted reversibly from a uniform distribution to a predominantly basal surface upon androgen deprivation. We noted that the steady-state levels of CK 8 protein remain rather constant throughout the various hormonal treatment, and the steady-state levels of CK 8 mRNA and the rate of CK 8 protein synthesis are consistently elevated. These results suggest that the turnover rate of CK 8 protein may be elevated in the prostatic epithelium from the castrated host. Similarly, the steady-state levels of CK 15 and 18 mRNA in VP and SV are also repressed in an androgen-dependent manner. These data, taken together, indicate that pairwise control of luminal (and possibly basal) specific cytokeratin gene expression remains intact in both VP and SV tissues and that the levels of CK mRNAs expression are negatively regulated by androgen.	UNIV TORONTO,BENTING INST,DEPT CLIN BIOCHEM & MED,MOLEC CARDIOL LAB,TORONTO M5G 1L5,ONTARIO,CANADA	University of Toronto	HSIEH, JT (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA056307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038649] Funding Source: NIH RePORTER; NCI NIH HHS [CA56307] Funding Source: Medline; NIDDK NIH HHS [DK38649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTATTER T, 1985, J HISTOCHEM CYTOCHEM, V33, P415, DOI 10.1177/33.5.2580881; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHANG C, 1987, J BIOL CHEM, V262, P11901; CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719, DOI 10.1210/endo-125-5-2719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY DS, 1990, UROL CLIN N AM, V17, P461; COOPER D, 1985, LAB INVEST, V52, P243; DEKLERK DP, 1975, BENIGN PROSTATIC HYP, P43; FEITZ WFJ, 1986, J UROLOGY, V136, P922, DOI 10.1016/S0022-5347(17)45133-0; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; GLEAVE M, 1991, CANCER RES, V51, P3753; GUTHRIE PD, 1990, MOL ENDOCRINOL, V4, P1343, DOI 10.1210/mend-4-9-1343; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ISAACS JT, 1989, PROSTATE S, V2, P33; KATZ AE, 1989, CANCER RES, V49, P5889; KIM KH, 1987, J CELL BIOL, V105, P3039, DOI 10.1083/jcb.105.6.3039; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C., 1987, GENITAL SYSTEM, P239; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO, P312; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORITA T, 1988, GENE, V68, P109; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RAMAEKERS FCS, 1989, PROSTATE, V14, P323, DOI 10.1002/pros.2990140405; SALTZMAN AG, 1987, J BIOL CHEM, V262, P432; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMAT A, 1988, DIFFERENTIATION, V37, P40, DOI 10.1111/j.1432-0436.1988.tb00794.x; SHERWOOD ER, 1990, J UROLOGY, V143, P167, DOI 10.1016/S0022-5347(17)39903-2; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUGIMURA Y, 1986, BIOL REPROD, V34, P985, DOI 10.1095/biolreprod34.5.985; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104	47	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2303	2310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370816				2022-12-27	WOS:A1992HB53200031
J	MACNULTY, EE; MCCLUE, SJ; CARR, IC; JESS, T; WAKELAM, MJO; MILLIGAN, G				MACNULTY, EE; MCCLUE, SJ; CARR, IC; JESS, T; WAKELAM, MJO; MILLIGAN, G			ALPHA-2-C10 ADRENERGIC-RECEPTORS EXPRESSED IN RAT-1 FIBROBLASTS CAN REGULATE BOTH ADENYLYLCYCLASE AND PHOSPHOLIPASE-D-MEDIATED HYDROLYSIS OF PHOSPHATIDYLCHOLINE BY INTERACTING WITH PERTUSSIS TOXIN-SENSITIVE GUANINE NUCLEOTIDE-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 BU1 CELLS; K+-CHANNEL; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; KINASE-C; GENERATION; ACTIVATION; SUBTYPES; GI2; IDENTIFICATION	The alpha-2-C10 adrenergic receptor from human platelets was expressed permanently in Rat-1 fibroblasts. A series of clones that varied in expression of the receptor from 0 to 3.5 pmol/mg of membrane protein were isolated. We have demonstrated recently in cells of one of these clones (1C) that the alpha-2-C10 receptor interacts directly with two distinct pertussis toxin-sensitive G-proteins, G(i)2 and G(i)3 (Milligan, G., Carr, C., Gould, G. W., Mullaney, I., and Lavan, B. E. (1991) J. Biol. Chem. 266, 6447-6455). High affinity GTPase activity in membranes of cells from the various clones was stimulated by the addition of the alpha-2-adrenergic agonist UK14304, defining that the receptor coupled productively to the G-protein signaling system. Maximal stimulation of high affinity GTPase activity correlated with the levels of receptor expressed. Clones expressing the receptor also demonstrated agonist-mediated inhibition of adenylylcyclase. Furthermore, the alpha-2-C10 receptor in one clone (1C), but not other clones, promoted a marked stimulation in the generation of water-soluble products derived from phosphatidylcholine. The concentration of UK14304 required to produce half-maximal regulation of GTPase activity (20-30 nM), of forskolin-amplified adenylylcyclase activity (30-40 nM), and of choline generation (30-40 nM) were similar. Transphosphatidylation experiments with cells of clone 1C indicated that the receptor-mediated hydrolysis of phosphatidylcholine was via the action of a phospholipase D. All of these effects were attenuated by pretreatment of the cells with pertussis toxin. Dose-effect curves of pertussis toxin-treatment demonstrated similar effective concentrations of the toxin in causing endogenous ADP-ribosylation of both G(i)2 and G(i)3, inhibition of receptor-stimulated GTPase activity, and phospholipase D activity. Receptor activation of phospholipase D activity was not dependent upon prior phospholipase C-dependent activation of protein kinase C, as alpha-2-adrenergic stimulation of inositol phosphate production was negligible and the presence of the selective protein kinase C inhibitor RO-31-8220, at concentrations up to 10-mu-M, had no effect on UK14304-mediated production of phosphatidylbutanol. These results demonstrate that expression of the alpha-2-C10 receptor in a heterologous system can result in receptor regulation of signaling elements that appear not to be primary targets for the receptor in vivo. Such results are important in respect to recent observations that transfection of a single defined receptor into separate cell lines can lead to the regulation of distinct effector systems (Vallar, L., Muca, C., Magni, M., Albert, P., Bunzow, J., Meldolesi, J. and Civelli, O. (1990) J. Biol. Chem. 265, 10320-10326). Here, we demonstrate that differences in the signaling pathways activated by a defined receptor can be recorded in individual clones and show for the first time a direct alpha-2-adrenergic regulation of a phospholipase D activity.	UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PHARMACOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Wakelam, Michael/0000-0003-4059-9276	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CODINA J, 1988, J BIOL CHEM, V263, P6746; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LIMBIRD LE, 1988, ALPHA 2 ADRENERGIC R; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1989, CELL SIGNAL, V1, P411, DOI 10.1016/0898-6568(89)90027-2; MILLIGAN G, 1987, BIOCHEM J, V245, P501, DOI 10.1042/bj2450501; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MILLIGAN G, 1987, BIOCHIM BIOPHYS ACTA, V929, P197, DOI 10.1016/0167-4889(87)90176-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MILLIGAN G, 1989, PROG GROWTH FACTOR R, V1, P171; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; POUYSSEGUR J, 1990, G PROTEINS, P555; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; VALLAR L, 1990, J BIOL CHEM, V265, P10320; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	36	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2149	2156						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346392				2022-12-27	WOS:A1992HB53200009
J	DORFMAN, DM; WILSON, DB; BRUNS, GAP; ORKIN, SH				DORFMAN, DM; WILSON, DB; BRUNS, GAP; ORKIN, SH			HUMAN TRANSCRIPTION FACTOR GATA-2 - EVIDENCE FOR REGULATION OF PREPROENDOTHELIN-1 GENE-EXPRESSION IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ZINC FINGER; DNA-BINDING FACTOR; SEQUENCE; ACTIVATION; PROTEINS; LOCALIZATION; COMPLEXES; NUMBER; COMMON; FAMILY	Previously, we showed that the promoter of the gene encoding preproendothelin-1 (PPET-1) contains a GATA motif that is essential for activity and interacts with a nuclear factor similar in size and binding specificity to the erythroid transcription factor GATA-1. To identify this endothelial GATA-binding protein, a human endothelial cell cDNA library was screened with oligonucleotide probes for a portion of the zinc finger domain of GATA-1. A 2.6-kilobase cDNA encoding a 470 amino acid protein was obtained. Sequence analysis revealed a predicted protein which is the human counterpart of a related chicken protein, designated GATA-2. Human GATA-2 is expressed by a variety of cells, including erythroid, HeLa, and endothelial cells. A complex of a GATA-containing probe and recombinant GATA-2 expressed in COS cells comigrates with that present in gel shift experiments with nuclear extract derived from endothelial cells. In addition, expressed human GATA-2 protein transactivates reporter gene constructs containing either minimal GATA promoter elements or the native PPET-1 promoter in a cotransfection assay. Retinoic acid treatment of endothelial cells results in down-regulation of GATA-2 expression as well as down-regulation of PPET-1 gene expression. Human homologs of other known GATA-binding transcription factors are either absent from endothelial cells (in the case of GATA-1) or made in small quantities and not significantly affected by retinoic acid in these cells (in the case of GATA-3), making it unlikely that they regulate the PPET-1 gene. We propose that GATA-2 is the GATA-binding protein required for PPET-1 gene expression in endothelial cells.	HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	DORFMAN, DM (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115, USA.		Wilson, David/K-7433-2014	Wilson, David/0000-0002-1826-7745	NHLBI NIH HHS [5P32HL07574] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FIBACH E, 1982, LEUKEMIA RES, V6, P781, DOI 10.1016/0145-2126(82)90060-1; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TSAI S, 1989, NATURE, V339, P448; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILSON DB, 1990, MOL CELL BIOL, V10, P9854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	36	280	283	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1279	1285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370462				2022-12-27	WOS:A1992GY96000093
J	VIITANEN, PV; LORIMER, GH; SEETHARAM, R; GUPTA, RS; OPPENHEIM, J; THOMAS, JO; COWAN, NJ				VIITANEN, PV; LORIMER, GH; SEETHARAM, R; GUPTA, RS; OPPENHEIM, J; THOMAS, JO; COWAN, NJ			MAMMALIAN MITOCHONDRIAL CHAPERONIN-60 FUNCTIONS AS A SINGLE TOROIDAL RING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MAJOR ANTIGEN; PROTEIN; GROES; PURIFICATION; BACTERIAL; SEQUENCE; PLANT	Chaperonins are thought to participate in the process of protein folding in bacteria and in eukaryotic mitochondria and chloroplasts. While some chaperonins are relatively well characterized, the structures of the mammalian chaperonins are unknown. We have expressed a mammalian mitochondrial chaperonin 60 in Escherichia coli and purified the recombinant protein to homogeneity. Structural and biochemical analyses of this protein establish a single toroidal structure of seven subunits, in contrast to the homologous bacterial, fungal, and plant chaperonin 60s, which have double toroidal structures comprising two layers of seven identical subunits each. The recombinant mammalian chaperonin 60, together with the mammalian chaperonin 10 (but not with bacterial chaperonin 10), facilitates the formation of catalytically active ribulose-bisphosphate carboxylase from an unfolded state in the presence of K+ and MgATP. Analysis of the partial reactions involved in this in vitro reconstitution reveals that the single toroid of chaperonin 60 can form stable complexes with both unfolded or partially folded [S-35]ribulose-bisphosphate carboxylase and mitochondrial (but not bacterial) chaperonin 10 in the presence of MgATP. We conclude that the minimal functional unit of chaperonin 60 is a single heptameric toroid.	DUPONT CO,DEPT CENT RES & DEV,EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,BIOTECHNOL RES,WILMINGTON,DE 19880; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	DuPont; DuPont; McMaster University; New York University; New York University				Oppenheim, Joel/0000-0002-6920-5624				BAIRD PN, 1988, NUCLEIC ACIDS RES, V16, P9047, DOI 10.1093/nar/16.18.9047; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Ellis R J, 1990, Semin Cell Biol, V1, P1; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUTCHISON EG, 1989, EMBO J, V8, P1484; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, IN PRESS BIOCHEMISTR; VIITANEN PV, 1991, IN PRESS PROTEIN SCI; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990	35	182	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					695	698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1346131				2022-12-27	WOS:A1992GY96000005
J	BAXTER, RC; BAYNE, ML; CASCIERI, MA				BAXTER, RC; BAYNE, ML; CASCIERI, MA			STRUCTURAL DETERMINANTS FOR BINARY AND TERNARY COMPLEX-FORMATION BETWEEN INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND IGF BINDING PROTEIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; REDUCED AFFINITY; RECEPTOR-BINDING; FACTOR (IGF)-I; HUMAN-PLASMA; SUBUNIT; PURIFICATION; MUTANTS; ANALOGS	Structural analogs of recombinant human insulin-like growth factor-I (IGF-I), with alterations to each of the B, C, A, and D domains, have been tested for their ability to form binary complexes with IGF-binding protein-3 (IGFBP-3) and ternary complexes with IGFBP-3 and the acid-labile subunit (alpha-subunit). Two functionally distinct regions of IGF-I have been identified. The first, involving residues 3 and 4 and the alpha-helix between residues 8 and 18 of the B-domain, as well as residues 49-51 in the A-domain, appears important for IGFBP-3 binding, such that substitution of these residues results in decreased binary complex available for alpha-subunit binding. The second region, distal to the IGFBP-3-binding epitope and primarily involving the D-domain and B-domain near residue 24, with some involvement of the C-domain, appears slightly inhibitory to binary complex formation, such that analogs with a truncated D-domain or with a Gly4 bridge substituted for the C-domain show enhanced binding to IGFBP-3. However, binary complexes formed from these analogs bind the alpha-subunit with reduced affinity, the effect being most marked when substitution of the C-domain, or replacement of Tyr24, is superimposed on D-domain truncation. It is concluded that although the alpha-subunit does not itself bind IGF-I, its interaction with IGFBP-3 in the ternary complex is dependent on structural determinants on IGF-I distal to the IGFBP-3 binding domain.	MERCK SHARP & DOHME LTD,DEPT GROWTH BIOCHEM,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOCHEM ENDOCRINOL,RAHWAY,NJ 07065	Merck & Company; Merck & Company	BAXTER, RC (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT ENDOCRINOL,CAMPERDOWN,NSW 2050,AUSTRALIA.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				BALLARD J, 1989, ACTA ENDOCRINOL-COP, V121, P751, DOI 10.1530/acta.0.1210751; BAR RS, 1990, ENDOCRINOLOGY, V127, P3243, DOI 10.1210/endo-127-6-3243; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BAXTER RC, 1986, CLIN ENDOCRINOL, V24, P267, DOI 10.1111/j.1365-2265.1986.tb03267.x; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BLUNDELL TL, 1983, FED PROC, V42, P2592; CASCIERI MA, 1988, ENDOCRINOLOGY, V123, P373, DOI 10.1210/endo-123-1-373; CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3229, DOI 10.1021/bi00409a016; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CLEMMONS DR, 1990, J BIOL CHEM, V265, P12210; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HINTZ RL, 1981, J CLIN ENDOCR METAB, V53, P100, DOI 10.1210/jcem-53-1-100; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KAUFMANN U, 1977, J CLIN ENDOCR METAB, V44, P160, DOI 10.1210/jcem-44-1-160; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; Shimasaki S, 1991, MODERN CONCEPTS INSU, P343; WHITE RM, 1981, J CLIN ENDOCR METAB, V53, P49, DOI 10.1210/jcem-53-1-49	27	55	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					60	65						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370451				2022-12-27	WOS:A1992GY43900015
J	THOENES, G; SOUDAIS, C; LEDEIST, F; GRISCELLI, C; FISCHER, A; LISOWSKAGROSPIERRE, B				THOENES, G; SOUDAIS, C; LEDEIST, F; GRISCELLI, C; FISCHER, A; LISOWSKAGROSPIERRE, B			STRUCTURAL-ANALYSIS OF LOW TCR-CD3 COMPLEX EXPRESSION IN T-CELLS OF AN IMMUNODEFICIENT PATIENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CD3 COMPLEX; NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; CD3-ZETA CHAIN; SUBUNIT INTERACTIONS; EPSILON-CHAIN; LYMPHOCYTES-T; ALPHA-CHAINS; DELTA-CHAIN; BETA-CHAINS	Normal membrane expression of the T cell receptor (TCR) depends on the coordinated synthesis and assembly of all seven proteins composing the complex, i.e. the TCR-alpha and beta-chains, the CD3-gamma, delta, and epsilon-chains, and the zeta-zeta or zeta-eta-dimer. In an experimental TCR membrane-defective T cell variant (Sussman, J. L., Bonifacino, J. S., Lippincott-Schwartz, J., Weissman, A. M., Saito, T., Klausner, R. D., and Ashwell, J. D. (1988) Cell 52, 85-95) and in two siblings whose lymphocytes express only a low level of the TCR/CD3 complex (Alarcon, B., Berkhout, B., Breitmeyer, J., and Terhorst, C. (1988) N. Engl. J. Med. 319, 1203-1208), a defect in zeta-chain synthesis and/or assembly was thought to account for the defective membrane synthesis of the whole complex. We report on another immunodeficient patient whose T lymphocytes express the T cell receptor at one-tenth of normal fluorescence intensity and are not triggered to proliferate in vitro by anti-CD3 or anti-CD2 antibodies. Biochemical analysis of the patient's surface-iodinated peripheral blood lymphocytes failed to detect TCR-alpha and beta, or CD3-gamma, delta, and epsilon-proteins but revealed the presence of the zeta-homodimer (probably as a result of the high proportion of natural killer cells). In the cytoplasm, TCR-alpha and beta-proteins and the zeta-chain were detected, but, using monoclonal anti-CD3 antibodies, the CD3-gamma, delta, and epsilon-chains were not. In addition, the CD3-epsilon-chain was not detected with polyclonal antiserum in a verv sensitive Western blotting detection system. The zeta-chain was shown to be synthesized by the patient's T and natural killer cells. Northern blot analysis revealed normal levels of normal-size TCR-beta and CD3-gamma, delta-gene-specific mRNAs and decreased levels of TCR-alpha mARN; CD3-epsilon-gene transcripts were of abnormal size and present in lower than normal amounts. These findings suggest that this defect in T cell receptor-CD3 expression involves a mutation in the CD3-epsilon-gene leading to the synthesis of an abnormal and unstable CD3-epsilon-subunit.	HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE DE SEVRES,F-75743 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			soudais, claire/F-9756-2016	soudais, claire/0000-0002-4387-6649				ALARCON B, 1990, Immunodeficiency Reviews, V2, P1; ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BORST J, 1984, NATURE, V312, P455, DOI 10.1038/312455a0; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVERS HC, 1990, ANNU REV IMMUNOL, V6, P629; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEISLER C, 1989, SCAND J IMMUNOL, V30, P191, DOI 10.1111/j.1365-3083.1989.tb01201.x; GEISLER C, 1989, J IMMUNOL, V143, P4069; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KONING F, 1988, J IMMUNOL, V140, P3126; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEDEIST F, 1991, EUR J IMMUNOL, V21, P1641, DOI 10.1002/eji.1830210709; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; OETTGEN HC, 1984, J BIOL CHEM, V259, P2039; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; REGUEIRO JR, 1991, PROGR IMMUNE DEFICIE, V3, P311; SAITO T, 1987, J IMMUNOL, V139, P625; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; THOENES G, 1990, NEW ENGL J MED, V322, P1399; UPPENKAMP M, 1988, J IMMUNOL, V140, P2802; VANDEGRIEND RJ, 1984, J IMMUNOL METHODS, V66, P285, DOI 10.1016/0022-1759(84)90340-5; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	45	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					487	493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370449				2022-12-27	WOS:A1992GY43900078
J	IMAMURA, M; MASAKI, T				IMAMURA, M; MASAKI, T			A NOVEL NONMUSCLE ALPHA-ACTININ - PURIFICATION AND CHARACTERIZATION OF CHICKEN LUNG ALPHA-ACTININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; SMOOTH-MUSCLE; PROTEIN; FILAMENTS; GELATION; CELLS; ACANTHAMOEBA; ACTINOGELIN; CLEAVAGE	Two distinct alpha-actinin-like proteins were detected in chicken lung extract by immunoblot analysis with monoclonal antibodies against alpha-actinin. The mobilities of these proteins on SDS-polyacrylamide gel electrophoresis are very close (almost-equal-to 100 kDa). On SDS-polyacrylamide gel electrophoresis in the presence of 6 M urea, however, one of the proteins migrates at 115 kDa and is clearly separated from the other protein (105 kDa). The 115-kDa protein was purified and shown to have at least three unique amino acid sequences which were not detected in other kinds of alpha-actinins: one locates at the extreme NH2-terminal region, and the others locate at the COOH-terminal half region. Immunoblot and proteolytic cleavage analyses revealed that the 115-kDa protein has structural divergence at the COOH-terminal region that includes Ca2+-binding EF-hand motifs. Falling-ball viscometric studies showed that although the 115-kDa protein-induced gelation of F-actin is sensitive to Ca2+, the gelation activity of the 115-kDa protein is much higher than that of Ca2+-insensitive gizzard alpha-actinin regardless of Ca2+. This indicates that the 115-kDa protein is distinct from other nonmuscle alpha-actinins by its Ca2+ sensitivity.	UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba	IMAMURA, M (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN.							ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; BARON MD, 1987, J BIOL CHEM, V262, P2558; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BRETSCHER A, 1979, EUR J BIOCHEM, V100, P237, DOI 10.1111/j.1432-1033.1979.tb02054.x; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; BURRIDGE K, 1982, COLD SPRING HARB SYM, V46, P487; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; DUHAIMAN AS, 1984, BIOCHEMISTRY-US, V23, P1600, DOI 10.1021/bi00303a003; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FAY FS, 1983, J CELL BIOL, V96, P783, DOI 10.1083/jcb.96.3.783; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; KOBAYASHI R, 1983, BIOCHIM BIOPHYS ACTA, V745, P209, DOI 10.1016/0167-4838(83)90051-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LAZARIDES E, 1976, J CELL BIOL, V68, P202, DOI 10.1083/jcb.68.2.202; MABUCHI I, 1985, J CELL BIOL, V100, P375, DOI 10.1083/jcb.100.2.375; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MASAKI T, 1969, J BIOCHEM-TOKYO, V66, P637; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; MIMURA N, 1986, J BIOL CHEM, V261, P680; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; OHTAKI T, 1985, EUR J BIOCHEM, V153, P609, DOI 10.1111/j.1432-1033.1985.tb09344.x; PODLUBNAYA ZA, 1975, J MOL BIOL, V92, P357, DOI 10.1016/0022-2836(75)90234-X; POLLARD TD, 1981, J BIOL CHEM, V256, P7666; PUSZKIN S, 1977, J BIOL CHEM, V252, P5529; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; ROSENBERG S, 1981, J BIOL CHEM, V256, P2986; SCHOOK W, 1978, BIOCHEM J, V176, P63; SINGH I, 1977, BIOCHIM BIOPHYS ACTA, V491, P29, DOI 10.1016/0005-2795(77)90038-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STORTI RV, 1976, CELL, V8, P521, DOI 10.1016/0092-8674(76)90220-8; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25927	25933						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334489				2022-12-27	WOS:A1992KD07300052
J	MARK, MR; LOKKER, NA; ZIONCHECK, TF; LUIS, EA; GODOWSKI, PJ				MARK, MR; LOKKER, NA; ZIONCHECK, TF; LUIS, EA; GODOWSKI, PJ			EXPRESSION AND CHARACTERIZATION OF HEPATOCYTE GROWTH-FACTOR RECEPTOR-IGG FUSION PROTEINS - EFFECTS OF MUTATIONS IN THE POTENTIAL PROTEOLYTIC CLEAVAGE SITE ON PROCESSING AND LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MET PROTO-ONCOGENE; TYROSINE KINASE; SCATTER FACTOR; C-MET; EPITHELIAL-CELLS; MUTAGENESIS; MIGRATION; PRECURSOR; LINES	The receptor for hepatocyte growth factor (HGF) is the product of the c-met proto-oncogene, a membrane-spanning tyrosine kinase receptor. To facilitate analysis of HGF and its receptor (HGFr), we expressed and purified a chimeric protein containing the extracellular domain (ECD) of the HGFr fused to the constant region of IgG heavy chain. This soluble form of the HGFr (sHGFr) bound HGF with an affinity similar to that of the authentic, membrane-associated receptor. The sHGFr also neutralized the binding of HGF to the HGFr expressed on A549 cells. Like the mature form of the HGFr, sHGFr is a heterodimer which arises by proteolytic processing within the ECD. In order to characterize the requirements for proteolytic processing of the ECD and the effects of cleavage on ligand binding, we expressed sHGFr variants containing amino acid substitutions in the putative processing site. Replacement of the P1 or P4 arginine, but not the P3 lysine, with alanine inhibited conversion to the alpha/beta heterodimer. This suggests that maturation is mediated by furin or a furin-like protease. Finally, we showed that processing of the sHGFr into the alpha/beta form is not required for high affinity binding to either pro- or mature HGF.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT METAB,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	GODOWSKI, PJ (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CACHIANES G, 1992, IN PRESS TECHNIQUE; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAMOW SM, 1990, BIOCHEMISTRY-US, V29, P9885, DOI 10.1021/bi00494a019; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CWIKEL BJ, 1987, J BIOL CHEM, V262, P14235; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GIORDANO S, 1989, ONCOGENE, V4, P1383; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALLBOOK F, 1988, MOL CELL BIOL, V8, P452, DOI 10.1128/MCB.8.1.452; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MCCUNE J, 1988, JCELL, V50, P55; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROSEN EM, 1990, EXP CELL RES, V186, P22, DOI 10.1016/0014-4827(90)90205-O; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; THORNE BA, 1989, J BIOL CHEM, V264, P3545; VERWEIJ CL, 1988, J BIOL CHEM, V263, P7921; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	41	70	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26166	26171						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334493				2022-12-27	WOS:A1992KD07300086
J	REZAIE, AR; ESMON, CT				REZAIE, AR; ESMON, CT			THE FUNCTION OF CALCIUM IN PROTEIN-C ACTIVATION BY THROMBIN AND THE THROMBIN-THROMBOMODULIN COMPLEX CAN BE DISTINGUISHED BY MUTATIONAL ANALYSIS OF PROTEIN-C DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-X; ANTICOAGULANT ACTIVITY; PROTEOLYTIC FORMATION; MONOCLONAL-ANTIBODY; STRUCTURAL-CHANGES; CA-2+ BINDING; DOMAIN; REGION; DNA	Protein C activation is catalyzed on endothelium by a complex between thrombin and thrombomodulin. Ca2+ stimulates protein C activation in the presence, and inhibits in the absence, of thrombomodulin. Protein C has Asp residues at the P3 and P3' positions relative to the scissile bond at Arg169-Leu. To determine the contribution of these residues to the Ca2+ effect on activation, we have expressed human 4-carboxyglutamic acid (Gla)-domainless protein C and 3 mutants with Asp --> Gly substitutions at P3, P3', and both positions. Ca2+ interaction with the protein C derivatives was monitored by changes in intrinsic fluorescence, and the Ca2+ dependence of activation by thrombin and a complex of thrombin-thrombomodulin with a soluble thrombomodulin derivative (the fourth through sixth epidermal growth factor domains). The affinity for Ca2+ of the mutants was reduced 3-6-fold, which was reflected by a comparable change in the Ca2+ concentration required for the half-maximal rate of activation by the thrombin-thrombomodulin complex. However, Ca2+ no longer effectively inhibited activation of the mutants by thrombin alone. We conclude that 1) the Asp residues play a specific role in the Ca2+-dependent inhibition of protein C activation by thrombin; 2) these mutations alter the affinity of Ca2+ for the high affinity binding site; and 3) the Asp residues in the P3 and P3' sites do not contribute in a positive fashion to rapid activation by the thrombin-thrombomodulin complex.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	ESMON, CT (corresponding author), OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-30340, R01 HL-29807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DITTMAN WA, 1990, BLOOD, V75, P329; DITTMAN WA, 1991, TRENDS CARDIOVAS MED, V1, P331, DOI 10.1016/1050-1738(91)90070-U; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINNELL BW, 1991, PROTEIN C RELATED AN, V11, P29; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOGG PJ, 1992, J BIOL CHEM, V267, P703; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBBONIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1991, BLOOD, V78, P1637; SUGO T, 1984, J BIOL CHEM, V259, P5705; WAKEFIELD TW, 1991, J VASC SURG, V14, P588; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	37	118	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26104	26109						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334492				2022-12-27	WOS:A1992KD07300078
J	SHIMOI, H; IIMURA, Y; OBATA, T; TADENUMA, M				SHIMOI, H; IIMURA, Y; OBATA, T; TADENUMA, M			MOLECULAR-STRUCTURE OF RAROBACTER-FAECITABIDUS PROTEASE-I - A YEAST-LYTIC SERINE PROTEASE HAVING MANNOSE-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORMITATOR VAR GLUCANOLYTICAE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CELL-WALLS; PURIFICATION; LYSIS; DNA; EXPRESSION; BACTERIAL; CLEAVAGE	Rarobacter faecitabidus protease I (RPI) is a serine protease exhibiting lytic activity toward living yeast cells. RPI is similar to elastase in its substrate specificity and has a lectin-like affinity for mannose. The gene encoding RPI was cloned to elucidate its structure and function. And its nucleotide sequence revealed that it contains an open reading frame encoding a 525-amino acid protein. Homology comparison indicated that prepro-RPI consists of three domains: (1) an NH2-terminal prepro domain not found in the mature form of RPI, (2) a protease domain homologous to the trypsin family of serine proteases, and (3) a COOH-terminal domain homologous to the COOH-terminal part of Oerskovia xanthineolytica beta-1,3-glucanase and the NH2-terminal part of the ricin B chain, a lectin isolated from the castor bean. The RPI gene and its mutant were subsequently expressed in Esherichia coli under its beta-galactosidase promoter to investigate the function of the COOH-terminal domain. The mutant RPI, whose COOH-terminal domain was truncated by site-directed mutagenesis, lost both its mannose-binding and yeast-lytic activity, although the protease activity was not affected. These findings suggest that the COOH-terminal domain actually participates in the mannose-binding activity and is required for yeast-lytic activity.			SHIMOI, H (corresponding author), NATL RES INST BREWING,2-6-30 TAKINOGAWA,KITA KU,TOKYO 114,JAPAN.							[Anonymous], 1982, METABOLISM GENE EXPR; BERGER S, 1987, METHODS ENZYMOLOGY G, V152; DENOBEL JG, 1990, YEAST, V6, P491, DOI 10.1002/yea.320060606; FARKAS V, 1990, ACTA BIOTECHNOL, V10, P225, DOI 10.1002/abio.370100303; FUNATSU M, 1978, AGR BIOL CHEM TOKYO, V42, P1975, DOI 10.1080/00021369.1978.10863294; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; HENDERSON G, 1987, J BACTERIOL, V169, P3778, DOI 10.1128/jb.169.8.3778-3784.1987; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOLMES WM, 1983, CELL, V32, P1029; HUNTER JB, 1988, BIOTECHNOL BIOENG, V31, P929, DOI 10.1002/bit.260310906; JAMES MNG, 1978, CAN J BIOCHEM CELL B, V56, P396, DOI 10.1139/o78-062; KITAMURA K, 1982, AGR BIOL CHEM TOKYO, V46, P963, DOI 10.1080/00021369.1982.10865178; KITAMURA K, 1982, AGR BIOL CHEM TOKYO, V46, P2093, DOI 10.1080/00021369.1982.10865384; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTO A, 1987, P NATL ACAD SCI USA, V84, P166, DOI 10.1073/pnas.84.1.166; NAGASAKI S, 1981, AGR BIOL CHEM TOKYO, V45, P2689, DOI 10.1080/00021369.1981.10864973; NAGASAKI S, 1976, AGR BIOL CHEM TOKYO, V40, P1059, DOI 10.1080/00021369.1976.10862176; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OBATA T, 1977, AGR BIOL CHEM TOKYO, V41, P2387, DOI 10.1080/00021369.1977.10862869; OBATA T, 1977, AGR BIOL CHEM TOKYO, V41, P671, DOI 10.1080/00021369.1977.10862560; OHARA T, 1989, J BIOL CHEM, V264, P20625; Peberdy J., 1990, BIOCH CELL WALLS MEM, P5, DOI [10.1007/978-3-642-74215-6_2, DOI 10.1007/978-3-642-74215-6_2]; Phaff H. J., 1977, Advances in Chemistry Series, V160, P244; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHIMOI H, 1991, AGR BIOL CHEM TOKYO, V55, P371, DOI 10.1080/00021369.1991.10870610; SHIMOI H, 1991, J BIOCHEM-TOKYO, V110, P608, DOI 10.1093/oxfordjournals.jbchem.a123628; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; TERADA I, 1990, J BIOL CHEM, V265, P6576; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUI T, 1986, AGR BIOL CHEM TOKYO, V50, P535, DOI 10.1080/00021369.1986.10867422; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x; YAMAMOTO N, 1988, INT J SYST BACTERIOL, V38, P7, DOI 10.1099/00207713-38-1-7; YAMAMOTO N, 1987, AGR BIOL CHEM TOKYO, V51, P1541, DOI 10.1080/00021369.1987.10868268	46	32	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25189	25195						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1339445				2022-12-27	WOS:A1992KB60300043
J	CAO, J; HOSLER, J; SHAPLEIGH, J; REVZIN, A; FERGUSONMILLER, S				CAO, J; HOSLER, J; SHAPLEIGH, J; REVZIN, A; FERGUSONMILLER, S			CYTOCHROME AA3 OF RHODOBACTER-SPHAEROIDES AS A MODEL FOR MITOCHONDRIAL CYTOCHROME-C-OXIDASE - THE COXII/COXIII OPERON CODES FOR STRUCTURAL AND ASSEMBLY PROTEINS HOMOLOGOUS TO THOSE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS W23; PARACOCCUS-DENITRIFICANS; SUBUNIT-III; FUNCTIONAL-PROPERTIES; PROTON TRANSLOCATION; ESCHERICHIA-COLI; PUF MUTANT; DNA; SEQUENCE; GENE	The coxII/coxIII operon of Rhodobacter sphaeroides cytochrome c oxidase has been sequenced and characterized by insertional inactivation/complementation analysis. The organization of the genes in this locus (coxII.orf1.orf3.coxIII) is the same as that of the equivalent operon of Paracoccus denitrificans (ctaC.ctaB.ctaG.ctaE), but unlike that of other bacteria whose cytochrome oxidase genes have been characterized so far. The predicted amino acid sequence homology with eukaryotic oxidases is also higher for Rb. sphaeroides (and P. denitrificans) than for other bacterial versions of the enzyme. The inactivation of coxII results in loss of the characteristic cytochrome oxidase spectrum from membranes of the mutant strain. Full recovery requires introduction into the bacterium of the complete operon containing coxII.orf1.orf3.coxIII; partial complementation yielding a spectrally altered enzyme is achieved with a plasmid containing coxII or coxII.orf1.orf3. These results indicate that the peptides ORF1, ORF3, and COXIII are all required for assembly of native cytochrome c oxidase, suggesting an oxidase-specific assembly or chaperonin function for the ORFs in Rb. sphaeroides similar to that observed for the homologous gene products in yeast, COX10 and COX11.	UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	CAO, J (corresponding author), MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824, USA.				NHLBI NIH HHS [HL07404, HL16101] Funding Source: Medline; NIGMS NIH HHS [GM 26916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016101, T32HL007404, R01HL016101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026916, R37GM026916] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CAO JL, 1991, GENE, V101, P133, DOI 10.1016/0378-1119(91)90235-4; CASEY RP, 1980, J BIOL CHEM, V255, P3994; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; Davis R., 1980, ADV BACTERIAL GENETI; DEVRIJ W, 1983, EUR J BIOCHEM, V131, P97; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FINEL M, 1986, BIOCHIM BIOPHYS ACTA, V851, P99, DOI 10.1016/0005-2728(86)90253-7; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GREGOY L, 1988, ADV MEMBRANE BIOCH B, P301; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HALTIA T, 1988, EUR J BIOCHEM, V172, P543, DOI 10.1111/j.1432-1033.1988.tb13923.x; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; HOSLER JP, 1989, J CELL BIOL, V107, pA618; KUHNNENTWIG L, 1985, EUR J BIOCHEM, V149, P147, DOI 10.1111/j.1432-1033.1985.tb08905.x; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LUDWIG B, 1987, FEMS MICROBIOL REV, V46, P431; Maniatis T., 1982, MOL CLONING; MATHER MW, 1990, 41ST P MOSB C, P94; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; POWER SD, 1984, J BIOL CHEM, V259, P6564; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PROCHASKA LJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P360, DOI 10.1016/0005-2728(81)90175-4; PUETTNER I, 1985, J BIOL CHEM, V260, P3719; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; Simon R., 1983, BIOTECHNOLOGY, V1, P37; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; THALENFELD BE, 1980, J BIOL CHEM, V255, P6173; THOMPSON DA, 1985, J INORG BIOCHEM, V23, P357, DOI 10.1016/0162-0134(85)85046-7; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; VANDEROOST J, 1991, J BIOENERG BIOMEMBR, V23, P257, DOI 10.1007/BF00762221; WHATLEY FR, 1981, ANN NY ACAD SCI, V361, P330, DOI 10.1111/j.1749-6632.1981.tb46529.x; Wikstrom M, 1985, ENZYMES BIOL MEMBR, V4, P111; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; ZIAI MR, 1988, ANAL BIOCHEM, V171, P192, DOI 10.1016/0003-2697(88)90141-8	49	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24273	24278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332950				2022-12-27	WOS:A1992KA26300023
J	KNAUS, UG; HEYWORTH, PG; KINSELLA, BT; CURNUTTE, JT; BOKOCH, GM				KNAUS, UG; HEYWORTH, PG; KINSELLA, BT; CURNUTTE, JT; BOKOCH, GM			PURIFICATION AND CHARACTERIZATION OF RAC-2 - A CYTOSOLIC GTP-BINDING PROTEIN THAT REGULATES HUMAN NEUTROPHIL NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; GUANINE-NUCLEOTIDES; ACTIVATING PROTEIN; PLASMA-MEMBRANE; IDENTIFICATION; CLONING; EXPRESSION; COMPONENTS	Human neutrophils and other phagocytes generate superoxide anion (O2-) as a means of destroying ingested microorganisms. O2- is produced by an NADPH-consuming oxidase composed of membrane and cytosolic components. Activation of the NADPH oxidase is absolutely dependent upon GTP, indicating the requirement for a GTP-binding protein in this process. We have utilized a five-step chromatographic procedure to isolate a GTP-binding protein from human neutrophil cytosol which can stimulate NADPH oxidase activity in a cell-free assay. Oxidase enhancing activity was shown to coisolate with this GTP-binding component, which was purified to apparent homogeneity. The GTP-binding protein was identified as Rac 2 by immunological reactivity and amino acid sequencing. Thus, Rac 2 appears to be a third cytosolic component required for human neutrophil NADPH oxidase activation. Recombinant Rac 2 was shown to bind guanine nucleotides in a Mg2+-dependent fashion. GDP dissociation rates were determined and shown to be regulated by the free Mg2+ concentration. Rac 2 was found to possess the highest rate of intrinsic GTP hydrolysis of any of the characterized members of the Ras superfamily. The biochemical properties of Rac 2 indicate it is likely to be subject to regulatory cofactors in vivo.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, IMM-14, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; NATL UNIV IRELAND UNIV COLL DUBLIN, MATER HOSP, CTR CARDIOVASC RES DEPT MED & EXPTL THERAPEUT, DUBLIN 4, IRELAND	Scripps Research Institute; Scripps Research Institute; Mater Misericordiae University Hospital; University College Dublin				Kinsella, B. Therese/0000-0003-3072-941X	NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1992, CLIN RES ABSTR, V40, P351; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, J BIOL CHEM, V266, P20840; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MURAO S, 1989, J BIOL CHEM, V264, P8356; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUILLIAM LA, 1992, SIGNAL TRANSDUCTION, V3, P25; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	48	170	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23575	23582						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331090				2022-12-27	WOS:A1992JZ23900026
J	ZANUSSI, S; DOLIANA, R; SEGAT, D; BONALDO, P; COLOMBATTI, A				ZANUSSI, S; DOLIANA, R; SEGAT, D; BONALDO, P; COLOMBATTI, A			THE HUMAN TYPE-VI COLLAGEN GENE - MESSENGER-RNA AND PROTEIN VARIANTS OF THE ALPHA-3 CHAIN GENERATED BY ALTERNATIVE SPLICING OF AN ADDITIONAL 5-END EXON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; GLOBULAR DOMAINS; MOSAIC STRUCTURE; MULTIPLE FORMS; HUMAN-TISSUES; FIBRONECTIN; CELLS; DNA; FIBROBLASTS; EXPRESSION	The amino- and carboxyl-terminal globular domains of type VI collagen are composed of several homologous modules similar to the type A collagen-binding modules present in von Willebrand factor. The human alpha3(VI) chain that contributes most of the amino-terminal globule appears heterogeneous in size as a result of alternative splicing of two exons (Stokes D. G., Saitta, B., Timpl, R., and Chu, M.-L. (1991) J. Biol. Chem. 266, 8626-8633). In the present study, we report a further characterization of the 5'-end of the gene of the human alpha3(VI) chain and show that transcriptton initiates at multiple sites. Southern blotting and DNA sequencing indicate that there is an additional type A exon (A9/N10) at about 1.8 kilobase pairs downstream of the exon coding for the signal peptide. The open reading frame of this additional exon reveals 1 cysteine and three potential N-glycosylation sites. Polymerase chain reaction, Northern blotting, and RNase protection assays demonstrate that exon A9/N10 is subject to alternative splicing in normal and tumor cell lines and that this generates more protein variants of the alpha3(VI) chain than expected before. A comparison with the corresponding amino-terminal globule of the chicken alpha3(VI) chain shows the presence of 1 additional cysteine in this portion of the molecule and suggests that human type VI collagen has more possibilities for structural and functional variations compared to chicken type VI collagen.	CTR RIFERIMENTO ONCOL,DIV ONCOL SPERIMENTALE 2,VIA PEDEMONTANA OCCIDENTALE 12,I-33081 AVIANO,ITALY; UNIV PADUA,IST ISTOL,I-35100 PADUA,ITALY; UNIV UDINE,DIPARTIMENTO BIOTECNOL & SCI MED,I-33100 UDINE,ITALY	IRCCS Aviano (CRO); University of Padua; University of Udine			Zanussi, Stefania/I-2558-2018; Doliana, Roberto/AAA-1479-2019	Zanussi, Stefania/0000-0003-0608-9766; Doliana, Roberto/0000-0002-8324-7564; Bonaldo, Paolo/0000-0002-9571-8140; colombatti, alfonso/0000-0002-3676-2379				AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BARONE MV, 1989, EMBO J, V8, P1079, DOI 10.1002/j.1460-2075.1989.tb03476.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14461; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FLEISCHMAJER R, 1991, J HISTOCHEM CYTOCHEM, V39, P51, DOI 10.1177/39.1.1983873; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAYMAN AR, 1991, EUR J BIOCHEM, V197, P177, DOI 10.1111/j.1432-1033.1991.tb15896.x; HECKMANN M, 1989, EUR J BIOCHEM, V182, P719, DOI 10.1111/j.1432-1033.1989.tb14884.x; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JAKKOLA S, 1989, J CLIN INVEST, V84, P253; JANDER R, 1983, EUR J BIOCHEM, V133, P39, DOI 10.1111/j.1432-1033.1983.tb07427.x; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1991, J CELL SCI, V99, P797; KIELTY CM, 1990, BIOCHEM J, V272, P787, DOI 10.1042/bj2720787; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OYAMA F, 1990, CANCER RES, V50, P1075; PELTONEN J, 1990, LAB INVEST, V62, P487; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SAITTA B, 1992, J BIOL CHEM, V26, P6188; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; VARTIO T, 1987, J CELL SCI, V88, P419; VEDA Y, 1990, VIRCHOWS ARCH A, V417, P291; VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373	48	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24082	24089						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1339440				2022-12-27	WOS:A1992JZ23900098
J	BAVIK, CO; BUSCH, C; ERIKSSON, U				BAVIK, CO; BUSCH, C; ERIKSSON, U			CHARACTERIZATION OF A PLASMA RETINOL-BINDING PROTEIN MEMBRANE-RECEPTOR EXPRESSED IN THE RETINAL-PIGMENT EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; VITAMIN-A; CELLS; IDENTIFICATION; HOMOLOGY; SIMILARITY; TRANSPORT; MECHANISM; CLONING; FAMILY	A specific membrane receptor for plasma retinol-binding protein (RBP) is expressed in the retinal pigment epithelium (RPE). When chemically cross-linking RBP to RPE membranes, an 86-kDa RBP.RBP receptor complex is formed, and a 63-kDa protein was identified as the RBP-binding membrane protein (Bavik, C.-O., Eriksson, U., Allen, R., and Peterson, P. (1991) J. Biol. Chem. 266,14978-14985). To explore in more detail the characteristics of this membrane receptor, we have generated a monoclonal antibody, A52, to the 63-kDa protein (p63). A52 binds the 86-kDa RBP.RBP receptor complex and p63. Several lines of evidence suggest that p63 is not a regular integral membrane protein, and it occurs in different forms. One form is firmly attached to membranes, is part of a high molecular weight complex, and is able to bind RBP. The other form of p63 can be removed from membranes by treatment with an alkaline buffer and is unable to bind RBP. Both forms of p63 contain extensive hydrophobic domains and are found in the detergent phase upon extraction with Triton X-114. The expression of p63 is restricted to RPE, and immunohistochemical localization of tissue sections from bovine retina showed highest expression in the basolateral portion of RPE cells. Immunofluorescence localization, using isolated RPE cells, showed that p63 is exposed on the cell surface of newly isolated RPE cells.	UNIV HOSP UPPSALA,DEPT PATHOL,S-75122 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	BAVIK, CO (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,POB 60202,S-10401 STOCKHOLM,SWEDEN.							BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; ERIKSSON U, 1986, CANCER RES, V46, P717; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GODOVAC-ZIMMERMANN J, 1985, BIOL CHEM H-S, V366, P431, DOI 10.1515/bchm3.1985.366.1.431; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HELLER J, 1975, J BIOL CHEM, V250, P3613; HOLMDAHL R, 1985, J IMMUNOL METHODS, V83, P379, DOI 10.1016/0022-1759(85)90260-1; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KATOH M, 1982, ACTA HISTOCHEM CYTOC, V15, P68, DOI 10.1267/ahc.15.68; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCGUIRE B, 1981, ENDOCRINOLOGY, V108, P180; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1976, J BIOL CHEM, V251, P6360; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	39	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23035	23042						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331074				2022-12-27	WOS:A1992JY16300052
J	BURSTEIN, ES; BRONDYK, WH; MACARA, IG				BURSTEIN, ES; BRONDYK, WH; MACARA, IG			AMINO-ACID-RESIDUES IN THE RAS-LIKE GTPASE RAB3A THAT SPECIFY SENSITIVITY TO FACTORS THAT REGULATE THE GTP/GDP CYCLING OF RAB3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-TERMINAL REGION; EXCHANGE PROTEIN; MUTATIONAL ANALYSIS; BINDING PROTEIN; 3-DIMENSIONAL STRUCTURES; SMG P21; DOMAIN; GAP; GDP; MEMBRANES	Two cellular factors have been described, Rab3A-GAP (GTPase-activating protein) and Rab3A-GRF (guanine nucleotide releasing factor) which, respectively, accelerate the intrinsic GTPase activity of, or the rate of dissociation of GDP from, the Ras-related GTP-binding protein, p25 Rab3A. Mutational analysis of p25 Rab3A was undertaken to define amino acid residues important for interaction with these factors. Mutations in residues 51-59, which correspond to the effector domain of p21 Ras, completely abolished sensitivity of p25 Rab3A to Rab3A-GRF and decreased the affinity of p25 Rab3A for Rab3A-GRF. Surprisingly, only one mutant in this region was Rab3A-GAP-insensitive, while the others retained partial, complete, or significantly increased GAP responsiveness. Mutations in the first G-domain had only modest effects on intrinsic GTPase activity and little effect on either Rab3A-GRF or Rab3A-GAP interactions. Truncation of 34 residues from the carboxyl terminus had no effect Rab3A-GAP sensitivity but facilitated Rab3A-GRF stimulation. Mutation T36N, analogous to the dominant inhibitory mutation T17N in Ras, which has been hypothesized to sequester an upstream activator of Ras, conferred a 10-fold higher affinity upon p25 Rab3A for Rab3A-GRF.	UNIV VERMONT, COLL MED, DEPT PATHOL, MED ALUMNI BLDG, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, VERMONT COMPREHENS CANC CTR, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont					NCI NIH HHS [CA56300] Funding Source: Medline; NEI NIH HHS [F32EY06411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY006411] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MITSOU MY, 1992, EMBO J, V11, P2391; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLARD G, 1990, NATURE, V349, P79; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEI C, 1992, ONCOGENE, V7, P467; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	37	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22715	22718						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331063				2022-12-27	WOS:A1992JY16300006
J	FUKUNAGA, K; SODERLING, TR; MIYAMOTO, E				FUKUNAGA, K; SODERLING, TR; MIYAMOTO, E			ACTIVATION OF CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-II AND PROTEIN-KINASE-C BY GLUTAMATE IN CULTURED RAT HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MICROTUBULE-ASSOCIATED PROTEIN-2; POSTSYNAPTIC DENSITY PROTEIN; CEREBELLAR GRANULE CELLS; SYNAPSIN-I; IMMUNOCYTOCHEMICAL LOCALIZATION; CA-2+-INDEPENDENT ACTIVITY; NMDA RECEPTORS; CYCLIC-AMP; CALMODULIN	In cultured rat hippocampal neurons, glutamate elevated the Ca2+-independent activity of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) through autophosphorylation when the neurons were incubated in Mg2+-free buffer, and this response was blocked by specific antagonists of the N-methyl-D-aspartate (NMDA) receptor. In addition, glutamate stimulated the transient translocation of protein kinase C (PKC) from the cytosol to the membrane fraction. This effect was not blocked by NMDA receptor antagonists but was partially blocked by DL-2-amino-3-phosphonopropionate. Quisqualate or trans-1-amoinocyclo-pentane-trans1,3-dicarboxylate produced a similar effect on the translocation of PKC. In the experiments with P-32-labeled cells, the phosphorylation of microtuble-associated protein 2 and synapsin I, as well as autophosphorylation of CaM kinase II, were found to be stimulated by exposure to glutamate. These results suggest that glutamate can activate CaM kinase II through the ionotropic NMDA receptor, which in turn increases the phosphorylation of microtuble-associated protein 2 and synapsin I. PKC was activated through the metabotropic glutamate receptor in the hippocampal neurons.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University	FUKUNAGA, K (corresponding author), KUMAMOTO UNIV,DEPT PHARMACOL,KUMAMOTO 860,JAPAN.				NINDS NIH HHS [NS 27037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; COLLEY PA, 1989, BRAIN RES, V495, P205, DOI 10.1016/0006-8993(89)90214-X; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FINN RC, 1980, NEUROSCI LETT, V19, P103, DOI 10.1016/0304-3940(80)90264-5; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FUKNAGA K, 1990, MOL CELL NEUROSCI, V1, P133; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KITANO T, 1987, J NEUROSCI, V7, P1520; KLANN E, 1991, J BIOL CHEM, V266, P24253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTSON MP, 1989, BRAIN RES, V490, P110, DOI 10.1016/0006-8993(89)90436-8; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1988, J BIOL CHEM, V263, P11540; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; ORIOKA M, 1992, J NEUROCHEM, V58, P1798; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; REYMANN KG, 1988, BRAIN RES, V461, P388, DOI 10.1016/0006-8993(88)90274-0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHOEPP DD, 1989, J NEUROCHEM, V53, P1865, DOI 10.1111/j.1471-4159.1989.tb09254.x; SCHOLZ WK, 1991, J NEUROSCI, V11, P2422; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; THIBAULT O, 1989, BRAIN RES, V476, P170, DOI 10.1016/0006-8993(89)91553-9; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAUCHI T, 1988, BIOCHIM BIOPHYS ACTA, V968, P77, DOI 10.1016/0167-4889(88)90046-8; ZATZ M, 1986, BRAIN RES, V385, P174, DOI 10.1016/0006-8993(86)91562-3	54	180	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22527	22533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1358879				2022-12-27	WOS:A1992JW71900084
J	CHEN, LH; KENYON, GL; CURTIN, F; HARAYAMA, S; BEMBENEK, ME; HAJIPOUR, G; WHITMAN, CP				CHEN, LH; KENYON, GL; CURTIN, F; HARAYAMA, S; BEMBENEK, ME; HAJIPOUR, G; WHITMAN, CP			4-OXALOCROTONATE TAUTOMERASE, AN ENZYME COMPOSED OF 62 AMINO-ACID-RESIDUES PER MONOMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; DIENELACTONE HYDROLASE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; META-CLEAVAGE; TRIOSEPHOSPHATE ISOMERASE; PLASMID; PROTEIN; GENE	The xylH gene encoding 4-oxalocrotonate tautomerase (4-OT) has been located on a subclone of the Pseudomonasputida mt-2 TOL plasmid pWW0 and inserted into an Escherichia coli expression vector. Severalof the genes of the metafission pathway encoded by pWW0 have been cloned in E. coli, but the overexpression of their gene products has met with limited success. By utilizing the E. coli alkaline phosphatase promoter (phoA) coupled with the proper positioning of a ribosome-binding region, we are able to express functional 4-OT in yields of at least 10 mg of pure enzyme/liter of culture. 4-OT has been previously characterized and shown to be an extremely efficient catalyst (Whitman, C. P., Aird, B. A., Gillespie, W. R., and Stolowich, N. J. (1991) J. Am. Chem. Soc. 113,3154-3162). Kinetic and physical characterization of the E. coli-expressed protein show that it is identical with that of the 4-OT isolated from P. putida. The functional unit is apparently a pentamer of identical subunits, each consisting of only 62 amino acid residues. This is the smallest enzyme subunit reported to date. The amino acid sequence, determined in part from automated Edman degradation and also deduced from the primary sequence of xylH, did not show homology with any of the sequences in the current data bases nor with any of the sequences of enzymes that catalyze similar reactions. We propose that the active site of 4-OT may be established by an overlap of subunits and comprised of amino acid residues belonging to several, if not all, of the subunits.	UNIV TEXAS, COLL PHARM, DIV MED CHEM, AUSTIN, TX 78712 USA; UNIV GENEVA, DEPT MED BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND; UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of Texas System; University of Texas Austin; University of Geneva; University of California System; University of California San Francisco				Harayama, Shigeaki/0000-0003-2103-7796	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017323, R01AR017323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041239, R01GM040570, R01GM041239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 17323] Funding Source: Medline; NIGMS NIH HHS [GM 40570, GM 41239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; ANDREWS AT, 1986, ELECTROPHORESIS THEO, P134; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P7; FRANTZ B, 1987, J BACTERIOL, V169, P704, DOI 10.1128/jb.169.2.704-709.1987; FREIFELDER D, 1982, PHYSICAL BIOCH, P455; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; HARAYAMA S, 1989, J BACTERIOL, V171, P6251, DOI 10.1128/jb.171.11.6251-6258.1989; HARAYAMA S, 1990, MOL GEN GENET, V221, P113, DOI 10.1007/BF00280375; HARAYAMA S, 1984, J BACTERIOL, V160, P251, DOI 10.1128/JB.160.1.251-255.1984; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P6956, DOI 10.1021/bi00242a021; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8441, DOI 10.1021/bi00098a023; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapworth A, 1901, J CHEM SOC, V79, P1265, DOI 10.1039/ct9017901265; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENN FM, 1991, GENE, V104, P91, DOI 10.1016/0378-1119(91)90470-V; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; OLLIS DL, 1985, J BIOL CHEM, V260, P9818; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; ROPER DI, 1990, FEBS LETT, V266, P63, DOI 10.1016/0014-5793(90)81507-K; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; SCHWAB JM, 1990, CHEM REV, V90, P1203, DOI 10.1021/cr00105a007; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITH SL, 1979, J BIOL CHEM, V254, P6222; STONE D, 1979, J BIOL CHEM, V254, P857; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2014, DOI 10.1073/pnas.82.7.2014; WHITMAN CP, 1991, J AM CHEM SOC, V113, P3154, DOI 10.1021/ja00008a052; ZOLG JW, 1981, NUCLEIC ACIDS RES, V9, P697, DOI 10.1093/nar/9.3.697	35	84	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17716	17721						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1339435				2022-12-27	WOS:A1992JM22300038
J	ROBERTSON, DE; NOLL, D; ROBERTS, MF				ROBERTSON, DE; NOLL, D; ROBERTS, MF			FREE AMINO-ACID DYNAMICS IN MARINE METHANOGENS - BETA-AMINO ACIDS AS COMPATIBLE SOLUTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOSPIRILLUM-HUNGATEI; HALOPHILIC BACTERIA; AMINOGLUTARIC ACID; NMR-SPECTROSCOPY; WATER-STRESS; OSMOREGULATION; GLUTAMATE; OSMOLYTE	Methanogenic archaebacteria respond to osmotic stress by accumulating a series of organic molecules which function as compatible solutes. In two strains of marine methanogenic archaebacteria, Methanogenium cariaci and Methanococcus thermolithotrophicus, four key organic solutes are observed: L-alpha-glutamate, beta-glutamate, N(epsilon)-acetyl-beta-lysine, and betaine. The first three of these are synthesized de novo; betaine is transported into the Mg. cariaci cells from the medium. Mesophilic Mg. cariaci will preferentially transport betaine from the extracellular medium if it is present to counterbalance the external NaCl. In its absence it synthesizes N(epsilon)-acetyl-beta-lysine as the dominant osmolyte. This zwitterionic compound occurs at levels in Mg. cariaci which are considerably greater (based on mu-mol/mg of protein) than in Mc. thermolithotrophicus grown in media of the same ionic strength. Intracellular potassium ion concentrations, determined by K-39 NMR spectroscopy and atomic absorption, differ significantly in the two cells. In Mc. thermolithotrophicus, intracellular K+ is balanced by the total concentration of anionic amino acid species, glutamate, and beta-glutamate. Turnover of the organic solutes has been monitored using C-13-pulse/C-12-chase, and N-15-pulse/N-14-chase experiments. Both beta-amino acids exhibit slower turnover rates when compared to L-alpha-glutamate or aspartate, consistent with their roles as compatible solutes. Biosynthetic information for the beta-amino acids is also provided by C-13-labeling experiments. Beta-glutamate shows a lag in C-13 uptake from (CO2)-C-13, indicative of its biosynthesis from a precursor (probably a macromolecule) not in equilibrium with the soluble L-alpha-glutamate pool. Confirmation of a novel route for beta-glutamate synthesis and the production of the beta-lysine moiety from the diaminopimelate pathway is deduced from [C-13(2)]acetate labeling patterns.	BOSTON COLL,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College								BAKHIET N, 1984, CURR MICROBIOL, V10, P195, DOI 10.1007/BF01627254; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; BOROWITZKA LJ, 1980, SCIENCE, V210, P650, DOI 10.1126/science.210.4470.650; BOTSFORD JL, 1984, ARCH MICROBIOL, V137, P124, DOI 10.1007/BF00414452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY RC, 1968, J BIOL CHEM, V243, P381; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; CHOI BS, 1986, BIOCHEMISTRY-US, V25, P2243, DOI 10.1021/bi00356a059; DANIELS L, 1984, BIOCHIM BIOPHYS ACTA, V768, P113, DOI 10.1016/0304-4173(84)90002-8; DOYLE RJ, 1988, MICROBIOL REV, V52, P554, DOI 10.1128/MMBR.52.4.554-567.1988; EKIEL I, 1983, J BACTERIOL, V156, P316, DOI 10.1128/JB.156.1.316-326.1983; EVANS JNS, 1986, SCIENCE, V231, P488, DOI 10.1126/science.3079919; GALINSKI EA, 1982, FEMS MICROBIOL LETT, V13, P357, DOI 10.1016/0378-1097(82)90191-4; GRIFFITH OW, 1986, ANNU REV BIOCHEM, V55, P855, DOI 10.1146/annurev.biochem.55.1.855; HENRICHS SM, 1985, APPL ENVIRON MICROB, V50, P543, DOI 10.1128/AEM.50.2.543-545.1985; IMHOFF JF, 1986, FEMS MICROBIOL LETT, V39, P57; JARRELL KF, 1984, CAN J MICROBIOL, V30, P663, DOI 10.1139/m84-099; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; KASHMAN Y, 1973, TETRAHEDRON, V29, P3655, DOI 10.1016/S0040-4020(01)93529-X; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; KENEALY WR, 1982, J BACTERIOL, V150, P1357, DOI 10.1128/JB.150.3.1357-1365.1982; KOGUT M, 1987, SCI PROG, V71, P381; Kushner DJ., 1985, BACTERIA, P171; LAI MC, 1991, J BACTERIOL, V173, P5252; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; MACKAY MA, 1983, MAR BIOL, V73, P301, DOI 10.1007/BF00392256; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MOSS M, 1987, J BIOL CHEM, V262, P14859; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; REED RH, 1986, FEMS MICROBIOL LETT, V39, P51; ROBERTS MF, 1990, J BIOL CHEM, V265, P18207; ROBERTSON DE, 1989, BIOCHIM BIOPHYS ACTA, V992, P320, DOI 10.1016/0304-4165(89)90091-3; ROBERTSON DE, 1990, APPL ENVIRON MICROB, V56, P1504, DOI 10.1128/AEM.56.5.1504-1508.1990; ROBERTSON DE, 1990, APPL ENVIRON MICROB, V56, P563, DOI 10.1128/AEM.56.2.563-565.1990; ROBERTSON DE, 1991, BIOFACTORS, V3, P1; SELTMANN G, 1989, J BASIC MICROB, V29, P547, DOI 10.1002/jobm.3620290820; SHPORER M, 1972, J MEMBRANE BIOL, V33, P385; SOWERS KR, 1990, P NATL ACAD SCI USA, V87, P9083, DOI 10.1073/pnas.87.23.9083; SPROTT GD, 1981, CAN J MICROBIOL, V27, P444, DOI 10.1139/m81-067; SUMMONS RE, 1981, PHYTOCHEMISTRY, V20, P1125, DOI 10.1016/0031-9422(81)83040-3; TAKEMOTO T, 1965, Yakugaku Zasshi, V85, P33; VREELAND RH, 1987, CRIT REV MICROBIOL, V14, P311, DOI 10.3109/10408418709104443; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YAP SF, 1983, ARCH MICROBIOL, V135, P224, DOI 10.1007/BF00414484	45	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14893	14901						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353078				2022-12-27	WOS:A1992JF08800060
J	BOCHKAREVA, ES; LISSIN, NM; FLYNN, GC; ROTHMAN, JE; GIRSHOVICH, AS				BOCHKAREVA, ES; LISSIN, NM; FLYNN, GC; ROTHMAN, JE; GIRSHOVICH, AS			POSITIVE COOPERATIVITY IN THE FUNCTIONING OF MOLECULAR CHAPERONE GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURED RHODANESE; ESCHERICHIA-COLI; ATP HYDROLYSIS; PROTEIN; PURIFICATION; ASSOCIATION; CARBOXYLASE	In the presence of its partner, GroES, the tetradecameric molecular chaperone GroEL binds 14 ATP molecules, half of which are hydrolyzed in a cooperative manner. Moreover GroEL can bind, with a positive cooperativity, more than two molecules of nonfolded protein rhodanese. The role of the cooperative mechanism in the functioning of GroEL is discussed.	ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR; SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LAB,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Russian Academy of Sciences; Memorial Sloan Kettering Cancer Center								BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DAHLQUIST FW, 1974, FEBS LETT, V49, P267, DOI 10.1016/0014-5793(74)80527-2; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROWITZ P, 1986, J BIOL CHEM, V261, P5652; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1990, TRENDS BIOTECHNOL, V8, P126, DOI 10.1016/0167-7799(90)90153-O; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TANDON S, 1986, J BIOL CHEM, V261, P5615; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Westley J, 1981, Methods Enzymol, V77, P285	30	151	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6796	6800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348056				2022-12-27	WOS:A1992HM05300052
J	MAKITA, Z; VLASSARA, H; CERAMI, A; BUCALA, R				MAKITA, Z; VLASSARA, H; CERAMI, A; BUCALA, R			IMMUNOCHEMICAL DETECTION OF ADVANCED GLYCOSYLATION END-PRODUCTS INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; NONENZYMATIC GLYCOSYLATION; PROTEIN GLYCOSYLATION; DIABETES-MELLITUS; MAILLARD REACTION; HUMAN COLLAGEN; GLUCOSE; ALBUMIN; IDENTIFICATION; AMINOGUANIDINE	Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures, the measurement of AGE compounds in vivo has remained difficult. As an approach to the study of AGE formation in vivo, we prepared polyclonal antiserum to an AGE epitope(s) which forms in vitro after incubation of glucose with ribonuclease (RNase). This antiserum proved suitable for the detection of AGEs which form in vivo. Both diabetic tissue and serum known to contain elevated levels of AGEs readily competed for antibody binding. Cross-reactivity studies revealed the presence of a common AGE epitope(s) which forms after the incubation of diverse proteins with glucose. Cross-reactive epitopes also formed with glucose 6-phosphate or fructose. These data suggest that tissue AGEs which form in vivo appear to contain a common immunological epitope which cross-reacts with AGEs prepared in vitro, supporting the concept that immunologically similar AGE structures form from the incubation of sugars with different proteins (Horiuchi, S., Araki, N., and Morino, Y. (1991) J. Biol. Chem. 266, 7329-7332). None of the known AGEs, such as 4-furanyl-2-furoyl-1H-imidazole, 1-alkyl-2-formyl-3,4-diglycosylpyrrole, pyrraline, carboxymethyllysine, or pentosidine, were found to compete for binding to anti-AGE antibody. These data further suggest that the dominant AGE epitope which forms from the reaction of glucose with proteins under native conditions is immunologically distinct from the structurally defined AGEs described to date.	ROCKEFELLER UNIV, MED BIOCHEM LAB, NEW YORK, NY 10021 USA	Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; BOOKCHIN RM, 1968, BIOCHEM BIOPH RES CO, V32, P86, DOI 10.1016/0006-291X(68)90430-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUCALA R, 1983, MOL IMMUNOL, V20, P1289, DOI 10.1016/0161-5890(83)90159-1; CHANG JCF, 1985, J BIOL CHEM, V260, P7970; COHEN MP, 1980, BIOCHEM BIOPH RES CO, V95, P765, DOI 10.1016/0006-291X(80)90852-9; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; EBLE AS, 1983, J BIOL CHEM, V258, P9406; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; FARMAR JG, 1988, J ORG CHEM, V53, P2346, DOI 10.1021/jo00245a039; FLUCKIGER R, 1984, METHOD ENZYMOL, V106, P77; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HORIUCHI S, 1985, J BIOL CHEM, V260, P482; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOENIG RJ, 1977, J BIOL CHEM, V252, P2992; KOHN RR, 1984, DIABETES, V33, P57, DOI 10.2337/diabetes.33.1.57; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MICHEEL F, 1959, CHEM BER-RECL, V92, P2836, DOI 10.1002/cber.19590921127; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P740, DOI 10.1016/0006-291X(89)92372-3; NICHOLLS K, 1989, LAB INVEST, V60, P486; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; SCHWIMMER S, 1953, J AM CHEM SOC, V75, P4855, DOI 10.1021/ja01115a525; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9	37	494	553	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5133	5138						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371995				2022-12-27	WOS:A1992HH74700023
J	ROCH, JM; SHAPIRO, IP; SUNDSMO, MP; OTERO, DAC; REFOLO, LM; ROBAKIS, NK; SAITOH, T				ROCH, JM; SHAPIRO, IP; SUNDSMO, MP; OTERO, DAC; REFOLO, LM; ROBAKIS, NK; SAITOH, T			BACTERIAL EXPRESSION, PURIFICATION, AND FUNCTIONAL MAPPING OF THE AMYLOID-BETA/A4 PROTEIN-PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; ESCHERICHIA-COLI; NEXIN-II; SECRETED FORM; GENE; DEGRADATION; DOMAIN; BRAIN	The secreted form of Alzheimer amyloid beta/A4 protein precursor (APP) has been shown to be involved in cell growth regulation (Saitoh, T., Sundsmo, M., Roch, J.M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T., and Schenk, D. B. (1989) Cell 58, 615-622). Using a strong prokaryotic expression system, we expressed, in Escherichia coli, peptide fragments covering different regions of the secreted form of APP-695. The longest of these fragments (KB75, 572 amino acids from Val-20 to Ile-591), which contained neither the Kunitz-type protease inhibitor (KPI) domain nor the amyloid beta/A4-protein domain, was purified and shown to be biologically active in terms of growth regulation. Two other APP fragments (KB48, 316 amino acids from Val-20 to Met-335; and RB17, 150 amino acids from Thr-296 to Pro-445), overlapping by only 40 amino acids at a close site C-terminal to the KPI insertion site, were also active. Furthermore, a chemically synthesized 40-residue peptide corresponding to this region of overlap also stimulated the growth of A-1 fibroblasts. These results establish the presence of growth-promoting activity in the secreted form of APP-695 and suggest that the site of this activity of APP-695 lies within a 40-amino acid domain next to the KPI insertion site.	UNIV CALIF SAN DIEGO, DEPT NEUROSCI, 0624, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; BUELL G, 1985, NUCLEIC ACIDS RES, V13, P1923, DOI 10.1093/nar/13.6.1923; COLE GM, 1990, BIOCHEM BIOPH RES CO, V170, P288, DOI 10.1016/0006-291X(90)91272-T; COLE GM, 1991, NEUROBIOL AGING, V12, P85, DOI 10.1016/0197-4580(91)90046-M; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DUVOISIN RM, 1986, GENE, V45, P193, DOI 10.1016/0378-1119(86)90254-4; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; GOTTESMAN S, 1978, J BACTERIOL, V133, P844, DOI 10.1128/JB.133.2.844-851.1978; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; JOACHIM C, 1991, AM J PATHOL, V138, P373; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KRISCH HM, 1974, J MOL BIOL, V88, P89, DOI 10.1016/0022-2836(74)90296-4; KRISCH HM, 1977, VIROLOGY, V78, P87, DOI 10.1016/0042-6822(77)90080-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1990, INT CONGR SER, V884, P179; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMON LD, 1978, NATURE, V275, P424, DOI 10.1038/275424a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1990, P NATL ACAD SCI USA, V87, P9020, DOI 10.1073/pnas.87.22.9020	57	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2214	2221						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346393				2022-12-27	WOS:A1992HB53200017
J	CHOI, SY; SCHERER, BJ; SCHNIER, J; DAVIES, MV; KAUFMAN, RJ; HERSHEY, JWB				CHOI, SY; SCHERER, BJ; SCHNIER, J; DAVIES, MV; KAUFMAN, RJ; HERSHEY, JWB			STIMULATION OF PROTEIN-SYNTHESIS IN COS CELLS TRANSFECTED WITH VARIANTS OF THE ALPHA-SUBUNIT OF INITIATION-FACTOR EIF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; FACTOR-II; PHOSPHORYLATION STATE; RABBIT RETICULOCYTES; MESSENGER-RNAS; HELA-CELLS; TRANSLATION; INHIBITION; MECHANISM; EXPRESSION	The role of eukaryotic initiation factor 2 (eIF-2) phosphorylation in translational control has been demonstrated in vivo by overexpressing variant forms of eIF-2-alpha that are not phosphorylated. COS-1 cells transiently transfected with expression vectors for human eIF-2-alpha contain 10-20-fold more eIF-2-alpha-subunit than the endogenous COS cell eIF-2 trimeric complex. Expression of the variant form of eIF-2-alpha, Ser51Asp, where Asp replaces Ser51, causes inhibition of protein synthesis, whereas the Ser48Asp variant does not. When either Ser48 or Ser51 is replaced by Ala, the variants stimulate dihydrofolate reductase synthesis when the eIF-2-alpha-kinase, DAI, is activated. In order to elucidate these mechanisms, we have separated eIF-2 trimeric complexes from free overexpressed eIF-2-alpha-subunits by fast protein liquid chromatography Superose chromatography. Pulse-labeled cells transfected with wild-type or variant DNAs produced eIF-2 preparations with greater than 10-fold higher specific radioactivity in the alpha-subunit compared to the gamma-subunit, thus demonstrating that the human eIF-2-alpha produced from the plasmids readily exchanges into COS cell eIF-2 complexes. Both wild-type and Ser48Ala variant forms of the free 2-alpha-subunit, further purified by MonoQ chromatography, are poor substrates for the heme-regulated eIF-2-alpha-kinase, HRI, but are good substrates for double-stranded RNA-activated inhibitor in vitro; the Ser51Ala variant subunit is not phosphorylated by either kinase. None of the purified free eIF-2-alpha subunits inhibits phosphorylation of eIF-2 in vitro, even at up to 8-fold molar excess. Examination of the extent of eIF-2-alpha-phosphorylation in the COS cell eIF-2 complexes by two-dimensional polyacrylamide gel electrophoresis shows that the stimulation of dihydrofolate reductase synthesis by the Ser51Ala variant is most readily explained by failure of eIF-2 to be phosphorylated. Stimulation by the Ser48Ala variant appears to occur by mitigation of the effect of phosphorylation at Ser51 since the double variant, Ser48AlaSer51Asp, inhibits protein synthesis less than the single variant Ser51Asp. The evidence argues strongly against there being a second site of phosphorylation involved in translational repression.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616; GENET INST,CAMBRIDGE,MA 02140	University of California System; University of California Davis					NIGMS NIH HHS [GM22135, GM07377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, T32GM007377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EY PL, 1986, METHOD ENZYMOL, V121, P497; GRACE M, 1984, P NATL ACAD SCI-BIOL, V81, P5379, DOI 10.1073/pnas.81.17.5379; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOWE JG, 1983, J BIOL CHEM, V258, P1954; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; JACKSON RJ, 1990, TRANSLATION EUKARYOT, P193; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KRAMER G, 1990, FEBS LETT, V267, P181, DOI 10.1016/0014-5793(90)80919-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAMUEL CE, 1984, J BIOL CHEM, V259, P13415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; WONG ST, 1982, J BIOL CHEM, V257, P5231	29	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					286	293						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346129				2022-12-27	WOS:A1992GY43900048
J	LUO, ZJ; SINGH, IS; FUJIHIRA, T; ERLICHMAN, J				LUO, ZJ; SINGH, IS; FUJIHIRA, T; ERLICHMAN, J			CHARACTERIZATION OF A MINIMAL PROMOTER ELEMENT REQUIRED FOR TRANSCRIPTION OF THE MOUSE TYPE-II-BETA REGULATORY SUBUNIT (RII-BETA) OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIC CELLS; MOLECULAR-CLONING; BOVINE BRAIN; IMMUNOGLOBULIN ENHANCER; BINDING-PROTEINS; SKELETAL-MUSCLE; CDNA STRUCTURE; RECEPTOR GENE; HUMAN TESTIS; DNA-BINDING	The 5'-flanking DNA of the mouse RIIbeta subunit of the cAMP-dependent protein kinase gene was characterized by transient transfection of RIIbeta-CAT constructs into mouse neuroblastoma cells (NB2a) and Chinese hamster ovary (CHO) cells and by gel mobility shift and footprinting assays. The minimal promoter of the RIIbeta gene was composed of two adjacent functional elements. A 3'-element which supported enhanced CAT activity was located between base pairs (bp) -267/-168 from the translation initiation start site. CAT plasmids containing these RIIbeta sequences showed 12- and 16-fold increased CAT activity in the NB2a and CHO cells, respectively, compared to the basic CAT vector. Plasmids containing 20 additional bp 5' to the -267/-168 fragment showed 2-fold more CAT activity than the shorter fragment in NB2a cells, while CAT activity in CHO cells was nearly the same for both constructs. CAT plasmids containing only this 20-bp fragment showed 9- and 13-fold increased CAT activity in NB2a and CHO cells, respectively. The core promoter of the RIIbeta gene lacked classical TATA and CAT sequences, but contained 3 copies of the Spl core consensus sequence. Gel mobility shift assays using P-32-labeled 5'-flanking DNA containing bp -291/-49 and nuclear extracts from NB2a and CHO cells displayed several retarded bands in the gels suggesting complex formation with nuclear DNA-binding factors. Unlabeled DNA containing bp -291/-49 blocked the appearance of all retarded bands. Competition using an oligonucleotide corresponding to the Sp1 DNA-binding site effectively blocked the appearance of the two more slowly migrating bands but did not affect the major rapidly migrating bands. DNase I footprinting analysis using purified Sp1 protein confirmed that Sp 1 could bind to the Sp1 sites. Methylation interference and mutational analysis showed that one of the faster migrating bands was the result of factor binding to the DNA sequence adjacent to the Sp1 sites. Additional tissue-specific nuclear-binding factor sequences were detected upstream of the core promoter. Our data suggest that the core promoter of the RIIbeta gene can initiate transcription from the DNA around the Sp1 sites but that there are tissue-specific nuclear factor-binding sites located distal to the Sp1 sites.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,1300 MORRIS PARK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				LUO, ZHIJUN/0000-0001-8105-5289	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-27736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1991, J BIOL CHEM, V266, P3944; BEEBE SJ, 1986, ENZYMES, V17, P43; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS RE, 1990, J BIOL CHEM, V265, P8152; HARTL FT, 1983, J BIOL CHEM, V258, P3950; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEISER M, 1986, J BIOL CHEM, V261, P1904; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; RUBIN CS, 1983, POSTTRANSLATIONAL CO, P81; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH IS, 1991, BIOCHEM BIOPH RES CO, V178, P221, DOI 10.1016/0006-291X(91)91802-J; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; STEIN JC, 1985, J BIOL CHEM, V260, P991; TASKEN KA, 1992, ENDOCRINOLOGY, V130, P1271, DOI 10.1210/en.130.3.1271; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WELDON SL, 1985, J BIOL CHEM, V260, P6440; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	57	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24738	24747						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332964				2022-12-27	WOS:A1992KA26300088
J	LYONS, CR; ORLOFF, GJ; CUNNINGHAM, JM				LYONS, CR; ORLOFF, GJ; CUNNINGHAM, JM			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF AN INDUCIBLE NITRIC-OXIDE SYNTHASE FROM A MURINE MACROPHAGE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; HUMAN-NEUTROPHILS; NITROGEN-OXIDES; RELAXING FACTOR; NITRATE; RELEASE; INDUCTION; INFECTION; MESSENGER	Macrophages activated by exposure to cytokines and/or to endotoxin produce nitric oxide (NO.), a free radical that is a mediator of the host response to infection. Activation induces the expression of nitric oxide synthase, the enzyme that catalyzes formation of NO. from L-arginine and molecular oxygen. We report the cloning of a cDNA encoding the inducible nitric oxide synthase from a murine macrophage cell line, RAW264.7, exposed to interferon-gamma and lipopolysaccharide. Oocytes injected with mRNA transcribed from this cDNA demonstrate arginine-dependent production of nitrite, a stable metabolite of NO.. Nitrite production is blocked by the enzyme inhibitor, N(G)-monomethylarginine, and is independent of calcium/calmodulin. RAW264.7 cells demonstrate rapid accumulation of the nitric oxide synthase-encoding mRNAs upon activation. Comparison of the deduced amino acid sequence to the calcium/calmodulin-dependent nitric oxide synthase previously purified (Bredt, D. S., and Snyder, S. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 682-685) and cloned (Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Synder, S. H. (1991) Nature 351, 714-718) from rat brain identifies shared binding sites for the cofactors NADPH and flavins in the C-terminal half of both proteins and an additional conserved region near the N terminus that may recognize L-arginine and/or contribute to the active site.	BRIGHAM & WOMENS HOSP,RM 925,THORN BLDG,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ADAMS LB, 1990, J IMMUNOL, V144, P2725; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5295; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LA, 1982, ANAL BIOCHEM, V1256, P131; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1987, J IMMUNOL, V138, P550; HOLLINGER TG, 1984, J EXP ZOOL, V230, P427, DOI 10.1002/jez.1402300312; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIEW FY, 1990, J IMMUNOL, V145, P4306; Maniatis T, 1989, DECONTAMINATION DILU; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1542; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; YUI Y, 1991, J BIOL CHEM, V266, P12544	37	905	928	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6370	6374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372907				2022-12-27	WOS:A1992HK31800096
J	YANAGA, F; ABE, M; KOGA, T; HIRATA, M				YANAGA, F; ABE, M; KOGA, T; HIRATA, M			SIGNAL TRANSDUCTION BY TUMOR-NECROSIS-FACTOR-ALPHA IS MEDIATED THROUGH A GUANINE NUCLEOTIDE-BINDING PROTEIN IN OSTEOBLAST-LIKE CELL-LINE, MC3T3-E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID CYCLOOXYGENASE; EPIDERMAL GROWTH-FACTOR; PERTUSSIS TOXIN; CHEMOTACTIC PEPTIDE; MOLECULAR-CLONING; SMOOTH-MUSCLE; GTP-BINDING; RECEPTOR; STIMULATION; EXPRESSION	Transmembrane signalling mechanisms of tumor necrosis factor-alpha (TNF-alpha) were examined with special reference to the involvement of G-protein, in intact and permeabilized murine osteoblast-like cells. TNF-alpha stimulated the release of H-3 radioactivity from intact cells labeled with [H-3]arachidonic acid within 10 min in a dose dependent manner and the production of lyso forms of phospholipids, an event presumably mediated through the activation of phospholipase A2. Production of cAMP and inositol 1,4,5-trisphosphate was not affected by TNF-alpha. Pretreatment of the cells with pertussis toxin inhibited the liberation of [H-3]arachidonate. GTP-gamma-S (guanosine 5'-3-O-(thio)triphosphate) reduced the binding affinity of [I-125]TNF-alpha to beta-escin-permeabilized cells. The addition of TNF-alpha together with an unhydrolyzable analog of GTP, GTP-gamma-S, to the beta-escin-permeabilized cells prelabeled with [H-3]arachidonic acid led to a release of the H-3 radioactivity. The production of prostaglandin E2 (PGE2) was markedly stimulated by TNF-alpha in a dose over 100 ng/ml, with a latent time of about 3 h, and the stimulation was abolished by pretreatment with pertussis toxin. The time and dose requirements for this process differed from those for the possible activation of phospholipase A2, thereby indicating that other process(es) in addition to the activation of phospholipase A2 may be responsible for the enhanced production of PGE2. The activity of cyclooxygenase (i.e. the combined activities of prostaglandin endoperoxide synthase and PGH2-PGE2 isomerase) was stimulated by TNF-alpha with much the same time and dose requirements as for the production of PGE2, and the activation was found to be due to the increased amount of the enzyme, as assessed by a Western blot analysis with anti-cyclooxygenase antibody. This process was also sensitive to pertussis toxin. Therefore, receptors for TNF-alpha in MC3T3-E1 cells apparently couple to G-protein sensitive to pertussis toxin and the coupling regulates the activations of phospholipase A2 and the de novo synthesis of cyclooxygenase.	KYUSHU UNIV,FAC DENT,DEPT BIOCHEM,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC DENT,DEPT ORAL SURG 2,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DIS CHEST RES INST,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University								BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAVIS HW, 1990, BIOCHEM J, V270, P401, DOI 10.1042/bj2700401; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HAMACHI T, 1986, BIOCHIM BIOPHYS ACTA, V889, P136, DOI 10.1016/0167-4889(86)90097-2; HIRATA M, 1984, J BIOCHEM-TOKYO, V96, P9, DOI 10.1093/oxfordjournals.jbchem.a134834; IKEBE T, 1988, J IMMUNOL, V140, P827; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; ITOH T, 1983, J PHYSIOL-LONDON, V337, P609, DOI 10.1113/jphysiol.1983.sp014645; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SILK ST, 1989, J BIOL CHEM, V264, P21466; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; YANAGA F, 1991, BIOCHIM BIOPHYS ACTA, V1094, P139; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	43	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5114	5121						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1371994				2022-12-27	WOS:A1992HH74700020
J	RAN, S; BENOS, DJ				RAN, S; BENOS, DJ			IMMUNOPURIFICATION AND STRUCTURAL-ANALYSIS OF A PUTATIVE EPITHELIAL CL- CHANNEL PROTEIN ISOLATED FROM BOVINE TRACHEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDUCTANCE CHLORIDE CHANNEL; CYSTIC-FIBROSIS; CELL-LINE; MEMBRANE; RECONSTITUTION; PHOSPHORYLATION; NITROCELLULOSE; SOLUBILIZATION; PURIFICATION; QUANTITIES	We have purified to homogeneity a 38-kDa protein (called p38) from bovine tracheal epithelium. This protein, when reconstituted into liposomes, mediates stilbene disulfonate-sensitive I--125 conductive uptake. On nonreduced or partially reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis, this protein associates into a doublet of 62-64 kDa. In some experiments a multimer of 140 kDa was also observed. Rabbit polyclonal anti-P38 antibodies have been produced and used to immunopurify the native transporter. Upon reconstitution of the immunoaffinity-purified protein into liposomes, a 260-fold enhancement of 4,4'-bis(isothiocyano)-2,2'-stilbenedisulfonate and valinomycin-sensitive I--125 uptake was observed as compared to proteoliposomes containing unseparated material. On Western blots of total solubilized tracheal membrane proteins or semipurified fractions, the antibody recognized the 62-64-kDa doublet much better than the original 38-kDa antigen. Similar protein bands were detected in T84 and CFPAC cells as well. However, if apical membrane proteins were first separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions, the antibody recognized major bands at 140 and approximately 240 kDa. Upon partial reduction, immunolabeling of these proteins diminished with the concomitant appearance of the 62-64-kDa doublet. Upon complete reduction, the appearance of 32- and 38-kDa proteins was evident with the disappearance of the 62-64-kDa doublet. We hypothesize that the native Cl- channel is a heteromer containing at least four subunits connected by S-S bridges.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIDDK NIH HHS [DK42017] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], METHODS ENZYMOL B; BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BEAR CE, 1988, FEBS LETT, V237, P145, DOI 10.1016/0014-5793(88)80189-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUER W, 1990, BIOCHIM BIOPHYS ACTA, V1022, P229, DOI 10.1016/0005-2736(90)90118-8; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; EDELMAN A, 1990, PED PUBL S, V5, P42; FINN AL, 1989, P NATL ACAD SCI USA, V86, P7649, DOI 10.1073/pnas.86.19.7649; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1986, FED PROC, V45, P2757; GOGELEIN H, 1988, BIOCHIM BIOPHYS ACTA, V947, P521, DOI 10.1016/0304-4157(88)90006-8; GOGELEIN H, 1987, PFLUG ARCH EUR J PHY, V409, P122, DOI 10.1007/BF00584758; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JCK, 1986, NEUROCHEM RES, V11, P733, DOI 10.1007/BF00965341; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; NICHOLSON DW, 1986, BIOCHIM BIOPHYS ACTA, V856, P515, DOI 10.1016/0005-2736(86)90143-4; NILSSON BO, 1987, J IMMUNOL METHODS, V99, P67; PRESTON CP, 1990, 1990 P CF C WASH; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RAN S, 1991, J BIOL CHEM, V266, P4782; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P5340; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	41	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3618	3625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371273				2022-12-27	WOS:A1992HE60700014
J	SHAHARABANY, M; HIZI, A				SHAHARABANY, M; HIZI, A			THE CATALYTIC FUNCTIONS OF CHIMERIC REVERSE TRANSCRIPTASES OF HUMAN IMMUNODEFICIENCY VIRUSES TYPE-1 AND TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; H ACTIVITY; MUTATIONAL ANALYSIS; HIV-1 REPLICATION; ESCHERICHIA-COLI; RIBONUCLEASE; EXPRESSION; DOMAIN; AIDS; ORGANIZATION	The reverse transcriptases (RTs) from human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2, respectively) are relatively highly related yet there are several significant differences in their catalytic activities. In an attempt to relate these functional dissimilarities to the differences in amino acid sequences, we have employed a novel approach of constructing chimeric molecules composed of complementary amino acid sequences derived from the two HIV RTs. These recombinant proteins were analyzed for their enzymatic activities and for their sensitivity to tetrahydroimidazo[4, 5, 1-jk][1, 4]benzodiazepin-2[1H]-one and thione (TIBO), which selectively inhibits only HIV-1 RT. The active chimeric RTs were used to map the TIBO binding site on the HIV-1 RT molecules and to localize the putative sequences responsible for the high RNase H activity of HIV-1 RT relative to that of HIV-2 RT. The results suggest that TIBO interacts with amino acid residues located around residue 200 within the DNA polymerase domain of HIV-1 RT which shows a relatively low similarity to HIV-2 RT. The difference in the RNase H activity maps to a position in the DNA polymerase domain rather than to the RNase H domain. Out of the 12 chimeric RTs generated, four were either fully active or hyperactive, three others lost most of their catalytic activities, and the rest were totally inactive. The pattern of catalytic activities of these hybrid proteins can be explained by a model for the initial folding of HIV RTs, which entails the formation of three distinct and independently folded regions. Each region can be formed by amino acid sequences derived exclusively from either HIV-1 RT or HIV-2 RT.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIRSCH MS, 1988, J INFECT DIS, V157, P427, DOI 10.1093/infdis/157.3.427; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LAZO PA, 1990, SEMIN ONCOL, V17, P269; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1989, J BIOL CHEM, V264, P13975; MYERS G, 1991, HUMAN RETROVIRUSES A; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1989, MOBILE DNA, P53; Weiss R, 1985, RNA TUMOR VIRUSES	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3674	3678						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371274				2022-12-27	WOS:A1992HE60700022
J	WILKIN, DJ; EDWARDS, PA				WILKIN, DJ; EDWARDS, PA			CALCIUM IONOPHORE TREATMENT IMPAIRS THE STEROL-MEDIATED SUPPRESSION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE, 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE, AND FARNESYL DIPHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; DENSITY LIPOPROTEIN RECEPTOR; PROTEIN KINASE-C; COORDINATE REGULATION; PHORBOL ESTER; RAT-LIVER; GENE; TRANSCRIPTION; EXPRESSION; SEQUENCE	We report that the sterol-mediated suppression of the mRNA levels of three cholesterogenic enzymes, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, HMG-CoA synthase, and farnesyl diphosphate (FPP) synthetase is partially overcome by the calcium ionophore A23187. Addition of A23187 to the human monocytic leukemia cell line THP-1 in the presence of fetal calf serum led to rapid increases in mRNA concentration of up to 40-fold for HMG-CoA synthase and 15-fold for HMG-CoA reductase with little or no change in FPP synthetase mRNA levels. Treatment of HepG2 cells with A23187 resulted in approximately 2-4-fold increases in the mRNA levels for these three enzymes. The increases in HMG-CoA synthase and HMG-CoA reductase mRNAs were maximal after treatment of THP-1 cells with 10-mu-g/ml A23187 for 3 h. The stimulation was blocked by actinomycin D but not by cycloheximide treatment. Ionophore treatment had no effect on the half-lives of the mRNAs for HMG-CoA reductase and HMG-CoA synthase. Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase. Finally, the stimulation of these mRNA levels by A23187 was reduced in cells in which protein kinase C had been inactivated by preincubation of the cells with a phorbol ester. Taken together, these data suggest that A23187 treatment results in increased transcription of HMG-CoA reductase, HMG-CoA synthase, and, in some cell types, FPP synthetase by a mechanism that does not involve de novo protein synthesis. We speculate that A23187 treatment results in the modification of a trans-acting factor(s) which is common for the transcription of all these genes.	UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WILKIN, DJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NCRR NIH HHS [RR 865] Funding Source: Medline; NHLBI NIH HHS [IT 32 HL-07412, HL-30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007412, P01HL030568] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BROWN MS, 1980, J LIPID RES, V21, P505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE CF, 1987, PLASMA LIPOPROTEINS, P261; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; POMPIDOU A, 1987, BIOCHEM BIOPH RES CO, V148, P435, DOI 10.1016/0006-291X(87)91130-2; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; SMITH JR, 1988, J BIOL CHEM, V263, P18480; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TSUCHIYA S, 1982, CANCER RES, V42, P1530; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	23	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2831	2836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1346397				2022-12-27	WOS:A1992HB53200107
J	BARANSKI, TJ; CANTOR, AB; KORNFELD, S				BARANSKI, TJ; CANTOR, AB; KORNFELD, S			LYSOSOMAL-ENZYME PHOSPHORYLATION .1. PROTEIN RECOGNITION DETERMINANTS IN BOTH LOBES OF PROCATHEPSIN D-MEDIATE ITS INTERACTION WITH UDP-GLCNAC-LYSOSOMAL ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; N-ACETYLGLUCOSAMINE; OLIGOMERIC PROTEINS; OLIGOSACCHARIDES; GLYCOPROTEINS; BIOSYNTHESIS; FIBROBLASTS; INTERFACES; TRANSPORT; SURFACE	We have investigated the nature of a protein domain that is shared among lysosomal hydrolases and is recognized by UDP-GlcNAc:lysosomal enzyme N-acetyl-glucosamine-1-phosphotransferase, the initial enzyme in the biosynthesis of mannose 6-phosphate residues. Previously, elements of this recognition domain were identified using a chimeric protein approach. The combined substitution of two regions (amino acids 188-230, particularly lysine 203, and 265-292) from the carboxyl lobe of the lysosomal hydrolase cathepsin D into the homologous positions of the related secretory protein glycopepsinogen was sufficient to confer recognition by phosphotransferase and subsequent phosphorylation of the oligosaccharides when this chimeric protein was expressed in Xenopus oocytes. (Baranski, T. J., Faust, P. L., and Kornfeld, S. (1990) Cell 63, 281-291). The current study demonstrates that when these two regions are replaced in cathepsin D by the homologous glycopepsinogen amino acids, the resultant chimeric molecule is poorly phosphorylated. However, when either of these regions is substituted individually, the chimeric molecules are well phosphorylated. The phosphorylation of these latter chimeric proteins is dependent on the presence of procathepsin D amino lobe elements. By analyzing a series of chimeric proteins that contain all eight combinations of three consecutive segments of the entire amino lobe of procathepsin D, it was found that multiple regions of the amino lobe of cathepsin D enhance phosphorylation of the chimeric proteins. These elements may be part of an extended carboxyl lobe recognition domain or comprise a second independent recognition domain.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)				Cantor, Alan/0000-0002-5136-028X	NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Maniatis T., 1982, MOL CLONING; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; STEIN M, 1957, METHOD ENZYMOL, V3, P154; TAKAHASHI T, 1981, METHOD ENZYMOL, V80, P565; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; WAHEED A, 1982, J BIOL CHEM, V257, P2322	27	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23342	23348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331081				2022-12-27	WOS:A1992JY16300097
J	NANDA, A; GUKOVSKAYA, A; TSENG, J; GRINSTEIN, S				NANDA, A; GUKOVSKAYA, A; TSENG, J; GRINSTEIN, S			ACTIVATION OF VACUOLAR-TYPE PROTON PUMPS BY PROTEIN-KINASE-C - ROLE IN NEUTROPHIL PH REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CYTOPLASMIC PH; NA+/H+ EXCHANGE; PLASMA-MEMBRANE; TRANSPORT; CELLS; INHIBITOR; IONOPHORE; OXIDASE; ATPASES	Activated neutrophils undergo a large burst of metabolic acid generation, yet maintain their cytosolic pH (pH(i)) within physiological limits. To analyze the underlying regulatory mechanisms, pH(i) was measured fluorimetrically in suspensions of human neutrophils. In acid loaded but otherwise unstimulated cells, pH(i) recovered rapidly via Na+/H+ exchange. Upon Na+ removal, recovery from an imposed acid load was negligible. Phorbol ester activation of acidified cells induced a rapid recovery of pH(i) partly due to a Zn2+-sensitive H+-conductive pathway. A third component of the regulatory response was apparent in Na+-free media containing Zn2+. Acid extrusion through this alternate pathway was voltage sensitive and capable of translocating H+ equivalents against their electrochemical gradient. This active H+ transport was inhibited by N-ethylmaleimide, by N,N'-dicyclohexylcarbodiimide and by nanomolar doses of bafilomycins A1 or B1, suggesting the involvement of vacuolar (V)-type H+ pumps. Cytosolic alkalinization was accompanied by extracellular acidification, indicative of translocation of H+ equivalents across the surface membrane and consistent with the sensitivity of the alkalinization to changes in plasma membrane potential. The activity of the V-type H+ pumps was virtually undetectable in resting cells, becoming apparent only after treatment with phorbol esters or other, chemically unrelated agonists of protein kinase C. These H+ pumps are likely to play a role in pH(i) homeostasis during the metabolic burst that accompanies neutrophil activation during infection and inflammation.	HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Gukovskaya, Anna/0000-0003-3737-5335				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BIDANI A, 1990, AM J PHYSIOL, V28, pC586; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BONNANO JA, 1991, AM J PHYSIOL, V260, pC618; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CALA PM, 1986, CURR TOP MEMBR TRANS, V26, P79; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; GURICH RW, 1989, AM J PHYSIOL, V257, pF777, DOI 10.1152/ajprenal.1989.257.5.F777; GURICH RW, 1991, J CLIN INVEST, V87, P1547, DOI 10.1172/JCI115167; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SAWYER RG, 1991, ANN SURG, V213, P253, DOI 10.1097/00000658-199103000-00013; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; SIMCHOWITZ L, 1985, J BIOL CHEM, V260, P3248; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	33	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22740	22746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331065				2022-12-27	WOS:A1992JY16300010
J	CARRILLO, N; CECCARELLI, EA; KRAPP, AR; BOGGIO, S; FERREYRA, RG; VIALE, AM				CARRILLO, N; CECCARELLI, EA; KRAPP, AR; BOGGIO, S; FERREYRA, RG; VIALE, AM			ASSEMBLY OF PLANT FERREDOXIN-NADP+ OXIDOREDUCTASE IN ESCHERICHIA-COLI REQUIRES GROE MOLECULAR CHAPERONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED-CHLOROPLASTS; EXPRESSION; PROTEINS; SPINACH; REDUCTASE; PURIFICATION; CDNA; PLASTOCYANIN; PENICILLINS; SEQUENCE	We have recently reported the expression in Escherichia coli of an enzymatically competent ferredoxin-NADP+ oxidoreductase from cloned pea genes encoding either the mature enzyme or its precursor protein (Ceccarelli, E. A., Viale, A. M., Krapp, A. R., and Carrillo, N. (1991) J. Biol. Chem. 266, 14283-14287). Processing to the mature form by bacterial protease(s) and FAD assembly occurred in the bacterial cytosol. Expression of ferredoxin-NADP+ reductase in chaperonin-deficient (groE-) mutants of E. coli resulted in partial reductase assembly at permissive growth temperatures (i.e. 30-degrees-C), and in total breakdown of holoenzyme assembly, and accumulation as aggregated inclusion bodies at non-permissive temperatures (i.e. 42-degrees-C). Coexpression in these mutants of a cloned groESL operon from the phototrophic bacterium Chromatium vinosum resulted in partial or total recoveries of ferredoxin-NADP+ reductase assembly. The overall results indicate that bacterial chaperonins are required for the productive folding/assembly of eucaryotic ferredoxin-NADP+ reductase expressed in E. coli.	UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT MICROBIOL,RA-2000 ROSARIO,ARGENTINA	National University of Rosario	CARRILLO, N (corresponding author), UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT CIENCIAS BIOL,SUIPACHA 531,RA-2000 ROSARIO,ARGENTINA.		Ceccarelli, Eduardo A./M-8699-2014	Ceccarelli, Eduardo A./0000-0001-5776-3306				ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; CARRILLO N, 1987, CURRENT TOPICS PHOTO, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COUGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835; COURTRIGHT JB, 1970, J BACTERIOL, V102, P722, DOI 10.1128/JB.102.3.722-728.1970; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; LINDSTROM EB, 1970, J BACTERIOL, V101, P218; LORIMER GH, 1991, 3RD INT C PLANT MOL; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; Maniatis T, 1989, DECONTAMINATION DILU; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MICHALOWSKI CB, 1989, PLANT PHYSIOL, V89, P817, DOI 10.1104/pp.89.3.817; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NORDLING M, 1990, FEBS LETT, V276, P98, DOI 10.1016/0014-5793(90)80517-M; ROTHSTEIN SJ, 1985, P NATL ACAD SCI USA, V82, P7955, DOI 10.1073/pnas.82.23.7955; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; VANCAMP W, 1990, P NATL ACAD SCI USA, V87, P9903, DOI 10.1073/pnas.87.24.9903; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALEY SG, 1974, BIOCHEM J, V139, P789, DOI 10.1042/bj1390789; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; ZANETTI G, 1982, EUR J BIOCHEM, V126, P453, DOI 10.1111/j.1432-1033.1982.tb06801.x; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	34	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15537	15541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1353496				2022-12-27	WOS:A1992JG11300045
J	KOH, GY; NUSSENZVEIG, DR; OKOLICANY, J; PRICE, DA; MAACK, T				KOH, GY; NUSSENZVEIG, DR; OKOLICANY, J; PRICE, DA; MAACK, T			DYNAMICS OF ATRIAL NATRIURETIC FACTOR-GUANYLATE CYCLASE RECEPTORS AND RECEPTOR-LIGAND COMPLEXES IN CULTURED GLOMERULAR MESANGIAL AND RENOMEDULLARY INTERSTITIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CLEARANCE RECEPTOR; ADRENAL ZONA GLOMERULOSA; CYCLIC-GMP ACCUMULATION; VASCULAR SMOOTH-MUSCLE; RAT RENAL GLOMERULI; INSULIN-RECEPTORS; FUNCTIONAL EXPRESSION; CYTOPLASMIC DOMAIN; C RECEPTORS; BINDING	The dynamics of the guanylate cyclase receptor of atrial natriuretic factor (GC(A)-ANF receptor) were investigated in cultured glomerular mesangial and renomedullary interstitial cells from the rat. In these cells, the GC(A)-ANF receptor did not mediate internalization and lysosomal hydrolysis of I-125-ANF1-28 and did not undergo ligand-induced endocytosis. Glomerular mesangial cells were able, however, to mediate internalization and lysosomal hydrolysis of I-125-ANF1-28 via clearance ANF (C-ANF) receptors and to promote rapid receptor-mediated internalization and lysosomal hydrolysis of I-125-(Sar1) angiotensin II. Radioligand specifically bound to surface GC(A)-ANF receptors was rapidly dissociated at 37-degrees-C (k(off) > 0.8 min-1), with a Q10(30-37-degrees-C) > 6. The dissociation was markedly slower at subphysiological temperatures (Q10(4-30-degrees-C), 2-3) or in the presence of 0.5 mM amiloride. The results demonstrate that the GC(A)-ANF receptor, contrary to C-ANF receptors and most other polypeptide hormone receptors, is a membrane resident protein that does not mediate internalization and lysosomal hydrolysis of ligand. The termination of the interaction of ANF with GC(A)-ANF receptors results from a physiological process that leads to rapid dissociation of receptor-ligand complexes. The unique dynamics of GC(A)-ANF receptor-ligand complexes are likely to contribute importantly to stimulus-response homeostasis of ANF.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,CTR CARDIOVASC,DEPT MED,NEW YORK,NY 10021	Cornell University; Cornell University			Koh, Gou Young/C-1615-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014241] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-14241] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DELEAN A, 1986, LIFE SCI, V39, P1109, DOI 10.1016/0024-3205(86)90203-1; FONTOURA BMA, 1990, AM J PHYSIOL, V258, pC692, DOI 10.1152/ajpcell.1990.258.4.C692; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER F, 1988, J BIOL CHEM, V263, P9395; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HOLLENBERG MD, 1979, PHARMACOL REV, V30, P393; HUGHES RJ, 1988, MOL ENDOCRINOL, V2, P117, DOI 10.1210/mend-2-2-117; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LAROSE L, 1991, BIOCHEMISTRY-US, V30, P8990, DOI 10.1021/bi00101a012; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MAACK T, 1988, BIOL MOL ASPECTS ATR, P57; MAGNUSSON S, 1989, BIOCHEM J, V257, P651, DOI 10.1042/bj2570651; MARSHALL S, 1985, J BIOL CHEM, V260, P4128; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MISONO KS, 1985, BIOCHEM BIOPH RES CO, V130, P994, DOI 10.1016/0006-291X(85)91713-9; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OHLSTEIN EH, 1985, HYPERTENSION, V7, P306, DOI 10.1161/01.HYP.7.2.306; OKOLICANY J, 1991, CAN J PHYSIOL PHARM, V69, P1561, DOI 10.1139/y91-232; PANDEY KN, 1991, FASEB J, V5, pA1020; PORTER JG, 1989, J BIOL CHEM, V264, P6689; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1985, BIOCHEM BIOPH RES CO, V127, P433, DOI 10.1016/S0006-291X(85)80179-0; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONNE O, 1980, J BIOL CHEM, V255, P7449; SUZUKI M, 1987, AM J PHYSIOL, V253, pF917, DOI 10.1152/ajprenal.1987.253.5.F917; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661	45	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11987	11994						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351054				2022-12-27	WOS:A1992HY94700053
J	GEBLER, JC; AEBERSOLD, R; WITHERS, SG				GEBLER, JC; AEBERSOLD, R; WITHERS, SG			GLU-537, NOT GLU-461, IS THE NUCLEOPHILE IN THE ACTIVE-SITE OF (LAC-Z) BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; SEQUENCE; IDENTIFICATION; SUBSTITUTION; GLYCOSIDASE; MUTAGENESIS; HYDROLYSIS; ALKYLATION; RESIDUE; TYR-503	The covalent intermediate formed during catalysis by the lac Z beta-galactosidase from Escherichia coli can be trapped by reaction of the enzyme with 2',4'-dinitrophenyl 2-deoxy-2-fluoro-beta-D-galactopyranoside, thereby inactivating the enzyme. Kinetic parameters for this inactivation process with the holo- and apoenzymes have been determined. The intermediate so formed turns over only very slowly (t1/2 = 11.5 h) resulting in reactivation of the enzyme. The nucleophilic amino acid involved has been identified as Glu-537 by using a tritium-labeled inactivator to label the enzyme, then cleaving the labeled protein into peptides and purifying and sequencing the labeled peptide. This residue is conserved in five homologous beta-galactosidases and is different from that (Glu-461) proposed to be the nucleophile (Herrchen, M., and Legler, G. (1984) Eur. J. Biochem. 138, 527-531) on the basis of affinity labeling studies with conduritol C cis-epoxide. A role for glutamic acid residue 461 as the acid/base catalyst is proposed and justified.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z1,BC,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia			Gebler, John/F-7114-2011	Gebler, John/0000-0003-0372-3725				BADER DE, 1988, BIOCHEM BIOPH RES CO, V153, P301, DOI 10.1016/S0006-291X(88)81222-1; BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BERVEN LA, 1986, CARBOHYD RES, V156, P282, DOI 10.1016/S0008-6215(00)90123-X; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BUTTERWORTH RF, 1971, SYNTH-INT J METHODS, P70; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; CUPPLES CG, 1988, GENETICS, V120, P637; DESCHAVANNE PJ, 1978, J BIOL CHEM, V253, P833; EDWARDS RA, 1990, BIOCHEM BIOPH RES CO, V171, P33, DOI 10.1016/0006-291X(90)91352-S; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; FOWLER AV, 1978, J BIOL CHEM, V253, P5283; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HAYNES LJ, 1955, ADV CARBOHYDR CHEM, V10, P213; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HUBER RE, 1979, BIOCHEMISTRY-US, V18, P4090, DOI 10.1021/bi00586a005; IMOTO T, 1972, ENZYMES, V7, P617; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KOENERS HJ, 1980, RECL TRAV CHIM PAY B, V99, P355; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LEGLER G, 1981, FEBS LETT, V135, P139, DOI 10.1016/0014-5793(81)80962-3; LEGLER G, 1990, ADV CARBOHYD CHEM, V48, P362; Lemieux R.U., 1971, PURE APPL CHEM, V25, P527; LOEFFLER RST, 1979, BIOCHEM J, V177, P145, DOI 10.1042/bj1770145; MCCLOSKEY CM, 1955, ORGANIC SYNTHESES CO, V3, P434; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3202, DOI 10.1021/bi00767a010; ONODERA KONOSHIN, 1968, CARBOHYD RES, V6, P276, DOI 10.1016/S0008-6215(00)81449-4; PAULSEN H, 1974, CHEM BER-RECL, V107, P1590, DOI 10.1002/cber.19741070519; RING M, 1985, BIOCHEM BIOPH RES CO, V131, P675, DOI 10.1016/0006-291X(85)91290-2; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; RING M, 1988, BIOCHEM BIOPH RES CO, V152, P1050, DOI 10.1016/S0006-291X(88)80390-5; ROSENBERG S, 1981, BIOCHEMISTRY-US, V20, P3189, DOI 10.1021/bi00514a031; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; SHELLING JG, 1984, CARBOHYD RES, V132, P241, DOI 10.1016/0008-6215(84)85222-2; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SINNOTT ML, 1973, BIOCHEM J, V133, P81, DOI 10.1042/bj1330081; SINNOTT ML, 1973, BIOCHEM J, V133, P89, DOI 10.1042/bj1330089; SINNOTT ML, 1978, BIOCHEM J, V175, P525, DOI 10.1042/bj1750525; SINNOTT ML, 1978, FEBS LETT, V94, P1, DOI 10.1016/0014-5793(78)80894-1; STOCKS HW, 1985, MOL BIOL EVOL, V2, P469; TRIUMBUR DE, 1992, J BIOL CHEM, V267, P10248; TULL D, 1991, J BIOL CHEM, V266, P15621; Wallenfels K., 1972, ENZYMES, V7, P617; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; YARIV J, 1971, FEBS LETT, V15, P24, DOI 10.1016/0014-5793(71)80070-4	49	169	172	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11126	11130						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350782				2022-12-27	WOS:A1992HX16900032
J	KILBOURNE, EJ; NANKOVA, BB; LEWIS, EJ; MCMAHON, A; OSAKA, H; SABBAN, DB; SABBAN, EL				KILBOURNE, EJ; NANKOVA, BB; LEWIS, EJ; MCMAHON, A; OSAKA, H; SABBAN, DB; SABBAN, EL			REGULATED EXPRESSION OF THE TYROSINE-HYDROXYLASE GENE BY MEMBRANE DEPOLARIZATION - IDENTIFICATION OF THE RESPONSIVE ELEMENT AND POSSIBLE 2ND MESSENGERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DOPAMINE-BETA-HYDROXYLASE; PC12 PHEOCHROMOCYTOMA CELLS; PROTEIN-KINASE-C; CYCLIC-AMP; SYMPATHETIC NEURONS; FOS; TRANSCRIPTION; RNA; JUN	Prolonged depolarization has been used as a model of adaptive changes in the expression of various proteins, such as ion channels and neurotransmitter biosynthetic enzymes, in response to increased trans-synaptic activity in the nervous system. In depolarized PC12 cells, tyrosine hydroxylase (TH) mRNA levels increased severalfold (Kilbourne, E. J., and Sabban, E. L. (1990) Mol. Brain Res. 8, 121-127). In this study, membrane depolarization caused an increase in the expression of the reporter gene chloramphenicol acetyltransferase (CAT), under transcriptional control of the 5' region of the rat TH gene. These results indicate that membrane depolarization leads to increased transcription of the TH gene. Protein kinase C inhibitors had no effect on the induction of TH mRNA by depolarization, as well as the increase in formation of CAT under control of the upstream region of the TH gene. The depolarization responsive element in the TH gene was mapped to the region containing the cAMP responsive element. This region of the TH gene also increased CAT activity in response to the calcium ionophore, ionomycin. Interestingly, combined treatment with cAMP analogs and membrane depolarization had a greater effect than either alone on TH mRNA levels, as well as on CAT activity in PC12 cells transfected with the plasmid containing the cAMP responsive element.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	New York Medical College; Oregon Health & Science University				Nankova, Bistra/0000-0002-3997-4369	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869, K04NS001121] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01121, NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAETGE EE, 1981, P NATL ACAD SCI-BIOL, V78, P1269, DOI 10.1073/pnas.78.2.1269; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHALAZONITIS A, 1980, J PHARMACOL EXP THER, V213, P139; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FAUCONBIGUET N, 1989, NEUROSCI LETT, V104, P189; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALL FL, 1988, J BIOL CHEM, V263, P4460; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HEFTI F, 1982, J NEUROSCI, V2, P1554; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KILBOURNE EJ, 1991, J NEUROSCI METH, V40, P193, DOI 10.1016/0165-0270(91)90068-B; KVETNANSKY R, 1970, ENDOCRINOLOGY, V87, P744, DOI 10.1210/endo-87-4-744; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MCMAHON A, 1992, IN PRESS J NEUROCHEM; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; OLASMAA M, 1991, J NEUROCHEM B, V57, P20; OTTEN U, 1977, BRAIN RES, V133, P291, DOI 10.1016/0006-8993(77)90765-X; RABE CS, 1982, J CYCLIC NUCLEOTIDE, P371; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYNAUD B, 1987, DEV BIOL, V119, P305, DOI 10.1016/0012-1606(87)90036-4; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1992, STRESS : NEUROENDOCRINE AND MOLECULAR APPROACHES, VOLS 1 AND 2, P325; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLING M, 1989, P NATL ACAD SCI USA, V86, P302; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STACHOWIAK MK, 1990, J BIOL CHEM, V265, P4694; STACHOWIAK MK, 1987, BRAIN RES, V359, P256; STUDELSKA DR, 1990, SOC NEUROSCI, V16; TANK AW, 1986, MOL PHARMACOL, V30, P497; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P197; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	63	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7563	7569						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348505				2022-12-27	WOS:A1992HN48500053
J	PALLANCK, L; LI, SH; SCHULMAN, LH				PALLANCK, L; LI, SH; SCHULMAN, LH			THE ANTICODON AND DISCRIMINATOR BASE ARE MAJOR DETERMINANTS OF CYSTEINE TRANSFER-RNA IDENTITY INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-SYNTHESIS; GENES; CONSTRUCTION; SPECIFICITY; INITIATION; METHIONINE; GLUTAMINE; CODON	Mutants of the Escherichia coli initiator tRNA (tRNA(fMet)) have been used to examine the role of the anticodon and discriminator base in in vivo aminoacylation of tRNAs by cysteinyl-tRNA synthetase. Substitution of the methionine anticodon CAU with the cysteine anticodon GCA was found to allow initiation of protein synthesis by the mutant tRNA from a complementary initiation codon in a reporter protein. Sequencing of the protein revealed that cysteine comprised about half of the amino acid at the N terminus. An additional mutation, converting the discriminator base of tRNA(GCA)fMet from A73 to the base present in tRNA(Cys) (U73), resulted in a 6-fold increase in the amount of protein produced and insertion of greater-than-or-equal-to 90% cysteine in response to the complementary initiation codon. Substitution of C73 or G73 at the discriminator position led to insertion of little or no cysteine, indicating the importance of U73 for recognition of the tRNA by cysteinyl-tRNA synthetase. Single base changes in the anticodon of tRNA(GCA)fMet) containing U73 from GCA to UCA, GUA, GCC, and (GCG (changes underlined) eliminated or dramatically reduced cysteine insertion by the mutant initiator tRNA indicating that all three cysteine anticodon bases are essential for specific aminoacylation of the tRNA with cysteine in vivo.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV BIOL & CANC, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [T32GMO7491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAKRABURTTY K, 1975, NUCLEIC ACIDS RES, V2, P1793, DOI 10.1093/nar/2.10.1793; CHAMBERS RW, 1973, J BIOL CHEM, V248, P5549; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; FRAVOLA L, 1964, BIOKHIMIYA, V29, P1177; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PALLANCK L, 1992, IN PRESS TRANSFER RN; SCHULMAN LH, 1973, J BIOL CHEM, V248, P1341; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SMITH D, 1989, J MOL BIOL, V206, P503, DOI 10.1016/0022-2836(89)90497-X; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	26	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7221	7223						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373131				2022-12-27	WOS:A1992HN48500008
J	HESS, P; PAYVAR, F				HESS, P; PAYVAR, F			HORMONE WITHDRAWAL TRIGGERS A PREMATURE AND SUSTAINED GENE ACTIVATION FROM DELAYED SECONDARY GLUCOCORTICOID RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CASEIN GENE; ALPHA-2U GLOBULIN SYNTHESIS; ONGOING PROTEIN-SYNTHESIS; CULTURED RAT HEPATOCYTES; DNA-BINDING; GROWTH-HORMONE; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; ALPHA-2U-GLOBULIN GENE; C-JUN	Glucocorticoid regulatory elements, denoted GREs and delayed secondary GREs (sGREs), bind the purified glucocorticoid receptors via distinctive sequence motifs and confer a primary and delayed secondary hormone inducibility, respectively, upon a linked reporter construct in stably transfected mammalian cells. The delayed secondary responses, but not the primary responses, are preceded by a time lag of several hours and blocked by protein synthesis inhibitors. In this report, we further characterized and distinguished these hormonal inductions. A 206-base pair DNA fragment from the hepatic rat alpha-2u-globulin (RUG) gene, containing at least two delayed sGREs, was specifically activated by glucocorticoids in a dose-dependent manner via a process which is sensitive to receptor antagonist RU486. Delayed sGRE-stimulated production of correctly initiated transcripts was preceded by a time lag of 2 h, a time when the GRE-mediated induction had reached maximal levels. A pulse of glucocorticoids sustained maximal activation of the delayed secondary response but not the primary response. In fact, hormone withdrawal triggered a premature induction of this delayed secondary response, suggesting that delayed sGREs are under both negative and positive control of the hormone receptor. Two separable elements of the 206-base pair fragment, including the 29-base pair sequence of a single receptor binding site, activated the reporter expression as effectively with transient, pulsatile exposure to hormone as with continuous exposure. Our results suggest that the information content of a hormonal pulse is retained, or ''memorized,'' more persistently by a receptor binding site of delayed sGREs than those of the prototypical GREs.	ST LOUIS UNIV,SCH MED,EA DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Saint Louis University					NCRR NIH HHS [RR05388] Funding Source: Medline; NIDDK NIH HHS [DK36385] Funding Source: Medline; NIGMS NIH HHS [T32GM08109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008109] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CHATTERJEE B, 1983, J BIOL CHEM, V258, P688; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CLEVER U, 1966, P NATL ACAD SCI USA, V56, P1470, DOI 10.1073/pnas.56.5.1470; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; FEIGELSON P, 1979, CELL NUCLEUS D, V8, P229; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GOODMAN HS, 1990, MOL ENDOCRINOL, V4, P1661, DOI 10.1210/mend-4-11-1661; HACHE RJG, 1987, MOL CELL BIOL, V7, P3538, DOI 10.1128/MCB.7.10.3538; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HESS P, 1990, P NATL ACAD SCI USA, V87, P2564, DOI 10.1073/pnas.87.7.2564; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KULKARNI AB, 1985, P NATL ACAD SCI USA, V82, P2579, DOI 10.1073/pnas.82.9.2579; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; LYNCH KR, 1982, CELL, V28, P185, DOI 10.1016/0092-8674(82)90388-9; MIYABE S, 1983, ENDOCRINOLOGY, V112, P2174, DOI 10.1210/endo-112-6-2174; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; MUNCK A, 1917, J STEROID BIOCHEM, V7, P1117; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NEBES VL, 1988, MOL ENDOCRINOL, V2, P444, DOI 10.1210/mend-2-5-444; NEBES VL, 1990, BIOCHEM BIOPH RES CO, V166, P133, DOI 10.1016/0006-291X(90)91921-E; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; PAYVAR F, 1983, NOBEL S, V57, P267; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; RAAKA BM, 1983, J BIOL CHEM, V258, P417; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGOLD GM, 1978, J TOXICOL ENV HEALTH, V4, P457, DOI 10.1080/15287397809529671; ROY AK, 1982, J BIOL CHEM, V257, P7834; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TAM SP, 1986, SCIENCE, V234, P1234, DOI 10.1126/science.3022381; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WIDMAN LE, 1982, J CELL PHYSIOL, V112, P316, DOI 10.1002/jcp.1041120303; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YAMAMOTO KR, 1989, AM ZOOL, V29, P537; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YAMAMOTO KR, 1983, NOBEL S, V57, P285; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMURA M, 1990, ENDOCRINOLOGY, V126, P427, DOI 10.1210/endo-126-1-427	53	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3490	3497						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1371120				2022-12-27	WOS:A1992HD15400102
J	CHAN, JC; SCANLON, M; ZHANG, HZ; JIA, LB; YU, DH; HUNG, MC; FRENCH, M; EASTMAN, EM				CHAN, JC; SCANLON, M; ZHANG, HZ; JIA, LB; YU, DH; HUNG, MC; FRENCH, M; EASTMAN, EM			MOLECULAR-CLONING AND CHARACTERIZATION OF V-MOS-ACTIVATED TRANSFORMATION-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE SARCOMA-VIRUS; INDUCED TRANSIN; GENE-PRODUCT; ONCOGENE; EXPRESSION; RNA; BACTERIOPHAGE; COLLAGENASE; FIBROBLASTS; MUTANTS	Using monoclonal antibodies we previously detected two forms of transformation-associated proteins, a 64-kDa protein and a 68-kDa protein, in temperature-sensitive 110-Moloney murine sarcoma virus-mutant-transformed rat kidney 6m2 cells. The identity and functions of the transformation-associated proteins were previously unknown. By molecular cloning techniques and immunoscreening, we have isolated two cDNA clones (34A and 79B3) that were found by Western blot analysis to code for a monoclonal anti-transformation-associated protein antibody-reactive polypeptide of approximately 58 kDa. Limited restriction enzyme mapping indicated 34A and 79B3 are two different cDNA clones. The nucleotide sequence of 34A cDNA was determined, and a search of GenBank revealed that it is identical to that of rat transin-2. The deduced amino acid sequence of 34A shares 71% sequence identity with rat transin and 41-76% identity with six human metalloproteinases. The limited restriction enzyme mapping and partial nucleotide sequencing data indicated that 79B3 may be the rat transin gene. When either 34A cDNA or 79B3 cDNA was used as a probe in Northern blot analysis, one mRNA band of approximately 1.9 kilobases was detected in 6m2 cells grown at the permissive temperature of 33-degrees-C, at which the cells exhibited transformation properties, and a much lower level in 6m2 cells grown at the nonpermissive temperature of 39-degrees-C, at which the cells reverted to normal phenotypes. These results suggest that at 39-degrees-C, these two genes were not transcribed at the same level as at 33-degrees-C. Zymogram and Western blot analysis of 6m2 cells further confirmed that the 64- and 68-kDa proteins have metalloproteinase activities and that the synthesis of metalloproteinases was also temperature-sensitive. Apparently, the two proteins we formerly designated transformation-associated proteins are members of the rat transin gene family. Therefore, within v-mos transformed 6m2 cells, the absence of transformation-associated protein (metalloproteinase) synthesis at the nonpermissive temperature was due to the absence of transcription of two rat transin genes.	LARK SEQUENCING TECHNOL INC,HOUSTON,TX 77024		CHAN, JC (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381				BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERGER SL, 1987, METHOD ENZYMOL, V152, P113; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHAN JC, 1986, BIOCHEM BIOPH RES CO, V134, P1223, DOI 10.1016/0006-291X(86)90381-5; CHAN JC, 1990, INT J CANCER, V46, P864, DOI 10.1002/ijc.2910460519; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMARS M, 1990, J VIROL, V64, P1421, DOI 10.1128/JVI.64.4.1421-1428.1990; LI W, 1987, VIROLOGY, V16, P691; LI WJ, 1987, INTERVIROLOGY, V28, P50, DOI 10.1159/000149996; LI WJ, 1989, CANCER RES, V49, P1746; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; NASH M, 1984, J VIROL, V50, P478, DOI 10.1128/JVI.50.2.478-488.1984; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPINUCCI C, 1988, JNCI-J NATL CANCER I, V80, P1416, DOI 10.1093/jnci/80.17.1416; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZHANG HZ, 1989, CANCER RES, V49, P5766; 1989, TITERING AMPLIFYING	22	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1099	1103						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370458				2022-12-27	WOS:A1992GY96000068
J	GREENBERG, SG; DAVIES, P; SCHEIN, JD; BINDER, LI				GREENBERG, SG; DAVIES, P; SCHEIN, JD; BINDER, LI			HYDROFLUORIC ACID-TREATED TAU-PHF PROTEINS DISPLAY THE SAME BIOCHEMICAL-PROPERTIES AS NORMAL TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SHARE ANTIGENIC DETERMINANTS; ALZHEIMERS-DISEASE; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; PROMOTING FACTORS; BRAIN; COMPONENT; ELECTROPHORESIS	Tau (tau) is a major constituent of paired helical filaments (PHF) found in Alzheimer's disease. The current study examines the possibility that the distinct properties of PHF-associated tau-proteins (tau(PHF)) result from post-translational modifications of normal soluble-tau (tau(s)). Following hydrofluoric acid (HF) treatment, tau(PHF) proteins are heat- and acid-stable, soluble in 2-(N-morpholino)ethanesulfonic acid buffers and display the same molecular weight, pI, and immunochemical properties as normal tau(s). Alkaline phosphatase treatment of dissociated PHF results in similar, although less extensive, electrophoretic changes and a reduction in PHF-1 immunoreactivity. Therefore, phosphorylation of normal tau(s). appears to be responsible for the distinct properties of tau(PHF). Although our results suggest that all of the normal tau-isoforms are in PHF, the relative abundance of individual tau-species differs in HF-treated PHF and tau(s) samples. Moreover, the loss of PHF following HF treatment suggests that post-translational modifications contribute to the structural stability of PHF.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; UNIV ALABAMA,SCH MED & DENT,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham	GREENBERG, SG (corresponding author), WM BURKE MED RES INST,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.				NIA NIH HHS [AG09031] Funding Source: Medline; PHS HHS [38623] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; BANCHER C, 1990, NEUROBIOL AGING, V11, P281; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DAVIES P, 1990, NEUROBIOL AGING, V10, P408; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GHANBARI H A, 1989, Society for Neuroscience Abstracts, V15, P1042; GHANBARIH, 1990, SOC NEUR ABSTR, V16, P282; GOEDERT M, 1991, NEUROSCI LETT, V126, P149, DOI 10.1016/0304-3940(91)90541-Z; GOEDERT M, 1990, EMBO J, V13, P4245; GREENBERG S G, 1989, Society for Neuroscience Abstracts, V15, P1038; GREENBERG SG, 1990, NEUROBIOL AGING, V11, P285; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HELANDER IM, 1989, FEBS LETT, V250, P565, DOI 10.1016/0014-5793(89)80797-5; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; KOSIK KS, 1984, P NATL ACAD SCI-BIOL, V81, P7941, DOI 10.1073/pnas.81.24.7941; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7948; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; Kwan S.P., 1980, GENETIC ENG, V2, P31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1991, SCIENCE, V251, P673; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PERRY G, 1987, BRAIN RES, V420, P233, DOI 10.1016/0006-8993(87)91243-1; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDEDA K, 1990, J NEUROSCI, V10, P3295; VINCENT IJ, 1990, BRAIN RES, V531, P127, DOI 10.1016/0006-8993(90)90765-4; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; WOLOZIN BL, 1988, P NATL ACAD SCI USA, V16, P6202; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	46	495	510	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					564	569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370450				2022-12-27	WOS:A1992GY43900088
J	PATEL, CV; GORSKI, DH; LEPAGE, DF; LINCECUM, J; WALSH, K				PATEL, CV; GORSKI, DH; LEPAGE, DF; LINCECUM, J; WALSH, K			MOLECULAR-CLONING OF A HOMEOBOX TRANSCRIPTION FACTOR FROM ADULT AORTIC SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN; GENE FAMILY; EXPRESSION; POU; HOMEODOMAIN; SEQUENCE; CELLS; REGION; PIT-1; HOX-2	We report here the cloning of a cDNA encoding a homeobox transcription factor from vascular smooth muscle and describe its unique pattern of mRNA expression at different stages in development. The cDNA isolated is 1576 base pairs in length not including the poly(A) tail and contains an open reading frame coding for a predicted 372-amino acid homeobox protein. During early embryogenesis, expression was detected in the neural tube with a sharp expression boundary occurring at an anterior position, in the myelencephalon, in the third and fourth branchial arches, and in vessels leading from the heart. In adults, however, transcripts were only detected in aortic smooth muscle and lung but were undetectable in cardiac or skeletal muscle, visceral smooth muscle, and many other tissues including brain. In neonates, expression was detected in the outflow tracts of the heart as well as in the cardiomyocytes. The expression pattern of this gene suggests that, although it likely has multiple roles during development, in the adult, it may participate in the control of vascular smooth muscle differentiation and proliferation.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Case Western Reserve University; Boston University	WALSH, K (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NHLBI NIH HHS [HL 45345] Funding Source: Medline; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; CAMPBELL JH, 1991, BASIC RES CARDIOL, V1, P3; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; FJOSE A, 1988, GENE AMST, V62, P11; GIAMPAOLO A, 1989, DIFFERENTIATION, V40, P191, DOI 10.1111/j.1432-0436.1989.tb00598.x; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUTLGARDHNILSSO.A, 1991, DIFFERENTIATION, V47, P99; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MUNRO JM, 1988, LAB INVEST, V58, P249; NAZARALI A, 1992, P NATL ACAD SCI USA, V89, P2883, DOI 10.1073/pnas.89.7.2883; ODENWALD WF, 1987, GENE DEV, V1, P482, DOI 10.1101/gad.1.5.482; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; TOURNIERLASSERVE E, 1989, MOL CELL BIOL, V9, P2273, DOI 10.1128/MCB.9.5.2273; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	39	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26085	26090						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361191				2022-12-27	WOS:A1992KD07300075
J	LYTLE, C; FORBUSH, B				LYTLE, C; FORBUSH, B			THE NA-K-CL COTRANSPORT PROTEIN OF SHARK RECTAL GLAND .2. REGULATION BY DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 BUMETANIDE BINDING; SQUID GIANT-AXON; NA/K/2CL COTRANSPORT; CO-TRANSPORT; CELLS; DEPHOSPHORYLATION; STIMULATION; INHIBITION; MECHANISM; SECRETION	We determined the relationship between the activation state and phosphorylation state of the Na-K-Cl cotransport protein in tubules isolated from the shark rectal gland, a prototypic chloride-secreting epithelium. In response to cAMP-dependent secretagogues (e.g. vasoactive intestinal peptide, adenosine, and forskolin) or osmotically induced changes in cell volume, the activation state of the cotransport protein (assessed from measurements of loop diuretic binding) increased 5-10 fold. The response was temporally associated with a comparable increase (3-9 fold) in cotransport protein phosphorylation. Graded changes in cotransporter activation evoked proportional changes in cotransporter phosphorylation. Under the conditions of our experiments, the 195-kDa cotransporter was the only membrane protein whose phosphorylation state increased conspicuously in response to both cAMP and cell shrinkage. Both stimuli promoted phosphorylation of the cotransport protein at serine and threonine residues. One of the cAMP-sensitive phosphoacceptors was found within a segment of the cotransport protein comprised of a sequence (Phe-Gly-His-Asn-Thr*-Ile-Asp-Ala-Val-Pro) that corresponds to a segment of the Na-K-Cl cotransport protein predicted by cDNA analysis, where the phosphoacceptor (Thr*) is threonine 189. Incubation of rectal gland tubules with K-252a or H-8, structurally different protein kinase inhibitors, rendered the cotransporter insensitive to both cAMP and cell shrinkage. We conclude that the rectal gland Na-K-Cl cotransport protein is regulated by direct reversible phosphorylation at serine and threonine sites.	MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672	Mount Desert Island Biological Laboratory	LYTLE, C (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTAMIRANO AA, 1988, AM J PHYSIOL, V254, pC582, DOI 10.1152/ajpcell.1988.254.4.C582; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; BURGER JW, 1960, SCIENCE, V131, P760; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FORBUSH B, 1988, BIOPHYS J, V53, pA222; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; GREGER R, 1988, COMP BIOCHEM PHYS A, V90, P733, DOI 10.1016/0300-9629(88)90692-5; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; KACHINTORN U, 1992, AM J PHYSIOL, V262, pC15, DOI 10.1152/ajpcell.1992.262.1.C15; KAJI D, 1991, FASEB J, V5, pA739; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, Biophysical Journal, V61, pA384; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; OGRADY SM, 1988, AM J PHYSIOL, V254, pC115, DOI 10.1152/ajpcell.1988.254.1.C115; PALFREY HC, 1980, J EXP BIOL, V89, P103; PALFREY HC, 1980, B MT DESERT ISL BIOL, V20, P146; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHUTTLEWORTH TJ, 1983, AM J PHYSIOL, V245, pR894, DOI 10.1152/ajpregu.1983.245.6.R894; SILVA P, 1977, AM J PHYSIOL, V233, pF298, DOI 10.1152/ajprenal.1977.233.4.F298; SILVA P, 1992, B MT DESERT ISL BIOL, V31, P65; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1991, AM J PHYSIOL, V261, pC543, DOI 10.1152/ajpcell.1991.261.3.C543; WELSH MJ, 1983, AM J PHYSIOL, V245, pF640, DOI 10.1152/ajprenal.1983.245.5.F640; Xu Jianchao, 1992, Journal of General Physiology, V100, p39A	33	251	252	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25438	25443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334094				2022-12-27	WOS:A1992KB60300080
J	WOEHLKE, G; WIFLING, K; DIMROTH, P				WOEHLKE, G; WIFLING, K; DIMROTH, P			SEQUENCE OF THE SODIUM-ION PUMP OXALOACETATE DECARBOXYLASE FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; KLEBSIELLA-PNEUMONIAE; MEMBRANE-PROTEINS; AEROGENES; TRANSPORT; SUBUNIT; TOPOLOGY; BIOTIN; CHAIN	A genomic library of Salmonella typhimurium DNA was constructed in the lambda-phage EMBL3 and screened by immunoblotting for expression of the oxaloacetate decarboxylase alpha-subunit. After subcloning on plasmids the entire sequence of the oxaloacetate decarboxylase was determined. The genes encoding subunits gamma (oadG), alpha (oadA), and beta (oadB) of the decarboxylase are clustered on the chromosome in that order. A typical consensus sequence of a promotor is not found upstream of the oadG gene, but putative ribosome binding regions can be identified before each subunit gene. The amino acid sequences are highly homologous to those of oxaloacetate decarboxylase from Klebsiella pneumoniae with 71% identity between the gamma-subunits, 92% identity between the alpha-subunits, and 93% identity between the beta-subunits. The homology between the corresponding beta-subunits appeared to exist only between the 312 N-terminal amino acid residues. It was shown that a cloning artifact has occurred during DNA sequence determination of the beta-subunit from K. pneumoniae and has led to erroneous results. The sequence of this polypeptide is corrected in the Appendix to this paper. A plasmid encoding the three oad genes and that for the anaerobic citrate carrier (citS) was cloned from the chromosomal DNA and used for sequence determination.	SWISS FED INST TECHNOL, INST MIKROBIOL, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich				Woehlke, Gunther/0000-0001-8462-9962				BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; DAGLEY S, 1954, J GEN MICROBIOL, V11, P218, DOI 10.1099/00221287-11-2-218; DIMROTH P, 1982, FEBS LETT, V141, P59, DOI 10.1016/0014-5793(82)80016-1; DIMROTH P, 1982, EUR J BIOCHEM, V121, P435, DOI 10.1111/j.1432-1033.1982.tb05806.x; DIMROTH P, 1990, J BIOL CHEM, V265, P7221; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1989, ARCH MICROBIOL, V151, P439, DOI 10.1007/BF00416604; DIMROTH P, 1982, EUR J BIOCHEM, V121, P443, DOI 10.1111/j.1432-1033.1982.tb05807.x; DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; DIMROTH P, 1983, EUR J BIOCHEM, V137, P107, DOI 10.1111/j.1432-1033.1983.tb07802.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; PFENNINGERLI XD, 1992, MOL MICROBIOL, V6, P1943, DOI 10.1111/j.1365-2958.1992.tb01367.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; STERN JR, 1967, BIOCHEMISTRY-US, V6, P3545, DOI 10.1021/bi00863a028; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WIFLING K, 1989, ARCH MICROBIOL, V152, P584, DOI 10.1007/BF00425491	27	38	43	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22798	22803						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331067				2022-12-27	WOS:A1992JY16300017
J	ERICKSON, RH; SUZUKI, Y; SEDLMAYER, A; KIM, YS				ERICKSON, RH; SUZUKI, Y; SEDLMAYER, A; KIM, YS			BIOSYNTHESIS AND DEGRADATION OF ALTERED IMMATURE FORMS OF INTESTINAL DIPEPTIDYL PEPTIDASE-IV IN A RAT STRAIN LACKING THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; AMINOPEPTIDASE-IV; EPITHELIAL-CELLS; ALKALINE-PHOSPHATASE; DIETARY-PROTEIN; SODIUM-BUTYRATE; SUGAR CHAINS; TRANSPORT; EXPRESSION; PLASMA	We have used a strain of rat (Fischer 344) lacking brush border membrane dipeptidyl peptidase IV activity to examine its effect on the intestinal assimilation of prolyl peptides. In addition, we have examined the biochemical basis for the enzyme deficiency. An analysis of several brush border membrane hydrolases in different regions of the small intestine demonstrates that these rats lack only dipeptidyl peptidase IV. They also have a greatly reduced ability to hydrolyze and absorb in vivo peptides of the NH2-X-Pro-Y type which are known substrates for the enzyme. Immunoblot analysis with polyclonal and monoclonal antibody indicates that the animals lack an identifiable dipeptidyl peptidase IV protein in intestinal epithelial cells. Levels and types of dipeptidyl peptidase IV mRNA were analyzed in several tissues and found to be similar to that of control animals. Biosynthetic labeling of intestinal explants revealed that two distinct forms (102 and 108 kDa) of dipeptidyl peptidase IV are initially synthesized by deficient rats, in contrast to the single protein (106 kDa) observed in normal animals. Pulse-chase labeling experiments (+/- endoglycosidase H) show that these two altered forms of dipeptidyl peptidase IV, although initially glycosylated with N-linked high mannose carbohydrate, fail to be processed to the mature complex glycosylated form and undergo intracellular degradation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	ERICKSON, RH (corresponding author), VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIDDK NIH HHS [DK17938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017938, R01DK017938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpers D. H., 1987, PHYSL GASTROINTESTIN, P1469; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BELLA AM, 1982, ARCH BIOCHEM BIOPHYS, V218, P156, DOI 10.1016/0003-9861(82)90330-7; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG YC, 1979, CLIN SCI, V57, P1; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DANIELSEN EM, 1984, FEBS LETT, V166, P28, DOI 10.1016/0014-5793(84)80038-1; DANIELSEN EM, 1989, J BIOL CHEM, V264, P13726; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; ERICKSON RH, 1990, ANNU REV MED, V41, P133; ERICKSON RH, 1985, BIOCHIM BIOPHYS ACTA, V756, P258; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GUAN D, 1988, AM J PHYSIOL, V255, pG212, DOI 10.1152/ajpgi.1988.255.2.G212; GUM JR, 1987, J BIOL CHEM, V262, P1092; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HARADA M, 1989, J CHROMATOGR-BIOMED, V493, P176, DOI 10.1016/S0378-4347(00)82721-8; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOPSUHAV.VK, 1969, HISTOCHEMISTRY, V17, P30, DOI 10.1007/BF00306327; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW SH, 1991, J BIOL CHEM, V266, P13391; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MORITA A, 1982, CANCER RES, V42, P4540; MORITA A, 1983, J CLIN INVEST, V72, P610, DOI 10.1172/JCI111009; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NATORI Y, 1989, AM J PATHOL, V134, P405; OGATA S, 1989, J BIOL CHEM, V264, P3596; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SILK DBA, 1974, CLIN SCI MOL MED, V46, P393, DOI 10.1042/cs0460393; SONG IS, 1986, GASTROENTEROLOGY, V91, P1234, DOI 10.1016/S0016-5085(86)80022-1; TAKASAKI S, 1991, BIOCHEMISTRY-US, V30, P9102, DOI 10.1021/bi00101a028; THOMPSON NL, 1991, BIOCHEM J, V273, P497, DOI 10.1042/bj2730497; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P1476; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426; YAMASHITA K, 1988, BIOCHEMISTRY-US, V27, P5565, DOI 10.1021/bi00415a026; YOSHIOKA M, 1987, AM J PHYSIOL, V253, pG781, DOI 10.1152/ajpgi.1987.253.6.G781	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21623	21629						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356989				2022-12-27	WOS:A1992JV01100058
J	TAKAHASHI, M; KAWAMOTO, S; ADELSTEIN, RS				TAKAHASHI, M; KAWAMOTO, S; ADELSTEIN, RS			EVIDENCE FOR INSERTED SEQUENCES IN THE HEAD REGION OF NONMUSCLE MYOSIN SPECIFIC TO THE NERVOUS-SYSTEM - CLONING OF THE CDNA-ENCODING THE MYOSIN HEAVY CHAIN-B ISOFORM OF VERTEBRATE NONMUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE; MESSENGER-RNAS; DICTYOSTELIUM-DISCOIDEUM; SYNTHETIC PEPTIDES; CELLULAR MYOSIN; DNA-SEQUENCE; GENE FAMILY; IDENTIFICATION; ACANTHAMOEBA	The complete amino acid sequence of a vertebrate nonmuscle myosin heavy chain-B isoform (MHC-B, 1976 amino acids, 229 kDa) has been deduced by using cDNA clones from chicken brain libraries. The chicken nonmuscle MHC-B shows overall similarity in primary structure to other MHCs in the areas contributing to the ATP-binding site and actin-binding site. Similar to other nonsarcomeric MHC IIs, there is a short uncoiled tail sequence at the carboxyl terminus of the molecule. It is in the uncoiled tail sequence that the greatest number of differences in amino acids sequence between MHC-A and B were found, which allowed generation of isoform-specific antibodies. These antibodies were used to determine the relative content of MHC-A and MHC-B in various tissues. During the cloning of the cDNA encoding chicken brain MHC-B, we found a 63-nucleotide insertion encoding 21 amino acids located in the head region of the MHC near to the actin-binding site and a 30 nucleotide insertion encoding 10 amino acids near to the ATP-binding site. Analysis using S- 1 nuclease showed that both inserts are expressed in a tissue-dependent manner; mRNA containing the inserts is present in tissues of the nervous system, but is absent from other nonmuscle cells, which contain the noninserted isoform of MHC-B. Similar inserts were found in corresponding positions in human cerebellar mRNA. Antibodies raised against a peptide synthesized based on the 21 amino acid insert found in chickens recognize a MHC isoform in the same tissues that are enriched for the mRNA. These insertions appear to be a mechanism for generating additional MHC-B isoforms specific to the nervous system.	NIH,MOLEC CARDIOL LAB,BLDG 10,RM 8N-202,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA			Takahashi, Masayuki/D-8079-2012	Takahashi, Masayuki/0000-0002-5923-2813; Adelstein, Robert/0000-0002-8683-2144				AUSUBEL FS, 1989, CURR PROTOCOL MOL BI, V1; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; COTE GP, 1985, J BIOL CHEM, V260, P4543; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; HOROWITZ JA, 1990, J BIOL CHEM, V265, P20646; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUROO M, 1991, J BIOL CHEM, V266, P3768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MURAKAMI N, 1990, J BIOL CHEM, V265, P1041; MURAKAMI N, 1992, CELL MOTIL CYTOSKEL, V22, P281, DOI 10.1002/cm.970220408; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SPUDICH JA, 1989, CELL REGUL, V1, P1; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; TAKAHASHI M, 1991, Journal of Cell Biology, V115, p333A; TAKAHASHI M, 1991, J CELL BIOCHEM, V15, P81; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	47	127	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17864	17871						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355479				2022-12-27	WOS:A1992JM22300060
J	POTTER, LR; GARBERS, DL				POTTER, LR; GARBERS, DL			DEPHOSPHORYLATION OF THE GUANYLYL CYCLASE-A RECEPTOR CAUSES DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ATRIAL-NATRIURETIC-FACTOR; PROTEIN-KINASE-C; RAT LUNG MEMBRANES; PEPTIDE RECEPTOR; CYCLIC-GMP; CGMP ACCUMULATION; ACTIVATION; PHOSPHORYLATION; MUSCLE; PURIFICATION	Atrial natriuretic peptide (ANP) binds to the guanylyl cyclase-A (GC-A) receptor found in tissues such as the kidney and adrenal gland, resulting in marked elevations of the intracellular signaling molecule, cGMP. Here, GC-A is shown to exist as a phosphoprotein when expressed in human embryonic 293 cells. The P-32 is principally associated with phosphoserine, with only trace amounts of phosphothreonine. The addition of ANP causes a time-dependent dephosphorylation of the receptor, as well as desensitization, which is not due to an ANP-mediated decrease in the amount of receptor protein. The mobility of GC-A on sodium dodecyl sulfate-polyacrylamide gel electrophoresis increases after treatment of cells with ANP, and protein phosphatase 2A induces the same mobility shift. The protein phosphatase also catalyzes dephosphorylation of GC-A, and this is directly correlated with decreases in ANP-stimulatable guanylyl cyclase activity. Okadaic acid, an inhibitor of protein phosphatase 2A, blocks both the dephosphorylation and the desensitization. Therefore, in contrast to many other cell surface receptors, GC-A is desensitized by ligand-induced dephosphorylation.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute	POTTER, LR (corresponding author), VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALLERMANN BJ, 1988, BIOCHEM BIOPH RES CO, V157, P755, DOI 10.1016/S0006-291X(88)80314-0; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG CH, 1990, EUR J PHARM-MOLEC PH, V189, P111, DOI 10.1016/0922-4106(90)90237-R; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; RAMARAO CS, 1988, J BIOL CHEM, V263, P1524; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SEKIYA M, 1991, LIFE SCI, V48, P1067, DOI 10.1016/0024-3205(91)90508-9; SHARMA RK, 1989, PROGR ATRIAL PEPTIDE, V3, P43; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; WARD GE, 1983, P NATL ACAD SCI-BIOL, V80, P5578, DOI 10.1073/pnas.80.18.5578; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	36	200	206	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14531	14534						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1353076				2022-12-27	WOS:A1992JF08800005
J	KIM, HS; KELLY, RE; EVANS, DR				KIM, HS; KELLY, RE; EVANS, DR			THE STRUCTURAL ORGANIZATION OF THE HAMSTER MULTIFUNCTIONAL PROTEIN CAD - CONTROLLED PROTEOLYSIS, DOMAINS, AND LINKERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE SYNTHETASE; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; DIHYDROOROTASE DOMAIN; MAMMALIAN-CELLS; YEAST GENE; URA2 GENE	CAD is a multidomain protein that catalyzes the first three steps in mammalian de novo pyrimidine biosynthesis. The 243-kDa polypeptide consists of four functional domains; glutamine amidotransferase (GLNase), carbamyl phosphate synthetase (CPSase), aspartate transcarbamylase (ATCase), and dihydroorotase (DHOase). Controlled proteolysis of hamster CAD was found to cleave the molecule into 18 fragments which successively accumulate and disappear during the course of digestion. Each fragment was isolated and partially sequenced to determine its location in the polypeptide chain. Proteolysis was found to usually occur at the junctions between the domains and subdomains identified by sequence homology. All proteases of low to moderate specificity cleaved the molecule in a similar fashion. The rate of proteolysis widely varied and the interdomain regions were not always accessible to proteases. Each of the major functional domains is postulated to consist of subdomains. The duplicated halves of the CPSase domain (116 kDa) have a homologous structure consisting of 11-, 25-26-, and 21-22-kDa subdomains. Prolonged digestion cleaved the DHOase domain (36.6 kDa) into two stable species suggesting that this region is comprised of 11.5- and 15.0-kDa subdomains. Similarly, proteolysis of the 21-kDa catalytic subdomain of the GLNase domain (40 kDa) indicated a bilobal structure consisting of 12.3- and 8.5-kDa chain segments. The connecting region between the two ATCase subdomains (16.4 and 18 kDa) was not cleaved. Copurification of many of the domains showed that they remain associated by noncovalent interactions even after the connecting segments have been cleaved. The chain segments, the linkers, which connect the domains and subdomains were conserved in length but not in sequence, were predicted to be relatively hydrophilic and flexible but did not show a tendency to assume a particular secondary structure. These studies provide a more detailed map of the structural organization of the CAD polypeptide.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University					NCI NIH HHS [CA-27674] Funding Source: Medline; NIGMS NIH HHS [GM-47399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BEIN K, 1991, J BIOL CHEM, V266, P3791; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KILSTRUP M, 1988, EUR J BIOCHEM, V176, P421, DOI 10.1111/j.1432-1033.1988.tb14299.x; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KRAUHS E, 1982, ANAL BIOCHEM, V119, P153, DOI 10.1016/0003-2697(82)90679-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUMBSBY PC, 1984, BIOCHEM J, V217, P435; SCULLY JL, 1991, PROTEINS, V9, P191, DOI 10.1002/prot.340090305; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; WERNER M, 1985, EUR J BIOCHEM, V146, P371, DOI 10.1111/j.1432-1033.1985.tb08663.x; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	46	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7177	7184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1348059				2022-12-27	WOS:A1992HM05300110
J	ASANO, M; EMORI, Y; SAIGO, K; SHIOKAWA, K				ASANO, M; EMORI, Y; SAIGO, K; SHIOKAWA, K			ISOLATION AND CHARACTERIZATION OF A XENOPUS CDNA WHICH ENCODES A HOMEODOMAIN HIGHLY HOMOLOGOUS TO DROSOPHILA-DISTAL-LESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HOMEOBOX GENE XHOX3; MESSENGER-RNA; EXPRESSION; EMBRYOS; PROTEIN	A novel homeobox gene of Xenopus was isolated from the ovary cDNA library. The homeodomain of the encoded protein was homologous to that of Drosophila Distal-less (Dll), and the gene was termed Xdll. The mRNA exists in a large amount in ovary, and in a small amount in testis, but was not detected in muscle, kidney, gut, and liver. The mRNA also occurs in a large amount in oocytes and is maintained in unfertilized eggs and cleavage stage embryos as a maternal mRNA at a low but distinctly detectable level. The amount of the mRNA per embryo increases gradually in later stages by zygotic expression. Embryo dissection experiment revealed that the transcript is abundant in the anterior region at the neurula stage, suggesting that Xdll may play a role in the establishment of the structures in the anterior part of the embryo.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN	University of Tokyo	ASANO, M (corresponding author), UNIV TOKYO,FAC SCI,INST ZOOL,MOLEC EMBRYOL LAB,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FUJII G, 1991, BIOCHEM BIOPH RES CO, V178, P1233, DOI 10.1016/0006-291X(91)91025-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GERHART J, 1980, BIOL REGUL DEV, V2, P136; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; NIEUWKOOP PD, 1969, NORMAL TABLE XENOPUS; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J, 1989, MOL CLONING LABORATO; SHIOKAWA K, 1990, ROUX ARCH DEV BIOL, V198, P322, DOI 10.1007/BF00383770; SHIOKAWA K, 1967, DEV BIOL, V16, P368, DOI 10.1016/0012-1606(67)90048-6; SHIOKAWA K, 1987, DEV GROWTH DIFFER, V29, P571; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	29	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5044	5047						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1347527				2022-12-27	WOS:A1992HH74700008
J	KURLAND, IJ; ELMAGHRABI, MR; CORREIA, JJ; PILKIS, SJ				KURLAND, IJ; ELMAGHRABI, MR; CORREIA, JJ; PILKIS, SJ			RAT-LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE - PROPERTIES OF PHOSPHO-FORMS AND DEPHOSPHO-FORMS AND OF 2 MUTANTS IN WHICH SER32 HAS BEEN CHANGED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; FRUCTOSE 2,6-BISPHOSPHATE; ISOCITRATE DEHYDROGENASE; ACTIVE-SITE; PHOSPHORYLATION; ENZYME; PHOSPHOFRUCTOKINASE-2; INACTIVATION; ACTIVATION	The mechanism by which cAMP-dependent protein kinase-catalyzed phosphorylation modulates the activities of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase was examined after site-specific mutation of the cAMP-dependent phosphorylation site (Ser32) to aspartic acid or alanine. The mutant and wild-type enzymes were overexpressed in Escherichia coli in a rich medium to levels as high as 30 mg/liter and were then purified to homogeneity. The kinetic properties of the Ser32-Ala mutant were identical with the dephosphorylated wild-type bifunctional enzyme. Mutation of Ser32 to aspartic acid mimicked several effects of cAMP-dependent phosphorylation: there was an increase in the K(m) for fructose 6-phosphate for 6-phosphofructo-2-kinase and an increase in the maximal velocity of fructose-2,6-bisphosphatase. Fructose-2,6-bisphosphatase activity of the Ser32-Asp mutant was 75% that of the phosphorylated wild-type enzyme, the mutant's kinase reaction had an identical dependence on fructose 6-phosphate, while its maximum velocity was only 60% that of the phosphorylated wild-type enzyme over a wide pH range. Furthermore, catalytic subunit-catalyzed in vitro phosphorylation of the Ser32-Ala mutant on Ser33 increased the K(m) for fructose 6-phosphate by 4-fold for the 6-phosphofructo-2-kinase. The results support the hypothesis that Ser32 is an important residue in the regulation of the activities of the bifunctional enzyme and that phosphorylation of Ser32 can be functionally substituted by aspartic acid. The results suggest a role for negative charge in the effect of phosphorylation.	UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Mississippi; University of Mississippi Medical Center	KURLAND, IJ (corresponding author), SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.				NIDDK NIH HHS [DK 38354, T32DK07521] Funding Source: Medline; NIGMS NIH HHS [GM 41117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN F, 1989, P NATL ACAD SCI USA, V86, P9643; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1987, J BIOL CHEM, V262, P11714; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FERSHT A, 1985, ENZYME STRUCTURE MEC, P109; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KEMP RG, 1990, FRUCTOSE 2 6 BISPHOS, P17; KOUNTZ PD, 1985, ARCH BIOCHEM BIOPHYS, V238, P531, DOI 10.1016/0003-9861(85)90197-3; KREBS EG, 1986, ENZYMES, V13, P3; LALOUX M, 1985, EUR J BIOCHEM, V148, P155, DOI 10.1111/j.1432-1033.1985.tb08819.x; LI L, 1992, IN PRESS J BIOL CHEM; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PILKIS SJ, 1987, ENZYMES, V18, P3; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STEWART HB, 1986, J BIOL CHEM, V261, P8793; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; TAULER A, 1990, J BIOL CHEM, V265, P15617; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V101, P1078; GRAPHPAD INPLOT PROG	40	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4416	4423						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1339450				2022-12-27	WOS:A1992HF64200026
J	LEACHMAN, SA; GALLAGHER, PJ; HERRING, BP; MCPHAUL, MJ; STULL, JT				LEACHMAN, SA; GALLAGHER, PJ; HERRING, BP; MCPHAUL, MJ; STULL, JT			BIOCHEMICAL-PROPERTIES OF CHIMERIC SKELETAL AND SMOOTH-MUSCLE MYOSIN LIGHT CHAIN KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN BINDING DOMAIN; AMINO-ACID SEQUENCE; SENSITIVE METHOD; CDNA; PHOSPHORYLATION; PURIFICATION; EXPRESSION; ORGANIZATION; INSITU; SITE	The molecular and biochemical properties of myosin light chain kinases from chicken skeletal and smooth muscle were investigated by recombinant DNA techniques. Deletion of the amino-terminal region of either the smooth or skeletal muscle myosin light chain kinase resulted in a decrease in V(max) with no significant change in K(m) values for light chain substrates. Skeletal/smooth muscle chimeric kinases were inactive when a 65-residue region amino-terminal of the catalytic core was exchanged between the two forms. Changing alanine 494 to glutamic acid within this region in the chicken skeletal muscle myosin light chain kinase increased the K(m) values for light chains 10-fold. These results are consistent with the hypothesis that the region amino-terminal of the catalytic core in myosin light chain kinases is involved in light chain recognition. A skeletal muscle kinase which contained the smooth muscle calmodulin binding domain remained regulated by Ca2+/calmodulin. Thus, the calmodulin binding domains of smooth and skeletal muscle myosin light chain kinases share structural elements necessary for regulation.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			McPhaul, Michael/AAC-7124-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26043, R37 HL026043, R01 HL026043, R01 HL026043-20] Funding Source: Medline; NIGMS NIH HHS [5T-32 GM08014, T32 GM008014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI IC, 1989, J BIOL CHEM, V264, P15843; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FOYT HL, 1985, J BIOL CHEM, V260, P7765; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1989, AM J PHYSIOL, V256, pC399, DOI 10.1152/ajpcell.1989.256.2.C399; HERRING BP, 1990, J BIOL CHEM, V265, P16588; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kamm K E, 1987, Prog Clin Biol Res, V245, P183; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Landon, 1977, Methods Enzymol, V47, P145; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYR GW, 1983, BIOCHEMISTRY-US, V22, P4316, DOI 10.1021/bi00287a024; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MOORE RL, 1985, J CELL PHYSIOL, V125, P301, DOI 10.1002/jcp.1041250219; MOORE RL, 1984, AM J PHYSIOL, V247, pC462, DOI 10.1152/ajpcell.1984.247.5.C462; NUNNALLY MH, 1984, J BIOL CHEM, V259, P1776; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; Sambrook J, 1989, MOL CLONING LABORATO; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TOKIMITSU I, 1987, ARCH BIOCHEM BIOPHYS, V256, P455, DOI 10.1016/0003-9861(87)90602-3; URDAL DL, 1984, J CHROMATOGR, V296, P171, DOI 10.1016/S0021-9673(01)96410-6; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4930	4938						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371510				2022-12-27	WOS:A1992HF64200095
J	ANDERSSON, H; BAKKER, E; VONHEIJNE, G				ANDERSSON, H; BAKKER, E; VONHEIJNE, G			DIFFERENT POSITIVELY CHARGED AMINO-ACIDS HAVE SIMILAR EFFECTS ON THE TOPOLOGY OF A POLYTOPIC TRANSMEMBRANE PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; MEMBRANE-PROTEINS; CYTOPLASMIC MEMBRANE; SIGNAL PEPTIDE; MICROSOMAL MEMBRANE; SECRETORY PROTEINS; PROCOAT PROTEIN; M13 PROCOAT; TRANSLOCATION; DOMAIN	Integral membrane proteins from a wide variety of sources conform to a "positive-inside rule," with many more positively charged amino acids in their cytoplasmic as compared to extracytoplasmic domains. A growing body of experimental work also points to positively charged residues in regions flanking the apolar transmembrane segments as being the main topological determinants. In this paper, we report a systematic comparison of the effects of positively (Arg, Lys, His) as well as negatively (Asp, Glu) charged residues on the membrane topology of a model Escherichia coli inner membrane protein. Our results show that positive charge is indeed the major factor determining the transmembrane topology, with Arg and Lys being of nearly equal efficiency. His, although normally a very weak topological determinant, can be potentiated by a lowering of the cytoplasmic pH. Asp and Glu affect the topology to similar extents and only when present in very high numbers.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,W-4500 OSNABRUCK,GERMANY	University Osnabruck	ANDERSSON, H (corresponding author), KAROLINSKA INST,CTR BIOTECHNOL,NOVUM,DEPT MOLEC BIOL,S-14157 HUDDINGE,SWEDEN.		von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				AKITA M, 1990, J BIOL CHEM, V265, P8164; BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BAKKER EP, 1983, BIOCHIM BIOPHYS ACTA, V730, P379, DOI 10.1016/0005-2736(83)90355-3; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DEVRIJE T, 1989, EUR J BIOCHEM, V180, P385; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KASHKET ER, 1977, J BACTERIOL, V130, P1017, DOI 10.1128/JB.130.3.1017-1023.1977; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Rottenberg H, 1979, Methods Enzymol, V55, P547; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; VANHEIJNE G, 1986, EMBO J, V5, P3021; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1990, J BIOL CHEM, V265, P21166; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	42	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1491	1495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1346135				2022-12-27	WOS:A1992HA48500018
J	TSUTSUMI, C; OKUNO, M; TANNOUS, L; PIANTEDOSI, R; ALLAN, M; GOODMAN, DS; BLANER, WS				TSUTSUMI, C; OKUNO, M; TANNOUS, L; PIANTEDOSI, R; ALLAN, M; GOODMAN, DS; BLANER, WS			RETINOIDS AND RETINOID-BINDING PROTEIN EXPRESSION IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; VISCERAL YOLK-SAC; VITAMIN-A STATUS; EPITHELIAL-CELLS; STELLATE CELLS; LIVER CELLS; WHOLE-BODY; METABOLISM; CHOLESTEROL; ACID	Adipose tissue has been reported to contain relatively high levels of the specific mRNA for retinol-binding protein (RBP) (Makover A., Soprano, D. R., Wyatt, M. L., and Goodman, D. S. (1989) J. Lipid Res. 30, 171-180). Studies were conducted to explore retinoid and retinoid-binding protein storage and metabolism in adipose tissue. In these studies, we measured RBP and cellular retinol-binding protein (CRBP) mRNA levels and retinoid levels in 6 adipose depots in male rats. Total RNA was isolated from inguinal, dorsal, mesenteric, epididymal, perinephric, and brown adipose tissue, and average RBP and CRBP mRNA levels were determined by Northern blot analysis. The relative levels of RBP mRNA in these 6 anatomically different adipose depots averaged, respectively, 6.3, 6.7, 16, 34, 37, and 21% of the level in a rat liver RNA standard. Retinoid levels in the 6 depots were similar and averaged approximately 6-7-mu-g of retinol eq/g of adipose tissue. Since adipose tissue contains several cell types, the cellular localizations of RBP and CRBP expression and retinoid storage were examined. RNA was prepared from isolated rat adipocytes and stromal-vascular cells. Cellular levels of the mRNAs for RBP, CRBP, apolipoprotein E (apoE), lipoprotein lipase, adipocyte P2, and adipsin were measured by Northern blot analysis. RBP was expressed almost exclusively in the adipocytes and only weakly in the stromal-vascular cells. Both CRBP and apoE mRNA levels were relatively high in the stromal-vascular cell preparations and only very low mRNA levels were found in the adipocytes. Lipoprotein lipase, adipsin, and adipocyte P2 mRNAs were found in substantial levels in both the adipocytes and stromal-vascular cells, but with higher levels present in the adipocytes. Cultured adipocytes synthesized RBP protein and secreted it into the medium. Only adipocytes (not stromal-vascular cells) contained retinol, at levels between 0.65-0.8-mu-g of retinol eq/10(6) cells. These studies demonstrate that adipocytes store retinoid and synthesize and secrete RBP, and suggest that rat adipocytes may be dynamically involved in retinoid storage and metabolism.	COLUMBIA UNIV,INST HUMAN NUTR,630 W 168TH ST,NEW YORK,NY 10032	Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005968, R37DK005968] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21006] Funding Source: Medline; NIDDK NIH HHS [DK 05968] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BJORNTORP P, 1985, NEW PERSPECTIVES ADI, P447; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3560; BLOMHOFF R, 1982, P NATL ACAD SCI USA, V79, P7926; CASTER WO, 1956, P SOC EXP BIOL MED, V91, P122, DOI 10.3181/00379727-91-22186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELL RB, 1985, J LIPID RES, V26, P327; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; FLOOD MT, 1983, INVEST OPHTH VIS SCI, V24, P1227; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIED SK, 1982, METABOLISM, V31, P876, DOI 10.1016/0026-0495(82)90176-7; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOODMAN DS, 1965, J LIPID RES, V6, P390; GOODMAN DS, 1980, J LIPID RES, V21, P699; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOODMAN DS, 1984, RETINOIDS, V2, P1; HARTMAN AD, 1978, LIFE SCI, V22, P1097; Hausman GJ, 1985, NEW PERSPECTIVES ADI, P1; HHERBERT J, 1991, INVEST OPHTHALMOL VI, V32, P302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS KC, 1990, J LIPID RES, V31, P1535; MAKOVER A, 1989, J LIPID RES, V30, P171; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1982, MOL CLONING LABORATO, P312; MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7; MOORE T, 1957, VITAMIN A, P209; MUTO Y, 1972, J BIOL CHEM, V247, P2542; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POND CM, 1989, COMP BIOCHEM PHYS A, V92, P455, DOI 10.1016/0300-9629(89)90591-4; RAISON J, 1988, HORM METAB RES, V20, P66, DOI 10.1055/s-2007-1010752; RAJAN N, 1990, J LIPID RES, V31, P821; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHREIBMAN PH, 1975, J CLIN INVEST, V55, P986, DOI 10.1172/JCI108028; SOPRANO DR, 1986, P NATL ACAD SCI USA, V83, P7330, DOI 10.1073/pnas.83.19.7330; SOPRANO DR, 1986, J LIPID RES, V27, P166; SOPRANO DR, 1988, J BIOL CHEM, V263, P17897; SOPRANO DR, 1988, J BIOL CHEM, V263, P2934; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609	48	262	265	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1805	1810						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370481				2022-12-27	WOS:A1992HA48500063
J	CHERIFI, Y; PIGEON, C; LEROMANCER, M; BADO, A; REYLDESMARS, F; LEWIN, MJM				CHERIFI, Y; PIGEON, C; LEROMANCER, M; BADO, A; REYLDESMARS, F; LEWIN, MJM			PURIFICATION OF A HISTAMINE-H3 RECEPTOR NEGATIVELY COUPLED TO PHOSPHOINOSITIDE TURNOVER IN THE HUMAN GASTRIC CELL-LINE HGT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROGENIC MICROVASCULAR LEAKAGE; RAT-BRAIN; SOMATOSTATIN RECEPTOR; MOLECULAR-CLONING; H-3; INHIBITION; LIGANDS; AIRWAYS; BINDING; CONTRACTIONS	The histamine H-3 receptor agonist (R)alpha-methylhistamine (MeHA) inhibited, in a nanomolar range, basal and carbachol-stimulated inositol phosphate formation in the human gastric tumoral cell line HGT1-clone 6. The inhibition was reversed by micromolar concentrations of the histamine H-3 receptor antagonist thioperamide and was sensitive to cholera or pertussis toxin treatment. Using [H-3]N(alpha)-MeHA as specific tracer, high affinity binding sites were demonstrated with a B(max) of 54 +/- 3 fmol/mg of protein and a K(D) of either 0.61 +/- 0.04 or 2.2 +/- 0.4 nM, in the absence or presence of 50 muM GTP[gamma]S, respectively. The binding sites were solubilized by Triton X-100 and prepurified by gel chromatography. They were separated from the histamine H-2 receptor sites by filtration through Sepharose-famotidine and finally retained on Sepharose-thioperamide. The purified sites concentrated in one single silver-stained protein band of 70 kDa in SDS-polyacrylamide gel electrophoresis. They specifically bound [H-3]N(alpha)-MeHA with a K(D) of 1.6 +/- 0.1 nM and a B(max) of 12,000 +/- 750 pmol/mg of protein. This corresponds to a 90,225-fold purification over cell lysate and a purity degree of 84%. Binding was competitively displaced by N(alpha)-MeHA (IC50 = 5.8 +/- 0.7 nM), (R)alpha-MeHA (IC50 = 9 +/- 1 nM), and thioperamide (IC50 = 85 +/- 10 nM), but not by famotidine (H-2 antagonist) or by mepyramine (H-1 antagonist). These findings provide the first evidence for solubilization, purification, and molecular mass characterization of the histamine H-3 receptor protein and for the negative coupling of this receptor phosphatidylinositol turnover through a so far unidentified G protein.			CHERIFI, Y (corresponding author), HOP BICHAT,UNITE RECH GASTROENTEROL,INSERM,U10,170 BLVD NEY,F-75877 PARIS 18,FRANCE.			Le Romancer, Muriel/0000-0002-8491-4015; BADO, Andre/0000-0002-8007-1460				ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ARRANG JM, 1990, EUR J PHARM-MOLEC PH, V188, P219, DOI 10.1016/0922-4106(90)90005-I; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BADO A, 1992, AM J PHYSIOL, V262, pG56, DOI 10.1152/ajpgi.1992.262.1.G56; BADO A, 1991, AM J PHYSIOL, V260, pG631, DOI 10.1152/ajpgi.1991.260.4.G631; BERTACCINI G, 1991, ITAL J GASTROENTEROL, V23, P378; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERET AM, 1985, AGENTS ACTIONS, V17, P436; CHEW CS, 1980, AM J PHYSIOL, V238, pG312, DOI 10.1152/ajpgi.1980.238.4.G312; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GARBARG M, 1989, EUR J PHARMACOL, V164, P1, DOI 10.1016/0014-2999(89)90225-2; GESPACH C, 1984, BIOCHEM BIOPH RES CO, V120, P641, DOI 10.1016/0006-291X(84)91304-4; GESPACH C, 1988, EUR J CLIN INVEST, V19, P1; HILL SJ, 1990, PHARMACOL REV, V42, P45; ICHINOSE M, 1990, J APPL PHYSIOL, V68, P21, DOI 10.1152/jappl.1990.68.1.21; ICHINOSE M, 1989, BRIT J PHARMACOL, V97, P13, DOI 10.1111/j.1476-5381.1989.tb11917.x; ICHINOSE M, 1989, EUR J PHARMACOL, V174, P49, DOI 10.1016/0014-2999(89)90872-8; KORTE A, 1990, BIOCHEM BIOPH RES CO, V168, P979, DOI 10.1016/0006-291X(90)91125-C; LABOISSE CL, 1982, CANCER RES, V42, P1541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN MJM, 1992, THERAPIE, V47, P93; LEWIN MJM, 1988, CONTROL ACID SECRETI, P3; LIN JS, 1990, BRAIN RES, V523, P325, DOI 10.1016/0006-8993(90)91508-E; LINARD C, 1992, REGUL PEPTIDES, V41, P219, DOI 10.1016/0167-0115(92)90115-B; LWIN MJM, 1991, SCAND J GASTROE S180, V26, P53; MENKVELD GJ, 1990, EUR J PHARMACOL, V186, P343, DOI 10.1016/0014-2999(90)90458-I; POLI E, 1991, LIFE SCI, V48, P63; REYLDESMARS F, 1991, CR ACAD SCI III-VIE, V312, P221; REYLDESMARS F, 1989, J BIOL CHEM, V264, P18789; REYLDESMARS F, 1986, REGUL PEPTIDES, V16, P207, DOI 10.1016/0167-0115(86)90020-0; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SCHLICKER E, 1988, N-S ARCH PHARMACOL, V337, P588; SCHWARTZ JC, 1990, AGENTS ACTIONS, V30, P13, DOI 10.1007/BF01968988; SOLL AH, 1987, PHYSL GASTROINTESTIN, P883; SOUMARMON A, 1974, BIOCHIM BIOPHYS ACTA, V339, P403, DOI 10.1016/0005-2736(74)90167-9; TRZECIAKOWSKI JP, 1987, J PHARMACOL EXP THER, V243, P874; WEST RE, 1990, J NEUROCHEM, V55, P1612, DOI 10.1111/j.1471-4159.1990.tb04946.x; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	41	53	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25315	25320						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334091				2022-12-27	WOS:A1992KB60300062
J	KRUPINSKI, J; LEHMAN, TC; FRANKENFIELD, CD; ZWAAGSTRA, JC; WATSON, PA				KRUPINSKI, J; LEHMAN, TC; FRANKENFIELD, CD; ZWAAGSTRA, JC; WATSON, PA			MOLECULAR DIVERSITY IN THE ADENYLYLCYCLASE FAMILY - EVIDENCE FOR 8 FORMS OF THE ENZYME AND CLONING OF TYPE-VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE; CDNA; MOBILIZATION; EXPRESSION; INHIBITION; SUBUNITS; SEQUENCE; RECEPTOR; BINDING; DOMAIN	The conservation of amino acid sequence among types I-IV adenylylcyclase has made it possible to apply the polymerase chain reaction to examine the extent of the molecular diversity within this family of enzymes. cDNA templates from rat heart, liver, kidney, guinea pig brain and testes, and mouse skeletal muscle were amplified with primers specific to adenylylcyclase sequences. Evidence was obtained for a total of eight distinct gene products divisible into five subfamilies. Five of the products correspond to regions from cloned forms of adenylylcyclase, while three are previously unidentified. As many as seven different adenylylcyclases are expressed in rat heart, liver, and kidney based on this analysis. Two newly identified polymerase chain reaction (PCR) products were utilized to screen a rat cDNA library from H35 Reuber hepatoma cells. A 6080-nucleotide cDNA contains an open reading frame encoding the 1166-amino acid type VI protein which has a predicted topography similar to that of other adenylylcyclases. The type VI message is abundantly expressed in rat heart, kidney, and brain. Human embryonal kidney cells stably expressing the cDNA showed an enhanced response to isoproterenol that could be inhibited by carbachol in intact cells. Increases in intracellular Ca2+ contribute to the inhibitory effect of carbachol.			KRUPINSKI, J (corresponding author), GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046395] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42365] Funding Source: Medline; NIGMS NIH HHS [GM46395] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COFFINO P, 1975, J CELL PHYSIOL, V85, P603, DOI 10.1002/jcp.1040850312; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1989, JAMA-J AM MED ASSOC, V262, P1819, DOI 10.1001/jama.262.13.1819; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	23	170	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24858	24862						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332969				2022-12-27	WOS:A1992KA26300104
J	HENRY, NL; SAYRE, MH; KORNBERG, RD				HENRY, NL; SAYRE, MH; KORNBERG, RD			PURIFICATION AND CHARACTERIZATION OF YEAST RNA POLYMERASE-II GENERAL INITIATION FACTOR-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIE; PROMOTER INVITRO; PROTEINS; BINDING; CLONING; SUBUNIT; MOTIFS; LIVER; DNA	Yeast RNA polymerase II general initiation factor g was purified to near homogeneity on the basis of its function in a reconstituted transcription system. Polypeptides of 30, 54, and 105 kDa co-purified with transcriptional activity, forming a complex with a mass of 300 kDa as judged by gel filtration, but only 100 kDa based on sedimentation in glycerol gradients, suggesting an elongated shape. Transcription activity could be reconstituted after separation of the three polypeptides under denaturing conditions; the 54- and 105-kDa subunits were both essential, while the 30-kDa subunit was slightly stimulatory. Factor g was required for initiation at all promoters tested, including those from Saccharomyces cerevisiae, Schizosaccharomyces pombe, and adenovirus. Factor g can stably associate with RNA polymerase II, as shown by co-sedimentation in a glycerol gradient.			HENRY, NL (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY JW, 1991, J BIOL CHEM, V266, P17771; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; GERARD M, 1991, J BIOL CHEM, V266, P20940; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	28	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23388	23392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331085				2022-12-27	WOS:A1992JY16300103
J	JUDWARE, R; PETRYSHYN, R				JUDWARE, R; PETRYSHYN, R			MECHANISM OF ACTION OF A CELLULAR INHIBITOR OF THE DSRNA-DEPENDENT PROTEIN-KINASE FROM 3T3-F442A CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HUMAN IMMUNODEFICIENCY VIRUS-1; FUNCTIONAL EXPRESSION; TRANSLATIONAL CONTROL; EIF-2-ALPHA KINASE; 3T3 CELLS; INTERFERON; ACTIVATION; BINDING; REGION	When mouse 3T3-F442A preadipocyte fibroblasts reach confluence in the appropriate culture medium, their growth is arrested, and the cells undergo terminal differentiation to adipocytes. Two proteins that may be involved in this process are interferon and the interferon-induced double-stranded RNA (dsRNA)-dependent protein kinase (DAI). In 3T3-F442A cells, interferon and DAI are transiently expressed with a maximum level of active kinase appearing at confluence. Interestingly, the level of active DAI was found to be low when cells were maintained under conditions nonpermissive for differentiation. This reduction in DAI was at least partly because of the presence of elevated levels of a specific inhibitor of DAI, termed dRF, which appeared to be a reversible inhibitor of the autophosphorylation (activation) of DAI. In the present study, the mechanism of action of dRF was investigated. Photocross-linking experiments indicated that dRF prevented the binding of ATP to DAI. Since the binding of ATP to DAI is dsRNA-dependent, we examined the effect of dRF on the binding of dsRNA to the kinase using RNA mobility shift assays. dRF was found to prevent the formation of DAI.dsRNA complexes without a direct effect on the dsRNA. This suggests that dRF exerts its effect through an interaction with DAI.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,750 E ADAMS ST,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					PHS HHS [E309T] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; Demaeyer E., 1988, INTERFERONS OTHER RE; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNTER T, 1975, J BIOL CHEM, V250, P409; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KURIHARCUCH W, 1978, P NATL ACAD SCI USA, V75, P6107, DOI 10.1073/pnas.75.12.6107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEUSING MA, 1987, CELL, V48, P691; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	37	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21685	21690						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1356990				2022-12-27	WOS:A1992JV01100067
J	HOLOHAN, PD; WHITE, KE; SOKOL, PP; REBBEOR, J				HOLOHAN, PD; WHITE, KE; SOKOL, PP; REBBEOR, J			PHOTOAFFINITY-LABELING OF THE ORGANIC CATION/H+ EXCHANGER IN RENAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; ALPHA-1-ADRENERGIC RECEPTOR; RABBIT KIDNEY; TRANSPORT; MECHANISMS; EXPRESSION; DRUGS; IDENTIFICATION	The brush border membrane of the proximal tubule contains two efflux pathways for organic cations from the cell to the tubular fluid: a P-glycoprotein and an organic cation[H+ exchanger. There is evidence that they transport many of the same substrates. Their structural relatedness is unknown and is the subject of this report. The experimental approach was to identify the exchanger with photoaffinity labeling reagents. The rationale was that if the P-glycoprotein and the organic cation/H+ exchanger transport many of the same substrates, then they might be photoaffinity labeled by the same reagents. [I-125]Iodoarylazidoprazosin and [H-3]azidopine are two reagents, which have been used, to photoaffinity label the P-glycoprotein. We found that several polypeptides were photolabeled in a time- and concentration-dependent manner. The photoincorporation into only two of these polypeptides (41 and 28 kDa) was blocked extensively by the presence of known substrates for the exchanger. The photoaffinity labeling of only the 41-kDa polypeptide was affected by treatment with the chemical reagents, N-ethylmaleimide and dithiothreitol, which are known to affect the exchanger reaction. The findings are consistent with the interpretation that a 41-kDa polypeptide is, or is a component of, the exchanger.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543	Bristol-Myers Squibb	HOLOHAN, PD (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041265] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44736] Funding Source: Medline; NIGMS NIH HHS [GM41265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1981, AM J PHYSIOL, V240, pF1, DOI 10.1152/ajprenal.1981.240.1.F1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAUTH C, 1988, AM J PHYSIOL, V254, pF351, DOI 10.1152/ajprenal.1988.254.3.F351; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FORD JM, 1990, PHARMACOL REV, V42, P155; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRANTHAM JJ, 1986, KIDNEY, P663; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HOLOHAN PD, 1990, PHARMACOLOGIST, V32, P179; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; INABA M, 1977, CANCER RES, V37, P4629; KINSELLA JL, 1979, J PHARMACOL EXP THER, V209, P443; KINSELLA JL, 1979, BIOCHIM BIOPHYS ACTA, V552, P468, DOI 10.1016/0005-2736(79)90191-3; LIEBERMAN DM, 1989, BIOCHEM BIOPH RES CO, V162, P244, DOI 10.1016/0006-291X(89)91988-8; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RAFIZADEH C, 1986, PFLUG ARCH EUR J PHY, V407, P404, DOI 10.1007/BF00652625; ROSS CR, 1983, ANNU REV PHARMACOL, V23, P65, DOI 10.1146/annurev.pa.23.040183.000433; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SEIDMAN CE, 1984, BIOCHEMISTRY-US, V23, P3765, DOI 10.1021/bi00311a031; SKOVSGAARD T, 1978, CANCER RES, V38, P1785; SOKOL PP, 1990, BIOCHEM PHARMACOL, V40, P1421, DOI 10.1016/0006-2952(90)90415-H; SOKOL PP, 1989, J PHARMACOL EXP THER, V251, P937; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; SOKOL PP, 1988, BIOCHIM BIOPHYS ACTA, V940, P209, DOI 10.1016/0005-2736(88)90196-4; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; SOKOL PP, 1986, J BIOL CHEM, V261, P3282; SOMOGYI A, 1987, TRENDS PHARMACOL SCI, V8, P354, DOI 10.1016/0165-6147(87)90146-5; STEFFENS TG, 1989, AM J PHYSIOL, V256, pF596, DOI 10.1152/ajprenal.1989.256.4.F596; STEFFENS TG, 1991, TRENDS BIOMEMBR BIOE, V1, P93; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TERMAN BI, 1986, J BIOL CHEM, V261, P5603; WEINER IM, 1985, KIDNEY PHYSL PATHOPH, P1703; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903	41	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13513	13519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1352295				2022-12-27	WOS:A1992JB74600066
J	EKI, T; MATSUMOTO, T; MURAKAMI, Y; HURWITZ, J				EKI, T; MATSUMOTO, T; MURAKAMI, Y; HURWITZ, J			THE REPLICATION OF DNA CONTAINING THE SIMIAN VIRUS-40 ORIGIN BY THE MONOPOLYMERASE AND DIPOLYMERASE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-III HOLOENZYME; LARGE TUMOR-ANTIGEN; SV40 ORIGIN; T-ANTIGEN; INVITRO REPLICATION; HELICASE ACTIVITY; ESCHERICHIA-COLI; PROTEIN COMPLEX; PRIMED DNA	The influence of DNA polymerase (pol) alpha and DNA primase on SV40 DNA replication was examined in both the monopolymerase and dipolymerase systems. The synthesis of oligoribonucleotides in the monopolymerase and dipolymerase systems, followed by pulse labeling with deoxynucleoside triphosphates, yielded short Okazaki fragments approximately 35 nucleotides in length that were chased into full-length Okazaki fragments with time. In the presence of activator 1 and proliferating cell nuclear antigen (PCNA), but no pol-delta, these short fragments hardly increased in size with time. DNA fragments of similar size (approximately 35 nucleotides) were previously observed in SV40 replication reactions carried out with crude extracts of HeLa cells in the presence of antibodies directed against PCNA (Bullock, P. A., Seo, Y. S., and Hurwitz, J. (1991) Mol. Cell. Biol. 11, 2350-2361). Thus, the pol alpha-primase complex appears to act processively for only a short distance. At high levels of pol-alpha and primase, both short and long DNA products were formed in both systems. In the presence of limiting amounts of pol-alpha and excess primase, the monopolymerase system inefficiently yielded longer length Okazaki fragments than those formed with excess pol-alpha and primase, whereas the dipolymerase system yielded both short and long DNA fragments. In the presence of limiting amounts of primase and excess pol-alpha, long products were formed in both systems, and virtually no short products accumulated. Thus, the ratio between the polymerase and primer ends available controls the size of the nascent product DNA strands. We examined whether PCNA, the T4 phage-encoded gene product 45 (T4 gp45), and the Escherichia coli beta-subunit of DNA polymerase III (dnaN gene product) supported SV40 DNA replication and the elongation of single-stranded DNA-binding protein-coated singly primed DNA in reactions catalyzed by pol-delta, T4 DNA pol, and E. coli DNA pol III*, respectively. In the presence of T4 gp44/62 and T4 gp32 (but not human single-stranded DNA-binding protein isolated from HeLa cells), T4 DNA pol was weakly activated by PCNA and the beta-subunit in lieu of T4 gp45 in the elongation of singly primed phi-X174 DNA. However, the other systems were specific for their analogous auxiliary factors. This specificity indicates the importance of protein-protein interactions.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034559, R01GM034559] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; EKI T, 1991, J BIOL CHEM, V266, P3087; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; NETHANEL T, 1990, J VIROL, V62, P2867; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	36	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7284	7294						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348504				2022-12-27	WOS:A1992HN48500017
J	CHUANG, TT; SALLESE, M; AMBROSINI, G; PARRUTI, G; DEBLASI, A				CHUANG, TT; SALLESE, M; AMBROSINI, G; PARRUTI, G; DEBLASI, A			HIGH EXPRESSION OF BETA-ADRENERGIC-RECEPTOR KINASE IN HUMAN PERIPHERAL-BLOOD LEUKOCYTES - ISOPROTERENOL AND PLATELET-ACTIVATING-FACTOR CAN INDUCE KINASE TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; AGONIST; PROTEIN; PURIFICATION; INHIBITION; RHODOPSIN; PATHWAYS; FAMILY	Receptor phosphorylation is a key step in the process of desensitization of the beta-adrenergic and other related receptors. A selective kinase (called beta-adrenergic receptor kinase, beta-ARK) has been identified which phosphorylates the agonist-occupied form of the receptor. Recently the bovine beta-ARK cDNA has been cloned and the highest levels of specific mRNA were found in highly innervated tissues. It was proposed that beta-ARK may be primarily active on synaptic receptors. In the present study, the cDNA of human beta-ARK was cloned and sequenced. The sequence was very similar to that of the bovine-beta-ARK (the overall amino acid homology was 98%). Very high levels of beta-ARK mRNA and kinase activity were found in peripheral blood leukocytes and in several myeloid and lymphoid leukemia cell lines. Since agonist-induced beta-ARK translocation is considered the first step involved in beta-ARK-mediated homologous desensitization, we screened a number of G-protein-coupled receptor agonists for their ability to induce beta-ARK translocation. In human mononuclear leukocytes, beta-AR agonist isoproterenol and platelet-activating factor were able to induce translocation of beta-ARK from cytosol to membrane. After 20 min of exposure to isoproterenol (10-mu-M), the cytosolic-beta-ARK activity decreased to 61% of control, while membrane-associated beta-ARK activity increased to 170%. 20-min exposure to platelet-activating factor (1-mu-M) reduced the cytosolic-beta-ARK activity to 42% of control with concomitant increase in membrane-beta-ARK activity to 214% of control. The high levels of beta-ARK expression in human peripheral blood leukocytes together with the ability of isoproterenol and platelet-activating factor to induce beta-ARK translocation, suggest a role for beta-ARK in modulating some receptor-mediated immune functions.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Sallese, Michele/J-5347-2016	Sallese, Michele/0000-0002-2555-3571				BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CROUCH MF, 1989, J BIOL CHEM, V264, P584; DEBLASI A, 1986, J LAB CLIN MED, V107, P86; DELMASCHIO A, 1989, GINKGOLIDES CHEM BIO, V2, P83; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Maniatis T., 1982, MOL CLONING; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MAZER B, 1991, J IMMUNOL, V146, P1914; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Roszman T., 1991, PROG NEUROENDOCRINIM, V4, P69; SCHWERTSCHLAG US, 1988, J BIOL CHEM, V263, P13791; SELIGMANN BE, 1982, J BIOL CHEM, V257, P6280; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	34	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6886	6892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1339451				2022-12-27	WOS:A1992HM05300067
J	MEIJER, AJ; BAQUET, A; GUSTAFSON, L; VANWOERKOM, GM; HUE, L				MEIJER, AJ; BAQUET, A; GUSTAFSON, L; VANWOERKOM, GM; HUE, L			MECHANISM OF ACTIVATION OF LIVER-GLYCOGEN SYNTHASE BY SWELLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; CELL-VOLUME REGULATION; PHOSPHORYLASE-A; AMINO-ACIDS; MEMBRANE; STIMULATION; GLUCOSE; PHOSPHATASE; METABOLISM; SYNTHETASE	The mechanism linking the stimulation of liver glycogen synthesis to swelling induced either by amino acids or hypotonicity was studied in hepatocytes, in gel-filtered liver extracts, and in purified preparations of particulate glycogen to which glycogen-metabolizing enzymes are bound. High concentrations of KCl, but not of potassium glutamate, were found to inhibit glycogen synthesis in permeabilized hepatocytes. Similarly, physiological concentrations (30-50 mM) of Cl- ions were also found to inhibit synthase phosphatase in vitro, whereas 10-20 mM Cl- ions, a concentration found in swollen hepatocytes, did not inhibit synthase phosphatase. Synthase phosphatase activity was more sensitive to inhibition by Cl- ions at low (0.1%) than at high (1%) concentrations of glycogen. By contrast, 10 mm glutamate and aspartate, a concentration observed in hepatocytes incubated with glutamine or proline, stimulated synthase phosphatase in vitro. Therefore, it is proposed that the fall in intracellular Cl- concentration as well as the increase in intracellular glutamate and aspartate concentrations, that are observed in swollen hepatocytes in the presence of amino acids, are responsible, at least in part, for the stimulation of synthase phosphatase and, hence, of glycogen synthesis.	UNIV AMSTERDAM,ACAD MED CTR,EC SLATER INST BIOCHEM RES,1105 AZ AMSTERDAM,NETHERLANDS; CATHOLIC UNIV LOUVAIN,SCH MED,METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; BAKKERGRUNWALD T, 1983, BIOCHIM BIOPHYS ACTA, V731, P239, DOI 10.1016/0005-2736(83)90014-7; BAQUET A, 1990, J BIOL CHEM, V265, P955; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI [10.1016/B978-0-12-091304-6.50017-3, DOI 10.1016/B978-0-12-091304-6.50017-3]; CHEN KS, 1985, J BIOL CHEM, V260, P4683; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; DEWULF H, 1970, EUR J BIOCHEM, V15, P1; FITZ JG, 1989, AM J PHYSIOL, V257, pG961, DOI 10.1152/ajpgi.1989.257.6.G961; GRAF J, 1988, RENAL PHYSIOL BIOCH, V11, P202; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOWARD LD, 1987, J MEMBRANE BIOL, V100, P53, DOI 10.1007/BF02209140; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; KRISTENSEN LO, 1986, AM J PHYSIOL, V251, pG575, DOI 10.1152/ajpgi.1986.251.5.G575; LANG F, 1989, PFLUG ARCH EUR J PHY, V413, P209, DOI 10.1007/BF00583532; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MOULE SK, 1987, BIOCHEM J, V241, P737, DOI 10.1042/bj2410737; MOULE SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P383, DOI 10.1016/0304-4157(90)90016-6; MVUMBI L, 1985, BIOCHEM J, V232, P697, DOI 10.1042/bj2320697; MVUMBI L, 1987, BIOCHEM J, V246, P367, DOI 10.1042/bj2460367; NOBES CD, 1989, BIOCHIM BIOPHYS ACTA, V987, P115, DOI 10.1016/0005-2736(89)90462-8; PLOMP PJAM, 1990, EUR J BIOCHEM, V191, P237, DOI 10.1111/j.1432-1033.1990.tb19115.x; ROGNSTAD R, 1986, BIOCHEM ARCH, V2, P185; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; STALMANS W, 1971, EUR J BIOCHEM, V18, P582, DOI 10.1111/j.1432-1033.1971.tb01279.x; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V181, P278, DOI 10.1016/0003-9861(77)90506-9	33	104	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5823	5828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1348248				2022-12-27	WOS:A1992HK31800019
J	CSANK, C; MARTINDALE, DW				CSANK, C; MARTINDALE, DW			ISOLEUCYL-TRANSFER RNA-SYNTHETASE FROM THE CILIATED PROTOZOAN TETRAHYMENA-THERMOPHILA - DNA-SEQUENCE, GENE-REGULATION, AND LEUCINE ZIPPER MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUTRITIONAL SHIFT-UP; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; STARVED TETRAHYMENA; RIBOSOME SYNTHESIS; YEAST; RECOGNITION; PYRIFORMIS; EXPRESSION	We have determined the nucleotide sequence of a protozoan aminoacyl-tRNA synthetase. The isoleucyl-tRNA synthetase (ileRS) gene [ilsA; formerly cupC, Martindale, D. W., Martindale, H. M., and Bruns, P. J. (1986) Nucleic Acids Res. 14, 1341-1354] from the ciliate Tetrahymena thermophila was sequenced and found to have eight introns, four transcription start sites, and a putative polypeptide of 1081 amino acids. A polypeptide 20 amino acids longer could be made if a transcribed in-frame ATG close to the start sites and with suboptimal sequence context is used. This gene was identified through hybridization and amino acid sequence similarity to the previously cloned and sequenced ileRS (cytoplasmic) gene from Saccharomyces cerevisiae [Englisch, U., Englisch, S., Markmeyer, P., Schischkoff, J., Sternbach, H., Kratzin, H., and Cramer, F. (1987) Biol. Chem. Hoppe-Seyler 368, 971-979; Martindale, D. W., Gu, Z. M., and Csank, C. (1989) Curr. Genet. 15, 99-106] with which it shares 47% of its amino acids. We also compared it to ileRS genes from E. coli and an archaebacterium. Two leucine zippers motifs were identified in the carboxyl-terminal domain of the polypeptide; one of these motifs is in the same area as the zinc finger motif found in the E. coli enzyme. The transcription pattern of the ilsA gene was monitored under various culture conditions and parallels changes in protein synthesis.	MCGILL UNIV, DEPT MICROBIOL, MACDONALD CAMPUS, Ste Anne De Bellevue H9X 1C0, QUEBEC, CANADA	McGill University								ANDREASEN PH, 1984, EUR J BIOCHEM, V140, P485, DOI 10.1111/j.1432-1033.1984.tb08128.x; BEC G, 1989, J BIOL CHEM, V264, P21131; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CAMERON IL, 1971, EXP CELL RES, V65, P265, DOI 10.1016/0014-4827(71)90001-2; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; DREISIG H, 1984, EUR J BIOCHEM, V140, P477, DOI 10.1111/j.1432-1033.1984.tb08127.x; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FASIOLO F, 1985, J BIOL CHEM, V260, P5571; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1986, ACCURACY MOL PROCESS, P67; FETT R, 1991, J BIOL CHEM, V266, P1448; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; HALLBERG RL, 1976, J CELL BIOL, V71, P383, DOI 10.1083/jcb.71.2.383; HANSEN TS, 1991, GENE, V105, P143, DOI 10.1016/0378-1119(91)90144-Z; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HARRIS CL, 1987, J BACTERIOL, V169, P2718, DOI 10.1128/jb.169.6.2718-2723.1987; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HECK JD, 1988, J BIOL CHEM, V263, P868; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HOROWITZ S, 1987, NUCLEIC ACIDS RES, V15, P141, DOI 10.1093/nar/15.1.141; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P11266, DOI 10.1021/bi00503a016; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JENAL U, 1991, J BIOL CHEM, V266, P10570; JORDANA X, 1987, J BIOL CHEM, V262, P7189; KARRER KM, 1986, MOL BIOL CILIATED PR; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTINDALE DW, 1985, J PROTOZOOL, V32, P644, DOI 10.1111/j.1550-7408.1985.tb03094.x; MARTINDALE DW, 1982, EXP CELL RES, V140, P227, DOI 10.1016/0014-4827(82)90172-0; MARTINDALE DW, 1986, NUCLEIC ACIDS RES, V14, P1341, DOI 10.1093/nar/14.3.1341; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; MOWAT D, 1974, EXP CELL RES, V84, P282, DOI 10.1016/0014-4827(74)90407-8; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEIDHARDT FC, 1975, ANNU REV MICROBIOL, V29, P215, DOI 10.1146/annurev.mi.29.100175.001243; NUREKI O, 1991, J BIOL CHEM, V266, P3268; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARKER J, 1974, J BIOL CHEM, V249, P1044; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STARGELL LA, 1990, NUCLEIC ACIDS RES, V18, P6637, DOI 10.1093/nar/18.22.6637; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	73	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4592	4599						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371507				2022-12-27	WOS:A1992HF64200049
J	ORR, DC; FIGUEIREDO, HT; MO, CL; PENN, CR; CAMERON, JM				ORR, DC; FIGUEIREDO, HT; MO, CL; PENN, CR; CAMERON, JM			DNA CHAIN TERMINATION ACTIVITY AND INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE BY CARBOCYCLIC 2',3'-DIDEHYDRO-2',3'-DIDEOXYGUANOSINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHADENOPATHY-ASSOCIATED VIRUS; HTLV-III; INVITRO; REPLICATION; POLYMERASES; 2',3'-DIDEOXYNUCLEOSIDES; PHOSPHONOFORMATE; INFECTIVITY; THERAPY; POTENT	Carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine (carbovir, NSC 614846) is an anti-retroviral agent that may be useful in the treatment of AIDS. We have examined the ability of (-)-enantiomeric carbovir triphosphate to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (EC 2.7.7.49). A comparison of inhibition kinetics was made with 3'-azido-2',3'-dideoxythymidine triphosphate and phosphonoformate. Inhibition of the reverse transcriptase was evaluated using poly(rA) . oligo(dT)12-18, poly(rC).oligo(dG)12-18, or influenza virion RNA template with a specific oligodeoxynucleotide as primer. (-)-Carbovir 5'-triphosphate was shown to be a potent inhibitor of HIV-1 reverse transcriptase with an apparent K(i) similar to that of 3'-azido-2 3'-dideoxythymidine triphosphate. Chain elongation studies utilizing an MS2 RNA template showed that (-)-carbovir 5'-triphosphate terminated transcription at positions identical to those where dideoxy-GTP terminated. This indicates that (-)-carbovir 5'-monophosphate is incorporated into the newly synthesized DNA and terminates transcription at that point. We conclude that (-)-carbovir 5'-triphosphate is a potent inhibitor of the HIV-1 reverse transcriptase enzyme and that (-)-carbovir most likely inhibits HIV by activity at the triphosphate level by a combination of direct competition for binding of the natural deoxynucleoside triphosphates to the reverse transcriptase and chain termination.	GLAXO GRP RES LTD,DEPT VIROL,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO GRP RES LTD,DEPT MED CHEM 2,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline; GlaxoSmithKline								BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; COATES JAV, 1991, ANTIVIR RES, V15, P161, DOI 10.1016/0166-3542(91)90033-N; DAGANI R, 1987, CHEM ENG NEWS, V65, P41, DOI 10.1021/cen-v065n047.p041; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HEIDENREICH O, 1990, EUR J BIOCHEM, V192, P621, DOI 10.1111/j.1432-1033.1990.tb19268.x; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MCKENNA CE, 1987, BIOCHEM PHARMACOL, V36, P3103, DOI 10.1016/0006-2952(87)90618-6; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; NAKASHIMA H, 1986, ANTIMICROB AGENTS CH, V30, P933, DOI 10.1128/AAC.30.6.933; OBERG B, 1983, PHARMACOL THERAPEUT, V19, P387; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SABOURIN CLK, 1978, ARCH BIOCHEM BIOPHYS, V187, P96, DOI 10.1016/0003-9861(78)90010-3; SANDSTROM EG, 1985, LANCET, V1, P1480; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIN PS, 1985, BIOCHEM PHARMACOL, V34, P4075, DOI 10.1016/0006-2952(85)90392-2; STARNES MC, 1987, J BIOL CHEM, V262, P988; STARNES MC, 1988, J BIOL CHEM, V263, P5132; STARNES MC, 1988, VIRUS GENES, V2, P241; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VRANG L, 1987, ANTIVIR RES, V7, P139, DOI 10.1016/0166-3542(87)90002-7; VRANG L, 1986, ANTIMICROB AGENTS CH, V29, P867, DOI 10.1128/AAC.29.5.867; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9	26	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4177	4182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371285				2022-12-27	WOS:A1992HE60700090
J	DEBOER, HC; PREISSNER, KT; BOUMA, BN; DEGROOT, PG				DEBOER, HC; PREISSNER, KT; BOUMA, BN; DEGROOT, PG			BINDING OF VITRONECTIN-THROMBIN-ANTITHROMBIN-III COMPLEX TO HUMAN ENDOTHELIAL-CELLS IS MEDIATED BY THE HEPARIN BINDING-SITE OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; EXTRACELLULAR-MATRIX; IDENTIFICATION; PURIFICATION; ASSOCIATION; INHIBITION; AFFINITY; CULTURE; PLASMA; SERUM	The interaction of vitronectin-thrombin-antithrombin III (VN.TAT) complex with endothelial cells (EC) was investigated. Binding was specific and time- and concentration-dependent. Kinetics revealed an apparent dissociation constant of 16 nm and 1.7 x 10(5) binding sites/endothelial cell. The binding determinant of the ternary complex was located on the VN moiety. Since the association of VN to TAT adds its specific properties to the VN.TAT complex, the involvement of the heparin binding domain and the cell attachment site of VN was investigated. Neither addition of RGD peptide nor blocking of the vitronectin receptor with a monoclonal antibody interfered with VN.TAT binding to EC. Addition of heparin, a VN-derived peptide comprising two heparin binding consensus sequences or a monoclonal antibody directed against the heparin binding domain on VN, completely inhibited VN.TAT binding to EC. These results indicate that the interaction is mediated through the heparin binding domain of VN. Digestion of heparan sulfate proteoglycans resulted in a decrease of VN.TAT binding to EC, indicating the involvement of heparin-like structures on the EC surface. Our findings point to an unrecognized mechanism by which VN may act as scavenger in order to enhance the clearance of end products of the clotting system via binding of the ternary VN.TAT complex to the luminal surface of EC.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,W-6350 BAD NAUHEIM,GERMANY	Kerckhoff Clinic; Max Planck Society	DEBOER, HC (corresponding author), UNIV HOSP UTRECHT,DEPT HAEMATOL,BOX 85500,3508 GA UTRECHT,NETHERLANDS.							BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BHAKDI S, 1988, CLIN EXP IMMUNOL, V74, P459; BJORK I, 1982, J BIOL CHEM, V257, P9487; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DESWART CAM, 1984, THROMB HAEMOSTASIS, V52, P66; HAMATI HF, 1989, J CELL BIOL, V108, P2495, DOI 10.1083/jcb.108.6.2495; ILL CR, 1985, J BIOL CHEM, V260, P5610; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KNOLLER S, 1991, EUR J BIOCHEM, V195, P801, DOI 10.1111/j.1432-1033.1991.tb15769.x; KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; MIMURO J, 1989, J BIOL CHEM, V264, P936; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P399; ROSENBERG RD, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)80523-6; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	23	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2264	2268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370815				2022-12-27	WOS:A1992HB53200025
J	SUNG, LA; FOWLER, VM; LAMBERT, K; SUSSMAN, MA; KARR, D; CHIEN, S				SUNG, LA; FOWLER, VM; LAMBERT, K; SUSSMAN, MA; KARR, D; CHIEN, S			MOLECULAR-CLONING AND CHARACTERIZATION OF HUMAN FETAL LIVER TROPOMODULIN - A TROPOMYOSIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE; ALPHA-TROPOMYOSIN; SKELETAL-MUSCLE; IDENTIFICATION; PURIFICATION; SEQUENCE; MYOSIN; ACTIN; CELLS; CDNA	Human erythrocyte tropomodulin is a novel tropomyosin regulatory protein that binds to the end of erythrocyte tropomyosin and blocks head-to-tail association of tropomyosin along actin filaments. It has been proposed to play a role in modulating the association of tropomyosin with the spectrin-actin complex in the erythrocyte membrane skeleton. Immunoscreening of a human fetal liver cDNA expression library in lambda-gt11, followed by 5'-end extension by polymerase chain reaction from the same library, yielded a composite cDNA sequence of 2665 base pairs (bp). It contains a 34-bp 5'-untranslated region, a 1.6-kilobase (kb) 3'-untranslated region, and a complete open reading frame of 1077 bp that encodes a protein of 359 amino acids with a calculated molecular mass of 40.6 kDa and a pI of 4.8. Authenticity of the tropomodulin cDNA was confirmed by a complete sequence match of 49 predicted amino acids with the sequences of three tryptic peptides of the erythrocyte tropomodulin. The sequence has no internal repeats and no significant homology with any known proteins. Secondary structure predictions indicate that tropomodulin may consist of a series of seven or eight short alpha-helical segments and fold into a somewhat compact shape. The tropomyosin binding activity has been mapped to an N-terminal region containing residues 39-138. Nine independent PCR clones, five from a human reticulocyte cDNA library and four from the fetal liver cDNA library, revealed identical N-terminal 103 amino acids, suggesting that the sequence reported here may also be of erythrocyte tropomodulin. Northern analysis of human reticulocyte RNA showed two hybridizing bands of 2.7 and 1.6 kb, indicating that the 2665-bp cDNA sequence reported here was that of the longer transcript.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	SUNG, LA (corresponding author), UNIV CALIF SAN DIEGO, DEPT APPL MECH & ENGN SCI BIOENGN, BSB 5028, MAIL CODE 0643, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL-44147, HL-43026] Funding Source: Medline; NIGMS NIH HHS [GM-34225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043026, R37HL044147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHIEN S, 1990, BIORHEOLOGY, V27, P327; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1985, J CELL BIOL, V100, P47, DOI 10.1083/jcb.100.1.47; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; PARRY DAD, 1975, J MOL BIOL, V98, P519, DOI 10.1016/S0022-2836(75)80084-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; SUNG LA, 1991, FASEB J, V5, pA1625; SUSSMAN MA, 1990, J MOL NEUROSCI, V2, P163, DOI 10.1007/BF02896841; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WINKELMANN JC, 1988, BLOOD, V72, P328; WONG AJ, 1985, J BIOL CHEM, V260, P46; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	32	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2616	2621						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370827				2022-12-27	WOS:A1992HB53200079
J	YAMAMOTO, KK; POUSETTE, A; CHOW, P; WILSON, H; ELSHAMI, S; FRENCH, CK				YAMAMOTO, KK; POUSETTE, A; CHOW, P; WILSON, H; ELSHAMI, S; FRENCH, CK			ISOLATION OF A CDNA-ENCODING A HUMAN SERUM MARKER FOR ACUTE-PANCREATITIS - IDENTIFICATION OF PANCREAS-SPECIFIC PROTEIN AS PANCREATIC PROCARBOXYPEPTIDASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE GENE FAMILY; AMINO-ACID SEQUENCE; CELLULAR-DAMAGE; RAT CARBOXYPEPTIDASE; ESCHERICHIA-COLI; ASSAY; DNA; PURIFICATION; POLYMERASE; CLONING	A human pancreas-specific protein (PASP), previously characterized as a serum marker for acute pancreatitis and pancreatic graft rejection, has been identified as pancreatic procarboxypeptidase B (PCPB). cDNAs encoding PASP/PCPB were isolated from a human pancreas cDNA library using a combination of nucleic acid hybridization screening and immunoscreening with antisera raised against native PASP. The deduced amino acid sequence of PASP/PCPB cDNA predicts the translation of a 416-amino acid preproenzyme with a 15-amino acid signal/leader peptide and a 95-amino acid activation peptide. The proenzyme portion of this protein has 76% identity with rat PCPB and 84% identity with bovine carboxypeptidase B. DNA and RNA blot analyses indicate that human PCPB mRNA (1,400 nucleotides) is transcribed from a single locus in the human genome in a tissue-specific fashion. N-terminal sequencing of native PASP and the specific immunoreactivity of bacterially expressed PASP/PCPB with native PASP antibodies confirm the identification of PASP as human pancreatic PCPB.	DIAGNOST PROD CORP,DEPT MOLEC BIOL,5700 W 96TH ST,LOS ANGELES,CA 90045; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; AVILES FX, 1985, BIOCHEM BIOPH RES CO, V130, P97, DOI 10.1016/0006-291X(85)90387-0; BARKIN JS, 1986, POSTGRAD MED, V79, P241, DOI 10.1080/00325481.1986.11699327; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DELK AS, 1985, CLIN CHEM, V31, P1294; FERNSTAD R, 1989, PANCREAS, V4, P44, DOI 10.1097/00006676-198902000-00007; FERNSTAD R, 1989, DIABETES, V38, P55, DOI 10.2337/diab.38.1.S55; FERNSTAD R, 1990, PANCREAS, V5, P42, DOI 10.1097/00006676-199001000-00006; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HONEY NK, 1986, HUM GENET, V72, P27, DOI 10.1007/BF00278813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOOSSA AR, 1984, NEW ENGL J MED, V311, P639, DOI 10.1056/NEJM198409063111005; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; POUSETTE A, 1988, PANCREAS, V3, P642, DOI 10.1097/00006676-198812000-00003; POUSETTE A, 1988, PANCREAS, V3, P421, DOI 10.1097/00006676-198808000-00009; REECK GR, 1972, BIOCHEMISTRY-US, V11, P3947, DOI 10.1021/bi00771a018; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2575	2581						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370825				2022-12-27	WOS:A1992HB53200072
J	HAEFLIGER, JA; BRUZZONE, R; JENKINS, NA; GILBERT, DJ; COPELAND, NG; PAUL, DL				HAEFLIGER, JA; BRUZZONE, R; JENKINS, NA; GILBERT, DJ; COPELAND, NG; PAUL, DL			4 NOVEL MEMBERS OF THE CONNEXIN FAMILY OF GAP JUNCTION PROTEINS - MOLECULAR-CLONING, EXPRESSION, AND CHROMOSOME MAPPING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-LINKAGE MAP; COMMUNICATION COMPARTMENTS; INTERSPECIFIC BACKCROSS; MOUSE EMBRYO; LIVER; LOCALIZATION; RAT; PERMEABILITY; CHANNELS; HEART	We have used low stringency hybridization and polymerase chain reaction (PCR) amplification with degenerate oligonucleotides to identify four new members of the rat connexin gene family. On the basis of their predicted molecular mass, these proteins have been designated connexin (Cx) 40 (Cx40), Cx37, Cx33, and Cx31.1. The new connexins exhibit all of the conserved structural features of the connexin family, including highly similar extracellular and transmembrane domains but divergent major cytoplasmic domains. On the basis of primary sequence similarity, the connexin family may be divided into two classes. Cx40, Cx37, and Cx33 are similar to the previously characterized Cx43 and Cx46. Cx31.1 is similar to Cx26, Cx31, and Cx32. Cx37 and Cx40 mRNAs are expressed in a wide variety of adult organs and tissues, with particular abundance in lung. However, their relative levels are different in many organs and thus their distribution is not completely coincident. Cx33 and Cx31.1 genes exhibit a much more restricted pattern of expression; mRNAs are detected only in testes and skin, respectively. Chromosomal mapping studies indicate that Cx26 and Cx46 are tightly linked on chromosome 14, and Cx37 and Cx31.1 are linked on chromosome 4, while the rest of the connexin genes are dispersed.	HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21072	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Bruzzone, Roberto/G-9355-2017; Bruzzone, Roberto/C-4719-2009	Bruzzone, Roberto/0000-0003-4373-1447; Bruzzone, Roberto/0000-0003-4373-1447; Haefliger, Jacques-Antoine/0000-0003-2732-1667	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM37751] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037751] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENETT MVL, 1991, NEURON, V6, P305; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1990, J BIOL CHEM, V265, P14439; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BLENNERHASSETT MG, 1984, NATURE, V309, P361, DOI 10.1038/309361a0; BUCHBERG AM, 1989, GENOMICS, V5, P363, DOI 10.1016/0888-7543(89)90071-2; BURT JM, 1988, P NATL ACAD SCI USA, V85, P3431, DOI 10.1073/pnas.85.10.3431; CECI JD, 1990, GENOMICS, V6, P673, DOI 10.1016/0888-7543(90)90503-M; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COX RD, 1991, GENOMICS, V10, P375, DOI 10.1016/0888-7543(91)90322-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Green EL, 1981, GENETICS PROBABILITY, P77; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; HISEH CL, 1991, SOMAT CELL MOLEC GEN, V17, P191; HOGAN A, 1991, IN PRESS DEVELOPMENT; HOH JH, 1991, J BIOL CHEM, V266, P6524; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JUSTICE MJ, 1990, GENETICS, V125, P855; KALIMI GH, 1988, J CELL BIOL, V107, P241, DOI 10.1083/jcb.107.1.241; KAM E, 1986, J INVEST DERMATOL, V87, P748, DOI 10.1111/1523-1747.ep12456937; KISTLER J, 1988, NATURE, V331, P721, DOI 10.1038/331721a0; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; LASH JA, 1990, J BIOL CHEM, V265, P13113; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LO CW, 1979, CELL, V18, P411, DOI 10.1016/0092-8674(79)90060-6; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MESNIL M, 1987, EXP CELL RES, V173, P524, DOI 10.1016/0014-4827(87)90292-8; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER T, 1988, BIOSCIENCE REP, V8, P445; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; OCHMAN H, 1988, GENETICS, V120, P21; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; SERRAS F, 1990, EXP CELL RES, V187, P284, DOI 10.1016/0014-4827(90)90093-P; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; WARNER A, 1988, J CELL SCI, V89, P1; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; WEIR MP, 1984, DEV BIOL, V102, P130, DOI 10.1016/0012-1606(84)90181-7; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; WILLS RBH, 1990, J SCI FOOD AGR, V53, P275, DOI 10.1002/jsfa.2740530216; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	61	325	340	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2057	2064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370487				2022-12-27	WOS:A1992HA48500098
J	NAKATA, K; MOTOMURA, M; NAKABAYASHI, H; IDO, A; TAMAOKI, T				NAKATA, K; MOTOMURA, M; NAKABAYASHI, H; IDO, A; TAMAOKI, T			A POSSIBLE MECHANISM OF INVERSE DEVELOPMENTAL REGULATION OF ALPHA-FETOPROTEIN AND ALBUMIN GENES - STUDIES WITH EPIDERMAL GROWTH-FACTOR AND PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; EXPRESSION; EXTRACT; RNA	Epidermal growth factor (EGF) and 12-O-tetradecanoylphorbol-13-acetate (TPA) synergistically suppress activities of the promoter and enhancer of the human alpha-fetoprotein (AFP) gene in HuH-7 human hepatoma cells as analyzed by transient transfection assays using the chloramphenicol acetyltransferase gene as a reporter. In contrast to the AFP gene, albumin promoter and enhancer activities were not affected by EGF and TPA. Unexpectedly, however, Northern blot analysis revealed that the albumin mRNA level as well as the AFP mRNA level were reduced by treatment with EGF and TPA. We propose that in HuH-7 cells, the AFP enhancer stimulates the albumin promoter as well as the AFP promoter; and consequently, inhibition of the AFP enhancer by EGF and TPA results in reduction of both AFP and albumin mRNA levels. The significance of the involvement of the AFP enhancer in albumin transcription is discussed in relation to the inverse pattern of expression of the AFP and albumin genes in neonatal growth.	UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary								BELANGER L, 1983, ADV ENZYME REGUL, V21, P73, DOI 10.1016/0065-2571(83)90009-2; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; MOOIBROEK MJ, 1988, BIOCHEM CELL BIOL, V66, P557, DOI 10.1139/o88-066; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKABAYASHI H, 1989, J BIOL CHEM, V264, P266; NAKABAYASHI H, 1991, IN PRESS MOL CELL BI; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAO K, 1990, MOL CELL BIOL, V10, P1461, DOI 10.1128/MCB.10.4.1461; NAKAO K, 1991, BIOCHEM BIOPH RES CO, V174, P1294, DOI 10.1016/0006-291X(91)91562-Q; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; URANO Y, 1984, GENE, V32, P255; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WATANABE K, 1987, J BIOL CHEM, V262, P4812	24	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1331	1334						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370467				2022-12-27	WOS:A1992GY96000101
J	HINCHMAN, SK; HENIKOFF, S; SCHUSTER, SM				HINCHMAN, SK; HENIKOFF, S; SCHUSTER, SM			A RELATIONSHIP BETWEEN ASPARAGINE SYNTHETASE-A AND ASPARTYL TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; EXPRESSION; MOTIFS; GENES	A highly conserved protein motif characteristic of Class II aminoacyl tRNA synthetases was found to align with a region of Escherichia coli asparagine synthetase A. The alignment was most striking for aspartyl tRNA synthetase, an enzyme with catalytic similarities to asparagine synthetase. To test whether this sequence reflects a conserved function, site-directed mutagenesis was used to replace the codon for Arg298 of asparagine synthetase A, which aligns with an invariant arginine in the Class II aminoacyl tRNA synthetases. The resulting genes were expressed in E. coli, and the gene products were assayed for asparagine synthetase activity in vitro. Every substitution of Arg298, even to a lysine, resulted in a loss of asparagine synthetase activity. Directed random mutagenesis was then used to create a variety of codon changes which resulted in amino acid substitutions within the conserved motif surrounding Arg298. Of the 15 mutant enzymes with amino acid substitutions yielding soluble enzyme, t3 with changes within the conserved region were found to have lost activity. These results are consistent with the possibility that asparagine synthetase A, one of the two unrelated asparagine synthetases in E. coli, evolved from an ancestral aminoacyl tRNA synthetase.	UNIV FLORIDA, J HILLIS MILLER HLTH CTR,COLL MED, DEPT BIOCHEM & MOLEC BIOL,BOX J 245, GAINESVILLE, FL 32610 USA; FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, SEATTLE, WA 98104 USA	State University System of Florida; University of Florida; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute				Henikoff, Steven/0000-0002-7621-8685	NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029009] Funding Source: NIH RePORTER; NCI NIH HHS [CA28725] Funding Source: Medline; NIGMS NIH HHS [GM29009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BAIROCH A, 1990, PROSITE DICT PROTEIN; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HUMBERT R, 1980, J BACTERIOL, V142, P212, DOI 10.1128/JB.142.1.212-220.1980; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; NAKAMURA M, 1981, NUCLEIC ACIDS RES, V9, P4669, DOI 10.1093/nar/9.18.4669; RAVEL JM, 1970, METHODS ENZYMOL    A, V17, P722; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; RUOLD MA, 1989, SCIENCE, V246, P1135; SARTAR G, 1990, BIOTECHNIQUES, V8, P404; SCOFIELD MA, 1990, J BIOL CHEM, V265, P12895; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANHEEKE G, 1989, J BIOL CHEM, V264, P5503; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; ZALKIN H, 1977, J BIOL CHEM, V252, P5341; ZEWLER C, 1982, J MOL BIOL, V155, P63	28	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					144	149						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1346128				2022-12-27	WOS:A1992GY43900028
J	KATO, J; SUZUKI, H; IKEDA, H				KATO, J; SUZUKI, H; IKEDA, H			PURIFICATION AND CHARACTERIZATION OF DNA TOPOISOMERASE-IV IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAGENIC PALINDROMIC SEQUENCES; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; ATTACHMENT SITES; REVERSE GYRASE; S-CEREVISIAE; GYRB GENE; RECOMBINATION; YEAST; REPLICATION	The subunits of topoisomerase IV (topo IV), the ParC and ParE proteins in Escherichia coli, were purified to near homogeneity from the respective overproducers. They revealed type II topoisomerase activity only when they were combined with each other. In the presence of Mg2+ and ATP, topo IV was capable of relaxing a negatively or positively supercoiled plasmid DNA or converting the knotted P4 phage DNA, whether nicked or ligated, to a simple ring. However, supercoiling activity was not detected. The topoisomerase activity was not detectable when the purified ParC and ParE proteins were combined with the purified GyrB and GyrA proteins, respectively. This is consistent with the result that neither a parC nor a parE mutation was compensated by transformation with a plasmid carrying either the gyrA or the gyrB gene. Simultaneous introduction of both the gyrA and gyrB plasmids corrected the phenotypic defect of parC and parE mutants. The results suggest that DNA gyrase can substitute for topo IV at least in some part of the function for chromosome partitioning. Antisera were prepared against the purified ParC, ParE, GyrA, and GyrB proteins and used to investigate cellular localization of these gene products. ParC protein was found to be specifically associated with inner membranes only in the presence of DNA. This result suggests that one of the functions of topo IV might be to anchor chromosomes on membranes as previously proposed for eukaryotic topoisomerase II.	KANAGAWA UNIV, DEPT APPL BIOL, HIRATSUKA, KANAGAWA 25912, JAPAN	Kanagawa University	KATO, J (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOLEC BIOL, PO TAKANAWA, TOKYO 108, JAPAN.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AGUILERA A, 1990, MOL CELL BIOL, V10, P1439, DOI 10.1128/MCB.10.4.1439; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; FUTAI M, 1973, BIOCHEMISTRY-US, V12, P2468, DOI 10.1021/bi00737a016; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GILSON E, 1990, NUCLEIC ACIDS RES, V18, P3941, DOI 10.1093/nar/18.13.3941; GUSTAFSSON P, 1983, EMBO J, V2, P27, DOI 10.1002/j.1460-2075.1983.tb01375.x; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; HIROTA Y, 1971, BIOMEMBRANE, V2, P13; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; MILLER CA, 1990, CELL, V62, P127, DOI 10.1016/0092-8674(90)90246-B; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; NORRIS V, 1986, J BACTERIOL, V168, P494, DOI 10.1128/jb.168.2.494-504.1986; SAKAKIBARA Y, 1976, J MOL BIOL, V108, P569, DOI 10.1016/S0022-2836(76)80137-4; Sambrook J, 1989, MOL CLONING LABORATO; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAHLE E, 1988, EMBO J, V7, P1889, DOI 10.1002/j.1460-2075.1988.tb03022.x; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YANG Y, 1988, P NATL ACAD SCI USA, V85, P8850, DOI 10.1073/pnas.85.23.8850; YASUDA S, 1983, J BACTERIOL, V154, P1153, DOI 10.1128/JB.154.3.1153-1161.1983	45	165	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25676	25684						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334483				2022-12-27	WOS:A1992KD07300015
J	CALLAHAN, HL; BEVERLEY, SM				CALLAHAN, HL; BEVERLEY, SM			A MEMBER OF THE ALDOKETO REDUCTASE FAMILY CONFERS METHOTREXATE RESISTANCE IN LEISHMANIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIHYDROFOLATE-REDUCTASE; ALCOHOL-DEHYDROGENASE; PROSTAGLANDIN ACTION; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; TETRAHYDROBIOPTERIN BIOSYNTHESIS; EXTRACHROMOSOMAL CIRCLES; THYMIDYLATE SYNTHASE; DNA AMPLIFICATION	Methotrexate (MTX)-resistant mutants of the parasitic protozoan Leishmania have been used as models for the mechanism and genetic basis of drug resistance in trypanosomatids and other cells. Three resistance mechanisms to MTX, a dihydrofolate reductase inhibitor, have been described in Leishmania: decreased uptake and accumulation of MTX via the folate/MTX transporter, amplification and overexpression of the dihydrofolate reductase-thymidylate synthase gene, and extrachromosomal amplification of H region DNA. We have now identified hmtx(r) as the H region gene conferring MTX resistance using a transfection-based approach. Data base searches show that the predicted HMTX(r) protein is related to members of the polyol dehydrogenase/carbonyl reductase family of aldoketo reductases, whose substrates include polyols, quinones, steroids, prostaglandins, fatty acids, and pterins. We therefore propose that HMTX(r) is also an oxidoreductase and suggest several biochemical mechanisms of resistance in Leishmania that could be exploited in the design of parasite-specific inhibitors.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	CALLAHAN, HL (corresponding author), WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV EXPTL THERAPEUT,WASHINGTON,DC 20307, USA.			Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI 21903] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021903, R01AI021903] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER ME, 1991, PROSTAGLANDINS, V42, P391, DOI 10.1016/0090-6980(91)90031-A; BAKER ME, 1991, MOL CELL ENDOCRINOL, V78, pC99, DOI 10.1016/0303-7207(91)90178-U; BAKER ME, 1990, FASEB J, V4, P222, DOI 10.1096/fasebj.4.2.2153594; BAKER ME, 1991, STEROIDS, V56, P354, DOI 10.1016/0039-128X(91)90067-6; BAKER ME, 1989, MOL ENDOCRINOL, V3, P88; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15960; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; HALLAM S, 1989, GENE, V74, P305; ICHINOSE H, 1991, BIOCHEM BIOPH RES CO, V179, P183, DOI 10.1016/0006-291X(91)91352-D; JORNVALL H, 1984, FEBS LETT, V165, P190, DOI 10.1016/0014-5793(84)80167-2; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPLER GM, 1987, NUCLEIC ACIDS RES, V15, P3369, DOI 10.1093/nar/15.8.3369; KATAKURA K, 1989, MOL BIOCHEM PARASIT, V34, P189, DOI 10.1016/0166-6851(89)90010-8; KAUR K, 1988, J BIOL CHEM, V263, P7020; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LOVINY T, 1985, BIOCHEM J, V230, P579, DOI 10.1042/bj2300579; MAREKOV L, 1990, FEBS LETT, V266, P51, DOI 10.1016/0014-5793(90)81504-H; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; NEILMANN HJ, 1988, EUR J BIOCHEM, V174, P454; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PARK YS, 1991, BIOCHEM BIOPH RES CO, V175, P738, DOI 10.1016/0006-291X(91)91628-P; PEOPLES OP, 1989, MOL MICROBIOL, V3, P349, DOI 10.1111/j.1365-2958.1989.tb00180.x; PETRILLOPEIXOTO ML, 1988, MOL CELL BIOL, V8, P5188, DOI 10.1128/MCB.8.12.5188; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; THONY B, 1987, NUCLEIC ACIDS RES, V15, P8479, DOI 10.1093/nar/15.20.8479; WERMUTH B, 1988, J BIOL CHEM, V263, P16185; WHITE TC, 1988, J BIOL CHEM, V263, P16977; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; YAMAMOTOOTAKE H, 1991, APPL ENVIRON MICROB, V57, P1418, DOI 10.1128/AEM.57.5.1418-1422.1991	41	93	96	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24165	24168						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1339441				2022-12-27	WOS:A1992KA26300005
J	ABRAHAMSEN, MS; LI, RS; DIETRICHGOETZ, W; MORRIS, DR				ABRAHAMSEN, MS; LI, RS; DIETRICHGOETZ, W; MORRIS, DR			MULTIPLE DNA ELEMENTS RESPONSIBLE FOR TRANSCRIPTIONAL REGULATION OF THE ORNITHINE DECARBOXYLASE GENE BY PROTEIN KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED LYMPHOCYTES; CYCLIC-AMP; MESSENGER-RNA; PHORBOL ESTER; FACTOR ATF; 5'-UNTRANSLATED REGION; PREINITIATION COMPLEX; SOMATOSTATIN GENE; CATALYTIC SUBUNIT; EUKARYOTIC CELLS	Transcription of the ornithine decarboxylase (ODC) gene is rapidly elevated by activation of protein kinase A (PKA). The additive influence of three cis-acting elements is responsible for this regulation in an adrenal carcinoma cell line. Two sites, CRE2 at -48 base pairs (bp) relative to the start of transcription and CRE3 at +95 bp, are identical to the core motif of the cAMP-responsive element (CRE) of the somatostatin gene and are conserved in the mouse, rat, and human ODC genes. Mutation of CRE2 resulted in a substantial decrease in basal promoter activity, as well as a 5-fold decrease in inducibility of the ODC promoter by PKA. CRE3 did not contribute to the basal activity of the ODC promoter, but mutation of this site resulted in a 2-fold decrease in inducibility by PKA. Deletion of a 45-bp sequence (GC-box) located 5' of CRE2, also resulted in a 2-fold decrease in inducibility of the ODC promoter. DNase I protection revealed the presence of protein binding at CRE2, the TATA box, and the GC-box of the ODC promoter. Mutation of CRE2 resulted in loss of protection of this sequence, as well as the 3' extension of the footprint over the TATA box, without affecting interactions at the GC box. Antibodies to the well characterized CRE-binding protein CREB recognized proteins binding to CRE2, suggesting that binding of CREB, or an antigenically related protein, is important for the activity of CRE2. Additionally, recombinant CREB bound to a DNA probe containing the CRE2 sequence.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Morris, David/G-4503-2011; Li, Runsheng/AFR-9519-2022	Li, Runsheng/0000-0003-1563-1844	NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NIDCR NIH HHS [DE08229] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; DAY RN, 1989, J BIOL CHEM, V264, P431; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRENS A, 1990, J BIOL CHEM, V265, P11810; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO K, 1990, J BIOL CHEM, V265, P13036; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MACH M, 1986, J BIOL CHEM, V261, P1697; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MARTON LJ, 1987, INHIBITION POLYAMINE, P70; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; OBRIEN TG, 1976, CANCER RES, V36, P2644; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHIMMER BP, 1977, MOL CELL ENDOCRINOL, V8, P135, DOI 10.1016/0303-7207(77)90025-9; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; UHLER MD, 1986, J BIOL CHEM, V261, P5360; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x; WHITE MW, 1987, MOL CELL BIOL, V7, P3004, DOI 10.1128/MCB.7.8.3004; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	71	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18866	18873						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1356108				2022-12-27	WOS:A1992JN50200093
J	YONEDA, K; HOHL, D; MCBRIDE, OW; WANG, M; CEHRS, KU; IDLER, WW; STEINERT, PM				YONEDA, K; HOHL, D; MCBRIDE, OW; WANG, M; CEHRS, KU; IDLER, WW; STEINERT, PM			THE HUMAN LORICRIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; EPIDERMAL ALPHA-KERATIN; CROSS-LINKED ENVELOPE; HUMAN INVOLUCRIN GENE; CORNIFIED ENVELOPE; CELL-ENVELOPE; THERMUS-AQUATICUS; DNA-POLYMERASE; FILAGGRIN; PROTEIN	Loricrin is the major protein component of the cornified cell envelope of terminally differentiated mammalian epidermal (stratum corneum) cells. Using a specific human cDNA clone, we have isolated and characterized the human loricrin gene. We show that it has a very simple structure of a single intron of 1188 base pairs (bp) in the 5'-untranslated region; there are no introns in coding sequences. By use of rodent-human somatic cell hybrids, followed by in situ hybridization with a biotin-labeled genomic DNA clone, the single-copy gene maps to chromosome location 1q21. Polymerase chain reaction analyses of genomic DNAs from different individuals show that human loricrin consists of two allelic size variants, due to sequence variations in its second glycine loop domain, and these variants segregate in the human population by normal Mendelian mechanisms. Furthermore, there are multiple sequence variants within these two size class alleles due to various deletions of 12 bp (4 amino acids) in the major loop of this glycine loop domain. By use of a specific loricrin antibody, we show by immunogold electron microscopy that loricrin initially appears in the granular layer of human epidermis and forms composite keratohyalin granules with profilaggrin, but localizes to the cell periphery (cell envelope) of fully differentiated stratum corneum cells.	NIAMS,SKIN BIOL LAB,BLDG 10,RM 9N228,BETHESDA,MD 20892; NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Hohl, Daniel M/N-7554-2016					ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; BADEN HP, 1987, J INVEST DERMATOL, V89, P454, DOI 10.1111/1523-1747.ep12460759; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HANIGAN H, 1978, BIOCHIM BIOPHYS ACTA, V522, P589, DOI 10.1016/0005-2744(78)90090-6; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JESSEN H, 1986, J INVEST DERMATOL, V87, P737, DOI 10.1111/1523-1747.ep12456866; KIM IG, 1992, J BIOL CHEM, V267, P7710; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P510; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LOBITZ CJ, 1982, J INVEST DERMATOL, V78, P150, DOI 10.1111/1523-1747.ep12506301; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; Odland G.F, 1991, PHYSL BIOCH MOL BIOL, P3; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; SHVETS YP, 1990, MOL BIOL, V24, P663; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; STEDINERT PM, 1991, INT J BIOL MACROMOL, V13, P130; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; TEZUKA T, 1987, J INVEST DERMATOL, V88, P47, DOI 10.1111/1523-1747.ep12464862; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; YONEDA K, 1991, J INVEST DERMATOL, V96, pA541; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	42	95	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18060	18066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1355480				2022-12-27	WOS:A1992JM22300089
J	LI, Y; JAISWAL, AK				LI, Y; JAISWAL, AK			REGULATION OF HUMAN NAD(P)H-QUINONE OXIDOREDUCTASE GENE - ROLE OF AP1 BINDING-SITE CONTAINED WITHIN HUMAN ANTIOXIDANT RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; PLANAR AROMATIC-COMPOUNDS; QUINONE REDUCTASE; TRANSCRIPTIONAL REGULATION; DT-DIAPHORASE; NAD(P)H-MENADIONE OXIDOREDUCTASE; PHENOLIC ANTIOXIDANTS; MESSENGER-RNA; NQO1 GENE	Deletion mutagenesis and transfection studies into hepatic (mouse hepatoma (Hepa- 1) and human hepatoblastoma (Hep-G2)) and nonhepatic (HeLa) cells indicated that high levels of expression of the human NAD(P)H:quinone oxidoreductase gene in tumor cells and its induction by beta-naphthoflavone and 3-(2)-tert-butyl-4-hydroxyanisole are mediated by human antioxidant response element (hARE) located in the region between -470 and -445. The hARE, when attached to the thymidine kinase promoter and transfected into several mammalian cells, expressed high levels of the chloramphenicol acetyltransferase gene that was inducible by beta-naphthonavone and 3-(2)-tert-butyl-4-hydroxyanisole. Nucleotide sequence analysis of the hARE revealed the presence of a recognition site for binding to the AP1 protein. Mutation of the AP1 binding site located within the hARE resulted in the loss of expression and induction upon transfection into various cell types. Band shift and competition assays with hARE and nuclear extracts from control and beta-naphthoflavone-treated Hepa-1, Hep-G2 and HeLa cells indicated specific interaction of regulatory protein(s) to the hARE. The supershift assays using antibodies against specific proteins of the AP1 family identified Jun-D and c-Fos as two members in the hARE-protein complex observed in band shift assays.	FOX CHASE CANC INST,DEPT PHARMACOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1988, MOL REPROD DEV; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IYANAGI T, 1987, CHEM SCRIPTA, V27A, P31; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN LF, 1987, CANCER LETT, V36, P341, DOI 10.1016/0304-3835(87)90028-0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PROCHASKA HJ, 1987, J BIOL CHEM, V262, P1931; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAL GD, 1989, BIOTECHNIQUES, V7, P514; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TALALAY P, 1982, ADV ENZYME REGUL, V20, P287, DOI 10.1016/0065-2571(82)90021-8; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; WILLIAMS JB, 1984, ARCH BIOCHEM BIOPHYS, V232, P408, DOI 10.1016/0003-9861(84)90556-3	40	332	337	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15097	15104						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1340765				2022-12-27	WOS:A1992JF08800087
J	MENDEZ, R; MORENO, A; DEHARO, C				MENDEZ, R; MORENO, A; DEHARO, C			REGULATION OF HEME-CONTROLLED EUKARYOTIC POLYPEPTIDE-CHAIN INITIATION FACTOR-II ALPHA-SUBUNIT KINASE OF RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STABILIZED TRANSLATIONAL INHIBITOR; EIF-2-ALPHA KINASE; GLOBIN SYNTHESIS; PEPTIDE; GLUTATHIONE; ACTIVATION; DISULFIDE; COMPONENT; SPECTRIN	We have obtained highly purified preparations of the heme-controlled eukaryotic initiation factor 2-alpha-subunit (eIF-2-alpha) kinase (HCI) from rabbit reticulocyte lysates containing five different polypeptides. One of these is a 87-kDa (p87) phosphopeptide which appears to show an autokinase activity. The controlled digestion with trypsin of HCI preparations leads to the suggestion that phosphorylation of p87 is not needed for kinase activity and, furthermore, that another 89-kDa polypeptide could be the kinase catalytic subunit. In agreement with this, monoclonal antibodies directed against p87 do not interfere with eIF-2-alpha kinase activity. Moreover, the anti-p87 antibodies and those directed against the mammalian 90-kDa heat shock protein recognize the same p87 polypeptide from rabbit reticulocyte lysates. Upon incubation of the HCI preparation with hemin (5-10-mu-M), the eIF-2-alpha kinase is converted into an inactive form and appears to become associated with related peptides forming high molecular weight complexes which can be reversibly activated by 2-mercaptoethanol. The maintenance of the integrity of the porphyrin ring is absolutely required for kinase inactivation and although the presence of metal ion is not essential, the iron and cobalt metalloporphyrins are more effective than protoporphyrin IX. The formation of the inactive form of HCI by hemin is prevented by either N-ethylmaleimide, monoclonal antibodies directed against p87, or phosphorylation of p87. The data strongly suggest that hemin regulates eIF-2-alpha kinase activity by promoting formation of the inactive dimer HCI.p87 via disulfide bonds and direct binding of hemin. A model of HCI regulation is discussed.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)				Mendez, Raul/0000-0002-1952-6905				ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DAWSON RMC, 1969, DATA BIOCH RES, P293; DEHARO C, 1983, P NATL ACAD SCI-BIOL, V80, P6843; GAITERO F, 1989, FEBS LETT, V257, P297, DOI 10.1016/0014-5793(89)81556-X; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P642, DOI 10.1016/0005-2787(78)90149-1; HRONIS TS, 1986, J BIOL CHEM, V261, P6234; HRONIS TS, 1981, J BIOL CHEM, V256, P1409; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; JACKSON RJ, 1982, NATO ADV STUDY I S A, V41, P363; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; KUDLICKI W, 1985, P NATL ACAD SCI USA, V82, P5332, DOI 10.1073/pnas.82.16.5332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTS RL, 1989, J BIOL CHEM, V264, P15542; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PALOMO C, 1985, ARCH BIOCHEM BIOPHYS, V239, P497, DOI 10.1016/0003-9861(85)90718-0; PELAEZ F, 1989, FEBS LETT, V250, P523, DOI 10.1016/0014-5793(89)80789-6; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SANZ A, 1985, J VIROL, V54, P199, DOI 10.1128/JVI.54.1.199-206.1985; SCHENDEL PF, 1973, J BIOL CHEM, V248, P8319; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654	33	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11500	11507						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350784				2022-12-27	WOS:A1992HX16900086
J	SLAPAK, CA; LECERF, JM; DANIEL, JC; LEVY, SB				SLAPAK, CA; LECERF, JM; DANIEL, JC; LEVY, SB			ENERGY-DEPENDENT ACCUMULATION OF DAUNORUBICIN INTO SUBCELLULAR COMPARTMENTS OF HUMAN LEUKEMIA-CELLS AND CYTOPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ASCITES TUMOR-CELLS; MURINE ERYTHROLEUKEMIA-CELLS; ANTHRACYCLINE-RESISTANT; DOXORUBICIN TRANSPORT; DRUG-RESISTANCE; FLOW-CYTOMETRY; LIVING CELLS; PROTON PUMP; ADRIAMYCIN	Anthracycline accumulation was evaluated by flow cytometry or radiolabeled drug assays in cells and cytoplasts (enucleated cells) prepared from parental and multidrug-resistant human K562 leukemia cells. Treatment with energy inhibitors, such as dinitrophenol (DNP) or sodium azide/deoxyglucose, led to a marked decrease in daunorubicin accumulation in parental cells and cytoplasts. Another ionophore, monensin, also caused a significant decrease in daunorubicin accumulation; however, ATPase inhibitors ouabain, vanadate, and N-ethylmaleimide had little or no effect. The lysosomotropic agents chloroquine and methylamine caused a moderate decrease in anthracycline accumulation. Fluorescence microscopy showed that the DNP-sensitive daunorubicin uptake occurred in a nonnuclear subcellular compartment. Studies using increasing daunorubicin concentrations demonstrated fluorescence quenching that occurred in the nonnuclear, DNP-sensitive compartment. The effect of inhibitors on the accumulation of rhodamine 123 and acridine orange strongly implicated lysosomes as the principal compartment of this inhibitable daunorubicin accumulation. Cytoplasts from P-glycoprotein containing multidrug-resistant K562 cells demonstrated a verapamil-reversible, decreased daunorubicin accumulation that was observed in resistant whole cells. Verapamil pretreatment of cytoplasts from resistant cells revealed the subcellular DNP-sensitive uptake present in parental cytoplasts. These studies demonstrate that cytoplasts are an effective means to study drug transport in mammalian cells without nuclear drug binding. Parental K562 cells and cytoplasts exhibit an energy-dependent accumulation of daunorubicin into cytoplasmic organelles that is also present in resistant cells and cytoplasts when P-glycoprotein mediated efflux is inhibited.	TUFTS UNIV,SCH MED,136 HARRISON AVE,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02111	Tufts University; Tufts Medical Center					NCI NIH HHS [F32-CA08774, CA-01613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA S, 1984, J CELL PHYSIOL, V120, P271, DOI 10.1002/jcp.1041200303; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHERVINSKY DS, 1976, J MED, V7, P63; DALMARK M, 1981, SCAND J CLIN LAB INV, V41, P633, DOI 10.3109/00365518109090508; DALMARK M, 1981, J GEN PHYSIOL, V78, P349, DOI 10.1085/jgp.78.4.349; DALMARK M, 1983, SCAND J CLIN LAB INV, V43, P241; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; Darzynkiewicz Z., 1990, FLOW CYTOMETRY SORTI, V2nd, P291; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; DECORTI G, 1989, CANCER RES, V49, P1921; EKSBORG S, 1978, J PHARM SCI, V67, P782, DOI 10.1002/jps.2600670613; FORGAC M, 1984, J BIOL CHEM, V259, P8101; GIGLI M, 1989, CANCER RES, V49, P560; GOSALVEZ M, 1974, EUR J CANCER, V10, P567, DOI 10.1016/0014-2964(74)90044-9; HARIO M, 1988, P NATL ACAD SCI USA, V85, P3580; HEYTLER PG, 1962, BIOCHEM BIOPH RES CO, V7, P272, DOI 10.1016/0006-291X(62)90189-4; HILL BT, 1976, EUR J CANCER, V12, P541, DOI 10.1016/0014-2964(76)90160-2; HINDENBURG AA, 1989, CANCER RES, V49, P4607; INABA M, 1979, CANCER RES, V39, P2200; INABA M, 1978, BIOCHEM PHARMACOL, V27, P2123, DOI 10.1016/0006-2952(78)90284-8; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KLOHS WB, 1989, MOL PHARMACOL, V34, P180; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MIKKELSEN RB, 1977, J MOL MED, V2, P33; MORIYAMA Y, 1982, J BIOCHEM-TOKYO, V92, P1333, DOI 10.1093/oxfordjournals.jbchem.a134053; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; POOLE DT, 1972, BIOCHIM BIOPHYS ACTA, V266, P463, DOI 10.1016/0005-2736(72)90102-2; Reed P W, 1979, Methods Enzymol, V55, P435; SEHESTED M, 1987, JNCI-J NATL CANCER I, V78, P171, DOI 10.1093/jnci/78.1.171; SIEGFRIED JM, 1985, BIOCHEM PHARMACOL, V34, P593, DOI 10.1016/0006-2952(85)90251-5; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SKOVSGAARD T, 1978, BIOCHEM PHARMACOL, V27, P1221, DOI 10.1016/0006-2952(78)90455-0; SLAPAK CA, 1990, CANCER RES, V50, P7895; SPETH PAJ, 1985, CYTOMETRY, V6, P143, DOI 10.1002/cyto.990060210; STEINBERG TH, 1984, J INFECT DIS, V149, P397, DOI 10.1093/infdis/149.3.397; SUNDMANENGBERG B, 1990, CANCER CHEMOTH PHARM, V25, P252, DOI 10.1007/BF00684881; TAPIERO H, 1982, CYTOMETRY, V2, P298; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VOLLOCH V, 1987, J CELL BIOL, V105, P137, DOI 10.1083/jcb.105.1.137; WIGLER MH, 1975, BIOCHEM BIOPH RES CO, V63, P669, DOI 10.1016/S0006-291X(75)80436-0; WISEMAN A, 1985, SOMAT CELL MOLEC GEN, V11, P541, DOI 10.1007/BF01534720; WONG W, 1985, BLOOD, V66, P999; YANOVICH S, 1983, CANCER RES, V43, P4167; YANOVICH S, 1989, CANCER RES, V49, P4499; YATSCOFF RW, 1981, SOMAT CELL GENET, V7, P1, DOI 10.1007/BF01544744	48	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10638	10644						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1350280				2022-12-27	WOS:A1992HV09000065
J	DARMOUL, D; LACASA, M; BARICAULT, L; MARGUET, D; SAPIN, C; TROTOT, P; BARBAT, A; TRUGNAN, G				DARMOUL, D; LACASA, M; BARICAULT, L; MARGUET, D; SAPIN, C; TROTOT, P; BARBAT, A; TRUGNAN, G			DIPEPTIDYL PEPTIDASE-IV (CD-26) GENE-EXPRESSION IN ENTEROCYTE-LIKE COLON CANCER CELL-LINES HT-29 AND CACO-2 - CLONING OF THE COMPLETE HUMAN CODING SEQUENCE AND CHANGES OF DIPEPTIDYL PEPTIDASE-IV MESSENGER-RNA LEVELS DURING CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; ASPARAGINE-LINKED OLIGOSACCHARIDES; INTESTINAL EPITHELIAL-CELLS; SUCRASE-ISOMALTASE; AMINOPEPTIDASE-IV; POSTNATAL-DEVELOPMENT; MICROVILLAR MEMBRANE; CARCINOMA-CELLS; TRANSGENIC MICE; RAT	A cDNA (DPCR1) specific for human intestinal dipeptidyl peptidase IV (DPP IV) has been isolated. This 1.7-kilobase cDNA, together with a previously published partial sequence, covers the entire open reading frame of human DPP IV plus 67 base pairs of the 3'-untranslated end. Human DPP IV is a 766-amino acid polypeptide with a high degree of homology with the rat liver protein. The characterization of this molecular probe allowed us to definitively confirm the identity of DPP IV with CD 26, a mouse thymocyte activation antigen, a conclusion strengthened by the fact that we observed identical patterns on Southern blot of human genomic DNA hybridized either with human DPP IV or mouse CD 26 cDNA probe. Using this new tool, we have investigated the expression of DPP IV during the onset of enterocytic differentiation of two cultured human colon cancer cell lines, HT-29 and Caco-2. Whatever the cell line and the culture conditions, DPP IV expression strictly correlates with the presence of a differentiated phenotype, as shown by enzyme activity and the steady state amount of the protein measured by indirect immunofluorescence and Western blot. Accordingly, DPP IV biosynthesis exclusively increases in cells that display an enterocytic differentiation. Neither the glycosylation nor the stability of the protein appear to be dependent on the state of enterocytic differentiation. The DPP IV mRNA level remains very low in undifferentiated cell populations and specifically increases in cells that undergo an enterocytic differentiation. These results strongly suggest that DPP IV gene expression is controlled at the transcriptional or posttranscriptional level during intestinal differentiation.	INSERM,U178,UNITE RECH DIFFERENCIAT CELLULAIRE INTESTINALE,16 AVE PAUL VAILLANT COUTURIEN,F-94807 VILLEJUIF,FRANCE; INST RECH SCI CANC,CNRS,UPR 72,F-94801 VILLEJUIF,FRANCE; CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Baricault, Laurent/G-3396-2017; Darmoul, Dalila/M-5812-2018; Marguet, Didier/B-9946-2008; Marguet, Didier/AGO-5421-2022	Darmoul, Dalila/0000-0002-1206-0655; Marguet, Didier/0000-0003-3198-5095; Krejbich Trotot, Pascale/0000-0001-7329-1716				BARTON RW, 1990, J LEUKOCYTE BIOL, V48, P291, DOI 10.1002/jlb.48.4.291; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BOOTH AG, 1979, BIOCHEM J, V179, P397, DOI 10.1042/bj1790397; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG YS, 1985, CANCER RES, V45, P2976; CLEVELAND D W, 1989, New Biologist, V1, P121; DANIELSEN EM, 1989, J BIOL CHEM, V264, P13726; DANIELSEN EM, 1982, BIOCHEM J, V202, P647, DOI 10.1042/bj2020647; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1991, EXPERIENTIA, V47, P1211, DOI 10.1007/BF01918387; DARMOUL D, 1991, AM J PHYSIOL, V24, pG6763; DAVID R, 1979, BIOCHEM J, V179, P379; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; FELLER AC, 1982, BRIT J HAEMATOL, V51, P227, DOI 10.1111/j.1365-2141.1982.tb02775.x; FOLTZERJOURDAINNE C, 1989, AM J PHYSIOL, V257, pG496, DOI 10.1152/ajpgi.1989.257.4.G496; FREUND JN, 1991, GASTROENTEROLOGY, V100, P388, DOI 10.1016/0016-5085(91)90207-2; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FREUND JN, 1990, CELL MOL BIOL, V36, P729; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FUKASAWA KM, 1978, BIOCHIM BIOPHYS ACTA, V535, P161, DOI 10.1016/0005-2795(78)90042-9; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; GRUBER M, 1988, CELL IMMUNOL, V113, P423, DOI 10.1016/0008-8749(88)90039-1; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HANSKI C, 1985, BIOL CHEM H-S, V366, P1169, DOI 10.1515/bchm3.1985.366.2.1169; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEGEN M, 1990, J IMMUNOL, V144, P2908; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; JACK HM, 1988, EMBO J, V7, P1041, DOI 10.1002/j.1460-2075.1988.tb02911.x; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LINDBERG T, 1966, CLIN SCI, V30, P505; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS PS, 1982, MOL CLONING LABORATO, P205; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; MESSER M, 1966, ANAL BIOCHEM, V14, P372; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; NEUTRA MR, 1980, IN VITRO EPITHELIA B, P261; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OGATA S, 1989, J BIOL CHEM, V264, P3596; OGIERDENIS E, 1989, J CELL BIOCHEM, V41, P13, DOI 10.1002/jcb.240410103; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; PINTO M, 1982, BIOL CELL, V44, P193; PINTO M, 1983, BIOL CELL, V47, P322; RAUL F, 1977, CELL TISSUE RES, V176, P167; ROUSSET M, 1989, J CELL PHYSIOL, V141, P627, DOI 10.1002/jcp.1041410322; SAHARA N, 1981, HISTOCHEMISTRY, V72, P229, DOI 10.1007/BF00517136; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SHAPIRO VA, 1986, J GEODYN, V5, P221, DOI 10.1016/0264-3707(86)90007-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAUC M, 1989, HISTOCHEMISTRY, V91, P17, DOI 10.1007/BF00501905; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P1476; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; TRUGNAN G, 1991, J BIOL CHEM, V266, P20849; WICE BM, 1985, J BIOL CHEM, V260, P139; YOSHIMOTO T, 1978, J BIOL CHEM, V253, P3708; YOSHIMOTO T, 1982, J BIOCHEM, V92, P275, DOI 10.1093/oxfordjournals.jbchem.a133924; YOSHIOKA M, 1991, INT J CANCER, V47, P916, DOI 10.1002/ijc.2910470622; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105; ZWEIBAUM A, 1984, INT J CANCER, V34, P591, DOI 10.1002/ijc.2910340502; ZWEIBAUM A, 1991, GASTROINTESTINAL SYS, V4, P223; ZWEIBAUM A, 1988, MAMMALIAN BRUSH BORD, P63	78	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4824	4833						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347043				2022-12-27	WOS:A1992HF64200081
J	BEBENEK, K; ROBERTS, JD; KUNKEL, TA				BEBENEK, K; ROBERTS, JD; KUNKEL, TA			THE EFFECTS OF DNTP POOL IMBALANCES ON FRAMESHIFT FIDELITY DURING DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; TRIPHOSPHATE POOLS; MAMMALIAN-CELLS; POLYMERASE-I; MUTAGENESIS; MUTATION; BACTERIOPHAGE-T4; MISALIGNMENT; SPECIFICITY; COMPLEX	The use of unequal concentrations of the four deoxynucleoside triphosphates (dNTPs) in DNA polymerization reactions alters base substitution error rates in a predictable way. Less is known about the effects of substrate imbalances on base addition and deletion error rates. Thus, we examined pool bias effects on frameshift fidelity during DNA synthesis catalyzed by replicative DNA polymerases. Imbalanced pools altered the frameshift fidelity of the human immunodeficiency virus type-1 reverse transcriptase. Both mutagenic and antimutagenic effects were observed for minus-one, plus-one, and minus-two nucleotide errors, in a highly sequence-specific manner. Most of this specificity can be rationalized by either of two models. One involves frameshifts initiated by pool bias-induced nucleotide misinsertion, and the other involves pool bias-initiated template-primer slippage. Several examples of complex mutations were also recovered more than once in small mutant collections. These contained closely spaced single-base substitution and minus-one base frameshift changes. The two changes occurred at a frequency much higher than predicted if they were generated independently. This suggests that when the polymerase makes one mistake, the probability that it will make a second mistake within the next few incorporations increases significantly. Perturbation of dNTP pools also affected the frameshift fidelity of the replicative yeast DNA polymerase-alpha. In reactions containing a low concentration of one dNTP, the error rate increased for one-nucleotide deletions at homopolymeric template nucleotides complementary to the dNTP whose concentration was low. We extended this approach to determine the frameshift fidelity of simian virus 40 origin-dependent semiconservative replication of double-stranded DNA in extracts of human cells. In reactions performed with an equal concentration of all four dNTPs, replication was highly accurate for minus-one-nucleotide errors. However, when the concentration of one dNTP was decreased, the replication error rate increased at complementary, homopolymeric template positions. This response provides an approach for describing frameshift accuracy during replication of the leading and lagging strands.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				ARECCO A, 1988, MUTAT RES, V200, P165, DOI 10.1016/0027-5107(88)90079-6; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; COHEN MB, 1981, J BIOL CHEM, V256, P8713; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P362; KUNZ BA, 1982, ENVIRON MUTAGEN, V4, P695; KUNZ BA, 1988, MUTAT RES, V200, P133, DOI 10.1016/0027-5107(88)90076-0; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; MEUTH M, 1984, MUTAT RES, V126, P107, DOI 10.1016/0027-5107(84)90051-4; PHEAR G, 1987, P NATL ACAD SCI USA, V84, P4450, DOI 10.1073/pnas.84.13.4450; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SARGENT RG, 1989, MOL GEN GENET, V217, P13; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SCHAAPER RM, 1982, MOL GEN GENET, V185, P404, DOI 10.1007/BF00334131; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1990, ANTIMUTAGENESIS ANTI, V2, P289	30	132	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3589	3596						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371272				2022-12-27	WOS:A1992HE60700010
J	FAKHRAI, H; MAINES, MD				FAKHRAI, H; MAINES, MD			EXPRESSION AND CHARACTERIZATION OF A CDNA FOR RAT-KIDNEY BILIVERDIN REDUCTASE - EVIDENCE SUGGESTING THE LIVER AND KIDNEY ENZYMES ARE THE SAME TRANSCRIPT PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE; MESSENGER-RNAS; SEQUENCE DATA; FORMS; VARIANTS; ACID; PURIFICATION; BROMOBENZENE; PATTERN; BRAIN	Biliverdin reductase is a unique dual cofactor- and PH-dependent enzyme that converts biliverdin to bilirubin and displays extensive inter-organ pI and molecular weight microheterogeneity. Presently we have explored the molecular basis for these properties. The amino acid composition and the sequences of NH2 termini plus five tryptic fragments of purified rat liver and kidney enzymes were obtained. A 62-nucleotide DNA probe was designed and in combination with antibody was used to screen a rat kidney cDNA library. A cDNA sequence of 1108 base pairs (bp) containing an 885-bp open reading frame was generated. The cloned cDNA probe detected a single mRNA of approximately 1500 bp in liver and kidney. The open reading frame encodes a 295 amino acid protein. Methionine and aspartic acid residues at positions 1 and 2 of the deduced protein are removed during processing. The deduced amino acid composition of the mature protein closely matched that of the purified rat liver and kidney enzymes. All liver peptides were found in the deduced amino acid sequence of kidney enzyme and the NH2 termini of both enzymes were identical. The expressed protein co-migrated with purified reductase and was recognized by antiserum to the enzyme. The expressed reductase displayed two distinct pH optima using a different cofactor at each pH: NADH at the lower pH 6.7-6.9 range and NADPH at pH 8.5-8.7. The findings suggest that the liver and kidney enzymes are the products of the same transcript(s) and that their microheterogeneity may reflect tissue-specific post-translational modifications.	UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester					NIEHS NIH HHS [ES04066, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, P30ES001247] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; CASCONE O, 1989, EUR J BIOCHEM, V179, P123, DOI 10.1111/j.1432-1033.1989.tb14529.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRYDMAN J, 1990, BIOCHIM BIOPHYS ACTA, V1040, P119, DOI 10.1016/0167-4838(90)90155-9; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P617, DOI 10.1016/0003-9861(89)90477-3; HUANG TJ, 1990, MOL PHARMACOL, V37, P25; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P114; MAINES MD, 1990, MOL PHARMACOL, V38, P481; MAINES MD, 1986, J BIOL CHEM, V261, P411; Maniatis T., 1982, MOL CLONING; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIGNEY EM, 1988, BIOCHEM J, V255, P431, DOI 10.1042/bj2550431; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPES R, 1982, PROTEIN PURIFICATION, P21; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; SUN Y, 1990, J BIOL CHEM, V265, P8212; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	29	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4023	4029						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371282				2022-12-27	WOS:A1992HE60700072
J	HUANG, P; FARQUHAR, D; PLUNKETT, W				HUANG, P; FARQUHAR, D; PLUNKETT, W			SELECTIVE ACTION OF 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE TRIPHOSPHATE ON HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE AND HUMAN DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACEBO-CONTROLLED TRIAL; CELLULAR PHARMACOLOGY; 3'-AZIDO-3'-DEOXYTHYMIDINE TRIPHOSPHATE; 3'-DEOXYTHYMIDIN-2'-ENE D4T; ANTI-HIV; POTENT; REPLICATION; CELLS; MECHANISM; FIDELITY	This study used DNA primer extension and sequencing gel analyses to evaluate the molecular action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate (D4TTP), 1 in comparison with 3'-azido-2',3'-dideoxythymidine triphosphate (AZTTP), on DNA strand elongation by human immunodeficiency virus reverse transcriptases (HIV-RT) and human DNA polymerases alpha (pol-alpha) and epsilon (pol-epsilon) purified from T-lymphoblastoid CEM cells. D4TTP was preferentially incorporated into the T sites of the elongating DNA strand by HIV-RT and terminated DNA synthesis at the incorporation sites. The DNA chain termination activity of D4TTP was equipotent to that of AZTTP. In contrast, D4TTP was a poor substrate for pol-alpha and pol-epsilon. The analogue was incorporated into DNA by the human enzymes about 10,000- to 20,000-fold less efficiently than by HIV-RT, whereas the incorporation of AZTTP by pol-alpha and pol-epsilon was not detectable by the DNA primer extension assay. Pol-epsilon, an enzyme with 3' --> 5'-exonuclease activity, was unable to remove the incorporated 2',3'-didehydro-2',3'-dideoxythymidine monophosphate (D4TMP) from the 3'-end of the DNA strand, whereas 3'-azido-2',3'-dideoxythymidine monophosphate was excised from DNA by pol-epsilon at about 20% of the rate for normal deoxynucleotide excision. The preferential incorporation of D4TTP by HIV-RT appears to be a molecular basis for the selective anti-HIV activity of D4T, whereas the inability of pol-epsilon to remove D4TMP from DNA may be related to the cytotoxicity of this compound.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,BOX 52,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA28596] Funding Source: Medline; NIAID NIH HHS [AI28213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUST EM, 1991, MOL PHARMACOL, V39, P246; AUGUST EM, 1988, BIOCHEM PHARMACOL, V37, P4419, DOI 10.1016/0006-2952(88)90655-7; BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BAZIN H, 1989, BIOCHEM PHARMACOL, V38, P109, DOI 10.1016/0006-2952(89)90157-3; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CHEN CH, 1991, MOL PHARMACOL, V39, P625; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CHOU J, 1985, DOSE EFFECT ANAL MIC, P5; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOCHER F, 1990, FEBS LETT, V259, P349, DOI 10.1016/0014-5793(90)80045-K; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FURMAN PA, 1988, AM J MED, V85, P176; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOGU SR, 1989, LIFE SCI, V45, pR3, DOI 10.1016/0024-3205(89)90135-5; HAMAMOTO Y, 1987, ANTIMICROB AGENTS CH, V31, P907, DOI 10.1128/AAC.31.6.907; HARRINGTON JA, 1987, BIOCHEM PHARMACOL, V36, P3757, DOI 10.1016/0006-2952(87)90031-1; HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1990, J BIOL CHEM, V265, P11914; LIN TS, 1987, BIOCHEM PHARMACOL, V36, P2713; MANSURI MM, 1989, J MED CHEM, V32, P461, DOI 10.1021/jm00122a029; MANSURI MM, 1990, ANTIMICROB AGENTS CH, V34, P637, DOI 10.1128/AAC.34.4.637; MARONGIU ME, 1990, BIOCHEM PHARMACOL, V39, P1523, DOI 10.1016/0006-2952(90)90516-N; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MUNCHPETERSEN B, 1988, BIOCHEM BIOPH RES CO, V157, P1369, DOI 10.1016/S0006-291X(88)81026-X; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Richman D D, 1988, Infect Dis Clin North Am, V2, P397; RICHMAN DD, 1988, AM J MED, V85, P208; Scanlon K J, 1989, Cancer Commun, V1, P269; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VRANG L, 1987, ANTIVIR RES, V7, P139, DOI 10.1016/0166-3542(87)90002-7; WONGSTAAL F, 1988, HIV OTHER HIGHLY PAT, P33	42	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2817	2822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370834				2022-12-27	WOS:A1992HB53200105
J	WALTER, EI; RATNOFF, WD; LONG, KE; KAZURA, JW; MEDOF, ME				WALTER, EI; RATNOFF, WD; LONG, KE; KAZURA, JW; MEDOF, ME			EFFECT OF GLYCOINOSITOLPHOSPHOLIPID ANCHOR LIPID GROUPS ON FUNCTIONAL-PROPERTIES OF DECAY-ACCELERATING FACTOR PROTEIN IN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPID MEMBRANE ANCHOR; FACTOR DAF; C-3 CONVERTASES; GLYCOSYL-PHOSPHATIDYLINOSITOL; LATERAL DIFFUSION; SURFACE PROTEINS; HUMAN-SERUM; COMPLEMENT	The inositol ring in the glycoinositolphospholipid (GPI) anchor of human decay-accelerating factor (DAF) is unmodified in nucleated cells, whereas it is fatty acid acylated in erythrocytes (E(hu)). To assess the effect of this and of the glycerol sn-2-associated acyl substituent on the abilities of DAF to cell membrane incorporate and function, 1) endogenous (physiologically anchored) DAF proteins bearing three- and two-"footed" GPI anchors were purified from E(hu) and HeLa cells and 2) synthetic DAF variants bearing alternative one-"footed" anchors (retaining either the sn-1 glycerol- or inositol-associated lipid) were prepared by alkaline hydroxylamine treatment and phosphatidylinositol-specific phospholipase D digestion of E(hu) DAF, respectively. The different DAF species were added to antibody-sensitized sheep erythrocytes (E(sh)A) and their abilities to insert into the plasma membranes of the cells and control subsequent complement activation on their surfaces were compared. DAF proteins bearing all four GPI anchor structures adhered to the E(sh) hemolytic intermediates and inhibited expression of C3 convertase (C4b2a BAR) activity. However, mixing of DAF-treated E(sh)A with untreated E(sh)AC142 and stripping of cell-associated DAF proteins with vesicles showed that only the physiologically anchored proteins remained stably associated with the lipid bilayer and functioned intrinsically. Both three- and two-"footed" E(hu) and HeLa DAF proteins exhibited comparable ability to incorporate and function in the intermediates as well as to accumulate to levels 1000-fold higher/cell in Schistosoma mansoni schistosomula. These findings indicate that 1) an intact inositolphospholipid-containing GPI anchor is necessary for stable membrane integration and intrinsic function, 2) endogenous GPI anchors (with either unsubstituted and acylated inositol) incorporate and function with comparable efficiency, and 3) the transfer of either endogenous DAF form can account for the previously described circumvented uptake of human C3b by blood stage schistosomula.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University	WALTER, EI (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106, USA.				NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK3818] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCH AS, 1986, J EXP MED, V163, P221, DOI 10.1084/jem.163.1.221; BOUMA SR, 1977, J BIOL CHEM, V252, P6759; COOK SL, 1980, BIOCHEMISTRY-US, V19, P4601, DOI 10.1021/bi00561a010; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FUJITA T, 1987, J EXP MED, V166, P1221, DOI 10.1084/jem.166.5.1221; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JOINER KA, 1988, J BIOL CHEM, V263, P11327; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; KINOSHITA T, 1986, J IMMUNOL, V136, P3390; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MOLD C, 1990, J IMMUNOL, V145, P3836; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; RAMALHO-PINTO F J, 1987, Memorias do Instituto Oswaldo Cruz, V82, P213, DOI 10.1590/S0074-02761987000800037; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; RATNOFF WD, 1990, BLOOD S1, V76, P389; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SMITH JD, 1983, PHYSL TREMATODES, P229; THOMAS J, 1987, BIOPHYS J, V51, P522; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; WALTER EI, 1990, J IMMUNOL, V144, P1030; ZALMAN LS, 1987, J EXP MED, V166, P947, DOI 10.1084/jem.166.4.947	41	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1245	1252						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370460				2022-12-27	WOS:A1992GY96000088
J	TARCSA, E; KEDEI, N; THOMAZY, V; FESUS, L				TARCSA, E; KEDEI, N; THOMAZY, V; FESUS, L			AN INVOLUCRIN-LIKE PROTEIN IN HEPATOCYTES SERVES AS A SUBSTRATE FOR TISSUE TRANSGLUTAMINASE DURING APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL-CELLS; CROSS-LINKING; AMINO-ACIDS; KERATINOCYTE; EXPRESSION; DEATH; DIFFERENTIATION; QUANTITATION; ENVELOPE; MARKER	Cornified envelopes and apoptotic bodies are transglutaminase-cross-linked end-products of physiological cell death pathways. The two structures have similar amino acid composition. Involucrin has been considered as a cornified envelope precursor protein expressed specifically in terminally differentiating keratinocytes and squamous epithelia. We report the presence in hepatocytes of an involucrin-like protein which could be purified from dog liver with procedures characteristic to involucrins. When compared to purified dog esophagus involucrin, the liver protein also reacts with anti-involucrin antibodies, has the same relative molecular mass, possesses similar amino acid composition, and shows almost identical peptide mapping pattern. The involucrin-like protein is detectable by immunohistochemistry in normal and apoptotic hepatocytes, is a substrate of tissue transglutaminase, and is incorporated into cross-linked apoptotic bodies. These results suggest that there are overlapping molecular components in the two characteristic forms (cornification and apoptosis) of naturally occurring cell death.	DEBRECEN UNIV MED,SCH MED,DEPT BIOCHEM,POB 6,H-4012 DEBRECEN,HUNGARY; DEBRECEN UNIV MED,SCH MED,DEPT PATHOL,H-4012 DEBRECEN,HUNGARY	University of Debrecen; University of Debrecen	FESUS, L (corresponding author), DEBRECEN UNIV MED,SCH MED,DEPT BIOCHEM,POB 6,H-4012 DEBRECEN,HUNGARY.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Green H, 1980, Harvey Lect, V74, P101; HEYDERMAN E, 1977, J CLIN PATHOL, V30, P138, DOI 10.1136/jcp.30.2.138; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KUBILUS J, 1990, J INVEST DERMATOL, V94, P210, DOI 10.1111/1523-1747.ep12874523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1984, MOL CELL BIOCHEM, V58, P7, DOI 10.1007/BF00240601; MAYALL FG, 1992, HISTOPATHOLOGY, V20, P53, DOI 10.1111/j.1365-2559.1992.tb00916.x; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; PARENTEAU NL, 1987, P NATL ACAD SCI USA, V84, P7571, DOI 10.1073/pnas.84.21.7571; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RORKE EA, 1991, J INVEST DERMATOL, V97, P543, DOI 10.1111/1523-1747.ep12481579; RUBIN AL, 1989, J CELL PHYSIOL, V138, P208, DOI 10.1002/jcp.1041380128; SAID JW, 1983, LAB INVEST, V49, P563; SCOTT M, 1985, CELL, V40, P585; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1989, J INVEST DERMATOL, V92, P721, DOI 10.1111/1523-1747.ep12721568; Sternberger LA, 1979, IMMUNOCYTOCHEMISTRY, P104; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TSENG H, 1990, MOL BIOL EVOL, V7, P293; Wyllie A H, 1980, Int Rev Cytol, V68, P251	31	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25648	25651						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1361185				2022-12-27	WOS:A1992KD07300008
J	TAYLOR, KL; POHL, J; KINKADE, JM				TAYLOR, KL; POHL, J; KINKADE, JM			UNIQUE AUTOLYTIC CLEAVAGE OF HUMAN MYELOPEROXIDASE - IMPLICATIONS FOR THE INVOLVEMENT OF ACTIVE-SITE MET409	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL MYELOPEROXIDASE; CHROMATOGRAPHIC FORMS; EOSINOPHIL PEROXIDASE; HEMI-MYELOPEROXIDASE; REDUCTIVE CLEAVAGE; MOLECULAR-CLONING; SUBUNIT STRUCTURE; GRANULOCYTES; LEUKOCYTES; RESONANCE	Myeloperoxidase (MPO) is a functionally important component of the normal human neutrophil host defense system. This enzyme possesses a dimeric structure composed of two heavy subunit (55-63 kDa)/light subunit (10-15 kDa) protomers, each of which is associated with a heme-like prosthetic group. In addition, MPO species of approximately 38 and 22 kDa have been reported by many different investigators, but their nature and mode of origin are not understood. In the present study, we demonstrate that when MPO is heated under nonreducing, denaturing conditions, these two species are produced via a novel autolytic cleavage of the heavy subunit. The 38-kDa species was isolated by fast-protein liquid chromatography and identified by sequencing as the carboxyl-terminal portion of the heavy subunit, and the cleavage was shown to occur exclusively between Met409 and Pro410. In order to further characterize this unusual cleavage reaction, the 22-kDa species was digested with endoproteinase Asp-N, and the peptide corresponding to its carboxyl terminus was isolated and analyzed by sequencing and mass spectrometry. These data indicated that during cleavage of the heavy subunit, Met409 was converted to homoserine lactone. Thus, the cleavage appeared to formally resemble the cyanogen bromide-dependent cleavage of Met-X peptide bonds. Recent x-ray crystallographic data for canine MPO have indicated that Met409 is in close proximity to the heme-like prosthetic group of MPO. Our studies suggest that interaction of Met409 with this group leads to the formation of a methionyl sulfonium derivative which undergoes intramolecular rearrangement with subsequent peptide cleavage under nonreducing conditions. This derivative may be, at least in part, responsible for the unusual spectral characteristics and enzymatic properties of the enzyme. The primary structure of the 22-kDa MPO species is also reported, and direct evidence is provided for asparagine-linked oligosaccharide moieties at two of the three predicted glycosylation sites.	EMORY UNIV, SCH MED, MICROCHEM FACIL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, WINSHIP CANC CTR, ATLANTA, GA 30322 USA	Emory University; Emory University	TAYLOR, KL (corresponding author), EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA.				NCI NIH HHS [R01 CA-22294] Funding Source: Medline; NIDCR NIH HHS [F32 DE-05541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGNER K, 1958, ACTA CHEM SCAND, V12, P89, DOI 10.3891/acta.chem.scand.12-0089; ANDERSEN MR, 1982, ARCH BIOCHEM BIOPHYS, V214, P273, DOI 10.1016/0003-9861(82)90031-5; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BABCOCK GT, 1985, BIOCHIM BIOPHYS ACTA, V828, P58, DOI 10.1016/0167-4838(85)90009-3; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V791, P75, DOI 10.1016/0167-4838(84)90283-8; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANG Y, 1970, BIOCHIM BIOPHYS ACTA, V215, P88, DOI 10.1016/0304-4165(70)90390-9; EGLINTON DG, 1982, BIOCHIM BIOPHYS ACTA, V703, P187, DOI 10.1016/0167-4838(82)90047-4; FELBERG NT, 1972, ARCH BIOCHEM BIOPHYS, V148, P407, DOI 10.1016/0003-9861(72)90158-0; GLOSSMANN H, 1971, J BIOL CHEM, V246, P6339; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARRISON JE, 1977, BIOCHIM BIOPHYS ACTA, V493, P247, DOI 10.1016/0005-2795(77)90181-7; HARRISON JE, 1978, BIOCHIM BIOPHYS ACTA, V536, P341, DOI 10.1016/0005-2795(78)90492-0; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HURST JK, 1990, PEROXIDASES CHEM BIO, P37; IKEDASAITO M, 1989, J BIOL CHEM, V264, P4559; IWAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P688, DOI 10.1093/oxfordjournals.jbchem.a122330; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LAWSON WB, 1961, J AM CHEM SOC, V83, P1509, DOI 10.1021/ja01467a051; MATHESON NR, 1981, BIOCHEMISTRY-US, V20, P325, DOI 10.1021/bi00505a015; MIYASAKI KT, 1986, ARCH BIOCHEM BIOPHYS, V246, P751, DOI 10.1016/0003-9861(86)90332-2; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3208, DOI 10.1021/bi00767a011; NAUSEEF WM, 1986, BLOOD, V67, P1504; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1987, BLOOD, V70, P1143; ODAJIMA T, 1972, BIOCHIM BIOPHYS ACTA, V284, P368, DOI 10.1016/0005-2744(72)90132-5; ODAJIMA T, 1980, J BIOCHEM-TOKYO, V87, P379, DOI 10.1093/oxfordjournals.jbchem.a132758; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; OLSEN RL, 1984, BIOCHEM J, V222, P701, DOI 10.1042/bj2220701; OLSSON I, 1972, SCAND J HAEMATOL, V9, P483; PEMBER SO, 1982, FEBS LETT, V140, P103, DOI 10.1016/0014-5793(82)80530-9; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; SCHULTZ J, 1962, ARCH BIOCHEM BIOPHYS, V96, P465, DOI 10.1016/0003-9861(62)90321-1; SCHULTZ J, 1983, BIOCHEMISTRY, V22; SIBBETT SS, 1984, BIOCHEMISTRY-US, V23, P3007, DOI 10.1021/bi00308a025; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; SVENSSON BE, 1987, BIOCHEM J, V242, P673, DOI 10.1042/bj2420673; TAYLOR KL, 1990, J BIOL CHEM, V265, P15938; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; WATERFIELD MD, 1986, PRACTICAL PROTEIN CH, pCH13; WRIGHT J, 1987, BIOCHIM BIOPHYS ACTA, V915, P68, DOI 10.1016/0167-4838(87)90126-9; WU NC, 1975, FEBS LETT, V60, P141, DOI 10.1016/0014-5793(75)80437-6; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	51	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25282	25288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334087				2022-12-27	WOS:A1992KB60300057
J	YOSHIDA, A; OHO, C; OMORI, A; KUWAHARA, R; ITO, T; TAKAHASHI, M				YOSHIDA, A; OHO, C; OMORI, A; KUWAHARA, R; ITO, T; TAKAHASHI, M			HPC-1 IS ASSOCIATED WITH SYNAPTOTAGMIN AND OMEGA-CONOTOXIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENSITIVE CALCIUM-CHANNEL; PROTEIN-KINASE-C; SYNAPTIC VESICLES; MOTIF; IDENTIFICATION; BINDING	Monoclonal antibodies were produced that recognize a membrane protein of 35,000 Da (p35) expressed in brain and adrenal medulla. They immunoprecipitated 50% of omega-conotoxin (omega-CgTX) receptor, a putative N-type calcium channel, solubilized from rat brain. Anti-synaptotagmin (p65) antibodies also immunoprecipitate omega-CgTX receptor (Leveque, C., Hoshino, T., David, P., Shoji-Kasai, Y., Leys, K., Omori, A., Lang, B., El Far, O., Sato, K., Martin-Moutot, N., Newsom-Davis, J., Takahashi, M., and Seagar, M. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3625-3629); however, immunoprecipitation by anti-p35 antibodies and anti-synaptotagmin antibodies was not additive. Furthermore, both p35 and synaptotagmin were recovered in the immunoprecipitates with anti-synaptotagmin and anti-p35 antibodies, respectively, indicating that a population of omega-CgTX receptor exists as a ternary complex with synaptotagmin and p35. A cDNA coding p35 was isolated from a rat brain cDNA library by immuno-screening, and the primary structure of the protein was revealed to be identical to that of HPC-1 (Inoue, A., Obata, K., and Akagawa, K. (1992) J. Biol. Chem. 267, 10613-10619). HPC-1 has a putative transmembrane segment at the C terminus and four heptad motifs, which may be involved in protein-protein interaction. These results suggest that HPC-1 may play a role in neurotransmitter release from nerve terminals by associating with omega-CgTX-sensitive N-type calcium channel and synaptotagmin.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN									Atlas D, 1990, Curr Top Cell Regul, V31, P129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P175; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; INOUE A, 1992, J BIOL CHEM, V267, P10613; LEE HC, 1980, J CELL BIOL, V85, P325, DOI 10.1083/jcb.85.2.325; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SAISU H, 1991, BIOCHEM BIOPH RES CO, V181, P59, DOI 10.1016/S0006-291X(05)81381-6; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1182, DOI 10.1016/0006-291X(89)92345-0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J	21	264	269	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24925	24928						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1334074				2022-12-27	WOS:A1992KB60300004
J	MARTIN, DW; SACHS, JR				MARTIN, DW; SACHS, JR			CROSS-LINKING OF THE ERYTHROCYTE (NA+,K+)-ATPASE - CHEMICAL CROSS-LINKERS INDUCE ALPHA-SUBUNIT-BAND-3 HETERODIMERS AND DO NOT INDUCE ALPHA-SUBUNIT HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; PREDOMINANT TRANSMEMBRANE POLYPEPTIDE; CELL-MEMBRANES; ANION TRANSPORT; BAND-3 PROTEIN; SODIUM; PUMP; POTASSIUM; CROSSLINKING; MECHANISM	Earlier studies (Periyasamy, S. M., Huang, W.-H., and Askari, A. (1983) J. Biol. Chem. 258,9878-9885) suggested that Cu2+ and o-phenanthroline induced the formation of cross-linked homodimers between alpha-subunits of the erythrocyte (Na+,K+)-ATPase. This was interpreted as indicating that alpha-subunits existed in close proximity in native erythrocyte membranes. The alpha-subunit and band 3 monomers have similar molecular weights (M(r) approximately 100,000) and exist in the membrane in molar ratios of approximately 1:3000 alpha-subunit:band 3. We explored the possibility that alpha-subunit and band 3 could be induced to form heterodimeric structures in the presence of cross-linking reagents. Using methods similar to those employed in the above-cited reference we demonstrated that cross-linked dimers containing phosphorylated alpha-subunits had proteolytic sensitivity that was inconsistent with the formation of alpha-subunit homodimers and fully consistent with heterodimer formation between alpha-subunit and band 3. The data also indicated that alpha-subunit-band 3 heterodimer formation is dependent on the conformational state of the (Na+,K+)-ATPase. Using the appropriate reagents we obtained cross-linked products which were consistent with heterodimer formation between alpha- and beta-subunits of the (Na+,K+)-ATPase. Our data argue against a close association between pairs of (Na+,K+)-ATPase alpha-subunits in the human red cell membrane.			MARTIN, DW (corresponding author), SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA.				NIDDK NIH HHS [DK-19185] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019185] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; ASKARI A, 1988, NA PLUS K PLUS PUM A, P149; AVRUSH J, 1972, P NATL ACAD SCI USA, V69, P1216, DOI 10.1073/pnas.69.5.1216; BENDER WW, 1971, J MOL BIOL, V58, P783, DOI 10.1016/0022-2836(71)90040-4; BLOSTEIN R, 1968, J BIOL CHEM, V243, P1957; BUXBAUM E, 1990, EUR J BIOCHEM, V193, P355, DOI 10.1111/j.1432-1033.1990.tb19346.x; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; FOSSEL ET, 1981, BIOCHIM BIOPHYS ACTA, V649, P557, DOI 10.1016/0005-2736(81)90160-7; GAFFNEY BJ, 1985, BIOCHIM BIOPHYS ACTA, V822, P289, DOI 10.1016/0304-4157(85)90012-7; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1988, NA PLUS K PLUS PUM A, P435; HOFFMAN JF, 1969, J GEN PHYSIOL, V54, pS343; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; HUANG WH, 1979, FEBS LETT, V101, P67, DOI 10.1016/0014-5793(79)81297-1; HUANG WH, 1988, METHOD ENZYMOL, V156, P345; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; JOINER CH, 1978, J PHYSIOL-LONDON, V283, P155, DOI 10.1113/jphysiol.1978.sp012494; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KAPLAN JH, 1985, J GEN PHYSIOL, V85, P123, DOI 10.1085/jgp.85.1.123; KNAUF PA, 1974, J GEN PHYSIOL, V63, P305, DOI 10.1085/jgp.63.3.305; KYTE J, 1975, J BIOL CHEM, V250, P7443; MARINETTI GV, 1974, BIOCHEM BIOPH RES CO, V61, P30, DOI 10.1016/0006-291X(74)90529-4; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MIDDAUGH CR, 1983, MOL CELL BIOCHEM, V50, P115; NORBY JG, 1991, SOC GEN PHY, V46, P173; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SKOU JC, 1969, BIOCHIM BIOPHYS ACTA, V185, P198, DOI 10.1016/0005-2744(69)90295-2; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; STECK TL, 1972, MEMBRANE RESEARCH, P71; WANG K, 1974, J BIOL CHEM, V249, P8005	40	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23922	23929						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1331105				2022-12-27	WOS:A1992JZ23900074
J	FRAIJ, BM; BIRCKBICHLER, PJ; PATTERSON, MK; LEE, KN; GONZALES, RA				FRAIJ, BM; BIRCKBICHLER, PJ; PATTERSON, MK; LEE, KN; GONZALES, RA			A RETINOIC ACID-INDUCIBLE MESSENGER-RNA FROM HUMAN ERYTHROLEUKEMIA-CELLS ENCODES A NOVEL TISSUE TRANSGLUTAMINASE HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; PIG LIVER TRANSGLUTAMINASE; DIFFERENTIAL EXPRESSION; ERYTHROCYTE-MEMBRANE; GENE-EXPRESSION; CDNA CLONES; SEQUENCE; PURIFICATION; RAT; CHROMATOGRAPHY	A 1.9-kilobase (kb) cDNA for a new transglutaminase protein has been cloned and sequenced from retinoic acid-induced human erythroleukemia (HEL) cells. Full-length cDNA analysis reveals an open reading frame coding for a polypeptide of 548 amino acid residues with a molecular weight of 61,740. The deduced amino acid sequence exhibited 98% identity to the human cellular transglutaminase sequence. The cysteine at position 277 in the active site and the putative Ca2+-binding pocket at residues 446-453 of cellular transglutaminase are conserved. Such evidence predicts that the encoded protein product is likely to be a transglutaminase homologue (TGase-H). Immunoprecipitation of the in vitro translation products from a synthetic TGase-H mRNA and from total protein of cultured erythroleukemia HEL cells revealed a protein with a molecular weight of 63,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Northern blot analysis of HEL cells and normal human fibroblast cells WI-38 using a cellular TGase probe detected the 1.9- and 4.0-kb RNA species at a relative abundance of 1:3 and 1:7, respectively. The 3'-end of the human cellular transglutaminase mRNA was also cloned and sequenced to allow comparison to the 3'-end of TGase-H reported here. This new piece gives a full length of 4012 nucleotides (4.0 kb) for human cellular transglutaminase. Comparison of the 5'-end (bases 1-1747) of the 1.9- and 4.0-kb cDNA sequences revealed a very high degree of identity. Beginning with base 1748, the sequences diverge showing no homology. The divergence point correlates with known intron-exon consensus boundaries indicative of alternative splicing.			FRAIJ, BM (corresponding author), SAMUEL ROBERTS NOBLE FDN INC,DIV BIOMED,NUTR SECT,MOLEC ANAL & SYNTH SECT,ARDMORE,OK 73402, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Birckbichler P J, 1978, Ann N Y Acad Sci, V312, P354, DOI 10.1111/j.1749-6632.1978.tb16813.x; BIRCKBICHLER PJ, 1976, CANCER RES, V36, P2911; BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; BUCK KJ, 1991, BIOTECHNIQUES, V11, P636; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRAIJ BM, 1989, CLIN CHEM, V35, P658; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1987, BLOOD, V70, P702; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KIM HC, 1991, J BIOL CHEM, V266, P536; KNIGHT CRL, 1990, BIOCHIM BIOPHYS ACTA, V1053, P13, DOI 10.1016/0167-4889(90)90019-A; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LOEWY AG, 1981, BIOCHIM BIOPHYS ACTA, V668, P177, DOI 10.1016/0005-2795(81)90161-6; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANIATIS T, 1983, MOL CLONING; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCLUNG JK, 1989, ANAL BIOCHEM, V177, P378, DOI 10.1016/0003-2697(89)90069-9; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; ONO T, 1984, J BIOL CHEM, V259, P9011; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; SEITZ J, 1991, BIOCHIM BIOPHYS ACTA, V1078, P139, DOI 10.1016/0167-4838(91)99002-A; SUEDHOFF T, 1990, CANCER RES, V50, P7830; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; Titus DE, 1991, PROMEGA PROTOCOLS AP; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	41	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22616	22623						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1358880				2022-12-27	WOS:A1992JW71900097
J	PARDY, K; ADAN, RAH; CARTER, DA; SEAH, V; BURBACH, JPH; MURPHY, D				PARDY, K; ADAN, RAH; CARTER, DA; SEAH, V; BURBACH, JPH; MURPHY, D			THE IDENTIFICATION OF A CIS-ACTING ELEMENT INVOLVED IN CYCLIC 3',5'-ADENOSINE-MONOPHOSPHATE REGULATION OF BOVINE VASOPRESSIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION ANALYSIS; MESSENGER-RNA REGULATION; HYPOTHALAMIC NUCLEI; OSMOTIC STIMULATION; C-FOS; TRANSCRIPTION FACTORS; SOMATOSTATIN GENE; RAT HYPOTHALAMUS; BRATTLEBORO RAT; AMP	Cyclic adenosine 3',5'-monophosphate (cAMP) has been implicated as an intracellular messenger mediating osmotic regulation of expression of the gene encoding the neuropeptide vasopressin (VP) in the hypothalamus. We have used a heterologous transient transfection system to demonstrate that cAMP regulates the bovine VP gene promoter following transfection into CV1 cells. Mutational analysis identified a bovine VP cAMP-responsive element (BVP-CRE) 120-112 base-pairs upstream of the start of transcription. DNase I footprint analysis using nuclear protein extract from CV1 cells showed protection at the site of the BVP-CRE. Protection of the BVP-CRE was also observed using purified AP1 protein, while there was a weak interaction with the BVP-CRE using purified rat CREB protein. Nuclear proteins purified from the rat supraoptic nucleus bind to the BVP-CRE. As transgenic mouse studies have shown that the bovine VP gene is subject to appropriate physiological regulation in the mouse hypothalamus (Ang, H. L., Funkhouser, J., Carter, D. A., Ho, M. Y., and Murphy, D. (1991) Soc. Neurosci. Abstr. 513, 12), these data indicate a role for the BVP-CRE element in mediating VP gene expression in vivo. These data demonstrate that cAMP regulates bovine VP gene expression in vitro via a cis-acting element within the VP promoter, and this activation may be mediated by members of the AP1/ATF/CREB family of transcription factors.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,NEUROPEPTIDE LAB,SINGAPORE 0511,SINGAPORE; UNIV UTRECHT,RUDOLF MAGNUS INST,3521 GD UTRECHT,NETHERLANDS	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Utrecht University			Carter, David/A-4479-2010; Murphy, David/C-3967-2012	Carter, David/0000-0002-8419-3975; Murphy, David/0000-0003-2946-0353				ANG HL, 1991, SOC NEUR ABSTR; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH JPH, 1986, J NEUROCHEM, V47, P1814, DOI 10.1111/j.1471-4159.1986.tb13093.x; BURBACH JPH, 1984, NEUROENDOCRINOLOGY, V39, P582; CARTER DA, 1990, CELL MOL NEUROBIOL, V10, P435, DOI 10.1007/BF00711185; CARTER DA, 1989, BRAIN RES, V487, P350, DOI 10.1016/0006-8993(89)90839-1; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINK JS, 1991, J BIOL CHEM, V266, P3882; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERMAN JP, 1991, MOL ENDOCRINOL, V5, P1447, DOI 10.1210/mend-5-10-1447; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAJZOUB JA, 1983, J BIOL CHEM, V258, P4061; Maxam A M, 1980, Methods Enzymol, V65, P499; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOHR E, 1990, FEBS LETT, V260, P305, DOI 10.1016/0014-5793(90)80130-B; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1987, AM J PATHOL, V129, P552; OEDING P, 1990, J NEUROENDOCRINOL, V2, P859, DOI 10.1111/j.1365-2826.1990.tb00652.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SAMBROOK J, 1987, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SHERMAN TG, 1988, J NEUROSCI, V8, P3785; SHERMAN TG, 1986, J NEUROSCI, V6, P1685; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; UHL GR, 1985, P NATL ACAD SCI USA, V82, P5555, DOI 10.1073/pnas.82.16.5555; VERBEECK MAE, 1990, FEBS LETT, V272, P89, DOI 10.1016/0014-5793(90)80455-R; YOUNG WS, 1987, MOL ENDOCRINOL, V1, P884, DOI 10.1210/mend-1-12-884; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	43	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21746	21752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1339438				2022-12-27	WOS:A1992JV01100076
J	STEELE, MI; LORENZ, D; HATTER, K; PARK, A; SOKATCH, JR				STEELE, MI; LORENZ, D; HATTER, K; PARK, A; SOKATCH, JR			CHARACTERIZATION OF THE MMSAB OPERON OF PSEUDOMONAS-AERUGINOSA PAO ENCODING METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE AND 3-HYDROXYISOBUTYRATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; SEQUENCE-ANALYSIS; CLONING; PUTIDA; GENE; DNA; PURIFICATION; CONSTRUCTION; EXPRESSION; VECTOR	A 5417-base pair (bp) region of Pseudomonas aeruginosa PAO chromosomal DNA containing the mmsAB operon and an upstream regulatory gene (mmsR) has been cloned and characterized: The operon contains two structural genes involved in valine metabolism: mmsA, which encodes methylmalonate-semialdehyde dehydrogenase; and mmsB, which encodes 3-hydroxy-isobutyrate dehydrogenase. mmsA and mmsB share the same orientation and are separated by a 16-bp noncoding region. The transcriptional start site for the operon has been pinpointed to a cytidine residue located 77 bp from the translational start site of the operon. mmsR is located on the opposite strand and begins 134 bp from the translational start site of mmsA. MmsR has been identified as a member of the XylS/AraC family of transcriptional regulators and appears to act as a positive regulator of the mmsAB operon. Sequence comparison of MmsA to other proteins in the data bases revealed that MmsA belongs to the aldehyde dehydrogenase (NAD+) superfamily. MmsB shares a 44% amino acid identity with 3-hydroxyisobutyrate dehydrogenase from rat liver. Mutants with insertionally inactivated mmsR, mmsA, and mmsB grow slowly on valine/isoleucine medium and exhibit reduced enzyme activity in cell-free extracts compared to P. aeruginosa PAO.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman	STEELE, MI (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT PEDIAT, POB 26901, OKLAHOMA CITY, OK 73190 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00873] Funding Source: Medline; NIDDK NIH HHS [DK27137] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIBA H, 1981, J BIOL CHEM, V256, P1905; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BANNERJEE D, 1970, J BIOL CHEM, V245, P1828; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYD LA, 1991, GENE, V103, P45, DOI 10.1016/0378-1119(91)90389-S; BURTON RM, 1953, J BIOL CHEM, V202, P873; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DEBARBOUILLE M, 1983, J BACTERIOL, V153, P1221; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; GOLDBERG JB, 1984, J BACTERIOL, V158, P1115, DOI 10.1128/JB.158.3.1115-1121.1984; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; HASEGAWA J, 1981, AGR BIOL CHEM TOKYO, V45, P2805, DOI 10.1080/00021369.1981.10864958; HATTER K, 1988, METHOD ENZYMOL, V166, P389; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, P3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HSU LC, 1991, J BIOL CHEM, V266, P12257; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUPIECKI FP, 1960, BIOCH PREP, V7, P69; LEI SP, 1985, J BACTERIOL, V164, P717, DOI 10.1128/JB.164.2.717-722.1985; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LINDAHL R, 1990, ENZYMOLOGY MOL BIOL, P1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARSHALL VD, 1972, J BACTERIOL, V110, P1073, DOI 10.1128/JB.110.3.1073-1081.1972; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RAMOS JL, 1990, NUCLEIC ACIDS RES, V18, P2149, DOI 10.1093/nar/18.8.2149; ROBINSON WG, 1963, METHOD ENZYMOL, V6, P549, DOI 10.1016/0076-6879(63)06220-0; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROUGRAFF PM, 1989, J BIOL CHEM, V264, P5899; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SOKATCH JR, 1981, J BACTERIOL, V148, P639, DOI 10.1128/JB.148.2.639-646.1981; TU GC, 1988, J BIOL CHEM, V263, P1218; TU GC, 1988, J BIOL CHEM, V263, P1212; WEINER H, 1990, ENZYMOLOGY MOL BIOL, P13; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	65	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13585	13592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1339433				2022-12-27	WOS:A1992JB74600077
J	HILLGARTNER, FB; CHEN, W; GOODRIDGE, AG				HILLGARTNER, FB; CHEN, W; GOODRIDGE, AG			OVEREXPRESSION OF THE ALPHA-THYROID HORMONE RECEPTOR IN AVIAN CELL-LINES - EFFECTS ON EXPRESSION OF THE MALIC ENZYME GENE ARE SELECTIVE AND CELL-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; V-ERBA ONCOGENE; TISSUE-SPECIFIC EXPRESSION; ACID SYNTHASE GENE; C-ERBA; RESPONSE ELEMENT; ERYTHROBLASTOSIS VIRUS; RETROVIRAL VECTORS; NUCLEAR RECEPTORS; LIPOGENIC ENZYMES	The role of the alpha-thyroid hormone receptor (TR-alpha) in regulation of transcription of the gene for chicken malic enzyme was analyzed in fibroblast cell lines normally unresponsive to triiodothyronine (T3). The gene for this transcription factor was introduced stably and overexpressed using a replication-competent retroviral vector. In chick embryo fibroblasts (CEF), overexpression of TR-alpha decreased malic enzyme activity by 90% in the absence of T3. Addition of T3 almost completely restored malic enzyme activity to the level of similarly treated control CEF infected with virus lacking TR-alpha. These TR-alpha-induced changes in malic enzyme activity were mediated by alterations in transcription of the malic enzyme gene. Similar results were obtained when transcriptional activity of TR-alpha was analyzed using a transient co-transfection system. Thus, the unliganded TR-alpha is a transcriptional repressor of the malic enzyme gene; binding of T3 to the receptor abolishes this repression. In contrast, stable overexpression of TR-alpha in QT6 cells had no effect on malic enzyme expression in the absence or presence of T3. Nuclear T3 binding was equally high in CEF and QT6 cells overexpressing TR-alpha. These findings suggest that cell-specific factors control the ability of TR-alpha to regulate the malic enzyme gene. Overexpression of TR-alpha in CEF had no effect on the expression of fatty acid synthase and acetyl-CoA carboxylase, lipogenic enzymes that are stimulated by T3 in hepatocytes in culture. Thus, gene-specific factors also may control the transcriptional activity of TR-alpha.			HILLGARTNER, FB (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, F32DK008097] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 21954] Funding Source: Medline; NIDDK NIH HHS [DK 08097, DK 25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BACK DW, 1986, J BIOL CHEM, V261, P2555; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISCHER PWF, 1978, ARCH BIOCHEM BIOPHYS, V190, P334; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLYNIAS MJ, 1984, BIOCHEMISTRY-US, V23, P3454, DOI 10.1021/bi00310a011; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GOODRIDGE AG, 1989, J NUTR, V119, P299, DOI 10.1093/jn/119.2.299; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MA XJ, 1990, J BIOL CHEM, V265, P18435; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MILSTED A, 1987, DNA-J MOLEC CELL BIO, V6, P213, DOI 10.1089/dna.1987.6.213; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; ROBINSON HL, 1976, J VIROL, V18, P856, DOI 10.1128/JVI.18.3.856-866.1976; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1976, P NATL ACAD SCI USA, V73, P3877, DOI 10.1073/pnas.73.11.3877; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; TAKAI T, 1988, J BIOL CHEM, V263, P2651; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WISE EM, 1964, P NATL ACAD SCI USA, V52, P1255, DOI 10.1073/pnas.52.5.1255; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	52	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12299	12306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1351057				2022-12-27	WOS:A1992HY94700096
J	SHI, GP; MUNGER, JS; MEARA, JP; RICH, DH; CHAPMAN, HA				SHI, GP; MUNGER, JS; MEARA, JP; RICH, DH; CHAPMAN, HA			MOLECULAR-CLONING AND EXPRESSION OF HUMAN ALVEOLAR MACROPHAGE CATHEPSIN-S, AN ELASTINOLYTIC CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; PLASMINOGEN-ACTIVATOR; DEGRADATION; PROTEINASE; NUCLEOTIDE; FIBROBLASTS; CLEAVAGE; INVITRO; SMOKERS; FORMS	Human alveolar macrophages (HAM) express an elastase activity of acidic pH optimum inhibitable by cysteine protease inhibitors. Recent studies indicate that the only known eukaryotic elastinolytic cysteine protease, cathepsin L, cannot completely account for this activity. In order to search for additional cysteine proteases with elastinolytic activity, low degeneracy oligonucleotide primers based on regions of strong homology among the known cysteine proteases were used to screen reverse-transcribed HAM RNA for cysteine proteases by the polymerase chain reaction. Among the cDNA sequences generated was a 493-base pair product highly homologous to bovine cathepsin S. Screening of a HAM cDNA eukaryotic expression library with this cDNA yielded a 1.7-kilobase full-length cDNA highly homologous to bovine cathepsin S (approximately 85% identical). This cDNA predicts a 331-amino acid preprocathepsin. Expression of this cDNA in COS cells revealed the active enzyme to be a single chain 28-kDa protease, as judged by active site labeling with a novel iodinated analogue of N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucylamido-(4-guanido)butane (E-64). The recombinant enzyme was found to be elastinolytic toward H-3-labeled elastin (bovine ligamentum nuchae) at pH 5.5 but with 25% of this activity retained at pH 7.0. Labeling of HAM with the active site probe revealed these cells express a 28-kDa cysteine protease, and Northern blot analysis revealed the presence of a approximately 1.7-kilobase cathepsin S mRNA. These data establish that human macrophages express at least two cysteine proteases with elastinolytic activity. The relatively broad pH range of human cathepsin S activity suggests this enzyme may contribute to the contact-dependent elastase activity of live human alveolar macrophages.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53708; UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53708	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Munger, John/0000-0002-9679-2983	PHS HHS [44712, 35653] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1987, CURRENT PROTOCOLS MO, V1; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; CHAPMAN HA, 1984, J CLIN INVEST, V74, P1693, DOI 10.1172/JCI111586; EIDELMAN D, 1990, AM REV RESPIR DIS, V141, P1547, DOI 10.1164/ajrccm/141.6.1547; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; FONG D, 1986, P NATL ACAD SCI USA, V83, P2909, DOI 10.1073/pnas.83.9.2909; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MORI K, 1980, TETRAHEDRON, V36, P87, DOI 10.1016/0040-4020(80)85029-0; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; REILLY JJ, 1991, AM J PHYSIOL, V261, pL41, DOI 10.1152/ajplung.1991.261.2.L41; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WAHL GM, 1987, METHOD ENZYMOL, V152, P415; WERB Z, 1980, J EXP MED, V152, P1537, DOI 10.1084/jem.152.6.1537; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5	28	281	297	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7258	7262						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373132				2022-12-27	WOS:A1992HN48500013
J	SUGIMOTO, Y; NAMBA, T; HONDA, A; HAYASHI, Y; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S				SUGIMOTO, Y; NAMBA, T; HONDA, A; HAYASHI, Y; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S			CLONING AND EXPRESSION OF A CDNA FOR MOUSE PROSTAGLANDIN-E RECEPTOR EP(3) SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLLECTING TUBULE CELLS; ADENYLATE-CYCLASE; BINDING PROTEIN; METABOLISM; MEDULLA; DNA	A functional cDNA clone for mouse EP3 subtype of prostaglandin (PG) E receptor was isolated from a mouse cDNA library using polymerase chain reaction based on the sequence of the human thromboxane A2 receptor and cross-hybridization screening. The mouse EP3 receptor consists of 365 amino acid residues with putative seven-transmembrane domains. The sequence revealed significant homology to the human thromboxane A2 receptor. Ligand binding studies using membranes of COS cells transfected with the cDNA revealed specific [H-3]PGE2 binding. The binding was displaced with unlabeled PGs in the order of PGE2 = PGE1 > iloprost > PGF2-alpha > PGD2. The EP3-selective agonists, M&B 28,767 or GR 63799X, potently competed for the [H-3]PGE2 binding, but no competition was found with EP1- or EP2-selective ligands. PGE2 and M&B 28,767 decreased forskolin-induced cAMP formation in a concentration-dependent manner in Chinese hamster ovary cells permanently expressing the cDNA. Northern blot analysis demonstrated that the EP3 mRNA is expressed abundantly in kidney, uterus, and mastocytoma P-815 cells and in a lesser amount in brain, thymus, lung, heart, stomach, and spleen.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Sugimoto, Yukihiko/AAV-6470-2021; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Sugimoto, Yukihiko/0000-0001-6973-932X; Hayashi, Yasunori/0000-0002-7560-3004				BRUNTON LL, 1976, J BIOL CHEM, V251, P3037; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COLLINS PW, 1986, J MED CHEM, V29, P437, DOI 10.1021/jm00154a001; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HEDQVIST P, 1972, NEUROPHARMACOLOGY, V11, P177, DOI 10.1016/0028-3908(72)90090-1; HEDQVIST P, 1972, PROSTAGLANDINS, P410; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MORII H, 1991, J NEUROCHEM, V57, P1281, DOI 10.1111/j.1471-4159.1991.tb08291.x; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1991, PROSTAGLANDINS, V42, P225, DOI 10.1016/0090-6980(91)90112-S; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WATANABE T, 1986, J BIOL CHEM, V261, P3430; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119	35	405	420	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6463	6466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1372606				2022-12-27	WOS:A1992HM05300004
J	THOMAS, PJ; SHENBAGAMURTHI, P; SONDEK, J; HULLIHEN, JM; PEDERSEN, PL				THOMAS, PJ; SHENBAGAMURTHI, P; SONDEK, J; HULLIHEN, JM; PEDERSEN, PL			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - EFFECTS OF THE MOST COMMON CYSTIC FIBROSIS-CAUSING MUTATION ON THE SECONDARY STRUCTURE AND STABILITY OF A SYNTHETIC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE-BINDING FOLD; PROTEIN CONFORMATION; 50-AMINO ACID; ATP SYNTHASE; GENE; IDENTIFICATION; DNA	Deletion of phenylalanine 508 (DELTA-Phe-508) in the cystic fibrosis transmembrane conductance regulator (CFTR) protein causes approximately 70% of all cases of cystic fibrosis. This residue lies in a region of the protein that we have synthesized chemically and shown to bind adenine nucleotides (Thomas, P. J., Shenbagamurthi, P., Ysern, X., and Pedersen, P. L. (1991) Science 251, 555-557). A peptide lacking this critical residue, but otherwise corresponding to this crucial part of the protein, now also has been chemically synthesized and purified. This mutant peptide (P-66) exhibits a significant loss of beta-sheet structure as compared with the wild type peptide (P-67). Furthermore, urea denaturation of peptide structure reveals that P-66 is less stable than P-67. Although under non-denaturing conditions both peptides bind adenine nucleotides with high affinity, the loss of structural stability is reflected in the binding function of the peptides. Thus, P-67, in contrast to P-66, retains a significant capacity for nucleotide binding in 4 M urea. These results suggest a model for impaired DELTA-Phe-508 CFTR function.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University			Thomas, Philip J/F-7115-2012	Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043962] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43962] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; ARORA KK, 1990, J BIOL CHEM, V265, P5324; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOLOTINA IA, 1980, MOL BIOL+, V14, P701; BRACK A, 1981, J AM CHEM SOC, V103, P6319, DOI 10.1021/ja00411a009; CALDERON RO, 1985, BIOCHEMISTRY-US, V24, P6044, DOI 10.1021/bi00343a004; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; PEDERSEN PL, 1975, J SUPRAMOL STR CELL, V3, P222, DOI 10.1002/jss.400030304; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANG JT, 1985, MICRODOMAINS POLYM S, P311	28	91	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5727	5730						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372891				2022-12-27	WOS:A1992HK31800002
J	SADOWSKI, HB; WHEELER, TT; YOUNG, DA				SADOWSKI, HB; WHEELER, TT; YOUNG, DA			GENE-EXPRESSION DURING 3T3-L1 ADIPOCYTE DIFFERENTIATION - CHARACTERIZATION OF INITIAL RESPONSES TO THE INDUCING AGENTS AND CHANGES DURING COMMITMENT TO DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ENHANCER BINDING-PROTEIN; FIBROBLAST GROWTH-FACTOR; ADIPOSE CONVERSION; INSULIN-RECEPTORS; MESSENGER-RNA; PREADIPOCYTE DIFFERENTIATION; ELECTROPHORETIC SEPARATION; RESPONSIVENESS INVITRO; DIHYDROTELEOCIDIN-B	The mouse 3T3-L1 fibroblastic cell line rapidly differentiates to an adipocyte phenotype when post-confluent cells are treated for 48 h in fetal calf serum-containing medium supplemented with 1-mu-M dexamethasone (D), 0.5 mM methylisobutylxanthine (M) and 10-mu-g/ml insulin (I). D and I act synergistically to commit the cells to differentiate 24-48 h after initiating treatment, and this is blocked by the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate. In order to identify cellular proteins involved in the differentiation process we analyzed differentiating 3T3-L1 cells using two-dimensional electrophoresis on large format gels. We observed changes in over 300 proteins during differentiation (over 100 within 5 h of initiating differentiation) and many of these are also changed at the level of mRNA (by analysis of in vitro translation products). About 75% of the initial changes were maximally induced by treatment with a combination of M and I, while no more than 10 proteins and their corresponding mRNAs were maximally induced by D within 3.5 h. Another 10 proteins were synergistically regulated by the combination of all three agents (DMI) within 3.5 h. Additional species were induced at later times. Five of these were synergistically induced by treatments that lead to differentiation, were first expressed at elevated levels during commitment and remained elevated in fully differentiated adipocytes. One or more of these proteins could well have a functional role in the commitment to and/or expression of the adipocyte differentiation program.	UNIV ROCHESTER, MED CTR,DEPT MED,E HENRY KEUTMANN LAB, ENDOCRINE METAB UNIT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT RADIAT BIOL & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, CTR ENVIRONM HLTH SCI, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA47650] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1984, EXP CELL RES, V152, P368, DOI 10.1016/0014-4827(84)90638-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG TH, 1978, J BIOL CHEM, V253, P4693; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COLBERT RA, 1986, P NATL ACAD SCI USA, V83, P72, DOI 10.1073/pnas.83.1.72; COLBERT RA, 1986, ENDOCRINOLOGY, V119, P2598, DOI 10.1210/endo-119-6-2598; COLBERT RA, 1986, J BIOL CHEM, V261, P4733; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; ELKS ML, 1985, J CELL PHYSIOL, V124, P191, DOI 10.1002/jcp.1041240204; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GAMOU S, 1986, CELL STRUCT FUNCT, V11, P21, DOI 10.1247/csf.11.21; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOPKINS NK, 1981, BIOCHIM BIOPHYS ACTA, V663, P457, DOI 10.1016/0005-2760(81)90174-0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Reed B C, 1980, Adv Enzyme Regul, V18, P97, DOI 10.1016/0065-2571(80)90011-4; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SHIMIZU Y, 1983, CANCER RES, V43, P4974; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEINBERG MM, 1982, J CELL PHYSIOL, P37; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VORIS BP, 1980, ANAL BIOCHEM, V104, P478, DOI 10.1016/0003-2697(80)90103-7; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	53	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4722	4731						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1371508				2022-12-27	WOS:A1992HF64200067
J	PUKAC, LA; OTTLINGER, ME; KARNOVSKY, MJ				PUKAC, LA; OTTLINGER, ME; KARNOVSKY, MJ			HEPARIN SUPPRESSES SPECIFIC 2ND MESSENGER PATHWAYS FOR PROTOONCOGENE EXPRESSION IN RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; INDEPENDENT PATHWAYS; PROLIFERATION; FOS; RNA; INHIBITION; ACTIVATION; INDUCTION	We investigated the molecular mechanisms underlying the ability of heparin to inhibit vascular smooth muscle cell (VSMC) growth. Previous experiments have shown that heparin inhibits induction of c-fos and c-myc protooncogene mRNA in rat VSMC stimulated by phorbol 12-myristate 13-acetate (PMA) but not when stimulated by epidermal growth factor (EGF) (Pukac, L. A., Castellot, J. J., Wright, T. C., Caleb, B. L., and Karnovsky, M. J. (1990) Cell Regul. 1, 435-443). The present experiments show that these mitogens activate distinct second messenger pathways in VSMC, because PMA but not EGF induction of c-fos and c-myc mRNA was suppressed in protein kinase C (PKC) down-regulated VSMC; this suggests that EGF does not act through a PKC-dependent pathway for induction of these genes. Heparin inhibited serum stimulation of c-fos mRNA in control VSMC, but heparin did not inhibit the smaller but significant serum stimulation of c-fos mRNA in PKC down-regulated VSMC, indicating that heparin may selectively inhibit PKC-dependent, but not PKC-independent, stimulation of gene expression. To further determine if heparin inhibits non-PKC pathways, VSMC were treated with dibutyryl cAMP, 3-isobutyl-1-methyl-xanthine, and Ca2+ ionophore A23187; stimulation of c-fos mRNA by this treatment was not inhibited by heparin. DNA synthesis and cell proliferation were inhibited in rat VSMC exposed briefly to heparin during the G0/G1 phase of the cell cycle. These experiments indicate heparin can act early in the cell cycle and suggest PKC-dependent but not PKC-independent signaling pathways for gene expression are selectively sensitive to heparin inhibition.			PUKAC, LA (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017747, R37HL017747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; REILLY CF, 1988, J CELL PHYSIOL, V136, P23, DOI 10.1002/jcp.1041360104; REILLY CF, 1987, J CELL PHYSIOL, V131, P149, DOI 10.1002/jcp.1041310203; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199	25	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3707	3711						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371276				2022-12-27	WOS:A1992HE60700027
J	MIRELS, L; BALL, WD				MIRELS, L; BALL, WD			NEONATAL RAT SUBMANDIBULAR-GLAND PROTEIN SMG-A AND PAROTID SECRETORY PROTEIN ARE ALTERNATIVELY REGULATED MEMBERS OF A SALIVARY PROTEIN MULTIGENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ACINAR-CELLS; MOUSE; EXPRESSION; SEQUENCES; AMYLASE; GENE; LOCALIZATION; COORDINATION; EXTIRPATION	Submandibular gland-A (SMG-A) is a major secretory product of the neonatal rat submandibular gland but is not synthesized by the acinar cells of the adult gland. The leucine-rich protein is a predominant product of the adult rat parotid gland. Preliminary data had indicated that the leucine-rich protein and SMG-A might be identical proteins whose expression was differently regulated in the parotid and submandibular salivary glands. cDNA clones encoding SMG-A and the leucine-rich protein were identified by homology to a major mouse parotid gland product, parotid secretory protein (PSP), and characterized. The leucine-rich protein shares extensive sequence homology with mouse PSP throughout its 5'-untranslated, protein coding and 3'-untranslated regions, prompting our suggestion that it should henceforth be referred to as rat PSP. SMG-A is more divergent, having greatest identity with rat and mouse PSP in its signal peptide and 3'-untranslated sequences. Transcripts homologous to SMG-A and rat PSP, but more closely related to SMG-A, were identified in rat sublingual gland by Northern blot analysis. These findings indicate that rat SMG-A and PSP arise from alternatively regulated members of a multigene family.	COLUMBIA UNIV,SCH DENT & ORAL SURG,NEW YORK,NY 10027; HOWARD UNIV,COLL MED,DEPT ANAT,WASHINGTON,DC 20059; HOWARD UNIV,COLL MED,CTR CANC,WASHINGTON,DC 20059	Columbia University; Howard University; Howard University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009428, R01DE006635] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06635, DE-09428] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1409; BALL WD, 1984, EUR J CELL BIOL, V33, P112; BALL WD, 1978, DIFFERENTIATION, V10, P147, DOI 10.1111/j.1432-0436.1978.tb00957.x; BALL WD, 1988, DEV BIOL, V125, P265, DOI 10.1016/0012-1606(88)90210-2; CHANG WWL, 1974, ANAT RECORD, V178, P187, DOI 10.1002/ar.1091780204; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; CUTLER LS, 1974, DEV BIOL, V41, P31, DOI 10.1016/0012-1606(74)90280-2; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DENNY PC, 1990, ANAT REC, V226, P489, DOI 10.1002/ar.1092260411; DICKINSON DP, 1989, MOL BIOL EVOL, V6, P80; DICKINSON DP, 1987, BIOCHEM BIOPH RES CO, V149, P784, DOI 10.1016/0006-291X(87)90436-0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANKS CT, 1971, AM J ANAT, V130, P195, DOI 10.1002/aja.1001300206; HEINRICH G, 1987, J BIOL CHEM, V262, P5262; JOHNSON DA, 1984, ARCH ORAL BIOL, V29, P215, DOI 10.1016/0003-9969(84)90058-X; KELLER PJ, 1975, BIOCHIM BIOPHYS ACTA, V379, P562, DOI 10.1016/0005-2795(75)90162-2; KOUSVELARI EE, 1984, BIOCHEM J, V222, P17, DOI 10.1042/bj2220017; MADSEN HO, 1985, NUCLEIC ACIDS RES, V13, P1, DOI 10.1093/nar/13.1.1; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MINAGUCHI K, 1989, J DENT RES, V68, P2, DOI 10.1177/00220345890680010201; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MOREIRA JE, 1991, AM J ANAT, V191, P167, DOI 10.1002/aja.1001910204; MOREIRA JE, 1990, DEV BIOL, V139, P370, DOI 10.1016/0012-1606(90)90306-4; OWERBACH D, 1980, GENETICS, V95, P129; POULSEN K, 1986, EMBO J, V5, P1891, DOI 10.1002/j.1460-2075.1986.tb04441.x; REDMAN RS, 1971, DEV BIOL, V25, P248, DOI 10.1016/0012-1606(71)90030-3; ROBINOVITCH MR, 1969, ARCH ORAL BIOL, V14, P935, DOI 10.1016/0003-9969(69)90270-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW P, 1986, J MOL BIOL, V192, P567, DOI 10.1016/0022-2836(86)90277-9; SHAW P, 1986, CELL, V47, P107, DOI 10.1016/0092-8674(86)90371-5; SHAW PH, 1984, GENE, V29, P77, DOI 10.1016/0378-1119(84)90168-9; TABAK LA, 1985, ARCH BIOCHEM BIOPHYS, V242, P383, DOI 10.1016/0003-9861(85)90222-X; WALLACH D, 1975, BIOCHIM BIOPHYS ACTA, V382, P552, DOI 10.1016/0005-2736(75)90222-9; YAGIL C, 1985, VIRCHOWS ARCH B, V49, P83, DOI 10.1007/BF02912087; YAMASHINA S, 1972, J HISTOCHEM CYTOCHEM, V20, P855, DOI 10.1177/20.11.855; ZAJICEK G, 1985, ANAT REC, V213, P150, DOI 10.1002/ar.1092130206	39	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2679	2687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370829				2022-12-27	WOS:A1992HB53200087
J	SARKADI, B; BAUZON, D; HUCKLE, WR; EARP, HS; BERRY, A; SUCHINDRAN, H; PRICE, EM; OLSEN, JC; BOUCHER, RC; SCARBOROUGH, GA				SARKADI, B; BAUZON, D; HUCKLE, WR; EARP, HS; BERRY, A; SUCHINDRAN, H; PRICE, EM; OLSEN, JC; BOUCHER, RC; SCARBOROUGH, GA			BIOCHEMICAL-CHARACTERIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN NORMAL AND CYSTIC-FIBROSIS EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; GENE-TRANSFER; IDENTIFICATION; EXPRESSION; TRANSPORT; PHOSPHORYLATION; PROTEINS	Affinity-purified polyclonal antibodies, raised against two synthetic peptides corresponding to the R domain and the C terminus of the human cystic fibrosis transmembrane conductance regulator (CFTR), were used to characterize and localize the protein in human epithelial cells. Employing an immunoblotting technique that ensures efficient detection of large hydrophobic proteins, both antibodies recognized an approximately 180-kDa protein in cell lysates and isolated membranes of airway epithelial cells from normal and cystic fibrosis (CF) patients and of T84 colon carcinoma cells. Reactivity with the anti-C terminus antibody, but not with the anti-R domain antibody, was eliminated by limited carboxypeptidase Y digestion. When normal CFTR cDNA was overexpressed via a retroviral vector in CF or normal airway epithelial cells or in mouse fibroblasts, the protein produced had an apparent molecular mass of about 180 kDa. The CFTR expressed in insect (Sf9) cells by a baculovirus vector had a molecular mass of about 140 kDa, probably representing a nonglycosylated form. The CFTR in epithelial cells appears to exist in several forms. N-glycosidase treatment of T84 cell membranes reduces the apparent molecular mass of the major CFTR band from 180 kDa to 140 kDa, but a fraction of the T84 cell CFTR could not be deglycosylated, and the CFTR in airway epithelial cell membranes could not be deglycosylated either. Moreover, wheat germ agglutinin absorbs the majority of the CFTR from detergent-solubilized T84 cell membranes but not from airway cell membranes. The CFTR in all epithelial cell types was found to be an integral membrane protein not solubilized by high salt or lithium diiodosalicylate treatment. Sucrose density gradient fractionation of crude membranes prepared from the airway epithelial cells, previously surface-labeled by enzymatic galactosidation, showed a plasma membrane localization for both the normal CFTR and the CFTR carrying the Phe508 deletion (DELTA-F 508). The CFTR in all cases co-localized with the Na+, K+-ATPase and the plasma membrane calcium ATPase, while the endoplasmic reticulum calcium ATPase and mitochondrial membrane markers were enriched at higher sucrose densities. Thus, the CFTR appears to be localized in the plasma membrane both in normal and DELTA-F 508 CF epithelial cells.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; NATL INST HAEMATOL & BLOOD TRANSFUS,BUDAPEST,HUNGARY	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Sarkadi, Balazs/I-5024-2013	Huckle, William/0000-0001-7838-329X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047121, P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00046] Funding Source: Medline; NHLBI NIH HHS [HL 34322, HL 47121] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KANTNER N, 1991, CELL, V64, P681; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PATTERSON MS, 1965, ANAL CHEM, V37, P854, DOI 10.1021/ac60226a017; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REDDEL RR, 1988, CANCER RES, V48, P1904; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SARKADI B, 1982, CELL CALCIUM, V3, P163, DOI 10.1016/0143-4160(82)90012-4; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SUMMERS MD, 1988, B TEXAS AGR EXPT STA, V1555; THILO L, 1983, METHOD ENZYMOL, V98, P415; WARD CL, 1990, PEDIATR PULM S, V5, P215; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	33	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2087	2095						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370488				2022-12-27	WOS:A1992HA48500102
J	MORIKAMI, A; AISO, K; ASAHI, T; NAKAMURA, K				MORIKAMI, A; AISO, K; ASAHI, T; NAKAMURA, K			THE DELTA'-SUBUNIT OF HIGHER-PLANT 6-SUBUNIT MITOCHONDRIAL F1-ATPASE IS HOMOLOGOUS TO THE DELTA-SUBUNIT OF ANIMAL MITOCHONDRIAL F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHLOROPLAST ATPASE; EPSILON-SUBUNIT; ALPHA-SUBUNIT; SWEET-POTATO; BETA-SUBUNIT; PURIFICATION; SEQUENCES; OPERON; GENES	Mitochondrial F1-ATPases purified from several dicotyledonous plants contain six different subunits of alpha, beta, gamma, delta, delta', and epsilon. Previous N-terminal amino acid sequence analyses indicated that the gamma-, delta-, and epsilon-subunits of the sweet potato mitochondrial F1 correspond to the gamma-subunit, the oligomycin sensitivity-conferring protein and the epsilon-subunit of animal mitochondrial F1F0 complex (Kimura, T., Nakamura, K., Kajiura, H., Hattori, H., Nelson, N., and Asahi, T. (1989) J. Biol. Chem. 264, 3183-3186). However, the N-terminal amino acid sequence of the delta'-subunit did not show any obvious homologies with known protein sequences. A cDNA clone for the delta'-subunit of the sweet potato mitochondrial F1 was identified by oligonucleotide-hybridization selection of a cDNA library. The 1.0-kilobase-long cDNA contained a 600-base pair open reading frame coding for a precursor for the delta'-subunit. The precursor for the delta'-subunit contained N-terminal presequence of 21-amino acid residues. The mature delta'-subunit is composed of 179 amino acids and its sequence showed similarities of about 31-36% amino acid positional identity with the delta-subunit of animal and fungal mitochondrial F1 and about 18-25% with the epsilon-subunit of bacterial F1 and chloroplast CF1. The sweet potato delta'-subunit contains N-terminal sequence of about 45-amino acid residues that is absent in other related subunits. It is concluded that the six-subunit plant mitochondrial F1 contains the subunit that is homologous to the oligomycin sensitivity-conferring protein as one of the component in addition to five subunits that are homologous to subunits of animal mitochondrial F1.	NAGOYA UNIV,SCH AGR,BIOCHEM LAB,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University								COX GB, 1987, BIOCHIM BIOPHYS ACTA, V890, P195, DOI 10.1016/0005-2728(87)90020-X; DUNN PPJ, 1985, BIOCHEM J, V225, P821, DOI 10.1042/bj2250821; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; ENGELBRECHT S, 1989, EUR J BIOCHEM, V181, P485, DOI 10.1111/j.1432-1033.1989.tb14750.x; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HORAK A, 1985, BIOCHIM BIOPHYS ACTA, V810, P310, DOI 10.1016/0005-2728(85)90215-4; HORAK A, 1990, FEBS LETT, V274, P9, DOI 10.1016/0014-5793(90)81316-G; HORAK A, 1987, BIOCHIM BIOPHYS ACTA, V893, P190, DOI 10.1016/0005-2728(87)90039-9; HOWE CJ, 1985, PLANT MOL BIOL, V4, P333, DOI 10.1007/BF02418255; IWASAKI Y, 1983, ARCH BIOCHEM BIOPHYS, V227, P164, DOI 10.1016/0003-9861(83)90359-4; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KIMURA T, 1990, J BIOL CHEM, V265, P6079; KRUSE B, 1984, EUR BIOENERG C REP B, V3, P607; QUAZZANI C, 1991, PLANT SCI, V74, P53; RANDALL SK, 1985, PLANT PHYSIOL, V79, P957, DOI 10.1104/pp.79.4.957; SHINOZAKI K, 1983, GENE, V24, P147; SPITSBERG VL, 1985, PLANT PHYSIOL, V77, P339, DOI 10.1104/pp.77.2.339; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER R, 1988, FEBS LETT, V230, P109, DOI 10.1016/0014-5793(88)80652-5; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	22	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					72	76						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370454				2022-12-27	WOS:A1992GY43900017
J	LADRAM, A; BULANT, M; NICOLAS, P				LADRAM, A; BULANT, M; NICOLAS, P			CHARACTERIZATION OF RECEPTORS FOR THYROTROPIN-RELEASING HORMONE-POTENTIATING PEPTIDE ON RAT ANTERIOR-PITUITARY MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE PRO-TRH; PANCREATIC-ISLETS; IMMUNOCYTOCHEMICAL DISTRIBUTION; CONNECTING PEPTIDES; PRECURSOR PEPTIDES; XENOPUS-LAEVIS; BRAIN; IDENTIFICATION; LOCALIZATION; PREPRO-TRH-(160-169)	Previous studies (Bulant, M., Delfour, A., Vaudry, H., and Nicolas, P. (1 988) J. Biol. Chem. 2 63, 17189-17196; Bulant, M., Roussel, J. P., Astier, H., Nicolas, P., and Vaudry, H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4439-4443) have shown that post-translational processing of rat thyrotropin-releasing hormone prohormone (pro-TRH) generates, besides thyrotropin-releasing hormone (TRH), a connecting decapeptide corresponding to prepro-TRH-(160-169), i.e. Ser-Phe-Pro-Trp-Met-Glu-Ser-Asp-Val-Thr. This peptide, which is named TRH-potentiating peptide (Ps4), is co-localized with TRH in the median eminence nerve endings and is involved in potentiation of the action of TRH on thyrotropin hormone release by pituitary in vitro and in vivo. To characterize the receptor(s) for TRH-potentiating peptide in the pituitary, a highly potent and metabolically stable derivative of Ps4, [I-Tyr0]Ps4, was radioiodinated. Binding of [I-125-Tyr-0]Ps4 to rat pituitary membrane homogenates was specific, saturable, reversible, and linear with membrane protein concentration. Equilibrium measurements performed over a large range of concentrations revealed a single homogeneous population of high affinity binding sites (K(d) = 0.22 nM; B(max) = 517 fmol/mg of membrane proteins). Several naturally occurring neuropeptides and hormones, including TRH, did not compete with [I-125-Tyr0]Ps4 in the binding, which suggests the binding sites are specific to Ps4. Using C-terminal deletion analogs of [Tyr0]Ps4, we further showed the critical role the C-terminal residues Thr10, Val9, and Asp8 play in conferring high binding affinity and selectivity. Binding site tissue distribution and cross-reactivity binding studies suggest that the action of TRH-potentiating peptide is mediated through interaction with a specific pituitary cell-surface receptor which differ from those for TRH. [I-Tyr0]Ps4 reported in this paper, through its high binding affinity and specificity, its very low nonspecific binding, its high resistance to enzymatic degradation, and its high potentiating action in vitro should allow further progress in understanding the in vivo physiological function of Ps4.	UNIV PARIS 07, INST JACQUES MONOD, BIOACTIVAT PEPTIDE LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite	BULANT, M (corresponding author), UNIV PARIS 07, INST JACQUES MONOD, BIOACTIVAT PEPTIDE LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.		Nicolas, Pierre/C-7908-2009					ARATANSPIRE S, 1984, ENDOCRINOLOGY, V114, P2369, DOI 10.1210/endo-114-6-2369; BOLER J, 1969, BIOCHEM BIOPH RES CO, V37, P705, DOI 10.1016/0006-291X(69)90868-7; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; BULANT M, 1992, FEBS LETT, V296, P292, DOI 10.1016/0014-5793(92)80307-3; BULANT M, 1990, P NATL ACAD SCI USA, V87, P4439, DOI 10.1073/pnas.87.12.4439; BURGUS R, 1969, CR ACAD SCI D NAT, V269, P1870; CARR FE, 1990, 72ND ANN M END SOC, P807; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; COCKLE SM, 1987, EUR J BIOCHEM, V165, P693, DOI 10.1111/j.1432-1033.1987.tb11496.x; DUTOUR A, 1989, PEPTIDES, V10, P523, DOI 10.1016/0196-9781(89)90136-8; GAY DD, 1981, INT J PEPT PROT RES, V18, P107; GKONOS PJ, 1989, MOL ENDOCRINOL, V3, P2101, DOI 10.1210/mend-3-12-2101; HOKFELT T, 1989, ANN NY ACAD SCI, V553, P76; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KUCHLER K, 1990, J BIOL CHEM, V265, P11731; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; LEDUQUE P, 1989, ENDOCRINOLOGY, V125, P1492, DOI 10.1210/endo-125-3-1492; LEE SL, 1988, J BIOL CHEM, V263, P16604; LIAO N, 1988, NEUROPEPTIDES, V11, P107, DOI 10.1016/0143-4179(88)90078-9; LIAO N, 1988, NEUROSCI LETT, V85, P24, DOI 10.1016/0304-3940(88)90422-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINO E, 1978, P NATL ACAD SCI USA, V75, P4265, DOI 10.1073/pnas.75.9.4265; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; VALENTIJN K, 1991, NEUROSCIENCE, V44, P223, DOI 10.1016/0306-4522(91)90263-N; WICKLER C, 1991, 73RD ANN M END SOC, P417; WU P, 1988, REGUL PEPTIDES, V22, P347, DOI 10.1016/0167-0115(88)90111-5; WU P, 1988, BRAIN RES, V456, P22, DOI 10.1016/0006-8993(88)90342-3; WU P, 1987, ENDOCRINOLOGY, V121, P108, DOI 10.1210/endo-121-1-108; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551	34	16	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25697	25702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334484				2022-12-27	WOS:A1992KD07300018
J	MENDOZA, JA; BUTLER, MC; HOROWITZ, PM				MENDOZA, JA; BUTLER, MC; HOROWITZ, PM			CHARACTERIZATION OF A STABLE, REACTIVATABLE COMPLEX BETWEEN CHAPERONIN-60 AND MITOCHONDRIAL RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; BOVINE LIVER RHODANESE; ESCHERICHIA-COLI; TERTIARY STRUCTURE; PROTEINS; GROEL; PURIFICATION; STATE; ATP	Efficient formation of the cpn60-rhodanese complex can be achieved by mixing unfolded rhodanese with excess cpn60 at low temperature. By employing these conditions, a stable and highly reactivatable complex is formed. The complex is not formed when native enzyme is used. Concentrations of NaCl, as high as 0.75 M, do not have any effect on the formation or disruption of the binary complex. cpn60-bound rhodanese contains an exposed hydrophobic surface, as detected by the binding of the fluorescent reporter, 1-anilinonaphthalene-8-sulfonic acid. The intrinsic fluorescence of cpn60-bound rhodanese reports that the average tryptophan is in an intermediate environment between that found in unfolded and native states. This form of rhodanese has an accessibility to quenching by acrylamide or iodide that is intermediate between the unfolded and native forms of the enzyme. Protease susceptibility studies show that rhodanese bound to cpn60 exhibits a trypsin digestion pattern similar to the native enzyme, although it is more rapidly proteolyzed. The results suggest that the conformation of cpn60-bound rhodanese resembles a native-like conformation, but with increased flexibility. Further, only intact rhodanese or enzyme lacking its N-terminal sequence can interact with cpn60 and form a stable binary complex. The protein fragment corresponding to the rhodanese N-terminal sequence did not form part of a stable complex with cpn60.			MENDOZA, JA (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1990, J BIOL CHEM, V265, P5967; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VONHIPPEL PH, 1964, SCIENCE, V145, P577, DOI 10.1126/science.145.3632.577; WEBER G, 1964, J BIOL CHEM, V239, P1415; WESTLEY J, 1959, J BIOL CHEM, V234, P2325; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24648	24654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1360012				2022-12-27	WOS:A1992KA26300075
J	CLONEY, LP; WU, HB; HEMMINGSEN, SM				CLONEY, LP; WU, HB; HEMMINGSEN, SM			EXPRESSION OF PLANT CHAPERONIN-60 GENES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; BACTERIOPHAGE-LAMBDA INFECTION; SUBUNIT BINDING-PROTEIN; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; GROEL; CHLOROPLASTS; COMPLEXES; PRECURSOR	We have examined the expression in Escherichia coli of genes encoding a plant chloroplast molecular chaperone, chaperonin-60. Purified plant chaperonin-60 is distinct in that it contains two polypeptides, p60cpn-60alpha and p60cpn-60beta, which have divergent amino acid sequences (Hemmingsen, S. M., and Ellis, R. J. (1986) Plant Physiol. 80, 269-276; Martel, R., Cloney, L. P., Pelcher, L. E., and Hemmingsen, S. M. (1990) Gene (Amst.) 94, 181-187). The precise polypeptide composition(s) of the active tetradecameric specie(s) (cpn60(14)) has not been determined. Genes encoding the mature forms of the Brassica napus chaperonin polypeptides have been expressed separately and in combination in E. coli to produce three novel strains: alpha, beta, and alphabeta. The plant cpn60 polypeptides accumulated in soluble forms and to similar high levels in each. There was no conclusive evidence that p60cpn-60alpha assembled into cpn60(14) species in a cells. In beta and alphabeta cells, the plant gene products assembled efficiently into cpn60(14) species. Thus, the assembly of p60cpn-60alpha required the presence of p60cpn-60beta, whereas the assembly of p60cpn-60beta could occur in the absence of p60cpn-60alpha. Significant proportions of the endogenous groEL polypeptides were not assembled into tetradecameric groEL14 in beta and alphabeta cells. Analysis of the tetradecameric species that did form indicated the presence of novel hybrid cpn60(14) species that contained both plant and bacterial cpn60 polypeptides.	NATL RES COUNCIL CANADA,INST PLANT BIOTECHNOL,110 GYMNASIUM PL,SASKATOON S7N 0W9,SASKATCHEWAN,CANADA	National Research Council Canada								AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAHL H, 1987, GENE DEV, V1, P57, DOI 10.1101/gad.1.1.57; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLONEY LP, 1992, J BIOL CHEM, V267, P23333; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, PLANT J, V1, P9, DOI 10.1111/j.1365-313X.1991.00009.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GATENBY AA, 1990, TRENDS BIOTECHNOL, V8, P354, DOI 10.1016/0167-7799(90)90224-L; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; KOCHAN J, 1982, J BACTERIOL, V149, P1166, DOI 10.1128/JB.149.3.1166-1170.1982; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; ROY H, 1988, TRENDS BIOCHEM SCI, V13, P163, DOI 10.1016/0968-0004(88)90139-9; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	30	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23327	23332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1358882				2022-12-27	WOS:A1992JY16300094
J	SUSA, M; KEELER, M; VARTICOVSKI, L				SUSA, M; KEELER, M; VARTICOVSKI, L			PLATELET-DERIVED GROWTH-FACTOR ACTIVATES MEMBRANE-ASSOCIATED PHOSPHATIDYLINOSITOL 3-KINASE AND MEDIATES ITS TRANSLOCATION FROM THE CYTOSOL - DETECTION OF ENZYME-ACTIVITY IN DETERGENT-SOLUBILIZED CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; BOVINE BRAIN; RAT-LIVER; PROTEIN; POLYPHOSPHOINOSITIDES; TRANSFORMATION; PURIFICATION; FIBROBLASTS; PI3-KINASE	Phosphatidylinositol 3-kinase (PI 3-kinase) activity has been detected in immune complexes with active protein tyrosine kinases, and its products have been measured in intact cells in response to growth stimuli. Both methods do not directly evaluate whole cell PI 3-kinase enzymatic activity. We have developed a sensitive method to measure PI 3-kinase activity in diluted, detergent-containing whole cell extracts and used this method to determine total, soluble, and membrane-associated PI 3-kinase activity in PDGF-stimulated NIH 3T3 fibroblasts. PDGF stimulation induced a 1.4-fold increase in total Nonidet P-40-extractable PI 3-kinase activity, which occurred within 1 min and was maintained above basal levels at 10 min. At the same time, PI 3-kinase activity in the soluble fraction decreased 30-50%. However, membrane-bound PI 3-kinase activity increased 2.4-fold at 1 min and 3.1-fold at 5 min. Translocation of the p85 PI 3-kinase subunit to the membrane was maximal at 10 min. These results suggest that PDGF-mediated activation of PI 3-kinase in membrane fraction results from initial intrinsic enzymatic activation followed by translocation from the cytosol.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,736 CAMBRIDGE ST,BOSTON,MA 02135					Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [R29CA53094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG J, 1992, J BIOL CHEM, V267, P4686	29	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22951	22956						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331070				2022-12-27	WOS:A1992JY16300039
J	YU, K; MORIOKA, H; FRITZE, LMS; BEELER, DL; JACKMAN, RW; ROSENBERG, RD				YU, K; MORIOKA, H; FRITZE, LMS; BEELER, DL; JACKMAN, RW; ROSENBERG, RD			TRANSCRIPTIONAL REGULATION OF THE THROMBOMODULIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING PROTEINS; AMP-INCREASING AGENTS; LEUKEMIA-CELL LINES; ENDOTHELIAL-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; VASCULAR ENDOTHELIUM; ENHANCED EXPRESSION; RNA-POLYMERASE; PROMOTER	The transcriptional start sites of the endogenous human thrombomodulin (TM) gene and transiently expressed TM promoter/CAT gene constructs were defined by nuclease S1 mapping which showed two closely spaced sites at +1 and +6, respectively. Transient expression and in vitro transcription assays of 5' and internal deletion mutants of the TM promoter/CAT gene constructs reveal that the region from -72 to -29 exhibits a positive acting domain which is essential for transcriptional activity, whereas the region from -373 to -225 possesses two positive acting subdomains, -343 to -277 and -245 to -225, which together augment transcriptional activity by about 40%. Electrophoretic mobility shift assays with a duplex oligonucleotide corresponding to -72 to -29 and DNase I footprinting experiments show two specific interaction products which individually or cooperatively protect the DNA sequence from about -60 to -30. These components are essential for TM gene transcription since affinity fractionation of nuclear extracts with a duplex oligonucleotide corresponding to -72 to -29 depletes the above interaction products and specifically inhibits in vitro transcription activity of the promoter, whereas addition of the eluted components specifically restores in vitro transcription activity of the promoter. Electrophoretic mobility shift assays with duplex oligonucleotides corresponding to -294 to -215, as well as -373 to -295 and DNase I footprinting experiments show two specific interaction products which individually bind to the two subdomains but not -72 to -29 and protect the coding and noncoding strands from -245 to -225, and the noncoding strand from -337 to -314, respectively. Transient expression studies reveal that the TM promoter construct starting at -51 and including the TATA box is responsive to TNF only in cell lines exhibiting sensitivity of the endogenous receptor gene to cytokine, whereas other promoter constructs possessing a TATA box sequence are insensitive to TNF in all cell types. Based upon the above data, the regulatory events involved in TNF-dependent transcriptional regulation of the TM gene can be defined with the experimental tools and conceptual framework developed by the present investigation.	MIT,DEPT BIOL,E25-229,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NHLBI NIH HHS [HL 33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey, 1986, BASIC METHODS MOL BI; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOFFA MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1267, DOI 10.1177/35.11.2821107; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; CONWAY EM, 1992, J CELL PHYSIOL, V151, P604, DOI 10.1002/jcp.1041510321; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDGAL CJS, 1983, P NATL ACAD SCI USA, V80, P3734; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIROKAWA K, 1990, J BIOCHEM-TOKYO, V108, P839, DOI 10.1093/oxfordjournals.jbchem.a123290; IMADA S, 1982, J BIOL CHEM, V257, P9108; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; ITO T, 1990, THROMB RES, V58, P615, DOI 10.1016/0049-3848(90)90307-X; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LEE ME, 1990, J BIOL CHEM, V265, P10446; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MCCACHREN SS, 1991, BLOOD, V78, P3128; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOFF GA, 1991, BLOOD, V77, P515; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x	42	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23237	23247						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1331078				2022-12-27	WOS:A1992JY16300082
J	HATAKEYAMA, K; HARADA, T; KAGAMIYAMA, H				HATAKEYAMA, K; HARADA, T; KAGAMIYAMA, H			IMP DEHYDROGENASE INHIBITORS REDUCE INTRACELLULAR TETRAHYDROBIOPTERIN LEVELS THROUGH REDUCTION OF INTRACELLULAR GTP LEVELS - INDICATIONS OF THE REGULATION OF GTP CYCLOHYDROLASE-I ACTIVITY BY RESTRICTION OF GTP AVAILABILITY IN THE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOPTERIN COFACTOR BIOSYNTHESIS; NITRIC-OXIDE SYNTHASE; INTERFERON-GAMMA; 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE; PURIFICATION; MACROPHAGES; METABOLISM; ACTIVATION; ACID; FIBROBLASTS	GTP cyclohydrolase I exhibits a positive homotropic cooperative binding to GTP, which raises the possibility of a role for GTP in regulating the enzyme reaction (Hatakeyama, K., Harada. T., Suzuki, S., Watanabe, Y., and Kagamiyama, H. (1989) J. Biol. Chem. 264, 21660-21664). We examined whether or not the intracellular GTP level is within the range of affecting GTP cyclohydrolase I activity, using PC-12 rat pheochromocytoma and IMR-32 human neuroblastoma cells. Since GTP cyclohydrolase I was the rate-limiting enzyme for the biosynthesis of tetrahydrobiopterin in these cell lines, the intracellular activities of this enzyme were reflected in the tetrahydrobiopterin contents. We found that the addition of guanine or guanosine increased GTP but not tetrahydrobiopterin in these cells. On the other hand, three IMP dehydrogenase inhibitors, tiazofurin, 2-amino-1,3,4-thiadiazole, and mycophenolic acid, decreased both GTP and tetrahydrobiopterin in a parallel and dose-dependent manner, and these effects were reversed by the simultaneous addition of guanine or guanosine. There was no evidence suggesting that these inhibitors inhibited other enzymes involved in the biosynthesis and regeneration of tetrahydrobiopterin. Comparing intracellular activities of GTP cyclohydrolase I in the inhibitor-treated cells with its substrate-velocity curve, we estimated that the intracellular concentration of free GTP is 150 muM at which point the activity of GTP cyclohydrolase I is elicited at its maximum velocity. Below this GTP concentration, GTP cyclohydrolase I activity is rapidly decreased. Therefore GTP can be a regulator for tetrahydrobiopterin biosynthesis.			HATAKEYAMA, K (corresponding author), OSAKA MED COLL,DEPT MED CHEM,TAKATSUKI,OSAKA 569,JAPAN.							BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOTTENSTEIN JE, 1983, ADV CELL NEUROBIOL, V4, P333; BRAUTIGAM M, 1984, J NEUROCHEM, V42, P390, DOI 10.1111/j.1471-4159.1984.tb02690.x; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CARTER SB, 1969, NATURE, V223, P848, DOI 10.1038/223848a0; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; COTE LJ, 1975, J NEUROBIOL, V6, P233, DOI 10.1002/neu.480060209; CRAINE JE, 1972, J BIOL CHEM, V247, P6082; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; EARLE MF, 1983, CANCER RES, V43, P133; FERRE J, 1988, CLIN CHIM ACTA, V271, P271; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; FRANKLIN TJ, 1977, EUR J BIOCHEM, V777, P113; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HASLER T, 1986, P319; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; INOUE Y, 1991, J BIOL CHEM, V266, P20791; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P3839, DOI 10.1016/0006-2952(82)90300-8; JOHNSON GS, 1979, J BIOL CHEM, V254, P95; KAUFMAN S, 1967, ANNU REV BIOCHEM, V36, P171, DOI 10.1146/annurev.bi.36.070167.001131; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; KETTLER R, 1974, NATURE, V249, P476, DOI 10.1038/249476a0; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KWON NS, 1989, J BIOL CHEM, V264, P20496; LIU MS, 1984, J BIOL CHEM, V259, P5078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; NELSON JA, 1977, CANCER RES, V37, P182; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; OCHI K, 1981, J BIOL CHEM, V256, P6866; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SMITH CM, 1977, J CYCLIC NUCL PROT, V3, P347; SMITH GK, 1986, J BIOL CHEM, V261, P2725; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TIETZ A, 1964, J BIOL CHEM, V239, P4081; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	48	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20734	20739						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1356983				2022-12-27	WOS:A1992JT97800036
J	SRIVATSAN, J; SMITH, DF; CUMMINGS, RD				SRIVATSAN, J; SMITH, DF; CUMMINGS, RD			THE HUMAN BLOOD FLUKE SCHISTOSOMA-MANSONI SYNTHESIZES GLYCOPROTEINS CONTAINING THE LEWIS-X ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LECTIN-AFFINITY-CHROMATOGRAPHY; SURFACE GLYCOPROTEINS; CARBOHYDRATE EPITOPES; MONOCLONAL-ANTIBODY; ADULT WORMS; BINDING; MEMBRANE; IDENTIFICATION; FRACTIONATION	Infection of vertebrates with the parasitic blood fluke Schistosoma mansoni induces a variety of host immune responses, which are directed against both protein and carbohydrate antigens. In this report, we describe our studies on the structures of antigenic oligosaccharides derived from glycoproteins synthesized by S. mansoni. Immobilized antibodies derived from the sera of infected hamsters and mice bind to a family of high molecular weight Asn-linked oligosaccharides in glycoproteins from the adult parasite. Structural analysis of the major antigenic oligosaccharides revealed that they have high amounts of fucose-linked alpha1,3 to N-acetylglucosamine residues within the linear repeating disaccharide (3Galbeta1-4GlcNAcbeta1)n, a poly-N-acetyllactosamine sequence containing the Lewis X antigenic blood group. The remarkable ability of S. mansoni to synthesize these vertebrate-type oligosaccharides may have implications in both the mechanisms of host-parasite interactions and on the development of vaccines to prevent this disease in humans.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI026725, R01AI026725] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26725] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI PO, 1991, MOL BIOCHEM PARASIT, V45, P215, DOI 10.1016/0166-6851(91)90088-N; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BENNETT JL, 1977, J PARASITOL, V63, P250, DOI 10.2307/3280054; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CINCANU I, 1984, CARBOHYD RES, V131, P209; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; COLLEY DG, 1989, PARASITOL TODAY, V5, P350, DOI 10.1016/0169-4758(89)90106-3; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; DONALD ASR, 1986, BIOCHEM J, V236, P821, DOI 10.1042/bj2360821; DUNNE DW, 1990, PARASITOL TODAY, V6, P45, DOI 10.1016/0169-4758(90)90068-F; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1978, J BIOL CHEM, V253, P6814; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GRYZCH JM, 1987, J EXP MED, V165, P865; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HAYUNGA EG, 1986, J PARASITOL, V72, P913, DOI 10.2307/3281844; HAYUNGA EG, 1986, J PARASITOL, V72, P283, DOI 10.2307/3281607; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; LINDER E, 1982, PARASITOLOGY, V85, P503, DOI 10.1017/S0031182000056286; LINDER E, 1991, J PARASITOL, V77, P391, DOI 10.2307/3283126; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; MACGREGOR AN, 1985, MOL BIOCHEM PARASIT, V16, P163, DOI 10.1016/0166-6851(85)90084-2; MAKAARU CK, 1992, J BIOL CHEM, V267, P2251; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; NAKATA N, 1991, GLYCOCONJUGATE J, V8, P250; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OMERALI P, 1986, J IMMUNOL, V137, P3601; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SANO M, 1992, J BIOL CHEM, V267, P1522; SIMPSON AJG, 1980, PARASITOLOGY, V81, P1, DOI 10.1017/S0031182000054986; STOFFYN P, 1971, J LIPID RES, V12, P318; SZILAGYI PJ, 1985, ANAL BIOCHEM, V148, P260, DOI 10.1016/0003-2697(85)90655-4; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; WEISS JB, 1986, J IMMUNOL, V136, P4275; WEISS JB, 1985, J IMMUNOL, V135, P1421; XU CB, 1991, EUR J IMMUNOL, V21, P1801, DOI 10.1002/eji.1830210804; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	53	111	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20196	20203						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1356976				2022-12-27	WOS:A1992JR85800072
J	HAMA, H; WILSON, TH				HAMA, H; WILSON, TH			PRIMARY STRUCTURE AND CHARACTERISTICS OF THE MELIBIOSE CARRIER OF KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CATION SPECIFICITY; TRANSPORT-SYSTEM; NUCLEOTIDE-SEQUENCE; SUGAR; GENE; NA+; LI+; REPLACEMENT; COTRANSPORT	The melB gene coding for the melibiose carrier of Klebsiella pneumoniae was cloned and sequenced. There were two potential translation initiation sites. It was predicted that the melibiose carrier consists of 471 (or 467) amino acid residues. Seventy-eight percent of the 471 amino acids were identical to the Escherichia coli melibiose carrier. Sugar transport characteristics were studied using an E. coli mel- mutant expressing cloned K. pneumoniae melB gene. Accumulation of melibiose via the K. pneumoniae melibiose carrier was not stimulated by adding NaCl or LiCl which stimulates melibiose accumulation via the E. coli melibiose carrier. Lactose was accumulated only in the presence of LiCl. TMG (methyl-1-thio-beta-D-galactopyranoside) was accumulated in the absence of added NaCl or LiCl. The accumulation was stimulated by LiCl but not by NaCl. Rapid H+ uptake was observed when melibiose or TMG was added to cell suspensions. These results suggest that the preferred cation couplings via K. pneumoniae melibiose carrier are H+-melibiose, Li+-lactose, and H+/Li+-TMG. This coupling spectrum is quite different from that of the E. coli melibiose carrier. It is of special interest that the K. pneumoniae melibiose carrier seems to be lacking the ability to recognize Na+ which is a preferred coupling cation of the E. coli melibiose carrier for all known sugar substrates. Further investigation of these two carriers may give us insight into the Na+ recognition site.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1988, J BIOL CHEM, V264, P11643; BOTFIELD MC, 1989, THESIS HARVARD U CAM; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HANATANI M, 1984, J BIOL CHEM, V259, P1807; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; LILJESTROM PL, 1987, NUCLEIC ACIDS RES, V15, P2213, DOI 10.1093/nar/15.5.2213; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; MIZUSHIMA K, 1992, IN PRESS MOL GEN GEN; NIIYA S, 1982, J BIOL CHEM, V257, P8902; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; REEVE ECR, 1973, GENET RES, V21, P273, DOI 10.1017/S001667230001346X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOTA S, 1985, J BACTERIOL, V162, P106, DOI 10.1128/JB.162.1.106-109.1985; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1985, ANN NY ACAD SCI, V456, P342, DOI 10.1111/j.1749-6632.1985.tb14884.x; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; TSUCHIYA T, 1977, BIOCHEM BIOPH RES CO, V76, P26, DOI 10.1016/0006-291X(77)91663-1; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON TH, 1982, MEMBRANES TRANSPORT, V2, P33; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18371	18376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1339436				2022-12-27	WOS:A1992JN50200023
J	ZHOU, J; HERTZ, JM; LEINONEN, A; TRYGGVASON, K				ZHOU, J; HERTZ, JM; LEINONEN, A; TRYGGVASON, K			COMPLETE AMINO-ACID-SEQUENCE OF THE HUMAN ALPHA-5(IV) COLLAGEN CHAIN AND IDENTIFICATION OF A SINGLE-BASE MUTATION IN EXON-23 CONVERTING GLYCINE-521 IN THE COLLAGENOUS DOMAIN TO CYSTEINE IN AN ALPORT SYNDROME PATIENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; IV COLLAGEN; MEMBRANE COLLAGEN; LONG ARM; GENE; ALPHA-1(IV); PROCOLLAGEN; MOUSE; ALPHA-1-CHAIN; CHROMOSOME-13	We have generated and characterized cDNA clones providing the complete amino acid sequence of the human type IV collagen chain whose gene has been shown to be mutated in X chromosome-linked Alport syndrome. The entire translation product has 1,685 amino acid residues. There is a 26-residue signal peptide, a 1,430-residue collagenous domain starting with a 14-residue noncollagenous sequence, and a Gly-Xaa-Yaa-repeat sequence interrupted at 22 locations, and a 229-residue carboxyl-terminal noncollagenous domain. The calculated molecular weight of the mature alpha-5(IV) chain is 158,303. Analysis of genomic DNA from members of a kindred with Alport syndrome revealed a new HindIII cleavage site within the coding sequence of one of the cDNA clones characterized. The proband had a new 1.25-kilobase HindIII fragment and a lack of a 1.35-kilobase fragment, and his mildly affected female cousin had both alleles. The mutation which was located to exon 23 was sequenced from a polymerase chain reaction-amplified product, and shown to be a G --> T change in the coding strand. The mutation changed the GGT codon of glycine 521 to cysteine. The same mutation was found in one allele of the female cousin. The results were confirmed by allele-specific hybridization analyses.	UNIV OULU, DEPT BIOCHEM, SF-90570 OULU, FINLAND; AARHUS UNIV, INST HUMAN GENET, DK-8000 AARHUS, DENMARK	Finland National Institute for Health & Welfare; University of Oulu; Aarhus University	ZHOU, J (corresponding author), UNIV OULU, BIOCTR, SF-90570 OULU, FINLAND.		Hertz, Jens Michael/H-6269-2014	Hertz, Jens Michael/0000-0003-0087-4739				Alport AC, 1927, BMJ-BRIT MED J, V1927, P504, DOI 10.1136/bmj.1.3454.504; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BOYD CD, 1986, HUM GENET, V74, P121, DOI 10.1007/BF00282074; BOYE E, 1991, GENOMICS, V11, P1125, DOI 10.1016/0888-7543(91)90040-L; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; ERLICH HA, 1988, NATURE, V331, P461, DOI 10.1038/331461a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KNEBELMANN B, 1992, IN PRESS AM J HUM GE; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Maniatis T., 1982, MOL CLONING; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NATH P, 1986, GENE, V43, P301, DOI 10.1016/0378-1119(86)90220-9; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1989, J BIOL CHEM, V264, P6318; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SMEETS HJM, 1992, IN PRESS KIDNEY INT; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1987, FEBS LETT, V225, P188; STUDENCKI AB, 1984, DNA-J MOLEC CELL BIO, V3, P7, DOI 10.1089/dna.1.1984.3.7; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOOD L, 1988, FEBS LETT, V227, P5, DOI 10.1016/0014-5793(88)81402-9; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y; ZHOU J, 1992, IN PRESS AM J HUM GE; [No title captured]	38	131	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12475	12481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1352287				2022-12-27	WOS:A1992HZ48300018
J	HUANG, SS; HUANG, JS				HUANG, SS; HUANG, JS			PURIFICATION AND CHARACTERIZATION OF THE NEU/ERB B2 LIGAND-GROWTH FACTOR FROM BOVINE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST CANCER; HER-2 NEU ONCOGENE; FACTOR RECEPTOR; POINT MUTATION; PROTEIN; GENE; EXPRESSION; PRODUCT; TRANSFORMATION	A neu/erb B2 ligand growth factor (NEL-GF) was purified to homogeneity from bovine kidney by a procedure involving ammonium sulfate fractionation (35-70% saturation) followed by sequential column chromatography on DEAE-cellulose (DE52), Sulfadex (sulfated Sephadex G-50), heparin-Sepharose 4B, and Superdex 75 (fast protein liquid chromatography). NEL-GF was found to be a 25-kDa polypeptide according to the analysis by gel filtration on Superdex 75 and 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. NEL-GF stimulated the tyrosine-specific autophosphorylation of the neu/erb B2 gene product purified by immunoabsorbent and tyrosine-specific phosphorylation of the neu/erb B2 gene product in intact dihydrofolate reductase (DHFR/G-8 cells (NIH 3T3 cells transfected with rat c-neu). NEL-GF also down-regulated the cell surface neu/erb B2 gene product in DHFR/G-8 cells. NEL-GF was mitogenic toward NIH 3T3 cells, DHFR/G-8 cells, A431 cells (human epidermoid carcinoma cells), and SK-BR-3 cells (human breast carcinoma cells) but inactive toward bovine aorta endothelial cells. NEL-GF was sensitive to 0.1% trifluoroacetic acid but resistant to 5% beta-mercaptoethanol and appeared to be distinct from a neu protein-specific activating factor (Davis, J. G., Hamuro, J., Shim, C. Y., Samanta, A., Greene, M. I., and Dobashi, K. (1991) Biochem. Biophys. Res. Commun. 179, 1536-1542) and a 30-kDa glycoprotein which competed with a monoclonal antibody for binding to the neu/erb B2 gene product (Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., and Lippman, M. E. (1990) Science 249, 1552-1555).			HUANG, SS (corresponding author), ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KUO MD, 1990, J BIOL CHEM, V265, P16455; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PATERSON MC, 1991, CANCER RES, V51, P550; PRESS MF, 1990, ONCOGENE, V5, P953; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TATEISHI M, 1991, EUR J CANCER, V27, P1372, DOI 10.1016/0277-5379(91)90012-3; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	27	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11508	11512						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1350785				2022-12-27	WOS:A1992HX16900087
J	KATAFUCHI, T; MIZUNO, T; HAGIWARA, H; ITAKURA, M; ITO, T; HIROSE, S				KATAFUCHI, T; MIZUNO, T; HAGIWARA, H; ITAKURA, M; ITO, T; HIROSE, S			MODULATION BY NACL OF ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR LEVELS AND CYCLIC-GMP RESPONSIVENESS TO ATRIAL-NATRIURETIC-PEPTIDE OF CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE GUANYLATE-CYCLASE; DOWN-REGULATION; BINDING-SITES; PURIFICATION; ACTIVATION; LUNG	Type C atrial natriuretic peptide (ANP) receptor levels in cultured vascular endothelial cells were found to be very sensitive to NaCl and shown to be inversely related to the magnitude of ANP-induced cGMP response of the cells. Endothelial cells from bovine carotid artery were subcultured in Eagle's minimum essential medium supplemented with 10% fetal bovine serum (MEM-FBS) and in MEM-FBS plus 25 and 50 mm NaCl. Determination, after several passages, of ANP receptor levels in these cells by I-125-ANP binding assay and affinity labeling revealed a marked reduction in the number of type C receptor in the NaCl-treated cells, whereas type A receptor density was not affected. RNase protection assay to estimate the levels of type C receptor mRNA indicated that the reduction occurred at a pre-translational level. In spite of the decrease in type C receptor number and no significant change in type A receptor (i.e. particulate guanylate cyclase) levels, cGMP response of the NaCl-treated cells to ANP was greatly exaggerated; this sensitization was also observed in membrane preparations. Simple masking of type C ANP receptor with C-ANF (des-[Gln18,Ser19,Gly20,Leu21,Gly22]ANP), a ring-deleted ANP analog, did not produce any sensitization of the cGMP response to ANP; therefore, the above phenomenon cannot simply be explained by the clearance function of the type C receptor. Although whether the type C receptor depletion is directly related to the sensitization of the type A receptor/cyclase is not known, the phenomenon reported and characterized here will serve as a useful basis for elucidating ANP receptor regulation and activation.			KATAFUCHI, T (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GAUQUELIN G, 1988, AM J PHYSIOL, V255, pF621, DOI 10.1152/ajprenal.1988.255.4.F621; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEITMAN DC, 1986, BIOCHIM BIOPHYS ACTA, V885, P74, DOI 10.1016/0167-4889(86)90040-6; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LYNCH DR, 1986, P NATL ACAD SCI USA, V83, P3357; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; OHUCHI S, 1989, BIOCHEM BIOPH RES CO, V158, P603, DOI 10.1016/S0006-291X(89)80092-0; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAHEKI T, 1991, J BIOL CHEM, V266, P11122; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58, DOI 10.1152/ajpheart.1991.260.1.H58; SCHIFFRIN EL, 1986, HYPERTENSION, V8, P141; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; TAKAYANAGI R, 1986, J HYPERTENS, V4, pS303; UCHIDA K, 1989, BIOCHEM J, V263, P671, DOI 10.1042/bj2630671	31	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7624	7629						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1348507				2022-12-27	WOS:A1992HN48500061
J	IKEDA, M; HAMANO, K; SHIBATA, T				IKEDA, M; HAMANO, K; SHIBATA, T			EPITOPE MAPPING OF ANTI-RECA PROTEIN IGGS BY REGION SPECIFIED POLYMERASE CHAIN-REACTION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; RECOMBINATION	Monoclonal IgGs were shown to be useful for the specific inhibition of a set of activities of the recA protein, a key protein in homologous genetic recombination. The mapping of the epitopes for these IgGs and site-directed mutagenesis based on the mapping will facilitate location of the functionally active sites on the tertiary structure of the protein, which is being solved by means of physicochemical techniques. We developed a novel technique for region-specified mutagenesis and applied the technique to epitope mapping. Using the polymerase chain reaction in the presence of deoxyinosine triphosphate, we introduced random base substitutions specifically into a region of the recA gene defined by a pair of primers. RecA mutants exhibiting altered antigenicity were selected, in plaque-immunoblotting experiments, from libraries of mutagenized recA genes constructed on the lambda-gt11 expression vector. Mutant recA genes were obtained at the frequency of about 10(-2) among the plaques expressing fused recA genes and then each one was expressed as a whole protein, which was characterized by enzyme-linked immunosorbent assay. Analyzing the DNA sequences of the mutant recA genes, we located at the amino acid sequence level the epitopes for two anti-recA IgGs which could not be located in previous studies. One of the antibodies was shown to prevent self-assembly of the recA protein and the other was suggested to inhibit the binding of double-stranded DNA. Thus, the active sites involved in these functions would be located in the space around or near the relevant epitope.	INST PHYS & CHEM RES,MICROBIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN								Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; IKAWA S, 1989, J BIOL CHEM, V264, P21167; IKEDA M, 1990, J BIOL CHEM, V265, P8948; KARU AE, 1982, BIOCHIMIE, V64, P723, DOI 10.1016/S0300-9084(82)80118-1; MAKINO O, 1987, J BIOL CHEM, V262, P12237; MAKINO O, 1985, J BIOL CHEM, V260, P5402; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1991, BIOCHIMIE, V73, P209, DOI 10.1016/0300-9084(91)90204-E; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	18	20	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6291	6296						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372903				2022-12-27	WOS:A1992HK31800086
J	NECKAMEYER, WS; WHITE, K				NECKAMEYER, WS; WHITE, K			A SINGLE LOCUS ENCODES BOTH PHENYLALANINE-HYDROXYLASE AND TRYPTOPHAN-HYDROXYLASE ACTIVITIES IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE-CONTAINING NEURONS; SEROTONIN-CONTAINING NEURONS; TYROSINE-HYDROXYLASE; DOPA DECARBOXYLASE; ESCHERICHIA-COLI; MESSENGER-RNA; SEQUENCE; EXPRESSION; GENE; MELANOGASTER	We have used a full-length clone encoding rabbit tryptophan hydroxylase (TRH) to isolate the Drosophila homologue (DTPH). Southern analysis of Drosophila genomic DNA reveals a pattern indicative of a single gene. The single transcript is expressed in adult head and body mRNA but is also detected in mRNA from early embryos. The embryonic transcript is ubiquitously expressed and appears to concentrate in yolk granules. In situ hybridization of TRH-homologous antisense RNA probe to sectioned tissue from third instar larvae demonstrated the presence of this transcript in fat body and cuticular tissue. Developmental immunoblot analysis using antibodies raised against a beta-galactosidase-Drosophila fusion protein revealed a 45-kDa embryonic protein also detected in female abdomens and a 50-kDa protein found in larval and adult stages. Immunocytochemical analysis of the Drosophila protein in the larval central nervous system showed that it appeared to be present in both serotonin- and catecholamine-containing neurons. A nonfusion protein generated in Escherichia coli hydroxylates both tryptophan and phenylalanine. We propose that there are only two aromatic amino acid hydroxylase genes in Drosophila: one encoding tyrosine hydroxylase, DTH, and DTPH, a gene encoding both tryptophan and phenylalanine hydroxylase activities.			NECKAMEYER, WS (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023510] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO 4671] Funding Source: Medline; NINDS NIH HHS [NS23510] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1986, J NEUROSCI, V6, P3682; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; ENGELS WR, 1986, FOCUS, V8, P6; GELTOSKY JE, 1980, BIOCHEM GENET, V18, P781, DOI 10.1007/BF00484593; GENETT HE, 1987, P NATL ACAD SCI USA, V82, P617; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Ichiyama A, 1976, Adv Exp Med Biol, V74, P103; ITOH N, 1985, DROS INF SERVICE, V61, P89; KATAROVA Z, 1990, EUR J NEUROSCI, V2, P190, DOI 10.1111/j.1460-9568.1990.tb00412.x; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; KUHN DM, 1980, P NATL ACAD SCI-BIOL, V77, P4688, DOI 10.1073/pnas.77.8.4688; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LIVINGSTONE MS, 1983, NATURE, V303, P67, DOI 10.1038/303067a0; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MARTINMORRIS LE, 1990, DEVELOPMENT, V110, P185; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORALES G, 1990, GENE, V93, P213, DOI 10.1016/0378-1119(90)90227-I; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RENSON J, 1962, J BIOL CHEM, V237, P2261; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VALLES AM, 1986, J NEUROSCI, V6, P1482; VALLES AM, 1988, J COMP NEUROL, V268, P414, DOI 10.1002/cne.902680310; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4199	4206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1371286				2022-12-27	WOS:A1992HE60700093
J	MARGUET, D; BERNARD, AM; VIVIER, I; DARMOUL, D; NAQUET, P; PIERRES, M				MARGUET, D; BERNARD, AM; VIVIER, I; DARMOUL, D; NAQUET, P; PIERRES, M			CDNA CLONING FOR MOUSE THYMOCYTE-ACTIVATING MOLECULE - A MULTIFUNCTIONAL ECTO-DIPEPTIDYL PEPTIDASE-IV (CD26) INCLUDED IN A SUBGROUP OF SERINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; MEMBRANE GLYCOPROTEIN; AMINOPEPTIDASE-N; BP-1/6C3 ANTIGEN; SEQUENCE; COLLAGEN; PROTEIN; HEPATOCYTES; INVOLVEMENT; ANTIBODIES	Thymocyte-activating molecule (THAM) was initially characterized as a developmentally regulated, dimeric cell-surface molecule capable of activating mouse thymocytes and T lymphocytes upon monoclonal antibody (mAb)-mediated cross-linking. We recently obtained structural evidence indicating that this molecule is the mouse homologue of the human T cell-activating ectoenzyme CD26 (dipeptidyl peptidase IV, DPP IV). We describe here the cloning and the characterization of THAM cDNA. Two clones (3.3 and 2.8 kilobases) were isolated. THAM-3.3 cDNA contains an open reading frame of 2,280 nucleotides that encodes a protein of 760 amino acids having a calculated size of 87,500 Da. Complete N-glycosylation at each of the nine potential sites would result in a mature 110,000-Da molecule. Protein sequence comparisons revealed a significant homology (in particular in the COOH-terminal domain) between THAM and the rat or human DPP IV or the yeast dipeptidyl aminopeptidase B molecules (92, 85, and 30% sequence identity, respectively). Structural comparison of serine proteases (i.e. acyl-amino acid hydrolase or prolyl endopeptidase) with the most conserved domain of THAM identified a stretch of 200 amino acids containing a putative catalytic triad arranged in a novel topological order (Ser-624, Asp-702, and His-734) thereby defining a subfamily of nonclassical serine proteases. Expression of THAM during thymus ontogeny was found to be mainly regulated at the transcriptional level as determined by RNase protection assay. To investigate directly some of the functions which have been ascribed to DPP IV, we transfected an ovalbumin/A(q)-reactive, THAM- T hybridoma cell line with THAM-3.3 cDNA. The resultant transfectants acquired (i) DPP IV enzymatic activity that precisely paralleled the density of surface-expressed THAM; (ii) an M(r) = 115,000 (reduced) and 110,00/128,000 (nonreduced) molecule that could be immunoprecipitated by the THAM-specific mAb H194-112; and (iii) the capacity of being triggered by this mAb to release interleukin-2. These data indicate that a single cDNA species can encode a multifunctional molecule (e.g. activation signal-transducing structure and ectopeptidase), the heterodimeric state of which very likely results from a differential post-translational modification of the same protein core.	INSERM, U178, UNITE RECH DIFFERENCIAT & NEUROENDOCRINOL CELLULES, F-94807 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	MARGUET, D (corresponding author), CNRS, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE.		Marguet, Didier/AGO-5421-2022; Darmoul, Dalila/M-5812-2018; Marguet, Didier/B-9946-2008	Marguet, Didier/0000-0003-3198-5095; Darmoul, Dalila/0000-0002-1206-0655; 				ABBS MT, 1983, CLIN SCI, V65, P551, DOI 10.1042/cs0650551; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; GORRELL MD, 1991, CELL IMMUNOL, V134, P205, DOI 10.1016/0008-8749(91)90343-A; GORVEL JP, 1990, J IMMUNOL, V144, P2899; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HANSKI C, 1985, BIOL CHEM H-S, V366, P1169, DOI 10.1515/bchm3.1985.366.2.1169; HEGEN M, 1990, J IMMUNOL, V144, P2908; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HONG WJ, 1988, J BIOL CHEM, V263, P16892; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HUSSAIN MM, 1985, BIOCHIM BIOPHYS ACTA, V815, P306, DOI 10.1016/0005-2736(85)90301-3; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Maniatis T, 1989, MOL CLONING; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MARQUEZ C, 1990, EUR J IMMUNOL, V20, P947, DOI 10.1002/eji.1830200436; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAQUET P, 1991, CURR OPIN IMMUNOL, V3, P326, DOI 10.1016/0952-7915(91)90032-V; NAQUET P, 1988, J IMMUNOL, V141, P4101; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OGATA S, 1989, J BIOL CHEM, V264, P3596; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PIERRES A, 1984, J IMMUNOL, V132, P2775; PONT S, 1985, EUR J IMMUNOL, V15, P1222, DOI 10.1002/eji.1830151215; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; VIVIER I, 1991, J IMMUNOL, V147, P447; WELCH PA, 1990, INT IMMUNOL, V2, P697, DOI 10.1093/intimm/2.8.697; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YOSHIMOTO T, 1981, J BIOCHEM, V90, P325, DOI 10.1093/oxfordjournals.jbchem.a133477	50	103	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2200	2208						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370813				2022-12-27	WOS:A1992HB53200015
J	SMITH, D; BURGIN, AB; HAAS, ES; PACE, NR				SMITH, D; BURGIN, AB; HAAS, ES; PACE, NR			INFLUENCE OF METAL-IONS ON THE RIBONUCLEASE-P REACTION - DISTINGUISHING SUBSTRATE BINDING FROM CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA PRECURSORS; ESCHERICHIA-COLI; M1 RNA; ENZYME; REQUIREMENTS; COMPONENT; CLEAVAGE; SUBUNIT; SITE	A high yield, photoactivated cross-linking reaction between a modified tRNA and RNase P RNA was used as a quantitative assay of substrate binding affinity. The cross-linking assay allows the effects of metal ions on substrate binding to be measured independently and in the absence of the pre-tRNA cleavage reaction. The results of this assay, in conjunction with the conventional cleavage assay, support the following conclusions about the nature of the RNase P RNA-tRNA binding interaction. (i) Monovalent cations act primarily to enhance enzyme-substrate binding, presumably by functioning as counterions. This enhancement can be attributed to a reduction in the tRNA off-rate. (ii) Although divalent cation is required for cleavage, the enzyme-substrate complex can form in the absence of divalent cation; the essential role of divalent cation in the reaction is thus catalytic. (iii) Ca2+ is as efficient as Mg2+ in promoting binding but supports catalysis only at a low rate.	INDIANA UNIV, INST MOLEC & CELLULAR BIOL, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	SMITH, D (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034527, R37GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527, GM13712] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BROWN JW, 1991, J BACTERIOL, V173, P3855, DOI 10.1128/JB.173.12.3855-3863.1991; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARTER BJ, 1990, J BIOL CHEM, V265, P7100; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GARDINER KJ, 1985, J BIOL CHEM, V260, P5415; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; Haydock K, 1985, Prog Clin Biol Res, V172A, P87; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PACE NR, 1990, J BIOL CHEM, V265, P3587; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; SURRATT CK, 1990, J BIOL CHEM, V265, P22513; TU AT, 1974, MET IONS BIOL SYST, V1, P2; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; Yarus M, 1979, Prog Nucleic Acid Res Mol Biol, V23, P195; YARUS M, 1983, GENE FUNCTION PROKAR, P23	24	140	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2429	2436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1370819				2022-12-27	WOS:A1992HB53200050
J	BLOCHBERGER, TC; VERGNES, JP; HEMPEL, J; HASSELL, JR				BLOCHBERGER, TC; VERGNES, JP; HEMPEL, J; HASSELL, JR			CDNA TO CHICK LUMICAN (CORNEAL KERATAN SULFATE PROTEOGLYCAN) REVEALS HOMOLOGY TO THE SMALL INTERSTITIAL PROTEOGLYCAN GENE FAMILY AND EXPRESSION IN MUSCLE AND INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CORE PROTEIN; LINKAGE-REGION; COLLAGEN; DECORIN; IDENTIFICATION; FIBROMODULIN; LOCALIZATION; SEQUENCE; BIGLYCAN	A 1.9-kb cDNA clone to chick lumican (keratan sulfate proteoglycan) was isolated by screening an expressing vector library made from chick corneal RNA with antiserum to chick corneal lumican. The cDNA clone contained an open reading frame coding for a 343-amino acid protein, M(r) = 38,640. Structural features of the deduced sequence include: a 18-amino acid signal peptide, cysteine residues at the N- and C-terminal regions, and a central leucine-rich region (comprising 62% of the protein) containing nine repeats of the sequence LXXLXLXXNXL/I, where X represents any amino acid. Lumican contains three variations of this sequence that are tandemly linked to form a unit and three units tandemly linked to form the leucine-rich region. The sequential arrangement of these repeats and their spacing suggest that this region arose by duplication. The deduced sequence shows five potential N-linked glycosylation sites, four of which are in the leucine-rich region. These sites are also potential keratan sulfate attachment sites. The cDNA clone to lumican hybridizes to a 2.0-kb mRNA found in tissues other than cornea, predominantly muscle and intestine. Radiolabeling and immunoprecipitation studies show that lumican core protein is also synthesized by these tissues. The primary structure of lumican is similar to fibromodulin, decorin, and biglycan, which indicates it belongs to the small interstitial proteoglycan gene family. The expression of lumican in tissues other than cornea indicates a broader role for lumican besides contributing to corneal transparency.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BLOCHBERGER, TC (corresponding author), UNIV PITTSBURGH, SCH MED, EYE & EAR INST PITTSBURGH, DEPT OPHTHALMOL, PITTSBURGH, PA 15213 USA.				NEI NIH HHS [EY08104, 5-P30-EY08098] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008104, R37EY008104, P30EY008098] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CINTRON C, 1978, J ULTRA MOL STRUCT R, V65, P13, DOI 10.1016/S0022-5320(78)90017-5; CONRAD GW, 1970, DEV BIOL, V21, P292, DOI 10.1016/0012-1606(70)90126-0; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; GLOSSL J, 1983, BIOCHEM J, V215, P295; HART GW, 1976, J BIOL CHEM, V251, P6513; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E D, 1969, Monogr Dev Biol, V1, P1; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Maurice DM, 1984, EYE B, V1, P1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRECENGOST PK, IN PRESS ARCH BIOCH; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; STUHLSATZ HW, 1971, HOPPESEYLERS Z PHYSL, V252, P289; SUGRUE SP, 1991, INVEST OPHTH VIS SCI, V32, P140; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TOOLE BP, 1971, DEV BIOL, V26, P28, DOI 10.1016/0012-1606(71)90104-7; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	43	211	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					347	352						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370446				2022-12-27	WOS:A1992GY43900057
J	KRATZKE, RA; OTTERSON, GA; LIN, AY; SHIMIZU, E; ALEXANDROVA, N; ZAJAC-KAYE, M; HOROWITZ, JM; KAYE, FJ				KRATZKE, RA; OTTERSON, GA; LIN, AY; SHIMIZU, E; ALEXANDROVA, N; ZAJAC-KAYE, M; HOROWITZ, JM; KAYE, FJ			FUNCTIONAL-ANALYSIS AT THE CYS(706) RESIDUE OF THE RETINOBLASTOMA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; TUMOR SUPPRESSOR GENES; CARCINOMA CELL-LINES; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; LEUCINE REPEATS; RB PROTEIN; PRODUCT; BINDING; EXPRESSION	A missense mutation at cysteine 706, resulting in a retinoblastoma (RB) protein defective in phosphorylation and oncoprotein binding, has been isolated from a human tumor cell line. Since this residue is conserved in murine RB and in the related p107 protein, we studied the activity of in vitro mutants flanking this position. These experiments demonstrated that the thiol atom at codon 706 does not possess intrinsic functional activity as small polar or nonpolar residues could substitute at either codons 706 or 707, while bulkier R-group changes in these positions interfered with in vitro oncoprotein binding or in vivo protein phosphorylation. A series of missense mutants in an adjacent leucine repeat domain also demonstrated a loss of oncoprotein binding that was proportional to the magnitude of amino acid substitutions. To determine whether the cysteine 706 --> phenylalanine RB mutant retained any protein binding activity, we examined its ability to precipitate MYC, which was recently identified as a potential RB-associated protein. These experiments demonstrated that the mutant RB product is capable of binding in vitro to c-myc and L-myc proteins with comparable affinity as wild-type RB. These findings raise questions about the functional role of the RB:MYC interactions and emphasize important differences in the binding patterns between MYC and the other RB-associated proteins.	NCI, NAVY ONCOL BRANCH, BETHESDA, MD 20889 USA; NCI, MED BRANCH, BETHESDA, MD 20889 USA; DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, DURHAM, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University; Duke University	KAYE, FJ (corresponding author), USN HOSP, NCI, NAVY MED ONCOL BRANCH, BLDG 8, RM 5101, BETHESDA, MD 20889 USA.		kaye, frederic/E-2437-2011		NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NCI NIH HHS [CA53248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOWEN HJ, 1991, FOCUS, V13, P125; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FUNG YKT, 1989, ONCOGENES, P303; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, IN PRESS ONCOGENES T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	50	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25998	26003						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1334491				2022-12-27	WOS:A1992KD07300062
J	SINICROPE, FA; DUDEJA, PK; BISSONNETTE, BM; SAFA, AR; BRASITUS, TA				SINICROPE, FA; DUDEJA, PK; BISSONNETTE, BM; SAFA, AR; BRASITUS, TA			MODULATION OF P-GLYCOPROTEIN-MEDIATED DRUG TRANSPORT BY ALTERATIONS IN LIPID FLUIDITY OF RAT-LIVER CANALICULAR MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; INTESTINAL MICROVILLUS MEMBRANES; NA+-H+ EXCHANGE; PLASMA-MEMBRANE; CROSS-RESISTANCE; LEUCINE AMINOPEPTIDASE; PHOTOACTIVE ANALOGS; ADENYLATE-CYCLASE; GENE-PRODUCT; TUMOR-CELLS	P-glycoprotein (P-gp) is believed to function as an ATP-dependent efflux pump for natural product anti-cancer drugs in multidrug-resistant (MDR) tumor cells and in certain normal tissues. P-gp has been localized to the apical plasma membrane of the bile canaliculus where it has been shown to transport [H-3]daunomycin. In this study, we investigated whether alterations in membrane lipid fluidity of canalicular membrane vesicles (CMV) could modulate the P-gp-mediated accumulation of [H-3]daunomycin and [H-3]vinblastine. Accumulation of both cytotoxic agents was stimulated by ATP, exhibited temperature dependence and osmotic sensitivity, and followed Michaelis-Menten kinetics. Alterations in CMV lipid fluidity were induced by the known fluidizers, 2-(2-methoxyethoxy)ethyl 8-(cis-2-n-octylcyclopropyl)octanoate (A2C) and benzyl alcohol, and were assessed by fluorescence polarization techniques using the fluorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH). Both A2C (2.5-5.0 muM) and benzyl alcohol (10-20 mM) produced a dose-dependent increase in CMV lipid fluidity. Moreover, both fluidizers, at the above doses, significantly inhibited (p < 0.05) the ATP-dependent accumulation of [H-3]daunomycin. [H-3]Vinblastine accumulation was also inhibited by A2C (p < 0.05). Lower doses of A2C (0.6 muM) and benzyl alcohol (1 mM) failed to influence either lipid fluidity or P-gp-mediated drug accumulation. Kinetic analysis revealed that A2C (5.0 muM) noncompetitively inhibited [H-3]daunomycin accumulation and uncompetitively inhibited [H-3]vinblastine accumulation with apparent K(i) values of almost-equal-to 1.5 and almost-equal-to 1.2 muM, respectively. Verapamil competitively inhibited P-gp-mediated accumulation of [H-3]daunomycin but failed to alter the fluidity of CMV. Taken together, the present results demonstrate that while increases in membrane fluidity of CMV are not necessarily required to inhibit P-gp-mediated drug accumulation, they can inhibit these processes, at least in CMV. Alterations in the physical state of CMV, therefore, appear to be at least one important modulator of P-gp function.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago					NATIONAL CANCER INSTITUTE [R01CA036745, R29CA047652, R37CA036745, R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078, CA-47652, CA-36745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK WT, 1988, BIOCHEM BIOPH RES CO, V153, P959, DOI 10.1016/S0006-291X(88)81321-4; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BIEDLER JL, 1970, CANCER RES, V30, P1174; BRASITUS TA, 1979, BIOCHEMISTRY-US, V18, P4136, DOI 10.1021/bi00586a013; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BRASITUS TA, 1980, BIOCHEMISTRY-US, V19, P2763, DOI 10.1021/bi00553a035; BRASITUS TA, 1986, BIOCHIM BIOPHYS ACTA, V855, P16, DOI 10.1016/0005-2736(86)90183-5; BRASITUS TA, 1988, ADV MEMBRANE FLUIDIT, V2, P227; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DAVIS RA, 1978, P NATL ACAD SCI USA, V75, P4130, DOI 10.1073/pnas.75.9.4130; DIPPLE I, 1978, BIOCHEM J, V174, P179, DOI 10.1042/bj1740179; DUDEJA PK, 1991, ARCH BIOCHEM BIOPHYS, V284, P338, DOI 10.1016/0003-9861(91)90305-3; DUDEJA PK, 1991, AM J PHYSIOL, V260, pG586, DOI 10.1152/ajpgi.1991.260.4.G586; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUFFY MM, 1984, CANCER RES, V44, P1863; HARIG JM, 1989, AM J PHYSIOL, V256, pG618, DOI 10.1152/ajpgi.1989.256.3.G618; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; INOUE M, 1983, J BIOL CHEM, V258, P5183; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; KEEFFE EB, 1980, GASTROENTEROLOGY, V79, P222; KESSEL D, 1988, BIOCHEM PHARMACOL, V37, P4253, DOI 10.1016/0006-2952(88)90603-X; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1977, J BIOL CHEM, V252, P1990; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLS PR, 1987, HEPATOLOGY, V7, P61, DOI 10.1002/hep.1840070114; MONTAUDON D, 1986, CANCER RES, V46, P5602; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; NAITO M, 1989, CANCER RES, V49, P1452; RAMU A, 1983, CANCER RES, V43, P5533; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SCHACHTER D, 1984, HEPATOLOGY, V4, P140, DOI 10.1002/hep.1840040124; SCHROEDER F, 1988, BIOCHIM BIOPHYS ACTA, V946, P85, DOI 10.1016/0005-2736(88)90460-9; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; SIMON FR, 1980, J CLIN INVEST, V65, P851, DOI 10.1172/JCI109737; SKOVSGAARD T, 1978, CANCER RES, V38, P4722; SWEET WD, 1986, BIOCHIM BIOPHYS ACTA, V861, P53, DOI 10.1016/0005-2736(86)90370-6; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P265; WHETTON AD, 1983, BIOCHEM PHARMACOL, V32, P1601, DOI 10.1016/0006-2952(83)90334-9; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	59	141	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24995	25002						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1360981				2022-12-27	WOS:A1992KB60300016
J	GRAF, R; MATTERA, R; CODINA, J; ESTES, MK; BIRNBAUMER, L				GRAF, R; MATTERA, R; CODINA, J; ESTES, MK; BIRNBAUMER, L			A TRUNCATED RECOMBINANT ALPHA SUBUNIT OF GI3 WITH A REDUCED AFFINITY FOR BETA-GAMMA DIMERS AND ALTERED GUANOSINE 5'-3-O-(THIO)TRIPHOSPHATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; AMINO-TERMINAL REGION; STIMULATORY G-PROTEIN; ADENYLATE-CYCLASE; K+ CHANNELS; PURIFICATION; RECEPTOR; NI; LIGANDS; SYSTEM	The baculovirus-based expression system was adapted to express a subunits of the complete (alpha(i3)) and an amino-terminally truncated (alpha(i3)') form of G(i3) and of two complete forms of G(s) (alpha(s-L) and alpha(s-S)). Subunits encoded in full length cDNAs were obtained with yields of 40-60 mg of recombinant protein/liter of cells, of which alpha(i3) was between 30 and 50% soluble, but alpha(s) subunits were only 5-10% soluble. Only the complete alpha(i3) was myristoylated. Alpha(i3) was purified in four steps. The purified protein bound 0.8-0.9 mol of guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) per mol of protein and had one predominant contaminant which was identified as a truncated form that begins with methionine 18 instead of methionine 1. Both the full length alpha(i3) and the truncated alpha(i3)' formed trimers with human erythrocyte betagamma as seen by their migration in sucrose density gradients and by an increased rate of ADP ribosylation by pertussis toxin, but compared to alpha(i3), alpha(i3)' interacted with betagamma with a reduced affinity and dissociated upon warming. At 32-degrees-C, only full length alpha(i3) was ADP-ribosylated; at 4-degrees-C, alpha(i3) and alpha(i3)' were both ADP-ribosylated, with the truncated form requiring approximately 200-fold higher concentrations of betagamma. A genetically engineered alpha(i3)' (alpha(i3)[18-354]) was also expressed in Sf9 cells. Yields, assessed as saturable GTPgammaS binding sites, were 3-5 mg per liter. Scatchard analysis showed that truncation of the amino terminus interferes with the ability of Mg2+ to promote high affinity binding of GTPgammaS. We conclude that the G protein alpha subunit amino terminus is not essential for interaction with betagamma dimers, but rather is important in determining the affinity of the alpha subunit for both the betagamma dimers and guanine nucleotide.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Baylor College of Medicine	GRAF, R (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.			Graf, Rolf/0000-0001-7449-7302	NHLBI NIH HHS [HL-45198] Funding Source: Medline; NICHD NIH HHS [HD-09581] Funding Source: Medline; NIDDK NIH HHS [DK-19318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CODINA J, 1984, J RECEPTOR RES, V4, P411, DOI 10.3109/10799898409042565; CODINA J, 1984, J BIOL CHEM, V259, P5871; CODINA J, 1988, J BIOL CHEM, V263, P6746; CODINA J, 1991, J RECEPTOR RES, V11, P587, DOI 10.3109/10799899109066429; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; ESTES MK, 1987, J VIROL, V61, P1488, DOI 10.1128/JVI.61.5.1488-1494.1987; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Maniatis T., 1982, MOL CLONING; MATTERA R, 1989, J BIOL CHEM, V264, P465; MATTERA R, 1986, J BIOL CHEM, V261, P11174; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OLATE J, 1988, J BIOL CHEM, V263, P10394; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SUNYER T, 1984, J BIOL CHEM, V259, P5447; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9	33	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24307	24314						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1332951				2022-12-27	WOS:A1992KA26300028
J	WEISZ, OA; MACHAMER, CE; HUBBARD, AL				WEISZ, OA; MACHAMER, CE; HUBBARD, AL			RAT-LIVER DIPEPTIDYLPEPTIDASE-IV CONTAINS COMPETING APICAL AND BASOLATERAL TARGETING INFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; CANINE KIDNEY-CELLS; HEPATOCYTE PLASMA-MEMBRANE; VESICULAR STOMATITIS-VIRUS; AMINO-ACID SEQUENCE; AMINOPEPTIDASE-N; PEPTIDASE-IV; MDCK CELLS; INTRACELLULAR-TRANSPORT; VIRAL GLYCOPROTEINS	Madin-Darby canine kidney (MDCK) cells deliver endogenous apical and basolateral proteins directly to the appropriate domains. We are investigating the molecular signals on a model plasma membrane hydrolase, dipeptidylpeptidase IV (DPPIV). Most newly synthesized rat liver DPPIV is delivered directly to the apical surface of transfected MDCK cells; however, about 20% is delivered first to the basolateral surface and reaches the apical surface via transcytosis (Casanova, J. E., Mishumi, Y., Ikehara, Y., Hubbard, A. L., and Mostov, K. E. (1991) J. Biol. Chem. 266, 24428-24432). A soluble form of DPPIV (solDPPIV) containing only the lumenal domain of the protein was efficiently transported and secreted by stably transfected MDCK cells. If this domain contains apical sorting information, we would expect 80% of the soluble protein to be secreted apically. Surprisingly, 95% of the secreted solDPPIV was found in the apical medium. The high efficiency of apical secretion suggested that the transmembrane domain and cytoplasmic tail of DPPIV might contain competing basolateral targeting information. To test this hypothesis, we investigated the trafficking of a chimera in which the cytoplasmic tail and transmembrane domains of DPPIV were joined to lysozyme, an exogenous protein which should not contain sorting information. This protein was delivered predominantly to the basolateral surface. Our results suggest that the lumenal domain of DPPIV carries dominant apical sorting information while the transmembrane domain and cytoplasmic tail of the molecule contains competing basolateral sorting information.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014114, R01GM029185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44375] Funding Source: Medline; NIGMS NIH HHS [GM29185, GM14114] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; ELOVSON J, 1980, J BIOL CHEM, V255, P5816; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; HARTEL S, 1988, HISTOCHEMISTRY, V89, P151, DOI 10.1007/BF00489918; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; HUBBARD AL, 1991, CELL, V66, P907; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW SH, 1991, J BIOL CHEM, V266, P19710; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; OJAKIAN GK, 1990, AM J PHYSIOL, V258, pC390, DOI 10.1152/ajpcell.1990.258.3.C390; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RODRIGUEZBOULAN E, 1989, ANNU REV PHYSIOL, V51, P741, DOI 10.1146/annurev.physiol.51.1.741; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; TIRUPPATHI C, 1986, ANAL BIOCHEM, V153, P330, DOI 10.1016/0003-2697(86)90100-4; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATT VM, 1989, J BIOL CHEM, V264, P5480; WEISZ O A, 1991, Journal of Cell Biology, V115, p194A; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923	51	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22282	22288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1358878				2022-12-27	WOS:A1992JW71900047
J	RANGNEKAR, VV; WAHEED, S; RANGNEKAR, VM				RANGNEKAR, VV; WAHEED, S; RANGNEKAR, VM			INTERLEUKIN-1-INDUCIBLE TUMOR-GROWTH ARREST IS CHARACTERIZED BY ACTIVATION OF CELL TYPE-SPECIFIC EARLY GENE-EXPRESSION PROGRAMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; PROTO-ONCOGENE FOS; NECROSIS FACTOR; C-MYC; EARLY RESPONSE; IL-1; ENCODES; LINE; BETA; DIFFERENTIATION	Human melanoma cells, A375-C6, were "committed" to growth arrest within a few hours of exposure to interleukin-1 (IL-1). Co-treatment with actinomycin D rescued the cells from the "commitment," suggesting that "early" gene activation events may be crucial for growth arrest. To understand the mechanism of IL-1 action, we are studying early genes whose expression is induced by the cytokine. Five early genes associated with IL-1 action in the melanoma cells were isolated by differential screening of a cDNA library, which was enriched for sequences representing IL-1 responsive genes (IRGs). Nucleotide sequencing identified four of the genes as gro-alpha, gro-beta, c-jun and nur77/NGF1-B/NAK1, respectively, while the fifth was judged as novel by GenBank search and designated IRG-9. None of the early genes was uniquely associated with the antiproliferative action of IL-1: other growth-inhibitory as well as growth-stimulatory signals induced these genes in diverse cell types. However, analysis of the induction patterns of the IRGs and other well known early genes revealed that IL-1 action in the melanoma cells is characterized by activation of a unique primary gene expression program. This program was defined by the magnitude and temporal pattern of induction of the five IRGs, feeble induction of c-fos, and lack of induction of Egr-1 and c-myc. We present evidence that this program is growth arrest-specific in the melanoma cells and that distinct cell type-specific programs are associated with IL-1 growth-regulatory actions in other tumor cells. Based on these data, we propose that early genes may play multifunctional roles in tumor growth control, but specificity for the growth arrest action of IL-1 is determined by the composite early gene induction program.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago					NCI NIH HHS [PTHB1 R29CA52839] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BOHMANN D, 1987, SCIENCE, V238, P1336; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1985, CANCER SURV, V4, P655; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ENDO Y, 1988, J IMMUNOL, V141, P2342; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HORUK R, 1987, J BIOL CHEM, V262, P16275; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KILLIAN PL, 1986, J IMMUNOL, V136, P4509; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LIU JW, 1991, J BIOL CHEM, V266, P5929; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MANIATIS T, 1982, MOL CLONING LAB MANU; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUSHIMA K, 1985, PHYSL METABOLIC IMMU, P253; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MUNOZ E, 1991, J IMMUNOL, V146, P136; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; NAKAMURA S, 1986, JPN J CANCER RES, V77, P767; ONOZAKI K, 1985, J IMMUNOL, V135, P314; ONOZAKI K, 1988, J IMMUNOL, V140, P112; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; USAI N, 1991, CANCER RES, V51, P769; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VILCEK J, 1987, J BIOL CHEM, V262, P11908; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	57	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6240	6248						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1372901				2022-12-27	WOS:A1992HK31800079
J	HOLLANDER, N				HOLLANDER, N			MEMBRANE DYNAMICS OF THE PHOSPHATIDYLINOSITOL-ANCHORED FORM AND THE TRANSMEMBRANE FORM OF THE CELL-ADHESION PROTEIN LFA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; LATERAL DIFFUSION; PLASMA-MEMBRANE; LYMPHOCYTES-T; COATED PITS; SURFACE; GLYCOPROTEIN; ENDOCYTOSIS	The cell adhesion glycoprotein LFA-3 is expressed on the cell surface of nucleated cells in both a membrane-spanning form and a glycosyl phosphatidylinositol-anchored form. To determine whether distinct membrane anchors direct the dynamics of a given protein, the turnover of biosynthetically S-35-labeled and biotin surface-labeled LFA-3 molecules was followed. It is shown here that (a) expression of the two LFA-3 forms is regenerated with similar kinetics after enzymatic removal from the cell surface; (b) neither of the distinct LFA-3 molecules undergoes constitutive internalization; and (c) transmembrane and glycosyl phosphatidylinositol-anchored LFA-3 have an unusually long life span with an identical half-life of 50 h. Thus, the type of membrane anchor is not affecting turnover characteristics of a particular cell surface glycoprotein.			HOLLANDER, N (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL.							ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HE TA, 1986, EMBO J, V5, P2489; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LOW MG, 1978, BIOCHIM BIOPHYS ACTA, V508, P565, DOI 10.1016/0005-2736(78)90100-1; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUBLIN DM, 1986, J IMMUNOL, V137, P1629; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MONOS DS, 1983, J IMMUNOL, V131, P341; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; TAUSK F, 1989, J IMMUNOL, V143, P3295; WALNER BP, 1987, J EXP MED, V166, P923	37	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5663	5667						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1372008				2022-12-27	WOS:A1992HH74700099
J	JALLAL, B; SCHLESSINGER, J; ULLRICH, A				JALLAL, B; SCHLESSINGER, J; ULLRICH, A			TYROSINE PHOSPHATASE INHIBITION PERMITS ANALYSIS OF SIGNAL TRANSDUCTION COMPLEXES IN P185HER2/NEU-OVEREXPRESSING HUMAN TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PROTO-ONCOGENE; NEU ONCOGENE; PDGF RECEPTOR; HUMAN-BREAST; KINASE RECEPTOR; GENE-PRODUCT; SI-LOCUS; PHOSPHORYLATION	The HER2/neu gene encodes a receptor tyrosine kinase that is highly homologous to the epidermal growth factor receptor. Overexpression of the receptor in mammary and ovarian carcinoma correlates with poor patient prognosis. To determine how the overexpression of a normal receptor leads to the generation of an oncogenic signal, we compared the patterns of tyrosine phosphorylation in tumor-derived human cell lines expressing high levels of p185HER2/neu. In intact SKBR3 cells, basal phosphorylation of p185HER2/neu was not detected. However, pretreatment of cells with the tyrosine phosphatase inhibitor, sodium orthovanadate, led to the detection of phosphotyrosine on phospholipase C-gamma (PLC-gamma), GTPase-activating protein but not on the RAF-1 kinase. Strikingly, PLC-gamma was detected in a complex which contained multiple tyrosine-phosphorylated polypeptides. This complex was detected only in cytoplasmic fractions and had a distinct composition in different p185HER2/neu-overexpressing cell lines. Although GTPase-activating protein has been found previously in association with proteins of 190 and 62 kDa in fibroblasts, in SKBR3 cells it was found associated with multiple additional tyrosine-phosphorylated polypeptides. These experiments show that SKBR3 cells possess high levels of protein tyrosine phosphatase that can act upon p185HER2/neu. Moreover, they reveal, for the first time, the presence of PLC-gamma and GTPase-activating protein in cytosolic complexes containing a variety of other tyrosine-phosphorylated polypeptides. These observations suggest novel possibilities for the specific definition of receptor-generated signals in tumor cells.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARLEY JM, 1987, ONCOGENE, V1, P423; VEUTER DJ, 1987, LANCET, V2, P69; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZHOU DJ, 1987, CANCER RES, V47, P6123; ZIPPEL R, 1989, EUR J CELL BIOL, V50, P428; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	59	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4357	4363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1347042				2022-12-27	WOS:A1992HF64200018
J	RAMAMOORTHY, R; DONELSON, JE; PAETZ, KE; MAYBODI, M; ROBERTS, SC; WILSON, ME				RAMAMOORTHY, R; DONELSON, JE; PAETZ, KE; MAYBODI, M; ROBERTS, SC; WILSON, ME			3 DISTINCT RNAS FOR THE SURFACE PROTEASE-GP63 ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT OF LEISHMANIA-DONOVANI-CHAGASI PROMASTIGOTES TO AN INFECTIOUS FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN GP63; MEXICANA PROMASTIGOTES; MEMBRANE GLYCOPROTEIN; INCREASING EXPRESSION; MOLECULAR-BIOLOGY; TUBULIN GENES; T-BRUCEI; ANTIGEN; IDENTIFICATION; PROTEIN	Leishmania sp. protozoa contain an abundant surface protease (gp63) that is important for the virulence of the parasite. We found that the average amount of gp63 expressed by Leishmania donovani chagasi promastigotes increases 6-11-fold as they develop from a less infectious form in logarithmic phase to a highly infectious form during stationary phase of cultivation in vitro. The predominant gp63 RNA switches from a 2.7 to a 3.0 kilobase (kb) RNA during the transition from log to stationary phase. Sequence analysis of gp63 cDNAs reveals that three different classes of gp63 RNAs, containing unique 3'-untranslated regions (3' UTRs), are expressed during growth to stationary phase. The predominant 2.7-(log) and 3.0-kb (stationary) class gp63 RNAs possess nearly identical coding regions, but they diverge in their 3' UTRs. A third class, consisting of 3.1- and 2.6-kb (constitutive) gp63 RNAs, is expressed at low levels throughout cultivation. This latter class encodes a gp63 with an additional 41 amino acids at its C terminus, replacing a potential signal for attachment of a glycolipid membrane anchor with a sequence that could be a transmembrane region. These findings are consistent with the regulated expression of different gp63 genes, resulting in different amounts of gp63 protein, during the promastigote's in vitro development to an infectious form.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, SW54-GH, IOWA CITY, IA 52242 USA; UNIV IOWA, VET ADM MED CTR, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa; Howard Hughes Medical Institute; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NIAID NIH HHS [AI00832, AI18954] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000832, R01AI018954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARD E, 1989, BIOCHEM CELL BIOL, V67, P516, DOI 10.1139/o89-083; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BOUVIER J, 1987, MOL BIOCHEM PARASIT, V24, P73, DOI 10.1016/0166-6851(87)90117-4; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1988, MOL BIOCHEM PARASIT, V27, P43, DOI 10.1016/0166-6851(88)90023-0; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; DETKE S, 1988, J BIOL CHEM, V263, P3418; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; ETGES R, 1986, J BIOL CHEM, V261, P9098; ETGES RJ, 1985, MOL BIOCHEM PARASIT, V14, P141, DOI 10.1016/0166-6851(85)90033-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG D, 1982, P NATL ACAD SCI-BIOL, V79, P7366, DOI 10.1073/pnas.79.23.7366; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; HANDMAN E, 1990, EXP PARASITOL, V70, P427, DOI 10.1016/0014-4894(90)90127-X; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JARDIM A, 1990, J EXP MED, V172, P645, DOI 10.1084/jem.172.2.645; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KINK JA, 1987, P NATL ACAD SCI USA, V84, P1253, DOI 10.1073/pnas.84.5.1253; KWEIDER M, 1989, PARASITE IMMUNOL, V11, P197, DOI 10.1111/j.1365-3024.1989.tb00659.x; KWEIDER M, 1987, J IMMUNOL, V138, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOCKWOOD WW, 1990, CLIN RES, V38, pA352; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; MAINGON RDC, 1990, UCLA SYM BI, V130, P191; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURRAY PJ, 1990, EXP PARASITOL, V71, P294, DOI 10.1016/0014-4894(90)90034-A; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PEARSON RD, 1980, J IMMUNOL, V125, P2195; PEARSON RD, 1983, REV INFECT DIS, V5, P907; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; RUSSELL DG, 1987, EUR J BIOCHEM, V164, P213, DOI 10.1111/j.1432-1033.1987.tb11013.x; SACKS DL, 1985, AM J TROP MED HYG, V34, P456, DOI 10.4269/ajtmh.1985.34.456; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; ULKER N, 1990, J IMMUNOL, V145, P214; WALTERS LL, 1989, AM J TROP MED HYG, V41, P295, DOI 10.4269/ajtmh.1989.41.295; WILSON ME, 1990, J IMMUNOL, V144, P4825; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON ME, 1989, J IMMUNOL, V143, P678; YANG DM, 1990, J IMMUNOL, V145, P2281; ZARLEY JH, 1991, IN PRESS J CLIN INVE	57	120	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1888	1895						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1370484				2022-12-27	WOS:A1992HA48500076
J	WOLF, FW; MARKS, RM; SARMA, V; BYERS, MG; KATZ, RW; SHOWS, TB; DIXIT, VM				WOLF, FW; MARKS, RM; SARMA, V; BYERS, MG; KATZ, RW; SHOWS, TB; DIXIT, VM			CHARACTERIZATION OF A NOVEL TUMOR NECROSIS FACTOR-ALPHA-INDUCED ENDOTHELIAL PRIMARY RESPONSE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTE CHEMOATTRACTANT; HUMAN VASCULAR ENDOTHELIUM; COLONY-STIMULATING FACTOR; ADHESION MOLECULE-1; C-MYC; PROCOAGULANT ACTIVITY; INSITU HYBRIDIZATION; PROTO-ONCOGENE; GROWTH-FACTOR; CELLS	The response of endothelial cells to the cytokine tumor necrosis factor-alpha (TNF) is complex, involving the induction and suppression of multiple genes and gene products. Differential screening of a TNF-stimulated, cycloheximide-treated human umbilical vein endothelial cell library has resulted in the cloning of several novel cDNAs whose protein products are involved in the primary response of the endothelium to TNF. One of these cDNAs, designated B12, is further characterized here. B12 is encoded by a 3.5-kilobase transcript and is induced rapidly and transiently by TNF. Transcript expression is found to be developmentally regulated in a tissue-specific manner, with B12 message being differentially expressed in the heart and liver during mouse embryogenesis. The open reading frame of B12 predicts a 316-amino acid sequence rich in charged residues, particularly at the carboxyl terminus, and has neither significant homology to other known proteins nor to any extant sequence motifs. B12 is found to be a highly conserved single-copy gene which is located in the q22 --> q23 region of human chromosome 17. Polyclonal antibodies raised against a large portion of the B12 open reading frame immunoprecipitate a 36-kilodalton polypeptide from wheat germ lysates programmed to translate in vitro transcribed B12 mRNA. The B12 protein is further shown to be induced in human umbilical vein endothelial cells by TNF, and the protein is shown to be rapidly de graded.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, 1301 CATHERINE ST, BOX 0602, ANN ARBOR, MI 48109 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Roswell Park Cancer Institute; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHLBI NIH HHS [HL45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BROUDY VC, 1987, J IMMUNOL, V139, P464; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; CAWTHON RM, 1991, GENOMICS, V9, P446, DOI 10.1016/0888-7543(91)90410-G; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Grunfeld C, 1990, Adv Intern Med, V35, P45; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Marston F. A. O., 1987, DNA CLONING, P59; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; ROBAYE B, 1991, AM J PATHOL, V138, P447; ROBINSON EA, 1989, P NATL ACAD SCI USA, V86, P1850, DOI 10.1073/pnas.86.6.1850; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIEFF CA, 1988, BLOOD, V72, P1316; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TRACEY KJ, 1989, LANCET, V1, P1122; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	63	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1317	1326						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1370465				2022-12-27	WOS:A1992GY96000099
J	YAMAUCHI, A; UCHIDA, S; KWON, HM; PRESTON, AS; ROBEY, RB; GARCIAPEREZ, A; BURG, MB; HANDLER, JS				YAMAUCHI, A; UCHIDA, S; KWON, HM; PRESTON, AS; ROBEY, RB; GARCIAPEREZ, A; BURG, MB; HANDLER, JS			CLONING OF A NA+-DEPENDENT AND CL--DEPENDENT BETAINE TRANSPORTER THAT IS REGULATED BY HYPERTONICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA; ACID; OSMOREGULATION; PROTEIN; CELLS; BLOOD; RAT	Many hypertonic bacteria, plants, marine animals, and the mammalian renal medulla are protected from the deleterious effects of high intracellular concentrations of electrolytes by accumulating high concentrations of the nonperturbing osmolyte betaine. When kidney-derived Madin-Darby canine kidney (MDCK) cells are cultured in hypertonic medium, they accumulate betaine to 1,000 times its medium concentration. This results from induction by hypertonicity of high rates of betaine transport into cells. We have isolated a cDNA (BGT-1) encoding a renal betaine transporter by screening an MDCK cell cDNA library for expression of a betaine transporter in Xenopus oocytes. The cDNA encodes a single protein of 614 amino acids, with an estimated molecular weight of 69 kDa. The deduced amino acid sequence exhibits highly significant sequence and topographic similarity to brain gamma-amino-n-butyric acid (GABA) and noradrenaline transporters, suggesting that the renal BGT-1 is a member of the brain GABA/noradrenaline transporter gene family. Expression in oocytes indicates that the BGT-1 protein has both betaine and GABA transport activities that are Cl-- as well as Na+-dependent and functionally similar to betaine and GABA transport in MDCK cells. Northern hybridization indicates that transporter mRNA is localized to the kidney medulla and is induced in MDCK cells by hypertonicity.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,725 N WOLFE ST,BALTIMORE,MD 21205; NHLBI,KIDNEY & ELECTROLYTE METAB LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Robey, R. Brooks/J-7099-2013; Uchida, Shinichi/D-1111-2013	Robey, R. Brooks/0000-0001-5059-3965; 				BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BOWERY NG, 1976, NATURE, V264, P281, DOI 10.1038/264281a0; FERKANY JW, 1978, LIFE SCI, V22, P2121, DOI 10.1016/0024-3205(78)90456-3; GERMANN WJ, 1986, J GEN PHYSIOL, V88, P237, DOI 10.1085/jgp.88.2.237; GOODYER PR, 1985, BIOCHIM BIOPHYS ACTA, V818, P45, DOI 10.1016/0005-2736(85)90136-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWON HM, 1991, AM J PHYSIOL, V260, pF258, DOI 10.1152/ajprenal.1991.260.2.F258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; NEEDHAM L, 1987, BIOCHIM BIOPHYS ACTA, V899, P44, DOI 10.1016/0005-2736(87)90237-9; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARKER JC, 1981, FED PROC, V40, P2872; ROBEY RB, 1991, J BIOL CHEM, V266, P10400; SCHOUSBOE A, 1979, J NEUROCHEM, V33, P181, DOI 10.1111/j.1471-4159.1979.tb11720.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRIGHT EM, 1985, BIOCHIM BIOPHYS ACTA, V818, P271, DOI 10.1016/0005-2736(85)90568-1; WRIGHT S H, 1989, FASEB Journal, V3, pA858; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	24	391	400	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					649	652						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1370453				2022-12-27	WOS:A1992GY43900100
